<SEC-DOCUMENT>0001564590-22-019085.txt : 20220510
<SEC-HEADER>0001564590-22-019085.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510081102
ACCESSION NUMBER:		0001564590-22-019085
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prelude Therapeutics Inc
		CENTRAL INDEX KEY:			0001678660
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811384762
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39527
		FILM NUMBER:		22907476

	BUSINESS ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		(302) 547-3768

	MAIL ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prelude Therapeutics Inc.
		DATE OF NAME CHANGE:	20160630
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>prld-10q_20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:prld="http://preludetx.com/20220331" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
prld-10q_20220331.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001678660_20220101_20220331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001678660_20220101_20220331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001678660_20220101_20220331">0001678660</ix:nonNumeric>
			<ix:nonNumeric id="F_000009" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001678660_20220101_20220331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000247" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000249" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000309" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000331" name="prld:ResearchTerm" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000334" name="prld:GracePeriodForPotentialRefund" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">P18M</ix:nonNumeric>
			<ix:nonNumeric id="F_000341" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000418" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">P4Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001678660_20220331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001678660_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000363" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_20210101_20211231">P8Y7M28D</ix:nonNumeric>
			<ix:nonNumeric id="F_000364" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_20220101_20220331">P8Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000365" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001678660_20220101_20220331">P7Y10M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000384" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331">P7Y6M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000385" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331">P9Y10M17D</ix:nonNumeric>
			<ix:nonNumeric id="F_000386" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331">P8Y5M1D</ix:nonNumeric>
			<ix:nonNumeric id="F_000387" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331">P9Y5M23D</ix:nonNumeric>
			<ix:nonNumeric id="F_000388" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331">P9Y2M23D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000368" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331" decimals="INF">0.31</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000369" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331" decimals="INF">6.00</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000370" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331" decimals="INF">11.73</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000371" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331" decimals="INF">13.05</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000372" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331" decimals="INF">31.14</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000373" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331" decimals="INF">5.99</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000374" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331" decimals="INF">11.72</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000375" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331" decimals="INF">13.04</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000376" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331" decimals="INF">31.13</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000377" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331" decimals="INF">88.98</ix:nonFraction>
			<ix:nonNumeric id="F_000416" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">P6Y21D</ix:nonNumeric>
			<ix:nonNumeric id="F_000417" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P6Y21D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="prld-20220331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001678660_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_20220504">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-05-04</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:OperatingLeaseUntilJune302023Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prld:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prld:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:OperatingLeaseUntilJune302023Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-10-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_prldExtension">
				<xbrli:measure>prld:Extension</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtStatementScenarioAxis_srtProFormaMember_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMaximumMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prld:DarwinHealthIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prld:DarwinHealthIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_prldInstallment">
				<xbrli:measure>prld:Installment</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_prldPlan">
				<xbrli:measure>prld:Plan</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFourMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFourMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001678660_20220101_20220331">10-Q</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentQuarterlyReport" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001678660_20220101_20220331" format="ixt:datemonthdayyearen">March 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001678660_20220101_20220331">2022</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentTransitionReport" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: <ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0001678660_20220101_20220331">001-39527</ix:nonNumeric><span style="font-weight:normal;">&#160;</span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001678660_20220101_20220331">PRELUDE THERAPEUTICS INC</ix:nonNumeric>ORPORATED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001678660_20220101_20220331">81-1384762</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine1" contextRef="C_0001678660_20220101_20220331">200 Powder Mill Road</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressCityOrTown" contextRef="C_0001678660_20220101_20220331">Wilmington</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressStateOrProvince" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressPostalZipCode" contextRef="C_0001678660_20220101_20220331">19803</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000026" name="dei:CityAreaCode" contextRef="C_0001678660_20220101_20220331">302</ix:nonNumeric>) <ix:nonNumeric id="F_000027" name="dei:LocalPhoneNumber" contextRef="C_0001678660_20220101_20220331">467-1280</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:Security12bTitle" contextRef="C_0001678660_20220101_20220331">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001678660_20220101_20220331">PRLD</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000008" name="dei:EntityCurrentReportingStatus" contextRef="C_0001678660_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;&#160;</span>&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000018" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001678660_20220101_20220331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;&#160;</span>&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityFilerCategory" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntitySmallBusiness" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityExTransitionPeriod" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span><span style="font-size:10pt;">&#160;</span><span style="font-family:Segoe UI Symbol;">&#160;</span>&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. &#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;&#160;</span>&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of May 4, 2022, the registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000014" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001678660_20220504" decimals="INF" format="ixt:numdotdecimal">47,695,639</ix:nonFraction> shares of voting and non-voting common stock, $0.0001 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IFINANCIAL_INFORMATION"><span style="text-decoration:underline;">FINANCIAL INFORMATION</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements </span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets (Unaudited)</span></a><span style="text-decoration:underline;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Statements of Operations and Comprehensive Loss (Unaudited)</span></a><span style="text-decoration:underline;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CHANGES_IN_CONVERTIBLE_PREFER"><span style="text-decoration:underline;">Statements of Changes in Stockholders&#8217; Equity (Deficit) (Unaudited)</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows (Unaudited)</span></a><span style="text-decoration:underline;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_UNAUDITED_INTERIM_FINANCIAL_STA"><span style="text-decoration:underline;">Notes to Unaudited Interim Financial Statements</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IFINANCIAL_INFORMATION">PART I&#8212;FINANCIAL INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">Item 1. Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRELUDE THERAPEUTICS INCORPORATED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">51,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">214,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,783</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:AssetsCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">269,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AssetsCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">295,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:RestrictedCash" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:RestrictedCash" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OtherAssets" contextRef="C_0001678660_20220331" decimals="-3" scale="3">309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OtherAssets" contextRef="C_0001678660_20211231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:Assets" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">280,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:Assets" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">305,098</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001678660_20220331" decimals="-3" scale="3">390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:Liabilities" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:Liabilities" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments (Note 8)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000060">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000061">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000076" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000077" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">487,149,741</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">36,293,331</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">36,200,299</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:CommonStockValue" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:CommonStockValue" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000085" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">12,850,259</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">11,402,037</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">11,402,037</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:CommonStockValue" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:CommonStockValue" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">512,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">505,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001678660_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001678660_20211231" decimals="-3" sign="-" scale="3">711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001678660_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">248,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001678660_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">219,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">261,812</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">285,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">280,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">305,098</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to unaudited interim financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRELUDE THERAPEUTICS INCORPORATED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:OperatingExpenses" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">30,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingExpenses" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per share information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share of common stock, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000104" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001678660_20220101_20220331" decimals="2" sign="-">0.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000105" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001678660_20210101_20210331" decimals="2" sign="-">0.47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001678660_20220101_20220331" decimals="0" format="ixt:numdotdecimal">47,066,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000107" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001678660_20210101_20210331" decimals="0" format="ixt:numdotdecimal">45,121,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities, net of tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to unaudited interim financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRELUDE THERAPEUTICS INCORPORATED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CHANGES_IN_CONVERTIBLE_PREFER">STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="30" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except shares)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">36,200,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">11,402,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">505,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">219,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">285,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000121" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">93,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000130" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">36,293,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">11,402,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">512,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">248,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">261,812</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="26" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except shares)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">32,595,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">11,110,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">319,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">107,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">212,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">210,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of common stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="prld:PaymentsOfOfferingCosts" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">2,583,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">291,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">161,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">161,412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:NetIncomeLoss" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000157" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">35,388,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:SharesOutstanding" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">11,402,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">485,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:StockholdersEquity" contextRef="C_0001678660_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">356,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to unaudited interim financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRELUDE THERAPEUTICS INCORPORATED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CASH_FLOWS">STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(UNAUDITED)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:ProfitLoss" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:ProfitLoss" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:ShareBasedCompensation" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:ShareBasedCompensation" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium and discount on marketable securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" scale="3">401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="prld:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="prld:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows provided by (used in) investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">42,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">41,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001678660_20210101_20210331" decimals="-3" sign="-" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows provided by financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the sale of common stock, net of offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">161,424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">161,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">144,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001678660_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">218,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,678</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001678660_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">362,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment in accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001678660_20220101_20220331" decimals="-3" scale="3">354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001678660_20210101_20210331" decimals="-3" scale="3">86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="prld:UnrealizedGainLossOnMarketableSecurities" contextRef="C_0001678660_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to unaudited interim financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRELUDE THERAPEUTICS INCORPORATED</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_UNAUDITED_INTERIM_FINANCIAL_STA">NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS</p><ix:nonNumeric id="F_000204" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Background</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prelude Therapeutics Incorporated (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;5, 2016 and is a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. Since beginning operations, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000205" name="prld:RisksAndLiquidityTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000205_dcnt_3e503d8f-5731-462c-a8d2-393b8365af47">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Risks and liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is subject to a number of risks common to early-stage companies in the biotechnology industry. Principal among these risks are the uncertainties in the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology, dependence on key personnel, compliance with government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval, or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and contractors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has incurred operating losses and has an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001678660_20220331" decimals="-5" sign="-" scale="6">248.6</ix:nonFraction>&#160;million at March&#160;31, 2022. The Company has no revenue to date and devotes its efforts to research and development. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash <span style="color:#000000;">equivalents, and marketable securities as of March&#160;31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2024.</span>&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fund its operating expenses and capital expenditure requirements after that date, the Company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;10, 2020, the World Health Organization characterized the novel&#160;COVID-19&#160;virus as a global pandemic. There is significant uncertainty as to the likely effects of this disease and emerging variants which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, CROs, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000205_dcnt_3e503d8f-5731-462c-a8d2-393b8365af47">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000206" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000206_dcnt_eb99e578-1bec-4651-8778-76489eba3725">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Summary of significant accounting policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary of significant accounting policies included in the Company&#8217;s financial statements for the year ended December&#160;31, 2021 can be found in &#8220;Note 3. Summary of significant accounting policies&#8221; of the Company&#8217;s Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 17, 2022. Those policies have not materially changed, except as set forth below.</p><ix:nonNumeric id="F_000213" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, the instructions to&#160;Form&#160;10-Q&#160;and&#160;Article&#160;10&#160;of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 found in the Form 10-K filed with the SEC on March 17, 2022. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric id="F_000214" name="us-gaap:UseOfEstimates" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p></ix:nonNumeric><ix:nonNumeric id="F_000215" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the historical and anticipated future losses, management has determined that the deferred tax assets generated by net operating losses and research and development credits do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of March&#160;31, 2022 and December&#160;31, 2021.</p></ix:nonNumeric><ix:nonNumeric id="F_000216" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted cash</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents include short-term highly liquid investments with an original maturity of 90&#160;days or less when purchased and are carried at fair value in the accompanying balance sheets.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#8217;s Chestnut Run Lease. See Note 8 for further details. </p><ix:nonNumeric id="F_000220" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:</span></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">51,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:RestrictedCash" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:RestrictedCash" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">55,678</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000217" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000217_dcnt_e5cd06b7-5ab7-47f2-a0b1-a28a41cbaeb1">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of investments in corporate debt securities and commercial paper that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity (deficit). Realized gains and losses as well as credit losses, if </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000206_dcnt_eb99e578-1bec-4651-8778-76489eba3725" continuedAt="F_000206_dcnt_6a27facd-7bc0-4c15-96fa-098b540d5259"><ix:continuation id="F_000217_dcnt_e5cd06b7-5ab7-47f2-a0b1-a28a41cbaeb1">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any, on marketable securities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are included in the Company's</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements of operations.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> classifies marketable securities that are available for use in current operations as current assets on the balance sheets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation><ix:nonNumeric id="F_000218" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#8217;s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses.</p><ix:nonNumeric id="F_000221" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000239" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">514,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000240" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">1,009,462</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000242" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">8,541,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000243" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">6,732,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000244" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">40,127</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000245" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_20220101_20220331" decimals="0" format="ixt:numdotdecimal">9,115,785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000246" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001678660_20210101_20210331" decimals="0" format="ixt:numdotdecimal">7,742,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the above table reflect the common stock equivalents.</p></ix:nonNumeric><ix:nonNumeric id="F_000219" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000219_dcnt_0453193f-ad9d-4f69-a21d-967abd193cde">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited interim financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In</span><span style="font-weight:bold;Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">June 2016, the FASB iss</span>ued ASU No. 2016-13, &#8220;<span style="font-style:italic;Background-color:#FFFFFF;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="Background-color:#FFFFFF;">&#8221; which has subsequently been amended by ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11, and ASU No. 2020-03 (&#8220;ASU 2016-03&#8221;). This guidance replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted this standard as of <ix:nonNumeric id="F_000248" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric> using a modified retrospective approach. It did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU No. 2021-10,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">&#8220;Government Assistance: Disclosures by Business Entities about Government Assistance&#8221;</span><span style="Background-color:#FFFFFF;">. The amendments in this Update improve financial reporting by requiring disclosures that increase the transparency of transactions with a government. The amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy (i) the type of transaction (ii) the accounting for the transaction, and (iii) the effect of the transaction on the entity&#8217;s financial statements. The Company adopted this </span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000206_dcnt_6a27facd-7bc0-4c15-96fa-098b540d5259"><ix:continuation id="F_000219_dcnt_0453193f-ad9d-4f69-a21d-967abd193cde">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">standard as of </span><span style="Background-color:#FFFFFF;">January 1, 2022</span><span style="Background-color:#FFFFFF;"> using a </span><span style="Background-color:#FFFFFF;">prospe</span><span style="Background-color:#FFFFFF;">ctive approach</span><span style="Background-color:#FFFFFF;"> and i</span><span style="Background-color:#FFFFFF;">t did </span><span style="Background-color:#FFFFFF;">no</span><span style="Background-color:#FFFFFF;">t have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000207" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities </p><ix:nonNumeric id="F_000222" name="us-gaap:MarketableSecuritiesTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following is a summary of the Company&#8217;s marketable securities.</span></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">180,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">178,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331" decimals="-3" scale="3">76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">216,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">214,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" scale="3">696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">260,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" contextRef="C_0001678660_20211231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" contextRef="C_0001678660_20211231" decimals="-3" scale="3">713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s marketable securities generally have contractual maturity dates of 15 months or less. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary, is primarily related to market factors and believes that it is more likely than not that it will be able to hold its debt securities to maturity. </span>Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.</p></ix:nonNumeric><ix:nonNumeric id="F_000208" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000208_dcnt_4f7f7630-f900-4f74-b677-bf73fd524fc7">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The Company follows the provisions of ASC 820, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Level&#160;1:</span><span style="color:#000000;"> Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Level&#160;2:</span><span style="color:#000000;"> Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Level&#160;3:</span><span style="color:#000000;"> Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></p></td></tr></table></div><ix:nonNumeric id="F_000223" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000223_dcnt_90047d22-eaca-4282-936c-e3db544531fa"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000208_dcnt_4f7f7630-f900-4f74-b677-bf73fd524fc7"><ix:continuation id="F_000223_dcnt_90047d22-eaca-4282-936c-e3db544531fa">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurement at reporting date using</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">47,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">178,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">47,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">214,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">259,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued Expenses and Other Current Liabilities</p><ix:nonNumeric id="F_000224" name="prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true"><ix:nonNumeric id="F_000209" name="prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,919</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="prld:AccruedResearchAndDevelopmentLiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="prld:AccruedResearchAndDevelopmentLiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" scale="3">354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001678660_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001678660_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000210" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000210_dcnt_64fc8324-ed49-4aa4-9691-f9d545fadfe1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Offering</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000289" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131" decimals="INF" format="ixt:numdotdecimal">2,875,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000290" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210131" decimals="INF">60.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131" decimals="-5" scale="6">161.4</ix:nonFraction> million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has two classes of common stock&#59; &#8220;voting common stock&#8221; and &#8220;non-voting common stock.&#8221; <span style="color:#000000;"><ix:nonNumeric id="F_000292" name="us-gaap:CommonStockVotingRights" contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders</ix:nonNumeric></span>. Except as otherwise required by law, the holders of non-voting common stock shall not be entitled to vote at any meetings of stockholders (or written actions in lieu of meetings) and the shares of non-voting common stock shall not be included in determining the number of shares voting or entitled to vote on any matter. Unless required by law, there shall be no cumulative voting. Any holder of non-voting common stock may elect to convert each share of non-voting common stock into one fully paid and non-assessable share of voting common stock at any time by providing written notice to the Company&#59; provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule&#160;13(d) group with such holder, would not beneficially own in excess of <ix:nonFraction unitRef="U_xbrlipure" id="F_000293" name="prld:BeneficialOwnershipPercentage" contextRef="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" scale="-2">9.99</ix:nonFraction>% of the Company&#8217;s common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in the Company&#8217;s restated certificate of incorporation. However, this ownership limitation may be increased (not to exceed <ix:nonFraction unitRef="U_xbrlipure" id="F_000294" name="prld:BeneficialOwnershipPercentage" contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" scale="-2">19.99</ix:nonFraction>%) or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#8217; notice to the Company.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000210_dcnt_64fc8324-ed49-4aa4-9691-f9d545fadfe1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000211" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000211_dcnt_c536569c-54a1-48a2-964c-ced286772e5a">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:66.11%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8<span style="color:#231F20;">. Commitments</span></p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company </span><span style="Background-color:#FFFFFF;">leases office and laboratory space in Wilmington, Delaware under a noncancelable lease (the &#8220;Lease&#8221;). During the first quarter of 2022, the Lease was amended to allow the Company the option to renew the Lease for two <ix:nonNumeric id="F_000295" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001678660_20220331" format="ixt-sec:durmonth">6</ix:nonNumeric>-month periods and the Company exercised its option to renew the lease for an additional <ix:nonNumeric id="F_000297" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" format="ixt-sec:durmonth">6</ix:nonNumeric> months until June 30, 2023. </span><ix:nonNumeric id="F_000298" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001678660_20220101_20220331"><span style="color:#231F20;">The</span><span style="color:#231F20;letter-spacing:0.05pt;"> second </span><span style="color:#231F20;">option</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">to</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">extend the Lease for an additional 6 months</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">was</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">not</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">recognized</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">as part</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">of the</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">Company&#8217;s measurement</span><span style="color:#231F20;letter-spacing:0.2pt;"> </span><span style="color:#231F20;">of the</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">right-of-use</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">asset</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">and operating</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">lease</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">liability</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">as of March&#160;31, 2022</span></ix:nonNumeric><span style="Background-color:#FFFFFF;">.&#160;</span><span style="color:#231F20;">The</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">discount</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">rate</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">used</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">to</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">account</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">for</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">the</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">Company&#8217;s operating</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">lease</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">under</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">ASC 842</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">is</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">the</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">Company&#8217;s</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">estimated</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">incremental</span><span style="color:#231F20;letter-spacing:0.2pt;"> </span><span style="color:#231F20;">borrowing</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">rate</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">of</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000296" name="prld:OperatingLeaseEstimatedIncrementalBorrowingRatePercent" contextRef="C_0001678660_20220101_20220331" decimals="3" scale="-2">6.0</ix:nonFraction></span>%.<span style="color:#231F20;letter-spacing:0.05pt;"> </span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent<span style="letter-spacing:0.05pt;"> </span>expense<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>three months<span style="letter-spacing:0.1pt;"> </span>ended<span style="letter-spacing:0.05pt;"> March&#160;31, 2022 </span>and<span style="letter-spacing:0.05pt;"> 2021 </span><span style="color:#000000;">was</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001678660_20220101_20220331" decimals="-5" scale="6">0.5</ix:nonFraction></span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">million</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001678660_20210101_20210331" decimals="-5" scale="6">0.3</ix:nonFraction> million, respectively. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000225" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future<span style="letter-spacing:0.25pt;"> </span>minimum<span style="letter-spacing:0.3pt;"> </span>annual<span style="letter-spacing:0.25pt;"> </span>lease<span style="letter-spacing:0.25pt;"> </span>payments<span style="letter-spacing:0.25pt;"> </span>under<span style="letter-spacing:0.25pt;"> the L</span>ease<span style="letter-spacing:0.2pt;"> </span>at<span style="letter-spacing:0.2pt;"> March&#160;31, 2022</span><span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.15pt;"> </span>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:9.81%;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" decimals="-3" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and noncurrent lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the fourth quarter of 2021, the Company </span>entered into a lease agreement (the &#8220;Chestnut Run Lease&#8221;)&#160;with a commencement date of the earlier of (i)&#160;the Landlord Work Substantial Completion Date (as such term is defined in the Chestnut Run Lease), or (ii)&#160;<span style="Background-color:#FFFFFF;">the date the Company takes possession of the premises for the conduct of the Company&#8217;s business (the &#8220;Commencement Date&#8221;). The Chestnut Run Lease premises includes approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000306" name="prld:AreaOfLeasePremises" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231" decimals="INF" format="ixt:numdotdecimal">81,000</ix:nonFraction> square feet, located at Chestnut Run Plaza in Wilmington, Delaware (the Premises). The Premises contains both office and lab space the Company intends to use for administrative, research and development and other activities. Upon the Commencement Date, the Company will recognize a right-of-use asset and operating lease liability in accordance with ASC 842. The Chestnut Run Lease has an initial term of <ix:nonNumeric id="F_000307" name="prld:InitialTermOfLease" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231" format="ixt-sec:durmonth">162</ix:nonNumeric> months with <ix:nonFraction unitRef="U_prldExtension" id="F_000308" name="prld:NumberOfLeaseExtensions" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231" decimals="INF">3</ix:nonFraction> <span style="-sec-ix-hidden:F_000309">five-year</span> extension options and certain expansion rights. The aggregate estimated rent payments due over the initial term of the Chestnut Run Lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="prld:AggregateEstimatedRentPaymentsDueOverInitialTerm" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231" decimals="-5" scale="6">33.8</ix:nonFraction>&#160;million. <ix:nonNumeric id="F_000226" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220101_20220331" escape="true" continuedAt="F_000226_cnt_1">The estimated rent payments due for the remainder of 2022 along with each of the next five years and thereafter is as follows:</ix:nonNumeric></span></p><ix:continuation id="F_000226_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining 9 months)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">24,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company paid a security deposit for the Chestnut Run Lease in the form of a letter of credit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:SecurityDeposit" contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million, which is included in the balance sheet as restricted cash as of March 31, 2022. The security deposit may be reduced to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:SecurityDeposit" contextRef="C_0001678660_srtStatementScenarioAxis_srtProFormaMember_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million over time in accordance with the terms of the Chestnut Run Lease.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s expansion of operations in the State of Delaware, the Company was approved for a grant from the State of Delaware in 2021 that will provide up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="prld:ReimbursementsForDevelopmentOfLabSpace" contextRef="C_0001678660_20220101_20220331" decimals="-5" scale="6">5.5</ix:nonFraction> million in reimbursements over <ix:nonNumeric id="F_000320" name="prld:ReimbursementsForDevelopmentOfLabSpacePeriod" contextRef="C_0001678660_20220101_20220331" format="ixt-sec:durwordsen">three years</ix:nonNumeric> for the development of lab space in addition to increasing jobs in Delaware to meet specific targeted levels through <ix:nonNumeric id="F_000321" name="prld:ReimbursementsForDevelopmentOfLabSpaceExpirationYear" contextRef="C_0001678660_20220101_20220331">2023</ix:nonNumeric>. During the first quarter of 2022, the Company received cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="prld:GrantForDevelopmentOfLabSpace" contextRef="C_0001678660_20220101_20220331" decimals="-5" scale="6">2.4</ix:nonFraction> million from the grant for the development of lab space. The Company has deferred the recognition of these grant funds as they relate to capitalized costs and has classified them as long-term liabilities on the balance sheet.&#160;The Company will recognize the grant funds in other income as grant income over the useful life of the related assets. If, after two years from the disbursement date, the incurred costs for lab space are less than the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="prld:DisbursementIncurredCostsForLabSpace" contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_20220101_20220331" decimals="-5" scale="6">2.4</ix:nonFraction> million received, the Company is required to pay back the difference between total funds received and allowable costs incurred. Additionally, if the Company leaves the State of Delaware within five years of the disbursement, the Company is required to return an amount equal to the amount of grant funds disbursed on a pro-rated basis. During the first quarter of 2022, the Company also received cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="prld:ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" contextRef="C_0001678660_20220101_20220331" decimals="-5" scale="6">0.3</ix:nonFraction> million for satisfying the first performance benchmark measurement. The Company recognized this in other income, net on the statement of operations and comprehensive loss. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000211_dcnt_c536569c-54a1-48a2-964c-ced286772e5a">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the Company&#8217;s employee headcount is fewer than the performance benchmark, the Company is required to repay the amount of grant funds received for the number of employees below the benchmark.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Defined Contribution Plan</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a 401(k)&#160;defined&#8209;contribution plan covering all employees. Participants are permitted to contribute up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000325" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="C_0001678660_20220101_20220331" decimals="INF" scale="-2">100</ix:nonFraction>% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. The Company provides a safe harbor match with a maximum amount of <ix:nonFraction unitRef="U_xbrlipure" id="F_000326" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001678660_20220101_20220331" decimals="2" scale="-2">3</ix:nonFraction>% of the participant&#8217;s compensation. For both the<span style="color:#000000;"> three months ended March&#160;31, 2022 and 2021, the Company made matching contributions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001678660_20220101_20220331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001678660_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Collaboration Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into a research collaboration agreement estimated to last for approximately <ix:nonNumeric id="F_000329" name="prld:EstimatedNumberOfYearResearchCollaborationAgreement" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930" format="ixt-sec:durwordsen">one year</ix:nonNumeric> (the &#8220;Darwin Health Agreement&#8221;) with Darwin Health, Inc. (&#8220;DarwinHealth&#8221;). Under the terms of the Darwin Health Agreement, DarwinHealth will utilize their drug discovery technologies and certified methodologies in precision oncology to advance and accelerate clinical development for certain of the Company&#8217;s programs across a broad range of tumor subtypes. The Company will pay DarwinHealth a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="prld:EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930" decimals="-5" scale="6">3.0</ix:nonFraction> million in <ix:nonFraction unitRef="U_prldInstallment" id="F_000333" name="prld:NumberOfEqualInstalments" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> equal installments over the <span style="-sec-ix-hidden:F_000331">one-year</span> term (the &#8220;Research Term&#8221;) to fund the research and, if the Company adopts any of DarwinHealth&#8217;s development ideas, the Company will be responsible for the development, manufacturing, and commercialization of any such products. In addition to research funding, DarwinHealth is eligible to receive future research, development and regulatory milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930" decimals="-5" scale="6">3.0</ix:nonFraction> million for each product candidate and is also eligible to receive tiered royalties in the low single digits on net sales of each product developed using DarwinHealth&#8217;s development technologies or methods. However, within <span style="-sec-ix-hidden:F_000334">eighteen-months</span> following the Research Term, the Company, in its sole discretion, may notify DarwinHealth that it will not utilize its development ideas and will be entitled to receive a refund of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="prld:PotentialRefundReceivableFromAgreement" contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Research and Development Arrangements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to assist in the performance of research and development activities. Expenditures to CROs will represent a significant cost in clinical development for the Company.</p></ix:continuation><ix:nonNumeric id="F_000212" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000212_dcnt_498ce3be-8a01-436b-91bf-d8039f11ac39">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has <ix:nonFraction unitRef="U_prldPlan" id="F_000336" name="prld:NumberOfEquityIncentivePlans" contextRef="C_0001678660_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> equity incentive plans: the 2016 Equity Incentive Plan, as amended, and the 2020 Equity Incentive Plan. New awards can only be granted under the 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and as of March&#160;31, 2022, <ix:nonFraction unitRef="U_xbrlishares" id="F_000337" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220331" decimals="INF" format="ixt:numdotdecimal">6,240,398</ix:nonFraction> shares were available for future grants. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January 1st of each year, commencing on January 1, 2021, and continuing for <ix:nonNumeric id="F_000339" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000340" name="prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331" decimals="2" format="ixt-sec:numwordsen" scale="-2">five</ix:nonFraction> percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. <ix:nonNumeric id="F_000338" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">The Company&#8217;s stock options vest based on the terms in each award agreement, generally over <span style="-sec-ix-hidden:F_000341">four-year</span> periods with <ix:nonFraction unitRef="U_xbrlipure" id="F_000343" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331" decimals="2" scale="-2">25</ix:nonFraction>% of options vesting after <ix:nonNumeric id="F_000342" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331" format="ixt-sec:duryear">1</ix:nonNumeric> year and then monthly thereafter, and have a term of <ix:nonNumeric id="F_000344" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>.</ix:nonNumeric> <span style="color:#000000;">&#160;</span> &#160;&#160; &#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000212_dcnt_498ce3be-8a01-436b-91bf-d8039f11ac39" continuedAt="F_000212_dcnt_b36756d2-2d19-48ac-b13c-3c65d83fa591">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. <ix:nonNumeric id="F_000227" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true" continuedAt="F_000227_cnt_1">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:</ix:nonNumeric></p><ix:continuation id="F_000227_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,629</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:continuation>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options</p><ix:nonNumeric id="F_000228" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000351" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001678660_20211231" decimals="INF" format="ixt:numdotdecimal">7,179,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001678660_20211231" decimals="2">15.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000363">8.66</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000352" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001678660_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">1,646,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000358" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001678660_20220101_20220331" decimals="2">10.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000353" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001678660_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">93,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000359" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001678660_20220101_20220331" decimals="2">1.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000354" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001678660_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">191,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001678660_20220101_20220331" decimals="2">17.86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001678660_20220331" decimals="INF" format="ixt:numdotdecimal">8,541,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001678660_20220331" decimals="2">14.54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000364">8.70</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001678660_20220331" decimals="INF" format="ixt:numdotdecimal">2,285,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000362" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001678660_20220331" decimals="2">8.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000365">7.85</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001678660_20220331" decimals="-5" scale="6">11.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001678660_20220331" decimals="-5" scale="6">6.7</ix:nonFraction>&#160;million, respectively.</p><ix:nonNumeric id="F_000229" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding at March&#160;31, 2022 under the Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.31 - $5.99</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000378" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331" decimals="INF" format="ixt:numdotdecimal">2,213,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">7.52</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000389" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331" decimals="2">1.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000394" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,300,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000400" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331" decimals="2">1.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.00 - $11.72</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000379" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,625,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000385">9.88</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000390" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331" decimals="2">10.58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000395" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331" decimals="INF" format="ixt:numdotdecimal">2,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000401" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331" decimals="2">10.09</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11.73 - $13.04</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000380" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331" decimals="INF" format="ixt:numdotdecimal">2,392,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000386">8.42</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000391" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331" decimals="2">12.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000396" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331" decimals="INF" format="ixt:numdotdecimal">893,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000402" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331" decimals="2">12.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.05 - $31.13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331" decimals="INF" format="ixt:numdotdecimal">607,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000387">9.48</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000392" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331" decimals="2">20.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000397" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331" decimals="INF" format="ixt:numdotdecimal">11,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000403" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331" decimals="2">15.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.14 - $88.98</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000382" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,700,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000388">9.23</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000393" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331" decimals="2">35.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000398" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331" decimals="INF" format="ixt:numdotdecimal">78,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000404" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331" decimals="2">57.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000383" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="C_0001678660_20220331" decimals="INF" format="ixt:numdotdecimal">8,541,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000399" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="C_0001678660_20220331" decimals="INF" format="ixt:numdotdecimal">2,285,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000405" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="2">7.62</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000406" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2">68.39</ix:nonFraction> per share for the three months ended March&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="-5" scale="6">0.6</ix:nonFraction> million for the three months ended March&#160;31, 2022. The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="-5" scale="6">6.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="-5" scale="6">3.7</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, related to stock options.&#160;As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220331" decimals="-5" scale="6">72.2</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric id="F_000411" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" format="ixt-sec:duryear">3.01</ix:nonNumeric>&#160;years.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000212_dcnt_b36756d2-2d19-48ac-b13c-3c65d83fa591"><ix:nonNumeric id="F_000230" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="4" scale="-2">84.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000413" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="4" scale="-2">117.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331" decimals="4" scale="-2">1.97</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000415" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="4" scale="-2">0.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000416">6.06</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000417">6.06</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Awards and Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issues restricted stock awards (&#8220;RSA&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_000418">four-year</span> period with <ix:nonFraction unitRef="U_xbrlipure" id="F_000419" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331" decimals="2" scale="-2">25</ix:nonFraction>% of awards vesting after one year and then monthly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSA is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSA expense is recorded on a straight-line basis over the vesting period.</p><ix:nonNumeric id="F_000231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001678660_20220101_20220331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSA stock-based payment awards:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">611,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000423" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231" decimals="2">2.29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">96,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000424" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331" decimals="2">2.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">514,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000425" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331" decimals="2">2.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction>&#160;million for both the three months ended March&#160;31, 2022 and 2021 related to RSAs. As of March&#160;31, 2022, the total unrecognized expense related to all RSAs was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric id="F_000429" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331" format="ixt-sec:duryear">1.63</ix:nonNumeric>&#160;years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, the Company granted restricted stock units (&#8220;RSU&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_000430">four-year</span> period with <ix:nonFraction unitRef="U_xbrlipure" id="F_000431" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231" decimals="2" scale="-2">25</ix:nonFraction>% of awards vesting after one year and then quarterly thereafter. Any unvested units will be forfeited upon termination of services. At March 31, 2022 there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331" decimals="INF" format="ixt:numdotdecimal">20,000</ix:nonFraction> RSUs outstanding which had a weighted-average grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000433" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001678660_20220331" decimals="2">18.32</ix:nonFraction>. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> RSUs granted or forfeited during the three months ended March 31, 2022. The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331" decimals="-3" scale="3">24</ix:nonFraction> thousand for the three months ended March 31, 2022 related to RSUs. At March&#160;31, 2022 the total unrecognized expense related to the RSUs was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million, which the Company expects to recognize over <ix:nonNumeric id="F_000438" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331" format="ixt-sec:duryear">3.51</ix:nonNumeric>&#160;years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:18pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which, as of March&#160;31, 2022, had <ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220331" decimals="INF" format="ixt:numdotdecimal">1,407,365</ix:nonFraction> shares of common stock reserved for future issuance. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year and continuing for&#160;ten years beginning in 2021, in an amount equal to&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000439" name="prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331" decimals="2" format="ixt-sec:numwordsen" scale="-2">one</ix:nonFraction>&#160;percent of the total number of shares of all classes of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. On January 1, 2022, <ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101" decimals="INF" format="ixt:numdotdecimal">476,023</ix:nonFraction> shares were added to the ESPP. &#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000442" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="prld:EligibleEmployeesContributionPercentage" contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331" decimals="INF" scale="-2">15</ix:nonFraction>% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="prld:ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction>&#160;worth of the Company&#8217;s common stock for each calendar&#160;year in which such right is outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP is considered compensatory under the FASB stock compensation rules. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million and nil for the three months ended March&#160;31, 2022 and 2021, respectively, related to the ESPP.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. <span style="color:#000000;">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations, intentions and belief. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below.&#160;These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, market size, potential growth opportunities, preclinical and clinical development activities, efficacy and safety profile of our product candidates, use of net proceeds from our offerings, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, commercial collaborations with third parties and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our target class- and technology platform-agnostic approach, we have built an efficient, fully-integrated drug discovery engine to identify compelling biological targets and create new chemical entities, or NCEs, that we rapidly advance into clinical trials. We believe our approach could result in better targeted cancer therapies. Our discovery excellence has been validated by our rapid progress in creating a wholly-owned, internally developed pipeline. Since our inception in 2016, we have received clearance from the U.S. Food and Drug Administration, or the FDA, for six investigational new drug applications, or INDs, and successfully advanced these programs into clinical trials. In addition, we have two unique programs in various stages of preclinical development that we plan to advance into clinical development in 2022.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By focusing on developing agents using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, we have developed a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet medical need where there are limited or no treatment options. We believe we can best address these diseases by developing therapies that target primary and secondary resistance mechanisms.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have advanced four candidates in clinical trials and intend to file two INDs in the second half of 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two clinical candidates that are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5, or PRMT5. The potency and selectivity of our product candidates is supported by preclinical data demonstrating nanomolar inhibition of PRMT5 and no inhibition of related enzymes at 1,000 times higher concentration of our product candidates. <span style="Background-color:#FFFFFF;">Our PRMT5 candidates are currently being studied in Phase 1 clinical trials in solid tumors and myeloid malignancies.&#160;&#160;</span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on data from the ongoing Phase 1 dose expansion studies of our PRMT5 candidates, we are concentrating our further development efforts on our PRT811 candidate in biomarker-selected patients in specific cancer types. PRT811 was selected based on its superior safety profile, higher level of target engagement, and unique brain penetrant properties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, for the PRMT5 program, we intend to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Focus clinical development in select patient populations where clinical activity has been observed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Complete data analysis of the ongoing expansion cohorts by mid-year to determine further development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Report next steps for the ongoing dose expansion cohorts in the second half of 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Determine appropriate development options for PRT811 based on emerging data from ongoing expansion cohorts.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT1419, our next clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. The potency and selectivity of PRT1419 is supported by preclinical data demonstrating nanomolar inhibition of MCL1 and no inhibition of related enzymes at 200 times higher concentration of our product candidate. We have begun enrolling patients with hematologic malignancies, including patients with myelodysplastic syndrome, or MDS, acute myeloid leukemia, or AML, non-Hodgkin&#8217;s lymphoma, or NHL, and multiple myeloma, or MM, into the Phase 1 clinical trial for the oral formulation of PRT1419. The dose escalation portion of the Phase 1 trial of both oral formulation and the IV formulation, which leverages the optimized physicochemical properties of PRT1419, are underway in patients with solid tumors and hematologic tumors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the data to date, we have prioritized development of the IV formulation of PRT1419 which demonstrated a desirable pharmacokinetic, pharmacodynamic and safety profile with potential for differentiation from competitor compounds. We intend to evaluate combinations with PRT1419 by mid-year, with the goal of establishing safety, clinical activity and a recommended Phase 2 dose in the second half of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT2527 is designed to be a potent and selective Cyclin-dependent kinase 9, or CDK9, inhibitor. In preclinical studies, PRT2527 was shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses. PRT2527 has demonstrated high potency and kinase selectivity which may offer improved efficacy and safety compared to less selective CDK9 inhibitors. Preclinical data demonstrated that treatment with PRT2527 depleted oncogenic drivers with short half-lives, such as MYC and MCL1, and effectively induced apoptosis. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid tumor models with&#160;MYC&#160;dysregulation. A phase one trial is underway evaluating escalating IV doses of PRT2527 as a monotherapy in patients with selected solid tumors, including sarcoma, prostate cancer, lung cancer, and other cancers with genomic alterations that lead to&#160;MYC&#160;dependence. We anticipate completing enrollment in the Phase 1 dose escalation study of PRT2527 with the goal of identifying a recommended Phase 2 dose in the second half of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our four clinical stage candidates, we are advancing two new preclinical programs. Our most advanced preclinical program has led to the identification of PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6. IND-enabling studies for PRT3645 are ongoing and we intend to complete IND-enabling studies, file an IND and initiate a Phase 1 clinical trial in the second half of 2022. Our second pre-clinical program targets Brahma homologue, or BRM, otherwise known as SMARCA2. We have identified SMARCA2 protein degraders that appear to be potent based on preclinical data demonstrating degradation of SMARCA2 at sub-nanomolar concentrations. Optimization of the lead compound, PRT-SCA2, is progressing, and we intend to complete IND-enabling studies and submit an IND application by year-end 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in February 2016 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. We have funded our operations primarily through the sale of convertible preferred stock and common stock. Our net loss was $29.5 million and $21.3&#160;million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $248.6&#160;million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we had $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266.2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million in cash, cash equivalents, and marketable securities. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expense and capital expenditures into the second half of 2024.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19 Impact</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are continuing to proactively monitor and assess the COVID-19 pandemic. Since early March 2020 we have been monitoring the potential impact on our business that may result from this rapidly evolving crisis and to avoid any unnecessary potential delays to our programs. At this time, our lead programs and research activities remain on track. The safety and well-being of employees, patients and partners is our highest priority. See the Risk Factor &#8220;<span style="font-style:italic;">The COVID-19 pandemic could adversely impact our business, including our clinical trials and clinical trial operations</span>&#8221; in Part II, Item 1A. &#8220;Risk Factors&#8221; below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not recognized any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">personnel expenses, including salaries, benefits and stock-based compensation expense for our employees engaged in research and development functions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs of funding research performed by third parties, including pursuant to agreements with clinical research organizations, or CROs, that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and nonclinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fees paid to consultants who assist with research and development activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses related to regulatory activities, including filing fees paid to regulatory agencies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We track outsourced development costs and other external research and development costs to specific product candidates on a program-by-program basis, fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including stock-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and human resource functions. General and administrative expense also includes corporate facility costs not otherwise included in research and development expense, including rent, utilities, depreciation and maintenance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expense will increase in the future to support our continued research and development activities and potential commercialization efforts. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. If any of our current or future product candidates obtains U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net consists primarily of interest earned on our cash equivalents and marketable securities and grant income received from the State of Delaware. We anticipate re-applying for the grant from the State of Delaware from time to time as long as we maintain qualifying headcount levels in the State of Delaware. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not recorded any income tax benefits for the net operating losses, or NOLs, we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Three Months Ended March&#160;31, 2022 and 2020</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our results of operations for the three months ended March&#160;31, 2022 and 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,821</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,470</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,351</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,467</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,497</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,970</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,288</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,967</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,321</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,288</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,967</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,321</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">667</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,465</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,165</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by $6.4 million to $22.8 million for the three months ended March&#160;31, 2022 from $16.5 million for the three months ended March&#160;31, 2021. <span style="color:#000000;">Included in research and development expenses for the quarter ended March 31, 2022, was $3.2 million of non-cash expense related to stock-based compensation expense, including employee stock options, compared to $1.8 million for the three months ended March 31, 2021. </span>The increase in research and development expense was primarily due to an increase in discovery-stage program expenses and from the growth and advancement of our clinical pipeline. Our chemistry, manufacturing and other costs for the trials also increased. We track our external research and development expenses on a program-by-program basis, such as fees paid to CROs, CMOs and research laboratories in connection with our pre-clinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses by program are summarized in the table below:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT543</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">918</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,265</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT811</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,367</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,790</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT1419 (Oral and IV)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,936</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT2527</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">848</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,078</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discovery programs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,402</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,094</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal costs, including personnel related</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,197</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,307</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,821</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,470</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.26%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $2.0 million to $7.5 million for the three months ended March&#160;31, 2022 from $5.5 million for the three months ended March&#160;31, 2021. Included in the general and administrative expenses for the quarter ended March 31, 2022, was $3.6 million of non-cash expense related to stock-based compensation expense, including employee stock options, as compared to $2.0 million for the same period in 2021. The increase in general and administrative expense was primarily due to an increase in non-cash stock-based compensation expense along with professional fees as we expanded our operations to support our research and development efforts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net increased by $0.2 million to $0.8 million for the three months ended March 31, 2022 from $0.7 million for the three months ended March 31, 2021, primarily due to the receipt and recognition of research and development tax credits from the State of Delaware during 2022, as well as interest earned on the investment of our cash proceeds. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception, we have funded our operations through the sale of convertible preferred stock and common stock<span style="color:#000000;">. </span>As of March&#160;31, 2022, we had $266.2&#160;million in cash, cash equivalents and marketable securities and had an accumulated deficit of $248.6&#160;million. We expect our existing cash, cash equivalents and marketable securities to enable us to fund our operating expenses and capital expenditure requirements <span style="color:#000000;">into the second half of 2024</span>. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Funding Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary use of cash is to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses needed to attract and retain skilled personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs associated with being a public company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs required to scale up our clinical, regulatory and manufacturing capabilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows a summary of our cash flows for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,895</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,143</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,548</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(986</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,810</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,806</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,681</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2022, we used $21.9&#160;million of cash in operating activities. Cash used in operating activities reflected our net loss of $29.5&#160;million and a $0.7&#160;million net increase in our operating assets and liabilities, offset by noncash charges of $8.3&#160;million, which consisted of $6.8&#160;million in stock-based compensation, $0.7 million in amortization of premiums and discounts on marketable securities, $0.4 million noncash lease expense, and $0.3 million in depreciation. The primary use of cash was to fund our operations related to the development of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, we used $16.1&#160;million of cash in operating activities. Cash used in operating activities reflected our net loss of $21.3&#160;million, offset by a $0.8&#160;million net decrease in our operating assets and liabilities and noncash charges of $4.3&#160;million, which consisted of $0.2&#160;million in depreciation and $3.9&#160;million in stock-based compensation. The primary use of cash was to fund our operations related to the development of our product candidates.<span style="Background-color:#FFFFFF;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2022, net cash provided by investing activities consisted primarily of $42.5 million in proceeds from maturities of marketable securities. <span style="color:#000000;">During the three months ended March 31, 2021 we used $1.0&#160;million of cash for the purchase of property and equipment.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2022, financing activities provided $0.2 million from the exercise of stock options. During the three months ended March&#160;31, 2021,<span style="color:#000000;"> financing activities provided $161.8 million, which reflected the receipt of net cash of $161.4 million from the sale of common stock as well as the receipt of $0.4 million from the exercise of stock options. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the three months ended March&#160;31, 2022, there were no material changes to our critical accounting policies and estimates from those described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Estimates&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2022.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the&#160;JOBS Act. Under the&#160;JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the&#160;JOBS Act&#160;until such time as those standards apply to private companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the&#160;JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest of (1) the last day of our first fiscal year (a) in which we have total annual gross revenues of at least $1.07 billion, or (b) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period and (3) December 31, 2025.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note&#160;3 <span style="Background-color:#FFFFFF;color:#000000;">to our interim financial statements included elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company and Smaller Reporting Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain conditions, as an emerging growth company, we may rely on certain other exemptions and reduced reporting requirements, including without limitation, exemption to the requirements for providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act. We will remain an emerging growth company until the earlier to occur of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of our IPO, (ii)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">Item 4. Controls and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedure<span style="Background-color:#FFFFFF;font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of March&#160;31, 2022, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules&#160;</span><span style="color:#000000;">13a-15(e)</span><span style="Background-color:#FFFFFF;">&#160;and&#160;</span><span style="color:#000000;">15d-15(e)</span><span style="Background-color:#FFFFFF;">&#160;of the&#160;</span><span style="color:#000000;">Securities Exchange Act of 1934</span><span style="Background-color:#FFFFFF;">, as amended, or the&#160;</span><span style="color:#000000;">Exchange Act</span><span style="Background-color:#FFFFFF;">. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the&#160;</span><span style="color:#000000;">Exchange Act</span><span style="Background-color:#FFFFFF;">&#160;is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of March&#160;31, 2022, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management determined that, as of March&#160;31, 2022, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item 1. Legal Proceedings.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. In addition, we may receive letters alleging infringement of patents or other intellectual property rights. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business, operating results, cash flows or financial conditions should such litigation be resolved unfavorably. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1A. Ri</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">sk Factors</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-style:normal;text-transform:none;font-variant: normal;">RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks and uncertainties described below, together with the other information contained in this <span style="color:#auto;">Quarterly</span> <span style="color:#auto;">R</span>eport<span style="color:#auto;"> on Form 10-Q</span>, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to several risks and uncertainties, including those immediately following this summary. Some of these risks are:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability. We have incurred significant operating losses since our inception and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability. Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We will require substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed or on terms acceptable to us, we could be forced to delay, reduce or eliminate our research or drug development programs, any future commercialization efforts or other operations. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We are highly dependent on the success of our product candidates, PRT543, PRT811, PRT1419 and PRT2527, which are in early clinical development. We have not completed successful late-stage pivotal clinical trials or obtained regulatory approval for any product candidate. We may never obtain approval for any of our product candidates or achieve or sustain profitability. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and/or commercialization of PRT543, PRT811, PRT1419, PRT2527 or our other product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">The COVID-19 pandemic could adversely impact our business, including our clinical trials and clinical trial operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Adverse side effects or other safety risks associated with PRT543, PRT811, PRT1419, PRT2527 or our other product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product, or result in significant negative consequences following marketing approval, if any. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We rely, and intend to continue to rely, on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or do not meet expected deadlines, our development programs may be delayed or subject to increased costs or we may be unable to obtain regulatory approval, each of which may have an adverse effect on our business, financial condition, results of operations and prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Manufacturing pharmaceutical products is complex and subject to product loss for a variety of reasons. We rely on third-party suppliers, including single source suppliers, to manufacture preclinical and clinical supplies of our product candidates and we intend to rely on third parties to produce commercial supplies of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may enter into collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue potential and ability to achieve profitability will be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel and manage our human capital.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize products similar or identical to ours, and our ability to commercialize our product candidates successfully may be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may become involved in lawsuits or administrative disputes to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We may not be able to effectively protect or enforce our intellectual property and proprietary rights throughout the world.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">If we are sued for infringing, misappropriating or otherwise violating intellectual property or proprietary rights of third parties, such litigation or disputes could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Rights to improvements to our product candidates may be held by third parties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">An active and liquid trading market for our common stock may never be sustained. As a result, you may not be able to resell your shares of common stock at or above the purchase price.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">The market price of our common stock is likely to be highly volatile, which could result in substantial losses for purchasers of our common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:13pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#365F91;"></span><span style="font-size:10pt;font-family:Times New Roman;">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Our Financial<span style="letter-spacing:0.05pt;"> </span>Position<span style="letter-spacing:0.05pt;"> </span>and Need for<span style="letter-spacing:0.05pt;"> </span>Capital</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.73%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited<span style="letter-spacing:0.1pt;"> </span>operating<span style="letter-spacing:0.05pt;"> </span>history,<span style="letter-spacing:0.05pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>make<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>difficult<span style="letter-spacing:0.1pt;"> </span>to evaluate<span style="letter-spacing:0.05pt;"> </span>the success<span style="letter-spacing:0.05pt;"> </span>of our business<span style="letter-spacing:0.05pt;"> </span>to date<span style="letter-spacing:0.05pt;"> </span>and to assess<span style="letter-spacing:0.05pt;"> </span>our future<span style="letter-spacing:0.05pt;"> </span>viability.<span style="letter-spacing:0.1pt;"> </span>We have incurred<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>operating<span style="letter-spacing:0.05pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>since<span style="letter-spacing:0.05pt;"> </span>our inception and have not generated<span style="letter-spacing:0.05pt;"> </span>any revenue.<span style="letter-spacing:0.05pt;"> </span>We expect<span style="letter-spacing:0.05pt;"> </span>to incur continued<span style="letter-spacing:0.05pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the foreseeable<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>never<span style="letter-spacing:0.05pt;"> </span>achieve<span style="letter-spacing:0.05pt;"> </span>or maintain<span style="letter-spacing:0.05pt;"> </span>profitability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment<span style="letter-spacing:1.4pt;"> </span>in<span style="letter-spacing:1.3pt;"> </span>drug<span style="letter-spacing:1.3pt;"> </span>development<span style="letter-spacing:1.4pt;"> </span>is<span style="letter-spacing:1.35pt;"> </span>a<span style="letter-spacing:1.3pt;"> </span>highly<span style="letter-spacing:1.35pt;"> </span>speculative<span style="letter-spacing:1.4pt;"> </span>undertaking<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:1.3pt;"> </span>involves<span style="letter-spacing:1.35pt;"> </span>a<span style="letter-spacing:1.25pt;"> </span>substantial<span style="letter-spacing:1.35pt;"> </span>degree<span style="letter-spacing:1.3pt;"> </span>of risk.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>commenced<span style="letter-spacing:0.15pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>2016<span style="letter-spacing:0.05pt;"> </span>and are<span style="letter-spacing:0.05pt;"> </span>a clinical-stage<span style="letter-spacing:0.2pt;"> </span>biopharmaceutical<span style="letter-spacing:0.2pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>with a limited operating<span style="letter-spacing:0.15pt;"> </span>history.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>have not yet<span style="letter-spacing:0.05pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialized</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we do not expect</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to generate</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from sales</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">several</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have been limited</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon which we or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evaluate</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. P</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redictions</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">about</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our future</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">success</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or viability</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be as accurate</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as they</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a longer</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">history</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or a history</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of successfully</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and commercializing cancer</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies.</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.8pt;">thre</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e months ended March&#160;31, 2022 and 202</span><span style="letter-spacing:0.8pt;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reported</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.5</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</span><span style="letter-spacing:0.55pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</span><span style="letter-spacing:0.55pt;">, 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accumulated</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deficit</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248.6</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million.</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to incur</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and development</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our ongoing operations.</span></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inception,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>focused<span style="letter-spacing:0.1pt;"> </span>substantially<span style="letter-spacing:0.2pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>resources<span style="letter-spacing:0.15pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>research, preclinical<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811<span style="letter-spacing:-0.05pt;">, </span>PRT1419 and PRT2527,<span style="letter-spacing:-0.05pt;"> </span>and our research efforts<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>potential<span style="letter-spacing:0.2pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates<span style="letter-spacing:0.2pt;"> </span>targeting<span style="letter-spacing:0.15pt;"> </span>PRMT5, MCL1,<span style="letter-spacing:0.05pt;"> </span>CDK9, and BRM, otherwise<span style="letter-spacing:0.75pt;"> </span>known<span style="letter-spacing:0.7pt;"> </span>as<span style="letter-spacing:0.7pt;"> </span>SMARCA2.<span style="letter-spacing:0.6pt;"> </span>As of March 31, 2022, our cash<span style="letter-spacing:0.05pt;">,</span> cash<span style="letter-spacing:0.05pt;"> </span>equivalents, and marketable securities<span style="letter-spacing:0.1pt;"> </span>were $266.2 million.</p>
<p style="margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:2.2pt;"> </span>expect<span style="letter-spacing:2.25pt;"> </span>to<span style="letter-spacing:2.2pt;"> </span>incur<span style="letter-spacing:2.25pt;"> </span>increasing<span style="letter-spacing:2.3pt;"> </span>levels<span style="letter-spacing:2.25pt;"> </span>of<span style="letter-spacing:2.2pt;"> </span>operating<span style="letter-spacing:2.3pt;"> </span>losses<span style="letter-spacing:2.25pt;"> </span>for<span style="letter-spacing:2.25pt;"> </span>the<span style="letter-spacing:2.25pt;"> </span>foreseeable<span style="letter-spacing:2.3pt;"> </span>future,<span style="letter-spacing:2.25pt;"> </span>particularly<span style="letter-spacing:2.35pt;"> </span>as<span style="letter-spacing:2.2pt;"> </span>we advance PRT543, PRT811, PRT1419 and PRT2527 through clinical development. Our prior losses, combined with expected<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>losses,<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>had<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to have an adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our stockholders&#8217;<span style="letter-spacing:0.1pt;"> </span>equity<span style="letter-spacing:0.05pt;"> </span>and working<span style="letter-spacing:0.05pt;"> </span>capital.<span style="letter-spacing:0.15pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>expenses<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>significantly<span style="letter-spacing:0.15pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>in connection<span style="letter-spacing:0.05pt;"> </span>with our additional<span style="letter-spacing:0.1pt;"> </span>planned<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our lead<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>ongoing Phase 1 clinical<span style="letter-spacing:0.05pt;"> </span>trials and<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>expansion<span style="letter-spacing:0.1pt;"> </span>cohorts<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543 and<span style="letter-spacing:0.05pt;"> </span>PRT811, the<span style="letter-spacing:0.1pt;"> </span>ongoing<span style="letter-spacing:0.05pt;"> </span>Phase<span style="letter-spacing:0.05pt;"> </span>1<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> both the oral formulation and IV formulation of </span>PRT1419, the ongoing Phase 1 clinical trial for PRT2527, and development<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>subsequent<span style="letter-spacing:0.1pt;"> </span>INDs<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:0.05pt;"> </span>to pursue,<span style="letter-spacing:0.05pt;"> </span>including PRT3645, a CDK 4/6 inhibitor, and<span style="letter-spacing:0.2pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>SMARCA2 protein<span style="letter-spacing:0.15pt;"> </span>degrader.<span style="letter-spacing:0.15pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain marketing<span style="letter-spacing:0.2pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.15pt;"> any of our </span>product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>incur<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>sales, marketing and outsourced manufacturing expenses in connection with the commercialization.<span style="letter-spacing:0.2pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>costs associated<span style="letter-spacing:0.1pt;"> </span>with operating<span style="letter-spacing:0.1pt;"> </span>as a public<span style="letter-spacing:0.05pt;"> </span>company.<span style="letter-spacing:0.05pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span>we expect<span style="letter-spacing:0.05pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>to incur<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>and increasing<span style="letter-spacing:0.15pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>losses<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>foreseeable<span style="letter-spacing:0.15pt;"> </span>future.<span style="letter-spacing:0.1pt;"> </span>Because<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>numerous<span style="letter-spacing:0.1pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>and uncertainties<span style="letter-spacing:0.15pt;"> </span>associated with<span style="letter-spacing:1.05pt;"> </span>developing<span style="letter-spacing:1.1pt;"> </span>pharmaceutical<span style="letter-spacing:1.2pt;"> </span>products,<span style="letter-spacing:1.1pt;"> </span>we<span style="letter-spacing:1.05pt;"> </span>are<span style="letter-spacing:1.1pt;"> </span>unable<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>predict<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>extent<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>any<span style="letter-spacing:1pt;"> </span>future<span style="letter-spacing:1.05pt;"> </span>losses<span style="letter-spacing:1.05pt;"> </span>or<span style="letter-spacing:1pt;"> </span>when<span style="letter-spacing:1pt;"> </span>we will<span style="letter-spacing:0.55pt;"> </span>become<span style="letter-spacing:0.55pt;"> </span>profitable,<span style="letter-spacing:0.6pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>at<span style="letter-spacing:0.55pt;"> </span>all.<span style="letter-spacing:0.55pt;"> </span>Even<span style="letter-spacing:0.5pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>do<span style="letter-spacing:0.5pt;"> </span>become<span style="letter-spacing:0.55pt;"> </span>profitable,<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.55pt;"> </span>not<span style="letter-spacing:0.5pt;"> </span>be<span style="letter-spacing:0.5pt;"> </span>able<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.45pt;"> </span>sustain<span style="letter-spacing:0.5pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>increase<span style="letter-spacing:0.55pt;"> </span>our profitability<span style="letter-spacing:0.2pt;"> </span>on a quarterly<span style="letter-spacing:0.1pt;"> </span>or annual<span style="letter-spacing:0.05pt;"> </span>basis.<span style="letter-spacing:0.05pt;"> </span>We expect<span style="letter-spacing:0.05pt;"> </span>our financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and operating<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>to fluctuate significantly<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>quarter-to-quarter<span style="letter-spacing:0.2pt;"> </span>and year-to-year<span style="letter-spacing:0.15pt;"> </span>due to a variety<span style="letter-spacing:0.1pt;"> </span>of factors,<span style="letter-spacing:0.1pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>of which are<span style="letter-spacing:0.05pt;"> </span>beyond our control.<span style="letter-spacing:0.1pt;"> </span>Accordingly,<span style="letter-spacing:0.1pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>should<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>rely<span style="letter-spacing:0.05pt;"> </span>upon the<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of any quarterly<span style="letter-spacing:0.1pt;"> </span>or annual<span style="letter-spacing:0.05pt;"> </span>periods<span style="letter-spacing:0.05pt;"> </span>as indications<span style="letter-spacing:0.1pt;"> </span>of future<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.1pt;"> </span>performance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.1pt;"> </span>profitable<span style="letter-spacing:0.15pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>upon our ability<span style="letter-spacing:0.1pt;"> </span>to generate<span style="letter-spacing:0.1pt;"> </span>revenue.<span style="letter-spacing:0.05pt;"> </span>To date,<span style="letter-spacing:0.05pt;"> </span>we have not generated<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>revenue<span style="letter-spacing:0.1pt;"> </span>and we do not know when, or if,<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>generate<span style="letter-spacing:0.1pt;"> </span>any revenue.<span style="letter-spacing:0.05pt;"> </span>We do not expect<span style="letter-spacing:0.05pt;"> </span>to generate<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>revenue<span style="letter-spacing:0.05pt;"> </span>unless<span style="letter-spacing:0.05pt;"> </span>and until<span style="letter-spacing:0.05pt;"> </span>we obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>and begin<span style="letter-spacing:0.05pt;"> </span>to sell,<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811, PRT1419, PRT2527, or<span style="letter-spacing:0.05pt;"> </span>another<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate.<span style="letter-spacing:0.15pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>generate<span style="letter-spacing:0.15pt;"> </span>revenue<span style="letter-spacing:0.1pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>on a number<span style="letter-spacing:0.05pt;"> </span>of factors, including,<span style="letter-spacing:0.05pt;"> </span>but not limited<span style="letter-spacing:0.1pt;"> </span>to, our ability<span style="letter-spacing:0.1pt;"> </span>to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">complete<span style="letter-spacing:0.1pt;"> </span>successful<span style="letter-spacing:0.1pt;"> </span>Phase 1 portions<span style="letter-spacing:0.05pt;"> </span>of PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811<span style="letter-spacing:-0.05pt;">, </span>PRT1419 and PRT2527<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.73%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate<span style="letter-spacing:0.5pt;"> </span>and<span style="letter-spacing:0.4pt;"> </span>successfully<span style="letter-spacing:0.5pt;"> </span>complete<span style="letter-spacing:0.5pt;"> </span>all<span style="letter-spacing:0.45pt;"> </span>safety,<span style="letter-spacing:0.45pt;"> </span>pharmacokinetic<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.4pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>studies<span style="letter-spacing:0.45pt;"> </span>required<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>obtain<span style="letter-spacing:0.45pt;"> </span>U.S. and foreign marketing approval for PRT543 as a treatment for patients with hematological malignancies<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>advanced<span style="letter-spacing:0.1pt;"> </span>solid<span style="letter-spacing:0.1pt;"> </span>tumors,<span style="letter-spacing:0.1pt;"> </span>PRT811 as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>glioblastoma<span style="letter-spacing:0.2pt;"> </span>and advanced<span style="letter-spacing:0.1pt;"> </span>solid<span style="letter-spacing:0.1pt;"> </span>tumors,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>PRT1419 as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>with certain<span style="letter-spacing:0.1pt;"> solid tumors and </span>hematological malignancies&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate<span style="letter-spacing:0.1pt;"> </span>and complete<span style="letter-spacing:0.1pt;"> </span>successful<span style="letter-spacing:0.1pt;"> </span>later-stage<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>meet<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>endpoints&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain favorable results from our<span style="letter-spacing:2.45pt;"> </span>clinical trials and<span style="letter-spacing:2.45pt;"> </span>apply for and<span style="letter-spacing:2.4pt;"> </span>obtain<span style="letter-spacing:2.45pt;"> </span>marketing approval<span style="letter-spacing:2.45pt;"> </span>for PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811<span style="letter-spacing:-0.05pt;">,</span> PRT1419, and PRT2527&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish<span style="letter-spacing:0.1pt;"> </span>licenses,<span style="letter-spacing:0.1pt;"> </span>collaborations,<span style="letter-spacing:0.15pt;"> </span>or strategic<span style="letter-spacing:0.1pt;"> </span>partnerships<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our programs&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successfully<span style="letter-spacing:0.8pt;"> </span>manufacture<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.7pt;"> </span>contract<span style="letter-spacing:0.8pt;"> </span>with<span style="letter-spacing:0.7pt;"> </span>others<span style="letter-spacing:0.75pt;"> </span>to<span style="letter-spacing:0.7pt;"> </span>manufacture<span style="letter-spacing:0.8pt;"> </span>PRT543,<span style="letter-spacing:0.65pt;"> </span>PRT811,<span style="letter-spacing:0.65pt;"> </span>PRT1419, PRT2527,<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>our other<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">commercialize<span style="letter-spacing:2pt;"> </span>PRT543,<span style="letter-spacing:1.75pt;"> </span>PRT811,<span style="letter-spacing:1.75pt;"> </span>PRT1419, PRT2527<span style="letter-spacing:1.75pt;"> </span>if<span style="letter-spacing:1.85pt;"> </span>approved,<span style="letter-spacing:1.85pt;"> </span>respectively,<span style="letter-spacing:1.95pt;"> </span>by<span style="letter-spacing:1.8pt;"> </span>building<span style="letter-spacing:1.8pt;"> </span>a<span style="letter-spacing:1.75pt;"> </span>sales<span style="letter-spacing:1.8pt;"> </span>force<span style="letter-spacing:1.8pt;"> </span>or entering<span style="letter-spacing:0.1pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>collaborations<span style="letter-spacing:0.15pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submit<span style="letter-spacing:1.3pt;"> </span>INDs<span style="letter-spacing:1.25pt;"> </span>for a<span style="letter-spacing:0.05pt;"> </span>kinase<span style="letter-spacing:0.1pt;"> </span>inhibitor and<span style="letter-spacing:1.3pt;"> </span>SMARCA2<span style="letter-spacing:1.1pt;"> </span>protein<span style="letter-spacing:1.25pt;"> </span>degrader<span style="letter-spacing:1.25pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>are<span style="letter-spacing:1.25pt;"> </span>made<span style="letter-spacing:1.25pt;"> </span>effective<span style="letter-spacing:1.3pt;"> </span>by<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>U.S. Food and Drug Administration,<span style="letter-spacing:0.15pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>FDA&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain,<span style="letter-spacing:0.05pt;"> </span>maintain,<span style="letter-spacing:0.1pt;"> </span>protect<span style="letter-spacing:0.1pt;"> </span>and defend<span style="letter-spacing:0.05pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>portfolio&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">achieve<span style="letter-spacing:0.3pt;"> </span>market<span style="letter-spacing:0.35pt;"> </span>acceptance<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>PRT543,<span style="letter-spacing:0.2pt;"> </span>PRT811,<span style="letter-spacing:0.2pt;"> </span>PRT1419, PRT2527<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:0.25pt;"> </span>other<span style="letter-spacing:0.25pt;"> </span>successful<span style="letter-spacing:0.3pt;"> </span>product<span style="letter-spacing:0.25pt;"> </span>candidates with the<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:0.1pt;"> </span>community<span style="letter-spacing:0.1pt;"> </span>and with third-party<span style="letter-spacing:0.15pt;"> </span>payors.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in designing, developing, and eventually commercializing<span style="letter-spacing:1.25pt;"> </span>products<span style="letter-spacing:1.1pt;"> </span>that<span style="letter-spacing:1.1pt;"> </span>generate<span style="letter-spacing:1.15pt;"> </span>significant<span style="letter-spacing:1.2pt;"> </span>revenue.<span style="letter-spacing:1.1pt;"> </span>This<span style="letter-spacing:1.05pt;"> </span>will<span style="letter-spacing:1.1pt;"> </span>require<span style="letter-spacing:1.15pt;"> </span>us<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>be<span style="letter-spacing:1pt;"> </span>successful<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1pt;"> </span>a<span style="letter-spacing:1pt;"> </span>range<span style="letter-spacing:1.05pt;"> </span>of challenging<span style="letter-spacing:0.15pt;"> </span>activities,<span style="letter-spacing:0.2pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>completing<span style="letter-spacing:0.15pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preclinical</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates, designing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establishing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangements</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with third parties</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the manufacture</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of clinical</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplies</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtaining</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and manufacturing,</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">selling</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which we may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">only in the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preliminary</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stages</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">most</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities.</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">succeed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, even if</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we do, may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generate</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enough to achieve</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profitability.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:1.25pt;"> </span>cases<span style="letter-spacing:1.3pt;"> </span>where<span style="letter-spacing:1.25pt;"> </span>we<span style="letter-spacing:1.25pt;"> </span>are<span style="letter-spacing:1.3pt;"> </span>successful<span style="letter-spacing:1.35pt;"> </span>in<span style="letter-spacing:1.25pt;"> </span>obtaining<span style="letter-spacing:1.3pt;"> </span>regulatory<span style="letter-spacing:1.35pt;"> </span>approval<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>market<span style="letter-spacing:1.35pt;"> </span>one<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>more<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>product candidates,<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:0.9pt;"> </span>revenue<span style="letter-spacing:0.95pt;"> </span>will<span style="letter-spacing:0.95pt;"> </span>be<span style="letter-spacing:0.9pt;"> </span>dependent,<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.9pt;"> </span>part,<span style="letter-spacing:0.95pt;"> </span>upon<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>size<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>markets<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>territories<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:0.9pt;"> </span>which<span style="letter-spacing:0.85pt;"> </span>we gain<span style="letter-spacing:1pt;"> </span>regulatory<span style="letter-spacing:1.05pt;"> </span>approval,<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>accepted<span style="letter-spacing:1pt;"> </span>price<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>product,<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>ability<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.95pt;"> </span>obtain<span style="letter-spacing:0.95pt;"> </span>coverage<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>reimbursement, and<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>territory.<span style="letter-spacing:0.2pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>addressable<span style="letter-spacing:0.15pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>not as significant<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>estimate,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>indication<span style="letter-spacing:0.15pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>authorities<span style="letter-spacing:0.2pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>narrower<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect,<span style="letter-spacing:0.1pt;"> </span>or the treatment<span style="letter-spacing:0.2pt;"> </span>population<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>narrowed<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>competition,<span style="letter-spacing:0.15pt;"> </span>physician<span style="letter-spacing:0.05pt;"> </span>choice<span style="letter-spacing:0.05pt;"> </span>or treatment<span style="letter-spacing:0.15pt;"> </span>guidelines,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not generate significant<span style="letter-spacing:0.15pt;"> </span>revenue<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>of such products,<span style="letter-spacing:0.05pt;"> </span>even if<span style="letter-spacing:0.05pt;"> </span>approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:1pt;"> </span>numerous<span style="letter-spacing:1pt;"> </span>risks<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>uncertainties<span style="letter-spacing:1.1pt;"> </span>associated<span style="letter-spacing:1pt;"> </span>with<span style="letter-spacing:0.9pt;"> </span>pharmaceutical<span style="letter-spacing:1.05pt;"> </span>product<span style="letter-spacing:0.95pt;"> </span>development,<span style="letter-spacing:1pt;"> </span>we are<span style="letter-spacing:0.1pt;"> </span>unable<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>accurately<span style="letter-spacing:0.15pt;"> </span>predict<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>timing<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>amount<span style="letter-spacing:0.05pt;"> </span>of increased<span style="letter-spacing:0.1pt;"> </span>expenses<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.05pt;"> </span>or when, or if,<span style="letter-spacing:0.05pt;"> </span>we will be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>achieve<span style="letter-spacing:0.1pt;"> </span>profitability.<span style="letter-spacing:0.2pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>decide<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>authorities<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>other jurisdictions<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>perform<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.1pt;"> </span>or clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>in addition<span style="letter-spacing:0.05pt;"> </span>to those<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:0.1pt;"> </span>expected,<span style="letter-spacing:0.05pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>there<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>any delays in<span style="letter-spacing:0.05pt;"> </span>establishing<span style="letter-spacing:0.15pt;"> </span>appropriate<span style="letter-spacing:0.15pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>arrangements<span style="letter-spacing:0.2pt;"> </span>for,<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>initiating<span style="letter-spacing:0.15pt;"> </span>or completing<span style="letter-spacing:0.1pt;"> </span>our current<span style="letter-spacing:0.1pt;"> </span>and planned clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>or in the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>of, any of our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>our expenses<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>materially and profitability<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be further<span style="letter-spacing:0.1pt;"> </span>delayed.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>achieve<span style="letter-spacing:0.1pt;"> </span>profitability,<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>sustain<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>profitability<span style="letter-spacing:0.2pt;"> </span>on a quarterly<span style="letter-spacing:0.1pt;"> </span>or annual<span style="letter-spacing:0.1pt;"> </span>basis.<span style="letter-spacing:0.1pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.1pt;"> </span>and remain<span style="letter-spacing:0.1pt;"> </span>profitable<span style="letter-spacing:0.1pt;"> </span>would depress<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our company<span style="letter-spacing:0.05pt;"> </span>and could impair<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>raise<span style="letter-spacing:0.05pt;"> </span>capital,<span style="letter-spacing:0.1pt;"> </span>expand our business,<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:0.1pt;"> </span>our research<span style="letter-spacing:0.1pt;"> </span>and development<span style="letter-spacing:0.1pt;"> </span>efforts,<span style="letter-spacing:0.1pt;"> </span>diversify our<span style="letter-spacing:0.85pt;"> </span>product<span style="letter-spacing:0.9pt;"> </span>offerings<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>even<span style="letter-spacing:0.8pt;"> </span>continue<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>operations.<span style="letter-spacing:0.9pt;"> </span>A<span style="letter-spacing:0.8pt;"> </span>decline<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>value<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>company<span style="letter-spacing:0.85pt;"> </span>could<span style="letter-spacing:0.85pt;"> </span>also<span style="letter-spacing:0.85pt;"> </span>cause you to lose<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>or part<span style="letter-spacing:0.05pt;"> </span>of your investment.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.05pt;"> </span>funding to pursue our business objectives.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are unable to raise<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.05pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>needed or on terms<span style="letter-spacing:0.05pt;"> </span>acceptable<span style="letter-spacing:0.1pt;"> </span>to us, we could be forced to delay,<span style="letter-spacing:0.05pt;"> </span>reduce<span style="letter-spacing:0.05pt;"> </span>or eliminate<span style="letter-spacing:0.1pt;"> </span>our research<span style="letter-spacing:0.05pt;"> </span>or drug development<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.05pt;"> </span>any future<span style="letter-spacing:0.05pt;"> </span>commercialization efforts<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.8pt;"> </span>expect<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>expenses<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>increase<span style="letter-spacing:0.9pt;"> </span>substantially<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>connection<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>ongoing<span style="letter-spacing:0.75pt;"> </span>activities,<span style="letter-spacing:0.9pt;"> </span>particularly<span style="letter-spacing:0.9pt;"> </span>as we<span style="letter-spacing:0.1pt;"> </span>advance<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates,<span style="letter-spacing:0.2pt;"> </span>PRT543,<span style="letter-spacing:0.05pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>pipeline<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates through<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>and seek<span style="letter-spacing:0.05pt;"> </span>to design<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>our discovery<span style="letter-spacing:0.05pt;"> </span>programs.<span style="letter-spacing:0.1pt;"> </span>We expect<span style="letter-spacing:1.25pt;"> </span>increased<span style="letter-spacing:1.3pt;"> </span>expenses<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>continue<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>research<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>development, expand operations and build our new facility,<span style="letter-spacing:1.25pt;"> </span>initiate<span style="letter-spacing:1.25pt;"> </span>additional<span style="letter-spacing:1.25pt;"> </span>clinical<span style="letter-spacing:1.25pt;"> </span>trials,<span style="letter-spacing:1.25pt;"> </span>and seek<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>lead<span style="letter-spacing:0.1pt;"> </span>programs<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we obtain marketing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any of our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>we expect<span style="letter-spacing:0.05pt;"> </span>to incur<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>commercialization<span style="letter-spacing:0.15pt;"> </span>expenses related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>manufacturing,<span style="letter-spacing:0.2pt;"> </span>marketing,<span style="letter-spacing:0.15pt;"> </span>sales<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>distribution.<span style="letter-spacing:0.2pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>we expect<span style="letter-spacing:0.05pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>to incur additional<span style="letter-spacing:0.15pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>as a public<span style="letter-spacing:0.05pt;"> </span>company.<span style="letter-spacing:0.05pt;"> </span>Accordingly,<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>need to obtain<span style="letter-spacing:0.05pt;"> </span>substantial additional<span style="letter-spacing:0.15pt;"> </span>funding<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>connection<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>continuing<span style="letter-spacing:0.1pt;"> </span>operations.<span style="letter-spacing:0.15pt;"> </span>Adequate<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>financing<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be available<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>us on favorable<span style="letter-spacing:0.1pt;"> </span>terms,<span style="letter-spacing:0.1pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all.<span style="letter-spacing:0.05pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>seek<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>due to favorable<span style="letter-spacing:0.1pt;"> </span>market conditions<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strategic<span style="letter-spacing:0.15pt;"> </span>considerations<span style="letter-spacing:0.2pt;"> </span>even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.2pt;"> </span>funds<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.1pt;"> </span>or future operating<span style="letter-spacing:0.15pt;"> </span>plans.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>unable<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>raise<span style="letter-spacing:0.1pt;"> </span>capital<span style="letter-spacing:0.15pt;"> </span>when<span style="letter-spacing:0.05pt;"> </span>needed<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>favorable<span style="letter-spacing:0.15pt;"> </span>terms,<span style="letter-spacing:0.15pt;"> </span>we could<span style="letter-spacing:0.05pt;"> </span>be forced<span style="letter-spacing:0.05pt;"> </span>to delay, reduce<span style="letter-spacing:0.05pt;"> </span>or eliminate<span style="letter-spacing:0.15pt;"> </span>our research<span style="letter-spacing:0.1pt;"> </span>and development<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.1pt;"> </span>our commercialization<span style="letter-spacing:0.2pt;"> </span>plans<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:1.15pt;"> </span>believe<span style="letter-spacing:1.2pt;"> </span>that<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>existing<span style="letter-spacing:1.2pt;"> </span>cash<span style="letter-spacing:1.15pt;">,</span><span style="letter-spacing:1.1pt;"> </span>cash<span style="letter-spacing:1.15pt;"> </span>equivalents, and marketable securities will<span style="letter-spacing:0.1pt;"> </span>enable<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>fund<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>expenses,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.15pt;"> </span>expenditure<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span><span style="color:#000000;">into the second half of 2024</span>. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Changes beyond our control may occur that would cause us to use our available capital before that time, including changes in and progress of our drug development activities and changes in regulation. Our future<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>depend on many<span style="letter-spacing:0.05pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:1.15pt;"> </span>progress,<span style="letter-spacing:1.15pt;"> </span>timing<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>results<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>preclinical<span style="letter-spacing:1.25pt;"> </span>studies<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trials<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>current<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>any<span style="letter-spacing:1.1pt;"> </span>future product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>extent<span style="letter-spacing:0.05pt;"> </span>to which we develop,<span style="letter-spacing:0.05pt;"> </span>in-license<span style="letter-spacing:0.1pt;"> </span>or acquire<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>pipeline<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or technologies&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.75pt;"> </span>number<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>development<span style="letter-spacing:0.8pt;"> </span>requirements<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>other<span style="letter-spacing:0.75pt;"> </span>product<span style="letter-spacing:0.75pt;"> </span>candidates<span style="letter-spacing:0.8pt;"> </span>that<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>may<span style="letter-spacing:0.7pt;"> </span>pursue,<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>other indications<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our current<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>pursue&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:2.35pt;"> </span>costs,<span style="letter-spacing:2.35pt;"> </span>timing<span style="letter-spacing:2.4pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>outcome<span style="letter-spacing:2.3pt;"> </span>of<span style="letter-spacing:2.25pt;"> </span>obtaining<span style="letter-spacing:2.3pt;"> </span>regulatory<span style="letter-spacing:2.35pt;"> </span>approvals<span style="letter-spacing:2.3pt;"> </span>of<span style="letter-spacing:2.25pt;"> </span>our<span style="letter-spacing:2.25pt;"> </span>current<span style="letter-spacing:2.35pt;"> </span>or<span style="letter-spacing:2.25pt;"> </span>future<span style="letter-spacing:2.3pt;"> </span>product candidates<span style="letter-spacing:0.1pt;"> </span>and any companion<span style="letter-spacing:0.05pt;"> </span>diagnostics<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>pursue&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing<span style="letter-spacing:0.2pt;"> </span>capabilities,<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>both<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>supplies<span style="letter-spacing:0.1pt;"> </span>of our current<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs involved in growing our organization to the size needed to allow for the research, development<span style="letter-spacing:0.1pt;"> </span>and potential<span style="letter-spacing:0.1pt;"> </span>commercialization<span style="letter-spacing:0.2pt;"> </span>of our current<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:2.4pt;"> </span>cost<span style="letter-spacing:2.4pt;"> </span>associated<span style="letter-spacing:2.45pt;"> </span>with<span style="letter-spacing:2.35pt;"> </span>commercializing any<span style="letter-spacing:2.35pt;"> </span>approved<span style="letter-spacing:2.4pt;"> </span>product<span style="letter-spacing:2.35pt;"> </span>candidates,<span style="letter-spacing:2.4pt;"> </span>including<span style="letter-spacing:2.35pt;"> </span>establishing sales,<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>and distribution<span style="letter-spacing:0.15pt;"> </span>capabilities&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.75pt;"> </span>cost<span style="letter-spacing:0.75pt;"> </span>associated<span style="letter-spacing:0.8pt;"> </span>with<span style="letter-spacing:0.7pt;"> </span>completing<span style="letter-spacing:0.8pt;"> </span>any<span style="letter-spacing:0.65pt;"> </span>post-marketing<span style="letter-spacing:0.8pt;"> </span>studies<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>trials<span style="letter-spacing:0.75pt;"> </span>required<span style="letter-spacing:0.75pt;"> </span>by<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>FDA<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>other regulatory<span style="letter-spacing:0.1pt;"> </span>authorities&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.1pt;"> </span>revenue,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>any,<span style="letter-spacing:0.05pt;"> </span>received<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>sales<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811, PRT1419, or<span style="letter-spacing:0.05pt;"> </span>PRT2527<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any are<span style="letter-spacing:0.05pt;"> </span>approved,<span style="letter-spacing:0.05pt;"> </span>or our other<span style="letter-spacing:0.05pt;"> </span>pipeline<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>and defending<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property-related<span style="letter-spacing:0.2pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>become subject<span style="letter-spacing:0.05pt;"> </span>to, including<span style="letter-spacing:0.05pt;"> </span>any litigation<span style="letter-spacing:0.15pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>outcome<span style="letter-spacing:0.05pt;"> </span>of such litigation&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs associated with potential product liability claims, including the costs associated with obtaining<span style="letter-spacing:0.05pt;"> </span>insurance<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>such claims<span style="letter-spacing:0.1pt;"> </span>and with defending<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>such claims&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to<span style="letter-spacing:1.4pt;"> </span>the<span style="letter-spacing:1.45pt;"> </span>extent<span style="letter-spacing:1.45pt;"> </span>we<span style="letter-spacing:1.35pt;"> </span>pursue<span style="letter-spacing:1.4pt;"> </span>strategic<span style="letter-spacing:1.45pt;"> </span>collaborations,<span style="letter-spacing:1.5pt;"> </span>including<span style="letter-spacing:1.4pt;"> </span>collaborations<span style="letter-spacing:1.5pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>commercialize<span style="letter-spacing:1.55pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or<span style="letter-spacing:0.05pt;"> </span>any of our other<span style="letter-spacing:0.05pt;"> </span>pipeline<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to establish and<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:0.15pt;"> </span>collaborations<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>favorable<span style="letter-spacing:0.15pt;"> </span>terms,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all,<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>timing<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>amount<span style="letter-spacing:0.1pt;"> </span>of any milestone<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>royalty<span style="letter-spacing:0.1pt;"> </span>payments<span style="letter-spacing:0.1pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to make<span style="letter-spacing:0.05pt;"> </span>or are<span style="letter-spacing:0.05pt;"> </span>eligible<span style="letter-spacing:0.1pt;"> </span>to receive<span style="letter-spacing:0.1pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>such collaborations,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.93%;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>to complete<span style="letter-spacing:0.1pt;"> </span>our planned clinical development<span style="letter-spacing:0.15pt;"> </span>programs<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>approval.<span style="letter-spacing:0.05pt;"> </span>Our ability<span style="letter-spacing:0.1pt;"> </span>to raise additional<span style="letter-spacing:0.15pt;"> </span>funds<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>depend on financial,<span style="letter-spacing:0.1pt;"> </span>economic<span style="letter-spacing:0.05pt;"> </span>and market<span style="letter-spacing:0.1pt;"> </span>conditions<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>which we may have<span style="letter-spacing:0.75pt;"> </span>no<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>limited<span style="letter-spacing:0.8pt;"> </span>control.<span style="letter-spacing:0.75pt;"> </span>If<span style="letter-spacing:0.75pt;"> </span>adequate<span style="letter-spacing:0.75pt;"> </span>funds<span style="letter-spacing:0.75pt;"> </span>are<span style="letter-spacing:0.75pt;"> </span>not<span style="letter-spacing:0.7pt;"> </span>available<span style="letter-spacing:0.8pt;"> </span>on<span style="letter-spacing:0.7pt;"> </span>commercially<span style="letter-spacing:0.85pt;"> </span>acceptable<span style="letter-spacing:0.8pt;"> </span>terms<span style="letter-spacing:0.8pt;"> </span>when<span style="letter-spacing:0.7pt;"> </span>needed, we<span style="letter-spacing:1.75pt;"> </span>may<span style="letter-spacing:1.8pt;"> </span>be<span style="letter-spacing:1.75pt;"> </span>forced<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:1.75pt;"> </span>delay,<span style="letter-spacing:1.8pt;"> </span>reduce<span style="letter-spacing:1.8pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>terminate<span style="letter-spacing:1.9pt;"> </span>the<span style="letter-spacing:1.75pt;"> </span>development<span style="letter-spacing:1.8pt;"> </span>or<span style="letter-spacing:1.7pt;"> </span>commercialization<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.7pt;"> </span>all<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.7pt;"> </span>part<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:1.7pt;"> </span>our research<span style="letter-spacing:0.15pt;"> </span>programs<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or we may<span style="letter-spacing:0.05pt;"> </span>be unable<span style="letter-spacing:0.05pt;"> </span>to take<span style="letter-spacing:0.05pt;"> </span>advantage<span style="letter-spacing:0.05pt;"> </span>of future<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>opportunities. Furthermore,<span style="letter-spacing:0.1pt;"> </span>any additional<span style="letter-spacing:0.1pt;"> </span>capital-raising<span style="letter-spacing:0.2pt;"> </span>efforts<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>divert<span style="letter-spacing:0.05pt;"> </span>our management<span style="letter-spacing:0.05pt;"> </span>from their day-to-day<span style="letter-spacing:0.05pt;"> </span>activities, which<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.6pt;"> </span>adversely<span style="letter-spacing:0.65pt;"> </span>affect<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>ability<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.55pt;"> </span>develop<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>commercialize<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.5pt;"> </span>current<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.5pt;"> </span>future<span style="letter-spacing:0.55pt;"> </span>product<span style="letter-spacing:0.55pt;"> </span>candidates, if<span style="letter-spacing:0.05pt;"> </span>approved.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>cause dilution<span style="letter-spacing:0.05pt;"> </span>to our stockholders,<span style="letter-spacing:0.05pt;"> </span>restrict<span style="letter-spacing:0.1pt;"> </span>our operations<span style="letter-spacing:0.05pt;"> </span>or require<span style="letter-spacing:0.05pt;"> </span>us to relinquish<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to our technologies<span style="letter-spacing:0.1pt;"> </span>or product candidates.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>time,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>ever,<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>we can generate<span style="letter-spacing:0.1pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>revenue,<span style="letter-spacing:0.05pt;"> </span>we expect<span style="letter-spacing:0.05pt;"> </span>to finance<span style="letter-spacing:0.05pt;"> </span>our cash<span style="letter-spacing:0.05pt;"> </span>needs through<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>combination<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>equity<span style="letter-spacing:0.1pt;"> </span>offerings,<span style="letter-spacing:0.15pt;"> </span>debt<span style="letter-spacing:0.05pt;"> </span>financings,<span style="letter-spacing:0.1pt;"> </span>collaborations,<span style="letter-spacing:0.15pt;"> </span>strategic<span style="letter-spacing:0.1pt;"> </span>alliances<span style="letter-spacing:0.1pt;"> </span>and marketing, distribution<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>licensing<span style="letter-spacing:0.15pt;"> </span>arrangements.<span style="letter-spacing:0.2pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>due to favorable<span style="letter-spacing:0.1pt;"> </span>market conditions<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strategic<span style="letter-spacing:0.15pt;"> </span>considerations,<span style="letter-spacing:0.2pt;"> </span>even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.2pt;"> </span>funds<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our current<span style="letter-spacing:0.1pt;"> </span>or future operating<span style="letter-spacing:0.15pt;"> </span>plans.<span style="letter-spacing:0.1pt;"> </span>To<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>extent<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>raise<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>capital<span style="letter-spacing:0.15pt;"> </span>through<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>of equity<span style="letter-spacing:0.05pt;"> </span>or convertible<span style="letter-spacing:0.1pt;"> </span>debt securities,<span style="letter-spacing:0.2pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>ownership<span style="letter-spacing:0.1pt;"> </span>interest<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be diluted,<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>terms<span style="letter-spacing:0.1pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>securities<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>liquidation<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.1pt;"> </span>preferences<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>adversely<span style="letter-spacing:0.15pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stockholder.<span style="letter-spacing:0.15pt;"> </span>Debt financing<span style="letter-spacing:0.1pt;"> </span>and preferred<span style="letter-spacing:0.1pt;"> </span>equity financing,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>available,<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>covenants<span style="letter-spacing:0.05pt;"> </span>limiting<span style="letter-spacing:0.1pt;"> </span>or restricting<span style="letter-spacing:0.15pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to take specific<span style="letter-spacing:0.15pt;"> </span>actions,<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>incurring<span style="letter-spacing:0.15pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>debt,<span style="letter-spacing:0.05pt;"> </span>making<span style="letter-spacing:0.05pt;"> </span>acquisitions<span style="letter-spacing:0.1pt;"> </span>or capital<span style="letter-spacing:0.1pt;"> </span>expenditures<span style="letter-spacing:0.1pt;"> </span>or declaring dividends.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we raise<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>funds<span style="letter-spacing:0.05pt;"> </span>through<span style="letter-spacing:0.05pt;"> </span>collaborations,<span style="letter-spacing:0.15pt;"> </span>strategic<span style="letter-spacing:0.1pt;"> </span>alliances<span style="letter-spacing:0.1pt;"> </span>or marketing,<span style="letter-spacing:0.1pt;"> </span>distribution<span style="letter-spacing:0.15pt;"> </span>or licensing arrangements<span style="letter-spacing:1.25pt;"> </span>with<span style="letter-spacing:1.1pt;"> </span>third<span style="letter-spacing:1.15pt;"> </span>parties,<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>may<span style="letter-spacing:1.15pt;"> </span>have<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>relinquish<span style="letter-spacing:1.15pt;"> </span>valuable<span style="letter-spacing:1.1pt;"> </span>rights<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:1.05pt;"> </span>technologies,<span style="letter-spacing:1.15pt;"> </span>future<span style="letter-spacing:1.1pt;"> </span>revenue streams,<span style="letter-spacing:0.9pt;"> </span>research<span style="letter-spacing:0.9pt;"> </span>programs<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>candidates<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>grant<span style="letter-spacing:0.85pt;"> </span>licenses<span style="letter-spacing:0.9pt;"> </span>on<span style="letter-spacing:0.8pt;"> </span>terms<span style="letter-spacing:0.9pt;"> </span>that<span style="letter-spacing:0.8pt;"> </span>may<span style="letter-spacing:0.8pt;"> </span>not<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.75pt;"> </span>favorable<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>us.<span style="letter-spacing:0.75pt;"> </span>If we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>unable<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>raise<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>funds<span style="letter-spacing:0.1pt;"> </span>through<span style="letter-spacing:0.1pt;"> </span>equity<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>debt<span style="letter-spacing:0.1pt;"> </span>financings<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>when needed,<span style="letter-spacing:0.05pt;"> </span>we may be required to delay, limit, reduce or terminate our research, product development or future commercialization<span style="letter-spacing:0.45pt;"> </span>efforts<span style="letter-spacing:0.35pt;"> </span>or<span style="letter-spacing:0.25pt;"> </span>grant<span style="letter-spacing:0.3pt;"> </span>rights<span style="letter-spacing:0.3pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>third<span style="letter-spacing:0.25pt;"> </span>parties<span style="letter-spacing:0.3pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>develop<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.2pt;"> </span>market<span style="letter-spacing:0.3pt;"> </span>product<span style="letter-spacing:0.25pt;"> </span>candidates<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:0.25pt;"> </span>we<span style="letter-spacing:0.2pt;"> </span>would otherwise<span style="letter-spacing:0.05pt;"> </span>prefer<span style="letter-spacing:0.1pt;"> </span>to develop<span style="letter-spacing:0.05pt;"> </span>and market<span style="letter-spacing:0.1pt;"> </span>ourselves.</p>
<p style="margin-top:0pt;line-height:7pt;margin-bottom:0pt;margin-left:3.7%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:-3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Design and Development of our Product Candidates</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:3.7%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are highly<span style="letter-spacing:0.05pt;"> </span>dependent<span style="letter-spacing:0.05pt;"> </span>on the success<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811<span style="letter-spacing:-0.05pt;">,</span> PRT1419 and PRT2527, which are in early<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>development.<span style="letter-spacing:0.1pt;"> </span>We have not completed<span style="letter-spacing:0.1pt;"> </span>successful<span style="letter-spacing:0.1pt;"> </span>late-stage<span style="letter-spacing:0.1pt;"> </span>pivotal<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or obtained<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any product candidate.<span style="letter-spacing:0.05pt;"> </span>We may<span style="letter-spacing:0.05pt;"> </span>never<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>or achieve<span style="letter-spacing:0.05pt;"> </span>or sustain profitability.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:3.7%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>dependent<span style="letter-spacing:0.05pt;"> </span>on our ability<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>and then<span style="letter-spacing:0.05pt;"> </span>successfully commercialize,<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates,<span style="letter-spacing:0.2pt;"> </span>PRT543,<span style="letter-spacing:0.05pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527. We<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>early<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>efforts and<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>lead<span style="letter-spacing:0.85pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>candidates,<span style="letter-spacing:0.9pt;"> </span>PRT543,<span style="letter-spacing:0.75pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527,<span style="letter-spacing:0.75pt;"> </span>are<span style="letter-spacing:0.85pt;"> </span>each<span style="letter-spacing:0.85pt;"> </span>currently<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.8pt;"> </span>Phase<span style="letter-spacing:0.8pt;"> </span>1<span style="letter-spacing:0.8pt;"> </span>clinical<span style="letter-spacing:0.9pt;"> </span>trial. Our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates are<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>earlier<span style="letter-spacing:0.15pt;"> </span>stages<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>development.<span style="letter-spacing:0.15pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>no products<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>sale<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>jurisdiction.<span style="letter-spacing:0.2pt;"> </span>There<span style="letter-spacing:0.1pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or our other<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in development<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>achieve<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>in their<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or obtain<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>approval.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>generate<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>revenues,<span style="letter-spacing:0.05pt;"> </span>which we do not expect<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>occur<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>years,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>ever,<span style="letter-spacing:0.05pt;"> </span>will depend<span style="letter-spacing:0.1pt;"> </span>heavily<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>successful<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>eventual<span style="letter-spacing:0.1pt;"> </span>commercialization<span style="letter-spacing:0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>development.<span style="letter-spacing:0.15pt;"> </span>The success<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811,<span style="letter-spacing:-0.05pt;"> </span>PRT1419<span style="letter-spacing:-0.05pt;"> </span>and PRT2527,<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>depend on several<span style="letter-spacing:0.1pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>following:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successful<span style="letter-spacing:0.1pt;"> </span>completion<span style="letter-spacing:0.1pt;"> </span>of preclinical<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acceptance<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:1.75pt;"> </span>INDs<span style="letter-spacing:1.75pt;"> </span>by<span style="letter-spacing:1.75pt;"> </span>the<span style="letter-spacing:1.8pt;"> </span>FDA<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>other<span style="letter-spacing:1.75pt;"> </span>similar<span style="letter-spacing:1.8pt;"> </span>clinical<span style="letter-spacing:1.8pt;"> </span>trial<span style="letter-spacing:1.8pt;"> </span>applications<span style="letter-spacing:1.8pt;"> </span>from<span style="letter-spacing:1.75pt;"> </span>foreign<span style="letter-spacing:1.75pt;"> </span>regulatory authorities<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our future<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our pipeline<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">timely<span style="letter-spacing:0.1pt;"> </span>and successful<span style="letter-spacing:0.1pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>of patients<span style="letter-spacing:0.1pt;"> </span>in, and completion<span style="letter-spacing:0.1pt;"> </span>of, clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>with favorable<span style="letter-spacing:0.1pt;"> </span>results&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">demonstration<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>safety,<span style="letter-spacing:0.9pt;"> </span>efficacy<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>acceptable<span style="letter-spacing:0.95pt;"> </span>risk-benefit<span style="letter-spacing:1pt;"> </span>profiles<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>candidates<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>the satisfaction<span style="letter-spacing:0.15pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and foreign<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>agencies&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<span style="letter-spacing:1.6pt;"> </span>ability,<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.6pt;"> </span>that<span style="letter-spacing:1.65pt;"> </span>of<span style="letter-spacing:1.6pt;"> </span>our<span style="letter-spacing:1.6pt;"> </span>collaborators,<span style="letter-spacing:1.75pt;"> </span>to<span style="letter-spacing:1.6pt;"> </span>develop<span style="letter-spacing:1.65pt;"> </span>and<span style="letter-spacing:1.6pt;"> </span>obtain<span style="letter-spacing:1.65pt;"> </span>clearance<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.6pt;"> </span>approval<span style="letter-spacing:1.65pt;"> </span>of<span style="letter-spacing:1.55pt;"> </span>companion diagnostics,<span style="letter-spacing:0.1pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>basis,<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">receipt<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>related<span style="letter-spacing:0.95pt;"> </span>terms<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>marketing<span style="letter-spacing:0.9pt;"> </span>approvals<span style="letter-spacing:0.85pt;"> </span>from<span style="letter-spacing:0.85pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>regulatory<span style="letter-spacing:0.9pt;"> </span>authorities,<span style="letter-spacing:0.95pt;"> </span>including<span style="letter-spacing:0.85pt;"> </span>the completion<span style="letter-spacing:0.1pt;"> </span>of any required<span style="letter-spacing:0.1pt;"> </span>post-marketing<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">raising<span style="letter-spacing:0.6pt;"> </span>additional<span style="letter-spacing:0.6pt;"> </span>funds<span style="letter-spacing:0.55pt;"> </span>necessary<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>complete<span style="letter-spacing:0.6pt;"> </span>clinical<span style="letter-spacing:0.6pt;"> </span>development<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>commercialize<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:0.45pt;"> </span>product candidates&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>maintaining<span style="letter-spacing:0.55pt;"> </span>patent,<span style="letter-spacing:0.5pt;"> </span>trade<span style="letter-spacing:0.5pt;"> </span>secret<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>other<span style="letter-spacing:0.5pt;"> </span>intellectual<span style="letter-spacing:0.6pt;"> </span>property<span style="letter-spacing:0.5pt;"> </span>protection<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>regulatory exclusivity<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">making<span style="letter-spacing:1.65pt;"> </span>arrangements<span style="letter-spacing:1.75pt;"> </span>with<span style="letter-spacing:1.6pt;"> </span>third-party<span style="letter-spacing:1.75pt;"> </span>manufacturers,<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.6pt;"> </span>establishing<span style="letter-spacing:1.7pt;"> </span>manufacturing<span style="letter-spacing:1.7pt;"> </span>capabilities,<span style="letter-spacing:1.7pt;"> </span>for both clinical<span style="letter-spacing:0.1pt;"> </span>and commercial<span style="letter-spacing:0.15pt;"> </span>supplies<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developing<span style="letter-spacing:0.05pt;"> </span>and implementing<span style="letter-spacing:0.15pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>and reimbursement<span style="letter-spacing:0.15pt;"> </span>strategies&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>and when approved,<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:0.05pt;"> </span>alone<span style="letter-spacing:0.05pt;"> </span>or in collaboration<span style="letter-spacing:0.15pt;"> </span>with others&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acceptance<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.4pt;"> </span>products,<span style="letter-spacing:0.45pt;"> </span>if<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.4pt;"> </span>when<span style="letter-spacing:0.4pt;"> </span>approved,<span style="letter-spacing:0.45pt;"> </span>by<span style="letter-spacing:0.4pt;"> </span>patients,<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>medical<span style="letter-spacing:0.5pt;"> </span>community<span style="letter-spacing:0.5pt;"> </span>and<span style="letter-spacing:0.4pt;"> </span>third-party payors&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">effectively<span style="letter-spacing:0.15pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>with other<span style="letter-spacing:0.05pt;"> </span>therapies&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining<span style="letter-spacing:0.05pt;"> </span>and maintaining<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payor<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and adequate<span style="letter-spacing:0.05pt;"> </span>reimbursement&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">protecting<span style="letter-spacing:0.1pt;"> </span>and enforcing<span style="letter-spacing:0.1pt;"> </span>our rights<span style="letter-spacing:0.05pt;"> </span>in our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>portfolio&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintaining<span style="letter-spacing:0.1pt;"> </span>a continued<span style="letter-spacing:0.05pt;"> </span>acceptable<span style="letter-spacing:0.1pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>profile<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>following<span style="letter-spacing:0.05pt;"> </span>approval.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>factors<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>beyond<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>control,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>possible<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>none of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>ever obtain<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expend<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.15pt;"> </span>time<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:0.15pt;"> </span>seeking<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>approval.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do not achieve<span style="letter-spacing:0.1pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>factors<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>timely<span style="letter-spacing:0.15pt;"> </span>manner<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>all,<span style="letter-spacing:0.05pt;"> </span>we could<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>or an inability<span style="letter-spacing:0.1pt;"> </span>to successfully<span style="letter-spacing:0.1pt;"> </span>commercialize<span style="letter-spacing:0.2pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>which would materially<span style="letter-spacing:0.15pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business. For example,<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.15pt;"> </span>be<span style="letter-spacing:0.1pt;"> </span>harmed<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>ongoing<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.2pt;"> </span>trials<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 or PRT2527, vary<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>our expectations.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug development<span style="letter-spacing:0.1pt;"> </span>involves<span style="letter-spacing:0.05pt;"> </span>a lengthy<span style="letter-spacing:0.05pt;"> </span>and expensive<span style="letter-spacing:0.05pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>uncertain<span style="letter-spacing:0.05pt;"> </span>as to the outcome.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently<span style="letter-spacing:0.1pt;"> </span>have three<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in Phase 1 clinical<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and additional<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.2pt;"> </span>development,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of failure<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>high. We are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:0.05pt;"> </span>to predict<span style="letter-spacing:0.1pt;"> </span>when or if our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>prove<span style="letter-spacing:0.1pt;"> </span>effective<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>safe<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>humans<span style="letter-spacing:0.1pt;"> </span>or will<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval.<span style="letter-spacing:0.05pt;"> </span>Before<span style="letter-spacing:0.05pt;"> </span>obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical<span style="letter-spacing:0.2pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and then<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>to demonstrate<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>and efficacy<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:1.25pt;"> </span>candidates<span style="letter-spacing:1.3pt;"> </span>in<span style="letter-spacing:1.2pt;"> </span>humans.<span style="letter-spacing:1.2pt;"> </span>Clinical<span style="letter-spacing:1.25pt;"> </span>testing<span style="letter-spacing:1.25pt;"> </span>is<span style="letter-spacing:1.2pt;"> </span>expensive,<span style="letter-spacing:1.2pt;"> </span>difficult<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>design<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>implement,<span style="letter-spacing:1.25pt;"> </span>can<span style="letter-spacing:1.15pt;"> </span>take<span style="letter-spacing:1.2pt;"> </span>many years<span style="letter-spacing:0.05pt;"> </span>to complete<span style="letter-spacing:0.1pt;"> </span>and is<span style="letter-spacing:0.05pt;"> </span>uncertain<span style="letter-spacing:0.1pt;"> </span>as to the<span style="letter-spacing:0.05pt;"> </span>outcome.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>occur<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>stage<span style="letter-spacing:0.1pt;"> </span>of testing.<span style="letter-spacing:0.1pt;"> </span>The outcome<span style="letter-spacing:0.05pt;"> </span>of preclinical<span style="letter-spacing:0.15pt;"> </span>testing and<span style="letter-spacing:0.05pt;"> </span>early<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>predictive<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>of later<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or of clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>same product<span style="letter-spacing:1.15pt;"> </span>candidates<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>other<span style="letter-spacing:1.15pt;"> </span>indications,<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>interim<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>preliminary<span style="letter-spacing:1.25pt;"> </span>results<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>a<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trial<span style="letter-spacing:1.2pt;"> </span>do<span style="letter-spacing:1.05pt;"> </span>not<span style="letter-spacing:1.05pt;"> </span>necessarily predict<span style="letter-spacing:0.15pt;"> </span>final<span style="letter-spacing:0.1pt;"> </span>results.<span style="letter-spacing:0.1pt;"> </span>Later-stage<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>differ<span style="letter-spacing:0.1pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>ways from<span style="letter-spacing:0.05pt;"> </span>early-stage<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials, including<span style="letter-spacing:0.9pt;"> </span>changes<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.85pt;"> </span>inclusion<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>exclusion<span style="letter-spacing:0.9pt;"> </span>criteria,<span style="letter-spacing:0.95pt;"> </span>efficacy<span style="letter-spacing:0.9pt;"> </span>endpoints,<span style="letter-spacing:0.85pt;"> </span>dosing<span style="letter-spacing:0.85pt;"> </span>regimen<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>statistical<span style="letter-spacing:0.95pt;"> </span>design. In<span style="letter-spacing:1.15pt;"> </span>particular,<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>small<span style="letter-spacing:1.25pt;"> </span>number<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>patients<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>current<span style="letter-spacing:1.2pt;"> </span>Phase<span style="letter-spacing:1.1pt;"> </span>1<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trials<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.15pt;"> </span>make<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>results<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>these trials<span style="letter-spacing:0.15pt;"> </span>less<span style="letter-spacing:0.1pt;"> </span>predictive<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>outcome<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>later<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>although<span style="letter-spacing:0.05pt;"> </span>we have observed<span style="letter-spacing:0.05pt;"> </span>encouraging clinical<span style="letter-spacing:0.15pt;"> </span>activity<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>dose<span style="letter-spacing:0.05pt;"> </span>escalation<span style="letter-spacing:0.15pt;"> </span>portion<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Phase<span style="letter-spacing:0.05pt;"> </span>1<span style="letter-spacing:0.05pt;"> </span>portion<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ongoing<span style="letter-spacing:0.05pt;"> </span>PRT543 and<span style="letter-spacing:0.05pt;"> </span>PRT811 clinical trials,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>primary<span style="letter-spacing:0.15pt;"> </span>objectives<span style="letter-spacing:0.15pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>determine<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>safety,<span style="letter-spacing:0.1pt;"> </span>tolerability<span style="letter-spacing:0.15pt;"> </span>and maximum<span style="letter-spacing:0.1pt;"> </span>tolerated<span style="letter-spacing:0.1pt;"> </span>dose of PRT543 and<span style="letter-spacing:1.85pt;"> </span>PRT811,<span style="letter-spacing:1.8pt;"> </span>respectively,<span style="letter-spacing:2pt;"> </span>and<span style="letter-spacing:1.85pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>determine<span style="letter-spacing:1.95pt;"> </span>a<span style="letter-spacing:1.85pt;"> </span>recommended<span style="letter-spacing:1.95pt;"> </span>Phase<span style="letter-spacing:1.85pt;"> </span>2<span style="letter-spacing:1.85pt;"> </span>dose<span style="letter-spacing:1.85pt;"> </span>for<span style="letter-spacing:1.85pt;"> </span>the<span style="letter-spacing:1.85pt;"> </span>expansion<span style="letter-spacing:1.85pt;"> </span>portion<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>our Phase<span style="letter-spacing:0.65pt;"> </span>1<span style="letter-spacing:0.65pt;"> </span>clinical<span style="letter-spacing:0.75pt;"> </span>trials,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>not<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>demonstrate<span style="letter-spacing:0.75pt;"> </span>efficacy.<span style="letter-spacing:0.75pt;"> </span>The<span style="letter-spacing:0.65pt;"> </span>assessments<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>clinical<span style="letter-spacing:0.75pt;"> </span>activity<span style="letter-spacing:0.7pt;"> </span>from<span style="letter-spacing:0.65pt;"> </span>this<span style="letter-spacing:0.65pt;"> </span>portion<span style="letter-spacing:0.65pt;"> </span>of the<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials,<span style="letter-spacing:0.15pt;"> </span>some<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>pre-specified,<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>predictive<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>in dose expansion cohorts,<span style="letter-spacing:0.1pt;"> </span>specific<span style="letter-spacing:0.15pt;"> </span>tumor<span style="letter-spacing:0.1pt;"> </span>types<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>further<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543 and<span style="letter-spacing:0.05pt;"> </span>PRT811. In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>while<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>believe certain<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>in patients,<span style="letter-spacing:0.1pt;"> </span>such as stable<span style="letter-spacing:0.05pt;"> </span>disease,<span style="letter-spacing:0.05pt;"> </span>suggest<span style="letter-spacing:0.05pt;"> </span>encouraging<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>activity,<span style="letter-spacing:0.1pt;"> </span>stable<span style="letter-spacing:0.05pt;"> </span>disease is not considered<span style="letter-spacing:0.7pt;"> </span>a<span style="letter-spacing:0.6pt;"> </span>response<span style="letter-spacing:0.65pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>regulatory<span style="letter-spacing:0.7pt;"> </span>purposes.<span style="letter-spacing:0.65pt;"> </span>Stable<span style="letter-spacing:0.6pt;"> </span>disease,<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>SD,<span style="letter-spacing:0.5pt;"> </span>is<span style="letter-spacing:0.6pt;"> </span>defined<span style="letter-spacing:0.6pt;"> </span>as<span style="letter-spacing:0.55pt;"> </span>failure<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.55pt;"> </span>meet<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>definition of<span style="letter-spacing:0.05pt;"> </span>objective<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>response<span style="letter-spacing:0.05pt;"> </span>or progressive<span style="letter-spacing:0.1pt;"> </span>disease.<span style="letter-spacing:0.05pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>events<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be observed<span style="letter-spacing:0.05pt;"> </span>in later<span style="letter-spacing:0.1pt;"> </span>trials that<span style="letter-spacing:0.05pt;"> </span>alter<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>anticipated<span style="letter-spacing:0.1pt;"> </span>risk-benefit<span style="letter-spacing:0.15pt;"> </span>profiles<span style="letter-spacing:0.1pt;"> </span>of PRT543<span style="letter-spacing:-0.05pt;"> </span>and PRT811.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>incur additional<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>or experience<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>in completing,<span style="letter-spacing:0.1pt;"> </span>or ultimately<span style="letter-spacing:0.15pt;"> </span>be unable to complete<span style="letter-spacing:0.1pt;"> </span>the development<span style="letter-spacing:0.1pt;"> </span>and/or commercialization<span style="letter-spacing:0.2pt;"> </span>of PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811,<span style="letter-spacing:-0.05pt;"> </span>PRT1419,<span style="letter-spacing:-0.05pt;"> </span>PRT2527<span style="letter-spacing:-0.05pt;"> </span>or our other<span style="letter-spacing:0.05pt;"> </span>product candidates.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>initiate<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>indication,<span style="letter-spacing:0.15pt;"> </span>we must<span style="letter-spacing:0.05pt;"> </span>submit<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of preclinical<span style="letter-spacing:0.25pt;"> </span>studies<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:0.15pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>authorities,<span style="letter-spacing:0.2pt;"> </span>respectively,<span style="letter-spacing:0.2pt;"> </span>along<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>information, including<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>about<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate&#8217;s<span style="letter-spacing:0.15pt;"> </span>chemistry,<span style="letter-spacing:0.1pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>and controls<span style="letter-spacing:0.1pt;"> </span>and our proposed clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>protocol,<span style="letter-spacing:0.05pt;"> </span>as part<span style="letter-spacing:0.05pt;"> </span>of an IND or comparable<span style="letter-spacing:0.1pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>filings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>preclinical<span style="letter-spacing:0.2pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>allows us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>initiate<span style="letter-spacing:0.15pt;"> </span>subsequent<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>under<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>IND,<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>lead<span style="letter-spacing:0.05pt;"> </span>to additional<span style="letter-spacing:0.1pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>and increase<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>costs of our preclinical<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>commencement<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>completion<span style="letter-spacing:0.15pt;"> </span>of our ongoing, planned<span style="letter-spacing:0.05pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>could significantly<span style="letter-spacing:0.2pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>costs.<span style="letter-spacing:0.05pt;"> </span>We may<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:0.1pt;"> </span>numerous<span style="letter-spacing:0.05pt;"> </span>unforeseen<span style="letter-spacing:0.1pt;"> </span>events<span style="letter-spacing:0.05pt;"> </span>during,<span style="letter-spacing:0.05pt;"> </span>or as a<span style="letter-spacing:0.85pt;"> </span>result<span style="letter-spacing:0.95pt;"> </span>of,<span style="letter-spacing:0.85pt;"> </span>clinical<span style="letter-spacing:0.95pt;"> </span>trials<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.9pt;"> </span>could<span style="letter-spacing:0.85pt;"> </span>delay<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>prevent<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>ability<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>obtain<span style="letter-spacing:0.85pt;"> </span>marketing<span style="letter-spacing:0.9pt;"> </span>approval<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>commercialize our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulators,<span style="letter-spacing:0.6pt;"> </span>institutional<span style="letter-spacing:0.65pt;"> </span>review<span style="letter-spacing:0.55pt;"> </span>boards,<span style="letter-spacing:0.55pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>IRBs,<span style="letter-spacing:0.5pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>ethics<span style="letter-spacing:0.55pt;"> </span>committees,<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>ECs,<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.55pt;"> </span>not<span style="letter-spacing:0.5pt;"> </span>authorize<span style="letter-spacing:0.6pt;"> </span>us<span style="letter-spacing:0.5pt;"> </span>or our investigators<span style="letter-spacing:0.15pt;"> </span>to commence<span style="letter-spacing:0.1pt;"> </span>a clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>or conduct<span style="letter-spacing:0.05pt;"> </span>a clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>a prospective<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>site&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA may disagree as to the design or implementation of our clinical trials or with our recommended<span style="letter-spacing:0.1pt;"> </span>Phase 2 doses<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any of our pipeline<span style="letter-spacing:0.1pt;"> </span>programs&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<span style="letter-spacing:0.45pt;"> </span>may<span style="letter-spacing:0.45pt;"> </span>experience<span style="letter-spacing:0.5pt;"> </span>delays<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>reaching,<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>fail<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>reach,<span style="letter-spacing:0.45pt;"> </span>agreement<span style="letter-spacing:0.5pt;"> </span>on<span style="letter-spacing:0.4pt;"> </span>acceptable<span style="letter-spacing:0.5pt;"> </span>clinical<span style="letter-spacing:0.5pt;"> </span>trial<span style="letter-spacing:0.5pt;"> </span>contracts or<span style="letter-spacing:1.3pt;"> </span>clinical<span style="letter-spacing:1.4pt;"> </span>trial<span style="letter-spacing:1.4pt;"> </span>protocols<span style="letter-spacing:1.4pt;"> </span>with<span style="letter-spacing:1.3pt;"> </span>prospective<span style="letter-spacing:1.35pt;"> </span>clinical<span style="letter-spacing:1.35pt;"> </span>research<span style="letter-spacing:1.35pt;"> </span>organizations,<span style="letter-spacing:1.35pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>CROs,<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>prospective trial<span style="letter-spacing:0.1pt;"> </span>sites&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical<span style="letter-spacing:1.45pt;"> </span>trials<span style="letter-spacing:1.45pt;"> </span>for<span style="letter-spacing:1.4pt;"> </span>our<span style="letter-spacing:1.35pt;"> </span>product<span style="letter-spacing:1.4pt;"> </span>candidates<span style="letter-spacing:1.45pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>produce<span style="letter-spacing:1.4pt;"> </span>negative<span style="letter-spacing:1.4pt;"> </span>or<span style="letter-spacing:1.35pt;"> </span>inconclusive<span style="letter-spacing:1.45pt;"> </span>results,<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:1.35pt;"> </span>we<span style="letter-spacing:1.35pt;"> </span>may decide,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulators<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.15pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials,<span style="letter-spacing:0.15pt;"> </span>delay<span style="letter-spacing:0.1pt;"> </span>or halt<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or abandon product<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>programs&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">lack<span style="letter-spacing:0.05pt;"> </span>of adequate<span style="letter-spacing:0.05pt;"> </span>funding<span style="letter-spacing:0.05pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:1.45pt;"> </span>number<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>patients<span style="letter-spacing:1.5pt;"> </span>required<span style="letter-spacing:1.5pt;"> </span>for<span style="letter-spacing:1.45pt;"> </span>clinical<span style="letter-spacing:1.45pt;"> </span>trials<span style="letter-spacing:1.45pt;"> </span>for<span style="letter-spacing:1.4pt;"> </span>our<span style="letter-spacing:1.35pt;"> </span>product<span style="letter-spacing:1.4pt;"> </span>candidates<span style="letter-spacing:1.45pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>be<span style="letter-spacing:1.35pt;"> </span>larger<span style="letter-spacing:1.45pt;"> </span>than<span style="letter-spacing:1.4pt;"> </span>we anticipate,<span style="letter-spacing:0.1pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>in these<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be slower<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we anticipate<span style="letter-spacing:0.1pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>be lower than we anticipate<span style="letter-spacing:0.1pt;"> </span>due to challenges<span style="letter-spacing:0.1pt;"> </span>in recruiting<span style="letter-spacing:0.1pt;"> </span>and enrolling<span style="letter-spacing:0.1pt;"> </span>suitable<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>meet<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>study criteria, participants<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>drop<span style="letter-spacing:0.05pt;"> </span>out<span style="letter-spacing:0.05pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>a higher<span style="letter-spacing:0.05pt;"> </span>rate<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we anticipate<span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>duration<span style="letter-spacing:0.05pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be longer<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we anticipate&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">competition<span style="letter-spacing:2.05pt;"> </span>for<span style="letter-spacing:1.95pt;"> </span>clinical<span style="letter-spacing:2pt;"> </span>trial<span style="letter-spacing:2pt;"> </span>participants<span style="letter-spacing:2.05pt;"> </span>from<span style="letter-spacing:1.95pt;"> </span>investigational<span style="letter-spacing:2.05pt;"> </span>and<span style="letter-spacing:1.9pt;"> </span>approved<span style="letter-spacing:1.95pt;"> </span>therapies<span style="letter-spacing:2pt;"> </span>may<span style="letter-spacing:1.95pt;"> </span>make<span style="letter-spacing:1.95pt;"> </span>it more<span style="letter-spacing:0.05pt;"> </span>difficult<span style="letter-spacing:0.15pt;"> </span>to enroll<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>in our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may experience difficulties in maintaining contact with patients after treatment, resulting in incomplete<span style="letter-spacing:0.1pt;"> </span>data&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>third-party<span style="letter-spacing:0.55pt;"> </span>collaborators<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.45pt;"> </span>fail<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>obtain<span style="letter-spacing:0.45pt;"> </span>regulatory<span style="letter-spacing:0.5pt;"> </span>approval<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>companion<span style="letter-spacing:0.4pt;"> </span>diagnostic<span style="letter-spacing:0.45pt;"> </span>tests,<span style="letter-spacing:0.4pt;"> </span>if required,<span style="letter-spacing:0.1pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>basis,<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<span style="letter-spacing:0.3pt;"> </span>third-party<span style="letter-spacing:0.45pt;"> </span>contractors<span style="letter-spacing:0.4pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>fail<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>meet<span style="letter-spacing:0.3pt;"> </span>their<span style="letter-spacing:0.3pt;"> </span>contractual<span style="letter-spacing:0.35pt;"> </span>obligations<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>us<span style="letter-spacing:0.25pt;"> </span>in<span style="letter-spacing:0.25pt;"> </span>a<span style="letter-spacing:0.25pt;"> </span>timely<span style="letter-spacing:0.35pt;"> </span>manner,<span style="letter-spacing:0.3pt;"> </span>or<span style="letter-spacing:0.25pt;"> </span>at all,<span style="letter-spacing:0.05pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with regulatory<span style="letter-spacing:0.1pt;"> </span>requirements&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>have<span style="letter-spacing:1.55pt;"> </span>to<span style="letter-spacing:1.55pt;"> </span>suspend<span style="letter-spacing:1.6pt;"> </span>or<span style="letter-spacing:1.55pt;"> </span>terminate<span style="letter-spacing:1.7pt;"> </span>clinical<span style="letter-spacing:1.65pt;"> </span>trials<span style="letter-spacing:1.65pt;"> </span>for<span style="letter-spacing:1.6pt;"> </span>our<span style="letter-spacing:1.55pt;"> </span>product<span style="letter-spacing:1.55pt;"> </span>candidates<span style="letter-spacing:1.6pt;"> </span>for<span style="letter-spacing:1.55pt;"> </span>various<span style="letter-spacing:1.55pt;"> </span>reasons, including<span style="letter-spacing:0.05pt;"> </span>a finding<span style="letter-spacing:0.05pt;"> </span>by us or by a Data Monitoring<span style="letter-spacing:0.1pt;"> </span>Committee<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a trial<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>participants<span style="letter-spacing:0.1pt;"> </span>are being exposed<span style="letter-spacing:0.05pt;"> </span>to unacceptable<span style="letter-spacing:0.1pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>risks&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our product candidates may have undesirable or unexpected side effects or other unexpected characteristics,<span style="letter-spacing:1.9pt;"> </span>causing<span style="letter-spacing:1.75pt;"> </span>us<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.7pt;"> </span>our<span style="letter-spacing:1.65pt;"> </span>investigators,<span style="letter-spacing:1.8pt;"> </span>regulators<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.65pt;"> </span>IRBs/ECs<span style="letter-spacing:1.65pt;"> </span>to<span style="letter-spacing:1.65pt;"> </span>suspend<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.65pt;"> </span>terminate<span style="letter-spacing:1.8pt;"> </span>the trials&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>of clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be greater<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we anticipate&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes<span style="letter-spacing:0.05pt;"> </span>to clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>protocol&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.1pt;"> </span>supply<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>materials<span style="letter-spacing:0.2pt;"> </span>necessary<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>for our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>insufficient<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inadequate<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>suspension<span style="letter-spacing:0.1pt;"> </span>of our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:1.9pt;"> </span>impact<span style="letter-spacing:1.95pt;"> </span>of<span style="letter-spacing:1.85pt;"> </span>the<span style="letter-spacing:1.85pt;"> </span>ongoing<span style="letter-spacing:1.8pt;"> </span>COVID-19<span style="letter-spacing:1.75pt;"> </span>pandemic,<span style="letter-spacing:1.85pt;"> </span>which<span style="letter-spacing:1.8pt;"> </span>may<span style="letter-spacing:1.85pt;"> </span>slow<span style="letter-spacing:1.8pt;"> </span>potential<span style="letter-spacing:1.9pt;"> </span>enrollment,<span style="letter-spacing:1.9pt;"> </span>reduce<span style="letter-spacing:1.85pt;"> </span>the number<span style="letter-spacing:0.05pt;"> </span>of eligible<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>or reduce<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>number<span style="letter-spacing:0.05pt;"> </span>of patients<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>remain<span style="letter-spacing:0.1pt;"> </span>in our trials.</p></td></tr></table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>delays<span style="letter-spacing:0.1pt;"> </span>caused<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>above factors,<span style="letter-spacing:0.1pt;"> </span>can be costly<span style="letter-spacing:0.05pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>negatively<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to complete<span style="letter-spacing:1.7pt;"> </span>a<span style="letter-spacing:1.55pt;"> </span>clinical<span style="letter-spacing:1.65pt;"> </span>trial<span style="letter-spacing:1.65pt;"> </span>or<span style="letter-spacing:1.55pt;"> </span>obtain<span style="letter-spacing:1.6pt;"> </span>timely<span style="letter-spacing:1.65pt;"> </span>marketing<span style="letter-spacing:1.65pt;"> </span>approvals.<span style="letter-spacing:1.6pt;"> </span>We<span style="letter-spacing:1.55pt;"> </span>do<span style="letter-spacing:1.55pt;"> </span>not<span style="letter-spacing:1.55pt;"> </span>know<span style="letter-spacing:1.55pt;"> </span>whether<span style="letter-spacing:1.6pt;"> </span>any<span style="letter-spacing:1.55pt;"> </span>of<span style="letter-spacing:1.55pt;"> </span>our<span style="letter-spacing:1.55pt;"> </span>planned preclinical<span style="letter-spacing:0.2pt;"> </span>studies<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>begin<span style="letter-spacing:0.1pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>basis<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all,<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>need to be restructured<span style="letter-spacing:0.15pt;"> </span>or will<span style="letter-spacing:0.05pt;"> </span>be completed<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>schedule,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.15pt;"> </span>all.<span style="letter-spacing:0.15pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>place<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>partial<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>full<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>hold<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our clinical trials for a variety of reasons, including safety concerns and noncompliance with regulatory requirements.<span style="letter-spacing:0.2pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>complete<span style="letter-spacing:0.15pt;"> </span>successful<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>regulatory approval<span style="letter-spacing:0.05pt;"> </span>and will<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to commercialize<span style="letter-spacing:0.2pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant<span style="letter-spacing:0.15pt;"> </span>preclinical<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>shorten<span style="letter-spacing:0.05pt;"> </span>any periods<span style="letter-spacing:0.05pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>which we may<span style="letter-spacing:0.05pt;"> </span>have the exclusive<span style="letter-spacing:1.35pt;"> </span>right<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>commercialize<span style="letter-spacing:1.45pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>product<span style="letter-spacing:1.25pt;"> </span>candidates<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>allow<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>competitors<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>bring<span style="letter-spacing:1.25pt;"> </span>products<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>market before<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>successfully<span style="letter-spacing:0.15pt;"> </span>commercialize<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>and results<span style="letter-spacing:0.1pt;"> </span>of operations.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we experience<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>or difficulties<span style="letter-spacing:0.15pt;"> </span>in enrolling<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.05pt;"> </span>in our ongoing or planned clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>our receipt<span style="letter-spacing:0.1pt;"> </span>of necessary<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>could be delayed<span style="letter-spacing:0.05pt;"> </span>or prevented.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.55pt;"> </span>not<span style="letter-spacing:0.5pt;"> </span>be<span style="letter-spacing:0.5pt;"> </span>able<span style="letter-spacing:0.55pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>initiate<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>continue<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:0.45pt;"> </span>ongoing<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>planned<span style="letter-spacing:0.5pt;"> </span>clinical<span style="letter-spacing:0.55pt;"> </span>trials<span style="letter-spacing:0.55pt;"> </span>for<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:0.45pt;"> </span>product<span style="letter-spacing:0.5pt;"> </span>candidates if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>unable<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>enroll<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.2pt;"> </span>number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>eligible<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>to participate<span style="letter-spacing:0.15pt;"> </span>in these<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>as required<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:0.15pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>authorities.<span style="letter-spacing:0.2pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>of our competitors<span style="letter-spacing:0.15pt;"> </span>currently have<span style="letter-spacing:0.05pt;"> </span>ongoing<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>treat<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>same<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>as our clinical<span style="letter-spacing:0.1pt;"> </span>product candidates,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:0.1pt;"> </span>be eligible<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>instead<span style="letter-spacing:0.05pt;"> </span>enroll<span style="letter-spacing:0.05pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>trials of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>competitors&#8217;<span style="letter-spacing:0.25pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates.<span style="letter-spacing:0.2pt;"> </span>This<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>acutely<span style="letter-spacing:0.15pt;"> </span>relevant<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543 for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>treatment of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>myeloid<span style="letter-spacing:0.1pt;"> </span>malignancies<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>solid<span style="letter-spacing:0.1pt;"> </span>tumors,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>adenoid<span style="letter-spacing:0.1pt;"> </span>cystic<span style="letter-spacing:0.1pt;"> </span>carcinoma,<span style="letter-spacing:0.15pt;"> </span>or ACC, indications<span style="letter-spacing:2.45pt;"> </span>for<span style="letter-spacing:2.4pt;"> </span>which<span style="letter-spacing:2.35pt;"> </span>investigational<span style="letter-spacing:2.45pt;"> </span>drugs<span style="letter-spacing:2.35pt;"> </span>by<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>competitors<span style="letter-spacing:2.45pt;"> </span>are<span style="letter-spacing:2.35pt;"> </span>competing<span style="letter-spacing:2.4pt;"> </span>for<span style="letter-spacing:2.35pt;"> </span>clinical<span style="letter-spacing:2.4pt;"> </span>trial<span style="letter-spacing:2.4pt;"> </span>participants. Patient<span style="letter-spacing:0.05pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>affected<span style="letter-spacing:0.1pt;"> </span>by other<span style="letter-spacing:0.05pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">severity<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>disease<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>investigation&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<span style="letter-spacing:0.1pt;"> </span>to recruit<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>investigators<span style="letter-spacing:0.15pt;"> </span>of appropriate<span style="letter-spacing:0.1pt;"> </span>competencies<span style="letter-spacing:0.1pt;"> </span>and experience&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>incidence<span style="letter-spacing:0.1pt;"> </span>and prevalence<span style="letter-spacing:0.1pt;"> </span>of our target<span style="letter-spacing:0.1pt;"> </span>indications&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinicians&#8217;<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>patients&#8217;<span style="letter-spacing:0.9pt;"> </span>awareness<span style="letter-spacing:0.85pt;"> </span>of,<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>perceptions<span style="letter-spacing:0.9pt;"> </span>as<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>potential<span style="letter-spacing:0.9pt;"> </span>advantages<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>risks<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>relation<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>available<span style="letter-spacing:0.15pt;"> </span>therapies,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>new drugs<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be approved<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:0.1pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>investigating&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">competing<span style="letter-spacing:0.1pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or trials<span style="letter-spacing:0.1pt;"> </span>with similar<span style="letter-spacing:0.1pt;"> </span>eligibility<span style="letter-spacing:0.15pt;"> </span>criteria&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">invasive<span style="letter-spacing:2.45pt;"> </span>procedures<span style="letter-spacing:2.45pt;"> </span>required<span style="letter-spacing:2.45pt;"> </span>to<span style="letter-spacing:2.35pt;"> </span>enroll<span style="letter-spacing:2.4pt;"> </span>patients<span style="letter-spacing:2.45pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.35pt;"> </span>obtain<span style="letter-spacing:2.4pt;"> </span>evidence<span style="letter-spacing:2.4pt;"> </span>of<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>product<span style="letter-spacing:2.4pt;"> </span>candidate&#8217;s performance<span style="letter-spacing:0.1pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">availability<span style="letter-spacing:0.15pt;"> </span>and efficacy<span style="letter-spacing:0.1pt;"> </span>of approved<span style="letter-spacing:0.05pt;"> </span>medications<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>disease<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>investigation&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">eligibility<span style="letter-spacing:0.15pt;"> </span>criteria<span style="letter-spacing:0.15pt;"> </span>defined<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>protocol<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>in question&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>size<span style="letter-spacing:0.05pt;"> </span>and nature<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>population<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>analysis<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>trial&#8217;s<span style="letter-spacing:0.1pt;"> </span>primary<span style="letter-spacing:0.1pt;"> </span>endpoints&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">efforts<span style="letter-spacing:0.1pt;"> </span>to facilitate<span style="letter-spacing:0.15pt;"> </span>timely<span style="letter-spacing:0.1pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">whether<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to a partial<span style="letter-spacing:0.1pt;"> </span>or full<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>hold on any of our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reluctance<span style="letter-spacing:0.1pt;"> </span>of physicians<span style="letter-spacing:0.1pt;"> </span>to encourage<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>participation<span style="letter-spacing:0.15pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to monitor<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>adequately<span style="letter-spacing:0.1pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>and after<span style="letter-spacing:0.1pt;"> </span>treatment&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>and maintain<span style="letter-spacing:0.1pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>consents&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">proximity<span style="letter-spacing:0.1pt;"> </span>and availability<span style="letter-spacing:0.15pt;"> </span>of clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>sites<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>prospective<span style="letter-spacing:0.1pt;"> </span>patients.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>inability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>enroll<span style="letter-spacing:0.1pt;"> </span>and maintain<span style="letter-spacing:0.1pt;"> </span>a sufficient<span style="letter-spacing:0.15pt;"> </span>number<span style="letter-spacing:0.05pt;"> </span>of patients<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>would result<span style="letter-spacing:0.1pt;"> </span>in significant<span style="letter-spacing:0.2pt;"> </span>delays<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>abandon<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>altogether.<span style="letter-spacing:0.15pt;"> </span>Enrollment<span style="letter-spacing:0.1pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>in our clinical<span style="letter-spacing:2pt;"> </span>trials,<span style="letter-spacing:2pt;"> </span>including<span style="letter-spacing:1.95pt;"> </span>due<span style="letter-spacing:1.9pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>the<span style="letter-spacing:1.9pt;"> </span>COVID-19<span style="letter-spacing:1.8pt;"> </span>pandemic,<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.9pt;"> </span>result<span style="letter-spacing:1.95pt;"> </span>in<span style="letter-spacing:1.85pt;"> </span>increased<span style="letter-spacing:1.95pt;"> </span>development<span style="letter-spacing:1.95pt;"> </span>costs,<span style="letter-spacing:1.9pt;"> </span>which would cause<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our company<span style="letter-spacing:0.05pt;"> </span>to decline<span style="letter-spacing:0.05pt;"> </span>and limit<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>financing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19<span style="letter-spacing:-0.05pt;"> </span>pandemic<span style="letter-spacing:0.05pt;"> </span>could adversely<span style="letter-spacing:0.1pt;"> </span>impact<span style="letter-spacing:0.05pt;"> </span>our business,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and clinical trial<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and in other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>in which we have planned<span style="letter-spacing:0.05pt;"> </span>or have active<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>sites<span style="letter-spacing:0.05pt;"> </span>and where our third-party<span style="letter-spacing:0.15pt;"> </span>manufacturers<span style="letter-spacing:0.1pt;"> </span>operate, could cause significant<span style="letter-spacing:0.1pt;"> </span>disruptions<span style="letter-spacing:0.05pt;"> </span>that could<span style="letter-spacing:0.05pt;"> </span>severely<span style="letter-spacing:0.1pt;"> </span>impact<span style="letter-spacing:0.1pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays<span style="letter-spacing:0.05pt;"> </span>or difficulties<span style="letter-spacing:0.15pt;"> </span>in screening,<span style="letter-spacing:0.1pt;"> </span>enrolling<span style="letter-spacing:0.1pt;"> </span>and maintaining<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>in our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators<span style="letter-spacing:0.15pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>site<span style="letter-spacing:0.05pt;"> </span>staff&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.15pt;"> </span>healthcare<span style="letter-spacing:1.2pt;"> </span>resources<span style="letter-spacing:1.2pt;"> </span>away<span style="letter-spacing:1.1pt;"> </span>from<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>conduct<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trials,<span style="letter-spacing:1.2pt;"> </span>including<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>diversion<span style="letter-spacing:1.2pt;"> </span>of hospitals<span style="letter-spacing:0.1pt;"> </span>serving<span style="letter-spacing:0.05pt;"> </span>as our clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>sites<span style="letter-spacing:0.05pt;"> </span>and hospital<span style="letter-spacing:0.1pt;"> </span>staff<span style="letter-spacing:0.1pt;"> </span>supporting<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.05pt;"> </span>of our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">inability<span style="letter-spacing:0.1pt;"> </span>or unwillingness<span style="letter-spacing:0.1pt;"> </span>of subjects<span style="letter-spacing:0.1pt;"> </span>to travel<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>sites&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays,<span style="letter-spacing:0.05pt;"> </span>difficulties,<span style="letter-spacing:0.15pt;"> </span>or incompleteness<span style="letter-spacing:0.15pt;"> </span>in data<span style="letter-spacing:0.05pt;"> </span>collection<span style="letter-spacing:0.1pt;"> </span>and analysis<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>activities&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">decreased implementation of protocol required clinical trial activities and quality of source data verification<span style="letter-spacing:0.15pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>sites&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>key<span style="letter-spacing:1.05pt;"> </span>clinical<span style="letter-spacing:1.15pt;"> </span>trial<span style="letter-spacing:1.1pt;"> </span>activities,<span style="letter-spacing:1.15pt;"> </span>such<span style="letter-spacing:1pt;"> </span>as<span style="letter-spacing:1pt;"> </span>clinical<span style="letter-spacing:1.1pt;"> </span>trial<span style="letter-spacing:1.1pt;"> </span>site<span style="letter-spacing:1.05pt;"> </span>monitoring,<span style="letter-spacing:1.1pt;"> </span>due<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:1pt;"> </span>limitations<span style="letter-spacing:1.15pt;"> </span>on travel<span style="letter-spacing:0.1pt;"> </span>imposed<span style="letter-spacing:0.05pt;"> </span>or recommended<span style="letter-spacing:0.1pt;"> </span>by federal<span style="letter-spacing:0.1pt;"> </span>or state<span style="letter-spacing:0.05pt;"> </span>governments,<span style="letter-spacing:0.1pt;"> </span>employers<span style="letter-spacing:0.1pt;"> </span>and others&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>employee<span style="letter-spacing:0.45pt;"> </span>resources<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.45pt;"> </span>would<span style="letter-spacing:0.4pt;"> </span>otherwise<span style="letter-spacing:0.45pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>focused<span style="letter-spacing:0.45pt;"> </span>on<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>conduct<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.4pt;"> </span>clinical<span style="letter-spacing:0.5pt;"> </span>trials and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.1pt;"> </span>and development<span style="letter-spacing:0.1pt;"> </span>activities,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>because<span style="letter-spacing:0.05pt;"> </span>of sickness<span style="letter-spacing:0.05pt;"> </span>of employees<span style="letter-spacing:0.1pt;"> </span>or their families<span style="letter-spacing:0.15pt;"> </span>or mitigation<span style="letter-spacing:0.15pt;"> </span>measures<span style="letter-spacing:0.1pt;"> </span>such as lock-downs<span style="letter-spacing:0.05pt;"> </span>and social<span style="letter-spacing:0.05pt;"> </span>distancing&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays due to production shortages resulting from any events affecting raw material supply or manufacturing<span style="letter-spacing:0.15pt;"> </span>capabilities<span style="letter-spacing:0.15pt;"> </span>domestically<span style="letter-spacing:0.15pt;"> </span>and abroad&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays<span style="letter-spacing:0.05pt;"> </span>in receiving<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>local<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>to initiate<span style="letter-spacing:0.1pt;"> </span>our planned<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays<span style="letter-spacing:0.05pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>sites<span style="letter-spacing:0.05pt;"> </span>receiving<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>supplies<span style="letter-spacing:0.05pt;"> </span>and materials<span style="letter-spacing:0.15pt;"> </span>needed<span style="letter-spacing:0.05pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption<span style="letter-spacing:1.55pt;"> </span>in<span style="letter-spacing:1.4pt;"> </span>global<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:1.4pt;"> </span>domestic<span style="letter-spacing:1.5pt;"> </span>shipping<span style="letter-spacing:1.45pt;"> </span>that<span style="letter-spacing:1.4pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>affect<span style="letter-spacing:1.45pt;"> </span>the<span style="letter-spacing:1.4pt;"> </span>transport<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:1.35pt;"> </span>clinical<span style="letter-spacing:1.45pt;"> </span>trial<span style="letter-spacing:1.45pt;"> </span>materials, such as investigational<span style="letter-spacing:0.15pt;"> </span>drug products<span style="letter-spacing:0.05pt;"> </span>used in our clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes<span style="letter-spacing:0.5pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>local<span style="letter-spacing:0.45pt;"> </span>regulations<span style="letter-spacing:0.5pt;"> </span>as<span style="letter-spacing:0.4pt;"> </span>part<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.4pt;"> </span>response<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>COVID-19<span style="letter-spacing:0.35pt;"> </span>pandemic<span style="letter-spacing:0.45pt;"> </span>which<span style="letter-spacing:0.4pt;"> </span>may<span style="letter-spacing:0.45pt;"> </span>require<span style="letter-spacing:0.5pt;"> </span>us<span style="letter-spacing:0.4pt;"> </span>to change<span style="letter-spacing:1.8pt;"> </span>the<span style="letter-spacing:1.8pt;"> </span>ways<span style="letter-spacing:1.75pt;"> </span>in<span style="letter-spacing:1.75pt;"> </span>which<span style="letter-spacing:1.75pt;"> </span>our<span style="letter-spacing:1.75pt;"> </span>clinical<span style="letter-spacing:1.85pt;"> </span>trials<span style="letter-spacing:1.85pt;"> </span>are<span style="letter-spacing:1.8pt;"> </span>conducted,<span style="letter-spacing:1.8pt;"> </span>which<span style="letter-spacing:1.75pt;"> </span>may<span style="letter-spacing:1.8pt;"> </span>result<span style="letter-spacing:1.85pt;"> </span>in<span style="letter-spacing:1.75pt;"> </span>unexpected<span style="letter-spacing:1.8pt;"> </span>costs, delays,<span style="letter-spacing:0.05pt;"> </span>or to discontinue<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>altogether&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays<span style="letter-spacing:0.8pt;"> </span>in<span style="letter-spacing:0.75pt;"> </span>necessary<span style="letter-spacing:0.85pt;"> </span>interactions<span style="letter-spacing:0.9pt;"> </span>with<span style="letter-spacing:0.75pt;"> </span>local<span style="letter-spacing:0.8pt;"> </span>regulators,<span style="letter-spacing:0.85pt;"> </span>ethics<span style="letter-spacing:0.75pt;"> </span>committees<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>other<span style="letter-spacing:0.75pt;"> </span>important<span style="letter-spacing:0.8pt;"> </span>agencies and contractors<span style="letter-spacing:0.1pt;"> </span>due to limitations<span style="letter-spacing:0.15pt;"> </span>in employee<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>or forced<span style="letter-spacing:0.05pt;"> </span>furlough<span style="letter-spacing:0.05pt;"> </span>of government<span style="letter-spacing:0.1pt;"> </span>employees&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>regulatory<span style="letter-spacing:0.6pt;"> </span>authorities<span style="letter-spacing:0.65pt;"> </span>such<span style="letter-spacing:0.5pt;"> </span>as<span style="letter-spacing:0.5pt;"> </span>FDA<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>European<span style="letter-spacing:0.55pt;"> </span>Medicines<span style="letter-spacing:0.6pt;"> </span>Agency,<span style="letter-spacing:0.5pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>EMA,<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>accept<span style="letter-spacing:0.5pt;"> </span>data from<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>in affected<span style="letter-spacing:0.1pt;"> </span>geographies&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">adverse<span style="letter-spacing:0.1pt;"> </span>impacts<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>global<span style="letter-spacing:0.1pt;"> </span>economic<span style="letter-spacing:0.1pt;"> </span>conditions<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>effect<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>impairing<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to raise<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>when needed.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such<span style="letter-spacing:0.05pt;"> </span>disruptions<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>impede,<span style="letter-spacing:0.1pt;"> </span>delay,<span style="letter-spacing:0.1pt;"> </span>limit<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>completion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our ongoing clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and preclinical<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or commencement<span style="letter-spacing:0.15pt;"> </span>of new clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and ultimately<span style="letter-spacing:0.15pt;"> </span>lead<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>delay<span style="letter-spacing:0.05pt;"> </span>or denial<span style="letter-spacing:0.05pt;"> </span>of regulatory approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>seriously<span style="letter-spacing:0.15pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>our operations<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and increase<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>expenses.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>close<span style="letter-spacing:0.1pt;"> </span>contact<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>CROs, CMOs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>sites<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>to mitigate<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>impact<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> the </span>COVID-19 pandemic on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>and current<span style="letter-spacing:0.1pt;"> </span>timelines.<span style="letter-spacing:0.15pt;"> </span>Measures<span style="letter-spacing:0.1pt;"> </span>we have taken<span style="letter-spacing:0.05pt;"> </span>in response<span style="letter-spacing:0.05pt;"> </span>to the COVID-19 pandemic include,<span style="letter-spacing:0.1pt;"> </span>where feasible,<span style="letter-spacing:0.1pt;"> </span>conducting<span style="letter-spacing:0.05pt;"> </span>remote<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>site<span style="letter-spacing:0.05pt;"> </span>activations<span style="letter-spacing:0.1pt;"> </span>and data<span style="letter-spacing:0.05pt;"> </span>monitoring,<span style="letter-spacing:0.1pt;"> </span>and limiting<span style="letter-spacing:0.15pt;"> </span>on-site<span style="letter-spacing:0.15pt;"> </span>patient<span style="letter-spacing:0.15pt;"> </span>visits<span style="letter-spacing:0.1pt;"> </span>by adjusting<span style="letter-spacing:0.1pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>assessments<span style="letter-spacing:0.1pt;"> </span>and protocol.<span style="letter-spacing:0.05pt;"> </span>However, despite<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>efforts,<span style="letter-spacing:0.1pt;"> </span>we have<span style="letter-spacing:0.05pt;"> </span>experienced<span style="letter-spacing:0.15pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>delays<span style="letter-spacing:0.1pt;"> </span>in trial<span style="letter-spacing:0.1pt;"> </span>site<span style="letter-spacing:0.05pt;"> </span>initiations,<span style="letter-spacing:0.15pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>participation<span style="letter-spacing:0.15pt;"> </span>and patient<span style="letter-spacing:0.1pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>in some<span style="letter-spacing:0.05pt;"> </span>of our clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to experience<span style="letter-spacing:0.1pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>in our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and preclinical<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>and delays<span style="letter-spacing:0.05pt;"> </span>in data<span style="letter-spacing:0.05pt;"> </span>collection<span style="letter-spacing:0.1pt;"> </span>and analysis.<span style="letter-spacing:0.1pt;"> </span>These delays<span style="letter-spacing:0.05pt;"> </span>so far<span style="letter-spacing:0.05pt;"> </span>have had a limited<span style="letter-spacing:0.1pt;"> </span>impact,<span style="letter-spacing:0.1pt;"> </span>but this<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>change<span style="letter-spacing:0.05pt;"> </span>as the COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>response<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>continues<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>evolve,<span style="letter-spacing:0.1pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>have an adverse<span style="letter-spacing:0.15pt;"> </span>impact<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>timelines<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.1pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the FDA, EMA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>health<span style="letter-spacing:0.1pt;"> </span>authorities,<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in delays<span style="letter-spacing:0.05pt;"> </span>in meetings<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to planned<span style="letter-spacing:0.05pt;"> </span>or completed clinical trials and ultimately of reviews and approvals of our product candidates. The global COVID-19 pandemic<span style="letter-spacing:1.1pt;"> </span>continues<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>rapidly<span style="letter-spacing:1.1pt;"> </span>evolve.<span style="letter-spacing:1.1pt;"> </span>The<span style="letter-spacing:1.05pt;"> </span>extent<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>which<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.05pt;"> </span>COVID-19<span style="letter-spacing:0.95pt;"> </span>pandemic<span style="letter-spacing:1.05pt;"> </span>may<span style="letter-spacing:1.05pt;"> </span>impact<span style="letter-spacing:1.1pt;"> </span>our<span style="letter-spacing:1pt;"> </span>business and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>depend<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>developments,<span style="letter-spacing:0.15pt;"> </span>which are<span style="letter-spacing:0.05pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>uncertain<span style="letter-spacing:0.1pt;"> </span>and cannot<span style="letter-spacing:0.05pt;"> </span>be predicted<span style="letter-spacing:0.1pt;"> </span>with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>effectiveness<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:0.1pt;"> </span>taken<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>to contain<span style="letter-spacing:0.05pt;"> </span>and treat<span style="letter-spacing:0.1pt;"> </span>the disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adverse<span style="letter-spacing:0.05pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:0.1pt;"> </span>with PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811,<span style="letter-spacing:-0.05pt;"> </span>PRT1419, PRT2527<span style="letter-spacing:-0.05pt;"> </span>or our other<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:0.05pt;"> </span>could delay<span style="letter-spacing:0.05pt;"> </span>or preclude<span style="letter-spacing:0.05pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>cause us to suspend or discontinue<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or abandon further<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>the commercial<span style="letter-spacing:0.1pt;"> </span>profile<span style="letter-spacing:0.1pt;"> </span>of an approved<span style="letter-spacing:0.05pt;"> </span>product,<span style="letter-spacing:0.05pt;"> </span>or result<span style="letter-spacing:0.05pt;"> </span>in significant<span style="letter-spacing:0.1pt;"> </span>negative<span style="letter-spacing:0.05pt;"> </span>consequences<span style="letter-spacing:0.05pt;"> </span>following<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>case<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>pharmaceuticals<span style="letter-spacing:0.15pt;"> </span>generally,<span style="letter-spacing:0.1pt;"> </span>we have observed<span style="letter-spacing:0.05pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>and adverse<span style="letter-spacing:0.05pt;"> </span>events<span style="letter-spacing:0.05pt;"> </span>associated with<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:0.65pt;"> </span>clinical<span style="letter-spacing:0.75pt;"> </span>product<span style="letter-spacing:0.7pt;"> </span>candidate,<span style="letter-spacing:0.75pt;"> </span>PRT543.<span style="letter-spacing:0.6pt;"> </span>These<span style="letter-spacing:0.65pt;"> </span>side<span style="letter-spacing:0.7pt;"> </span>effects<span style="letter-spacing:0.75pt;"> </span>included<span style="letter-spacing:0.7pt;"> </span>diarrhea,<span style="letter-spacing:0.75pt;"> </span>nausea<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>fatigue,<span style="letter-spacing:0.7pt;"> </span>but<span style="letter-spacing:0.6pt;"> </span>none of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>side<span style="letter-spacing:0.1pt;"> </span>effects<span style="letter-spacing:0.15pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>considered<span style="letter-spacing:0.15pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>PRT543. At the<span style="letter-spacing:0.05pt;"> </span>highest<span style="letter-spacing:0.05pt;"> </span>dose level<span style="letter-spacing:0.05pt;"> </span>of our clinical<span style="letter-spacing:0.1pt;"> </span>product candidate,<span style="letter-spacing:0.95pt;"> </span>PRT543,<span style="letter-spacing:0.8pt;"> </span>there<span style="letter-spacing:0.9pt;"> </span>were<span style="letter-spacing:0.85pt;"> </span>occurrences<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>grade<span style="letter-spacing:0.9pt;"> </span>4<span style="letter-spacing:0.85pt;"> </span>thrombocytopenia<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.9pt;"> </span>were<span style="letter-spacing:0.85pt;"> </span>deemed<span style="letter-spacing:0.9pt;"> </span>related<span style="letter-spacing:0.95pt;"> </span>to<span style="letter-spacing:0.85pt;"> </span>PRT543, but<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>toxicity<span style="letter-spacing:0.15pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span>reversible<span style="letter-spacing:0.15pt;"> </span>after<span style="letter-spacing:0.15pt;"> </span>a one to two week drug holiday<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>affected<span style="letter-spacing:0.1pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>remained<span style="letter-spacing:0.1pt;"> </span>on the study<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>restarted<span style="letter-spacing:0.15pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>lower<span style="letter-spacing:0.1pt;"> </span>dose.<span style="letter-spacing:0.05pt;"> </span>We have also<span style="letter-spacing:0.05pt;"> </span>observed<span style="letter-spacing:0.05pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>and adverse<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.1pt;"> </span>with PRT811.<span style="letter-spacing:1.2pt;"> </span>These<span style="letter-spacing:1.25pt;"> </span>side<span style="letter-spacing:1.3pt;"> </span>effects<span style="letter-spacing:1.35pt;"> </span>included<span style="letter-spacing:1.3pt;"> </span>nausea,<span style="letter-spacing:1.25pt;"> </span>constipation,<span style="letter-spacing:1.3pt;"> </span>vomiting<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>hyponatremia,<span style="letter-spacing:1.3pt;"> </span>but<span style="letter-spacing:1.2pt;"> </span>none<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>these<span style="letter-spacing:1.25pt;"> </span>side effects<span style="letter-spacing:0.1pt;"> </span>were considered<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to PRT811.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results<span style="letter-spacing:0.05pt;"> </span>of our ongoing and planned<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>reveal<span style="letter-spacing:0.05pt;"> </span>a high and unacceptable<span style="letter-spacing:0.1pt;"> </span>severity<span style="letter-spacing:0.1pt;"> </span>and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates<span style="letter-spacing:0.3pt;"> </span>could<span style="letter-spacing:0.25pt;"> </span>result<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>delay,<span style="letter-spacing:0.25pt;"> </span>suspension<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>termination<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>clinical<span style="letter-spacing:0.3pt;"> </span>trials<span style="letter-spacing:0.3pt;"> </span>by<span style="letter-spacing:0.2pt;"> </span>us<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>regulatory<span style="letter-spacing:0.3pt;"> </span>authorities<span style="letter-spacing:0.3pt;"> </span>for a number of reasons. Furthermore, clinical trials by their nature utilize a sample of the potential patient population.<span style="letter-spacing:0.9pt;"> </span>With<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:0.85pt;"> </span>limited<span style="letter-spacing:0.9pt;"> </span>number<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>subjects<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>limited<span style="letter-spacing:0.9pt;"> </span>duration<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>exposure,<span style="letter-spacing:0.85pt;"> </span>rare<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>severe<span style="letter-spacing:0.85pt;"> </span>side<span style="letter-spacing:0.85pt;"> </span>effects<span style="letter-spacing:0.9pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or those<span style="letter-spacing:0.05pt;"> </span>of our competitors<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>only be uncovered<span style="letter-spacing:0.05pt;"> </span>with a significantly<span style="letter-spacing:0.15pt;"> </span>larger<span style="letter-spacing:0.1pt;"> </span>number<span style="letter-spacing:0.05pt;"> </span>of patients<span style="letter-spacing:0.1pt;"> </span>exposed<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>drug.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:0.15pt;"> </span>due<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>high<span style="letter-spacing:0.05pt;"> </span>mortality<span style="letter-spacing:0.2pt;"> </span>rates<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>cancers<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we are<span style="letter-spacing:0.05pt;"> </span>initially<span style="letter-spacing:0.15pt;"> </span>pursuing<span style="letter-spacing:0.05pt;"> </span>development and<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>pretreated<span style="letter-spacing:1.25pt;"> </span>nature<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.15pt;"> </span>many<span style="letter-spacing:1.2pt;"> </span>patients<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>ongoing<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trials<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>PRT543,<span style="letter-spacing:1.05pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, a material<span style="letter-spacing:0.15pt;"> </span>percentage<span style="letter-spacing:0.1pt;"> </span>of patients<span style="letter-spacing:0.1pt;"> </span>in these<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>die<span style="letter-spacing:0.05pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>a trial,<span style="letter-spacing:0.1pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>impact<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.05pt;"> </span>of PRT543, PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, respectively.<span style="letter-spacing:0.2pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>elect<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to delay,<span style="letter-spacing:0.05pt;"> </span>suspend<span style="letter-spacing:0.05pt;"> </span>or terminate<span style="letter-spacing:0.15pt;"> </span>any clinical<span style="letter-spacing:0.15pt;"> </span>trial,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>prospects<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>harmed<span style="letter-spacing:0.1pt;"> </span>and our ability<span style="letter-spacing:0.1pt;"> </span>to generate product<span style="letter-spacing:1.25pt;"> </span>revenues<span style="letter-spacing:1.25pt;"> </span>from<span style="letter-spacing:1.25pt;"> </span>this<span style="letter-spacing:1.25pt;"> </span>product<span style="letter-spacing:1.25pt;"> </span>candidate<span style="letter-spacing:1.3pt;"> </span>will<span style="letter-spacing:1.2pt;"> </span>be<span style="letter-spacing:1.15pt;"> </span>delayed<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>eliminated.<span style="letter-spacing:1.3pt;"> </span>Serious<span style="letter-spacing:1.2pt;"> </span>adverse<span style="letter-spacing:1.2pt;"> </span>events,<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>SAEs, observed<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>hinder<span style="letter-spacing:0.1pt;"> </span>or prevent<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>acceptance<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>Any of these occurrences<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business,<span style="letter-spacing:0.05pt;"> </span>prospects,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>significantly.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.1pt;"> </span>with undesirable<span style="letter-spacing:0.1pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or have characteristics<span style="letter-spacing:0.25pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>unexpected,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>elect<span style="letter-spacing:0.05pt;"> </span>to abandon or limit<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>to more<span style="letter-spacing:0.05pt;"> </span>narrow<span style="letter-spacing:0.05pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>or subpopulations<span style="letter-spacing:1.6pt;"> </span>in<span style="letter-spacing:1.45pt;"> </span>which<span style="letter-spacing:1.45pt;"> </span>the<span style="letter-spacing:1.5pt;"> </span>undesirable<span style="letter-spacing:1.55pt;"> </span>side<span style="letter-spacing:1.5pt;"> </span>effects<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:1.45pt;"> </span>other<span style="letter-spacing:1.5pt;"> </span>characteristics<span style="letter-spacing:1.65pt;"> </span>are<span style="letter-spacing:1.5pt;"> </span>less<span style="letter-spacing:1.5pt;"> </span>prevalent,<span style="letter-spacing:1.55pt;"> </span>less<span style="letter-spacing:1.5pt;"> </span>severe<span style="letter-spacing:1.5pt;"> </span>or more<span style="letter-spacing:0.1pt;"> </span>acceptable<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>risk-benefit<span style="letter-spacing:0.2pt;"> </span>perspective,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.15pt;"> </span>expectations<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product candidates,<span style="letter-spacing:1.3pt;"> </span>if<span style="letter-spacing:1.25pt;"> </span>approved.<span style="letter-spacing:1.25pt;"> </span>We<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>also<span style="letter-spacing:1.2pt;"> </span>be<span style="letter-spacing:1.15pt;"> </span>required<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>modify<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>study<span style="letter-spacing:1.2pt;"> </span>plans<span style="letter-spacing:1.2pt;"> </span>based<span style="letter-spacing:1.2pt;"> </span>on<span style="letter-spacing:1.15pt;"> </span>findings<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>clinical trials.<span style="letter-spacing:1.15pt;"> </span>Such<span style="letter-spacing:1.05pt;"> </span>side<span style="letter-spacing:1.1pt;"> </span>effects<span style="letter-spacing:1.15pt;"> </span>could<span style="letter-spacing:1.1pt;"> </span>also<span style="letter-spacing:1.1pt;"> </span>affect<span style="letter-spacing:1.15pt;"> </span>patient<span style="letter-spacing:1.15pt;"> </span>recruitment<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>ability<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>enrolled<span style="letter-spacing:1.15pt;"> </span>patients<span style="letter-spacing:1.15pt;"> </span>to<span style="letter-spacing:1pt;"> </span>complete<span style="letter-spacing:1.1pt;"> </span>the trial.<span style="letter-spacing:0.15pt;"> </span>Many<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>initially<span style="letter-spacing:0.2pt;"> </span>showed<span style="letter-spacing:0.05pt;"> </span>promise<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>early<span style="letter-spacing:0.1pt;"> </span>stage<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>have later<span style="letter-spacing:0.1pt;"> </span>been found to cause<span style="letter-spacing:0.05pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects that<span style="letter-spacing:1.15pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevented</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">further</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development.</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">draw</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusions,</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confirm</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determinations,</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictive</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">labeling,</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deny</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval of the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>possible<span style="letter-spacing:0.1pt;"> </span>that,<span style="letter-spacing:0.1pt;"> </span>as we test<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in larger,<span style="letter-spacing:0.1pt;"> </span>longer<span style="letter-spacing:0.05pt;"> </span>and more<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials, including<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>different<span style="letter-spacing:0.15pt;"> </span>dosing<span style="letter-spacing:0.1pt;"> </span>regimens,<span style="letter-spacing:0.1pt;"> </span>or as the<span style="letter-spacing:0.05pt;"> </span>use of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>becomes<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>widespread following<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>approval,<span style="letter-spacing:0.1pt;"> </span>illnesses,<span style="letter-spacing:0.15pt;"> </span>injuries,<span style="letter-spacing:0.15pt;"> </span>discomforts<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>events<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>were observed<span style="letter-spacing:0.05pt;"> </span>in earlier<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as conditions<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>did not occur<span style="letter-spacing:0.05pt;"> </span>or went undetected<span style="letter-spacing:0.1pt;"> </span>in previous<span style="letter-spacing:0.05pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be reported<span style="letter-spacing:0.1pt;"> </span>by patients.<span style="letter-spacing:1.2pt;"> </span>If<span style="letter-spacing:1.15pt;"> </span>such<span style="letter-spacing:1.1pt;"> </span>side<span style="letter-spacing:1.15pt;"> </span>effects<span style="letter-spacing:1.2pt;"> </span>become<span style="letter-spacing:1.15pt;"> </span>known<span style="letter-spacing:1.1pt;"> </span>later<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>development<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>upon<span style="letter-spacing:1.1pt;"> </span>approval,<span style="letter-spacing:1.15pt;"> </span>if<span style="letter-spacing:1.15pt;"> </span>any,<span style="letter-spacing:1.1pt;"> </span>such<span style="letter-spacing:1.1pt;"> </span>findings<span style="letter-spacing:1.1pt;"> </span>may harm<span style="letter-spacing:0.05pt;"> </span>our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects<span style="letter-spacing:0.1pt;"> </span>significantly.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>and we or others<span style="letter-spacing:0.05pt;"> </span>later<span style="letter-spacing:0.1pt;"> </span>identify undesirable<span style="letter-spacing:0.15pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>caused<span style="letter-spacing:0.05pt;"> </span>by treatment<span style="letter-spacing:0.15pt;"> </span>with such drug, a number<span style="letter-spacing:0.05pt;"> </span>of potentially<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>negative consequences<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory<span style="letter-spacing:0.1pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>withdraw<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>drug&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may<span style="letter-spacing:0.05pt;"> </span>be required<span style="letter-spacing:0.1pt;"> </span>to recall<span style="letter-spacing:0.1pt;"> </span>a product<span style="letter-spacing:0.05pt;"> </span>or change<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>way the<span style="letter-spacing:0.05pt;"> </span>drug is<span style="letter-spacing:0.05pt;"> </span>administered<span style="letter-spacing:0.15pt;"> </span>to patients&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory<span style="letter-spacing:0.9pt;"> </span>authorities<span style="letter-spacing:0.95pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>require<span style="letter-spacing:0.9pt;"> </span>additional<span style="letter-spacing:0.9pt;"> </span>warnings<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>labeling,<span style="letter-spacing:0.9pt;"> </span>such<span style="letter-spacing:0.8pt;"> </span>as<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.75pt;"> </span>contraindication<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>a boxed<span style="letter-spacing:0.05pt;"> </span>warning,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>issue<span style="letter-spacing:0.1pt;"> </span>safety<span style="letter-spacing:0.1pt;"> </span>alerts,<span style="letter-spacing:0.15pt;"> </span>Dear<span style="letter-spacing:0.05pt;"> </span>Healthcare<span style="letter-spacing:0.15pt;"> </span>Provider<span style="letter-spacing:0.1pt;"> </span>letters,<span style="letter-spacing:0.15pt;"> </span>press<span style="letter-spacing:0.05pt;"> </span>releases<span style="letter-spacing:0.1pt;"> </span>or other communications<span style="letter-spacing:0.15pt;"> </span>containing<span style="letter-spacing:0.1pt;"> </span>warnings<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>about<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<span style="letter-spacing:1.25pt;"> </span>may<span style="letter-spacing:1.3pt;"> </span>be<span style="letter-spacing:1.25pt;"> </span>required<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>implement<span style="letter-spacing:1.35pt;"> </span>a<span style="letter-spacing:1.25pt;"> </span>Risk<span style="letter-spacing:1.25pt;"> </span>Evaluation<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>Mitigation<span style="letter-spacing:1.35pt;"> </span>Strategy,<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>REMS,<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>create<span style="letter-spacing:1.3pt;"> </span>a medication<span style="letter-spacing:0.1pt;"> </span>guide<span style="letter-spacing:0.05pt;"> </span>outlining<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>of such side<span style="letter-spacing:0.05pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>distribution<span style="letter-spacing:0.15pt;"> </span>to patients&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">additional<span style="letter-spacing:0.8pt;"> </span>restrictions<span style="letter-spacing:0.85pt;"> </span>may<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.65pt;"> </span>imposed<span style="letter-spacing:0.7pt;"> </span>on<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>marketing<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>promotion<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>particular<span style="letter-spacing:0.8pt;"> </span>product<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>the manufacturing<span style="letter-spacing:0.15pt;"> </span>processes<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>or any component<span style="letter-spacing:0.05pt;"> </span>thereof&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we could<span style="letter-spacing:0.05pt;"> </span>be sued and held<span style="letter-spacing:0.05pt;"> </span>liable<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>caused<span style="letter-spacing:0.05pt;"> </span>to patients&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to regulatory<span style="letter-spacing:0.1pt;"> </span>investigations<span style="letter-spacing:0.15pt;"> </span>and government<span style="letter-spacing:0.1pt;"> </span>enforcement<span style="letter-spacing:0.1pt;"> </span>actions&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>drug could<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>competitive&#59;<span style="letter-spacing:0.15pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our reputation<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>suffer.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>events<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>achieving<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>maintaining<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>acceptance<span style="letter-spacing:0.1pt;"> </span>of our product candidates,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>approved,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>significantly<span style="letter-spacing:0.2pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preliminary,<span style="letter-spacing:0.1pt;"> </span>interim<span style="letter-spacing:0.1pt;"> </span>and topline<span style="letter-spacing:0.05pt;"> </span>data from<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we announce or publish<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>to time<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>change as more<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.05pt;"> </span>data become<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>and are subject<span style="letter-spacing:0.05pt;"> </span>to audit<span style="letter-spacing:0.05pt;"> </span>and verification procedures<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could result<span style="letter-spacing:0.05pt;"> </span>in material<span style="letter-spacing:0.1pt;"> </span>changes in the final<span style="letter-spacing:0.05pt;"> </span>data.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<span style="letter-spacing:1.2pt;"> </span>time<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>time,<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>publicly<span style="letter-spacing:1.2pt;"> </span>disclose<span style="letter-spacing:1.25pt;"> </span>preliminary,<span style="letter-spacing:1.3pt;"> </span>interim<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>topline<span style="letter-spacing:1.15pt;"> </span>data<span style="letter-spacing:1.15pt;"> </span>from<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trials, such<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>preliminary<span style="letter-spacing:0.25pt;"> </span>data<span style="letter-spacing:0.15pt;"> </span>analysis<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>Phase<span style="letter-spacing:0.1pt;"> </span>1<span style="letter-spacing:0.1pt;"> </span>dose<span style="letter-spacing:0.05pt;"> </span>expansion<span style="letter-spacing:0.1pt;"> </span>portions<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>PRT543 and<span style="letter-spacing:0.05pt;"> </span>PRT811 trials. These<span style="letter-spacing:0.05pt;"> </span>updates<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>based<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>preliminary<span style="letter-spacing:0.2pt;"> </span>analysis<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>then-available<span style="letter-spacing:0.2pt;"> </span>data,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>and related<span style="letter-spacing:0.1pt;"> </span>findings<span style="letter-spacing:0.05pt;"> </span>and conclusions<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to change<span style="letter-spacing:0.05pt;"> </span>following<span style="letter-spacing:0.05pt;"> </span>a more<span style="letter-spacing:0.05pt;"> </span>comprehensive<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>particular study<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.35pt;"> </span>trial.<span style="letter-spacing:0.4pt;"> </span>Additionally,<span style="letter-spacing:0.4pt;"> </span>interim<span style="letter-spacing:0.4pt;"> </span>data<span style="letter-spacing:0.35pt;"> </span>from<span style="letter-spacing:0.35pt;"> </span>clinical<span style="letter-spacing:0.4pt;"> </span>trials<span style="letter-spacing:0.4pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>we<span style="letter-spacing:0.3pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>complete<span style="letter-spacing:0.4pt;"> </span>are<span style="letter-spacing:0.35pt;"> </span>subject<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>risk<span style="letter-spacing:0.35pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>one or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>outcomes<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>materially<span style="letter-spacing:0.2pt;"> </span>change<span style="letter-spacing:0.1pt;"> </span>as patient<span style="letter-spacing:0.1pt;"> </span>enrollment<span style="letter-spacing:0.1pt;"> </span>continues<span style="letter-spacing:0.05pt;"> </span>and more<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>data become<span style="letter-spacing:0.1pt;"> </span>available.<span style="letter-spacing:0.15pt;"> </span>Therefore,<span style="letter-spacing:0.15pt;"> </span>positive<span style="letter-spacing:0.15pt;"> </span>interim<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>ongoing<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be predictive<span style="letter-spacing:0.1pt;"> </span>of such results<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>completed<span style="letter-spacing:0.15pt;"> </span>study<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>trial.<span style="letter-spacing:0.15pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>make<span style="letter-spacing:0.1pt;"> </span>assumptions,<span style="letter-spacing:0.1pt;"> </span>estimations,<span style="letter-spacing:0.15pt;"> </span>calculations<span style="letter-spacing:0.15pt;"> </span>and conclusions<span style="letter-spacing:0.1pt;"> </span>as part<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>analyses<span style="letter-spacing:0.05pt;"> </span>of data,<span style="letter-spacing:0.05pt;"> </span>and we may<span style="letter-spacing:0.05pt;"> </span>not have received<span style="letter-spacing:0.1pt;"> </span>or had the<span style="letter-spacing:0.05pt;"> </span>opportunity<span style="letter-spacing:0.1pt;"> </span>to fully<span style="letter-spacing:0.05pt;"> </span>and carefully<span style="letter-spacing:0.1pt;"> </span>evaluate all<span style="letter-spacing:0.1pt;"> </span>data.<span style="letter-spacing:0.1pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>result,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>topline<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we report<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>differ<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>studies,<span style="letter-spacing:0.05pt;"> </span>or different<span style="letter-spacing:1.45pt;"> </span>conclusions<span style="letter-spacing:1.45pt;"> </span>or<span style="letter-spacing:1.3pt;"> </span>considerations<span style="letter-spacing:1.45pt;"> </span>may<span style="letter-spacing:1.35pt;"> </span>qualify<span style="letter-spacing:1.35pt;"> </span>such<span style="letter-spacing:1.3pt;"> </span>results,<span style="letter-spacing:1.4pt;"> </span>once<span style="letter-spacing:1.3pt;"> </span>additional<span style="letter-spacing:1.4pt;"> </span>data<span style="letter-spacing:1.35pt;"> </span>have<span style="letter-spacing:1.3pt;"> </span>been<span style="letter-spacing:1.3pt;"> </span>received<span style="letter-spacing:1.4pt;"> </span>and fully<span style="letter-spacing:0.55pt;"> </span>evaluated.<span style="letter-spacing:0.6pt;"> </span>Topline<span style="letter-spacing:0.55pt;"> </span>data<span style="letter-spacing:0.55pt;"> </span>also<span style="letter-spacing:0.5pt;"> </span>remain<span style="letter-spacing:0.55pt;"> </span>subject<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.45pt;"> </span>audit<span style="letter-spacing:0.5pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>verification<span style="letter-spacing:0.6pt;"> </span>procedures<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.5pt;"> </span>result<span style="letter-spacing:0.55pt;"> </span>in<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span>final data<span style="letter-spacing:2pt;"> </span>being<span style="letter-spacing:2pt;"> </span>materially<span style="letter-spacing:2.1pt;"> </span>different<span style="letter-spacing:2.05pt;"> </span>from<span style="letter-spacing:2pt;"> </span>the<span style="letter-spacing:1.95pt;"> </span>preliminary<span style="letter-spacing:2.05pt;"> </span>data<span style="letter-spacing:1.95pt;"> </span>we<span style="letter-spacing:1.9pt;"> </span>previously<span style="letter-spacing:2pt;"> </span>published.<span style="letter-spacing:1.95pt;"> </span>As<span style="letter-spacing:1.9pt;"> </span>a<span style="letter-spacing:1.9pt;"> </span>result,<span style="letter-spacing:2pt;"> </span>topline<span style="letter-spacing:1.95pt;"> </span>data should<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>viewed<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>caution<span style="letter-spacing:0.1pt;"> </span>until<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>final<span style="letter-spacing:0.1pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>available.<span style="letter-spacing:0.15pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>report<span style="letter-spacing:0.05pt;"> </span>interim<span style="letter-spacing:0.1pt;"> </span>analyses<span style="letter-spacing:0.05pt;"> </span>of only<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>endpoints<span style="letter-spacing:0.1pt;"> </span>rather<span style="letter-spacing:0.15pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>endpoints.<span style="letter-spacing:0.1pt;"> </span>Adverse<span style="letter-spacing:0.1pt;"> </span>changes<span style="letter-spacing:0.1pt;"> </span>between<span style="letter-spacing:0.1pt;"> </span>preliminary<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>interim<span style="letter-spacing:0.15pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>and final data<span style="letter-spacing:0.7pt;"> </span>could<span style="letter-spacing:0.7pt;"> </span>significantly<span style="letter-spacing:0.8pt;"> </span>harm<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:0.65pt;"> </span>business<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>prospects.<span style="letter-spacing:0.75pt;"> </span>Further,<span style="letter-spacing:0.7pt;"> </span>additional<span style="letter-spacing:0.75pt;"> </span>disclosure<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>interim<span style="letter-spacing:0.7pt;"> </span>data<span style="letter-spacing:0.65pt;"> </span>by<span style="letter-spacing:0.6pt;"> </span>us<span style="letter-spacing:0.6pt;"> </span>or by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>volatility<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock.<span style="letter-spacing:0.1pt;"> </span>See the<span style="letter-spacing:1.3pt;"> </span>description<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>risks<span style="letter-spacing:1.3pt;"> </span>under<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>heading<span style="letter-spacing:1.25pt;"> </span>&#8220;Risks<span style="letter-spacing:1.25pt;"> </span>Related<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>Common<span style="letter-spacing:1.2pt;"> </span>Stock&#8221;<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.25pt;"> </span>more disclosure<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of volatility<span style="letter-spacing:0.15pt;"> </span>in our stock<span style="letter-spacing:0.05pt;"> </span>price.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<span style="letter-spacing:0.1pt;"> </span>others,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>agencies,<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not accept<span style="letter-spacing:0.05pt;"> </span>or agree<span style="letter-spacing:0.05pt;"> </span>with our assumptions,<span style="letter-spacing:0.1pt;"> </span>estimates, calculations,<span style="letter-spacing:0.2pt;"> </span>conclusions<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>analyses<span style="letter-spacing:0.05pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>interpret<span style="letter-spacing:0.1pt;"> </span>or weigh the<span style="letter-spacing:0.05pt;"> </span>importance<span style="letter-spacing:0.1pt;"> </span>of data<span style="letter-spacing:0.05pt;"> </span>differently,<span style="letter-spacing:0.15pt;"> </span>which could impact<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>particular<span style="letter-spacing:0.15pt;"> </span>program,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>approvability<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>particular<span style="letter-spacing:0.15pt;"> </span>product candidate<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>product<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>company<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>general.<span style="letter-spacing:1.2pt;"> </span>In<span style="letter-spacing:1.15pt;"> </span>addition,<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>information<span style="letter-spacing:1.3pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>choose<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>publicly<span style="letter-spacing:1.2pt;"> </span>disclose regarding<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>particular<span style="letter-spacing:0.2pt;"> </span>study<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>typically<span style="letter-spacing:0.15pt;"> </span>selected<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of available information.</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not agree</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with what we determine</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or otherwise</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate information</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosure,</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclose</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be deemed</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decisions,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusions,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">views, activities</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or otherwise</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a particular</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preliminary</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or topline</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we report</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">differ</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from late,</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actual</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results,</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others,</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities,</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disagree</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusions</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reached, our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize,</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT543, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT811</span><span style="letter-spacing:0.05pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT1419</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> PRT2527, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harmed,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects.</span></p>
<p style="margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>expend our limited<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.05pt;"> </span>to pursue a particular<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.05pt;"> </span>or indication<span style="letter-spacing:0.05pt;"> </span>and fail<span style="letter-spacing:0.05pt;"> </span>to capitalize<span style="letter-spacing:0.1pt;"> </span>on product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>or indications<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be more<span style="letter-spacing:0.05pt;"> </span>profitable<span style="letter-spacing:0.1pt;"> </span>or for<span style="letter-spacing:0.05pt;"> </span>which there<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>a greater likelihood<span style="letter-spacing:0.1pt;"> </span>of success.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>managerial<span style="letter-spacing:0.15pt;"> </span>resources,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>focus<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.1pt;"> </span>programs<span style="letter-spacing:0.1pt;"> </span>and product candidates<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we identify<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>specific<span style="letter-spacing:0.1pt;"> </span>indications.<span style="letter-spacing:0.1pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>forego<span style="letter-spacing:0.05pt;"> </span>or delay<span style="letter-spacing:0.05pt;"> </span>pursuit<span style="letter-spacing:0.05pt;"> </span>of opportunities with<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>indications<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>later<span style="letter-spacing:0.15pt;"> </span>prove<span style="letter-spacing:0.05pt;"> </span>to have greater<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.15pt;"> </span>potential.<span style="letter-spacing:0.1pt;"> </span>Our resource<span style="letter-spacing:2pt;"> </span>allocation<span style="letter-spacing:2pt;"> </span>decisions<span style="letter-spacing:2pt;"> </span>may<span style="letter-spacing:1.95pt;"> </span>cause<span style="letter-spacing:1.95pt;"> </span>us<span style="letter-spacing:1.9pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>fail<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>capitalize<span style="letter-spacing:2pt;"> </span>on<span style="letter-spacing:1.85pt;"> </span>viable<span style="letter-spacing:1.9pt;"> </span>commercial<span style="letter-spacing:2pt;"> </span>products<span style="letter-spacing:1.9pt;"> </span>or<span style="letter-spacing:1.85pt;"> </span>profitable market<span style="letter-spacing:0.1pt;"> </span>opportunities.<span style="letter-spacing:0.1pt;"> </span>Our spending<span style="letter-spacing:0.05pt;"> </span>on current<span style="letter-spacing:0.1pt;"> </span>and future<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.1pt;"> </span>and development<span style="letter-spacing:0.1pt;"> </span>programs<span style="letter-spacing:0.1pt;"> </span>and product candidates<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>specific<span style="letter-spacing:0.15pt;"> </span>indications<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not yield<span style="letter-spacing:0.05pt;"> </span>any commercially<span style="letter-spacing:0.15pt;"> </span>viable<span style="letter-spacing:0.05pt;"> </span>products.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we do not accurately evaluate<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.15pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>or target<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a particular<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>relinquish<span style="letter-spacing:0.1pt;"> </span>valuable rights<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>through<span style="letter-spacing:0.1pt;"> </span>collaboration,<span style="letter-spacing:0.2pt;"> </span>licensing<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>royalty<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>in cases<span style="letter-spacing:0.05pt;"> </span>in which it would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>been more<span style="letter-spacing:0.05pt;"> </span>advantageous<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>us to retain<span style="letter-spacing:0.1pt;"> </span>sole<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to such product<span style="letter-spacing:0.05pt;"> </span>candidate.</p>
<p style="margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>not be successful<span style="letter-spacing:0.1pt;"> </span>in our efforts<span style="letter-spacing:0.1pt;"> </span>to design<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="letter-spacing:0.05pt;"> </span>key<span style="letter-spacing:0.05pt;"> </span>element<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>strategy<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:0.1pt;"> </span>molecular<span style="letter-spacing:0.1pt;"> </span>targets<span style="letter-spacing:0.1pt;"> </span>and intervention<span style="letter-spacing:0.1pt;"> </span>points<span style="letter-spacing:0.05pt;"> </span>leading<span style="letter-spacing:0.05pt;"> </span>to treatment failure,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>then<span style="letter-spacing:0.1pt;"> </span>apply<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>expertise<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cancer<span style="letter-spacing:0.05pt;"> </span>biology<span style="letter-spacing:0.05pt;"> </span>and medicinal<span style="letter-spacing:0.1pt;"> </span>chemistry,<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as our in-depth understanding<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>current<span style="letter-spacing:0.65pt;"> </span>landscape<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>oncology<span style="letter-spacing:0.6pt;"> </span>treatments,<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.55pt;"> </span>design<span style="letter-spacing:0.55pt;"> </span>solutions<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.55pt;"> </span>can<span style="letter-spacing:0.5pt;"> </span>be<span style="letter-spacing:0.5pt;"> </span>precisely<span style="letter-spacing:0.6pt;"> </span>tailored in<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>target<span style="letter-spacing:0.15pt;"> </span>class<span style="letter-spacing:0.1pt;"> </span>agnostic<span style="letter-spacing:0.05pt;"> </span>fashion.<span style="letter-spacing:0.05pt;"> </span>The therapeutic<span style="letter-spacing:0.1pt;"> </span>design<span style="letter-spacing:0.05pt;"> </span>and development<span style="letter-spacing:0.1pt;"> </span>activities<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>conducting<span style="letter-spacing:0.05pt;"> </span>may not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>successful<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>developing<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>safe<span style="letter-spacing:0.05pt;"> </span>and effective<span style="letter-spacing:0.1pt;"> </span>in treating<span style="letter-spacing:0.1pt;"> </span>cancer<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>diseases. Our<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.15pt;"> </span>programs<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>initially<span style="letter-spacing:0.2pt;"> </span>show<span style="letter-spacing:0.05pt;"> </span>promise<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>identifying<span style="letter-spacing:0.15pt;"> </span>potential<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>yet<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to yield product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a number<span style="letter-spacing:0.05pt;"> </span>of reasons,<span style="letter-spacing:0.05pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the target selection methodology used may not be successful in identifying potential product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential<span style="letter-spacing:1.7pt;"> </span>product<span style="letter-spacing:1.65pt;"> </span>candidates<span style="letter-spacing:1.7pt;"> </span>may,<span style="letter-spacing:1.6pt;"> </span>on<span style="letter-spacing:1.55pt;"> </span>further<span style="letter-spacing:1.65pt;"> </span>study,<span style="letter-spacing:1.6pt;"> </span>be<span style="letter-spacing:1.55pt;"> </span>shown<span style="letter-spacing:1.55pt;"> </span>to<span style="letter-spacing:1.55pt;"> </span>have<span style="letter-spacing:1.55pt;"> </span>harmful<span style="letter-spacing:1.65pt;"> </span>side<span style="letter-spacing:1.6pt;"> </span>effects<span style="letter-spacing:1.65pt;"> </span>or<span style="letter-spacing:1.55pt;"> </span>other characteristics<span style="letter-spacing:1.4pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>indicate<span style="letter-spacing:1.3pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>they<span style="letter-spacing:1.25pt;"> </span>are<span style="letter-spacing:1.25pt;"> </span>unlikely<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>be<span style="letter-spacing:1.15pt;"> </span>drugs<span style="letter-spacing:1.2pt;"> </span>that<span style="letter-spacing:1.2pt;"> </span>will<span style="letter-spacing:1.2pt;"> </span>obtain<span style="letter-spacing:1.2pt;"> </span>marketing<span style="letter-spacing:1.25pt;"> </span>approval<span style="letter-spacing:1.2pt;"> </span>or achieve<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>acceptance&#59;<span style="letter-spacing:0.1pt;"> </span>or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:4pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be effective<span style="letter-spacing:0.1pt;"> </span>in treating<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>targeted<span style="letter-spacing:0.1pt;"> </span>diseases.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<span style="letter-spacing:0.1pt;"> </span>programs<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>design<span style="letter-spacing:0.05pt;"> </span>new product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>technical,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>and human<span style="letter-spacing:0.1pt;"> </span>resources.<span style="letter-spacing:0.15pt;"> </span>We may<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:0.05pt;"> </span>to focus<span style="letter-spacing:0.05pt;"> </span>our efforts<span style="letter-spacing:0.1pt;"> </span>and resources<span style="letter-spacing:0.1pt;"> </span>on a potential<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>that ultimately<span style="letter-spacing:0.2pt;"> </span>proves<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>be unsuccessful.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:0.05pt;"> </span>to identify<span style="letter-spacing:0.1pt;"> </span>and design<span style="letter-spacing:0.05pt;"> </span>suitable<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>for preclinical<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>development,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>revenues<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>of products<span style="letter-spacing:0.05pt;"> </span>in future periods,<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>to our financial<span style="letter-spacing:0.1pt;"> </span>position<span style="letter-spacing:0.05pt;"> </span>and adversely<span style="letter-spacing:0.1pt;"> </span>impact<span style="letter-spacing:0.1pt;"> </span>our stock price.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Government<span style="letter-spacing:0.05pt;"> </span>Regulation</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>of pharmaceutical<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>are subject<span style="letter-spacing:0.05pt;"> </span>to extensive<span style="letter-spacing:0.1pt;"> </span>regulation, and we may<span style="letter-spacing:0.05pt;"> </span>not obtain<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>approvals<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>PRT543,<span style="letter-spacing:-0.05pt;"> </span>PRT811,<span style="letter-spacing:-0.05pt;"> </span>PRT1419,<span style="letter-spacing:-0.05pt;"> </span>PRT2527<span style="letter-spacing:-0.05pt;"> </span>or any other product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>basis<span style="letter-spacing:0.05pt;"> </span>or at all.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical<span style="letter-spacing:0.1pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>manufacturing,<span style="letter-spacing:0.1pt;"> </span>labeling,<span style="letter-spacing:0.05pt;"> </span>packaging, storage, recordkeeping,<span style="letter-spacing:0.05pt;"> </span>advertising, promotion,<span style="letter-spacing:1.25pt;"> </span>export,<span style="letter-spacing:1.2pt;"> </span>import,<span style="letter-spacing:1.25pt;"> </span>marketing,<span style="letter-spacing:1.25pt;"> </span>distribution,<span style="letter-spacing:1.3pt;"> </span>adverse<span style="letter-spacing:1.15pt;"> </span>event<span style="letter-spacing:1.15pt;"> </span>reporting,<span style="letter-spacing:1.2pt;"> </span>including<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>submission<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>safety and<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>post-marketing<span style="letter-spacing:0.25pt;"> </span>information<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>reports,<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>possible<span style="letter-spacing:0.15pt;"> </span>activities<span style="letter-spacing:0.25pt;"> </span>relating<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>PRT543,<span style="letter-spacing:0.05pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, currently<span style="letter-spacing:0.1pt;"> </span>our only product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in planned<span style="letter-spacing:0.05pt;"> </span>or ongoing clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as any other<span style="letter-spacing:0.05pt;"> </span>product candidate<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>develop<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future,<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.15pt;"> </span>regulation.<span style="letter-spacing:0.15pt;"> </span>Marketing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of drugs<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States<span style="letter-spacing:0.1pt;"> </span>requires<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>submission<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>NDA to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA, and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not permitted<span style="letter-spacing:0.1pt;"> </span>to market<span style="letter-spacing:0.1pt;"> </span>any product candidate<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>United<span style="letter-spacing:1.2pt;"> </span>States<span style="letter-spacing:1.2pt;"> </span>until<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>obtain<span style="letter-spacing:1.15pt;"> </span>approval<span style="letter-spacing:1.15pt;"> </span>from<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>FDA<span style="letter-spacing:1.05pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>NDA<span style="letter-spacing:1.05pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>that<span style="letter-spacing:1.15pt;"> </span>product.<span style="letter-spacing:1.15pt;"> </span>An<span style="letter-spacing:1.1pt;"> </span>NDA must<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>supported<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>and preclinical<span style="letter-spacing:0.15pt;"> </span>data,<span style="letter-spacing:0.05pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as extensive<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>regarding pharmacology,<span style="letter-spacing:0.15pt;"> </span>chemistry,<span style="letter-spacing:0.15pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>controls.<span style="letter-spacing:0.15pt;"> </span>Our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>must<span style="letter-spacing:0.05pt;"> </span>be approved<span style="letter-spacing:0.05pt;"> </span>by comparable regulatory<span style="letter-spacing:0.1pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.15pt;"> </span>prior<span style="letter-spacing:0.05pt;"> </span>to commercialization.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>NDA is<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>guaranteed,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>process<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>expensive<span style="letter-spacing:0.1pt;"> </span>and uncertain<span style="letter-spacing:0.15pt;"> </span>process<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>take<span style="letter-spacing:0.1pt;"> </span>several<span style="letter-spacing:0.15pt;"> </span>years.<span style="letter-spacing:0.1pt;"> </span>Of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>large<span style="letter-spacing:0.1pt;"> </span>number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States, only<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>small<span style="letter-spacing:0.2pt;"> </span>percentage<span style="letter-spacing:0.2pt;"> </span>will<span style="letter-spacing:0.15pt;"> </span>successfully<span style="letter-spacing:0.2pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complete</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA regulatory</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be commercialized.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receive regulatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdictions.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>FDA also<span style="letter-spacing:0.1pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.15pt;"> </span>discretion<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>process.<span style="letter-spacing:0.1pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>number<span style="letter-spacing:0.1pt;"> </span>and types<span style="letter-spacing:0.05pt;"> </span>of preclinical<span style="letter-spacing:0.15pt;"> </span>studies and<span style="letter-spacing:0.45pt;"> </span>clinical<span style="letter-spacing:0.55pt;"> </span>trials<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:0.45pt;"> </span>will<span style="letter-spacing:0.45pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>required<span style="letter-spacing:0.5pt;"> </span>for<span style="letter-spacing:0.45pt;"> </span>NDA<span style="letter-spacing:0.35pt;"> </span>approval<span style="letter-spacing:0.45pt;"> </span>varies<span style="letter-spacing:0.45pt;"> </span>depending<span style="letter-spacing:0.45pt;"> </span>on<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>product<span style="letter-spacing:0.45pt;"> </span>candidate,<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>disease or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>designed<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>treat<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>to any particular product<span style="letter-spacing:0.1pt;"> </span>candidate.<span style="letter-spacing:0.15pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>successful,<span style="letter-spacing:0.1pt;"> </span>we believe<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>expansion<span style="letter-spacing:0.05pt;"> </span>portions<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>Phase 1 clinical<span style="letter-spacing:0.1pt;"> </span>trials of<span style="letter-spacing:0.05pt;"> </span>PRT543 or<span style="letter-spacing:0.05pt;"> </span>PRT811 may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>support<span style="letter-spacing:0.1pt;"> </span>FDA approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>NDA for<span style="letter-spacing:0.1pt;"> </span>PRT543 or<span style="letter-spacing:0.05pt;"> </span>PRT811, respectively,<span style="letter-spacing:0.2pt;"> </span>but<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>disagree<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>sufficiency<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our data<span style="letter-spacing:0.05pt;"> </span>and require<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials. Additionally,<span style="letter-spacing:0.2pt;"> </span>depending<span style="letter-spacing:0.15pt;"> </span>upon<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>expansion<span style="letter-spacing:0.15pt;"> </span>portions<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>Phase<span style="letter-spacing:0.05pt;"> </span>1<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543 or PRT811,<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>choose<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>seek<span style="letter-spacing:1.2pt;"> </span>Subpart<span style="letter-spacing:1.2pt;"> </span>H<span style="letter-spacing:1.15pt;"> </span>accelerated<span style="letter-spacing:1.3pt;"> </span>approval<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>PRT543<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>PRT811,<span style="letter-spacing:1.1pt;"> </span>respectively,<span style="letter-spacing:1.3pt;"> </span>which would require<span style="letter-spacing:0.1pt;"> </span>completion<span style="letter-spacing:0.1pt;"> </span>of a confirmatory<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>to validate<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>benefit<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>drug. Despite<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>time and expense<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.2pt;"> </span>studies<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>failure<span style="letter-spacing:0.1pt;"> </span>can occur<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>any stage.<span style="letter-spacing:0.05pt;"> </span>The results<span style="letter-spacing:0.1pt;"> </span>of preclinical<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>early<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.2pt;"> </span>trials<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>may not be predictive<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of our later-stage<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>failure<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>multitude<span style="letter-spacing:0.1pt;"> </span>of factors<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>flaws<span style="letter-spacing:0.05pt;"> </span>in trial<span style="letter-spacing:0.1pt;"> </span>design,<span style="letter-spacing:0.05pt;"> </span>dose selection, placebo<span style="letter-spacing:2.1pt;"> </span>effect,<span style="letter-spacing:2.15pt;"> </span>patient<span style="letter-spacing:2.15pt;"> </span>enrollment<span style="letter-spacing:2.15pt;"> </span>criteria<span style="letter-spacing:2.2pt;"> </span>and<span style="letter-spacing:2.05pt;"> </span>failure<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2pt;"> </span>demonstrate<span style="letter-spacing:2.1pt;"> </span>favorable<span style="letter-spacing:2.1pt;"> </span>safety<span style="letter-spacing:2.05pt;"> </span>or<span style="letter-spacing:2pt;"> </span>efficacy<span style="letter-spacing:2.1pt;"> </span>traits,<span style="letter-spacing:2.1pt;"> </span>and failure<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>can occur<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>any stage.<span style="letter-spacing:0.05pt;"> </span>Companies<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>industry<span style="letter-spacing:0.05pt;"> </span>frequently<span style="letter-spacing:0.1pt;"> </span>suffer setbacks<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>advancement<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>due<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>lack<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>efficacy<span style="letter-spacing:0.1pt;"> </span>or adverse<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>profiles,<span style="letter-spacing:0.1pt;"> </span>notwithstanding promising<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>earlier<span style="letter-spacing:0.15pt;"> </span>trials.<span style="letter-spacing:0.15pt;"> </span>Based<span style="letter-spacing:0.05pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>negative<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inconclusive<span style="letter-spacing:0.15pt;"> </span>results,<span style="letter-spacing:0.15pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>decide,<span style="letter-spacing:0.05pt;"> </span>or regulators<span style="letter-spacing:0.1pt;"> </span>may require<span style="letter-spacing:0.15pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or preclinical<span style="letter-spacing:0.15pt;"> </span>studies.<span style="letter-spacing:0.05pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>obtained<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials are<span style="letter-spacing:0.1pt;"> </span>susceptible<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>varying<span style="letter-spacing:0.1pt;"> </span>interpretations,<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulators<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not interpret<span style="letter-spacing:0.1pt;"> </span>our data<span style="letter-spacing:0.05pt;"> </span>as favorably<span style="letter-spacing:0.1pt;"> </span>as we do, which may<span style="letter-spacing:0.05pt;"> </span>further<span style="letter-spacing:0.1pt;"> </span>delay,<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>or prevent<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.9pt;"> </span>FDA<span style="letter-spacing:0.85pt;"> </span>could<span style="letter-spacing:0.95pt;"> </span>delay,<span style="letter-spacing:0.95pt;"> </span>limit<span style="letter-spacing:1pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>deny<span style="letter-spacing:0.9pt;"> </span>approval<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:0.9pt;"> </span>product<span style="letter-spacing:0.95pt;"> </span>candidate<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:0.95pt;"> </span>many<span style="letter-spacing:0.95pt;"> </span>reasons,<span style="letter-spacing:0.95pt;"> </span>including<span style="letter-spacing:0.9pt;"> </span>because the<span style="letter-spacing:0.05pt;"> </span>FDA:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.05pt;"> </span>not deem<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>to be safe<span style="letter-spacing:0.05pt;"> </span>and effective&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">determines<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>does not have an acceptable<span style="letter-spacing:0.1pt;"> </span>benefit-risk<span style="letter-spacing:0.15pt;"> </span>profile&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">determines in<span style="letter-spacing:2.45pt;"> </span>the case of<span style="letter-spacing:2.45pt;"> </span>an<span style="letter-spacing:2.45pt;"> </span>NDA<span style="letter-spacing:2.4pt;"> </span>seeking accelerated approval<span style="letter-spacing:2.45pt;"> </span>that<span style="letter-spacing:2.45pt;"> </span>the<span style="letter-spacing:2.45pt;"> </span>NDA<span style="letter-spacing:2.35pt;"> </span>does<span style="letter-spacing:2.4pt;"> </span>not<span style="letter-spacing:2.4pt;"> </span>provide evidence<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>represents<span style="letter-spacing:0.1pt;"> </span>a meaningful<span style="letter-spacing:0.1pt;"> </span>advantage<span style="letter-spacing:0.05pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>therapies&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">determines that the objective response rate, or ORR,<span style="letter-spacing:2.45pt;"> </span>and duration of response are not clinically meaningful&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:2.05pt;"> </span>not<span style="letter-spacing:2pt;"> </span>agree<span style="letter-spacing:2.05pt;"> </span>that<span style="letter-spacing:2.05pt;"> </span>the<span style="letter-spacing:2.05pt;"> </span>data<span style="letter-spacing:2.05pt;"> </span>collected<span style="letter-spacing:2.1pt;"> </span>from<span style="letter-spacing:2.05pt;"> </span>preclinical<span style="letter-spacing:2.15pt;"> </span>studies<span style="letter-spacing:2.05pt;"> </span>and<span style="letter-spacing:2pt;"> </span>clinical<span style="letter-spacing:2.1pt;"> </span>trials<span style="letter-spacing:2.05pt;"> </span>are<span style="letter-spacing:2pt;"> </span>acceptable<span style="letter-spacing:2.05pt;"> </span>or sufficient<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>support<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>submission<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>NDA or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>submission<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>approval, and may<span style="letter-spacing:0.05pt;"> </span>impose<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>preclinical<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may determine that adverse events experienced by participants in our clinical trials represent an unacceptable<span style="letter-spacing:0.1pt;"> </span>level<span style="letter-spacing:0.05pt;"> </span>of risk&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may determine that population studied in the clinical trial may not be sufficiently broad or representative<span style="letter-spacing:0.15pt;"> </span>to assure<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>full<span style="letter-spacing:0.05pt;"> </span>population<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we seek<span style="letter-spacing:0.05pt;"> </span>approval&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.4pt;"> </span>not<span style="letter-spacing:0.35pt;"> </span>accept<span style="letter-spacing:0.4pt;"> </span>clinical<span style="letter-spacing:0.45pt;"> </span>data<span style="letter-spacing:0.4pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>trials,<span style="letter-spacing:0.45pt;"> </span>which<span style="letter-spacing:0.35pt;"> </span>are<span style="letter-spacing:0.4pt;"> </span>conducted<span style="letter-spacing:0.4pt;"> </span>at<span style="letter-spacing:0.4pt;"> </span>clinical<span style="letter-spacing:0.45pt;"> </span>facilities<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.3pt;"> </span>countries<span style="letter-spacing:0.4pt;"> </span>where the<span style="letter-spacing:0.05pt;"> </span>standard<span style="letter-spacing:0.05pt;"> </span>of care<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>potentially<span style="letter-spacing:0.1pt;"> </span>different<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.05pt;"> </span>disagree<span style="letter-spacing:0.1pt;"> </span>regarding<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>formulation,<span style="letter-spacing:0.15pt;"> </span>labeling<span style="letter-spacing:0.1pt;"> </span>and/or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>specifications&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.45pt;"> </span>not<span style="letter-spacing:0.4pt;"> </span>approve<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>manufacturing<span style="letter-spacing:0.55pt;"> </span>processes<span style="letter-spacing:0.5pt;"> </span>associated<span style="letter-spacing:0.5pt;"> </span>with<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.4pt;"> </span>product<span style="letter-spacing:0.45pt;"> </span>candidate<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.35pt;"> </span>may<span style="letter-spacing:0.4pt;"> </span>determine that<span style="letter-spacing:0.05pt;"> </span>a manufacturing<span style="letter-spacing:0.15pt;"> </span>facility<span style="letter-spacing:0.1pt;"> </span>does not have an acceptable<span style="letter-spacing:0.1pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>status&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.05pt;"> </span>change<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>policies<span style="letter-spacing:0.1pt;"> </span>or adopt<span style="letter-spacing:0.05pt;"> </span>new regulations&#59;<span style="letter-spacing:0.15pt;"> </span>or</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may<span style="letter-spacing:0.05pt;"> </span>not file<span style="letter-spacing:0.05pt;"> </span>a submission<span style="letter-spacing:0.1pt;"> </span>due to, among<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>reasons,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>content<span style="letter-spacing:0.05pt;"> </span>or formatting<span style="letter-spacing:0.15pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>submission.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:1.15pt;"> </span>have<span style="letter-spacing:1.15pt;"> </span>not<span style="letter-spacing:1.15pt;"> </span>obtained<span style="letter-spacing:1.2pt;"> </span>FDA<span style="letter-spacing:1.1pt;"> </span>approval<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>any<span style="letter-spacing:1.15pt;"> </span>product.<span style="letter-spacing:1.2pt;"> </span>This<span style="letter-spacing:1.15pt;"> </span>lack<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.15pt;"> </span>experience<span style="letter-spacing:1.25pt;"> </span>may<span style="letter-spacing:1.15pt;"> </span>impede<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>ability<span style="letter-spacing:1.2pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>in a timely<span style="letter-spacing:0.1pt;"> </span>manner,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>all,<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>experience<span style="letter-spacing:0.2pt;"> </span>delays<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span>obtaining<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>fail<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>obtain<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 or PRT2527, our<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>prospects<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>harmed<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to generate<span style="letter-spacing:0.1pt;"> </span>revenues<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be materially impaired<span style="letter-spacing:0.1pt;"> </span>which would adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our business,<span style="letter-spacing:0.05pt;"> </span>prospects,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and results<span style="letter-spacing:0.1pt;"> </span>of operations.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The accelerated<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>pathway for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not lead<span style="letter-spacing:0.05pt;"> </span>to a faster<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or regulatory<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>and does not increase<span style="letter-spacing:0.05pt;"> </span>the likelihood<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates will<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA&#8217;s<span style="letter-spacing:0.05pt;"> </span>accelerated<span style="letter-spacing:0.2pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>program,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>approve<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>serious<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>life- threatening<span style="letter-spacing:0.15pt;"> </span>illness<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>provides<span style="letter-spacing:0.05pt;"> </span>meaningful<span style="letter-spacing:0.1pt;"> </span>therapeutic<span style="letter-spacing:0.1pt;"> </span>benefit<span style="letter-spacing:0.1pt;"> </span>to patients<span style="letter-spacing:0.1pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.1pt;"> </span>treatments<span style="letter-spacing:0.15pt;"> </span>based<span style="letter-spacing:0.05pt;"> </span>upon a surrogate<span style="letter-spacing:0.15pt;"> </span>endpoint<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>reasonably<span style="letter-spacing:0.15pt;"> </span>likely<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>predict<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>benefit,<span style="letter-spacing:0.1pt;"> </span>or on a clinical<span style="letter-spacing:0.1pt;"> </span>endpoint<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>can be measured<span style="letter-spacing:0.15pt;"> </span>earlier<span style="letter-spacing:0.15pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>irreversible<span style="letter-spacing:0.15pt;"> </span>morbidity<span style="letter-spacing:0.1pt;"> </span>or mortality,<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>reasonably<span style="letter-spacing:0.1pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>to predict<span style="letter-spacing:0.1pt;"> </span>an effect<span style="letter-spacing:0.1pt;"> </span>on irreversible<span style="letter-spacing:0.2pt;"> </span>morbidity<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mortality<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>benefit,<span style="letter-spacing:0.15pt;"> </span>taking<span style="letter-spacing:0.1pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>account<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>severity,<span style="letter-spacing:0.1pt;"> </span>rarity,<span style="letter-spacing:0.1pt;"> </span>or prevalence of<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>condition<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>availability<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>lack<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>alternative<span style="letter-spacing:0.6pt;"> </span>treatments.<span style="letter-spacing:0.6pt;"> </span>We<span style="letter-spacing:0.45pt;"> </span>may<span style="letter-spacing:0.5pt;"> </span>seek<span style="letter-spacing:0.5pt;"> </span>accelerated<span style="letter-spacing:0.6pt;"> </span>approval<span style="letter-spacing:0.5pt;"> </span>for<span style="letter-spacing:0.5pt;"> </span>one or<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>basis<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>ORR with<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>acceptable<span style="letter-spacing:0.15pt;"> </span>duration<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>response,<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>surrogate endpoint<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we believe<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>reasonably<span style="letter-spacing:0.1pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>to predict<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>benefit.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>granted<span style="letter-spacing:0.1pt;"> </span>accelerated<span style="letter-spacing:0.2pt;"> </span>approval,<span style="letter-spacing:0.1pt;"> </span>post-marketing<span style="letter-spacing:0.2pt;"> </span>confirmatory<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to describe<span style="letter-spacing:0.1pt;"> </span>the anticipated<span style="letter-spacing:0.75pt;"> </span>effect<span style="letter-spacing:0.75pt;"> </span>on<span style="letter-spacing:0.65pt;"> </span>irreversible<span style="letter-spacing:0.8pt;"> </span>morbidity<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>mortality<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>other<span style="letter-spacing:0.7pt;"> </span>clinical<span style="letter-spacing:0.75pt;"> </span>benefit.<span style="letter-spacing:0.75pt;"> </span>These<span style="letter-spacing:0.65pt;"> </span>confirmatory<span style="letter-spacing:0.8pt;"> </span>trials<span style="letter-spacing:0.7pt;"> </span>must be<span style="letter-spacing:0.95pt;"> </span>completed<span style="letter-spacing:1.05pt;"> </span>with<span style="letter-spacing:0.95pt;"> </span>due<span style="letter-spacing:0.95pt;"> </span>diligence<span style="letter-spacing:1.05pt;"> </span>and,<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.95pt;"> </span>some<span style="letter-spacing:1pt;"> </span>cases,<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>FDA<span style="letter-spacing:0.9pt;"> </span>may<span style="letter-spacing:1pt;"> </span>require<span style="letter-spacing:1.05pt;"> </span>that<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>trial<span style="letter-spacing:1pt;"> </span>be<span style="letter-spacing:0.9pt;"> </span>designed,<span style="letter-spacing:0.95pt;"> </span>initiated, and/or<span style="letter-spacing:0.1pt;"> </span>fully<span style="letter-spacing:0.1pt;"> </span>enrolled<span style="letter-spacing:0.15pt;"> </span>prior<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>approval.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any of our competitors<span style="letter-spacing:0.15pt;"> </span>were to receive<span style="letter-spacing:0.1pt;"> </span>full<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>basis<span style="letter-spacing:0.05pt;"> </span>of a confirmatory<span style="letter-spacing:0.2pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>indication<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>seeking<span style="letter-spacing:0.1pt;"> </span>accelerated<span style="letter-spacing:0.2pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>we receive<span style="letter-spacing:0.1pt;"> </span>accelerated approval,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>indication<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>seeking<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>no longer<span style="letter-spacing:0.05pt;"> </span>qualify<span style="letter-spacing:0.05pt;"> </span>as a condition<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which there<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>an unmet<span style="letter-spacing:0.05pt;"> </span>medical need<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>accelerated<span style="letter-spacing:0.2pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>would be more<span style="letter-spacing:0.05pt;"> </span>difficult<span style="letter-spacing:0.15pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>not occur.<span style="letter-spacing:0.05pt;"> </span>Moreover,<span style="letter-spacing:0.05pt;"> </span>the FDA may<span style="letter-spacing:0.1pt;"> </span>withdraw<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>under<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>accelerated<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>pathway if,<span style="letter-spacing:0.05pt;"> </span>for example:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.6pt;"> </span>trial<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>trials<span style="letter-spacing:0.6pt;"> </span>required<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>verify<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>predicted<span style="letter-spacing:0.6pt;"> </span>clinical<span style="letter-spacing:0.6pt;"> </span>benefit<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:0.5pt;"> </span>product<span style="letter-spacing:0.55pt;"> </span>candidate<span style="letter-spacing:0.6pt;"> </span>fail<span style="letter-spacing:0.55pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>verify such<span style="letter-spacing:1.4pt;"> </span>benefit<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>do<span style="letter-spacing:1.4pt;"> </span>not<span style="letter-spacing:1.4pt;"> </span>demonstrate<span style="letter-spacing:1.5pt;"> </span>sufficient<span style="letter-spacing:1.55pt;"> </span>clinical<span style="letter-spacing:1.5pt;"> </span>benefit<span style="letter-spacing:1.5pt;"> </span>to<span style="letter-spacing:1.4pt;"> </span>justify<span style="letter-spacing:1.5pt;"> </span>the<span style="letter-spacing:1.45pt;"> </span>risks<span style="letter-spacing:1.45pt;"> </span>associated<span style="letter-spacing:1.5pt;"> </span>with<span style="letter-spacing:1.35pt;"> </span>the drug&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other<span style="letter-spacing:0.8pt;"> </span>evidence<span style="letter-spacing:0.8pt;"> </span>demonstrates<span style="letter-spacing:0.9pt;"> </span>that<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>product<span style="letter-spacing:0.8pt;"> </span>candidate<span style="letter-spacing:0.85pt;"> </span>is<span style="letter-spacing:0.8pt;"> </span>not<span style="letter-spacing:0.75pt;"> </span>shown<span style="letter-spacing:0.75pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.75pt;"> </span>safe<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>effective<span style="letter-spacing:0.85pt;"> </span>under<span style="letter-spacing:0.8pt;"> </span>the conditions<span style="letter-spacing:0.1pt;"> </span>of use&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we fail<span style="letter-spacing:0.05pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>any required<span style="letter-spacing:0.1pt;"> </span>post-approval<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>with due diligence&#59;<span style="letter-spacing:0.1pt;"> </span>or</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we disseminate<span style="letter-spacing:0.15pt;"> </span>false<span style="letter-spacing:0.05pt;"> </span>or misleading<span style="letter-spacing:0.1pt;"> </span>promotional<span style="letter-spacing:0.1pt;"> </span>materials<span style="letter-spacing:0.15pt;"> </span>relating<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>in foreign<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.1pt;"> </span>would prevent<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates from<span style="letter-spacing:0.05pt;"> </span>being marketed<span style="letter-spacing:0.05pt;"> </span>in those<span style="letter-spacing:0.05pt;"> </span>jurisdictions,<span style="letter-spacing:0.1pt;"> </span>and any approval<span style="letter-spacing:0.05pt;"> </span>we are granted<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates in the United States<span style="letter-spacing:0.05pt;"> </span>would not assure<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>in foreign<span style="letter-spacing:0.05pt;"> </span>jurisdictions.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:1.95pt;"> </span>order<span style="letter-spacing:2pt;"> </span>to<span style="letter-spacing:1.95pt;"> </span>market<span style="letter-spacing:2.05pt;"> </span>and<span style="letter-spacing:1.95pt;"> </span>sell<span style="letter-spacing:2pt;"> </span>our<span style="letter-spacing:1.95pt;"> </span>products<span style="letter-spacing:2pt;"> </span>in<span style="letter-spacing:1.95pt;"> </span>any<span style="letter-spacing:1.95pt;"> </span>jurisdiction<span style="letter-spacing:2.1pt;"> </span>outside<span style="letter-spacing:2pt;"> </span>the<span style="letter-spacing:2pt;"> </span>United<span style="letter-spacing:2pt;"> </span>States,<span style="letter-spacing:2pt;"> </span>we<span style="letter-spacing:1.9pt;"> </span>must<span style="letter-spacing:1.95pt;"> </span>obtain separate<span style="letter-spacing:0.15pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approvals<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with numerous<span style="letter-spacing:0.05pt;"> </span>and varying<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>requirements.<span style="letter-spacing:0.15pt;"> </span>The approval procedure<span style="letter-spacing:0.1pt;"> </span>varies<span style="letter-spacing:0.1pt;"> </span>among<span style="letter-spacing:0.1pt;"> </span>countries<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>testing.<span style="letter-spacing:0.1pt;"> </span>The time<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>may differ<span style="letter-spacing:2.05pt;"> </span>substantially<span style="letter-spacing:2.05pt;"> </span>from<span style="letter-spacing:1.95pt;"> </span>that<span style="letter-spacing:1.95pt;"> </span>required<span style="letter-spacing:2pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>obtain<span style="letter-spacing:1.95pt;"> </span>FDA<span style="letter-spacing:1.85pt;"> </span>approval.<span style="letter-spacing:1.95pt;"> </span>The<span style="letter-spacing:1.9pt;"> </span>regulatory<span style="letter-spacing:2pt;"> </span>approval<span style="letter-spacing:1.95pt;"> </span>process<span style="letter-spacing:1.95pt;"> </span>outside<span style="letter-spacing:1.95pt;"> </span>the United<span style="letter-spacing:0.15pt;"> </span>States<span style="letter-spacing:0.15pt;"> </span>generally<span style="letter-spacing:0.2pt;"> </span>includes<span style="letter-spacing:0.15pt;"> </span>all<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>risks<span style="letter-spacing:0.15pt;"> </span>associated<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>obtaining<span style="letter-spacing:0.1pt;"> </span>FDA approval.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>many countries<span style="letter-spacing:0.15pt;"> </span>outside<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.1pt;"> </span>it<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>be approved<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:0.15pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>the product<span style="letter-spacing:2pt;"> </span>can<span style="letter-spacing:1.95pt;"> </span>be<span style="letter-spacing:1.95pt;"> </span>approved<span style="letter-spacing:1.95pt;"> </span>for<span style="letter-spacing:1.95pt;"> </span>sale<span style="letter-spacing:1.95pt;"> </span>in<span style="letter-spacing:1.9pt;"> </span>that<span style="letter-spacing:1.95pt;"> </span>country.<span style="letter-spacing:1.95pt;"> </span>We<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.95pt;"> </span>not<span style="letter-spacing:1.9pt;"> </span>obtain<span style="letter-spacing:1.95pt;"> </span>approvals<span style="letter-spacing:1.95pt;"> </span>from<span style="letter-spacing:1.95pt;"> </span>regulatory<span style="letter-spacing:2pt;"> </span>authorities outside<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>United<span style="letter-spacing:0.15pt;"> </span>States<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>timely<span style="letter-spacing:0.2pt;"> </span>basis,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all.<span style="letter-spacing:0.1pt;"> </span>Approval<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>ensure<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>regulatory authorities<span style="letter-spacing:0.2pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>or jurisdictions,<span style="letter-spacing:0.15pt;"> </span>and approval<span style="letter-spacing:0.05pt;"> </span>by one regulatory<span style="letter-spacing:0.1pt;"> </span>authority<span style="letter-spacing:0.1pt;"> </span>outside<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States does<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.1pt;"> </span>ensure<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.2pt;"> </span>authorities<span style="letter-spacing:0.25pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>countries<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA. We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not be<span style="letter-spacing:2.3pt;"> </span>able<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>submit<span style="letter-spacing:2.35pt;"> </span>for<span style="letter-spacing:2.35pt;"> </span>marketing<span style="letter-spacing:2.4pt;"> </span>approvals<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>may<span style="letter-spacing:2.35pt;"> </span>not<span style="letter-spacing:2.3pt;"> </span>receive<span style="letter-spacing:2.4pt;"> </span>necessary<span style="letter-spacing:2.4pt;"> </span>approvals<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.25pt;"> </span>commercialize<span style="letter-spacing:2.45pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>in any market.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>or maintain<span style="letter-spacing:0.05pt;"> </span>orphan drug designation<span style="letter-spacing:0.05pt;"> </span>or exclusivity<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product candidates.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory<span style="letter-spacing:0.05pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>in some<span style="letter-spacing:0.05pt;"> </span>jurisdictions,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the United States, may designate<span style="letter-spacing:0.05pt;"> </span>drugs for relatively small<span style="letter-spacing:0.2pt;"> </span>patient<span style="letter-spacing:0.2pt;"> </span>populations<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>&#8220;orphan<span style="letter-spacing:0.1pt;"> </span>drugs.&#8221;<span style="letter-spacing:0.1pt;"> </span>Under<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Orphan<span style="letter-spacing:0.05pt;"> </span>Drug<span style="letter-spacing:0.05pt;"> </span>Act,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>designate<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>an orphan<span style="letter-spacing:0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>intended<span style="letter-spacing:0.05pt;"> </span>to treat<span style="letter-spacing:0.1pt;"> </span>a rare<span style="letter-spacing:0.05pt;"> </span>disease<span style="letter-spacing:0.05pt;"> </span>or condition,<span style="letter-spacing:0.05pt;"> </span>which is<span style="letter-spacing:0.05pt;"> </span>generally<span style="letter-spacing:0.1pt;"> </span>defined<span style="letter-spacing:0.05pt;"> </span>as a patient<span style="letter-spacing:0.1pt;"> </span>population of<span style="letter-spacing:0.05pt;"> </span>fewer<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>200,000<span style="letter-spacing:0.05pt;"> </span>individuals<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>disease<span style="letter-spacing:0.05pt;"> </span>or condition<span style="letter-spacing:0.05pt;"> </span>affects<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>200,000 individuals<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>there<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>reasonable<span style="letter-spacing:0.15pt;"> </span>expectation<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>of developing<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>drug for<span style="letter-spacing:0.05pt;"> </span>the type<span style="letter-spacing:0.05pt;"> </span>of disease<span style="letter-spacing:0.05pt;"> </span>or condition<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be recovered<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>designation<span style="letter-spacing:0.15pt;"> </span>entitles<span style="letter-spacing:0.15pt;"> </span>a party<span style="letter-spacing:0.05pt;"> </span>to financial<span style="letter-spacing:0.1pt;"> </span>incentives,<span style="letter-spacing:0.1pt;"> </span>such as opportunities<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:0.05pt;"> </span>funding towards<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>costs,<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>advantages<span style="letter-spacing:0.05pt;"> </span>and user-fee<span style="letter-spacing:0.1pt;"> </span>waivers.<span style="letter-spacing:0.05pt;"> </span>Additionally,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>a product<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>has orphan designation<span style="letter-spacing:0.15pt;"> </span>subsequently<span style="letter-spacing:0.15pt;"> </span>receives<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>first<span style="letter-spacing:0.15pt;"> </span>FDA approval<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>disease<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>condition<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which it<span style="letter-spacing:0.05pt;"> </span>has such designation,<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>entitled<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>orphan<span style="letter-spacing:0.15pt;"> </span>drug<span style="letter-spacing:0.1pt;"> </span>exclusivity,<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>means<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>approve<span style="letter-spacing:0.1pt;"> </span>any other<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>to market<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>drug for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>indication<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>seven<span style="letter-spacing:0.05pt;"> </span>years,<span style="letter-spacing:0.05pt;"> </span>except<span style="letter-spacing:0.05pt;"> </span>in certain circumstances,<span style="letter-spacing:0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>showing<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>superiority<span style="letter-spacing:0.1pt;"> </span>(i.e.,<span style="letter-spacing:0.05pt;"> </span>another<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>safer,<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>effective<span style="letter-spacing:0.1pt;"> </span>or makes<span style="letter-spacing:0.05pt;"> </span>a major<span style="letter-spacing:0.45pt;"> </span>contribution<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>patient<span style="letter-spacing:0.5pt;"> </span>care)<span style="letter-spacing:0.45pt;"> </span>over<span style="letter-spacing:0.45pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>product<span style="letter-spacing:0.45pt;"> </span>with<span style="letter-spacing:0.4pt;"> </span>orphan<span style="letter-spacing:0.45pt;"> </span>exclusivity<span style="letter-spacing:0.5pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>where<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>manufacturer<span style="letter-spacing:0.5pt;"> </span>is<span style="letter-spacing:0.4pt;"> </span>unable to<span style="letter-spacing:0.05pt;"> </span>assure<span style="letter-spacing:0.1pt;"> </span>sufficient<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>quantity.<span style="letter-spacing:0.05pt;"> </span>Competitors,<span style="letter-spacing:0.1pt;"> </span>however, may<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of different<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the same<span style="letter-spacing:0.1pt;"> </span>indication<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>orphan<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>has exclusivity,<span style="letter-spacing:0.1pt;"> </span>or obtain<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>but for<span style="letter-spacing:0.05pt;"> </span>a different<span style="letter-spacing:0.1pt;"> </span>indication<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which the<span style="letter-spacing:0.05pt;"> </span>orphan<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>has exclusivity.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">apply</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orphan</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug designation</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">geographies</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, obtaining</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an orphan</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug designation</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can be difficult,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be successful</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">doing so. Even if</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orphan</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug designation</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in specific indications,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">first</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orphan- designated</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indication,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncertainties</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with developing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, exclusive</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be limited</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we seek</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an indication</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">broader than the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orphan-designated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indication</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lost</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">later</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determines</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">request</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orphan designation</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defective</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturer</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assure</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sufficient</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quantities</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product to meet</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">needs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patients</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rare</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disease</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or condition.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does not ensure</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we will</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receive</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusivity</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assure</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any future</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for orphan</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in any other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">geography</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or with respect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to any other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be granted. Orphan drug designation</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">neither</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shortens</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or regulatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a drug, nor gives the drug any advantage</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process.</span></p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A Breakthrough Therapy Designation<span style="letter-spacing:0.05pt;"> </span>by the FDA<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any of our current<span style="letter-spacing:0.05pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates may<span style="letter-spacing:0.05pt;"> </span>not lead<span style="letter-spacing:0.05pt;"> </span>to a faster<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or regulatory<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>and it<span style="letter-spacing:0.05pt;"> </span>would not increase the likelihood<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>seek<span style="letter-spacing:0.05pt;"> </span>a Breakthrough<span style="letter-spacing:0.05pt;"> </span>Therapy<span style="letter-spacing:0.05pt;"> </span>Designation<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>one or more<span style="letter-spacing:0.05pt;"> </span>of our current<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>product candidates.<span style="letter-spacing:1.25pt;"> </span>A<span style="letter-spacing:1.15pt;"> </span>breakthrough<span style="letter-spacing:1.25pt;"> </span>therapy<span style="letter-spacing:1.2pt;"> </span>is<span style="letter-spacing:1.2pt;"> </span>defined<span style="letter-spacing:1.2pt;"> </span>as<span style="letter-spacing:1.15pt;"> </span>a<span style="letter-spacing:1.15pt;"> </span>drug<span style="letter-spacing:1.15pt;"> </span>that<span style="letter-spacing:1.2pt;"> </span>is<span style="letter-spacing:1.2pt;"> </span>intended,<span style="letter-spacing:1.15pt;"> </span>alone<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>combination<span style="letter-spacing:1.2pt;"> </span>with<span style="letter-spacing:1.1pt;"> </span>one<span style="letter-spacing:1.1pt;"> </span>or more<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>drugs,<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>treat<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>or life-threatening<span style="letter-spacing:0.2pt;"> </span>disease<span style="letter-spacing:0.05pt;"> </span>or condition,<span style="letter-spacing:0.05pt;"> </span>and preliminary<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically<span style="letter-spacing:0.15pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>endpoints,<span style="letter-spacing:0.05pt;"> </span>such as substantial<span style="letter-spacing:0.1pt;"> </span>treatment<span style="letter-spacing:0.15pt;"> </span>effects<span style="letter-spacing:0.1pt;"> </span>observed<span style="letter-spacing:0.05pt;"> </span>early<span style="letter-spacing:0.05pt;"> </span>in clinical<span style="letter-spacing:0.05pt;"> </span>development.<span style="letter-spacing:0.05pt;"> </span>For drugs<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>been<span style="letter-spacing:0.05pt;"> </span>designated<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>breakthrough<span style="letter-spacing:0.15pt;"> </span>therapies,<span style="letter-spacing:0.15pt;"> </span>interaction<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>communication<span style="letter-spacing:0.2pt;"> </span>between<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA and the<span style="letter-spacing:0.05pt;"> </span>sponsor<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>can help<span style="letter-spacing:0.05pt;"> </span>to identify<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>most<span style="letter-spacing:0.05pt;"> </span>efficient<span style="letter-spacing:0.15pt;"> </span>path<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>while<span style="letter-spacing:0.05pt;"> </span>minimizing<span style="letter-spacing:0.1pt;"> </span>the number<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:1.35pt;"> </span>patients<span style="letter-spacing:1.45pt;"> </span>placed<span style="letter-spacing:1.4pt;"> </span>in<span style="letter-spacing:1.35pt;"> </span>ineffective<span style="letter-spacing:1.5pt;"> </span>control<span style="letter-spacing:1.4pt;"> </span>regimens.<span style="letter-spacing:1.45pt;"> </span>Drugs<span style="letter-spacing:1.35pt;"> </span>designated<span style="letter-spacing:1.45pt;"> </span>as<span style="letter-spacing:1.35pt;"> </span>breakthrough<span style="letter-spacing:1.45pt;"> </span>therapies<span style="letter-spacing:1.45pt;"> </span>by<span style="letter-spacing:1.3pt;"> </span>the FDA<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>eligible<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>priority<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>supported<span style="letter-spacing:0.05pt;"> </span>by clinical<span style="letter-spacing:0.1pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>submission<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>NDA.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>breakthrough<span style="letter-spacing:0.15pt;"> </span>therapy<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>discretion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA. Accordingly,<span style="letter-spacing:0.1pt;"> </span>even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:0.1pt;"> </span>that one<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>meets<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>criteria<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>designation<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>breakthrough<span style="letter-spacing:0.15pt;"> </span>therapy,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>disagree and instead<span style="letter-spacing:0.05pt;"> </span>determine<span style="letter-spacing:0.1pt;"> </span>not to make<span style="letter-spacing:0.05pt;"> </span>such designation.<span style="letter-spacing:0.1pt;"> </span>In any event,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>receipt<span style="letter-spacing:0.1pt;"> </span>of a Breakthrough Therapy Designation<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>faster<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>review,<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>compared<span style="letter-spacing:0.05pt;"> </span>to drugs considered<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>approval<span style="letter-spacing:1.2pt;"> </span>under<span style="letter-spacing:1.2pt;"> </span>conventional<span style="letter-spacing:1.25pt;"> </span>FDA<span style="letter-spacing:1.1pt;"> </span>procedures<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>it<span style="letter-spacing:1.15pt;"> </span>would<span style="letter-spacing:1.1pt;"> </span>not<span style="letter-spacing:1.1pt;"> </span>assure<span style="letter-spacing:1.15pt;"> </span>ultimate<span style="letter-spacing:1.2pt;"> </span>approval<span style="letter-spacing:1.15pt;"> </span>by<span style="letter-spacing:1.1pt;"> </span>the FDA.<span style="letter-spacing:0.05pt;"> </span>In<span style="letter-spacing:0.1pt;"> </span>addition,<span style="letter-spacing:0.15pt;"> </span>even<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>one<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates<span style="letter-spacing:0.2pt;"> </span>qualify<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>breakthrough<span style="letter-spacing:0.2pt;"> </span>therapies,<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may later<span style="letter-spacing:0.1pt;"> </span>decide<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>no longer<span style="letter-spacing:0.05pt;"> </span>meets<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>conditions<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>qualification<span style="letter-spacing:0.15pt;"> </span>or that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>period<span style="letter-spacing:0.05pt;"> </span>for FDA<span style="letter-spacing:-0.05pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>not be shortened.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we are unable to successfully<span style="letter-spacing:0.1pt;"> </span>develop,<span style="letter-spacing:0.05pt;"> </span>validate,<span style="letter-spacing:0.1pt;"> </span>obtain<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of and commercialize companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.05pt;"> </span>tests<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.05pt;"> </span>such tests,<span style="letter-spacing:0.05pt;"> </span>or experience<span style="letter-spacing:0.05pt;"> </span>significant delays<span style="letter-spacing:0.05pt;"> </span>in doing so, we may<span style="letter-spacing:0.05pt;"> </span>not realize<span style="letter-spacing:0.1pt;"> </span>the full<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.1pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="letter-spacing:1.15pt;"> </span>companion<span style="letter-spacing:1.2pt;"> </span>diagnostic<span style="letter-spacing:1.25pt;"> </span>is<span style="letter-spacing:1.2pt;"> </span>a<span style="letter-spacing:1.15pt;"> </span>medical<span style="letter-spacing:1.25pt;"> </span>device,<span style="letter-spacing:1.2pt;"> </span>often<span style="letter-spacing:1.2pt;"> </span>an<span style="letter-spacing:1.15pt;"> </span><span style="font-style:italic;">in</span><span style="font-style:italic;letter-spacing:1.1pt;"> </span><span style="font-style:italic;">vitro</span><span style="font-style:italic;letter-spacing:1.15pt;"> </span>device,<span style="letter-spacing:1.15pt;"> </span>which<span style="letter-spacing:1.1pt;"> </span>provides<span style="letter-spacing:1.15pt;"> </span>information<span style="letter-spacing:1.25pt;"> </span>that<span style="letter-spacing:1.15pt;"> </span>is essential<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>safe<span style="letter-spacing:0.05pt;"> </span>and effective<span style="letter-spacing:0.1pt;"> </span>use of a corresponding<span style="letter-spacing:0.1pt;"> </span>therapeutic<span style="letter-spacing:0.1pt;"> </span>drug product.<span style="letter-spacing:0.05pt;"> </span>A companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.05pt;"> </span>can be<span style="letter-spacing:0.05pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:0.15pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>most<span style="letter-spacing:0.1pt;"> </span>likely<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>benefit<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>therapeutic<span style="letter-spacing:0.1pt;"> </span>product.<span style="letter-spacing:0.05pt;"> </span>In the<span style="letter-spacing:0.05pt;"> </span>future,<span style="letter-spacing:0.05pt;"> </span>we may evaluate<span style="letter-spacing:0.1pt;"> </span>opportunities<span style="letter-spacing:0.1pt;"> </span>to develop,<span style="letter-spacing:0.05pt;"> </span>either<span style="letter-spacing:0.1pt;"> </span>by ourselves<span style="letter-spacing:0.1pt;"> </span>or with collaborators,<span style="letter-spacing:0.15pt;"> </span>companion diagnostic<span style="letter-spacing:0.05pt;"> </span>tests for our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>indications.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>generally<span style="letter-spacing:0.1pt;"> </span>developed<span style="letter-spacing:0.05pt;"> </span>in conjunction<span style="letter-spacing:0.1pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>program<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an associated therapeutic<span style="letter-spacing:0.15pt;"> </span>product.<span style="letter-spacing:0.1pt;"> </span>To<span style="letter-spacing:0.05pt;"> </span>date,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA has required<span style="letter-spacing:0.1pt;"> </span>premarket<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of the vast majority of<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.05pt;"> </span>diagnostics<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>cancer therapies.<span style="letter-spacing:0.15pt;"> </span>Generally,<span style="letter-spacing:0.1pt;"> </span>when<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.1pt;"> </span>diagnostic<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>essential<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>safe<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>effective<span style="letter-spacing:0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a drug product,<span style="letter-spacing:0.05pt;"> </span>the FDA requires<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>companion<span style="letter-spacing:0.1pt;"> </span>diagnostic<span style="letter-spacing:0.15pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>before<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>concurrent<span style="letter-spacing:0.1pt;"> </span>with approval<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>therapeutic product<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.45pt;"> </span>before<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.45pt;"> </span>product<span style="letter-spacing:1.5pt;"> </span>can<span style="letter-spacing:1.45pt;"> </span>be<span style="letter-spacing:1.45pt;"> </span>commercialized.<span style="letter-spacing:1.65pt;"> </span>The<span style="letter-spacing:1.45pt;"> </span>approval<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>a<span style="letter-spacing:1.4pt;"> </span>companion<span style="letter-spacing:1.45pt;"> </span>diagnostic<span style="letter-spacing:1.5pt;"> </span>as<span style="letter-spacing:1.4pt;"> </span>part<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>the therapeutic<span style="letter-spacing:1.35pt;"> </span>product&#8217;s<span style="letter-spacing:1.35pt;"> </span>labeling<span style="letter-spacing:1.35pt;"> </span>limits<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>use<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>therapeutic<span style="letter-spacing:1.3pt;"> </span>product<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>only<span style="letter-spacing:1.2pt;"> </span>those<span style="letter-spacing:1.25pt;"> </span>patients<span style="letter-spacing:1.3pt;"> </span>who<span style="letter-spacing:1.2pt;"> </span>express<span style="letter-spacing:1.25pt;"> </span>the specific<span style="letter-spacing:0.1pt;"> </span>genetic<span style="letter-spacing:0.05pt;"> </span>alteration<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.1pt;"> </span>was developed<span style="letter-spacing:0.05pt;"> </span>to detect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.1pt;"> </span>diagnostic<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>meetings<span style="letter-spacing:0.1pt;"> </span>with regulatory<span style="letter-spacing:0.1pt;"> </span>authorities,<span style="letter-spacing:0.15pt;"> </span>such as<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:0.9pt;"> </span>pre-submission<span style="letter-spacing:1.05pt;"> </span>meeting<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>requirement<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.85pt;"> </span>submit<span style="letter-spacing:0.9pt;"> </span>an<span style="letter-spacing:0.85pt;"> </span>investigational<span style="letter-spacing:1pt;"> </span>device<span style="letter-spacing:0.9pt;"> </span>exemption<span style="letter-spacing:0.95pt;"> </span>application.<span style="letter-spacing:0.95pt;"> </span>In the<span style="letter-spacing:0.1pt;"> </span>case<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>designated<span style="letter-spacing:0.1pt;"> </span>as &#8220;significant<span style="letter-spacing:0.15pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>device,&#8221;<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of an investigational device<span style="letter-spacing:0.1pt;"> </span>exemption<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA and<span style="letter-spacing:0.05pt;"> </span>IRB<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>before<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>used in conjunction<span style="letter-spacing:0.1pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>clinical trials<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a corresponding<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be successful<span style="letter-spacing:0.1pt;"> </span>in developing,<span style="letter-spacing:0.05pt;"> </span>validating,<span style="letter-spacing:0.1pt;"> </span>obtaining<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of and commercializing<span style="letter-spacing:0.2pt;"> </span>a companion diagnostic,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:0.2pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>address<span style="letter-spacing:0.05pt;"> </span>a number<span style="letter-spacing:0.05pt;"> </span>of scientific,<span style="letter-spacing:0.15pt;"> </span>technical,<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>and logistical challenges.<span style="letter-spacing:1.25pt;"> </span>We<span style="letter-spacing:1.15pt;"> </span>have<span style="letter-spacing:1.15pt;"> </span>no<span style="letter-spacing:1.15pt;"> </span>prior<span style="letter-spacing:1.2pt;"> </span>experience<span style="letter-spacing:1.25pt;"> </span>with<span style="letter-spacing:1.15pt;"> </span>medical<span style="letter-spacing:1.25pt;"> </span>device<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>diagnostic<span style="letter-spacing:1.2pt;"> </span>test<span style="letter-spacing:1.15pt;"> </span>development.<span style="letter-spacing:1.2pt;"> </span>If<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>choose<span style="letter-spacing:1.15pt;"> </span>to develop<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>FDA approval<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>companion<span style="letter-spacing:0.1pt;"> </span>diagnostic<span style="letter-spacing:0.15pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel. We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rely</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">design,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validation</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacture</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of companion diagnostic</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests,</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receipt</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals,</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supply</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostics.</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties are</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostics</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or experience delays</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in doing so, we may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be unable</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enroll</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enough patients</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our current</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and planned</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the development</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be adversely</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affected,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these therapeutic</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">realize</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">full</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any of these</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutics</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which a companion</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is necessary</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">select</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate,</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">failure</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully develop</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cause</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or contribute</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to delayed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enrollment</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our clinical</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may prevent</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiating</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pivotal</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial.</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">success</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates that</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:2.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:2.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tied</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:2.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:2.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dependent</span><span style="letter-spacing:2.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:2.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:2.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receipt</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:2.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approvals</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continued</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companion</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercially available</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us on reasonable</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relevant</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">geographies.</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any failure</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to do so could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and financial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition.</span></p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we decide<span style="letter-spacing:0.05pt;"> </span>to pursue a Fast Track Designation<span style="letter-spacing:0.05pt;"> </span>by the FDA,<span style="letter-spacing:-0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not lead<span style="letter-spacing:0.05pt;"> </span>to a faster<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or regulatory<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>process.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>Fast<span style="letter-spacing:0.1pt;"> </span>Track<span style="letter-spacing:0.1pt;"> </span>Designation<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>a drug is<span style="letter-spacing:0.05pt;"> </span>intended<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the treatment<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>serious<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>life-threatening<span style="letter-spacing:0.25pt;"> </span>condition<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>demonstrates<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>potential<span style="letter-spacing:0.15pt;"> </span>to address<span style="letter-spacing:0.05pt;"> </span>unmet medical<span style="letter-spacing:0.2pt;"> </span>needs<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.15pt;"> </span>this<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>sponsor<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.15pt;"> </span>apply<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>Fast<span style="letter-spacing:0.15pt;"> </span>Track<span style="letter-spacing:0.1pt;"> </span>Designation.<span style="letter-spacing:0.1pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>FDA has broad<span style="letter-spacing:0.05pt;"> </span>discretion<span style="letter-spacing:0.1pt;"> </span>whether<span style="letter-spacing:0.05pt;"> </span>to grant<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:0.05pt;"> </span>designation,<span style="letter-spacing:0.1pt;"> </span>so even if<span style="letter-spacing:0.05pt;"> </span>we believe<span style="letter-spacing:0.05pt;"> </span>a particular<span style="letter-spacing:0.1pt;"> </span>product candidate<span style="letter-spacing:0.05pt;"> </span>is eligible for<span style="letter-spacing:1.25pt;"> </span>this<span style="letter-spacing:1.25pt;"> </span>designation,<span style="letter-spacing:1.3pt;"> </span>we<span style="letter-spacing:1.2pt;"> </span>cannot<span style="letter-spacing:1.25pt;"> </span>assure<span style="letter-spacing:1.25pt;"> </span>you<span style="letter-spacing:1.2pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>FDA<span style="letter-spacing:1.15pt;"> </span>would<span style="letter-spacing:1.2pt;"> </span>decide<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>grant<span style="letter-spacing:1.25pt;"> </span>it.<span style="letter-spacing:1.25pt;"> </span>Even<span style="letter-spacing:1.2pt;"> </span>if<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>do<span style="letter-spacing:1.15pt;"> </span>receive<span style="letter-spacing:1.25pt;"> </span>Fast Track<span style="letter-spacing:0.1pt;"> </span>Designation,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>faster<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>or approval<span style="letter-spacing:0.05pt;"> </span>compared<span style="letter-spacing:0.05pt;"> </span>to conventional<span style="letter-spacing:0.15pt;"> </span>FDA procedures.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>FDA may<span style="letter-spacing:0.05pt;"> </span>withdraw<span style="letter-spacing:0.05pt;"> </span>Fast<span style="letter-spacing:0.05pt;"> </span>Track<span style="letter-spacing:0.05pt;"> </span>Designation<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>believes<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>designation is<span style="letter-spacing:0.05pt;"> </span>no longer<span style="letter-spacing:0.05pt;"> </span>supported<span style="letter-spacing:0.05pt;"> </span>by data<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>program.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if<span style="letter-spacing:0.05pt;"> </span>we obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>the terms<span style="letter-spacing:0.05pt;"> </span>of approvals,<span style="letter-spacing:0.05pt;"> </span>ongoing regulation<span style="letter-spacing:0.05pt;"> </span>of our products<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>post-approval<span style="letter-spacing:0.1pt;"> </span>restrictions<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>how<span style="letter-spacing:-0.05pt;"> </span>we manufacture<span style="letter-spacing:0.05pt;"> </span>and market our products<span style="letter-spacing:0.05pt;"> </span>and compliance<span style="letter-spacing:0.1pt;"> </span>with such requirements<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>resources,<span style="letter-spacing:0.05pt;"> </span>which could materially<span style="letter-spacing:0.15pt;"> </span>impair<span style="letter-spacing:0.05pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to generate<span style="letter-spacing:0.05pt;"> </span>revenue.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:0.95pt;"> </span>product<span style="letter-spacing:0.95pt;"> </span>candidates<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:0.95pt;"> </span>which<span style="letter-spacing:0.9pt;"> </span>we<span style="letter-spacing:0.9pt;"> </span>receive<span style="letter-spacing:1pt;"> </span>accelerated<span style="letter-spacing:1.05pt;"> </span>approval<span style="letter-spacing:0.95pt;"> </span>from<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>FDA<span style="letter-spacing:0.85pt;"> </span>are<span style="letter-spacing:0.95pt;"> </span>required<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.9pt;"> </span>undergo one or more<span style="letter-spacing:0.05pt;"> </span>confirmatory<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>such a product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>fails<span style="letter-spacing:0.1pt;"> </span>to meet<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>and efficacy<span style="letter-spacing:0.05pt;"> </span>endpoints in such confirmatory<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>authority<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>withdraw its conditional<span style="letter-spacing:0.05pt;"> </span>approval. There is no assurance<span style="letter-spacing:1.25pt;"> </span>that<span style="letter-spacing:1.2pt;"> </span>any<span style="letter-spacing:1.15pt;"> </span>such<span style="letter-spacing:1.15pt;"> </span>product<span style="letter-spacing:1.2pt;"> </span>will<span style="letter-spacing:1.2pt;"> </span>successfully<span style="letter-spacing:1.25pt;"> </span>advance<span style="letter-spacing:1.2pt;"> </span>through<span style="letter-spacing:1.2pt;"> </span>its<span style="letter-spacing:1.2pt;"> </span>confirmatory<span style="letter-spacing:1.3pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>trial(s).<span style="letter-spacing:1.25pt;"> </span>Therefore, even<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidate<span style="letter-spacing:0.2pt;"> </span>receives<span style="letter-spacing:0.2pt;"> </span>accelerated<span style="letter-spacing:0.25pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA, such<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>withdrawn<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>a later<span style="letter-spacing:0.1pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of a product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>granted,<span style="letter-spacing:0.05pt;"> </span>an approved<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>and its<span style="letter-spacing:0.05pt;"> </span>manufacturer<span style="letter-spacing:0.15pt;"> </span>and marketer are subject to ongoing review and extensive regulation, which may include the requirement to implement<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>REMS or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>costly<span style="letter-spacing:0.1pt;"> </span>post-marketing<span style="letter-spacing:0.2pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and surveillance<span style="letter-spacing:0.15pt;"> </span>to monitor<span style="letter-spacing:0.1pt;"> </span>the safety<span style="letter-spacing:0.05pt;"> </span>or efficacy<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>product.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>must<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>concerning<span style="letter-spacing:0.05pt;"> </span>advertising<span style="letter-spacing:0.1pt;"> </span>and promotion<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any of our product candidates<span style="letter-spacing:1.35pt;"> </span>for<span style="letter-spacing:1.3pt;"> </span>which<span style="letter-spacing:1.25pt;"> </span>we<span style="letter-spacing:1.25pt;"> </span>obtain<span style="letter-spacing:1.3pt;"> </span>marketing<span style="letter-spacing:1.35pt;"> </span>approval.<span style="letter-spacing:1.3pt;"> </span>Promotional<span style="letter-spacing:1.35pt;"> </span>communications<span style="letter-spacing:1.4pt;"> </span>with<span style="letter-spacing:1.25pt;"> </span>respect<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>prescription drugs<span style="letter-spacing:0.7pt;"> </span>are<span style="letter-spacing:0.7pt;"> </span>subject<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>a<span style="letter-spacing:0.65pt;"> </span>variety<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>legal<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>regulatory<span style="letter-spacing:0.7pt;"> </span>restrictions<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>must<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.6pt;"> </span>consistent<span style="letter-spacing:0.7pt;"> </span>with<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>information<span style="letter-spacing:0.75pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>product&#8217;s<span style="letter-spacing:0.1pt;"> </span>approved<span style="letter-spacing:0.05pt;"> </span>labeling.<span style="letter-spacing:0.1pt;"> </span>Thus, we will<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to promote<span style="letter-spacing:0.05pt;"> </span>any products<span style="letter-spacing:0.05pt;"> </span>we develop<span style="letter-spacing:0.05pt;"> </span>for indications<span style="letter-spacing:0.05pt;"> </span>or uses<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which they<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not approved.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>manufacturers<span style="letter-spacing:0.2pt;"> </span>of approved<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>and those<span style="letter-spacing:0.05pt;"> </span>manufacturers&#8217;<span style="letter-spacing:0.15pt;"> </span>facilities<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to ensure that<span style="letter-spacing:0.1pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>control<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>procedures<span style="letter-spacing:0.15pt;"> </span>conform<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>good<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>practices,<span style="letter-spacing:0.15pt;"> </span>or cGMPs, which<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>relating<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>quality<span style="letter-spacing:0.05pt;"> </span>control<span style="letter-spacing:0.05pt;"> </span>and quality<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as the<span style="letter-spacing:0.05pt;"> </span>corresponding maintenance<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>records<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>documentation<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>reporting<span style="letter-spacing:0.15pt;"> </span>requirements.<span style="letter-spacing:0.2pt;"> </span>We and our contract<span style="letter-spacing:0.1pt;"> </span>manufacturing organizations,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>CMOs,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>periodic<span style="letter-spacing:0.15pt;"> </span>unannounced<span style="letter-spacing:0.1pt;"> </span>inspections<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to monitor<span style="letter-spacing:0.1pt;"> </span>and ensure compliance<span style="letter-spacing:0.1pt;"> </span>with cGMPs.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<span style="letter-spacing:0.1pt;"> </span>assuming<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>and our CMOs<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>expend<span style="letter-spacing:0.05pt;"> </span>time,<span style="letter-spacing:0.1pt;"> </span>money<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>effort<span style="letter-spacing:0.1pt;"> </span>in all<span style="letter-spacing:0.05pt;"> </span>areas<span style="letter-spacing:0.05pt;"> </span>of regulatory<span style="letter-spacing:0.1pt;"> </span>compliance,<span style="letter-spacing:0.1pt;"> </span>including manufacturing,<span style="letter-spacing:0.2pt;"> </span>production,<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>surveillance<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>control.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>not able<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with post-approval<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>requirements,<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approvals<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>withdrawn<span style="letter-spacing:0.05pt;"> </span>by regulatory<span style="letter-spacing:1.8pt;"> </span>authorities<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.7pt;"> </span>our<span style="letter-spacing:1.7pt;"> </span>ability<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:1.7pt;"> </span>market<span style="letter-spacing:1.8pt;"> </span>any<span style="letter-spacing:1.7pt;"> </span>future<span style="letter-spacing:1.75pt;"> </span>products<span style="letter-spacing:1.7pt;"> </span>could<span style="letter-spacing:1.7pt;"> </span>be<span style="letter-spacing:1.65pt;"> </span>limited,<span style="letter-spacing:1.75pt;"> </span>which<span style="letter-spacing:1.65pt;"> </span>could<span style="letter-spacing:1.7pt;"> </span>adversely affect<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to achieve<span style="letter-spacing:0.05pt;"> </span>or sustain<span style="letter-spacing:0.05pt;"> </span>profitability.<span style="letter-spacing:0.15pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>of compliance<span style="letter-spacing:0.1pt;"> </span>with post-approval regulations<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>have a negative<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our operating<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition.</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to ongoing enforcement<span style="letter-spacing:0.1pt;"> </span>of post-marketing<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.1pt;"> </span>by regulatory<span style="letter-spacing:0.05pt;"> </span>agencies,<span style="letter-spacing:0.05pt;"> </span>and we could be subject<span style="letter-spacing:0.05pt;"> </span>to substantial<span style="letter-spacing:0.1pt;"> </span>penalties, including<span style="letter-spacing:0.05pt;"> </span>withdrawal of our product<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>the market,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we fail<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with all<span style="letter-spacing:0.05pt;"> </span>regulatory requirements<span style="letter-spacing:0.1pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>we experience<span style="letter-spacing:0.05pt;"> </span>unanticipated<span style="letter-spacing:0.05pt;"> </span>problems<span style="letter-spacing:0.05pt;"> </span>with our products,<span style="letter-spacing:0.05pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>and if<span style="letter-spacing:0.05pt;"> </span>any of them<span style="letter-spacing:0.05pt;"> </span>are approved.</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:1.15pt;"> </span>product<span style="letter-spacing:1.2pt;"> </span>candidate<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>which<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>obtain<span style="letter-spacing:1.15pt;"> </span>marketing<span style="letter-spacing:1.2pt;"> </span>approval,<span style="letter-spacing:1.15pt;"> </span>along<span style="letter-spacing:1.15pt;"> </span>with<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>manufacturing<span style="letter-spacing:1.25pt;"> </span>processes, post-approval<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>data,<span style="letter-spacing:0.1pt;"> </span>labeling,<span style="letter-spacing:0.15pt;"> </span>advertising<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>promotional<span style="letter-spacing:0.15pt;"> </span>activities<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such product,<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to continual<span style="letter-spacing:0.15pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>authorities.<span style="letter-spacing:0.2pt;"> </span>These<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>include, but<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>to,<span style="letter-spacing:0.05pt;"> </span>restrictions<span style="letter-spacing:0.2pt;"> </span>governing<span style="letter-spacing:0.1pt;"> </span>promotion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>product,<span style="letter-spacing:0.1pt;"> </span>submissions<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.1pt;"> </span>and other post-marketing<span style="letter-spacing:0.15pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>and reports,<span style="letter-spacing:0.1pt;"> </span>registration<span style="letter-spacing:0.15pt;"> </span>and listing<span style="letter-spacing:0.1pt;"> </span>requirements,<span style="letter-spacing:0.15pt;"> </span>cGMP requirements<span style="letter-spacing:0.15pt;"> </span>relating<span style="letter-spacing:0.05pt;"> </span>to manufacturing,<span style="letter-spacing:0.2pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>control,<span style="letter-spacing:0.1pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>assurance<span style="letter-spacing:0.15pt;"> </span>and corresponding<span style="letter-spacing:0.1pt;"> </span>maintenance<span style="letter-spacing:0.1pt;"> </span>of records<span style="letter-spacing:0.05pt;"> </span>and documents,<span style="letter-spacing:0.05pt;"> </span>and requirements<span style="letter-spacing:0.15pt;"> </span>regarding<span style="letter-spacing:0.1pt;"> </span>drug distribution<span style="letter-spacing:0.15pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>distribution<span style="letter-spacing:0.15pt;"> </span>of samples<span style="letter-spacing:0.1pt;"> </span>to physicians<span style="letter-spacing:0.1pt;"> </span>and recordkeeping.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>FDA and other<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>and state<span style="letter-spacing:0.05pt;"> </span>agencies,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Department<span style="letter-spacing:0.1pt;"> </span>of Justice,<span style="letter-spacing:0.1pt;"> </span>closely<span style="letter-spacing:0.05pt;"> </span>regulate compliance<span style="letter-spacing:0.1pt;"> </span>with all<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>governing<span style="letter-spacing:0.05pt;"> </span>prescription<span style="letter-spacing:0.15pt;"> </span>drug products, including requirements<span style="letter-spacing:0.1pt;"> </span>pertaining<span style="letter-spacing:0.05pt;"> </span>to marketing<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>promotion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>accordance<span style="letter-spacing:0.15pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>provisions<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>approved<span style="letter-spacing:0.05pt;"> </span>labeling<span style="letter-spacing:0.1pt;"> </span>and manufacturing of<span style="letter-spacing:0.7pt;"> </span>products<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.7pt;"> </span>accordance<span style="letter-spacing:0.8pt;"> </span>with<span style="letter-spacing:0.7pt;"> </span>cGMP<span style="letter-spacing:0.7pt;"> </span>requirements.<span style="letter-spacing:0.85pt;"> </span>For<span style="letter-spacing:0.7pt;"> </span>example,<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>FDA<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>other<span style="letter-spacing:0.7pt;"> </span>agencies<span style="letter-spacing:0.7pt;"> </span>actively<span style="letter-spacing:0.75pt;"> </span>enforce the<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>prohibiting<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>promotion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>off-label<span style="letter-spacing:0.15pt;"> </span>uses,<span style="letter-spacing:0.05pt;"> </span>and a company<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>found to have improperly<span style="letter-spacing:0.15pt;"> </span>promoted<span style="letter-spacing:0.1pt;"> </span>off-label<span style="letter-spacing:0.1pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to significant<span style="letter-spacing:0.15pt;"> </span>liability.<span style="letter-spacing:0.15pt;"> </span>Violations<span style="letter-spacing:0.1pt;"> </span>of such requirements<span style="letter-spacing:0.15pt;"> </span>may lead<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>investigations<span style="letter-spacing:0.25pt;"> </span>alleging<span style="letter-spacing:0.2pt;"> </span>violations<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>Federal<span style="letter-spacing:0.15pt;"> </span>Food,<span style="letter-spacing:0.1pt;"> </span>Drug,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>Cosmetic<span style="letter-spacing:0.15pt;"> </span>Act,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>FDCA, and<span style="letter-spacing:0.05pt;"> </span>other statutes,<span style="letter-spacing:1.05pt;"> </span>including<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>False<span style="letter-spacing:1pt;"> </span>Claims<span style="letter-spacing:1pt;"> </span>Act<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>other<span style="letter-spacing:1pt;"> </span>federal<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>state<span style="letter-spacing:0.95pt;"> </span>healthcare<span style="letter-spacing:1pt;"> </span>fraud<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>abuse<span style="letter-spacing:0.95pt;"> </span>laws<span style="letter-spacing:0.9pt;"> </span>as<span style="letter-spacing:0.9pt;"> </span>well<span style="letter-spacing:0.95pt;"> </span>as state<span style="letter-spacing:1.2pt;"> </span>consumer<span style="letter-spacing:1.15pt;"> </span>protection<span style="letter-spacing:1.2pt;"> </span>laws.<span style="letter-spacing:1.1pt;"> </span>Our<span style="letter-spacing:1.1pt;"> </span>failure<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>comply<span style="letter-spacing:1.15pt;"> </span>with<span style="letter-spacing:1.1pt;"> </span>all<span style="letter-spacing:1.15pt;"> </span>regulatory<span style="letter-spacing:1.2pt;"> </span>requirements,<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>later<span style="letter-spacing:1.2pt;"> </span>discovery<span style="letter-spacing:1.15pt;"> </span>of previously<span style="letter-spacing:0.15pt;"> </span>unknown<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>events<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>problems<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>products,<span style="letter-spacing:0.1pt;"> </span>manufacturers<span style="letter-spacing:0.2pt;"> </span>or manufacturing processes,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>yield<span style="letter-spacing:0.05pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>results,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="line-height:5pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">litigation</span><span style="letter-spacing:0.15pt;"> </span>involving<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>taking<span style="letter-spacing:0.05pt;"> </span>our products&#59;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">restrictions</span><span style="letter-spacing:0.15pt;"> </span>on such products,<span style="letter-spacing:0.05pt;"> </span>manufacturers<span style="letter-spacing:0.15pt;"> </span>or manufacturing<span style="letter-spacing:0.15pt;"> </span>processes&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">restrictions</span><span style="letter-spacing:0.15pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>labeling<span style="letter-spacing:0.1pt;"> </span>or marketing<span style="letter-spacing:0.1pt;"> </span>of a product&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">restrictions</span><span style="letter-spacing:0.15pt;"> </span>on product<span style="letter-spacing:0.05pt;"> </span>distribution<span style="letter-spacing:0.15pt;"> </span>or use&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">requirements</span><span style="letter-spacing:0.15pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>post-marketing<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>or clinical<span style="letter-spacing:0.1pt;"> </span>trials&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">warning</span><span style="letter-spacing:0.05pt;"> </span>or untitled<span style="letter-spacing:0.1pt;"> </span>letters&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">withdrawal</span><span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>market&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">refusal</span><span style="letter-spacing:0.1pt;"> </span>to approve<span style="letter-spacing:0.05pt;"> </span>pending<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>or supplements<span style="letter-spacing:0.1pt;"> </span>to approved<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we submit&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">recall</span><span style="letter-spacing:0.1pt;"> </span>of products&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">fines,</span><span style="letter-spacing:0.05pt;"> </span>restitution<span style="letter-spacing:0.15pt;"> </span>or disgorgement<span style="letter-spacing:0.1pt;"> </span>of profits<span style="letter-spacing:0.1pt;"> </span>or revenues&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">suspension</span><span style="letter-spacing:0.05pt;"> </span>or withdrawal<span style="letter-spacing:0.05pt;"> </span>of marketing<span style="letter-spacing:0.1pt;"> </span>approvals&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">damage</span><span style="letter-spacing:0.05pt;"> </span>to relationships<span style="letter-spacing:0.15pt;"> </span>with any potential<span style="letter-spacing:0.1pt;"> </span>collaborators&#59;</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">unfavorable</span><span style="letter-spacing:0.1pt;"> </span>press<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and damage<span style="letter-spacing:0.05pt;"> </span>to our reputation&#59;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">refusal</span><span style="letter-spacing:0.1pt;"> </span>to permit<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>import<span style="letter-spacing:0.1pt;"> </span>or export<span style="letter-spacing:0.05pt;"> </span>of our products&#59;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">product</span><span style="letter-spacing:0.05pt;"> </span>seizure&#59;<span style="letter-spacing:0.1pt;"> </span>or</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;<span style="margin-left:45pt;">injunctions</span><span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>imposition<span style="letter-spacing:0.1pt;"> </span>of civil<span style="letter-spacing:0.05pt;"> </span>or criminal<span style="letter-spacing:0.1pt;"> </span>penalties.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compliance<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>or any future<span style="letter-spacing:0.05pt;"> </span>collaborator<span style="letter-spacing:0.15pt;"> </span>with regulatory<span style="letter-spacing:0.1pt;"> </span>requirements,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>monitoring or pharmacovigilance,<span style="letter-spacing:0.15pt;"> </span>and with requirements<span style="letter-spacing:0.15pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>of products<span style="letter-spacing:0.05pt;"> </span>for the pediatric<span style="letter-spacing:0.05pt;"> </span>population can also<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>penalties.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current<span style="letter-spacing:0.05pt;"> </span>and future<span style="letter-spacing:0.05pt;"> </span>relationships<span style="letter-spacing:0.1pt;"> </span>with customers<span style="letter-spacing:0.1pt;"> </span>and third-party<span style="letter-spacing:0.1pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to applicable anti-kickback,<span style="letter-spacing:0.1pt;"> </span>fraud and abuse, transparency,<span style="letter-spacing:0.05pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>privacy,<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.05pt;"> </span>laws and regulations, which could expose<span style="letter-spacing:0.05pt;"> </span>us to significant<span style="letter-spacing:0.1pt;"> </span>penalties,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>criminal,<span style="letter-spacing:0.1pt;"> </span>civil,<span style="letter-spacing:0.1pt;"> </span>and administrative<span style="letter-spacing:0.15pt;"> </span>penalties, contractual<span style="letter-spacing:0.05pt;"> </span>damages,<span style="letter-spacing:0.05pt;"> </span>reputational<span style="letter-spacing:0.1pt;"> </span>harm and diminished<span style="letter-spacing:0.1pt;"> </span>profits<span style="letter-spacing:0.1pt;"> </span>and future<span style="letter-spacing:0.05pt;"> </span>earnings.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare<span style="letter-spacing:0.15pt;"> </span>providers,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>physicians,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>play<span style="letter-spacing:0.05pt;"> </span>a primary<span style="letter-spacing:0.1pt;"> </span>role<span style="letter-spacing:0.05pt;"> </span>in the recommendation<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prescription<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval.<span style="letter-spacing:0.05pt;"> </span>Our current and<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>arrangements<span style="letter-spacing:0.2pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.15pt;"> </span>providers,<span style="letter-spacing:0.15pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>and customers<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>expose<span style="letter-spacing:0.05pt;"> </span>us to broadly applicable<span style="letter-spacing:0.15pt;"> </span>fraud<span style="letter-spacing:0.1pt;"> </span>and abuse<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>laws and regulations<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>constrain<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or financial arrangements<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>relationships<span style="letter-spacing:1.05pt;"> </span>through<span style="letter-spacing:0.95pt;"> </span>which<span style="letter-spacing:0.9pt;"> </span>we<span style="letter-spacing:0.9pt;"> </span>research,<span style="letter-spacing:1pt;"> </span>as<span style="letter-spacing:0.9pt;"> </span>well<span style="letter-spacing:0.95pt;"> </span>as,<span style="letter-spacing:0.9pt;"> </span>market,<span style="letter-spacing:1pt;"> </span>sell<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>distribute<span style="letter-spacing:1pt;"> </span>any<span style="letter-spacing:0.9pt;"> </span>products for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval.<span style="letter-spacing:0.05pt;"> </span>Restrictions<span style="letter-spacing:0.1pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>and state<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>laws and regulations<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be applicable<span style="letter-spacing:0.1pt;"> </span>to our business<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>following:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.4pt;"> </span>federal<span style="letter-spacing:0.4pt;"> </span>Anti-Kickback<span style="letter-spacing:0.35pt;"> </span>Statute<span style="letter-spacing:0.35pt;"> </span>prohibits,<span style="letter-spacing:0.4pt;"> </span>among<span style="letter-spacing:0.35pt;"> </span>other<span style="letter-spacing:0.35pt;"> </span>things,<span style="letter-spacing:0.35pt;"> </span>persons<span style="letter-spacing:0.35pt;"> </span>from<span style="letter-spacing:0.35pt;"> </span>knowingly<span style="letter-spacing:0.3pt;"> </span>and<span style="letter-spacing:0.3pt;"> </span>willfully soliciting,<span style="letter-spacing:1.25pt;"> </span>offering,<span style="letter-spacing:1.25pt;"> </span>receiving<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>providing<span style="letter-spacing:1.2pt;"> </span>remuneration,<span style="letter-spacing:1.3pt;"> </span>directly<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>indirectly,<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>cash<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>kind,<span style="letter-spacing:1.1pt;"> </span>to induce<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>reward,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>return<span style="letter-spacing:0.1pt;"> </span>for,<span style="letter-spacing:0.1pt;"> </span>either<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>referral<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>individual<span style="letter-spacing:0.15pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>purchase,<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:0.05pt;"> </span>or recommendation<span style="letter-spacing:0.15pt;"> </span>of, any good or service,<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which payment<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be made<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>a federal<span style="letter-spacing:0.1pt;"> </span>healthcare program<span style="letter-spacing:0.05pt;"> </span>such as Medicare<span style="letter-spacing:0.1pt;"> </span>and Medicaid&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.7pt;"> </span>federal<span style="letter-spacing:0.75pt;"> </span>civil and criminal false claims laws,<span style="letter-spacing:0.7pt;"> </span>including<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>False<span style="letter-spacing:0.7pt;"> </span>Claims<span style="letter-spacing:0.7pt;"> </span>Act,<span style="letter-spacing:0.65pt;"> </span>which<span style="letter-spacing:0.65pt;"> </span>can<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.65pt;"> </span>enforced<span style="letter-spacing:0.7pt;"> </span>by<span style="letter-spacing:0.65pt;"> </span>civil<span style="letter-spacing:0.7pt;"> </span>whistleblower<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>qui tam<span style="letter-spacing:2.4pt;"> </span>actions<span style="letter-spacing:2.4pt;"> </span>on<span style="letter-spacing:2.35pt;"> </span>behalf<span style="letter-spacing:2.4pt;"> </span>of<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>government,<span style="letter-spacing:2.45pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>criminal<span style="letter-spacing:2.45pt;"> </span>false<span style="letter-spacing:2.4pt;"> </span>claims<span style="letter-spacing:2.45pt;"> </span>laws<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>civil<span style="letter-spacing:2.4pt;"> </span>monetary penalties<span style="letter-spacing:0.15pt;"> </span>law,<span style="letter-spacing:0.05pt;"> </span>prohibit<span style="letter-spacing:0.15pt;"> </span>individuals<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>entities<span style="letter-spacing:0.15pt;"> </span>from,<span style="letter-spacing:0.1pt;"> </span>among<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>things,<span style="letter-spacing:0.1pt;"> </span>knowingly presenting,<span style="letter-spacing:0.1pt;"> </span>or causing<span style="letter-spacing:0.05pt;"> </span>to be presented<span style="letter-spacing:0.1pt;"> </span>false<span style="letter-spacing:0.05pt;"> </span>or fraudulent<span style="letter-spacing:0.1pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:0.05pt;"> </span>by a federal<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.05pt;"> </span>program, or making<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>false<span style="letter-spacing:0.1pt;"> </span>statement<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>record<span style="letter-spacing:0.1pt;"> </span>material<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>false<span style="letter-spacing:0.1pt;"> </span>claim<span style="letter-spacing:0.1pt;"> </span>or avoiding,<span style="letter-spacing:0.05pt;"> </span>decreasing<span style="letter-spacing:0.1pt;"> </span>or concealing<span style="letter-spacing:0.1pt;"> </span>an obligation<span style="letter-spacing:0.1pt;"> </span>to pay money<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>government&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.8pt;"> </span>federal<span style="letter-spacing:0.85pt;"> </span>Health<span style="letter-spacing:0.8pt;"> </span>Insurance<span style="letter-spacing:0.85pt;"> </span>Portability<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>Accountability<span style="letter-spacing:0.8pt;"> </span>Act<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>1996,<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.7pt;"> </span>HIPAA,<span style="letter-spacing:0.65pt;"> </span>prohibits,<span style="letter-spacing:0.8pt;"> </span>among other<span style="letter-spacing:1.55pt;"> </span>things,<span style="letter-spacing:1.55pt;"> </span>knowingly<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.5pt;"> </span>willfully<span style="letter-spacing:1.6pt;"> </span>executing,<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:1.5pt;"> </span>attempting<span style="letter-spacing:1.55pt;"> </span>to<span style="letter-spacing:1.45pt;"> </span>execute,<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.45pt;"> </span>scheme<span style="letter-spacing:1.5pt;"> </span>to<span style="letter-spacing:1.45pt;"> </span>defraud<span style="letter-spacing:1.5pt;"> </span>any healthcare<span style="letter-spacing:0.15pt;"> </span>benefit<span style="letter-spacing:0.15pt;"> </span>program,<span style="letter-spacing:0.1pt;"> </span>regardless<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>payor<span style="letter-spacing:0.05pt;"> </span>(e.g.,<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:0.05pt;"> </span>or private),<span style="letter-spacing:0.1pt;"> </span>and knowingly and willfully falsifying,<span style="letter-spacing:0.15pt;"> </span>concealing<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>covering<span style="letter-spacing:0.1pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>trick<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>device<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>material<span style="letter-spacing:0.15pt;"> </span>fact<span style="letter-spacing:0.05pt;"> </span>or making<span style="letter-spacing:0.05pt;"> </span>any materially false,<span style="letter-spacing:0.1pt;"> </span>fictitious<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fraudulent<span style="letter-spacing:0.15pt;"> </span>statements<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>connection<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>delivery<span style="letter-spacing:0.15pt;"> </span>of, or payment<span style="letter-spacing:0.05pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>healthcare benefits,<span style="letter-spacing:0.1pt;"> </span>items<span style="letter-spacing:0.1pt;"> </span>or services<span style="letter-spacing:0.1pt;"> </span>relating<span style="letter-spacing:0.1pt;"> </span>to healthcare<span style="letter-spacing:0.1pt;"> </span>matters&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIPAA,<span style="letter-spacing:0.55pt;"> </span>as<span style="letter-spacing:0.6pt;"> </span>amended<span style="letter-spacing:0.65pt;"> </span>by<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>Health<span style="letter-spacing:0.65pt;"> </span>Information<span style="letter-spacing:0.75pt;"> </span>Technology<span style="letter-spacing:0.65pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>Economic<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>Clinical<span style="letter-spacing:0.7pt;"> </span>Health<span style="letter-spacing:0.65pt;"> </span>Act,<span style="letter-spacing:0.55pt;"> </span>or HITECH, and<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>implementing<span style="letter-spacing:0.2pt;"> </span>regulations,<span style="letter-spacing:0.15pt;"> </span>impose<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>on certain<span style="letter-spacing:0.1pt;"> </span>covered<span style="letter-spacing:0.05pt;"> </span>healthcare providers,<span style="letter-spacing:1.4pt;"> </span>health<span style="letter-spacing:1.35pt;"> </span>plans,<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.3pt;"> </span>healthcare<span style="letter-spacing:1.4pt;"> </span>clearinghouses<span style="letter-spacing:1.35pt;"> </span>as<span style="letter-spacing:1.25pt;"> </span>well<span style="letter-spacing:1.3pt;"> </span>as<span style="letter-spacing:1.25pt;"> </span>their<span style="letter-spacing:1.3pt;"> </span>respective<span style="letter-spacing:1.35pt;"> </span>business<span style="letter-spacing:1.3pt;"> </span>associates and<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>subcontractors<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>perform<span style="letter-spacing:0.15pt;"> </span>services<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>them<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>use, or disclosure<span style="letter-spacing:0.1pt;"> </span>of, individually<span style="letter-spacing:0.15pt;"> </span>identifiable<span style="letter-spacing:0.2pt;"> </span>health<span style="letter-spacing:0.1pt;"> </span>information,<span style="letter-spacing:0.2pt;"> </span>relating<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>privacy,<span style="letter-spacing:0.05pt;"> </span>security,<span style="letter-spacing:0.1pt;"> </span>and transmission<span style="letter-spacing:0.15pt;"> </span>of such individually<span style="letter-spacing:0.1pt;"> </span>identifiable<span style="letter-spacing:0.15pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>information&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Health<span style="letter-spacing:0.1pt;"> </span>Care<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>Education<span style="letter-spacing:0.1pt;"> </span>Reconciliation<span style="letter-spacing:0.15pt;"> </span>Act<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>2010, collectively<span style="letter-spacing:0.15pt;"> </span>referred<span style="letter-spacing:0.1pt;"> </span>to as the ACA,<span style="letter-spacing:1.8pt;"> </span>requires<span style="letter-spacing:1.95pt;"> </span>certain<span style="letter-spacing:1.95pt;"> </span>manufacturers<span style="letter-spacing:1.95pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>drugs,<span style="letter-spacing:1.85pt;"> </span>devices,<span style="letter-spacing:1.85pt;"> </span>biologics<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:1.8pt;"> </span>medical<span style="letter-spacing:1.9pt;"> </span>supplies<span style="letter-spacing:1.85pt;"> </span>to<span style="letter-spacing:1.8pt;"> </span>annually report<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Centers<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>Medicare<span style="letter-spacing:0.15pt;"> </span>&#38;<span style="letter-spacing:0.05pt;"> </span>Medicaid<span style="letter-spacing:0.15pt;"> </span>Services,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>CMS, information<span style="letter-spacing:0.15pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to payments<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:2.35pt;"> </span>transfers<span style="letter-spacing:2.4pt;"> </span>of<span style="letter-spacing:2.3pt;"> </span>value<span style="letter-spacing:2.35pt;"> </span>provided<span style="letter-spacing:2.35pt;"> </span>to,<span style="letter-spacing:2.3pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>ownership<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>investment<span style="letter-spacing:2.4pt;"> </span>interests<span style="letter-spacing:2.4pt;"> </span>held<span style="letter-spacing:2.3pt;"> </span>by,<span style="letter-spacing:2.25pt;"> </span>physicians, defined<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>include<span style="letter-spacing:1.3pt;"> </span>doctors,<span style="letter-spacing:1.25pt;"> </span>dentists,<span style="letter-spacing:1.3pt;"> </span>optometrists,<span style="letter-spacing:1.35pt;"> </span>podiatrists<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>chiropractors,<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>their<span style="letter-spacing:1.25pt;"> </span>immediate family<span style="letter-spacing:0.15pt;"> </span>members.<span style="letter-spacing:0.1pt;"> </span>Beginning<span style="letter-spacing:0.05pt;"> </span>in 2022, applicable<span style="letter-spacing:0.1pt;"> </span>manufacturers<span style="letter-spacing:0.15pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be required<span style="letter-spacing:0.1pt;"> </span>to report<span style="letter-spacing:0.05pt;"> </span>such information<span style="letter-spacing:0.2pt;"> </span>regarding<span style="letter-spacing:0.15pt;"> </span>payments<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>transfers<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>provided,<span style="letter-spacing:0.05pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as ownership<span style="letter-spacing:0.05pt;"> </span>and investment interests<span style="letter-spacing:0.1pt;"> </span>held,<span style="letter-spacing:0.05pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>previous<span style="letter-spacing:0.05pt;"> </span>year<span style="letter-spacing:0.05pt;"> </span>to physician<span style="letter-spacing:0.05pt;"> </span>assistants,<span style="letter-spacing:0.1pt;"> </span>nurse practitioners,<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.05pt;"> </span>nurse specialists,<span style="letter-spacing:0.15pt;"> </span>anesthesiologist<span style="letter-spacing:0.15pt;"> </span>assistants,<span style="letter-spacing:0.1pt;"> </span>certified<span style="letter-spacing:0.15pt;"> </span>nurse<span style="letter-spacing:0.05pt;"> </span>anesthetists<span style="letter-spacing:0.15pt;"> </span>and certified<span style="letter-spacing:0.15pt;"> </span>nurse-midwives&#59;<span style="letter-spacing:0.15pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">analogous<span style="letter-spacing:0.95pt;"> </span>state<span style="letter-spacing:0.95pt;"> </span>laws<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>regulations<span style="letter-spacing:0.95pt;"> </span>such<span style="letter-spacing:0.85pt;"> </span>as<span style="letter-spacing:0.85pt;"> </span>state<span style="letter-spacing:0.9pt;"> </span>anti-kickback<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>false<span style="letter-spacing:0.9pt;"> </span>claims<span style="letter-spacing:0.95pt;"> </span>laws<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>analogous non-U.S. fraud<span style="letter-spacing:0.05pt;"> </span>and abuse<span style="letter-spacing:0.05pt;"> </span>laws and regulations,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>apply<span style="letter-spacing:0.05pt;"> </span>to sales<span style="letter-spacing:0.05pt;"> </span>or marketing<span style="letter-spacing:0.1pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>and claims<span style="letter-spacing:0.15pt;"> </span>involving<span style="letter-spacing:0.1pt;"> </span>healthcare<span style="letter-spacing:0.15pt;"> </span>items<span style="letter-spacing:0.1pt;"> </span>or services<span style="letter-spacing:0.1pt;"> </span>reimbursed<span style="letter-spacing:0.1pt;"> </span>by non-governmental<span style="letter-spacing:0.15pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payors, including<span style="letter-spacing:0.1pt;"> </span>private<span style="letter-spacing:0.15pt;"> </span>insurers.<span style="letter-spacing:0.15pt;"> </span>Some<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with the pharmaceutical<span style="letter-spacing:0.15pt;"> </span>industry&#8217;s<span style="letter-spacing:0.1pt;"> </span>voluntary<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>guidelines<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:0.1pt;"> </span>compliance<span style="letter-spacing:0.05pt;"> </span>regulations promulgated<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>federal<span style="letter-spacing:0.15pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>drug manufacturers<span style="letter-spacing:0.15pt;"> </span>to report<span style="letter-spacing:0.05pt;"> </span>information related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>payments<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>transfers<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>physicians<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>providers,<span style="letter-spacing:0.1pt;"> </span>marketing expenditures,<span style="letter-spacing:0.1pt;"> </span>or drug pricing,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>increases.<span style="letter-spacing:0.1pt;"> </span>State<span style="letter-spacing:0.05pt;"> </span>and local<span style="letter-spacing:0.05pt;"> </span>laws require<span style="letter-spacing:0.1pt;"> </span>the registration<span style="letter-spacing:0.1pt;"> </span>of pharmaceutical<span style="letter-spacing:0.2pt;"> </span>sales<span style="letter-spacing:0.1pt;"> </span>representatives.<span style="letter-spacing:0.2pt;"> </span>State<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>non-U.S.<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>govern<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>privacy<span style="letter-spacing:0.05pt;"> </span>and security of<span style="letter-spacing:0.05pt;"> </span>health<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.1pt;"> </span>circumstances,<span style="letter-spacing:0.2pt;"> </span>many<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>differ<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>ways and often<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not preempted<span style="letter-spacing:0.1pt;"> </span>by HIPAA,<span style="letter-spacing:-0.05pt;"> </span>thus<span style="letter-spacing:0.05pt;"> </span>complicating<span style="letter-spacing:0.15pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>efforts.</p></td></tr></table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>ensure<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.05pt;"> </span>with applicable<span style="letter-spacing:0.1pt;"> </span>healthcare laws and regulations<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>costs.<span style="letter-spacing:0.05pt;"> </span>It<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>possible<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:0.05pt;"> </span>authorities<span style="letter-spacing:0.1pt;"> </span>will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable<span style="letter-spacing:0.15pt;"> </span>fraud<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>abuse<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>healthcare<span style="letter-spacing:0.15pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>found to be in violation of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>laws or any other<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>apply<span style="letter-spacing:0.05pt;"> </span>to us, we may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to significant civil,<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:0.1pt;"> </span>and administrative<span style="letter-spacing:0.2pt;"> </span>penalties,<span style="letter-spacing:0.1pt;"> </span>damages,<span style="letter-spacing:0.05pt;"> </span>fines,<span style="letter-spacing:0.05pt;"> </span>disgorgement,<span style="letter-spacing:0.1pt;"> </span>imprisonment,<span style="letter-spacing:0.15pt;"> </span>exclusion<span style="letter-spacing:0.05pt;"> </span>from government<span style="letter-spacing:0.15pt;"> </span>funded<span style="letter-spacing:0.1pt;"> </span>healthcare<span style="letter-spacing:0.15pt;"> </span>programs,<span style="letter-spacing:0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>Medicare<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>Medicaid<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>programs, contractual<span style="letter-spacing:0.15pt;"> </span>damages,<span style="letter-spacing:0.1pt;"> </span>reputational<span style="letter-spacing:0.2pt;"> </span>harm,<span style="letter-spacing:0.1pt;"> </span>diminished<span style="letter-spacing:0.1pt;"> </span>profits<span style="letter-spacing:0.1pt;"> </span>and future<span style="letter-spacing:0.05pt;"> </span>earnings,<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>integrity<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>and oversight<span style="letter-spacing:0.15pt;"> </span>obligations,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>curtailment<span style="letter-spacing:0.15pt;"> </span>or restructuring<span style="letter-spacing:0.15pt;"> </span>of our operations,<span style="letter-spacing:0.1pt;"> </span>any of which could<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affect our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>operate<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any of the<span style="letter-spacing:0.05pt;"> </span>physicians<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>healthcare providers<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>entities<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>whom<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.1pt;"> </span>to do business<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>found to be not in compliance<span style="letter-spacing:0.1pt;"> </span>with applicable<span style="letter-spacing:0.1pt;"> </span>laws, they<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to significant<span style="letter-spacing:0.15pt;"> </span>criminal,<span style="letter-spacing:0.1pt;"> </span>civil<span style="letter-spacing:0.05pt;"> </span>and administrative<span style="letter-spacing:0.2pt;"> </span>sanctions,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>exclusions<span style="letter-spacing:0.1pt;"> </span>from government<span style="letter-spacing:0.15pt;"> </span>funded<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.1pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.</span></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to perceived increases in health care costs in recent years, there have been and continue to be proposals by the federal government, state governments, regulators, and third-party payors to control these costs and, more generally, to reform the U.S. health care system. Certain of these proposals could limit the prices we are able to charge for our products or the amounts of reimbursement available for our products and could limit the acceptance and availability of our products. Further, while the United States has begun shifting to pay-for-performance rather than fee-for-service models and has been embracing many shared-risk arrangements, CMS and OIG specifically excluded medical device manufacturers from utilizing the new, more flexible Stark Law exceptions and Anti-Kickback Statute safe harbors under the Final Rules, part of the U.S. Department of Health and Human Services&#8217; Regulatory Sprint to Coordinated Care, which were published on December 2, 2020 in the Federal Register and were largely effective January 19, 2021. The exclusion of manufacturers from utilizing these exceptions and safe harbors will not allow us to avail ourselves of immunity from liability under the laws, potentially inviting greater scrutiny over our shared risk arrangements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on November 16, 2020 the OIG published a Special Fraud Alert addressing manufacturer Speaker Programs signaling both a more narrow government view of AKS compliance with respect to such programs as well as the potential for increased enforcement in this space by government oversight agencies such as the OIG and DOJ. In response to this Special Fraud Alert, PhRMA issued its Statement on Revisions to the PhRMA Code on Interactions with Health Care Professionals on August 6, 2021 asserting, among other things, that pharmaceutical companies should not pay for or provide alcohol in connection with speaker programs. The updated PhRMA Code updates also clarified that repeat attendance at a speaker program on the same or substantially the same topic where a meal is provided to the attendee is generally not appropriate. The updated PhRMA Code was made effective as of January 1, 2022.&#160;&#160;AdvaMed has not made corollary revisions to its Code of Ethics to date. We continue to assess industry response to the Special Fraud Alert and have and may continue to make modifications to certain aspects of our speaker programs, which may have a detrimental impact on our ability to educate healthcare providers about our products and to promote use of our products, which may lead to decreased product sales and negatively impact our business, financial condition and results of operations.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive healthcare legislation, signed into law in the United States in March 2010, titled the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively, the ACA, imposes certain stringent compliance, recordkeeping, and reporting requirements on companies in various sectors of the life sciences industry, and enhanced penalties for non-compliance.&#160;&#160;Despite the ACA going into effect over a decade ago, there have been numerous legal and Congressional challenges to the law&#8217;s provisions and the effect of certain provisions have made compliance costly. More recently, in June 2021, a case challenging the constitutionality of the ACA&#8217;s individual mandate (<span style="font-style:italic;">California v. Texas</span>) was overturned at the Supreme Court.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict what additional new legislation, agency priorities, and rulemakings may be on the horizon as the United States continues to reassess how it pays for healthcare. As a result, we cannot quantify or predict what impact any changes might have on our business and results of operations. However, any changes that lower reimbursement for our products could materially and adversely affect our business, financial condition and results of operations.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legal, regulatory and commercial policy influences are subjecting our industry to significant changes, and we cannot predict whether new regulations or policies will emerge from U.S. federal or state governments, foreign governments, or third-party payors. Government and commercial payors may, in the future, consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect reimbursement for healthcare products such as our systems. These policies have included, and may in the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness, and costs, of different treatment technologies and modalities&#59; imposing price controls and taxes on medical device providers&#59; and other measures. Future significant changes in the healthcare systems in the United States or elsewhere could also have a negative impact on the demand for our current and future products. These include changes that may reduce reimbursement rates for our products and changes that may be proposed or implemented by the current or future laws or regulations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Governments<span style="letter-spacing:0.05pt;"> </span>outside<span style="letter-spacing:0.05pt;"> </span>of the United States<span style="letter-spacing:0.05pt;"> </span>tend to impose<span style="letter-spacing:0.05pt;"> </span>strict<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>controls,<span style="letter-spacing:0.05pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affect our revenues,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly the countries of the European Union, or the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, such as arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. In addition, the recent withdrawal of the United Kingdom from its membership in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU, often referred to as &#8220;Brexit&#8221;, could lead to legal and regulatory uncertainty in the United Kingdom and may lead to the United Kingdom and EU adopting divergent laws and regulations, including those related to the pricing of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prescription</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceuticals,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kingdom</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determines</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU laws</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to replicate</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or replace.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kingdom were to significantly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alter</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its regulations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affecting</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the pricing of prescription</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceuticals,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">face</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a result,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brexit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impair</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to transact</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kingdom.</span></p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Laws and regulations<span style="letter-spacing:0.05pt;"> </span>governing<span style="letter-spacing:0.05pt;"> </span>any international<span style="letter-spacing:0.1pt;"> </span>operations<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>have in the future<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>preclude<span style="letter-spacing:0.05pt;"> </span>us from<span style="letter-spacing:0.05pt;"> </span>developing,<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.05pt;"> </span>and selling<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>and products<span style="letter-spacing:0.05pt;"> </span>outside<span style="letter-spacing:0.05pt;"> </span>of the United States<span style="letter-spacing:0.05pt;"> </span>and require<span style="letter-spacing:0.05pt;"> </span>us to develop<span style="letter-spacing:0.05pt;"> </span>and implement<span style="letter-spacing:0.1pt;"> </span>costly<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>programs.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expand<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>outside<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>we must<span style="letter-spacing:0.05pt;"> </span>dedicate<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>to comply with<span style="letter-spacing:0.05pt;"> </span>numerous<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>jurisdiction<span style="letter-spacing:0.15pt;"> </span>in which we plan<span style="letter-spacing:0.05pt;"> </span>to operate.<span style="letter-spacing:0.05pt;"> </span>The Foreign<span style="letter-spacing:0.05pt;"> </span>Corrupt Practices<span style="letter-spacing:0.2pt;"> </span>Act,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>FCPA,<span style="letter-spacing:0.05pt;"> </span>prohibits<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>U.S. individual<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>paying,<span style="letter-spacing:0.1pt;"> </span>offering,<span style="letter-spacing:0.15pt;"> </span>authorizing<span style="letter-spacing:0.15pt;"> </span>payment<span style="letter-spacing:0.1pt;"> </span>or offering<span style="letter-spacing:1.95pt;"> </span>anything<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.85pt;"> </span>value,<span style="letter-spacing:1.9pt;"> </span>directly<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.85pt;"> </span>indirectly,<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>any<span style="letter-spacing:1.85pt;"> </span>foreign<span style="letter-spacing:1.85pt;"> </span>official,<span style="letter-spacing:1.9pt;"> </span>political<span style="letter-spacing:1.9pt;"> </span>party<span style="letter-spacing:1.85pt;"> </span>or<span style="letter-spacing:1.8pt;"> </span>candidate<span style="letter-spacing:1.9pt;"> </span>for<span style="letter-spacing:1.85pt;"> </span>the purpose<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>influencing<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>act<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>decision<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>in order<span style="letter-spacing:0.05pt;"> </span>to assist<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>individual<span style="letter-spacing:0.1pt;"> </span>or business<span style="letter-spacing:0.05pt;"> </span>in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United<span style="letter-spacing:0.1pt;"> </span>States<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>accounting<span style="letter-spacing:0.1pt;"> </span>provisions<span style="letter-spacing:0.15pt;"> </span>requiring<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>company<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:0.15pt;"> </span>books<span style="letter-spacing:0.05pt;"> </span>and records that<span style="letter-spacing:1.8pt;"> </span>accurately<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.75pt;"> </span>fairly<span style="letter-spacing:1.85pt;"> </span>reflect<span style="letter-spacing:1.85pt;"> </span>all<span style="letter-spacing:1.8pt;"> </span>transactions<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.75pt;"> </span>the<span style="letter-spacing:1.8pt;"> </span>company,<span style="letter-spacing:1.8pt;"> </span>including<span style="letter-spacing:1.8pt;"> </span>international<span style="letter-spacing:1.9pt;"> </span>subsidiaries,<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:1.75pt;"> </span>to devise<span style="letter-spacing:0.05pt;"> </span>and maintain<span style="letter-spacing:0.1pt;"> </span>an adequate<span style="letter-spacing:0.05pt;"> </span>system<span style="letter-spacing:0.05pt;"> </span>of internal<span style="letter-spacing:0.1pt;"> </span>accounting<span style="letter-spacing:0.05pt;"> </span>controls<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>international<span style="letter-spacing:0.15pt;"> </span>operations.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FCPA is<span style="letter-spacing:0.1pt;"> </span>expensive<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>difficult,<span style="letter-spacing:0.2pt;"> </span>particularly<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>which corruption<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because,<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:0.1pt;"> </span>countries,<span style="letter-spacing:0.15pt;"> </span>hospitals<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>operated<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>government,<span style="letter-spacing:0.1pt;"> </span>and doctors<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>hospital<span style="letter-spacing:0.1pt;"> </span>employees are<span style="letter-spacing:0.1pt;"> </span>considered<span style="letter-spacing:0.15pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>officials.<span style="letter-spacing:0.2pt;"> </span>Certain<span style="letter-spacing:0.1pt;"> </span>payments<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>hospitals<span style="letter-spacing:0.1pt;"> </span>in connection<span style="letter-spacing:0.05pt;"> </span>with clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>work have been deemed<span style="letter-spacing:0.05pt;"> </span>to be improper<span style="letter-spacing:0.1pt;"> </span>payments<span style="letter-spacing:0.05pt;"> </span>to government<span style="letter-spacing:0.1pt;"> </span>officials<span style="letter-spacing:0.15pt;"> </span>and have led<span style="letter-spacing:0.05pt;"> </span>to FCPA<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:0.1pt;"> </span>actions.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United<span style="letter-spacing:0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>sharing<span style="letter-spacing:0.05pt;"> </span>with certain<span style="letter-spacing:0.1pt;"> </span>non-U.S. nationals,<span style="letter-spacing:0.1pt;"> </span>of information<span style="letter-spacing:0.15pt;"> </span>classified<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>national<span style="letter-spacing:0.05pt;"> </span>security purposes,<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span>well<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span>certain<span style="letter-spacing:1.3pt;"> </span>products<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>technical<span style="letter-spacing:1.3pt;"> </span>data<span style="letter-spacing:1.25pt;"> </span>relating<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>those<span style="letter-spacing:1.2pt;"> </span>products.<span style="letter-spacing:1.2pt;"> </span>If<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>expand<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>presence outside<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>United<span style="letter-spacing:1.1pt;"> </span>States,<span style="letter-spacing:1.1pt;"> </span>it<span style="letter-spacing:1.1pt;"> </span>will<span style="letter-spacing:1.1pt;"> </span>require<span style="letter-spacing:1.15pt;"> </span>us<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>dedicate<span style="letter-spacing:1.15pt;"> </span>additional<span style="letter-spacing:1.1pt;"> </span>resources<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1pt;"> </span>comply<span style="letter-spacing:1.05pt;"> </span>with<span style="letter-spacing:1pt;"> </span>these<span style="letter-spacing:1.05pt;"> </span>laws,<span style="letter-spacing:1pt;"> </span>and these<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>preclude<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>developing,<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>or selling<span style="letter-spacing:0.1pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and products outside<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>our growth potential<span style="letter-spacing:0.1pt;"> </span>and increase<span style="letter-spacing:0.1pt;"> </span>our development<span style="letter-spacing:0.1pt;"> </span>costs.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:1.2pt;"> </span>failure<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>comply<span style="letter-spacing:1.2pt;"> </span>with<span style="letter-spacing:1.15pt;"> </span>laws<span style="letter-spacing:1.15pt;"> </span>governing<span style="letter-spacing:1.2pt;"> </span>international<span style="letter-spacing:1.3pt;"> </span>business<span style="letter-spacing:1.2pt;"> </span>practices<span style="letter-spacing:1.25pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>result<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>substantial<span style="letter-spacing:1.25pt;"> </span>civil and<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:0.15pt;"> </span>penalties<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>suspension<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>debarment<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>contracting.<span style="letter-spacing:0.1pt;"> </span>The Securities<span style="letter-spacing:0.1pt;"> </span>and Exchange Commission, or the SEC, also may suspend or bar issuers from trading securities on U.S.<span style="letter-spacing:2.45pt;"> </span>exchanges for violations<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>FCPA&#8217;s<span style="letter-spacing:-0.05pt;"> </span>accounting<span style="letter-spacing:0.05pt;"> </span>provisions.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we fail<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with environmental,<span style="letter-spacing:0.1pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>and safety<span style="letter-spacing:0.05pt;"> </span>laws and regulations,<span style="letter-spacing:0.05pt;"> </span>we could become<span style="letter-spacing:0.05pt;"> </span>subject to fines<span style="letter-spacing:0.05pt;"> </span>or penalties<span style="letter-spacing:0.1pt;"> </span>or incur costs<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could harm our business.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to numerous<span style="letter-spacing:0.05pt;"> </span>foreign,<span style="letter-spacing:0.05pt;"> </span>federal,<span style="letter-spacing:0.1pt;"> </span>state<span style="letter-spacing:0.05pt;"> </span>and local<span style="letter-spacing:0.05pt;"> </span>environmental, health<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>laws and regulations,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>governing<span style="letter-spacing:0.05pt;"> </span>laboratory<span style="letter-spacing:0.1pt;"> </span>procedures<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>handling,<span style="letter-spacing:0.05pt;"> </span>use, storage,<span style="letter-spacing:0.1pt;"> </span>treatment<span style="letter-spacing:0.15pt;"> </span>and disposal<span style="letter-spacing:0.05pt;"> </span>of hazardous<span style="letter-spacing:0.05pt;"> </span>materials<span style="letter-spacing:0.15pt;"> </span>and wastes.<span style="letter-spacing:0.05pt;"> </span>Our operations<span style="letter-spacing:0.1pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>use of hazardous and flammable<span style="letter-spacing:0.15pt;"> </span>materials,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>chemicals<span style="letter-spacing:0.1pt;"> </span>and biological<span style="letter-spacing:0.1pt;"> </span>materials.<span style="letter-spacing:0.15pt;"> </span>Our operations<span style="letter-spacing:0.05pt;"> </span>also produce hazardous waste<span style="letter-spacing:1.9pt;"> </span>products.<span style="letter-spacing:1.9pt;"> </span>We<span style="letter-spacing:1.85pt;"> </span>generally<span style="letter-spacing:1.95pt;"> </span>contract<span style="letter-spacing:1.95pt;"> </span>with<span style="letter-spacing:1.85pt;"> </span>third<span style="letter-spacing:1.85pt;"> </span>parties<span style="letter-spacing:1.9pt;"> </span>for<span style="letter-spacing:1.85pt;"> </span>the<span style="letter-spacing:1.85pt;"> </span>disposal<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>these<span style="letter-spacing:1.85pt;"> </span>materials<span style="letter-spacing:1.95pt;"> </span>and<span style="letter-spacing:1.8pt;"> </span>wastes.<span style="letter-spacing:1.85pt;"> </span>We cannot<span style="letter-spacing:0.1pt;"> </span>eliminate<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.1pt;"> </span>of contamination<span style="letter-spacing:0.15pt;"> </span>or injury<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>materials.<span style="letter-spacing:0.15pt;"> </span>In the<span style="letter-spacing:0.05pt;"> </span>event<span style="letter-spacing:0.05pt;"> </span>of contamination<span style="letter-spacing:0.15pt;"> </span>or injury resulting<span style="letter-spacing:2.1pt;"> </span>from<span style="letter-spacing:2.05pt;"> </span>our<span style="letter-spacing:2pt;"> </span>use<span style="letter-spacing:2pt;"> </span>of<span style="letter-spacing:1.95pt;"> </span>hazardous<span style="letter-spacing:2pt;"> </span>materials,<span style="letter-spacing:2.1pt;"> </span>we<span style="letter-spacing:1.95pt;"> </span>could<span style="letter-spacing:2pt;"> </span>be<span style="letter-spacing:1.95pt;"> </span>held<span style="letter-spacing:2pt;"> </span>liable<span style="letter-spacing:2.05pt;"> </span>for<span style="letter-spacing:2pt;"> </span>any<span style="letter-spacing:1.95pt;"> </span>resulting<span style="letter-spacing:2.05pt;"> </span>damages,<span style="letter-spacing:2pt;"> </span>and<span style="letter-spacing:1.95pt;"> </span>any liability<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>exceed<span style="letter-spacing:0.05pt;"> </span>our resources,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>any available<span style="letter-spacing:0.1pt;"> </span>insurance.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>leasing<span style="letter-spacing:0.05pt;"> </span>and operation<span style="letter-spacing:0.1pt;"> </span>of real<span style="letter-spacing:0.05pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>us to liability<span style="letter-spacing:0.15pt;"> </span>pursuant<span style="letter-spacing:0.05pt;"> </span>to certain<span style="letter-spacing:0.1pt;"> </span>of these laws<span style="letter-spacing:1.9pt;"> </span>or<span style="letter-spacing:1.9pt;"> </span>regulations.<span style="letter-spacing:2pt;"> </span>Under<span style="letter-spacing:1.9pt;"> </span>existing<span style="letter-spacing:2pt;"> </span>U.S.<span style="letter-spacing:1.85pt;"> </span>environmental<span style="letter-spacing:2.05pt;"> </span>laws<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:1.9pt;"> </span>regulations,<span style="letter-spacing:2pt;"> </span>current<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:1.9pt;"> </span>previous<span style="letter-spacing:1.9pt;"> </span>owners<span style="letter-spacing:1.85pt;"> </span>or operators<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>real<span style="letter-spacing:0.1pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>entities<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>disposed<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>arranged<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>disposal<span style="letter-spacing:0.1pt;"> </span>of hazardous<span style="letter-spacing:0.05pt;"> </span>substances<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be held<span style="letter-spacing:0.1pt;"> </span>strictly,<span style="letter-spacing:0.15pt;"> </span>jointly<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>severally<span style="letter-spacing:0.15pt;"> </span>liable<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>of investigating<span style="letter-spacing:0.15pt;"> </span>or remediating<span style="letter-spacing:0.15pt;"> </span>contamination<span style="letter-spacing:0.15pt;"> </span>caused<span style="letter-spacing:0.05pt;"> </span>by hazardous<span style="letter-spacing:0.05pt;"> </span>substance<span style="letter-spacing:0.05pt;"> </span>releases,<span style="letter-spacing:0.1pt;"> </span>even if<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>did not know of and were not responsible<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>releases.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>incur<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>liabilities<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our financial<span style="letter-spacing:0.1pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>and operating<span style="letter-spacing:1.3pt;"> </span>results<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.25pt;"> </span>failure<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>comply<span style="letter-spacing:1.25pt;"> </span>with<span style="letter-spacing:1.2pt;"> </span>such<span style="letter-spacing:1.2pt;"> </span>laws<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>regulations,<span style="letter-spacing:1.25pt;"> </span>including,<span style="letter-spacing:1.2pt;"> </span>among<span style="letter-spacing:1.2pt;"> </span>other<span style="letter-spacing:1.2pt;"> </span>things,<span style="letter-spacing:1.2pt;"> </span>civil<span style="letter-spacing:1.2pt;"> </span>or criminal<span style="letter-spacing:0.15pt;"> </span>fines<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>penalties,<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>damage<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:0.1pt;"> </span>injury<span style="letter-spacing:0.1pt;"> </span>claims,<span style="letter-spacing:0.15pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>upgrades<span style="letter-spacing:0.1pt;"> </span>to our facilities<span style="letter-spacing:0.15pt;"> </span>or changes<span style="letter-spacing:0.05pt;"> </span>to our operating<span style="letter-spacing:0.1pt;"> </span>procedures,<span style="letter-spacing:0.1pt;"> </span>or injunctions<span style="letter-spacing:0.1pt;"> </span>limiting<span style="letter-spacing:0.1pt;"> </span>or altering<span style="letter-spacing:0.1pt;"> </span>our operations.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:0.15pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>insurance<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>cover<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and expenses<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.05pt;"> </span>due to injuries<span style="letter-spacing:0.1pt;"> </span>to our employees, this insurance may not provide adequate coverage against potential liabilities. We do not maintain<span style="letter-spacing:0.15pt;"> </span>insurance<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>environmental<span style="letter-spacing:0.2pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>toxic<span style="letter-spacing:0.1pt;"> </span>tort<span style="letter-spacing:0.1pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be asserted<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>us in connection with our storage<span style="letter-spacing:0.05pt;"> </span>or disposal<span style="letter-spacing:0.05pt;"> </span>of biological,<span style="letter-spacing:0.1pt;"> </span>hazardous<span style="letter-spacing:0.05pt;"> </span>or radioactive<span style="letter-spacing:0.1pt;"> </span>materials.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>in order<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with current<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>environmental,<span style="letter-spacing:0.15pt;"> </span>health and<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.1pt;"> </span>laws and regulations.<span style="letter-spacing:0.1pt;"> </span>These current<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>laws and regulations,<span style="letter-spacing:0.1pt;"> </span>which are<span style="letter-spacing:0.05pt;"> </span>becoming<span style="letter-spacing:0.05pt;"> </span>increasingly more<span style="letter-spacing:1.25pt;"> </span>stringent,<span style="letter-spacing:1.3pt;"> </span>may<span style="letter-spacing:1.25pt;"> </span>impair<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>research,<span style="letter-spacing:1.25pt;"> </span>development<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>production<span style="letter-spacing:1.2pt;"> </span>efforts.<span style="letter-spacing:1.25pt;"> </span>Our<span style="letter-spacing:1.15pt;"> </span>failure<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>comply<span style="letter-spacing:1.2pt;"> </span>with<span style="letter-spacing:1.15pt;"> </span>these laws and regulations<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>fines,<span style="letter-spacing:0.05pt;"> </span>penalties<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>sanctions.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.73%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject<span style="letter-spacing:0.05pt;"> </span>to certain<span style="letter-spacing:0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>and certain<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>anti-corruption,<span style="letter-spacing:0.1pt;"> </span>anti-money<span style="letter-spacing:0.1pt;"> </span>laundering,<span style="letter-spacing:0.05pt;"> </span>export control,<span style="letter-spacing:0.05pt;"> </span>sanctions<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.05pt;"> </span>laws and regulations.<span style="letter-spacing:0.05pt;"> </span>We can face<span style="letter-spacing:0.05pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>consequences<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>violations.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.73%;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. and<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>anti-corruption,<span style="letter-spacing:0.2pt;"> </span>anti-money<span style="letter-spacing:0.15pt;"> </span>laundering,<span style="letter-spacing:0.15pt;"> </span>export<span style="letter-spacing:0.1pt;"> </span>control,<span style="letter-spacing:0.1pt;"> </span>sanctions<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.05pt;"> </span>laws and regulations<span style="letter-spacing:0.2pt;"> </span>prohibit,<span style="letter-spacing:0.2pt;"> </span>among<span style="letter-spacing:0.15pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>things,<span style="letter-spacing:0.15pt;"> </span>companies<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>employees,<span style="letter-spacing:0.15pt;"> </span>agents,<span style="letter-spacing:0.1pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>legal<span style="letter-spacing:0.1pt;"> </span>counsel, accountants,<span style="letter-spacing:0.15pt;"> </span>consultants,<span style="letter-spacing:0.15pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>partners<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>authorizing,<span style="letter-spacing:0.1pt;"> </span>promising,<span style="letter-spacing:0.1pt;"> </span>offering,<span style="letter-spacing:0.1pt;"> </span>providing, soliciting,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>receiving<span style="letter-spacing:0.15pt;"> </span>directly<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>indirectly,<span style="letter-spacing:0.15pt;"> </span>corrupt<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>improper<span style="letter-spacing:0.15pt;"> </span>payments<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>anything<span style="letter-spacing:0.1pt;"> </span>else<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>to or from recipients<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>public<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:0.15pt;"> </span>sector.<span style="letter-spacing:0.1pt;"> </span>Violations<span style="letter-spacing:0.1pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>laws can result<span style="letter-spacing:0.1pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>criminal<span style="letter-spacing:0.1pt;"> </span>fines<span style="letter-spacing:0.05pt;"> </span>and civil penalties,<span style="letter-spacing:0.15pt;"> </span>imprisonment,<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>loss<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>privileges,<span style="letter-spacing:0.15pt;"> </span>debarment,<span style="letter-spacing:0.15pt;"> </span>tax<span style="letter-spacing:0.1pt;"> </span>reassessments,<span style="letter-spacing:0.2pt;"> </span>breach<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>contract<span style="letter-spacing:0.1pt;"> </span>and fraud litigation,<span style="letter-spacing:0.2pt;"> </span>reputational<span style="letter-spacing:0.2pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>consequences.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>direct<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>indirect<span style="letter-spacing:0.15pt;"> </span>interactions<span style="letter-spacing:0.15pt;"> </span>with officials<span style="letter-spacing:0.15pt;"> </span>and employees<span style="letter-spacing:0.1pt;"> </span>of government<span style="letter-spacing:0.1pt;"> </span>agencies<span style="letter-spacing:0.05pt;"> </span>or government-affiliated<span style="letter-spacing:0.25pt;"> </span>hospitals,<span style="letter-spacing:0.1pt;"> </span>universities<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>organizations.<span style="letter-spacing:0.05pt;"> </span>We also<span style="letter-spacing:2.4pt;"> </span>expect<span style="letter-spacing:2.4pt;"> </span>our<span style="letter-spacing:2.35pt;"> </span>non-U.S.<span style="letter-spacing:2.35pt;"> </span>activities to<span style="letter-spacing:2.35pt;"> </span>increase<span style="letter-spacing:2.45pt;"> </span>over<span style="letter-spacing:2.4pt;"> </span>time.<span style="letter-spacing:2.4pt;"> </span>We<span style="letter-spacing:2.35pt;"> </span>expect<span style="letter-spacing:2.4pt;"> </span>to<span style="letter-spacing:2.35pt;"> </span>rely<span style="letter-spacing:2.4pt;"> </span>on<span style="letter-spacing:2.35pt;"> </span>third<span style="letter-spacing:2.4pt;"> </span>parties<span style="letter-spacing:2.45pt;"> </span>for<span style="letter-spacing:2.4pt;"> </span>research, preclinical<span style="letter-spacing:0.15pt;"> </span>studies<span style="letter-spacing:0.05pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and/or<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:0.1pt;"> </span>permits,<span style="letter-spacing:0.1pt;"> </span>licenses,<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>registrations<span style="letter-spacing:0.15pt;"> </span>and other marketing<span style="letter-spacing:0.15pt;"> </span>approvals.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>held<span style="letter-spacing:0.1pt;"> </span>liable<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>corrupt<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>illegal<span style="letter-spacing:0.1pt;"> </span>activities<span style="letter-spacing:0.15pt;"> </span>of our personnel,<span style="letter-spacing:0.05pt;"> </span>agents,<span style="letter-spacing:0.05pt;"> </span>or partners,<span style="letter-spacing:0.1pt;"> </span>even if<span style="letter-spacing:0.05pt;"> </span>we do not explicitly<span style="letter-spacing:0.1pt;"> </span>authorize<span style="letter-spacing:0.1pt;"> </span>or have prior<span style="letter-spacing:0.05pt;"> </span>knowledge of such activities.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:0.05pt;"> </span>violations<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>described<span style="letter-spacing:0.1pt;"> </span>above may<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>civil<span style="letter-spacing:0.05pt;"> </span>and criminal<span style="letter-spacing:0.1pt;"> </span>fines and<span style="letter-spacing:0.05pt;"> </span>penalties,<span style="letter-spacing:0.15pt;"> </span>imprisonment,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of export<span style="letter-spacing:0.05pt;"> </span>or import<span style="letter-spacing:0.1pt;"> </span>privileges,<span style="letter-spacing:0.1pt;"> </span>debarment,<span style="letter-spacing:0.1pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>reassessments,<span style="letter-spacing:0.15pt;"> </span>breach<span style="letter-spacing:0.05pt;"> </span>of contract<span style="letter-spacing:0.1pt;"> </span>and fraud<span style="letter-spacing:0.05pt;"> </span>litigation,<span style="letter-spacing:0.15pt;"> </span>reputational<span style="letter-spacing:0.15pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>consequences.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Our Reliance<span style="letter-spacing:0.05pt;"> </span>on Third Parties</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely,<span style="letter-spacing:0.05pt;"> </span>and intend<span style="letter-spacing:0.05pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>to rely,<span style="letter-spacing:0.05pt;"> </span>on third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>to conduct our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and perform<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>of our research<span style="letter-spacing:0.05pt;"> </span>and preclinical<span style="letter-spacing:0.1pt;"> </span>studies.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>do not satisfactorily<span style="letter-spacing:0.15pt;"> </span>carry<span style="letter-spacing:0.05pt;"> </span>out their<span style="letter-spacing:0.05pt;"> </span>contractual duties,<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with applicable<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.1pt;"> </span>or do not meet<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.05pt;"> </span>deadlines,<span style="letter-spacing:0.05pt;"> </span>our development<span style="letter-spacing:0.1pt;"> </span>programs<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be delayed<span style="letter-spacing:0.05pt;"> </span>or subject<span style="letter-spacing:0.05pt;"> </span>to increased<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>or we may<span style="letter-spacing:0.05pt;"> </span>be unable to obtain regulatory<span style="letter-spacing:0.05pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>each of which may<span style="letter-spacing:0.05pt;"> </span>have an adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.05pt;"> </span>condition, results<span style="letter-spacing:0.05pt;"> </span>of operations<span style="letter-spacing:0.05pt;"> </span>and prospects.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>independently<span style="letter-spacing:0.15pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>aspects<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.15pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>or clinical<span style="letter-spacing:0.1pt;"> </span>trials ourselves.<span style="letter-spacing:0.1pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>dependent<span style="letter-spacing:0.05pt;"> </span>on third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>our ongoing and planned<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.05pt;"> </span>of PRT543,<span style="letter-spacing:0.05pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.2pt;"> </span>studies<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates. The<span style="letter-spacing:1.4pt;"> </span>timing<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>the<span style="letter-spacing:1.45pt;"> </span>initiation<span style="letter-spacing:1.55pt;"> </span>and<span style="letter-spacing:1.4pt;"> </span>completion<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>these<span style="letter-spacing:1.45pt;"> </span>trials<span style="letter-spacing:1.5pt;"> </span>will<span style="letter-spacing:1.45pt;"> </span>therefore<span style="letter-spacing:1.5pt;"> </span>be<span style="letter-spacing:1.4pt;"> </span>partially<span style="letter-spacing:1.5pt;"> </span>controlled<span style="letter-spacing:1.45pt;"> </span>by<span style="letter-spacing:1.35pt;"> </span>such<span style="letter-spacing:1.35pt;"> </span>third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>play<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>role<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.05pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>subsequent<span style="letter-spacing:0.05pt;"> </span>collection and<span style="letter-spacing:0.05pt;"> </span>analysis<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>data.<span style="letter-spacing:0.1pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>CROs and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not our employees,<span style="letter-spacing:0.1pt;"> </span>and we will<span style="letter-spacing:0.05pt;"> </span>not be able to control<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>aspects<span style="letter-spacing:0.05pt;"> </span>of their<span style="letter-spacing:0.05pt;"> </span>activities.<span style="letter-spacing:0.15pt;"> </span>Nevertheless,<span style="letter-spacing:0.1pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>responsible<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>ensuring<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.05pt;"> </span>is conducted<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>accordance<span style="letter-spacing:0.1pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>protocol<span style="letter-spacing:0.05pt;"> </span>and legal,<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>and scientific<span style="letter-spacing:0.15pt;"> </span>standards,<span style="letter-spacing:0.1pt;"> </span>and our reliance<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>CROs and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not relieve<span style="letter-spacing:0.1pt;"> </span>us of our regulatory<span style="letter-spacing:0.1pt;"> </span>responsibilities.<span style="letter-spacing:0.2pt;"> </span>We and our CROs<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.15pt;"> </span>required<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>comply<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.1pt;"> </span>good<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>practices,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>GCP, requirements,<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>and guidelines<span style="letter-spacing:0.15pt;"> </span>enforced<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA for<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in clinical<span style="letter-spacing:0.1pt;"> </span>development.<span style="letter-spacing:0.1pt;"> </span>Regulatory<span style="letter-spacing:0.05pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>enforce these<span style="letter-spacing:0.1pt;"> </span>GCP requirements<span style="letter-spacing:0.2pt;"> </span>through<span style="letter-spacing:0.1pt;"> </span>periodic<span style="letter-spacing:0.15pt;"> </span>inspections<span style="letter-spacing:0.1pt;"> </span>of trial<span style="letter-spacing:0.1pt;"> </span>sponsors,<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>investigators<span style="letter-spacing:0.15pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>trial sites.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>CROs or<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>sites<span style="letter-spacing:0.1pt;"> </span>fail<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.15pt;"> </span>GCP requirements,<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>data generated<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>deemed<span style="letter-spacing:0.1pt;"> </span>unreliable,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>us to perform<span style="letter-spacing:0.1pt;"> </span>additional clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>before<span style="letter-spacing:0.1pt;"> </span>approving<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>applications.<span style="letter-spacing:0.15pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>assure<span style="letter-spacing:0.1pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>that,<span style="letter-spacing:0.1pt;"> </span>upon inspection,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>FDA will<span style="letter-spacing:0.1pt;"> </span>determine<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>GCPs. In addition,<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>must<span style="letter-spacing:0.05pt;"> </span>be conducted<span style="letter-spacing:0.05pt;"> </span>with product<span style="letter-spacing:0.05pt;"> </span>produced<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>cGMP regulations.<span style="letter-spacing:0.1pt;"> </span>Our failure<span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.1pt;"> </span>of third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>on whom we rely<span style="letter-spacing:0.05pt;"> on </span>to comply with<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>stop<span style="letter-spacing:0.1pt;"> </span>and/or<span style="letter-spacing:0.1pt;"> </span>repeat<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials,<span style="letter-spacing:0.1pt;"> </span>which would delay<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>marketing approval<span style="letter-spacing:0.05pt;"> </span>process.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>no<span style="letter-spacing:0.1pt;"> </span>guarantee<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>CROs, clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>investigators<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>rely will<span style="letter-spacing:0.1pt;"> </span>devote<span style="letter-spacing:0.1pt;"> </span>adequate<span style="letter-spacing:0.1pt;"> </span>time<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>activities<span style="letter-spacing:0.15pt;"> </span>or perform<span style="letter-spacing:0.1pt;"> </span>as contractually<span style="letter-spacing:0.15pt;"> </span>required.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to meet<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.05pt;"> </span>deadlines,<span style="letter-spacing:0.1pt;"> </span>adhere<span style="letter-spacing:0.05pt;"> </span>to our clinical<span style="letter-spacing:0.1pt;"> </span>protocols<span style="letter-spacing:0.1pt;"> </span>or meet<span style="letter-spacing:0.05pt;"> </span>regulatory requirements,<span style="letter-spacing:0.2pt;"> </span>otherwise<span style="letter-spacing:0.05pt;"> </span>perform<span style="letter-spacing:0.1pt;"> </span>in a substandard<span style="letter-spacing:0.1pt;"> </span>manner,<span style="letter-spacing:0.05pt;"> </span>or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">engagements</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with us, the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timelines for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extended</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delayed</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be suspended</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or terminated.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">site</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminates</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reason,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follow-up information</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjects</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enrolled</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unless</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjects</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to another qualified</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">site,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be difficult</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or impossible.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:0.15pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>have relationships<span style="letter-spacing:0.15pt;"> </span>with other<span style="letter-spacing:0.05pt;"> </span>entities,<span style="letter-spacing:0.1pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>of which may<span style="letter-spacing:0.05pt;"> </span>be our competitors<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>whom<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>conducting<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>development activities<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our competitive<span style="letter-spacing:0.15pt;"> </span>position.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>do not successfully<span style="letter-spacing:0.1pt;"> </span>carry<span style="letter-spacing:0.05pt;"> </span>out their contractual<span style="letter-spacing:0.15pt;"> </span>duties,<span style="letter-spacing:0.1pt;"> </span>meet<span style="letter-spacing:0.1pt;"> </span>expected<span style="letter-spacing:0.1pt;"> </span>deadlines<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>in accordance<span style="letter-spacing:0.1pt;"> </span>with regulatory requirements<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our stated<span style="letter-spacing:0.05pt;"> </span>protocols,<span style="letter-spacing:0.1pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain,<span style="letter-spacing:0.05pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>be delayed<span style="letter-spacing:0.05pt;"> </span>in obtaining,<span style="letter-spacing:0.05pt;"> </span>marketing approvals<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be delayed<span style="letter-spacing:0.05pt;"> </span>in our efforts<span style="letter-spacing:0.1pt;"> </span>to, successfully<span style="letter-spacing:0.1pt;"> </span>commercialize<span style="letter-spacing:0.2pt;"> </span>our products.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>complex<span style="letter-spacing:0.05pt;"> </span>and subject<span style="letter-spacing:0.05pt;"> </span>to product<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a variety<span style="letter-spacing:0.1pt;"> </span>of reasons. We rely<span style="letter-spacing:0.05pt;"> </span>on third-party<span style="letter-spacing:0.1pt;"> </span>suppliers,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>single<span style="letter-spacing:0.05pt;"> </span>source<span style="letter-spacing:0.05pt;"> </span>suppliers,<span style="letter-spacing:0.05pt;"> </span>to manufacture<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.1pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>supplies<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>and we intend<span style="letter-spacing:0.05pt;"> </span>to rely<span style="letter-spacing:0.05pt;"> </span>on third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>to produce commercial supplies<span style="letter-spacing:0.05pt;"> </span>of any approved<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate.<span style="letter-spacing:0.05pt;"> </span>This reliance<span style="letter-spacing:0.05pt;"> </span>on third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>increases<span style="letter-spacing:0.05pt;"> </span>the risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we will not have sufficient<span style="letter-spacing:0.1pt;"> </span>quantities<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>or products<span style="letter-spacing:0.05pt;"> </span>or such quantities<span style="letter-spacing:0.1pt;"> </span>at an acceptable cost<span style="letter-spacing:0.05pt;"> </span>or quality,<span style="letter-spacing:0.05pt;"> </span>which could delay,<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:0.05pt;"> </span>or impair<span style="letter-spacing:0.05pt;"> </span>our development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>efforts.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>facilities.<span style="letter-spacing:0.2pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>rely,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.1pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>to rely,<span style="letter-spacing:0.05pt;"> </span>on third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the manufacture<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.15pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>testing,<span style="letter-spacing:0.1pt;"> </span>product development<span style="letter-spacing:0.05pt;"> </span>purposes, to support<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>application<span style="letter-spacing:0.15pt;"> </span>submissions,<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>manufacture<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of our product candidates<span style="letter-spacing:0.15pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.05pt;"> </span>to contract<span style="letter-spacing:0.1pt;"> </span>with analytical<span style="letter-spacing:0.1pt;"> </span>laboratories<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>release and<span style="letter-spacing:0.05pt;"> </span>stability<span style="letter-spacing:0.15pt;"> </span>testing<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.15pt;"> </span>This<span style="letter-spacing:0.05pt;"> </span>reliance<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>increases<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>not have<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.2pt;"> </span>quantities<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>quantities<span style="letter-spacing:0.15pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>acceptable<span style="letter-spacing:0.1pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>or quality, which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>delay,<span style="letter-spacing:0.1pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>efforts.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>ongoing COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in disruptions<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.1pt;"> </span>or an extended<span style="letter-spacing:0.05pt;"> </span>shutdown of certain<span style="letter-spacing:0.1pt;"> </span>businesses, which could<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>of our contract<span style="letter-spacing:0.1pt;"> </span>manufacturers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>establish<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>manufacturers<span style="letter-spacing:0.2pt;"> </span>or do so on favorable<span style="letter-spacing:0.1pt;"> </span>terms. Even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>establish<span style="letter-spacing:0.15pt;"> </span>agreements<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>manufacturers,<span style="letter-spacing:0.15pt;"> </span>reliance<span style="letter-spacing:0.1pt;"> </span>on third-party<span style="letter-spacing:0.15pt;"> </span>manufacturers entails<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>risks,<span style="letter-spacing:0.05pt;"> </span>including:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reliance<span style="letter-spacing:0.1pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>regulatory,<span style="letter-spacing:0.1pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>and quality<span style="letter-spacing:0.05pt;"> </span>assurance&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reliance<span style="letter-spacing:0.95pt;"> </span>on<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>third<span style="letter-spacing:0.85pt;"> </span>party<span style="letter-spacing:0.85pt;"> </span>for<span style="letter-spacing:0.85pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>development,<span style="letter-spacing:0.9pt;"> </span>analytical<span style="letter-spacing:0.9pt;"> </span>testing,<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>data<span style="letter-spacing:0.85pt;"> </span>generation<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>support regulatory<span style="letter-spacing:0.1pt;"> </span>applications&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">operations<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>third-party<span style="letter-spacing:0.9pt;"> </span>manufacturers<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>suppliers<span style="letter-spacing:0.8pt;"> </span>could<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.7pt;"> </span>disrupted<span style="letter-spacing:0.8pt;"> </span>by<span style="letter-spacing:0.7pt;"> </span>conditions<span style="letter-spacing:0.8pt;"> </span>unrelated<span style="letter-spacing:0.8pt;"> </span>to our business<span style="letter-spacing:0.05pt;"> </span>or operations,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>bankruptcy<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>manufacturer<span style="letter-spacing:0.15pt;"> </span>or supplier,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>issuance<span style="letter-spacing:0.05pt;"> </span>of an FDA<span style="letter-spacing:0.05pt;"> </span>Form<span style="letter-spacing:0.15pt;"> </span>483<span style="letter-spacing:0.1pt;"> </span>notice<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>warning<span style="letter-spacing:0.1pt;"> </span>letter,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>enforcement<span style="letter-spacing:0.15pt;"> </span>action<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>regulatory authority&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>possible<span style="letter-spacing:0.05pt;"> </span>breach<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>agreement<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>party&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible misappropriation of our proprietary information, including our trade secrets and know-how&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:1pt;"> </span>possible<span style="letter-spacing:1pt;"> </span>termination<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:0.95pt;"> </span>nonrenewal<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:1pt;"> </span>agreement<span style="letter-spacing:1.05pt;"> </span>by<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:1pt;"> </span>third<span style="letter-spacing:1pt;"> </span>party<span style="letter-spacing:1pt;"> </span>at<span style="letter-spacing:1pt;"> </span>a<span style="letter-spacing:0.9pt;"> </span>time<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.95pt;"> </span>costly<span style="letter-spacing:0.95pt;"> </span>or inconvenient<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>us&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">carrier<span style="letter-spacing:0.1pt;"> </span>disruptions<span style="letter-spacing:0.1pt;"> </span>or increased<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>beyond our control&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure<span style="letter-spacing:0.1pt;"> </span>to deliver<span style="letter-spacing:0.1pt;"> </span>our drugs<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>specified<span style="letter-spacing:0.1pt;"> </span>storage<span style="letter-spacing:0.05pt;"> </span>conditions<span style="letter-spacing:0.1pt;"> </span>and in a timely<span style="letter-spacing:0.1pt;"> </span>manner.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>only<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>supply<span style="letter-spacing:0.1pt;"> </span>arrangements<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>place<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>respect<span style="letter-spacing:0.15pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>and these arrangements<span style="letter-spacing:0.4pt;"> </span>do<span style="letter-spacing:0.25pt;"> </span>not<span style="letter-spacing:0.25pt;"> </span>extend<span style="letter-spacing:0.3pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>commercial<span style="letter-spacing:0.4pt;"> </span>supply.<span style="letter-spacing:0.3pt;"> </span>We<span style="letter-spacing:0.25pt;"> </span>acquire<span style="letter-spacing:0.3pt;"> </span>many<span style="letter-spacing:0.3pt;"> </span>key<span style="letter-spacing:0.2pt;"> </span>materials<span style="letter-spacing:0.35pt;"> </span>on<span style="letter-spacing:0.2pt;"> </span>a<span style="letter-spacing:0.2pt;"> </span>purchase<span style="letter-spacing:0.25pt;"> </span>order<span style="letter-spacing:0.25pt;"> </span>basis.<span style="letter-spacing:0.25pt;"> </span>As a<span style="letter-spacing:0.05pt;"> </span>result,<span style="letter-spacing:0.1pt;"> </span>we do not have long-term<span style="letter-spacing:0.1pt;"> </span>committed<span style="letter-spacing:0.1pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>with respect<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and other materials.<span style="letter-spacing:0.2pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>establish<span style="letter-spacing:0.15pt;"> </span>one or more<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to develop<span style="letter-spacing:0.05pt;"> </span>and scale<span style="letter-spacing:0.05pt;"> </span>up the<span style="letter-spacing:0.05pt;"> </span>drug manufacturing<span style="letter-spacing:0.2pt;"> </span>process,<span style="letter-spacing:0.1pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>testing,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>generate<span style="letter-spacing:0.15pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>to support<span style="letter-spacing:0.05pt;"> </span>a regulatory<span style="letter-spacing:0.1pt;"> </span>submission.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we obtain marketing<span style="letter-spacing:1.25pt;"> </span>approval<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>any<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>product<span style="letter-spacing:1.15pt;"> </span>candidates,<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>will<span style="letter-spacing:1.15pt;"> </span>need<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>establish<span style="letter-spacing:1.2pt;"> </span>an<span style="letter-spacing:1.1pt;"> </span>agreement<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>commercial manufacture<span style="letter-spacing:0.1pt;"> </span>with a third<span style="letter-spacing:0.05pt;"> </span>party.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.25pt;"> </span>addition,<span style="letter-spacing:0.3pt;"> </span>we<span style="letter-spacing:0.25pt;"> </span>are<span style="letter-spacing:0.3pt;"> </span>dependent<span style="letter-spacing:0.3pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>a<span style="letter-spacing:0.25pt;"> </span>sole<span style="letter-spacing:0.3pt;"> </span>supplier<span style="letter-spacing:0.35pt;"> </span>for<span style="letter-spacing:0.3pt;"> </span>certain<span style="letter-spacing:0.3pt;"> </span>components<span style="letter-spacing:0.25pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>our<span style="letter-spacing:0.2pt;"> </span>manufacturing<span style="letter-spacing:0.35pt;"> </span>process.<span style="letter-spacing:0.25pt;"> </span>Even if<span style="letter-spacing:1.5pt;"> </span>we<span style="letter-spacing:1.45pt;"> </span>are<span style="letter-spacing:1.5pt;"> </span>able<span style="letter-spacing:1.5pt;"> </span>to<span style="letter-spacing:1.4pt;"> </span>replace<span style="letter-spacing:1.5pt;"> </span>any<span style="letter-spacing:1.4pt;"> </span>raw<span style="letter-spacing:1.4pt;"> </span>materials<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>other<span style="letter-spacing:1.45pt;"> </span>materials<span style="letter-spacing:1.55pt;"> </span>with<span style="letter-spacing:1.4pt;"> </span>an<span style="letter-spacing:1.4pt;"> </span>alternative,<span style="letter-spacing:1.55pt;"> </span>such<span style="letter-spacing:1.4pt;"> </span>alternatives<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.45pt;"> </span>cost more,<span style="letter-spacing:0.45pt;"> </span>result<span style="letter-spacing:0.5pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>lower<span style="letter-spacing:0.45pt;"> </span>yields<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>not<span style="letter-spacing:0.4pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>as<span style="letter-spacing:0.4pt;"> </span>suitable<span style="letter-spacing:0.5pt;"> </span>for<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:0.4pt;"> </span>purposes.<span style="letter-spacing:0.4pt;"> </span>In<span style="letter-spacing:0.35pt;"> </span>addition,<span style="letter-spacing:0.4pt;"> </span>some<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>materials<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.4pt;"> </span>we<span style="letter-spacing:0.35pt;"> </span>use to<span style="letter-spacing:0.05pt;"> </span>manufacture<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>complex<span style="letter-spacing:0.05pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materials,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be more</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficult</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to substitute. Therefore,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disruptions</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arising</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our sole</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suppliers</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in delays</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and additional</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory submissions.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party<span style="letter-spacing:0.15pt;"> </span>manufacturers<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.05pt;"> </span>with cGMP regulations<span style="letter-spacing:0.1pt;"> </span>or similar<span style="letter-spacing:0.1pt;"> </span>regulatory requirements<span style="letter-spacing:0.2pt;"> </span>outside<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA determines<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>CMOs<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not in compliance<span style="letter-spacing:0.1pt;"> </span>with FDA laws<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>regulations,<span style="letter-spacing:0.2pt;"> </span>including<span style="letter-spacing:0.15pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>governing<span style="letter-spacing:0.1pt;"> </span>cGMPs,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA may<span style="letter-spacing:0.1pt;"> </span>deny<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>application,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>NDA, approval until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>in compliance.<span style="letter-spacing:0.1pt;"> </span>Moreover,<span style="letter-spacing:0.05pt;"> </span>our failure,<span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.1pt;"> </span>of our third-party<span style="letter-spacing:0.15pt;"> </span>manufacturers<span style="letter-spacing:0.15pt;"> </span>and suppliers,<span style="letter-spacing:0.1pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with applicable<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in sanctions<span style="letter-spacing:0.1pt;"> </span>being<span style="letter-spacing:0.05pt;"> </span>imposed<span style="letter-spacing:0.05pt;"> </span>on us, including<span style="letter-spacing:0.05pt;"> </span>clinical holds, fines, injunctions, civil penalties, seizures or recalls of product candidates or products, operating restrictions<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:0.15pt;"> </span>prosecutions,<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of which could<span style="letter-spacing:0.05pt;"> </span>significantly<span style="letter-spacing:0.15pt;"> </span>and adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>supplies<span style="letter-spacing:0.05pt;"> </span>of our products.<span style="letter-spacing:2.4pt;"> </span>In<span style="letter-spacing:2.35pt;"> </span>addition,<span style="letter-spacing:2.4pt;"> </span>approved<span style="letter-spacing:2.4pt;"> </span>products<span style="letter-spacing:2.4pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>facilities at<span style="letter-spacing:2.4pt;"> </span>which<span style="letter-spacing:2.35pt;"> </span>they<span style="letter-spacing:2.35pt;"> </span>are<span style="letter-spacing:2.35pt;"> </span>manufactured<span style="letter-spacing:2.4pt;"> </span>are<span style="letter-spacing:2.35pt;"> </span>required<span style="letter-spacing:2.4pt;"> </span>to maintain<span style="letter-spacing:0.2pt;"> </span>ongoing<span style="letter-spacing:0.1pt;"> </span>compliance<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.15pt;"> </span>FDA requirements<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>similar<span style="letter-spacing:0.15pt;"> </span>agencies, including<span style="letter-spacing:0.1pt;"> </span>ensuring<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>quality<span style="letter-spacing:0.1pt;"> </span>control<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>procedures<span style="letter-spacing:0.15pt;"> </span>conform<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>cGMP<span style="letter-spacing:0.05pt;"> </span>requirements.<span style="letter-spacing:0.15pt;"> </span>As such, our<span style="letter-spacing:0.05pt;"> </span>CMOs<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>continual<span style="letter-spacing:0.15pt;"> </span>review<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>periodic<span style="letter-spacing:0.15pt;"> </span>inspections<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>assess<span style="letter-spacing:0.1pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>with cGMPs. Furthermore,<span style="letter-spacing:0.8pt;"> </span>although<span style="letter-spacing:0.75pt;"> </span>we<span style="letter-spacing:0.7pt;"> </span>do<span style="letter-spacing:0.7pt;"> </span>not<span style="letter-spacing:0.7pt;"> </span>have<span style="letter-spacing:0.7pt;"> </span>day-to-day<span style="letter-spacing:0.8pt;"> </span>control<span style="letter-spacing:0.75pt;"> </span>over<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>operations<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:0.65pt;"> </span>CMOs,<span style="letter-spacing:0.65pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>are<span style="letter-spacing:0.7pt;"> </span>responsible for<span style="letter-spacing:0.05pt;"> </span>ensuring<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>with applicable<span style="letter-spacing:0.1pt;"> </span>laws and regulations,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>cGMPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>manufacturers<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>suppliers<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to numerous<span style="letter-spacing:0.05pt;"> </span>environmental,<span style="letter-spacing:0.15pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>and safety<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>governing<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>handling,<span style="letter-spacing:0.05pt;"> </span>use, storage,<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:0.15pt;"> </span>and disposal<span style="letter-spacing:0.05pt;"> </span>of waste products,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:0.1pt;"> </span>with civil<span style="letter-spacing:0.05pt;"> </span>or criminal<span style="letter-spacing:0.1pt;"> </span>fines<span style="letter-spacing:0.05pt;"> </span>and penalties<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such third<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:0.1pt;"> </span>Based on the<span style="letter-spacing:0.05pt;"> </span>severity<span style="letter-spacing:0.1pt;"> </span>of regulatory<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be brought<span style="letter-spacing:1.2pt;"> </span>against<span style="letter-spacing:1.2pt;"> </span>these<span style="letter-spacing:1.2pt;"> </span>third<span style="letter-spacing:1.2pt;"> </span>parties<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>future,<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>clinical<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>commercial<span style="letter-spacing:1.25pt;"> </span>supply<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>drug<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>packaging<span style="letter-spacing:1.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>services<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be interrupted<span style="letter-spacing:0.1pt;"> </span>or limited,<span style="letter-spacing:0.1pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.05pt;"> </span>with other<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates and<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>access<span style="letter-spacing:0.1pt;"> </span>to manufacturing<span style="letter-spacing:0.15pt;"> </span>facilities.<span style="letter-spacing:0.15pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not obtain<span style="letter-spacing:0.05pt;"> </span>access<span style="letter-spacing:0.05pt;"> </span>to these<span style="letter-spacing:0.05pt;"> </span>facilities<span style="letter-spacing:0.15pt;"> </span>on a priority<span style="letter-spacing:0.15pt;"> </span>basis<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all.<span style="letter-spacing:0.1pt;"> </span>There<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.1pt;"> </span>number<span style="letter-spacing:0.05pt;"> </span>of manufacturers<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>operate<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>cGMP regulations<span style="letter-spacing:0.1pt;"> </span>and that might<span style="letter-spacing:0.05pt;"> </span>be capable<span style="letter-spacing:0.05pt;"> </span>of manufacturing<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>us.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>prepare<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>later-stage<span style="letter-spacing:0.2pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.15pt;"> </span>commercialization,<span style="letter-spacing:0.2pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>need to take<span style="letter-spacing:0.05pt;"> </span>steps<span style="letter-spacing:0.05pt;"> </span>to increase<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>scale<span style="letter-spacing:0.05pt;"> </span>of production<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>We have not yet<span style="letter-spacing:0.05pt;"> </span>scaled<span style="letter-spacing:0.05pt;"> </span>up the manufacturing<span style="letter-spacing:0.1pt;"> </span>process for<span style="letter-spacing:0.05pt;"> </span>any of our product<span style="letter-spacing:0.05pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>Third<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>manufacturers<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be unable<span style="letter-spacing:0.05pt;"> </span>to successfully<span style="letter-spacing:0.1pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>the manufacturing<span style="letter-spacing:0.2pt;"> </span>capacity<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>in a timely<span style="letter-spacing:0.1pt;"> </span>or cost-effective<span style="letter-spacing:0.2pt;"> </span>manner,<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all.<span style="letter-spacing:0.05pt;"> </span>In addition,<span style="letter-spacing:1.2pt;"> </span>quality<span style="letter-spacing:1.2pt;"> </span>issues<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>arise<span style="letter-spacing:1.2pt;"> </span>during<span style="letter-spacing:1.2pt;"> </span>scale-up<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>commercial<span style="letter-spacing:1.3pt;"> </span>activities.<span style="letter-spacing:1.25pt;"> </span>For<span style="letter-spacing:1.1pt;"> </span>example,<span style="letter-spacing:1.15pt;"> </span>if<span style="letter-spacing:1.15pt;"> </span>microbial,<span style="letter-spacing:1.2pt;"> </span>viral<span style="letter-spacing:1.15pt;"> </span>or other<span style="letter-spacing:0.1pt;"> </span>contaminations<span style="letter-spacing:0.2pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>discovered<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>or in the<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>facilities<span style="letter-spacing:0.15pt;"> </span>in which our product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>made,<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>facilities<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>need to be closed<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an extended<span style="letter-spacing:0.05pt;"> </span>period<span style="letter-spacing:0.05pt;"> </span>of time to investigate<span style="letter-spacing:0.1pt;"> </span>and remedy<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>contamination.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.2pt;"> </span>in place<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>redundant<span style="letter-spacing:0.05pt;"> </span>supply<span style="letter-spacing:0.05pt;"> </span>or a second<span style="letter-spacing:0.1pt;"> </span>source<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>bulk<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>substance.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>CMOs for<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.15pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>cannot<span style="letter-spacing:0.05pt;"> </span>perform<span style="letter-spacing:0.1pt;"> </span>as agreed, we may be required to replace such CMOs. Although we believe that there are several potential alternative<span style="letter-spacing:0.85pt;"> </span>manufacturers<span style="letter-spacing:0.85pt;"> </span>who<span style="letter-spacing:0.7pt;"> </span>could<span style="letter-spacing:0.75pt;"> </span>manufacture<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.7pt;"> </span>product<span style="letter-spacing:0.75pt;"> </span>candidates,<span style="letter-spacing:0.8pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>may<span style="letter-spacing:0.7pt;"> </span>incur<span style="letter-spacing:0.7pt;"> </span>added<span style="letter-spacing:0.65pt;"> </span>costs<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>delays in<span style="letter-spacing:0.05pt;"> </span>identifying<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>qualifying<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>replacement<span style="letter-spacing:0.15pt;"> </span>manufacturer<span style="letter-spacing:0.15pt;"> </span>or be able<span style="letter-spacing:0.05pt;"> </span>to reach<span style="letter-spacing:0.05pt;"> </span>agreement<span style="letter-spacing:0.1pt;"> </span>with any alternative<span style="letter-spacing:0.2pt;"> </span>manufacturer.<span style="letter-spacing:0.2pt;"> </span>Further,<span style="letter-spacing:0.1pt;"> </span>our third-party<span style="letter-spacing:0.15pt;"> </span>manufacturers<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:0.1pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>or shipping difficulties<span style="letter-spacing:0.2pt;"> </span>due<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>resource<span style="letter-spacing:0.15pt;"> </span>constraints<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>of natural<span style="letter-spacing:0.1pt;"> </span>disasters,<span style="letter-spacing:0.1pt;"> </span>labor<span style="letter-spacing:0.05pt;"> </span>disputes,<span style="letter-spacing:0.05pt;"> </span>unstable<span style="letter-spacing:0.05pt;"> </span>political environments, including the ongoing conflict in Ukraine,<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>public<span style="letter-spacing:0.15pt;"> </span>health<span style="letter-spacing:0.15pt;"> </span>epidemics<span style="letter-spacing:0.2pt;"> </span>such<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>COVID-19 pandemic.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>third-party manufacturers<span style="letter-spacing:1.75pt;"> </span>cannot<span style="letter-spacing:1.65pt;"> </span>perform<span style="letter-spacing:1.7pt;"> </span>as<span style="letter-spacing:1.6pt;"> </span>agreed,<span style="letter-spacing:1.65pt;"> </span>we<span style="letter-spacing:1.6pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>be<span style="letter-spacing:1.55pt;"> </span>required<span style="letter-spacing:1.65pt;"> </span>to<span style="letter-spacing:1.55pt;"> </span>replace<span style="letter-spacing:1.65pt;"> </span>such<span style="letter-spacing:1.55pt;"> </span>manufacturers<span style="letter-spacing:1.7pt;"> </span>and<span style="letter-spacing:1.55pt;"> </span>we<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>be unable<span style="letter-spacing:0.05pt;"> </span>to replace<span style="letter-spacing:0.1pt;"> </span>them<span style="letter-spacing:0.05pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>basis<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>anticipated<span style="letter-spacing:0.15pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>dependence<span style="letter-spacing:0.1pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>manufacture<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or products<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>adversely<span style="letter-spacing:0.15pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our future<span style="letter-spacing:0.05pt;"> </span>profit<span style="letter-spacing:0.1pt;"> </span>margins<span style="letter-spacing:0.1pt;"> </span>and our ability<span style="letter-spacing:0.1pt;"> </span>to commercialize<span style="letter-spacing:0.2pt;"> </span>any products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>obtain marketing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>on a timely<span style="letter-spacing:0.1pt;"> </span>and competitive<span style="letter-spacing:0.15pt;"> </span>basis.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>enter<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>collaborations<span style="letter-spacing:0.1pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>collaborations<span style="letter-spacing:0.1pt;"> </span>are not successful,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to capitalize<span style="letter-spacing:0.1pt;"> </span>on the market<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>collaborators<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>of some<span style="letter-spacing:0.05pt;"> </span>of our product candidates<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>select<span style="letter-spacing:0.15pt;"> </span>basis.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>have not entered<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>any collaborations<span style="letter-spacing:0.15pt;"> </span>to date.<span style="letter-spacing:0.05pt;"> </span>Our likely<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any future<span style="letter-spacing:1.25pt;"> </span>collaboration<span style="letter-spacing:1.35pt;"> </span>arrangements<span style="letter-spacing:1.35pt;"> </span>include<span style="letter-spacing:1.25pt;"> </span>large<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>mid-size<span style="letter-spacing:1.25pt;"> </span>pharmaceutical<span style="letter-spacing:1.3pt;"> </span>companies,<span style="letter-spacing:1.25pt;"> </span>regional<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>national pharmaceutical<span style="letter-spacing:0.2pt;"> </span>companies<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>biotechnology<span style="letter-spacing:0.15pt;"> </span>companies.<span style="letter-spacing:0.1pt;"> </span>We face<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>competition<span style="letter-spacing:0.1pt;"> </span>in seeking<span style="letter-spacing:0.05pt;"> </span>appropriate collaborators.<span style="letter-spacing:0.2pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>reach<span style="letter-spacing:0.05pt;"> </span>a definitive<span style="letter-spacing:0.1pt;"> </span>agreement<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a future<span style="letter-spacing:0.05pt;"> </span>collaboration<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>depend, among<span style="letter-spacing:0.05pt;"> </span>other things,<span style="letter-spacing:0.1pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>assessment<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>collaborator&#8217;s<span style="letter-spacing:0.2pt;"> </span>resources<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>expertise,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>terms<span style="letter-spacing:0.1pt;"> </span>and conditions<span style="letter-spacing:0.1pt;"> </span>of the proposed<span style="letter-spacing:0.05pt;"> </span>collaboration<span style="letter-spacing:0.15pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>proposed<span style="letter-spacing:0.05pt;"> </span>collaborator&#8217;s<span style="letter-spacing:0.15pt;"> </span>evaluation<span style="letter-spacing:0.1pt;"> </span>of a number<span style="letter-spacing:0.05pt;"> </span>of factors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>enter<span style="letter-spacing:0.1pt;"> </span>into<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.2pt;"> </span>with any third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>have limited<span style="letter-spacing:0.1pt;"> </span>control<span style="letter-spacing:0.05pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>the amount<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>timing<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:0.15pt;"> </span>dedicate<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>of our<span style="letter-spacing:1.7pt;"> </span>product<span style="letter-spacing:1.75pt;"> </span>candidates.<span style="letter-spacing:1.8pt;"> </span>Our<span style="letter-spacing:1.7pt;"> </span>ability<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:1.7pt;"> </span>generate<span style="letter-spacing:1.8pt;"> </span>revenues<span style="letter-spacing:1.75pt;"> </span>from<span style="letter-spacing:1.75pt;"> </span>these<span style="letter-spacing:1.75pt;"> </span>arrangements<span style="letter-spacing:1.85pt;"> </span>will<span style="letter-spacing:1.7pt;"> </span>depend<span style="letter-spacing:1.65pt;"> </span>on<span style="letter-spacing:1.65pt;"> </span>our<span style="letter-spacing:1.65pt;"> </span>future collaborators&#8217;<span style="letter-spacing:0.15pt;"> </span>abilities<span style="letter-spacing:0.15pt;"> </span>and efforts<span style="letter-spacing:0.1pt;"> </span>to successfully<span style="letter-spacing:0.1pt;"> </span>perform<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>functions<span style="letter-spacing:0.1pt;"> </span>assigned<span style="letter-spacing:0.05pt;"> </span>to them<span style="letter-spacing:0.05pt;"> </span>in these arrangements. Collaborations<span style="letter-spacing:0.15pt;"> </span>with future<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:0.15pt;"> </span>involving<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>would pose numerous<span style="letter-spacing:0.05pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>to us, including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>following:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators<span style="letter-spacing:0.4pt;"> </span>have<span style="letter-spacing:0.25pt;"> </span>significant<span style="letter-spacing:0.35pt;"> </span>discretion<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>determining<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>efforts<span style="letter-spacing:0.3pt;"> </span>and<span style="letter-spacing:0.2pt;"> </span>resources<span style="letter-spacing:0.3pt;"> </span>that<span style="letter-spacing:0.25pt;"> </span>they<span style="letter-spacing:0.25pt;"> </span>will<span style="letter-spacing:0.25pt;"> </span>apply<span style="letter-spacing:0.25pt;"> </span>to these<span style="letter-spacing:0.05pt;"> </span>collaborations<span style="letter-spacing:0.15pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>not perform<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>obligations<span style="letter-spacing:0.1pt;"> </span>as expected&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators<span style="letter-spacing:2.25pt;"> </span>may<span style="letter-spacing:2.15pt;"> </span>de-emphasize<span style="letter-spacing:2.2pt;"> </span>or<span style="letter-spacing:2.1pt;"> </span>not<span style="letter-spacing:2.1pt;"> </span>pursue<span style="letter-spacing:2.1pt;"> </span>development<span style="letter-spacing:2.15pt;"> </span>and<span style="letter-spacing:2.05pt;"> </span>commercialization<span style="letter-spacing:2.25pt;"> </span>of<span style="letter-spacing:2.05pt;"> </span>our<span style="letter-spacing:2.05pt;"> </span>product candidates<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>elect<span style="letter-spacing:0.05pt;"> </span>not to continue<span style="letter-spacing:0.05pt;"> </span>or renew development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>programs<span style="letter-spacing:0.1pt;"> </span>based<span style="letter-spacing:0.05pt;"> </span>on clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>results,<span style="letter-spacing:0.1pt;"> </span>changes<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>collaborators&#8217;<span style="letter-spacing:0.15pt;"> </span>strategic<span style="letter-spacing:0.1pt;"> </span>focus,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>as a result<span style="letter-spacing:0.1pt;"> </span>of a sale<span style="letter-spacing:0.05pt;"> </span>or disposition<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>unit<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>function,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.15pt;"> </span>funding<span style="letter-spacing:0.1pt;"> </span>or external<span style="letter-spacing:0.1pt;"> </span>factors<span style="letter-spacing:0.1pt;"> </span>such as an acquisition<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>diverts<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>or creates<span style="letter-spacing:0.1pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>priorities&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators<span style="letter-spacing:0.95pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>delay<span style="letter-spacing:0.8pt;"> </span>clinical<span style="letter-spacing:0.85pt;"> </span>trials,<span style="letter-spacing:0.85pt;"> </span>provide<span style="letter-spacing:0.8pt;"> </span>insufficient<span style="letter-spacing:0.9pt;"> </span>funding<span style="letter-spacing:0.8pt;"> </span>for<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.75pt;"> </span>clinical<span style="letter-spacing:0.85pt;"> </span>trial<span style="letter-spacing:0.85pt;"> </span>program,<span style="letter-spacing:0.8pt;"> </span>stop<span style="letter-spacing:0.8pt;"> </span>a clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>abandon a product<span style="letter-spacing:0.05pt;"> </span>candidate,<span style="letter-spacing:0.1pt;"> </span>repeat<span style="letter-spacing:0.05pt;"> </span>or conduct<span style="letter-spacing:0.05pt;"> </span>new clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>or require<span style="letter-spacing:0.1pt;"> </span>a new formulation<span style="letter-spacing:0.15pt;"> </span>of a product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>testing&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators<span style="letter-spacing:0.2pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>independently<span style="letter-spacing:0.15pt;"> </span>develop,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:0.05pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.05pt;"> </span>directly or indirectly<span style="letter-spacing:0.1pt;"> </span>with our products<span style="letter-spacing:0.05pt;"> </span>or product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>if the collaborators<span style="letter-spacing:0.1pt;"> </span>believe that competitive products<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>to be successfully<span style="letter-spacing:0.1pt;"> </span>developed<span style="letter-spacing:0.05pt;"> </span>or can be commercialized<span style="letter-spacing:0.2pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>terms<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are more<span style="letter-spacing:0.05pt;"> </span>economically<span style="letter-spacing:0.1pt;"> </span>attractive<span style="letter-spacing:0.15pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>ours&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a<span style="letter-spacing:1.1pt;"> </span>collaborator<span style="letter-spacing:1.25pt;"> </span>with<span style="letter-spacing:1.1pt;"> </span>marketing<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>distribution<span style="letter-spacing:1.25pt;"> </span>rights<span style="letter-spacing:1.15pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>multiple<span style="letter-spacing:1.2pt;"> </span>products<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:1.15pt;"> </span>not<span style="letter-spacing:1.1pt;"> </span>commit<span style="letter-spacing:1.15pt;"> </span>sufficient resources<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>and distribution<span style="letter-spacing:0.15pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>relative<span style="letter-spacing:0.1pt;"> </span>to other<span style="letter-spacing:0.05pt;"> </span>products&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.1pt;"> </span>not<span style="letter-spacing:1.05pt;"> </span>properly<span style="letter-spacing:1.1pt;"> </span>obtain,<span style="letter-spacing:1.1pt;"> </span>maintain,<span style="letter-spacing:1.1pt;"> </span>defend<span style="letter-spacing:1.05pt;"> </span>or<span style="letter-spacing:1pt;"> </span>enforce<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:1pt;"> </span>intellectual<span style="letter-spacing:1.15pt;"> </span>property<span style="letter-spacing:1.05pt;"> </span>rights<span style="letter-spacing:1.05pt;"> </span>or may<span style="letter-spacing:0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>in such a way as to invite<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>proceedings<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>jeopardize<span style="letter-spacing:0.1pt;"> </span>or invalidate<span style="letter-spacing:0.1pt;"> </span>our proprietary information<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>expose<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property related<span style="letter-spacing:0.1pt;"> </span>proceedings&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disputes<span style="letter-spacing:2.05pt;"> </span>may<span style="letter-spacing:2.05pt;"> </span>arise<span style="letter-spacing:2.05pt;"> </span>between<span style="letter-spacing:2pt;"> </span>the<span style="letter-spacing:2pt;"> </span>collaborators<span style="letter-spacing:2.1pt;"> </span>and<span style="letter-spacing:1.95pt;"> </span>us<span style="letter-spacing:1.95pt;"> </span>that<span style="letter-spacing:2pt;"> </span>result<span style="letter-spacing:2.05pt;"> </span>in<span style="letter-spacing:1.95pt;"> </span>the<span style="letter-spacing:2pt;"> </span>delay<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:1.95pt;"> </span>termination<span style="letter-spacing:2.1pt;"> </span>of<span style="letter-spacing:1.95pt;"> </span>the research,<span style="letter-spacing:1.8pt;"> </span>development<span style="letter-spacing:1.8pt;"> </span>or<span style="letter-spacing:1.7pt;"> </span>commercialization<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.7pt;"> </span>our<span style="letter-spacing:1.7pt;"> </span>products<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.7pt;"> </span>product<span style="letter-spacing:1.75pt;"> </span>candidates<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.65pt;"> </span>that<span style="letter-spacing:1.7pt;"> </span>result<span style="letter-spacing:1.75pt;"> </span>in costly<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>or arbitration<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>diverts<span style="letter-spacing:0.1pt;"> </span>management<span style="letter-spacing:0.1pt;"> </span>attention<span style="letter-spacing:0.1pt;"> </span>and resources&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborations<span style="letter-spacing:1.95pt;"> </span>may<span style="letter-spacing:1.85pt;"> </span>be<span style="letter-spacing:1.8pt;"> </span>terminated<span style="letter-spacing:1.95pt;"> </span>and,<span style="letter-spacing:1.8pt;"> </span>if<span style="letter-spacing:1.85pt;"> </span>terminated,<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.8pt;"> </span>result<span style="letter-spacing:1.85pt;"> </span>in<span style="letter-spacing:1.75pt;"> </span>a<span style="letter-spacing:1.75pt;"> </span>need<span style="letter-spacing:1.75pt;"> </span>for<span style="letter-spacing:1.8pt;"> </span>additional<span style="letter-spacing:1.85pt;"> </span>capital<span style="letter-spacing:1.85pt;"> </span>to pursue<span style="letter-spacing:0.05pt;"> </span>further<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaboration<span style="letter-spacing:0.95pt;"> </span>agreements<span style="letter-spacing:0.9pt;"> </span>may<span style="letter-spacing:0.8pt;"> </span>not<span style="letter-spacing:0.75pt;"> </span>lead<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>development<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>commercialization<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>product<span style="letter-spacing:0.8pt;"> </span>candidates<span style="letter-spacing:0.85pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>most<span style="letter-spacing:0.05pt;"> </span>efficient<span style="letter-spacing:0.15pt;"> </span>manner<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all&#59;<span style="letter-spacing:0.05pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>collaborator<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ours<span style="letter-spacing:0.1pt;"> </span>were to be involved<span style="letter-spacing:0.05pt;"> </span>in a business<span style="letter-spacing:0.05pt;"> </span>combination,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>continued<span style="letter-spacing:0.05pt;"> </span>pursuit<span style="letter-spacing:0.05pt;"> </span>and emphasis<span style="letter-spacing:0.1pt;"> </span>on our product<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>or commercialization<span style="letter-spacing:0.2pt;"> </span>program<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be delayed,<span style="letter-spacing:0.05pt;"> </span>diminished<span style="letter-spacing:0.1pt;"> </span>or terminated.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>establish<span style="letter-spacing:0.15pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>collaborations,<span style="letter-spacing:0.2pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>relating<span style="letter-spacing:0.1pt;"> </span>to product<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>regulatory approval<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>commercialization<span style="letter-spacing:0.25pt;"> </span>described<span style="letter-spacing:0.15pt;"> </span>herein<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>apply<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>activities<span style="letter-spacing:0.15pt;"> </span>of any such future collaborators.</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Commercialization<span style="letter-spacing:0.15pt;"> </span>of our Product Candidates</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The incidence<span style="letter-spacing:0.05pt;"> </span>and prevalence<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>target<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.05pt;"> </span>populations<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>have not been established<span style="letter-spacing:0.1pt;"> </span>with precision.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the market<span style="letter-spacing:0.05pt;"> </span>opportunities<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>are smaller<span style="letter-spacing:0.1pt;"> </span>than we estimate<span style="letter-spacing:0.1pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>any approval<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we obtain<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>based on a narrower definition<span style="letter-spacing:0.1pt;"> </span>of the patient<span style="letter-spacing:0.05pt;"> </span>population,<span style="letter-spacing:0.05pt;"> </span>our revenue<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>and ability<span style="letter-spacing:0.1pt;"> </span>to achieve<span style="letter-spacing:0.05pt;"> </span>profitability<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be adversely<span style="letter-spacing:0.1pt;"> </span>affected.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.1pt;"> </span>total<span style="letter-spacing:0.15pt;"> </span>addressable<span style="letter-spacing:0.2pt;"> </span>market<span style="letter-spacing:0.2pt;"> </span>opportunity<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates we<span style="letter-spacing:1.35pt;"> </span>may<span style="letter-spacing:1.4pt;"> </span>develop<span style="letter-spacing:1.4pt;"> </span>will<span style="letter-spacing:1.4pt;"> </span>ultimately<span style="letter-spacing:1.5pt;"> </span>depend<span style="letter-spacing:1.35pt;"> </span>upon,<span style="letter-spacing:1.35pt;"> </span>among<span style="letter-spacing:1.4pt;"> </span>other<span style="letter-spacing:1.4pt;"> </span>things,<span style="letter-spacing:1.4pt;"> </span>the<span style="letter-spacing:1.4pt;"> </span>diagnosis<span style="letter-spacing:1.35pt;"> </span>criteria<span style="letter-spacing:1.45pt;"> </span>included<span style="letter-spacing:1.35pt;"> </span>in<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>final labeling<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>each<span style="letter-spacing:1.2pt;"> </span>such<span style="letter-spacing:1.15pt;"> </span>product<span style="letter-spacing:1.2pt;"> </span>candidate<span style="letter-spacing:1.25pt;"> </span>if<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>product<span style="letter-spacing:1.2pt;"> </span>candidates<span style="letter-spacing:1.25pt;"> </span>are<span style="letter-spacing:1.2pt;"> </span>approved<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>sale<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>these<span style="letter-spacing:1.15pt;"> </span>indications, acceptance<span style="letter-spacing:1.3pt;"> </span>by<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>medical<span style="letter-spacing:1.3pt;"> </span>community,<span style="letter-spacing:1.3pt;"> </span>patient<span style="letter-spacing:1.3pt;"> </span>access,<span style="letter-spacing:1.2pt;"> </span>drug<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>any<span style="letter-spacing:1.15pt;"> </span>related<span style="letter-spacing:1.25pt;"> </span>companion<span style="letter-spacing:1.2pt;"> </span>diagnostic<span style="letter-spacing:1.25pt;"> </span>pricing<span style="letter-spacing:1.2pt;"> </span>and their<span style="letter-spacing:0.9pt;"> </span>reimbursement.<span style="letter-spacing:1pt;"> </span>We<span style="letter-spacing:0.85pt;"> </span>may<span style="letter-spacing:0.9pt;"> </span>initially<span style="letter-spacing:1pt;"> </span>seek<span style="letter-spacing:0.9pt;"> </span>regulatory<span style="letter-spacing:0.95pt;"> </span>approval<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>some<span style="letter-spacing:0.85pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>candidates<span style="letter-spacing:0.9pt;"> </span>as<span style="letter-spacing:0.8pt;"> </span>therapies for<span style="letter-spacing:1.35pt;"> </span>relapsed<span style="letter-spacing:1.4pt;"> </span>or<span style="letter-spacing:1.3pt;"> </span>refractory<span style="letter-spacing:1.45pt;"> </span>patients.<span style="letter-spacing:1.4pt;"> </span>The<span style="letter-spacing:1.3pt;"> </span>number<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>patients<span style="letter-spacing:1.35pt;"> </span>in<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.25pt;"> </span>targeted<span style="letter-spacing:1.35pt;"> </span>commercial<span style="letter-spacing:1.4pt;"> </span>markets<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>elsewhere may<span style="letter-spacing:0.1pt;"> </span>turn<span style="letter-spacing:0.1pt;"> </span>out<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>lower<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>expected,<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be otherwise<span style="letter-spacing:0.05pt;"> </span>amenable<span style="letter-spacing:0.1pt;"> </span>to treatment<span style="letter-spacing:0.15pt;"> </span>with our drugs,<span style="letter-spacing:0.05pt;"> </span>or new<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>become<span style="letter-spacing:0.1pt;"> </span>increasingly<span style="letter-spacing:0.15pt;"> </span>difficult<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:0.1pt;"> </span>or gain<span style="letter-spacing:0.05pt;"> </span>access<span style="letter-spacing:0.05pt;"> </span>to, all<span style="letter-spacing:0.05pt;"> </span>of which would adversely<span style="letter-spacing:0.1pt;"> </span>affect our results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and our business.</p>
<p style="margin-top:0pt;line-height:7pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if<span style="letter-spacing:0.05pt;"> </span>any of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>receives<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to achieve<span style="letter-spacing:0.05pt;"> </span>the degree<span style="letter-spacing:0.05pt;"> </span>of market<span style="letter-spacing:0.05pt;"> </span>acceptance<span style="letter-spacing:0.05pt;"> </span>by physicians,<span style="letter-spacing:0.05pt;"> </span>patients,<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.1pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>and others<span style="letter-spacing:0.05pt;"> </span>in the medical<span style="letter-spacing:0.1pt;"> </span>community necessary<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.1pt;"> </span>success.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:1.8pt;"> </span>any<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:1.75pt;"> </span>our<span style="letter-spacing:1.75pt;"> </span>product<span style="letter-spacing:1.8pt;"> </span>candidates<span style="letter-spacing:1.8pt;"> </span>receives<span style="letter-spacing:1.8pt;"> </span>marketing<span style="letter-spacing:1.8pt;"> </span>approval,<span style="letter-spacing:1.75pt;"> </span>it<span style="letter-spacing:1.75pt;"> </span>may<span style="letter-spacing:1.75pt;"> </span>nonetheless<span style="letter-spacing:1.8pt;"> </span>fail<span style="letter-spacing:1.75pt;"> </span>to<span style="letter-spacing:1.7pt;"> </span>gain<span style="letter-spacing:1.75pt;"> </span>sufficient market<span style="letter-spacing:0.15pt;"> </span>acceptance<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>physicians,<span style="letter-spacing:0.15pt;"> </span>patients,<span style="letter-spacing:0.15pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>payors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:0.1pt;"> </span>community.<span style="letter-spacing:0.1pt;"> </span>For example, current<span style="letter-spacing:0.15pt;"> </span>cancer<span style="letter-spacing:0.1pt;"> </span>treatments,<span style="letter-spacing:0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.15pt;"> </span>targeted<span style="letter-spacing:0.15pt;"> </span>therapies,<span style="letter-spacing:0.15pt;"> </span>chemotherapy,<span style="letter-spacing:0.1pt;"> </span>and radiation<span style="letter-spacing:0.1pt;"> </span>therapy,<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>well established<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>medical<span style="letter-spacing:0.15pt;"> </span>community,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>doctors<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to rely<span style="letter-spacing:0.05pt;"> </span>on these<span style="letter-spacing:0.05pt;"> </span>treatments.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our product candidates<span style="letter-spacing:0.1pt;"> </span>do not achieve<span style="letter-spacing:0.05pt;"> </span>an adequate<span style="letter-spacing:0.05pt;"> </span>level<span style="letter-spacing:0.05pt;"> </span>of acceptance,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not generate<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.15pt;"> </span>product revenues and we may<span style="letter-spacing:0.05pt;"> </span>not become<span style="letter-spacing:0.05pt;"> </span>profitable.<span style="letter-spacing:0.1pt;"> </span>The degree<span style="letter-spacing:0.05pt;"> </span>of market<span style="letter-spacing:0.1pt;"> </span>acceptance<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>if approved for commercial<span style="letter-spacing:0.15pt;"> </span>sale,<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>depend on a number<span style="letter-spacing:0.05pt;"> </span>of factors,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>efficacy<span style="letter-spacing:0.1pt;"> </span>and potential<span style="letter-spacing:0.1pt;"> </span>advantages<span style="letter-spacing:0.05pt;"> </span>compared<span style="letter-spacing:0.05pt;"> </span>to alternative<span style="letter-spacing:0.15pt;"> </span>treatments&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>acceptance<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>as front-line<span style="letter-spacing:0.15pt;"> </span>treatment<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>indications&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>prevalence<span style="letter-spacing:0.1pt;"> </span>and severity<span style="letter-spacing:0.1pt;"> </span>of any side<span style="letter-spacing:0.05pt;"> </span>effects,<span style="letter-spacing:0.1pt;"> </span>in particular<span style="letter-spacing:0.15pt;"> </span>compared<span style="letter-spacing:0.05pt;"> </span>to alternative<span style="letter-spacing:0.15pt;"> </span>treatments&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations<span style="letter-spacing:0.15pt;"> </span>or warnings<span style="letter-spacing:0.05pt;"> </span>contained<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>labeling<span style="letter-spacing:0.1pt;"> </span>approved<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>FDA&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>size<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>target<span style="letter-spacing:0.1pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>population&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.25pt;"> </span>willingness<span style="letter-spacing:0.25pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.2pt;"> </span>target<span style="letter-spacing:0.25pt;"> </span>patient<span style="letter-spacing:0.25pt;"> </span>population<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>try<span style="letter-spacing:0.2pt;"> </span>new<span style="letter-spacing:0.15pt;"> </span>therapies<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.15pt;"> </span>physicians<span style="letter-spacing:0.25pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>prescribe<span style="letter-spacing:0.25pt;"> </span>these therapies&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<span style="letter-spacing:0.1pt;"> </span>to offer<span style="letter-spacing:0.05pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:0.15pt;"> </span>prices&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>convenience<span style="letter-spacing:0.05pt;"> </span>and ease<span style="letter-spacing:0.05pt;"> </span>of administration<span style="letter-spacing:0.15pt;"> </span>compared<span style="letter-spacing:0.05pt;"> </span>to alternative<span style="letter-spacing:0.15pt;"> </span>treatments&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>strength<span style="letter-spacing:0.1pt;"> </span>of marketing<span style="letter-spacing:0.1pt;"> </span>and distribution<span style="letter-spacing:0.15pt;"> </span>support&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">publicity<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and competing<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>and treatments&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>existence<span style="letter-spacing:0.1pt;"> </span>of distribution<span style="letter-spacing:0.15pt;"> </span>and/or<span style="letter-spacing:0.05pt;"> </span>use restrictions,<span style="letter-spacing:0.15pt;"> </span>such as through<span style="letter-spacing:0.05pt;"> </span>a REMS&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>availability<span style="letter-spacing:0.15pt;"> </span>of third-party<span style="letter-spacing:0.15pt;"> </span>payor<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and adequate<span style="letter-spacing:0.05pt;"> </span>reimbursement&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>timing<span style="letter-spacing:0.1pt;"> </span>of any marketing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>in relation<span style="letter-spacing:0.1pt;"> </span>to other<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>approvals&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">support<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:0.1pt;"> </span>advocacy<span style="letter-spacing:0.05pt;"> </span>groups&#59;<span style="letter-spacing:0.05pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any restrictions<span style="letter-spacing:0.15pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>use of our products<span style="letter-spacing:0.05pt;"> </span>together<span style="letter-spacing:0.1pt;"> </span>with other<span style="letter-spacing:0.05pt;"> </span>medications.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:7pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently<span style="letter-spacing:0.05pt;"> </span>have no marketing<span style="letter-spacing:0.05pt;"> </span>and sales<span style="letter-spacing:0.05pt;"> </span>organization<span style="letter-spacing:0.05pt;"> </span>and have no experience<span style="letter-spacing:0.05pt;"> </span>as a company<span style="letter-spacing:0.05pt;"> </span>in commercializing<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>and we may<span style="letter-spacing:0.05pt;"> </span>have to invest<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.05pt;"> </span>to develop<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>capabilities.<span style="letter-spacing:0.15pt;"> </span>If we are unable to establish<span style="letter-spacing:0.1pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>and marketing<span style="letter-spacing:0.05pt;"> </span>capabilities<span style="letter-spacing:0.15pt;"> </span>or enter<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>to market<span style="letter-spacing:0.05pt;"> </span>and sell<span style="letter-spacing:0.05pt;"> </span>our products,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to generate<span style="letter-spacing:0.05pt;"> </span>revenue.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>sales<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>infrastructure<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>sale,<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>or distribution<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.2pt;"> </span>products.<span style="letter-spacing:0.1pt;"> </span>To<span style="letter-spacing:0.05pt;"> </span>achieve<span style="letter-spacing:0.1pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>success<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we obtain marketing<span style="letter-spacing:0.1pt;"> </span>approval,<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>need to establish<span style="letter-spacing:0.1pt;"> </span>sales,<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>and distribution<span style="letter-spacing:0.15pt;"> </span>capabilities,<span style="letter-spacing:0.1pt;"> </span>either<span style="letter-spacing:0.05pt;"> </span>ourselves<span style="letter-spacing:0.05pt;"> </span>or through<span style="letter-spacing:0.05pt;"> </span>collaboration<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>risks<span style="letter-spacing:0.1pt;"> </span>involved<span style="letter-spacing:0.1pt;"> </span>with establishing<span style="letter-spacing:0.1pt;"> </span>our own sales<span style="letter-spacing:0.05pt;"> </span>and marketing<span style="letter-spacing:0.1pt;"> </span>capabilities.<span style="letter-spacing:0.15pt;"> </span>For example,<span style="letter-spacing:0.05pt;"> </span>recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial<span style="letter-spacing:0.55pt;"> </span>launch<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.35pt;"> </span>product<span style="letter-spacing:0.4pt;"> </span>candidate<span style="letter-spacing:0.45pt;"> </span>for<span style="letter-spacing:0.4pt;"> </span>which<span style="letter-spacing:0.35pt;"> </span>we<span style="letter-spacing:0.35pt;"> </span>recruit<span style="letter-spacing:0.45pt;"> </span>a<span style="letter-spacing:0.35pt;"> </span>sales<span style="letter-spacing:0.4pt;"> </span>force<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>establish<span style="letter-spacing:0.45pt;"> </span>marketing<span style="letter-spacing:0.45pt;"> </span>capabilities is<span style="letter-spacing:0.05pt;"> </span>delayed<span style="letter-spacing:0.05pt;"> </span>or does not occur<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any reason,<span style="letter-spacing:0.05pt;"> </span>we would have prematurely<span style="letter-spacing:0.15pt;"> </span>or unnecessarily<span style="letter-spacing:0.05pt;"> </span>incurred<span style="letter-spacing:0.05pt;"> </span>these commercialization<span style="letter-spacing:0.25pt;"> </span>expenses.<span style="letter-spacing:0.1pt;"> </span>These efforts<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.05pt;"> </span>to be costly,<span style="letter-spacing:0.05pt;"> </span>and our investment<span style="letter-spacing:0.1pt;"> </span>would be lost<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we cannot<span style="letter-spacing:0.05pt;"> </span>retain<span style="letter-spacing:0.1pt;"> </span>or reposition<span style="letter-spacing:0.1pt;"> </span>our sales<span style="letter-spacing:0.05pt;"> </span>and marketing<span style="letter-spacing:0.1pt;"> </span>personnel.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>inhibit<span style="letter-spacing:0.1pt;"> </span>our efforts<span style="letter-spacing:0.1pt;"> </span>to commercialize<span style="letter-spacing:0.2pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>on our own include:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our inability<span style="letter-spacing:0.1pt;"> </span>to recruit,<span style="letter-spacing:0.1pt;"> </span>train<span style="letter-spacing:0.05pt;"> </span>and retain<span style="letter-spacing:0.1pt;"> </span>adequate<span style="letter-spacing:0.05pt;"> </span>numbers<span style="letter-spacing:0.05pt;"> </span>of effective<span style="letter-spacing:0.1pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>and marketing<span style="letter-spacing:0.1pt;"> </span>personnel&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our inability<span style="letter-spacing:0.1pt;"> </span>to raise<span style="letter-spacing:0.05pt;"> </span>financing<span style="letter-spacing:0.1pt;"> </span>necessary<span style="letter-spacing:0.1pt;"> </span>to build<span style="letter-spacing:0.05pt;"> </span>our commercialization<span style="letter-spacing:0.2pt;"> </span>infrastructure&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:2.35pt;"> </span>inability<span style="letter-spacing:2.4pt;"> </span>of<span style="letter-spacing:2.3pt;"> </span>sales<span style="letter-spacing:2.35pt;"> </span>personnel<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>obtain<span style="letter-spacing:2.35pt;"> </span>access<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>physicians<span style="letter-spacing:2.4pt;"> </span>or<span style="letter-spacing:2.3pt;"> </span>educate<span style="letter-spacing:2.35pt;"> </span>an<span style="letter-spacing:2.3pt;"> </span>adequate<span style="letter-spacing:2.35pt;"> </span>number<span style="letter-spacing:2.35pt;"> </span>of physicians<span style="letter-spacing:0.1pt;"> </span>as to the<span style="letter-spacing:0.05pt;"> </span>benefits<span style="letter-spacing:0.1pt;"> </span>of our products&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">unfavorable<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payor<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and reimbursement<span style="letter-spacing:0.15pt;"> </span>in any geography&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive<span style="letter-spacing:0.15pt;"> </span>disadvantage<span style="letter-spacing:0.1pt;"> </span>relative<span style="letter-spacing:0.1pt;"> </span>to companies<span style="letter-spacing:0.1pt;"> </span>with more<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>lines&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p></td></tr></table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:2.3pt;"> </span>we<span style="letter-spacing:2.25pt;"> </span>enter<span style="letter-spacing:2.3pt;"> </span>into<span style="letter-spacing:2.3pt;"> </span>arrangements<span style="letter-spacing:2.4pt;"> </span>with<span style="letter-spacing:2.25pt;"> </span>third<span style="letter-spacing:2.3pt;"> </span>parties<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.25pt;"> </span>perform<span style="letter-spacing:2.35pt;"> </span>sales<span style="letter-spacing:2.3pt;"> </span>and<span style="letter-spacing:2.2pt;"> </span>marketing<span style="letter-spacing:2.3pt;"> </span>services,<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.2pt;"> </span>product revenues<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>profitability,<span style="letter-spacing:0.2pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>any,<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>likely<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>be lower<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we were to market<span style="letter-spacing:0.1pt;"> </span>and sell<span style="letter-spacing:0.05pt;"> </span>any products<span style="letter-spacing:0.05pt;"> </span>that we<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:0.1pt;"> </span>ourselves.<span style="letter-spacing:0.15pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be successful<span style="letter-spacing:0.1pt;"> </span>in entering<span style="letter-spacing:0.1pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>with third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to market<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>sell<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.7pt;"> </span>product<span style="letter-spacing:0.75pt;"> </span>candidates<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.7pt;"> </span>may<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.7pt;"> </span>unable<span style="letter-spacing:0.75pt;"> </span>to<span style="letter-spacing:0.7pt;"> </span>do<span style="letter-spacing:0.7pt;"> </span>so<span style="letter-spacing:0.7pt;"> </span>on<span style="letter-spacing:0.7pt;"> </span>terms<span style="letter-spacing:0.8pt;"> </span>that<span style="letter-spacing:0.75pt;"> </span>are<span style="letter-spacing:0.75pt;"> </span>acceptable<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.7pt;"> </span>us.<span style="letter-spacing:0.7pt;"> </span>We<span style="letter-spacing:0.7pt;"> </span>likely will<span style="letter-spacing:1.3pt;"> </span>have<span style="letter-spacing:1.25pt;"> </span>little<span style="letter-spacing:1.3pt;"> </span>control<span style="letter-spacing:1.25pt;"> </span>over<span style="letter-spacing:1.25pt;"> </span>such<span style="letter-spacing:1.2pt;"> </span>third<span style="letter-spacing:1.25pt;"> </span>parties,<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>any<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>these<span style="letter-spacing:1.25pt;"> </span>third<span style="letter-spacing:1.25pt;"> </span>parties<span style="letter-spacing:1.3pt;"> </span>may<span style="letter-spacing:1.25pt;"> </span>fail<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>devote<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>necessary resources<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>attention<span style="letter-spacing:0.1pt;"> </span>to sell<span style="letter-spacing:0.05pt;"> </span>and market<span style="letter-spacing:0.1pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>effectively.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we do not establish<span style="letter-spacing:0.1pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>and marketing capabilities<span style="letter-spacing:1.3pt;"> </span>successfully,<span style="letter-spacing:1.25pt;"> </span>either<span style="letter-spacing:1.25pt;"> </span>on<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>own<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>collaboration<span style="letter-spacing:1.3pt;"> </span>with<span style="letter-spacing:1.15pt;"> </span>third<span style="letter-spacing:1.2pt;"> </span>parties,<span style="letter-spacing:1.25pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>will<span style="letter-spacing:1.15pt;"> </span>not<span style="letter-spacing:1.1pt;"> </span>be<span style="letter-spacing:1.1pt;"> </span>successful<span style="letter-spacing:1.2pt;"> </span>in commercializing<span style="letter-spacing:0.2pt;"> </span>any of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we receive<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>competition,<span style="letter-spacing:0.1pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.05pt;"> </span>in others<span style="letter-spacing:0.05pt;"> </span>discovering,<span style="letter-spacing:0.1pt;"> </span>developing<span style="letter-spacing:0.05pt;"> </span>or commercializing products<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>or more<span style="letter-spacing:0.05pt;"> </span>successfully<span style="letter-spacing:0.1pt;"> </span>than we do.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>of pharmaceutical<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>competitive.<span style="letter-spacing:0.15pt;"> </span>We face competition<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>respect<span style="letter-spacing:0.15pt;"> </span>to our current<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and will<span style="letter-spacing:0.05pt;"> </span>face<span style="letter-spacing:0.05pt;"> </span>competition<span style="letter-spacing:0.1pt;"> </span>with respect<span style="letter-spacing:0.1pt;"> </span>to any product candidates<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:0.05pt;"> </span>or commercialize<span style="letter-spacing:0.2pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>future,<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>major<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>companies, specialty<span style="letter-spacing:0.1pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>and existing<span style="letter-spacing:0.1pt;"> </span>or emerging<span style="letter-spacing:0.1pt;"> </span>biotechnology<span style="letter-spacing:0.1pt;"> </span>companies,<span style="letter-spacing:0.1pt;"> </span>academic<span style="letter-spacing:0.05pt;"> </span>research institutions<span style="letter-spacing:2.45pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>governmental<span style="letter-spacing:2.4pt;"> </span>agencies<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>public<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>private<span style="letter-spacing:2.4pt;"> </span>research<span style="letter-spacing:2.4pt;"> </span>institutions<span style="letter-spacing:2.4pt;"> </span>worldwide.<span style="letter-spacing:2.3pt;"> </span>There are<span style="letter-spacing:2.3pt;"> </span>a number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>biotechnology<span style="letter-spacing:0.15pt;"> </span>companies<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>pursuing<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>of precision oncology<span style="letter-spacing:0.1pt;"> </span>therapies<span style="letter-spacing:0.1pt;"> </span>optimized<span style="letter-spacing:0.1pt;"> </span>to effectively<span style="letter-spacing:0.15pt;"> </span>target<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>key driver<span style="letter-spacing:0.05pt;"> </span>mechanisms<span style="letter-spacing:0.1pt;"> </span>in cancers<span style="letter-spacing:0.05pt;"> </span>with high unmet<span style="letter-spacing:0.05pt;"> </span>need, including<span style="letter-spacing:0.1pt;"> </span>Arvinas Inc., Aurigene, Black Diamond<span style="letter-spacing:0.05pt;"> </span>Therapeutics,<span style="letter-spacing:0.1pt;"> </span>Inc., Boehringer Ingelheim, C4 Therapeutics, Constellation<span style="letter-spacing:0.15pt;"> </span>Pharmaceuticals,<span style="letter-spacing:0.15pt;"> </span>Inc., Eli Lilly and Company, F. Hoffman-La Roche, Foghorn Therapeutics Inc., Fochon Pharmaceuticals, G1 Therapeutics Inc., Genentech, Kronos Bio, Inc.,<span style="letter-spacing:0.05pt;"> Kura Oncology, Inc., </span>Kymera Therapeutics Inc., <span style="letter-spacing:0.05pt;">Mirati Therapeutics Inc., Nuvation Bio Inc. </span>Repare<span style="letter-spacing:0.05pt;"> </span>Therapeutics<span style="letter-spacing:0.1pt;"> </span>Inc.,<span style="letter-spacing:0.05pt;"> </span>Revolution<span style="letter-spacing:0.05pt;"> </span>Medicines,<span style="letter-spacing:0.1pt;"> </span>Inc., Relay Therapeutics,<span style="letter-spacing:0.1pt;"> </span>Inc., Springworks Therapeutics, Inc., Syndax Pharmaceuticals, Inc., and Zentalis<span style="letter-spacing:0.1pt;"> </span>Pharmaceuticals,<span style="letter-spacing:0.15pt;"> </span>Inc.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:1.25pt;"> </span>we<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.25pt;"> </span>face<span style="letter-spacing:1.25pt;"> </span>competition<span style="letter-spacing:1.3pt;"> </span>from<span style="letter-spacing:1.25pt;"> </span>companies<span style="letter-spacing:1.3pt;"> </span>developing<span style="letter-spacing:1.25pt;"> </span>product<span style="letter-spacing:1.25pt;"> </span>candidates<span style="letter-spacing:1.3pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>are<span style="letter-spacing:1.2pt;"> </span>based<span style="letter-spacing:1.2pt;"> </span>on<span style="letter-spacing:1.15pt;"> </span>targeting pathways<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>adaptive<span style="letter-spacing:0.1pt;"> </span>resistance,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>Amgen Inc., AbbVie Inc., AstraZeneca plc,<span style="letter-spacing:0.05pt;"> </span>GlaxoSmithKline plc,<span style="letter-spacing:0.1pt;"> </span>Ideaya Biosciences, Johnson &#38; Johnson Services, Inc., Pfizer Inc., Tango Therapeutics, Inc., Vincerx Pharma, Inc., Novartis AG, and Gilead Sciences, Inc.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically,<span style="letter-spacing:0.2pt;"> </span>with respect to our PRMT5 programs, PRT543 and PRT811, several companies are developing PRMT5 inhibitors with clinical trials ongoing, including Amgen (AMG193), GlaxoSmithKline (GSK3326595), Ideaya Biosciences (IDE397), Johnson &#38; Johnson (JNJ-64619178), Pfizer (PF-06939999), and Tango Therapeutics (TNG908). For our MCL1 program, PRT1419, other companies are developing MCL1 inhibitors with monotherapy and/or combination trials ongoing, including Amgen (AMG176), AstraZeneca (AZD5991), Novartis (MIK665), and Gilead (GS-9716). For our CDK9 program, PRT2527, both AstraZeneca (AZD4573), Vincerx (VIP512), and Kronos (KB-0742) have CDK9 programs in Phase 1 clinical trials. For our CDK4/6 program, PRT3645, Novartis (ribociclib), Lilly (abemaciclib), Pfizer (palbociclib), G1 Therapeutics (G1T38), and Fochon Pharmaceuticals (FCN-437) have clinical trials ongoing.&#160;&#160;For our SMARCA2 (BRM) degrader program, other companies, including Amgen, Aurigene, C4 Therapeutics, F. Hoffmann-La Roche, Foghorn Therapeutics, Inc., Kymera Therapeutics, Arvinas, Genentech, Boehringer Ingelheim, and Lilly have publicly disclosed their pre-clinical research efforts.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>which we are<span style="letter-spacing:0.05pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>or against<span style="letter-spacing:0.05pt;"> </span>which we may<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>future, either<span style="letter-spacing:0.15pt;"> </span>alone<span style="letter-spacing:0.1pt;"> </span>or through<span style="letter-spacing:0.05pt;"> </span>collaborations,<span style="letter-spacing:0.15pt;"> </span>have significantly<span style="letter-spacing:0.15pt;"> </span>greater<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>and expertise<span style="letter-spacing:0.1pt;"> </span>in research<span style="letter-spacing:0.1pt;"> </span>and development,<span style="letter-spacing:0.1pt;"> </span>manufacturing,<span style="letter-spacing:0.15pt;"> </span>preclinical<span style="letter-spacing:0.1pt;"> </span>testing,<span style="letter-spacing:0.05pt;"> </span>conducting clinical<span style="letter-spacing:0.05pt;"> </span>trials,<span style="letter-spacing:0.05pt;"> </span>obtaining regulatory<span style="letter-spacing:0.05pt;"> </span>approvals and marketing<span style="letter-spacing:0.15pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we do. Mergers<span style="letter-spacing:0.1pt;"> </span>and acquisitions<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>and biotechnology industries<span style="letter-spacing:1.3pt;"> </span>may<span style="letter-spacing:1.25pt;"> </span>result<span style="letter-spacing:1.3pt;"> </span>in<span style="letter-spacing:1.2pt;"> </span>even<span style="letter-spacing:1.2pt;"> </span>more<span style="letter-spacing:1.25pt;"> </span>resources<span style="letter-spacing:1.3pt;"> </span>being<span style="letter-spacing:1.25pt;"> </span>concentrated<span style="letter-spacing:1.3pt;"> </span>among<span style="letter-spacing:1.25pt;"> </span>a<span style="letter-spacing:1.2pt;"> </span>smaller<span style="letter-spacing:1.3pt;"> </span>number<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>competitors. Smaller<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>early-stage<span style="letter-spacing:0.15pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>prove<span style="letter-spacing:0.05pt;"> </span>to be significant<span style="letter-spacing:0.15pt;"> </span>competitors,<span style="letter-spacing:0.15pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>through collaborative arrangements with large and established companies. These third parties compete with us in recruiting<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>retaining<span style="letter-spacing:0.15pt;"> </span>qualified<span style="letter-spacing:0.15pt;"> </span>scientific,<span style="letter-spacing:0.2pt;"> </span>management<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>sales<span style="letter-spacing:0.1pt;"> </span>and marketing<span style="letter-spacing:0.1pt;"> </span>personnel,<span style="letter-spacing:0.05pt;"> </span>establishing<span style="letter-spacing:0.1pt;"> </span>clinical trial<span style="letter-spacing:1.35pt;"> </span>sites<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>patient<span style="letter-spacing:1.35pt;"> </span>registration<span style="letter-spacing:1.35pt;"> </span>for<span style="letter-spacing:1.25pt;"> </span>clinical<span style="letter-spacing:1.3pt;"> </span>trials,<span style="letter-spacing:1.3pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span>well<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.2pt;"> </span>acquiring<span style="letter-spacing:1.3pt;"> </span>technologies<span style="letter-spacing:1.3pt;"> </span>complementary<span style="letter-spacing:1.35pt;"> </span>to,<span style="letter-spacing:1.2pt;"> </span>or necessary<span style="letter-spacing:0.1pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>our programs.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:0.1pt;"> </span>we also face competition<span style="letter-spacing:0.05pt;"> </span>more broadly across the oncology market<span style="letter-spacing:0.05pt;"> </span>for cost-effective<span style="letter-spacing:0.15pt;"> </span>and reimbursable<span style="letter-spacing:0.2pt;"> </span>cancer<span style="letter-spacing:0.1pt;"> </span>treatments.<span style="letter-spacing:0.2pt;"> </span>There<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>a variety<span style="letter-spacing:0.1pt;"> </span>of available<span style="letter-spacing:0.1pt;"> </span>drug therapies<span style="letter-spacing:0.1pt;"> </span>marketed<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>cancer.<span style="letter-spacing:0.05pt;"> </span>In many cases,<span style="letter-spacing:0.1pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>administered<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>combination<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>enhance<span style="letter-spacing:0.1pt;"> </span>efficacy.<span style="letter-spacing:0.1pt;"> </span>While<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any are approved,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>compete<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.1pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>therapies,<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>extent<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>ultimately<span style="letter-spacing:0.15pt;"> </span>used in combination<span style="letter-spacing:0.15pt;"> </span>with or as an adjunct<span style="letter-spacing:0.05pt;"> </span>to these<span style="letter-spacing:0.05pt;"> </span>therapies,<span style="letter-spacing:0.1pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be competitive<span style="letter-spacing:0.15pt;"> </span>with them. Some<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>branded<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>protection,<span style="letter-spacing:0.1pt;"> </span>and others<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>on a generic<span style="letter-spacing:0.05pt;"> </span>basis. Insurers and other third-party payors may also encourage the use of<span style="letter-spacing:2.45pt;"> </span>generic products or<span style="letter-spacing:2.45pt;"> </span>specific branded products.<span style="letter-spacing:0.1pt;"> </span>As a result,<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtaining</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acceptance</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of, and gaining</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any of our product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">introduce</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pose</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenges.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">many companies</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new oncology</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutics,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we cannot</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">what the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standard</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of care</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be as our product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progress</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.2pt;"> </span>opportunity<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>reduced<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>eliminated<span style="letter-spacing:0.2pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:0.2pt;"> </span>develop<span style="letter-spacing:0.05pt;"> </span>and commercialize products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>safer,<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>effective,<span style="letter-spacing:0.1pt;"> </span>have fewer<span style="letter-spacing:0.05pt;"> </span>or less<span style="letter-spacing:0.05pt;"> </span>severe<span style="letter-spacing:0.05pt;"> </span>side<span style="letter-spacing:0.05pt;"> </span>effects,<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>convenient<span style="letter-spacing:0.05pt;"> </span>to administer, are less expensive or with a more favorable labeling than our current or future product candidates. Our competitors<span style="letter-spacing:1.45pt;"> </span>also<span style="letter-spacing:1.35pt;"> </span>may<span style="letter-spacing:1.35pt;"> </span>obtain<span style="letter-spacing:1.35pt;"> </span>FDA,<span style="letter-spacing:1.25pt;"> </span>foreign<span style="letter-spacing:1.35pt;"> </span>regulatory<span style="letter-spacing:1.4pt;"> </span>authority,<span style="letter-spacing:1.4pt;"> </span>or<span style="letter-spacing:1.3pt;"> </span>other<span style="letter-spacing:1.35pt;"> </span>marketing<span style="letter-spacing:1.35pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>regulatory<span style="letter-spacing:1.35pt;"> </span>approval<span style="letter-spacing:1.3pt;"> </span>for their<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>rapidly<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>ours,<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in our competitors establishing<span style="letter-spacing:2.45pt;"> </span>a<span style="letter-spacing:2.35pt;"> </span>strong<span style="letter-spacing:2.4pt;"> </span>market<span style="letter-spacing:2.45pt;"> </span>position<span style="letter-spacing:2.4pt;"> </span>before<span style="letter-spacing:2.4pt;"> </span>we<span style="letter-spacing:2.35pt;"> </span>are<span style="letter-spacing:2.35pt;"> </span>able<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>enter<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.35pt;"> </span>market.<span style="letter-spacing:2.4pt;"> </span>The<span style="letter-spacing:2.3pt;"> </span>key<span style="letter-spacing:2.3pt;"> </span>competitive<span style="letter-spacing:2.45pt;"> </span>factors affecting<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>success<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>approved,<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>to be their<span style="letter-spacing:0.05pt;"> </span>efficacy,<span style="letter-spacing:0.1pt;"> </span>safety, convenience,<span style="letter-spacing:0.05pt;"> </span>price,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>level<span style="letter-spacing:0.05pt;"> </span>of generic<span style="letter-spacing:0.05pt;"> </span>competition<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>availability<span style="letter-spacing:0.15pt;"> </span>of reimbursement<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>government<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>payors.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if<span style="letter-spacing:0.05pt;"> </span>we are able<span style="letter-spacing:0.05pt;"> </span>to commercialize<span style="letter-spacing:0.15pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>the products<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to unfavorable<span style="letter-spacing:0.05pt;"> </span>pricing<span style="letter-spacing:0.05pt;"> </span>regulations,<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.1pt;"> </span>reimbursement<span style="letter-spacing:0.1pt;"> </span>practices<span style="letter-spacing:0.1pt;"> </span>or healthcare<span style="letter-spacing:0.05pt;"> </span>reform<span style="letter-spacing:0.05pt;"> </span>initiatives, which would harm our business.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products<span style="letter-spacing:0.1pt;"> </span>vary<span style="letter-spacing:0.1pt;"> </span>widely<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>country<span style="letter-spacing:0.05pt;"> </span>to country.<span style="letter-spacing:0.05pt;"> </span>Current<span style="letter-spacing:0.05pt;"> </span>and future<span style="letter-spacing:0.05pt;"> </span>legislation<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>significantly<span style="letter-spacing:0.15pt;"> </span>change<span style="letter-spacing:0.05pt;"> </span>the approval<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>in ways that<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and cause<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:0.05pt;"> </span>in obtaining<span style="letter-spacing:0.05pt;"> </span>approvals.<span style="letter-spacing:0.05pt;"> </span>Some countries<span style="letter-spacing:0.1pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of a drug before<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>can be marketed.<span style="letter-spacing:0.1pt;"> </span>In many<span style="letter-spacing:0.05pt;"> </span>countries,<span style="letter-spacing:0.05pt;"> </span>the pricing review<span style="letter-spacing:2.15pt;"> </span>period<span style="letter-spacing:2.15pt;"> </span>begins<span style="letter-spacing:2.15pt;"> </span>after<span style="letter-spacing:2.15pt;"> </span>marketing<span style="letter-spacing:2.15pt;"> </span>or<span style="letter-spacing:2.05pt;"> </span>product<span style="letter-spacing:2.1pt;"> </span>licensing<span style="letter-spacing:2.15pt;"> </span>approval<span style="letter-spacing:2.1pt;"> </span>is<span style="letter-spacing:2.1pt;"> </span>granted.<span style="letter-spacing:2.1pt;"> </span>To<span style="letter-spacing:2.05pt;"> </span>obtain<span style="letter-spacing:2.1pt;"> </span>reimbursement<span style="letter-spacing:2.2pt;"> </span>or pricing<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.1pt;"> </span>countries,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be required<span style="letter-spacing:0.1pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>a clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>compares<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>cost- effectiveness<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>to other<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>therapies.<span style="letter-spacing:0.1pt;"> </span>In some<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>markets,<span style="letter-spacing:0.1pt;"> </span>prescription pharmaceutical<span style="letter-spacing:0.15pt;"> </span>pricing<span style="letter-spacing:0.05pt;"> </span>remains<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to continuing<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:0.1pt;"> </span>control<span style="letter-spacing:0.05pt;"> </span>even after<span style="letter-spacing:0.1pt;"> </span>initial<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.05pt;"> </span>is granted. As<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.5pt;"> </span>result,<span style="letter-spacing:1.6pt;"> </span>we<span style="letter-spacing:1.5pt;"> </span>might<span style="letter-spacing:1.55pt;"> </span>obtain<span style="letter-spacing:1.55pt;"> </span>marketing<span style="letter-spacing:1.55pt;"> </span>approval<span style="letter-spacing:1.5pt;"> </span>for<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.45pt;"> </span>product<span style="letter-spacing:1.5pt;"> </span>candidate<span style="letter-spacing:1.55pt;"> </span>in<span style="letter-spacing:1.45pt;"> </span>a<span style="letter-spacing:1.45pt;"> </span>particular<span style="letter-spacing:1.6pt;"> </span>country,<span style="letter-spacing:1.5pt;"> </span>but<span style="letter-spacing:1.45pt;"> </span>then<span style="letter-spacing:1.5pt;"> </span>be subject<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>price<span style="letter-spacing:0.85pt;"> </span>regulations<span style="letter-spacing:0.9pt;"> </span>that<span style="letter-spacing:0.85pt;"> </span>delay<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>commercial<span style="letter-spacing:0.9pt;"> </span>launch<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.8pt;"> </span>product,<span style="letter-spacing:0.8pt;"> </span>possibly<span style="letter-spacing:0.8pt;"> </span>for<span style="letter-spacing:0.8pt;"> </span>lengthy<span style="letter-spacing:0.8pt;"> </span>time<span style="letter-spacing:0.8pt;"> </span>periods, and<span style="letter-spacing:0.05pt;"> </span>negatively<span style="letter-spacing:0.15pt;"> </span>impact<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>revenues,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any, we are<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.05pt;"> </span>to generate<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>in that<span style="letter-spacing:0.05pt;"> </span>country. Adverse<span style="letter-spacing:0.1pt;"> </span>pricing<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>hinder<span style="letter-spacing:0.05pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to recoup<span style="letter-spacing:0.05pt;"> </span>our investment<span style="letter-spacing:0.1pt;"> </span>in one or more<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates, even if<span style="letter-spacing:0.05pt;"> </span>such product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>commercialize<span style="letter-spacing:0.25pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>successfully<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>depend in part<span style="letter-spacing:0.05pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>extent<span style="letter-spacing:0.05pt;"> </span>to which<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>adequate<span style="letter-spacing:0.1pt;"> </span>reimbursement<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>and related<span style="letter-spacing:0.1pt;"> </span>treatments<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be available<span style="letter-spacing:0.1pt;"> </span>from third-party<span style="letter-spacing:1.4pt;"> </span>payors,<span style="letter-spacing:1.3pt;"> </span>including<span style="letter-spacing:1.3pt;"> </span>government<span style="letter-spacing:1.35pt;"> </span>healthcare<span style="letter-spacing:1.35pt;"> </span>programs,<span style="letter-spacing:1.35pt;"> </span>private<span style="letter-spacing:1.3pt;"> </span>health<span style="letter-spacing:1.25pt;"> </span>insurers<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>other<span style="letter-spacing:1.25pt;"> </span>organizations. Third-party<span style="letter-spacing:0.15pt;"> </span>payors<span style="letter-spacing:0.1pt;"> </span>decide<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>medications<span style="letter-spacing:0.15pt;"> </span>they<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>pay for<span style="letter-spacing:0.05pt;"> </span>and establish<span style="letter-spacing:0.1pt;"> </span>reimbursement<span style="letter-spacing:0.15pt;"> </span>levels.<span style="letter-spacing:0.05pt;"> </span>In the<span style="letter-spacing:0.05pt;"> </span>United States,<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>principal<span style="letter-spacing:1.2pt;"> </span>decisions<span style="letter-spacing:1.2pt;"> </span>about<span style="letter-spacing:1.15pt;"> </span>reimbursement<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>new<span style="letter-spacing:1.05pt;"> </span>medicines<span style="letter-spacing:1.15pt;"> </span>are<span style="letter-spacing:1.1pt;"> </span>typically<span style="letter-spacing:1.15pt;"> </span>made<span style="letter-spacing:1.1pt;"> </span>by<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>CMS,<span style="letter-spacing:1.05pt;"> </span>which decides<span style="letter-spacing:0.1pt;"> </span>whether<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>what extent<span style="letter-spacing:0.05pt;"> </span>a new medicine<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be covered<span style="letter-spacing:0.05pt;"> </span>and reimbursed<span style="letter-spacing:0.1pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>Medicare.<span style="letter-spacing:0.1pt;"> </span>Private payors<span style="letter-spacing:0.05pt;"> </span>often,<span style="letter-spacing:0.05pt;"> </span>but not always,<span style="letter-spacing:0.05pt;"> </span>follow<span style="letter-spacing:0.05pt;"> </span>CMS&#8217;s decisions<span style="letter-spacing:0.1pt;"> </span>regarding<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and reimbursement.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="letter-spacing:0.05pt;"> </span>primary<span style="letter-spacing:0.15pt;"> </span>trend<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>U.S. healthcare<span style="letter-spacing:0.15pt;"> </span>industry<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>elsewhere<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>cost<span style="letter-spacing:0.1pt;"> </span>containment.<span style="letter-spacing:0.15pt;"> </span>Third-party<span style="letter-spacing:0.1pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>have attempted<span style="letter-spacing:0.1pt;"> </span>to control<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>by limiting<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>amount<span style="letter-spacing:0.05pt;"> </span>of reimbursement<span style="letter-spacing:0.15pt;"> </span>for particular<span style="letter-spacing:0.1pt;"> </span>medications. Increasingly,<span style="letter-spacing:1.35pt;"> </span>third-party<span style="letter-spacing:1.4pt;"> </span>payors<span style="letter-spacing:1.3pt;"> </span>are<span style="letter-spacing:1.3pt;"> </span>requiring<span style="letter-spacing:1.35pt;"> </span>that<span style="letter-spacing:1.3pt;"> </span>drug<span style="letter-spacing:1.25pt;"> </span>companies<span style="letter-spacing:1.35pt;"> </span>provide<span style="letter-spacing:1.3pt;"> </span>them<span style="letter-spacing:1.3pt;"> </span>with<span style="letter-spacing:1.2pt;"> </span>predetermined<span style="letter-spacing:1.35pt;"> </span>discounts from<span style="letter-spacing:0.8pt;"> </span>list<span style="letter-spacing:0.8pt;"> </span>prices<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.75pt;"> </span>are<span style="letter-spacing:0.8pt;"> </span>challenging<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>prices<span style="letter-spacing:0.75pt;"> </span>charged<span style="letter-spacing:0.75pt;"> </span>for<span style="letter-spacing:0.75pt;"> </span>medical<span style="letter-spacing:0.8pt;"> </span>products.<span style="letter-spacing:0.75pt;"> </span>Coverage<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>reimbursement<span style="letter-spacing:0.85pt;"> </span>may not be available for any product that we commercialize and, even if these are available, the level of reimbursement<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>satisfactory.<span style="letter-spacing:0.2pt;"> </span>Reimbursement<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>demand<span style="letter-spacing:0.1pt;"> </span>for,<span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of, any product candidate<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>approval.<span style="letter-spacing:0.1pt;"> </span>Obtaining<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>maintaining<span style="letter-spacing:0.15pt;"> </span>coverage<span style="letter-spacing:0.1pt;"> </span>and adequate reimbursement<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our products<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be difficult.<span style="letter-spacing:0.15pt;"> </span>We may<span style="letter-spacing:0.05pt;"> </span>be required<span style="letter-spacing:0.1pt;"> </span>to conduct<span style="letter-spacing:0.05pt;"> </span>expensive<span style="letter-spacing:0.05pt;"> </span>pharmacoeconomic studies<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>justify<span style="letter-spacing:2.4pt;"> </span>coverage<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.25pt;"> </span>reimbursement<span style="letter-spacing:2.4pt;"> </span>or<span style="letter-spacing:2.25pt;"> </span>the<span style="letter-spacing:2.3pt;"> </span>level<span style="letter-spacing:2.3pt;"> </span>of<span style="letter-spacing:2.25pt;"> </span>reimbursement<span style="letter-spacing:2.4pt;"> </span>relative<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.25pt;"> </span>other<span style="letter-spacing:2.3pt;"> </span>therapies.<span style="letter-spacing:2.35pt;"> </span>If coverage<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>adequate<span style="letter-spacing:0.1pt;"> </span>reimbursement<span style="letter-spacing:0.2pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>only to limited<span style="letter-spacing:0.1pt;"> </span>levels,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to successfully<span style="letter-spacing:0.1pt;"> </span>commercialize<span style="letter-spacing:0.2pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidate<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which we obtain<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>approval.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>develop,<span style="letter-spacing:0.1pt;"> </span>either<span style="letter-spacing:0.15pt;"> </span>by ourselves<span style="letter-spacing:0.1pt;"> </span>or with collaborators,<span style="letter-spacing:0.15pt;"> </span>companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.1pt;"> </span>tests<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.95pt;"> </span>candidates<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:0.95pt;"> </span>certain<span style="letter-spacing:1pt;"> </span>indications.<span style="letter-spacing:1pt;"> </span>We,<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>our<span style="letter-spacing:0.9pt;"> </span>collaborators,<span style="letter-spacing:1.05pt;"> </span>if<span style="letter-spacing:0.95pt;"> </span>any,<span style="letter-spacing:0.85pt;"> </span>will<span style="letter-spacing:0.9pt;"> </span>be<span style="letter-spacing:0.85pt;"> </span>required<span style="letter-spacing:0.95pt;"> </span>to<span style="letter-spacing:0.85pt;"> </span>obtain<span style="letter-spacing:0.9pt;"> </span>coverage and<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>tests<span style="letter-spacing:0.1pt;"> </span>separate<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>apart<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>and reimbursement<span style="letter-spacing:0.15pt;"> </span>we seek<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>once approved.<span style="letter-spacing:0.05pt;"> </span>While<span style="letter-spacing:0.05pt;"> </span>we have not yet<span style="letter-spacing:0.05pt;"> </span>developed<span style="letter-spacing:0.05pt;"> </span>any companion<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:0.1pt;"> </span>test<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>reasons<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:0.95pt;"> </span>may<span style="letter-spacing:0.95pt;"> </span>also<span style="letter-spacing:0.95pt;"> </span>be<span style="letter-spacing:0.9pt;"> </span>significant<span style="letter-spacing:1.05pt;"> </span>delays<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.9pt;"> </span>obtaining<span style="letter-spacing:0.95pt;"> </span>coverage<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>reimbursement<span style="letter-spacing:1pt;"> </span>for<span style="letter-spacing:0.9pt;"> </span>newly<span style="letter-spacing:0.85pt;"> </span>approved<span style="letter-spacing:0.9pt;"> </span>drugs, and<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.15pt;"> </span>be<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.15pt;"> </span>limited<span style="letter-spacing:0.2pt;"> </span>than<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>purposes<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>similar regulatory<span style="letter-spacing:1.25pt;"> </span>authorities<span style="letter-spacing:1.3pt;"> </span>outside<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>United<span style="letter-spacing:1.2pt;"> </span>States.<span style="letter-spacing:1.2pt;"> </span>Moreover,<span style="letter-spacing:1.2pt;"> </span>eligibility<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>coverage<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>reimbursement<span style="letter-spacing:1.25pt;"> </span>does not<span style="letter-spacing:0.05pt;"> </span>imply<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>a drug will<span style="letter-spacing:0.05pt;"> </span>be paid<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>in all<span style="letter-spacing:0.05pt;"> </span>cases<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>a rate<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>covers<span style="letter-spacing:0.05pt;"> </span>our costs,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>research, development,<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property,<span style="letter-spacing:0.05pt;"> </span>manufacture,<span style="letter-spacing:0.1pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>and distribution<span style="letter-spacing:0.1pt;"> </span>expenses. Interim<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:0.1pt;"> </span>levels for new drugs,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>applicable,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>not be sufficient<span style="letter-spacing:0.15pt;"> </span>to cover<span style="letter-spacing:0.05pt;"> </span>our costs<span style="letter-spacing:0.05pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>not be made<span style="letter-spacing:0.05pt;"> </span>permanent. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rates</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vary</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">according</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">setting</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">used,</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">levels</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">already</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">set</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drugs</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorporated</span><span style="letter-spacing:2.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</span><span style="letter-spacing:2.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing payments</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services.</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drugs</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be reduced</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by mandatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounts</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or rebates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by government</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payors</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relaxation</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">presently</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict imports</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drugs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where they</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be sold</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">often</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rely</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policy</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limitations</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">setting</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement policies,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">methods</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">apart</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determinations.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promptly</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and adequate</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rates</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payors</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any approved products</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have a material</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our operating</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to raise</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital needed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to commercialize</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our overall</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability<span style="letter-spacing:0.15pt;"> </span>lawsuits<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>us could cause us to incur substantial<span style="letter-spacing:0.1pt;"> </span>liabilities<span style="letter-spacing:0.15pt;"> </span>and to limit commercialization<span style="letter-spacing:0.2pt;"> </span>of any products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>develop.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>face<span style="letter-spacing:0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>inherent<span style="letter-spacing:0.15pt;"> </span>risk<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>exposure<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in human<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.1pt;"> </span>and will<span style="letter-spacing:0.05pt;"> </span>face<span style="letter-spacing:0.05pt;"> </span>an even greater<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we commercialize<span style="letter-spacing:0.2pt;"> </span>any products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>develop.<span style="letter-spacing:0.05pt;"> </span>If we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>successfully<span style="letter-spacing:0.1pt;"> </span>defend<span style="letter-spacing:0.05pt;"> </span>ourselves<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>any claims<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or products<span style="letter-spacing:0.05pt;"> </span>caused injuries,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>incur<span style="letter-spacing:0.1pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>liabilities.<span style="letter-spacing:0.15pt;"> </span>Regardless<span style="letter-spacing:0.05pt;"> </span>of merit<span style="letter-spacing:0.1pt;"> </span>or eventual<span style="letter-spacing:0.05pt;"> </span>outcome,<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:0.15pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>result in:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">decreased<span style="letter-spacing:0.1pt;"> </span>demand<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>develop&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injury<span style="letter-spacing:0.05pt;"> </span>to our reputation<span style="letter-spacing:0.1pt;"> </span>and significant<span style="letter-spacing:0.15pt;"> </span>negative<span style="letter-spacing:0.05pt;"> </span>media<span style="letter-spacing:0.05pt;"> </span>attention&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiation<span style="letter-spacing:0.15pt;"> </span>of investigations<span style="letter-spacing:0.15pt;"> </span>by regulators&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">withdrawal<span style="letter-spacing:0.05pt;"> </span>of clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>participants&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">significant<span style="letter-spacing:0.15pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>and costs<span style="letter-spacing:0.05pt;"> </span>to defend<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>litigation&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion<span style="letter-spacing:0.1pt;"> </span>of management<span style="letter-spacing:0.1pt;"> </span>and scientific<span style="letter-spacing:0.15pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>operations&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">substantial<span style="letter-spacing:0.1pt;"> </span>monetary<span style="letter-spacing:0.1pt;"> </span>awards<span style="letter-spacing:0.05pt;"> </span>to trial<span style="letter-spacing:0.1pt;"> </span>participants<span style="letter-spacing:0.15pt;"> </span>or patients&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">loss<span style="letter-spacing:0.05pt;"> </span>of revenue&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>of our management<span style="letter-spacing:0.1pt;"> </span>to pursue<span style="letter-spacing:0.05pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>strategy&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>inability<span style="letter-spacing:0.1pt;"> </span>to commercialize<span style="letter-spacing:0.2pt;"> </span>any products<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>develop.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>insurance<span style="letter-spacing:0.15pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and certain<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be<span style="letter-spacing:0.6pt;"> </span>adequate<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>cover<span style="letter-spacing:0.65pt;"> </span>all<span style="letter-spacing:0.65pt;"> </span>liabilities<span style="letter-spacing:0.75pt;"> </span>that<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.6pt;"> </span>incur.<span style="letter-spacing:0.6pt;"> </span>We<span style="letter-spacing:0.55pt;"> </span>likely<span style="letter-spacing:0.6pt;"> </span>will<span style="letter-spacing:0.6pt;"> </span>need<span style="letter-spacing:0.55pt;"> </span>to<span style="letter-spacing:0.55pt;"> </span>increase<span style="letter-spacing:0.65pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>insurance<span style="letter-spacing:0.65pt;"> </span>coverage<span style="letter-spacing:0.6pt;"> </span>as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>increasingly<span style="letter-spacing:0.15pt;"> </span>expensive.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.05pt;"> </span>to maintain<span style="letter-spacing:0.1pt;"> </span>insurance<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>a reasonable<span style="letter-spacing:0.1pt;"> </span>cost<span style="letter-spacing:0.05pt;"> </span>or in an<span style="letter-spacing:0.05pt;"> </span>amount<span style="letter-spacing:0.1pt;"> </span>adequate<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>satisfy<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>arise.<span style="letter-spacing:0.1pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>successful<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:0.15pt;"> </span>claim<span style="letter-spacing:0.1pt;"> </span>or series<span style="letter-spacing:0.1pt;"> </span>of claims brought<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>us could<span style="letter-spacing:0.05pt;"> </span>decrease<span style="letter-spacing:0.1pt;"> </span>our cash<span style="letter-spacing:0.05pt;"> </span>and adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Employee<span style="letter-spacing:0.05pt;"> </span>Matters<span style="letter-spacing:0.1pt;"> </span>and Our Operations</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>depends on our ability<span style="letter-spacing:0.1pt;"> </span>to retain<span style="letter-spacing:0.05pt;"> </span>key employees<span style="letter-spacing:0.1pt;"> </span>and to attract,<span style="letter-spacing:0.1pt;"> </span>retain<span style="letter-spacing:0.05pt;"> </span>and motivate qualified<span style="letter-spacing:0.1pt;"> </span>personnel<span style="letter-spacing:0.05pt;"> </span>and manage our human capital.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:0.15pt;"> </span>biotechnology<span style="letter-spacing:0.1pt;"> </span>and pharmaceutical<span style="letter-spacing:0.15pt;"> </span>industries<span style="letter-spacing:0.1pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>upon our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to attract,<span style="letter-spacing:0.1pt;"> </span>motivate<span style="letter-spacing:0.1pt;"> </span>and retain<span style="letter-spacing:0.1pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>qualified<span style="letter-spacing:0.1pt;"> </span>managerial,<span style="letter-spacing:0.1pt;"> </span>scientific<span style="letter-spacing:0.15pt;"> </span>and medical<span style="letter-spacing:0.1pt;"> </span>personnel.<span style="letter-spacing:0.05pt;"> </span>We are highly<span style="letter-spacing:1.2pt;"> </span>dependent<span style="letter-spacing:1.2pt;"> </span>on<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>development<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>management<span style="letter-spacing:1.25pt;"> </span>expertise<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>Kris<span style="letter-spacing:1.15pt;"> </span>Vaddi,<span style="letter-spacing:1.1pt;"> </span>Ph.D.,<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>founder<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>Chief Executive<span style="letter-spacing:0.1pt;"> </span>Officer,<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>principal<span style="letter-spacing:0.15pt;"> </span>members<span style="letter-spacing:0.1pt;"> </span>of our management,<span style="letter-spacing:0.1pt;"> </span>scientific<span style="letter-spacing:0.15pt;"> </span>and clinical<span style="letter-spacing:0.1pt;"> </span>team.<span style="letter-spacing:0.05pt;"> </span>We currently<span style="letter-spacing:0.1pt;"> </span>do not maintain<span style="letter-spacing:0.1pt;"> </span>key person<span style="letter-spacing:0.05pt;"> </span>insurance<span style="letter-spacing:0.1pt;"> </span>on these<span style="letter-spacing:0.05pt;"> </span>individuals.<span style="letter-spacing:0.1pt;"> </span>Although we have entered into employment agreements<span style="letter-spacing:0.1pt;"> </span>with our executive<span style="letter-spacing:0.1pt;"> </span>officers,<span style="letter-spacing:0.1pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>of them<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>terminate<span style="letter-spacing:0.15pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>employment<span style="letter-spacing:0.1pt;"> </span>with us at<span style="letter-spacing:0.05pt;"> </span>any time.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>industry<span style="letter-spacing:0.1pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>experienced<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>high<span style="letter-spacing:0.05pt;"> </span>rate<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>turnover<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>recent<span style="letter-spacing:0.05pt;"> </span>years.<span style="letter-spacing:0.05pt;"> </span>Our ability<span style="letter-spacing:0.1pt;"> </span>to compete<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>highly competitive<span style="letter-spacing:0.2pt;"> </span>pharmaceuticals<span style="letter-spacing:0.2pt;"> </span>industry<span style="letter-spacing:0.1pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>upon our ability<span style="letter-spacing:0.1pt;"> </span>to attract,<span style="letter-spacing:0.1pt;"> </span>retain<span style="letter-spacing:0.1pt;"> </span>and motivate<span style="letter-spacing:0.1pt;"> </span>highly<span style="letter-spacing:0.05pt;"> </span>skilled<span style="letter-spacing:0.1pt;"> </span>and experienced<span style="letter-spacing:0.15pt;"> </span>personnel<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>scientific,<span style="letter-spacing:0.2pt;"> </span>clinical,<span style="letter-spacing:0.15pt;"> </span>regulatory,<span style="letter-spacing:0.15pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:0.15pt;"> </span>skills<span style="letter-spacing:0.1pt;"> </span>and experience. We conduct<span style="letter-spacing:0.05pt;"> </span>our operations<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>greater<span style="letter-spacing:0.1pt;"> </span>Delaware<span style="letter-spacing:0.05pt;"> </span>area,<span style="letter-spacing:0.05pt;"> </span>a region<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>home<span style="letter-spacing:0.05pt;"> </span>to other<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.1pt;"> </span>companies as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:0.1pt;"> </span>academic<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.15pt;"> </span>institutions and in addition, the COVID-19 pandemic has increased companies&#8217; willingness to hire remote workers,<span style="letter-spacing:0.2pt;"> </span>resulting<span style="letter-spacing:0.1pt;"> </span>in fierce<span style="letter-spacing:0.1pt;"> </span>competition<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>qualified<span style="letter-spacing:0.1pt;"> </span>personnel.<span style="letter-spacing:0.05pt;"> </span>We may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>attract<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>retain<span style="letter-spacing:0.15pt;"> </span>qualified<span style="letter-spacing:0.15pt;"> </span>personnel<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>due<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>intense<span style="letter-spacing:0.05pt;"> </span>competition<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a limited number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>qualified<span style="letter-spacing:0.15pt;"> </span>personnel<span style="letter-spacing:0.1pt;"> </span>among<span style="letter-spacing:0.1pt;"> </span>pharmaceutical<span style="letter-spacing:0.2pt;"> </span>companies.<span style="letter-spacing:0.15pt;"> </span>Many of the<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>companies against<span style="letter-spacing:0.55pt;"> </span>which<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>compete<span style="letter-spacing:0.55pt;"> </span>have<span style="letter-spacing:0.5pt;"> </span>greater<span style="letter-spacing:0.6pt;"> </span>financial<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.5pt;"> </span>other<span style="letter-spacing:0.55pt;"> </span>resources,<span style="letter-spacing:0.6pt;"> </span>different<span style="letter-spacing:0.55pt;"> </span>risk<span style="letter-spacing:0.5pt;"> </span>profiles<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.45pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>longer<span style="letter-spacing:0.5pt;"> </span>history in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>industry<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we do. Our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">higher</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunities</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or better</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunities</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">career</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advancement.</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:1.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attract</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and retain</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">high quality</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negatively</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to successfully develop</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and to grow our business</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as currently contemplated.</span></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect<span style="letter-spacing:0.05pt;"> </span>to expand our development<span style="letter-spacing:0.1pt;"> </span>and regulatory<span style="letter-spacing:0.05pt;"> </span>capabilities<span style="letter-spacing:0.15pt;"> </span>and potentially<span style="letter-spacing:0.1pt;"> </span>implement<span style="letter-spacing:0.1pt;"> </span>sales, marketing<span style="letter-spacing:0.05pt;"> </span>and distribution<span style="letter-spacing:0.1pt;"> </span>capabilities,<span style="letter-spacing:0.15pt;"> </span>and as a result,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>encounter<span style="letter-spacing:0.05pt;"> </span>difficulties<span style="letter-spacing:0.15pt;"> </span>in managing our growth, which could disrupt<span style="letter-spacing:0.05pt;"> </span>our operations.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.7pt;"> March&#160;31, 2022</span>,<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:0.7pt;"> </span>had<span style="letter-spacing:0.7pt;"> </span>118 full-time<span style="letter-spacing:0.85pt;"> </span>employees.<span style="letter-spacing:0.8pt;"> </span>We<span style="letter-spacing:0.65pt;"> </span>expect<span style="letter-spacing:0.7pt;"> </span>significant<span style="letter-spacing:0.8pt;"> </span>growth<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>number<span style="letter-spacing:0.7pt;"> </span>of our employees<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>scope<span style="letter-spacing:0.05pt;"> </span>of our operations,<span style="letter-spacing:0.1pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>areas<span style="letter-spacing:0.05pt;"> </span>of clinical<span style="letter-spacing:0.1pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>clinical operations,<span style="letter-spacing:0.1pt;"> </span>manufacturing,<span style="letter-spacing:0.15pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>affairs<span style="letter-spacing:0.1pt;"> </span>and, if<span style="letter-spacing:0.05pt;"> </span>any of our product candidates<span style="letter-spacing:0.05pt;"> </span>receives<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.05pt;"> </span>approval, sales,<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.1pt;"> </span>and distribution.<span style="letter-spacing:0.15pt;"> </span>To manage<span style="letter-spacing:0.05pt;"> </span>our anticipated<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>growth, we must<span style="letter-spacing:0.05pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to implement<span style="letter-spacing:0.05pt;"> </span>and improve<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>managerial,<span style="letter-spacing:0.15pt;"> </span>operational<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>systems,<span style="letter-spacing:0.1pt;"> </span>expand our facilities<span style="letter-spacing:0.15pt;"> </span>and continue<span style="letter-spacing:0.05pt;"> </span>to recruit<span style="letter-spacing:0.1pt;"> </span>and train additional<span style="letter-spacing:0.15pt;"> </span>qualified<span style="letter-spacing:0.15pt;"> </span>personnel.<span style="letter-spacing:0.1pt;"> </span>Due<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our limited<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.1pt;"> </span>experience<span style="letter-spacing:0.1pt;"> </span>of our management<span style="letter-spacing:1.1pt;"> </span>team<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:1pt;"> </span>managing<span style="letter-spacing:1.05pt;"> </span>a<span style="letter-spacing:1pt;"> </span>company<span style="letter-spacing:1.05pt;"> </span>with<span style="letter-spacing:1pt;"> </span>such<span style="letter-spacing:1pt;"> </span>anticipated<span style="letter-spacing:1.1pt;"> </span>growth<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:1pt;"> </span>with<span style="letter-spacing:1pt;"> </span>developing<span style="letter-spacing:1.05pt;"> </span>sales,<span style="letter-spacing:1pt;"> </span>marketing and<span style="letter-spacing:1.55pt;"> </span>distribution<span style="letter-spacing:1.7pt;"> </span>infrastructure,<span style="letter-spacing:1.75pt;"> </span>we<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>not<span style="letter-spacing:1.55pt;"> </span>be<span style="letter-spacing:1.55pt;"> </span>able<span style="letter-spacing:1.6pt;"> </span>to<span style="letter-spacing:1.5pt;"> </span>effectively<span style="letter-spacing:1.65pt;"> </span>manage<span style="letter-spacing:1.55pt;"> </span>the<span style="letter-spacing:1.55pt;"> </span>expansion<span style="letter-spacing:1.55pt;"> </span>of<span style="letter-spacing:1.5pt;"> </span>our<span style="letter-spacing:1.5pt;"> </span>operations<span style="letter-spacing:1.6pt;"> </span>or recruit<span style="letter-spacing:0.1pt;"> </span>and train<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>qualified<span style="letter-spacing:0.1pt;"> </span>personnel.<span style="letter-spacing:0.05pt;"> </span>The expansion<span style="letter-spacing:0.05pt;"> </span>of our operations<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>lead<span style="letter-spacing:0.05pt;"> </span>to significant<span style="letter-spacing:0.15pt;"> </span>costs and may<span style="letter-spacing:0.05pt;"> </span>divert<span style="letter-spacing:0.05pt;"> </span>our management<span style="letter-spacing:0.1pt;"> </span>and business<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>resources.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>rely,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>foreseeable<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to rely,<span style="letter-spacing:0.05pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>part<span style="letter-spacing:0.05pt;"> </span>on certain third-party<span style="letter-spacing:0.2pt;"> </span>contract<span style="letter-spacing:0.15pt;"> </span>organizations,<span style="letter-spacing:0.15pt;"> </span>advisors<span style="letter-spacing:0.05pt;"> </span>and consultants<span style="letter-spacing:0.1pt;"> </span>to provide<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>services,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>assuming substantial<span style="letter-spacing:1.4pt;"> </span>responsibilities<span style="letter-spacing:1.5pt;"> </span>for<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>conduct<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:1.3pt;"> </span>our<span style="letter-spacing:1.3pt;"> </span>clinical<span style="letter-spacing:1.4pt;"> </span>trials<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>manufacture<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>PRT543,<span style="letter-spacing:1.2pt;"> </span>PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 and PRT2527, or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.15pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>assure<span style="letter-spacing:0.1pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>services<span style="letter-spacing:0.1pt;"> </span>of such third-party<span style="letter-spacing:0.15pt;"> </span>contract organizations,<span style="letter-spacing:0.15pt;"> </span>advisors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>timely<span style="letter-spacing:0.15pt;"> </span>basis<span style="letter-spacing:0.1pt;"> </span>when needed,<span style="letter-spacing:0.05pt;"> </span>or that we<span style="letter-spacing:0.5pt;"> </span>can<span style="letter-spacing:0.5pt;"> </span>find<span style="letter-spacing:0.55pt;"> </span>qualified<span style="letter-spacing:0.6pt;"> </span>replacements.<span style="letter-spacing:0.6pt;"> </span>In<span style="letter-spacing:0.45pt;"> </span>addition,<span style="letter-spacing:0.5pt;"> </span>if<span style="letter-spacing:0.5pt;"> </span>we<span style="letter-spacing:0.45pt;"> </span>are<span style="letter-spacing:0.5pt;"> </span>unable<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.45pt;"> </span>effectively<span style="letter-spacing:0.6pt;"> </span>manage<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:0.45pt;"> </span>outsourced<span style="letter-spacing:0.5pt;"> </span>activities or<span style="letter-spacing:1.6pt;"> </span>if<span style="letter-spacing:1.65pt;"> </span>the<span style="letter-spacing:1.65pt;"> </span>quality<span style="letter-spacing:1.6pt;"> </span>or<span style="letter-spacing:1.55pt;"> </span>accuracy<span style="letter-spacing:1.6pt;"> </span>of<span style="letter-spacing:1.55pt;"> </span>the<span style="letter-spacing:1.6pt;"> </span>services<span style="letter-spacing:1.65pt;"> </span>provided<span style="letter-spacing:1.6pt;"> </span>by<span style="letter-spacing:1.55pt;"> </span>our<span style="letter-spacing:1.55pt;"> </span>vendors<span style="letter-spacing:1.6pt;"> </span>or<span style="letter-spacing:1.55pt;"> </span>consultants<span style="letter-spacing:1.65pt;"> </span>is<span style="letter-spacing:1.6pt;"> </span>compromised<span style="letter-spacing:1.65pt;"> </span>for<span style="letter-spacing:1.6pt;"> </span>any reason,<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>extended,<span style="letter-spacing:0.1pt;"> </span>delayed<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>terminated,<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>marketing approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or any future<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>advance<span style="letter-spacing:0.05pt;"> </span>our business.<span style="letter-spacing:0.05pt;"> </span>We cannot<span style="letter-spacing:0.1pt;"> </span>assure<span style="letter-spacing:0.1pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>properly<span style="letter-spacing:0.1pt;"> </span>manage<span style="letter-spacing:0.1pt;"> </span>our existing<span style="letter-spacing:0.1pt;"> </span>vendors<span style="letter-spacing:0.05pt;"> </span>or consultants<span style="letter-spacing:0.1pt;"> </span>or find<span style="letter-spacing:0.05pt;"> </span>other competent<span style="letter-spacing:0.1pt;"> </span>outside<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.05pt;"> </span>and consultants<span style="letter-spacing:0.1pt;"> </span>on economically<span style="letter-spacing:0.1pt;"> </span>reasonable<span style="letter-spacing:0.1pt;"> </span>terms,<span style="letter-spacing:0.1pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>effectively<span style="letter-spacing:0.2pt;"> </span>manage<span style="letter-spacing:0.1pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>expand<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>organization,<span style="letter-spacing:0.15pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to successfully<span style="letter-spacing:0.2pt;"> </span>implement<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>tasks<span style="letter-spacing:0.15pt;"> </span>necessary<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>further<span style="letter-spacing:0.2pt;"> </span>develop<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>commercialize<span style="letter-spacing:0.3pt;"> </span>PRT543, PRT811<span style="letter-spacing:0.05pt;">, </span>PRT1419 or PRT2527, our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>pipeline<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or any future<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and, accordingly,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not achieve<span style="letter-spacing:0.05pt;"> </span>our research,<span style="letter-spacing:0.1pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>goals.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees,<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.05pt;"> </span>investigators,<span style="letter-spacing:0.1pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs, consultants,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.05pt;"> </span>and any potential commercial<span style="letter-spacing:0.1pt;"> </span>partners<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>engage in misconduct<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>improper<span style="letter-spacing:0.05pt;"> </span>activities,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>non-compliance with regulatory<span style="letter-spacing:0.05pt;"> </span>standards<span style="letter-spacing:0.05pt;"> </span>and requirements<span style="letter-spacing:0.1pt;"> </span>and insider<span style="letter-spacing:0.05pt;"> </span>trading.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:1.85pt;"> </span>are<span style="letter-spacing:1.9pt;"> </span>exposed<span style="letter-spacing:1.9pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>the<span style="letter-spacing:1.9pt;"> </span>risk<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>fraud<span style="letter-spacing:1.85pt;"> </span>or<span style="letter-spacing:1.8pt;"> </span>other<span style="letter-spacing:1.85pt;"> </span>misconduct<span style="letter-spacing:1.9pt;"> </span>by<span style="letter-spacing:1.8pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>employees,<span style="letter-spacing:1.9pt;"> </span>clinical<span style="letter-spacing:1.9pt;"> </span>trial<span style="letter-spacing:1.9pt;"> </span>investigators, CROs,<span style="letter-spacing:1.15pt;"> </span>CMOs,<span style="letter-spacing:1.2pt;"> </span>consultants,<span style="letter-spacing:1.3pt;"> </span>vendors<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>any<span style="letter-spacing:1.15pt;"> </span>potential<span style="letter-spacing:1.25pt;"> </span>commercial<span style="letter-spacing:1.3pt;"> </span>partners.<span style="letter-spacing:1.25pt;"> </span>Misconduct<span style="letter-spacing:1.25pt;"> </span>by<span style="letter-spacing:1.15pt;"> </span>these<span style="letter-spacing:1.2pt;"> </span>parties<span style="letter-spacing:1.25pt;"> </span>could include<span style="letter-spacing:0.6pt;"> </span>intentional,<span style="letter-spacing:0.65pt;"> </span>reckless<span style="letter-spacing:0.65pt;"> </span>and/or<span style="letter-spacing:0.6pt;"> </span>negligent<span style="letter-spacing:0.65pt;"> </span>conduct<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>disclosure<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>unauthorized<span style="letter-spacing:0.65pt;"> </span>activities<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>us<span style="letter-spacing:0.5pt;"> </span>that<span style="letter-spacing:0.55pt;"> </span>violates: (i)<span style="letter-spacing:0.1pt;"> </span>FDA regulations<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:0.15pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>authorities,<span style="letter-spacing:0.2pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>laws that<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>the reporting<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>true,<span style="letter-spacing:0.9pt;"> </span>complete<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>accurate<span style="letter-spacing:0.95pt;"> </span>information,<span style="letter-spacing:1pt;"> </span>(ii)<span style="letter-spacing:0.95pt;"> </span>manufacturing<span style="letter-spacing:1pt;"> </span>standards,<span style="letter-spacing:0.95pt;"> </span>(iii)<span style="letter-spacing:0.95pt;"> </span>federal<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>state<span style="letter-spacing:0.9pt;"> </span>health and<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>privacy,<span style="letter-spacing:0.1pt;"> </span>security,<span style="letter-spacing:0.15pt;"> </span>fraud<span style="letter-spacing:0.1pt;"> </span>and abuse,<span style="letter-spacing:0.05pt;"> </span>government<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>reporting,<span style="letter-spacing:0.1pt;"> </span>transparency<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>requirements,<span style="letter-spacing:0.15pt;"> </span>and other healthcare laws and regulations in the United States and abroad, (iv) sexual harassment and other workplace<span style="letter-spacing:0.05pt;"> </span>misconduct,<span style="letter-spacing:0.1pt;"> </span>or (v)<span style="letter-spacing:0.05pt;"> </span>laws that<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>true,<span style="letter-spacing:0.05pt;"> </span>complete<span style="letter-spacing:0.1pt;"> </span>and accurate<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>of financial<span style="letter-spacing:0.1pt;"> </span>information or<span style="letter-spacing:0.05pt;"> </span>data.<span style="letter-spacing:0.1pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>misconduct<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>involve<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>improper<span style="letter-spacing:0.1pt;"> </span>use of information<span style="letter-spacing:0.15pt;"> </span>obtained<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>course<span style="letter-spacing:0.05pt;"> </span>of clinical trials,<span style="letter-spacing:0.1pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in regulatory<span style="letter-spacing:0.1pt;"> </span>sanctions<span style="letter-spacing:0.1pt;"> </span>and cause<span style="letter-spacing:0.05pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>to our reputation.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>adopted<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>code<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.15pt;"> </span>to all<span style="letter-spacing:0.05pt;"> </span>of our employees,<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.05pt;"> </span>as a disclosure<span style="letter-spacing:0.1pt;"> </span>program<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.2pt;"> </span>applicable<span style="letter-spacing:0.25pt;"> </span>policies<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.15pt;"> </span>procedures,<span style="letter-spacing:0.25pt;"> </span>but<span style="letter-spacing:0.15pt;"> </span>it<span style="letter-spacing:0.2pt;"> </span>is<span style="letter-spacing:0.2pt;"> </span>not<span style="letter-spacing:0.15pt;"> </span>always<span style="letter-spacing:0.2pt;"> </span>possible<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>identify<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.15pt;"> </span>deter<span style="letter-spacing:0.2pt;"> </span>employee<span style="letter-spacing:0.2pt;"> </span>misconduct, and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>precautions<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>take<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>detect<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>this<span style="letter-spacing:0.1pt;"> </span>activity<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>effective<span style="letter-spacing:0.15pt;"> </span>in controlling<span style="letter-spacing:0.1pt;"> </span>unknown or unmanaged<span style="letter-spacing:0.1pt;"> </span>risks<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>losses<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>protecting<span style="letter-spacing:0.1pt;"> </span>us from<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:0.1pt;"> </span>investigations<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>or lawsuits stemming<span style="letter-spacing:0.9pt;"> </span>from<span style="letter-spacing:0.85pt;"> </span>a<span style="letter-spacing:0.8pt;"> </span>failure<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>comply<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.8pt;"> </span>these<span style="letter-spacing:0.85pt;"> </span>laws<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>regulations.<span style="letter-spacing:0.85pt;"> </span>If<span style="letter-spacing:0.8pt;"> </span>any<span style="letter-spacing:0.75pt;"> </span>such<span style="letter-spacing:0.75pt;"> </span>actions<span style="letter-spacing:0.8pt;"> </span>are<span style="letter-spacing:0.8pt;"> </span>instituted<span style="letter-spacing:0.85pt;"> </span>against<span style="letter-spacing:0.8pt;"> </span>us, and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>successful<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>defending<span style="letter-spacing:0.1pt;"> </span>ourselves<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>asserting<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>rights,<span style="letter-spacing:0.1pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>a significant impact<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>imposition<span style="letter-spacing:0.1pt;"> </span>of significant<span style="letter-spacing:0.15pt;"> </span>civil,<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:0.1pt;"> </span>and administrative<span style="letter-spacing:0.2pt;"> </span>penalties, damages,<span style="letter-spacing:1.15pt;"> </span>fines,<span style="letter-spacing:1.15pt;"> </span>disgorgement,<span style="letter-spacing:1.2pt;"> </span>imprisonment,<span style="letter-spacing:1.25pt;"> </span>exclusion<span style="letter-spacing:1.15pt;"> </span>from<span style="letter-spacing:1.15pt;"> </span>government<span style="letter-spacing:1.2pt;"> </span>funded<span style="letter-spacing:1.1pt;"> </span>healthcare<span style="letter-spacing:1.15pt;"> </span>programs,<span style="letter-spacing:1.15pt;"> </span>such<span style="letter-spacing:1.05pt;"> </span>as Medicare,<span style="letter-spacing:0.1pt;"> </span>Medicaid<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>healthcare<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.1pt;"> </span>contractual<span style="letter-spacing:0.1pt;"> </span>damages,<span style="letter-spacing:0.05pt;"> </span>reputational<span style="letter-spacing:0.15pt;"> </span>harm, diminished profits<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>earnings,<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>integrity<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>and oversight<span style="letter-spacing:0.1pt;"> </span>obligations,<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>curtailment<span style="letter-spacing:0.15pt;"> </span>or restructuring<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations,<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>adversely<span style="letter-spacing:0.15pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to operate<span style="letter-spacing:0.05pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>and our results<span style="letter-spacing:0.1pt;"> </span>of operations.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.1pt;"> </span>technology<span style="letter-spacing:0.05pt;"> </span>systems,<span style="letter-spacing:0.1pt;"> </span>or those<span style="letter-spacing:0.05pt;"> </span>of our third-party<span style="letter-spacing:0.1pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs, or other<span style="letter-spacing:0.05pt;"> </span>vendors, contractors<span style="letter-spacing:0.1pt;"> </span>or consultants,<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>or suffer<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:0.1pt;"> </span>breaches,<span style="letter-spacing:0.05pt;"> </span>cyber-attacks,<span style="letter-spacing:0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>or leakage<span style="letter-spacing:0.05pt;"> </span>of data and other<span style="letter-spacing:0.05pt;"> </span>disruptions,<span style="letter-spacing:0.05pt;"> </span>which could result<span style="letter-spacing:0.05pt;"> </span>in a material<span style="letter-spacing:0.1pt;"> </span>disruption<span style="letter-spacing:0.05pt;"> </span>of our development<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.05pt;"> </span>compromise sensitive<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.05pt;"> </span>to our business<span style="letter-spacing:0.05pt;"> </span>or prevent<span style="letter-spacing:0.05pt;"> </span>us from<span style="letter-spacing:0.05pt;"> </span>accessing<span style="letter-spacing:0.05pt;"> </span>critical<span style="letter-spacing:0.1pt;"> </span>information,<span style="letter-spacing:0.1pt;"> </span>potentially exposing<span style="letter-spacing:0.05pt;"> </span>us to liability<span style="letter-spacing:0.15pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affecting<span style="letter-spacing:0.1pt;"> </span>our business.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>increasingly<span style="letter-spacing:0.1pt;"> </span>dependent<span style="letter-spacing:0.05pt;"> </span>upon information<span style="letter-spacing:0.15pt;"> </span>technology<span style="letter-spacing:0.05pt;"> </span>systems,<span style="letter-spacing:0.1pt;"> </span>infrastructure<span style="letter-spacing:0.2pt;"> </span>and data<span style="letter-spacing:0.05pt;"> </span>to operate<span style="letter-spacing:0.05pt;"> </span>our business.<span style="letter-spacing:1.15pt;"> </span>In<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>ordinary<span style="letter-spacing:1.1pt;"> </span>course<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>business,<span style="letter-spacing:1.1pt;"> </span>we<span style="letter-spacing:1.05pt;"> </span>collect,<span style="letter-spacing:1.15pt;"> </span>store<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>transmit<span style="letter-spacing:1.15pt;"> </span>confidential<span style="letter-spacing:1.2pt;"> </span>information<span style="letter-spacing:1.2pt;"> </span>(including but<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.1pt;"> </span>to intellectual<span style="letter-spacing:0.15pt;"> </span>property,<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>and personal<span style="letter-spacing:0.05pt;"> </span>information).<span style="letter-spacing:0.15pt;"> </span>It<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>critical that<span style="letter-spacing:0.85pt;"> </span>we<span style="letter-spacing:0.8pt;"> </span>do<span style="letter-spacing:0.8pt;"> </span>so<span style="letter-spacing:0.8pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.8pt;"> </span>secure<span style="letter-spacing:0.85pt;"> </span>manner<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>maintain<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>confidentiality<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>integrity<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>such<span style="letter-spacing:0.75pt;"> </span>confidential<span style="letter-spacing:0.9pt;"> </span>information. We<span style="letter-spacing:1.35pt;"> </span>also<span style="letter-spacing:1.35pt;"> </span>have<span style="letter-spacing:1.3pt;"> </span>outsourced<span style="letter-spacing:1.35pt;"> </span>elements<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:1.3pt;"> </span>our<span style="letter-spacing:1.3pt;"> </span>operations<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:1.3pt;"> </span>third<span style="letter-spacing:1.35pt;"> </span>parties,<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:1.3pt;"> </span>as<span style="letter-spacing:1.3pt;"> </span>a<span style="letter-spacing:1.3pt;"> </span>result<span style="letter-spacing:1.4pt;"> </span>we<span style="letter-spacing:1.3pt;"> </span>manage<span style="letter-spacing:1.35pt;"> </span>a<span style="letter-spacing:1.3pt;"> </span>number<span style="letter-spacing:1.35pt;"> </span>of third-party<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.15pt;"> </span>who have access<span style="letter-spacing:0.05pt;"> </span>to our confidential information.<span style="letter-spacing:0.2pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>internal<span style="letter-spacing:0.15pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>technology<span style="letter-spacing:0.1pt;"> </span>systems<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>infrastructure<span style="letter-spacing:0.2pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>vulnerable<span style="letter-spacing:0.1pt;"> </span>to damage<span style="letter-spacing:0.05pt;"> </span>from natural<span style="letter-spacing:0.15pt;"> </span>disasters,<span style="letter-spacing:0.15pt;"> </span>terrorism,<span style="letter-spacing:0.2pt;"> </span>war,<span style="letter-spacing:0.05pt;"> </span>telecommunication<span style="letter-spacing:0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>electrical<span style="letter-spacing:0.2pt;"> </span>failures.<span style="letter-spacing:0.15pt;"> </span>System<span style="letter-spacing:0.1pt;"> </span>failures<span style="letter-spacing:0.15pt;"> </span>or outages,<span style="letter-spacing:0.05pt;"> </span>including any potential<span style="letter-spacing:0.1pt;"> </span>disruptions<span style="letter-spacing:0.1pt;"> </span>due to significantly<span style="letter-spacing:0.15pt;"> </span>increased<span style="letter-spacing:0.1pt;"> </span>global<span style="letter-spacing:0.05pt;"> </span>demand<span style="letter-spacing:0.05pt;"> </span>on certain<span style="letter-spacing:0.1pt;"> </span>cloud-based<span style="letter-spacing:0.05pt;"> </span>systems<span style="letter-spacing:0.05pt;"> </span>during the COVID-19 pandemic,<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>compromise<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to perform<span style="letter-spacing:0.1pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>functions<span style="letter-spacing:0.1pt;"> </span>in a timely<span style="letter-spacing:0.1pt;"> </span>manner,<span style="letter-spacing:0.05pt;"> </span>which could harm<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>delay<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>reporting.<span style="letter-spacing:0.1pt;"> </span>Such failures<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>materially<span style="letter-spacing:0.15pt;"> </span>adversely affect<span style="letter-spacing:0.1pt;"> </span>our operating<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, given their size and complexity and the increasing amounts<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>confidential<span style="letter-spacing:0.2pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>they<span style="letter-spacing:0.1pt;"> </span>maintain,<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>internal<span style="letter-spacing:0.15pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>technology<span style="letter-spacing:0.1pt;"> </span>systems<span style="letter-spacing:0.15pt;"> </span>and those<span style="letter-spacing:0.05pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>potentially<span style="letter-spacing:0.15pt;"> </span>vulnerable<span style="letter-spacing:0.15pt;"> </span>to breakdown<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>damage<span style="letter-spacing:0.05pt;"> </span>or interruption<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>service<span style="letter-spacing:0.1pt;"> </span>interruptions,<span style="letter-spacing:0.15pt;"> </span>system<span style="letter-spacing:0.05pt;"> </span>malfunction,<span style="letter-spacing:0.1pt;"> </span>accidents<span style="letter-spacing:0.1pt;"> </span>by our employees<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>service<span style="letter-spacing:0.15pt;"> </span>providers,<span style="letter-spacing:0.15pt;"> </span>natural<span style="letter-spacing:0.1pt;"> </span>disasters,<span style="letter-spacing:0.1pt;"> </span>terrorism,<span style="letter-spacing:0.15pt;"> </span>war and telecommunication<span style="letter-spacing:0.2pt;"> </span>and electrical failures,<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as security<span style="letter-spacing:0.1pt;"> </span>breaches<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>inadvertent<span style="letter-spacing:0.1pt;"> </span>or intentional<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>by our employees,<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>CROs, CMOs, vendors,<span style="letter-spacing:0.05pt;"> </span>contractors,<span style="letter-spacing:0.1pt;"> </span>consultants,<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>partners<span style="letter-spacing:0.1pt;"> </span>and/or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>or from cyber-attacks<span style="letter-spacing:0.1pt;"> </span>by malicious<span style="letter-spacing:0.15pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>(including<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>deployment<span style="letter-spacing:0.1pt;"> </span>of harmful<span style="letter-spacing:0.1pt;"> </span>malware,<span style="letter-spacing:0.05pt;"> </span>ransomware,<span style="letter-spacing:0.1pt;"> </span>denial-of-service<span style="letter-spacing:0.2pt;"> </span>attacks, social<span style="letter-spacing:0.05pt;"> </span>engineering<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>means<span style="letter-spacing:0.05pt;"> </span>to affect<span style="letter-spacing:0.1pt;"> </span>service<span style="letter-spacing:0.1pt;"> </span>reliability<span style="letter-spacing:0.15pt;"> </span>and threaten<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>confidentiality,<span style="letter-spacing:0.15pt;"> </span>integrity<span style="letter-spacing:0.1pt;"> </span>and availability<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>information),<span style="letter-spacing:0.2pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>compromise<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>system<span style="letter-spacing:0.1pt;"> </span>infrastructure,<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our third-party<span style="letter-spacing:0.15pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants,<span style="letter-spacing:0.15pt;"> </span>or lead<span style="letter-spacing:0.05pt;"> </span>to data<span style="letter-spacing:0.05pt;"> </span>leakage.<span style="letter-spacing:0.05pt;"> </span>The risk<span style="letter-spacing:0.05pt;"> </span>of a security<span style="letter-spacing:0.1pt;"> </span>breach<span style="letter-spacing:0.05pt;"> </span>or disruption,<span style="letter-spacing:0.15pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>through<span style="letter-spacing:0.05pt;"> </span>cyber-attacks<span style="letter-spacing:0.15pt;"> </span>or cyber<span style="letter-spacing:0.05pt;"> </span>intrusion,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>by computer<span style="letter-spacing:0.1pt;"> </span>hackers,<span style="letter-spacing:0.05pt;"> </span>foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted<span style="letter-spacing:0.15pt;"> </span>attacks<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>intrusions<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>around<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>world<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>increased.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>generally increasing<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>attack<span style="letter-spacing:0.1pt;"> </span>surface<span style="letter-spacing:0.15pt;"> </span>available<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>exploitation,<span style="letter-spacing:0.1pt;"> </span>as more<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>and individuals<span style="letter-spacing:0.1pt;"> </span>work online<span style="letter-spacing:0.05pt;"> </span>and work remotely,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>such,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>cybersecurity<span style="letter-spacing:0.2pt;"> </span>incident<span style="letter-spacing:0.15pt;"> </span>potentially<span style="letter-spacing:0.15pt;"> </span>occurring,<span style="letter-spacing:0.1pt;"> </span>and our investment<span style="letter-spacing:0.1pt;"> </span>in risk mitigations<span style="letter-spacing:0.2pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>incident,<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>increasing.<span style="letter-spacing:0.15pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:0.1pt;"> </span>there<span style="letter-spacing:0.1pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>been<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>in phishing<span style="letter-spacing:0.05pt;"> </span>and spam emails<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>well<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>social<span style="letter-spacing:0.15pt;"> </span>engineering<span style="letter-spacing:0.2pt;"> </span>attempts<span style="letter-spacing:0.2pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>&#8220;hackers&#8221;<span style="letter-spacing:0.15pt;"> </span>hoping<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>COVID-19 pandemic<span style="letter-spacing:0.1pt;"> </span>to their<span style="letter-spacing:0.1pt;"> </span>advantage.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>anticipate<span style="letter-spacing:0.15pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>types<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:0.15pt;"> </span>threats,<span style="letter-spacing:0.15pt;"> </span>nor<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to implement preventive<span style="letter-spacing:0.15pt;"> </span>measures<span style="letter-spacing:0.15pt;"> </span>effective<span style="letter-spacing:0.15pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:0.15pt;"> </span>threats.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>techniques<span style="letter-spacing:0.15pt;"> </span>used by cyber<span style="letter-spacing:0.05pt;"> </span>criminals<span style="letter-spacing:0.15pt;"> </span>change frequently,<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>recognized<span style="letter-spacing:0.15pt;"> </span>until<span style="letter-spacing:0.1pt;"> </span>launched<span style="letter-spacing:0.05pt;"> </span>and can originate<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>a wide variety<span style="letter-spacing:0.1pt;"> </span>of sources,<span style="letter-spacing:0.05pt;"> </span>including outside<span style="letter-spacing:1.5pt;"> </span>groups<span style="letter-spacing:1.5pt;"> </span>such<span style="letter-spacing:1.45pt;"> </span>as<span style="letter-spacing:1.45pt;"> </span>external<span style="letter-spacing:1.55pt;"> </span>service<span style="letter-spacing:1.55pt;"> </span>providers,<span style="letter-spacing:1.55pt;"> </span>organized<span style="letter-spacing:1.5pt;"> </span>crime<span style="letter-spacing:1.55pt;"> </span>affiliates,<span style="letter-spacing:1.55pt;"> </span>terrorist<span style="letter-spacing:1.55pt;"> </span>organizations<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>hostile foreign<span style="letter-spacing:0.55pt;"> </span>governments<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>agencies.<span style="letter-spacing:0.55pt;"> </span>To<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>extent<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:0.55pt;"> </span>any<span style="letter-spacing:0.5pt;"> </span>disruption<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>security<span style="letter-spacing:0.6pt;"> </span>breach<span style="letter-spacing:0.55pt;"> </span>were<span style="letter-spacing:0.5pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>result<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>loss<span style="letter-spacing:0.5pt;"> </span>of, or<span style="letter-spacing:0.8pt;"> </span>damage<span style="letter-spacing:0.85pt;"> </span>to,<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>data<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>applications,<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>those<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>third-party<span style="letter-spacing:0.9pt;"> </span>CROs,<span style="letter-spacing:0.7pt;"> </span>CMOs,<span style="letter-spacing:0.75pt;"> </span>vendors<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.75pt;"> </span>other<span style="letter-spacing:0.8pt;"> </span>contractors and<span style="letter-spacing:1.1pt;"> </span>consultants,<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>inappropriate<span style="letter-spacing:1.25pt;"> </span>disclosure<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>confidential<span style="letter-spacing:1.25pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>proprietary<span style="letter-spacing:1.2pt;"> </span>information,<span style="letter-spacing:1.25pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>could<span style="letter-spacing:1.15pt;"> </span>incur<span style="letter-spacing:1.1pt;"> </span>liability and<span style="letter-spacing:0.1pt;"> </span>reputational<span style="letter-spacing:0.25pt;"> </span>damage<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>further<span style="letter-spacing:0.15pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>commercialization<span style="letter-spacing:0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or any<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be delayed.<span style="letter-spacing:0.05pt;"> </span>Any breach,<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>or compromise<span style="letter-spacing:0.1pt;"> </span>of clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>participant personal<span style="letter-spacing:0.95pt;"> </span>data<span style="letter-spacing:0.95pt;"> </span>may<span style="letter-spacing:0.95pt;"> </span>also<span style="letter-spacing:0.95pt;"> </span>subject<span style="letter-spacing:0.95pt;"> </span>us<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.9pt;"> </span>civil<span style="letter-spacing:0.95pt;"> </span>fines<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>penalties,<span style="letter-spacing:1pt;"> </span>including<span style="letter-spacing:0.9pt;"> </span>under<span style="letter-spacing:0.9pt;"> </span>HIPAA,<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.9pt;"> </span>relevant<span style="letter-spacing:0.95pt;"> </span>state and<span style="letter-spacing:1.2pt;"> </span>federal<span style="letter-spacing:1.3pt;"> </span>privacy<span style="letter-spacing:1.25pt;"> </span>laws<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>United<span style="letter-spacing:1.25pt;"> </span>States.<span style="letter-spacing:1.25pt;"> </span>The<span style="letter-spacing:1.15pt;"> </span>costs<span style="letter-spacing:1.2pt;"> </span>related<span style="letter-spacing:1.25pt;"> </span>to<span style="letter-spacing:1.15pt;"> </span>significant<span style="letter-spacing:1.3pt;"> </span>security<span style="letter-spacing:1.25pt;"> </span>breaches<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.15pt;"> </span>disruptions could<span style="letter-spacing:0.05pt;"> </span>be material<span style="letter-spacing:0.15pt;"> </span>and exceed<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>limits<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>cybersecurity<span style="letter-spacing:0.15pt;"> </span>insurance<span style="letter-spacing:0.1pt;"> </span>we maintain<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>such risks.<span style="letter-spacing:0.05pt;"> </span>If the information<span style="letter-spacing:0.2pt;"> </span>technology<span style="letter-spacing:0.1pt;"> </span>systems<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and consultants become<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to disruptions<span style="letter-spacing:0.1pt;"> </span>or security<span style="letter-spacing:0.1pt;"> </span>breaches,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>have insufficient<span style="letter-spacing:0.15pt;"> </span>recourse<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>such third<span style="letter-spacing:0.05pt;"> </span>parties and<span style="letter-spacing:1.1pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>may<span style="letter-spacing:1.15pt;"> </span>have<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>expend<span style="letter-spacing:1.1pt;"> </span>significant<span style="letter-spacing:1.25pt;"> </span>resources<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>mitigate<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>impact<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>such<span style="letter-spacing:1.05pt;"> </span>an<span style="letter-spacing:1.05pt;"> </span>event,<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>develop<span style="letter-spacing:1.1pt;"> </span>and implement<span style="letter-spacing:0.1pt;"> </span>protections<span style="letter-spacing:0.1pt;"> </span>to prevent<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>events<span style="letter-spacing:0.05pt;"> </span>of this<span style="letter-spacing:0.05pt;"> </span>nature<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>occurring.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>experienced<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>system<span style="letter-spacing:0.1pt;"> </span>failure,<span style="letter-spacing:0.15pt;"> </span>accident<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:0.1pt;"> </span>breach<span style="letter-spacing:0.05pt;"> </span>to date,<span style="letter-spacing:0.05pt;"> </span>and believe<span style="letter-spacing:0.05pt;"> </span>that our<span style="letter-spacing:0.55pt;"> </span>data<span style="letter-spacing:0.6pt;"> </span>protection<span style="letter-spacing:0.65pt;"> </span>efforts<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.5pt;"> </span>our<span style="letter-spacing:0.5pt;"> </span>investment<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>information<span style="letter-spacing:0.65pt;"> </span>technology<span style="letter-spacing:0.55pt;"> </span>reduce<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>likelihood<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>such<span style="letter-spacing:0.5pt;"> </span>incidents in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future,<span style="letter-spacing:0.05pt;"> </span>we cannot<span style="letter-spacing:0.05pt;"> </span>assure<span style="letter-spacing:0.05pt;"> </span>you that<span style="letter-spacing:0.05pt;"> </span>our data<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>efforts<span style="letter-spacing:0.1pt;"> </span>and our investment<span style="letter-spacing:0.1pt;"> </span>in information<span style="letter-spacing:0.15pt;"> </span>technology will<span style="letter-spacing:0.1pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>breakdowns,<span style="letter-spacing:0.1pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>leakages,<span style="letter-spacing:0.05pt;"> </span>breaches<span style="letter-spacing:0.05pt;"> </span>in our systems,<span style="letter-spacing:0.1pt;"> </span>or those<span style="letter-spacing:0.05pt;"> </span>of our third-party<span style="letter-spacing:0.15pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractors<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants,<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>cyber<span style="letter-spacing:0.05pt;"> </span>incidents<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse effect<span style="letter-spacing:1.45pt;"> </span>upon<span style="letter-spacing:1.35pt;"> </span>our<span style="letter-spacing:1.35pt;"> </span>reputation,<span style="letter-spacing:1.45pt;"> </span>business,<span style="letter-spacing:1.4pt;"> </span>operations<span style="letter-spacing:1.45pt;"> </span>or<span style="letter-spacing:1.35pt;"> </span>financial<span style="letter-spacing:1.45pt;"> </span>condition.<span style="letter-spacing:1.4pt;"> </span>For<span style="letter-spacing:1.35pt;"> </span>example,<span style="letter-spacing:1.4pt;"> </span>if<span style="letter-spacing:1.4pt;"> </span>such<span style="letter-spacing:1.3pt;"> </span>an<span style="letter-spacing:1.3pt;"> </span>event<span style="letter-spacing:1.35pt;"> </span>were<span style="letter-spacing:1.3pt;"> </span>to occur<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>cause<span style="letter-spacing:0.15pt;"> </span>interruptions<span style="letter-spacing:0.25pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>operations,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other contractors<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants,<span style="letter-spacing:0.15pt;"> </span>it<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in a material<span style="letter-spacing:0.15pt;"> </span>disruption<span style="letter-spacing:0.1pt;"> </span>of our programs<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>of our product<span style="letter-spacing:0.15pt;"> </span>candidates<span style="letter-spacing:0.2pt;"> </span>could<span style="letter-spacing:0.15pt;"> </span>be<span style="letter-spacing:0.1pt;"> </span>delayed.<span style="letter-spacing:0.15pt;"> </span>In<span style="letter-spacing:0.1pt;"> </span>addition,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>loss<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trial<span style="letter-spacing:0.15pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>PRT543, PRT811, PRT1419, PRT2527 or any<span style="letter-spacing:0.85pt;"> </span>other<span style="letter-spacing:0.9pt;"> </span>product<span style="letter-spacing:0.85pt;"> </span>candidates<span style="letter-spacing:0.9pt;"> </span>could<span style="letter-spacing:0.85pt;"> </span>result<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>delays<span style="letter-spacing:0.85pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.8pt;"> </span>marketing<span style="letter-spacing:0.9pt;"> </span>approval<span style="letter-spacing:0.85pt;"> </span>efforts<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>significantly<span style="letter-spacing:0.95pt;"> </span>increase our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>recover<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>reproduce<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>data.<span style="letter-spacing:0.1pt;"> </span>Furthermore,<span style="letter-spacing:0.15pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>disruptions<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our internal<span style="letter-spacing:0.1pt;"> </span>information technology<span style="letter-spacing:0.1pt;"> </span>systems<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs,<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractors</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and consultants,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or security</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breaches</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss,</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misappropriation</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unauthorized</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access,</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use,</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosure</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of,</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevention</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidential</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(including</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trade</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">secrets</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property, proprietary</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information),</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in financial,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and reputational</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to us. For example,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any such event</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">leads</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to unauthorized</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use, or disclosure</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of personal</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information,</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjects</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or employees,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could harm</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reputation</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directly,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compel</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notification</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws and foreign law</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalents,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to mandatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corrective</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and otherwise</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us to liability</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws and regulations</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protect</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">privacy</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information,</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal and financial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exposure</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and reputational</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have an adverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our business.</span></p>
<p style="margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure<span style="letter-spacing:0.05pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with health<span style="letter-spacing:0.05pt;"> </span>and data protection<span style="letter-spacing:0.1pt;"> </span>laws and regulations<span style="letter-spacing:0.05pt;"> </span>could lead<span style="letter-spacing:0.05pt;"> </span>to government enforcement<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>(which could include<span style="letter-spacing:0.05pt;"> </span>civil<span style="letter-spacing:0.1pt;"> </span>or criminal<span style="letter-spacing:0.1pt;"> </span>penalties),<span style="letter-spacing:0.1pt;"> </span>private<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:0.1pt;"> </span>and/or adverse publicity<span style="letter-spacing:0.1pt;"> </span>and could negatively<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our operating<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.05pt;"> </span>and business.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.15pt;"> </span>collaborators<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>federal,<span style="letter-spacing:0.15pt;"> </span>state<span style="letter-spacing:0.1pt;"> </span>and foreign<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>laws and regulations<span style="letter-spacing:0.15pt;"> </span>(i.e.,<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>address<span style="letter-spacing:0.1pt;"> </span>privacy<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>security).<span style="letter-spacing:0.15pt;"> </span>In the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>numerous federal<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:0.05pt;"> </span>laws and regulations,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>privacy<span style="letter-spacing:0.05pt;"> </span>laws, state<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>breach notification<span style="letter-spacing:0.2pt;"> </span>laws,<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:0.1pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>privacy<span style="letter-spacing:0.05pt;"> </span>laws and federal<span style="letter-spacing:0.1pt;"> </span>and state<span style="letter-spacing:0.05pt;"> </span>consumer<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>laws (e.g., Section<span style="letter-spacing:1.25pt;"> </span>5<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>Federal<span style="letter-spacing:1.25pt;"> </span>Trade<span style="letter-spacing:1.25pt;"> </span>Commission<span style="letter-spacing:1.3pt;"> </span>Act),<span style="letter-spacing:1.25pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>govern<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>collection,<span style="letter-spacing:1.25pt;"> </span>use,<span style="letter-spacing:1.15pt;"> </span>disclosure<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>protection<span style="letter-spacing:1.25pt;"> </span>of health-related<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>personal<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>apply<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our collaborators. In addition,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.05pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>(including<span style="letter-spacing:0.1pt;"> </span>research<span style="letter-spacing:0.1pt;"> </span>institutions<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>which we obtain<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.2pt;"> </span>trial<span style="letter-spacing:0.2pt;"> </span>data)<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.15pt;"> </span>subject<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>privacy<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:0.15pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>under<span style="letter-spacing:0.1pt;"> </span>HIPAA, as<span style="letter-spacing:0.05pt;"> </span>amended<span style="letter-spacing:0.1pt;"> </span>by HITECH. Depending<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>facts<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>circumstances,<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:0.15pt;"> </span>penalties<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>knowingly obtain,<span style="letter-spacing:0.1pt;"> </span>use,<span style="letter-spacing:0.05pt;"> </span>or disclose<span style="letter-spacing:0.1pt;"> </span>individually<span style="letter-spacing:0.1pt;"> </span>identifiable<span style="letter-spacing:0.15pt;"> </span>health<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>maintained<span style="letter-spacing:0.1pt;"> </span>by a HIPAA-covered entity<span style="letter-spacing:0.05pt;"> </span>in a manner<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>not authorized<span style="letter-spacing:0.1pt;"> </span>or permitted<span style="letter-spacing:0.1pt;"> </span>by HIPAA.</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May 25, 2018. The GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliant companies of up to the greater of &#8364;20 million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection, use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes restrictions on cross-border data transfer. The GDPR will increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. In addition, the GDPR prohibits the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to pending legal challenges that, if successful, could invalidate these mechanisms, restrict our ability to process personal data of Europeans outside of Europe and adversely impact our business. For example, in July 2020, the European Courts of Justice invalidated the EU-U.S. Privacy Shield, which enabled the transfer of personal data from EU to the U.S. for companies that had self-certified to the Privacy Shield. On August 10, 2020, the U.S. Department of Commerce and the European Commission announced new discussions to evaluate the potential for an enhanced EU-U.S. Privacy Shield framework to comply with the July 16 judgment of the Court of Justice. While the Court of Justice upheld the use of other data transfer mechanisms, such as the Binding Corporate Rules, the decision has led to some uncertainty regarding the use of such mechanisms for data transfers to the United States, and the court made clear that reliance on Binding Corporate Rules alone may not necessarily be sufficient in all circumstances. Use of the data transfer mechanisms must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals. The European Data Protection Board issued additional guidance regarding the Court of Justice&#8217;s decision on November 11, 2020 which imposes higher burdens on the use of data transfer mechanisms, such as the Binding Corporate Rules, for cross-border data transfers. To comply with this guidance, we may need to implement additional safeguards to further enhance the security of data transferred out of the European Economic Area, which could increase our compliance costs, expose us to further regulatory scrutiny and liability, and adversely affect our business. To the extent that we were to rely on Privacy Shield, we will not be able to do so in the future, which could increase our costs and our ability to efficiently process personal data from the EU.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, Brexit has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, while the Data Protection Act of 2018, that &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. Beginning in 2021, the United Kingdom became a &#8220;third country&#8221; under the GDPR. We may, however, incur liabilities, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operational losses</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GDPR and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU Member</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kingdom privacy</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws in connection</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with any measures</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we take</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to comply</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with them.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.1pt;"> </span>addition,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>state<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>California<span style="letter-spacing:0.2pt;"> </span>recently<span style="letter-spacing:0.15pt;"> </span>enacted<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>California<span style="letter-spacing:0.15pt;"> </span>Consumer<span style="letter-spacing:0.1pt;"> </span>Privacy<span style="letter-spacing:0.1pt;"> </span>Act,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>CCPA, which creates<span style="letter-spacing:1.25pt;"> </span>new<span style="letter-spacing:1.15pt;"> </span>individual<span style="letter-spacing:1.25pt;"> </span>privacy<span style="letter-spacing:1.2pt;"> </span>rights<span style="letter-spacing:1.15pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>California<span style="letter-spacing:1.2pt;"> </span>consumers<span style="letter-spacing:1.2pt;"> </span>(as<span style="letter-spacing:1.15pt;"> </span>defined<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>CCPA)<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>places<span style="letter-spacing:1.15pt;"> </span>increased privacy<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:1.85pt;"> </span>security<span style="letter-spacing:1.95pt;"> </span>obligations<span style="letter-spacing:1.95pt;"> </span>on<span style="letter-spacing:1.85pt;"> </span>entities<span style="letter-spacing:1.95pt;"> </span>handling<span style="letter-spacing:1.9pt;"> </span>certain<span style="letter-spacing:1.9pt;"> </span>personal<span style="letter-spacing:1.85pt;"> </span>data<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>consumers<span style="letter-spacing:1.9pt;"> </span>or<span style="letter-spacing:1.8pt;"> </span>households.<span style="letter-spacing:1.85pt;"> </span>The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection,<span style="letter-spacing:0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>sharing<span style="letter-spacing:0.1pt;"> </span>practices,<span style="letter-spacing:0.15pt;"> </span>provide<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>consumers<span style="letter-spacing:0.15pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>ways to opt-out<span style="letter-spacing:0.05pt;"> </span>of certain<span style="letter-spacing:0.1pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>or transfers<span style="letter-spacing:0.1pt;"> </span>of personal<span style="letter-spacing:1.25pt;"> </span>information,<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>provide<span style="letter-spacing:1.25pt;"> </span>consumers<span style="letter-spacing:1.3pt;"> </span>with<span style="letter-spacing:1.2pt;"> </span>additional<span style="letter-spacing:1.3pt;"> </span>causes<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>action.<span style="letter-spacing:1.25pt;"> </span>The<span style="letter-spacing:1.2pt;"> </span>CCPA<span style="letter-spacing:1.15pt;"> </span>went<span style="letter-spacing:1.2pt;"> </span>into<span style="letter-spacing:1.2pt;"> </span>effect<span style="letter-spacing:1.25pt;"> </span>on January<span style="letter-spacing:0.1pt;"> </span>1,<span style="letter-spacing:0.05pt;"> </span>2020<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>became<span style="letter-spacing:0.1pt;"> </span>enforceable<span style="letter-spacing:0.15pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>California<span style="letter-spacing:0.1pt;"> </span>Attorney<span style="letter-spacing:0.05pt;"> </span>General<span style="letter-spacing:0.05pt;"> </span>on July<span style="letter-spacing:0.05pt;"> </span>1, 2020, along<span style="letter-spacing:0.05pt;"> </span>with related regulations<span style="letter-spacing:1.05pt;"> </span>which<span style="letter-spacing:0.9pt;"> </span>came<span style="letter-spacing:0.95pt;"> </span>into<span style="letter-spacing:0.95pt;"> </span>force<span style="letter-spacing:0.95pt;"> </span>on<span style="letter-spacing:0.9pt;"> </span>August<span style="letter-spacing:0.9pt;"> </span>14,<span style="letter-spacing:0.9pt;"> </span>2020<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>may<span style="letter-spacing:0.95pt;"> </span>impact<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:0.9pt;"> </span>business<span style="letter-spacing:0.95pt;"> </span>activities<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>exemplifies the<span style="letter-spacing:0.1pt;"> </span>vulnerability<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>evolving<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>environment<span style="letter-spacing:0.15pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:0.1pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>and protected health<span style="letter-spacing:0.05pt;"> </span>information.<span style="letter-spacing:0.15pt;"> </span>Additionally,<span style="letter-spacing:0.1pt;"> </span>although<span style="letter-spacing:0.05pt;"> </span>not effective<span style="letter-spacing:0.1pt;"> </span>until<span style="letter-spacing:0.05pt;"> </span>January<span style="letter-spacing:0.05pt;"> </span>1, 2023, the<span style="letter-spacing:0.05pt;"> </span>California<span style="letter-spacing:0.1pt;"> </span>Privacy Rights Act (the<span style="letter-spacing:0.1pt;"> </span>&#8220;CPRA&#8221;), which<span style="letter-spacing:0.05pt;"> </span>expands<span style="letter-spacing:0.1pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>CCPA, was<span style="letter-spacing:0.05pt;"> </span>passed<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>election<span style="letter-spacing:0.1pt;"> </span>on November<span style="letter-spacing:0.05pt;"> </span>3, 2020. The CCPA gives<span style="letter-spacing:0.1pt;"> </span>(and<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>CPRA will<span style="letter-spacing:0.1pt;"> </span>give)<span style="letter-spacing:0.1pt;"> </span>California<span style="letter-spacing:0.15pt;"> </span>residents<span style="letter-spacing:0.15pt;"> </span>expanded<span style="letter-spacing:0.1pt;"> </span>privacy<span style="letter-spacing:0.1pt;"> </span>rights,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:0.05pt;"> </span>to request correction,<span style="letter-spacing:0.15pt;"> </span>access,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>deletion<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>personal<span style="letter-spacing:0.05pt;"> </span>information,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:0.05pt;"> </span>to opt out of certain<span style="letter-spacing:0.1pt;"> </span>personal<span style="letter-spacing:0.05pt;"> </span>information sharing,<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:0.05pt;"> </span>to receive<span style="letter-spacing:0.1pt;"> </span>detailed<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>about<span style="letter-spacing:0.05pt;"> </span>how their<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:0.1pt;"> </span>is processed. The CCPA and<span style="letter-spacing:0.05pt;"> </span>CPRA provide<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>unlimited<span style="letter-spacing:0.15pt;"> </span>civil<span style="letter-spacing:0.1pt;"> </span>penalties<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>violations,<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:0.15pt;"> </span>right<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>action<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>data breaches<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>expected<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>breach<span style="letter-spacing:0.1pt;"> </span>litigation.<span style="letter-spacing:0.2pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>CCPA and<span style="letter-spacing:0.05pt;"> </span>CPRA may<span style="letter-spacing:0.1pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>compliance costs<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>potential<span style="letter-spacing:0.2pt;"> </span>liability,<span style="letter-spacing:0.25pt;"> </span>particularly<span style="letter-spacing:0.25pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>event<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>breach.<span style="letter-spacing:0.1pt;"> </span>Additionally,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>CCPA has<span style="letter-spacing:0.05pt;"> </span>prompted<span style="letter-spacing:0.1pt;"> </span>a number<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>proposals<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>U.S. for<span style="letter-spacing:0.1pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>state-level<span style="letter-spacing:0.2pt;"> </span>privacy<span style="letter-spacing:0.1pt;"> </span>legislation<span style="letter-spacing:0.2pt;"> </span>that,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>passed,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>increase our potential<span style="letter-spacing:0.1pt;"> </span>liability,<span style="letter-spacing:0.15pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>our compliance<span style="letter-spacing:0.1pt;"> </span>costs,<span style="letter-spacing:0.05pt;"> </span>and adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our business. Other states are also seeking to regulate consumer privacy stringently, and both Virginia and Colorado signed comprehensive privacy legislation in 2021. These laws (the Virginia Consumer Data Protection Act and the Colorado Privacy Act) are set to come into force in 2023 and a number of other state legislatures are actively considering passing similar consumer privacy laws, including those in New York and Washington.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance<span style="letter-spacing:1.45pt;"> </span>with<span style="letter-spacing:1.4pt;"> </span>U.S.<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.4pt;"> </span>international<span style="letter-spacing:1.55pt;"> </span>data<span style="letter-spacing:1.45pt;"> </span>protection<span style="letter-spacing:1.5pt;"> </span>laws<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:1.35pt;"> </span>regulations<span style="letter-spacing:1.45pt;"> </span>could<span style="letter-spacing:1.4pt;"> </span>require<span style="letter-spacing:1.45pt;"> </span>us<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>take<span style="letter-spacing:1.4pt;"> </span>on more<span style="letter-spacing:0.1pt;"> </span>onerous<span style="letter-spacing:0.1pt;"> </span>obligations<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>our contracts,<span style="letter-spacing:0.1pt;"> </span>restrict<span style="letter-spacing:0.15pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to collect,<span style="letter-spacing:0.1pt;"> </span>use and disclose<span style="letter-spacing:0.1pt;"> </span>data,<span style="letter-spacing:0.05pt;"> </span>or in some<span style="letter-spacing:0.05pt;"> </span>cases, impact<span style="letter-spacing:0.2pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>operate<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>jurisdictions.<span style="letter-spacing:0.2pt;"> </span>Failure<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>U.S. and<span style="letter-spacing:0.05pt;"> </span>international<span style="letter-spacing:0.2pt;"> </span>data<span style="letter-spacing:0.1pt;"> </span>protection laws and regulations<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in government<span style="letter-spacing:0.1pt;"> </span>enforcement<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>(which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>civil,<span style="letter-spacing:0.05pt;"> </span>criminal,<span style="letter-spacing:0.05pt;"> </span>and administrative<span style="letter-spacing:0.25pt;"> </span>penalties),<span style="letter-spacing:0.1pt;"> </span>private<span style="letter-spacing:0.1pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>and/or<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>publicity<span style="letter-spacing:0.1pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>negatively<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our operating results<span style="letter-spacing:0.1pt;"> </span>and business.<span style="letter-spacing:0.05pt;"> </span>Moreover,<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trial<span style="letter-spacing:0.1pt;"> </span>subjects<span style="letter-spacing:0.1pt;"> </span>about<span style="letter-spacing:0.05pt;"> </span>whom we or our potential<span style="letter-spacing:0.1pt;"> </span>collaborators<span style="letter-spacing:0.1pt;"> </span>obtain information,<span style="letter-spacing:1.05pt;"> </span>as<span style="letter-spacing:0.9pt;"> </span>well<span style="letter-spacing:0.95pt;"> </span>as<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>providers<span style="letter-spacing:1pt;"> </span>who<span style="letter-spacing:0.9pt;"> </span>share<span style="letter-spacing:0.9pt;"> </span>this<span style="letter-spacing:0.9pt;"> </span>information<span style="letter-spacing:1pt;"> </span>with<span style="letter-spacing:0.85pt;"> </span>us,<span style="letter-spacing:0.85pt;"> </span>may<span style="letter-spacing:0.9pt;"> </span>contractually<span style="letter-spacing:1pt;"> </span>limit<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:0.85pt;"> </span>ability<span style="letter-spacing:0.95pt;"> </span>to use<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>disclose<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>information.<span style="letter-spacing:0.15pt;"> </span>Claims<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we have violated<span style="letter-spacing:0.1pt;"> </span>individuals&#8217;<span style="letter-spacing:0.1pt;"> </span>privacy<span style="letter-spacing:0.05pt;"> </span>rights,<span style="letter-spacing:0.05pt;"> </span>failed<span style="letter-spacing:0.1pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with data<span style="letter-spacing:0.1pt;"> </span>protection<span style="letter-spacing:0.15pt;"> </span>laws,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>breached<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>contractual<span style="letter-spacing:0.15pt;"> </span>obligations,<span style="letter-spacing:0.15pt;"> </span>even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>liable,<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be expensive and time<span style="letter-spacing:0.05pt;"> </span>consuming<span style="letter-spacing:0.05pt;"> </span>to defend<span style="letter-spacing:0.05pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in adverse<span style="letter-spacing:0.05pt;"> </span>publicity<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We or the third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>upon whom we depend may<span style="letter-spacing:0.05pt;"> </span>be adversely<span style="letter-spacing:0.1pt;"> </span>affected<span style="letter-spacing:0.1pt;"> </span>by natural<span style="letter-spacing:0.05pt;"> </span>disasters<span style="letter-spacing:0.1pt;"> </span>and our business<span style="letter-spacing:0.05pt;"> </span>continuity<span style="letter-spacing:0.05pt;"> </span>and disaster<span style="letter-spacing:0.1pt;"> </span>recovery<span style="letter-spacing:0.05pt;"> </span>plans may<span style="letter-spacing:0.05pt;"> </span>not adequately<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:0.05pt;"> </span>us from<span style="letter-spacing:0.05pt;"> </span>a serious<span style="letter-spacing:0.05pt;"> </span>disaster.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>located<span style="letter-spacing:0.05pt;"> </span>in Delaware.<span style="letter-spacing:0.05pt;"> </span>Any unplanned<span style="letter-spacing:0.05pt;"> </span>event,<span style="letter-spacing:0.05pt;"> </span>such as flood,<span style="letter-spacing:0.05pt;"> </span>fire,<span style="letter-spacing:0.05pt;"> </span>explosion,<span style="letter-spacing:0.05pt;"> </span>earthquake, extreme<span style="letter-spacing:0.2pt;"> </span>weather<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.15pt;"> </span>medical<span style="letter-spacing:0.2pt;"> </span>epidemic,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>COVID-19 pandemic,<span style="letter-spacing:0.1pt;"> </span>power<span style="letter-spacing:0.05pt;"> </span>shortage, telecommunication<span style="letter-spacing:1.25pt;"> </span>failure<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>other<span style="letter-spacing:1.1pt;"> </span>natural<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>manmade<span style="letter-spacing:1.05pt;"> </span>accidents<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>incidents<span style="letter-spacing:1.1pt;"> </span>that<span style="letter-spacing:1.05pt;"> </span>result<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1pt;"> </span>us<span style="letter-spacing:1pt;"> </span>being<span style="letter-spacing:1.05pt;"> </span>unable<span style="letter-spacing:1.05pt;"> </span>to fully<span style="letter-spacing:0.1pt;"> </span>utilize<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>facilities,<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>manufacturing<span style="letter-spacing:0.2pt;"> </span>facilities<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.2pt;"> </span>CMOs, may<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>and adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our ability<span style="letter-spacing:0.1pt;"> </span>to operate<span style="letter-spacing:0.05pt;"> </span>our business,<span style="letter-spacing:0.05pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>on a daily<span style="letter-spacing:0.05pt;"> </span>basis,<span style="letter-spacing:0.05pt;"> </span>and have significant<span style="letter-spacing:0.1pt;"> </span>negative consequences<span style="letter-spacing:0.1pt;"> </span>on our financial<span style="letter-spacing:0.1pt;"> </span>and operating<span style="letter-spacing:0.1pt;"> </span>conditions.<span style="letter-spacing:0.1pt;"> </span>For example,<span style="letter-spacing:0.05pt;"> </span>our operations<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>concentrated<span style="letter-spacing:0.1pt;"> </span>primarily on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>east<span style="letter-spacing:0.1pt;"> </span>coast<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>weather<span style="letter-spacing:0.1pt;"> </span>event<span style="letter-spacing:0.1pt;"> </span>or natural<span style="letter-spacing:0.1pt;"> </span>disaster,<span style="letter-spacing:0.1pt;"> </span>such as a hurricane<span style="letter-spacing:0.1pt;"> </span>or heavy<span style="letter-spacing:2pt;"> </span>snowstorm,<span style="letter-spacing:2.05pt;"> </span>could<span style="letter-spacing:2.05pt;"> </span>have<span style="letter-spacing:2pt;"> </span>a<span style="letter-spacing:2pt;"> </span>material<span style="letter-spacing:2.15pt;"> </span>adverse<span style="letter-spacing:2.05pt;"> </span>effect<span style="letter-spacing:2.1pt;"> </span>on<span style="letter-spacing:2pt;"> </span>a<span style="letter-spacing:2pt;"> </span>substantial<span style="letter-spacing:2.1pt;"> </span>portion<span style="letter-spacing:2.05pt;"> </span>of<span style="letter-spacing:2pt;"> </span>our<span style="letter-spacing:2pt;"> </span>operations.<span style="letter-spacing:2.1pt;"> </span>Extreme weather<span style="letter-spacing:0.1pt;"> </span>conditions<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>natural<span style="letter-spacing:0.15pt;"> </span>disasters<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>further<span style="letter-spacing:0.15pt;"> </span>disrupt<span style="letter-spacing:0.1pt;"> </span>our operations,<span style="letter-spacing:0.1pt;"> </span>and have a material<span style="letter-spacing:0.15pt;"> </span>and adverse effect<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prospects.<span style="letter-spacing:0.15pt;"> </span>In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear, and may heighten or intensify existing risk of natural disasters.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>a natural<span style="letter-spacing:0.1pt;"> </span>disaster,<span style="letter-spacing:0.1pt;"> </span>power outage or<span style="letter-spacing:2.3pt;"> </span>other<span style="letter-spacing:2.35pt;"> </span>event<span style="letter-spacing:2.35pt;"> </span>occurred<span style="letter-spacing:2.35pt;"> </span>that<span style="letter-spacing:2.35pt;"> </span>prevented<span style="letter-spacing:2.35pt;"> </span>us<span style="letter-spacing:2.25pt;"> </span>from<span style="letter-spacing:2.3pt;"> </span>using<span style="letter-spacing:2.3pt;"> </span>all<span style="letter-spacing:2.3pt;"> </span>or<span style="letter-spacing:2.25pt;"> </span>a<span style="letter-spacing:2.25pt;"> </span>significant<span style="letter-spacing:2.4pt;"> </span>portion<span style="letter-spacing:2.3pt;"> </span>of<span style="letter-spacing:2.25pt;"> </span>our<span style="letter-spacing:2.25pt;"> </span>headquarters,<span style="letter-spacing:2.35pt;"> </span>that damaged<span style="letter-spacing:0.1pt;"> </span>critical<span style="letter-spacing:0.2pt;"> </span>infrastructure,<span style="letter-spacing:0.2pt;"> </span>such as our research<span style="letter-spacing:0.1pt;"> </span>facilities<span style="letter-spacing:0.15pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>facilities<span style="letter-spacing:0.15pt;"> </span>of our third-party CMOs,<span style="letter-spacing:1.9pt;"> </span>or<span style="letter-spacing:1.9pt;"> </span>that<span style="letter-spacing:1.95pt;"> </span>otherwise<span style="letter-spacing:1.95pt;"> </span>disrupted<span style="letter-spacing:2pt;"> </span>operations,<span style="letter-spacing:2pt;"> </span>it<span style="letter-spacing:1.95pt;"> </span>may<span style="letter-spacing:1.95pt;"> </span>be<span style="letter-spacing:1.85pt;"> </span>difficult<span style="letter-spacing:2pt;"> </span>or,<span style="letter-spacing:1.85pt;"> </span>in<span style="letter-spacing:1.85pt;"> </span>certain<span style="letter-spacing:1.95pt;"> </span>cases,<span style="letter-spacing:1.9pt;"> </span>impossible,<span style="letter-spacing:1.95pt;"> </span>for<span style="letter-spacing:1.9pt;"> </span>us<span style="letter-spacing:1.85pt;"> </span>to continue<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>business<span style="letter-spacing:1.2pt;"> </span>for<span style="letter-spacing:1.15pt;"> </span>a<span style="letter-spacing:1.1pt;"> </span>substantial<span style="letter-spacing:1.2pt;"> </span>period<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>time.<span style="letter-spacing:1.15pt;"> </span>The<span style="letter-spacing:1.1pt;"> </span>disaster<span style="letter-spacing:1.2pt;"> </span>recovery<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>business<span style="letter-spacing:1.15pt;"> </span>continuity<span style="letter-spacing:1.2pt;"> </span>plans<span style="letter-spacing:1.15pt;"> </span>we have in place<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>prove<span style="letter-spacing:0.05pt;"> </span>inadequate<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>event<span style="letter-spacing:0.05pt;"> </span>of a serious<span style="letter-spacing:0.05pt;"> </span>disaster<span style="letter-spacing:0.1pt;"> </span>or similar<span style="letter-spacing:0.1pt;"> </span>event.<span style="letter-spacing:0.05pt;"> </span>We may<span style="letter-spacing:0.05pt;"> </span>incur substantial expenses<span style="letter-spacing:1.35pt;"> </span>as<span style="letter-spacing:1.3pt;"> </span>a<span style="letter-spacing:1.25pt;"> </span>result<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>limited<span style="letter-spacing:1.35pt;"> </span>nature<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.25pt;"> </span>disaster<span style="letter-spacing:1.35pt;"> </span>recovery<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>business<span style="letter-spacing:1.3pt;"> </span>continuity<span style="letter-spacing:1.35pt;"> </span>plans,<span style="letter-spacing:1.3pt;"> </span>which<span style="letter-spacing:1.25pt;"> </span>could have<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>material<span style="letter-spacing:0.2pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>effect<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.1pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>part<span style="letter-spacing:0.1pt;"> </span>of our risk<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:0.1pt;"> </span>policy,<span style="letter-spacing:0.05pt;"> </span>we maintain<span style="letter-spacing:0.1pt;"> </span>insurance coverage<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>levels<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>appropriate<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.1pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>event<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an accident<span style="letter-spacing:0.1pt;"> </span>or incident<span style="letter-spacing:0.15pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>facilities,<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>assure<span style="letter-spacing:0.1pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>amounts<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>insurance<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be sufficient<span style="letter-spacing:0.15pt;"> </span>to satisfy<span style="letter-spacing:0.1pt;"> </span>any damages<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.8pt;"> </span>losses.<span style="letter-spacing:1.85pt;"> </span>If<span style="letter-spacing:1.85pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>facilities,<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.8pt;"> </span>the<span style="letter-spacing:1.85pt;"> </span>manufacturing<span style="letter-spacing:1.95pt;"> </span>facilities<span style="letter-spacing:1.95pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>our<span style="letter-spacing:1.8pt;"> </span>third-party<span style="letter-spacing:1.95pt;"> </span>CMOs,<span style="letter-spacing:1.8pt;"> </span>are<span style="letter-spacing:1.85pt;"> </span>unable<span style="letter-spacing:1.8pt;"> </span>to operate<span style="letter-spacing:0.7pt;"> </span>because<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>an<span style="letter-spacing:0.65pt;"> </span>accident<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>incident<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:0.6pt;"> </span>other<span style="letter-spacing:0.65pt;"> </span>reason,<span style="letter-spacing:0.65pt;"> </span>even<span style="letter-spacing:0.6pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>a<span style="letter-spacing:0.6pt;"> </span>short<span style="letter-spacing:0.65pt;"> </span>period<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>time,<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>all<span style="letter-spacing:0.65pt;"> </span>of our<span style="letter-spacing:1.15pt;"> </span>research<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>development<span style="letter-spacing:1.25pt;"> </span>programs<span style="letter-spacing:1.25pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>be<span style="letter-spacing:1.15pt;"> </span>harmed.<span style="letter-spacing:1.2pt;"> </span>Any<span style="letter-spacing:1.15pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interruption</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and adverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our business,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects.</span></p>
<p style="margin-top:15pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax laws or regulations<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are applied<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>to us may<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.1pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>cash flow, financial<span style="letter-spacing:0.05pt;"> </span>condition<span style="letter-spacing:0.05pt;"> </span>or results<span style="letter-spacing:0.05pt;"> </span>of operations.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New income,<span style="letter-spacing:0.1pt;"> </span>sales,<span style="letter-spacing:0.1pt;"> </span>use or other<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>laws, statutes,<span style="letter-spacing:0.1pt;"> </span>rules,<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.1pt;"> </span>or ordinances<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be enacted<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>any time,<span style="letter-spacing:0.05pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>performance.<span style="letter-spacing:0.1pt;"> </span>Further,<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.05pt;"> </span>tax laws, statutes,<span style="letter-spacing:0.15pt;"> </span>rules,<span style="letter-spacing:0.1pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ordinances<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be interpreted,<span style="letter-spacing:0.15pt;"> </span>changed,<span style="letter-spacing:0.05pt;"> </span>modified<span style="letter-spacing:0.1pt;"> </span>or applied<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>to us. For example,<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>Tax<span style="letter-spacing:1.25pt;"> </span>Cuts<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.25pt;"> </span>Jobs<span style="letter-spacing:1.25pt;"> </span>Act,<span style="letter-spacing:1.25pt;"> </span>enacted<span style="letter-spacing:1.3pt;"> </span>many<span style="letter-spacing:1.3pt;"> </span>significant<span style="letter-spacing:1.4pt;"> </span>changes<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>U.S.<span style="letter-spacing:1.15pt;"> </span>tax<span style="letter-spacing:1.25pt;"> </span>laws.<span style="letter-spacing:1.2pt;"> </span>Future<span style="letter-spacing:1.25pt;"> </span>guidance from<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Internal<span style="letter-spacing:0.1pt;"> </span>Revenue Service<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>authorities<span style="letter-spacing:0.15pt;"> </span>with respect<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>Tax Cuts and Jobs Act may<span style="letter-spacing:0.05pt;"> </span>affect us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>aspects<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Tax<span style="letter-spacing:0.05pt;"> </span>Cuts and Jobs Act could<span style="letter-spacing:0.05pt;"> </span>be repealed<span style="letter-spacing:0.1pt;"> </span>or modified<span style="letter-spacing:0.1pt;"> </span>in future<span style="letter-spacing:0.05pt;"> </span>legislation.<span style="letter-spacing:0.15pt;"> </span>For example,<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>CARES Act<span style="letter-spacing:0.1pt;"> </span>modified<span style="letter-spacing:0.2pt;"> </span>certain<span style="letter-spacing:0.2pt;"> </span>provisions<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>Tax<span style="letter-spacing:0.1pt;"> </span>Cuts<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>Jobs<span style="letter-spacing:0.1pt;"> </span>Act.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.1pt;"> </span>addition,<span style="letter-spacing:0.15pt;"> </span>it<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>uncertain<span style="letter-spacing:0.2pt;"> </span>if and<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>what<span style="letter-spacing:1.35pt;"> </span>extent<span style="letter-spacing:1.4pt;"> </span>various<span style="letter-spacing:1.4pt;"> </span>states<span style="letter-spacing:1.45pt;"> </span>will<span style="letter-spacing:1.4pt;"> </span>conform<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.4pt;"> </span>Tax<span style="letter-spacing:1.35pt;"> </span>Cuts<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.35pt;"> </span>Jobs<span style="letter-spacing:1.35pt;"> </span>Act,<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>CARES<span style="letter-spacing:1.2pt;"> </span>Act,<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.3pt;"> </span>any<span style="letter-spacing:1.3pt;"> </span>newly enacted<span style="letter-spacing:0.1pt;"> </span>federal<span style="letter-spacing:0.15pt;"> </span>tax<span style="letter-spacing:0.1pt;"> </span>legislation.<span style="letter-spacing:0.2pt;"> </span>Changes<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:0.1pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>rates,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>realization<span style="letter-spacing:0.15pt;"> </span>of net<span style="letter-spacing:0.05pt;"> </span>deferred<span style="letter-spacing:0.1pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>assets<span style="letter-spacing:0.05pt;"> </span>relating<span style="letter-spacing:0.1pt;"> </span>to our<span style="letter-spacing:0.9pt;"> </span>operations,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>taxation<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>foreign<span style="letter-spacing:0.9pt;"> </span>earnings,<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>deductibility<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>expenses<span style="letter-spacing:0.9pt;"> </span>under<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>Tax<span style="letter-spacing:0.85pt;"> </span>Cuts<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>Jobs Act,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>CARES Act<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.15pt;"> </span>reform<span style="letter-spacing:0.2pt;"> </span>legislation<span style="letter-spacing:0.25pt;"> </span>could<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>material<span style="letter-spacing:0.25pt;"> </span>impact<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>value<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>deferred<span style="letter-spacing:0.15pt;"> </span>tax assets,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in significant<span style="letter-spacing:0.15pt;"> </span>one-time<span style="letter-spacing:0.1pt;"> </span>charges,<span style="letter-spacing:0.05pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>our future<span style="letter-spacing:0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>tax<span style="letter-spacing:0.05pt;"> </span>expense.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability<span style="letter-spacing:0.1pt;"> </span>to use our net operating<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>carryforwards<span style="letter-spacing:0.05pt;"> </span>and certain<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>tax attributes<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be limited.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Unused losses incurred in taxable years beginning on or prior to December 31, 2017, will carry forward to offset future taxable income, if any, until such unused losses expire. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely but the deductibility of such federal net operating losses (particularly those generated in taxable years beginning after December 31, 2020) in taxable years beginning after December 31, 2020, is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. In addition, both our current and our future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) if we undergo, or have undergone, an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. We have not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study and the fact that there may be additional ownership changes in the future. As a result, our net operating loss carryforwards generated in taxable years beginning on or before December 31, 2017, may expire prior to being used, and the deductibility of our net operating loss carryforwards generated in taxable years beginning after December 31, 2017 in taxable years beginning after December 31, 2020, may be limited, and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use all or a material portion of our net operating losses and other tax attributes, which could adversely affect our future cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>engage in strategic<span style="letter-spacing:0.1pt;"> </span>transactions<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could impact<span style="letter-spacing:0.05pt;"> </span>our liquidity,<span style="letter-spacing:0.1pt;"> </span>increase<span style="letter-spacing:0.05pt;"> </span>our expenses<span style="letter-spacing:0.05pt;"> </span>and present<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>distractions<span style="letter-spacing:0.1pt;"> </span>to our management.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<span style="letter-spacing:0.1pt;"> </span>time<span style="letter-spacing:0.1pt;"> </span>to time,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>consider<span style="letter-spacing:0.05pt;"> </span>strategic<span style="letter-spacing:0.1pt;"> </span>transactions,<span style="letter-spacing:0.15pt;"> </span>such as acquisitions<span style="letter-spacing:0.1pt;"> </span>of companies,<span style="letter-spacing:0.1pt;"> </span>businesses<span style="letter-spacing:0.1pt;"> </span>or assets<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>out-licensing<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in-licensing<span style="letter-spacing:0.15pt;"> </span>of products,<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or technologies.<span style="letter-spacing:0.1pt;"> </span>Additional<span style="letter-spacing:0.05pt;"> </span>potential transactions<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>consider<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>a variety<span style="letter-spacing:0.1pt;"> </span>of different<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>arrangements,<span style="letter-spacing:0.1pt;"> </span>including spin-offs, strategic<span style="letter-spacing:0.15pt;"> </span>partnerships,<span style="letter-spacing:0.15pt;"> </span>joint<span style="letter-spacing:0.1pt;"> </span>ventures,<span style="letter-spacing:0.1pt;"> </span>restructurings,<span style="letter-spacing:0.2pt;"> </span>divestitures,<span style="letter-spacing:0.15pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>combinations<span style="letter-spacing:0.1pt;"> </span>and investments.<span style="letter-spacing:0.1pt;"> </span>Any such<span style="letter-spacing:0.25pt;"> </span>transaction<span style="letter-spacing:0.35pt;"> </span>may<span style="letter-spacing:0.3pt;"> </span>require<span style="letter-spacing:0.35pt;"> </span>us<span style="letter-spacing:0.25pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>incur<span style="letter-spacing:0.3pt;"> </span>non-recurring<span style="letter-spacing:0.35pt;"> </span>or<span style="letter-spacing:0.25pt;"> </span>other<span style="letter-spacing:0.3pt;"> </span>charges,<span style="letter-spacing:0.3pt;"> </span>may<span style="letter-spacing:0.3pt;"> </span>increase<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:0.2pt;"> </span>near<span style="letter-spacing:0.25pt;"> </span>term<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>long-term expenditures<span style="letter-spacing:2pt;"> </span>and<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.9pt;"> </span>pose<span style="letter-spacing:1.85pt;"> </span>significant<span style="letter-spacing:2pt;"> </span>integration<span style="letter-spacing:1.95pt;"> </span>challenges<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.85pt;"> </span>disrupt<span style="letter-spacing:1.9pt;"> </span>our<span style="letter-spacing:1.85pt;"> </span>management<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.85pt;"> </span>business,<span style="letter-spacing:1.9pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.1pt;"> </span>our operations<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>results.<span style="letter-spacing:0.1pt;"> </span>For example,<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>transactions<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>entail<span style="letter-spacing:0.05pt;"> </span>numerous operational<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>risks,<span style="letter-spacing:0.05pt;"> </span>including:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">exposure<span style="letter-spacing:0.05pt;"> </span>to unknown liabilities&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disruption<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:1pt;"> </span>business<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>diversion<span style="letter-spacing:1.05pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>management&#8217;s<span style="letter-spacing:1.1pt;"> </span>time<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>attention<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.95pt;"> </span>order<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.95pt;"> </span>develop acquired<span style="letter-spacing:0.05pt;"> </span>products,<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or technologies&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">incurrence<span style="letter-spacing:0.1pt;"> </span>of substantial<span style="letter-spacing:0.1pt;"> </span>debt<span style="letter-spacing:0.05pt;"> </span>or dilutive<span style="letter-spacing:0.1pt;"> </span>issuances<span style="letter-spacing:0.1pt;"> </span>of equity<span style="letter-spacing:0.05pt;"> </span>securities<span style="letter-spacing:0.15pt;"> </span>to pay for<span style="letter-spacing:0.05pt;"> </span>acquisitions&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">higher<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>expected<span style="letter-spacing:0.05pt;"> </span>acquisition<span style="letter-spacing:0.1pt;"> </span>and integration<span style="letter-spacing:0.1pt;"> </span>costs&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">write-downs<span style="letter-spacing:0.05pt;"> </span>of assets<span style="letter-spacing:0.05pt;"> </span>or goodwill<span style="letter-spacing:0.05pt;"> </span>or impairment<span style="letter-spacing:0.15pt;"> </span>charges&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">increased<span style="letter-spacing:0.1pt;"> </span>amortization<span style="letter-spacing:0.15pt;"> </span>expenses&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulty<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.25pt;"> </span>cost<span style="letter-spacing:0.3pt;"> </span>in<span style="letter-spacing:0.25pt;"> </span>combining<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>operations,<span style="letter-spacing:0.35pt;"> </span>systems<span style="letter-spacing:0.35pt;"> </span>and<span style="letter-spacing:0.25pt;"> </span>personnel<span style="letter-spacing:0.3pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>any<span style="letter-spacing:0.2pt;"> </span>acquired<span style="letter-spacing:0.25pt;"> </span>businesses<span style="letter-spacing:0.3pt;"> </span>with our operations,<span style="letter-spacing:0.1pt;"> </span>systems<span style="letter-spacing:0.1pt;"> </span>and personnel&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impairment<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>relationships<span style="letter-spacing:0.4pt;"> </span>with<span style="letter-spacing:0.25pt;"> </span>key<span style="letter-spacing:0.25pt;"> </span>suppliers<span style="letter-spacing:0.35pt;"> </span>or<span style="letter-spacing:0.25pt;"> </span>customers<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>any<span style="letter-spacing:0.25pt;"> </span>acquired<span style="letter-spacing:0.3pt;"> </span>businesses<span style="letter-spacing:0.35pt;"> </span>due<span style="letter-spacing:0.25pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>changes in management<span style="letter-spacing:0.1pt;"> </span>and ownership&#59;<span style="letter-spacing:0.05pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.5%;text-indent:-3.8%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">inability<span style="letter-spacing:0.1pt;"> </span>to retain<span style="letter-spacing:0.1pt;"> </span>key employees<span style="letter-spacing:0.1pt;"> </span>of any acquired<span style="letter-spacing:0.05pt;"> </span>businesses.</p></td></tr></table></div>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our portfolio<span style="letter-spacing:0.1pt;"> </span>of investments<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to market,<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:0.1pt;"> </span>and credit<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>reduce<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:0.05pt;"> </span>value.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our investments<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>decline<span style="letter-spacing:0.05pt;"> </span>due to increases<span style="letter-spacing:0.1pt;"> </span>in interest<span style="letter-spacing:0.1pt;"> </span>rates,<span style="letter-spacing:0.05pt;"> </span>downgrades<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>bonds and other<span style="letter-spacing:0.1pt;"> </span>securities<span style="letter-spacing:0.2pt;"> </span>included<span style="letter-spacing:0.05pt;"> </span>in our commercial<span style="letter-spacing:0.15pt;"> </span>money<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>account<span style="letter-spacing:0.05pt;"> </span>portfolio<span style="letter-spacing:0.1pt;"> </span>and instability<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>global<span style="letter-spacing:0.05pt;"> </span>financial markets<span style="letter-spacing:1.15pt;"> </span>that<span style="letter-spacing:1.1pt;"> </span>reduces<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>liquidity<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>securities<span style="letter-spacing:1.2pt;"> </span>included<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:1.05pt;"> </span>portfolio.<span style="letter-spacing:1.1pt;"> </span>In<span style="letter-spacing:1pt;"> </span>addition,<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.05pt;"> </span>COVID-19<span style="letter-spacing:0.95pt;"> </span>pandemic has<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>adversely<span style="letter-spacing:0.15pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>markets<span style="letter-spacing:0.1pt;"> </span>in some<span style="letter-spacing:0.05pt;"> </span>or all<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>worldwide.<span style="letter-spacing:0.05pt;"> </span>Each of these events<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>cause<span style="letter-spacing:0.1pt;"> </span>us to record<span style="letter-spacing:0.05pt;"> </span>charges<span style="letter-spacing:0.05pt;"> </span>to reduce<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>carrying<span style="letter-spacing:0.1pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our investment<span style="letter-spacing:0.1pt;"> </span>portfolio<span style="letter-spacing:0.1pt;"> </span>or sell<span style="letter-spacing:0.05pt;"> </span>investments for<span style="letter-spacing:0.1pt;"> </span>less<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>acquisition<span style="letter-spacing:0.15pt;"> </span>cost.<span style="letter-spacing:0.1pt;"> </span>Although<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>attempt<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>mitigate<span style="letter-spacing:0.15pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>through<span style="letter-spacing:0.05pt;"> </span>diversification<span style="letter-spacing:0.2pt;"> </span>of our investments<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>continuous<span style="letter-spacing:0.1pt;"> </span>monitoring<span style="letter-spacing:0.1pt;"> </span>of our portfolio&#8217;s<span style="letter-spacing:0.15pt;"> </span>overall<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>profile,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of our investments<span style="letter-spacing:0.1pt;"> </span>may nevertheless<span style="letter-spacing:0.1pt;"> </span>decline.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Intellectual<span style="letter-spacing:0.1pt;"> </span>Property</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we are unable to obtain<span style="letter-spacing:0.05pt;"> </span>and maintain<span style="letter-spacing:0.05pt;"> </span>sufficient<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.05pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>the scope<span style="letter-spacing:0.05pt;"> </span>of the patent<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>not sufficiently<span style="letter-spacing:0.15pt;"> </span>broad, third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>our competitors,<span style="letter-spacing:0.1pt;"> </span>could develop<span style="letter-spacing:0.05pt;"> </span>and commercialize<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:0.1pt;"> </span>or identical<span style="letter-spacing:0.1pt;"> </span>to ours, and our ability<span style="letter-spacing:0.1pt;"> </span>to commercialize<span style="letter-spacing:0.15pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>successfully<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be adversely<span style="letter-spacing:0.1pt;"> </span>affected.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.1pt;"> </span>depends<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>large<span style="letter-spacing:0.1pt;"> </span>part<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to protect<span style="letter-spacing:0.1pt;"> </span>our proprietary<span style="letter-spacing:0.1pt;"> </span>technologies<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we believe<span style="letter-spacing:0.05pt;"> </span>are important<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.9pt;"> </span>our<span style="letter-spacing:0.9pt;"> </span>business,<span style="letter-spacing:0.95pt;"> </span>including<span style="letter-spacing:0.95pt;"> </span>pursuing,<span style="letter-spacing:0.95pt;"> </span>obtaining<span style="letter-spacing:0.95pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>maintaining<span style="letter-spacing:1pt;"> </span>patent<span style="letter-spacing:0.95pt;"> </span>protection<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>United<span style="letter-spacing:0.9pt;"> </span>States and other countries intended to cover the compositions of matter of<span style="letter-spacing:2.45pt;"> </span>our<span style="letter-spacing:2.45pt;"> </span>product candidates, for example, PRT543, PRT811, PRT1419 and PRT2527, their methods of use, related technologies and other inventions that are important<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>protection,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>rely<span style="letter-spacing:0.1pt;"> </span>on trade<span style="letter-spacing:0.05pt;"> </span>secrets<span style="letter-spacing:0.1pt;"> </span>to protect<span style="letter-spacing:0.1pt;"> </span>aspects<span style="letter-spacing:0.05pt;"> </span>of our business<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>amenable<span style="letter-spacing:0.15pt;"> </span>to,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>consider<span style="letter-spacing:0.1pt;"> </span>appropriate<span style="letter-spacing:0.1pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>protection.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we do not adequately<span style="letter-spacing:0.15pt;"> </span>pursue,<span style="letter-spacing:0.1pt;"> </span>obtain,<span style="letter-spacing:0.1pt;"> </span>maintain,<span style="letter-spacing:0.15pt;"> </span>protect<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>enforce<span style="letter-spacing:0.1pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property,<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>our competitors,<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>erode<span style="letter-spacing:0.05pt;"> </span>or negate<span style="letter-spacing:0.05pt;"> </span>any competitive<span style="letter-spacing:0.15pt;"> </span>advantage<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>have, which could<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>and ability<span style="letter-spacing:0.1pt;"> </span>to achieve<span style="letter-spacing:0.05pt;"> </span>profitability.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect our proprietary position, we have currently filed patent applications in the United States related to our product candidates that we consider important to our business, including patent applications relating to compositions of matter covering our compounds, the processes for manufacturing such compounds and use of such compounds in therapies. We have also filed patent applications in foreign jurisdictions relating to PRT543, PRT811, and PRT1419.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application and approval process is expensive, time-consuming and complex. We may not be able to file, prosecute and maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, depending on the terms of any future license agreements to which we may become a party, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain the patents, covering technology licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. The standards applied by the United States Patent and Trademark Office, or the USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Thus, we cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">found</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalid</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and unenforceable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or will be</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">threatened</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or whether</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any issued</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercializing competing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aspects</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our current</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">only</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. patent</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT543 that</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to expire</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earlier</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. patent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRT811 that</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expire</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no earlier</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14, 2039</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#59; and one issued U.S. patent covering PRT1419 that is expected to expire no earlier than November 8, 2039.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We do not yet</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have issued</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on all</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.7pt;"> </span>pending<span style="letter-spacing:0.75pt;"> </span>patent<span style="letter-spacing:0.75pt;"> </span>applications<span style="letter-spacing:0.8pt;"> </span>cannot<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.7pt;"> </span>enforced<span style="letter-spacing:0.75pt;"> </span>against<span style="letter-spacing:0.75pt;"> </span>third<span style="letter-spacing:0.7pt;"> </span>parties<span style="letter-spacing:0.75pt;"> </span>practicing<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>technology<span style="letter-spacing:0.7pt;"> </span>claimed in such applications<span style="letter-spacing:0.1pt;"> </span>unless<span style="letter-spacing:0.05pt;"> </span>and until<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>least<span style="letter-spacing:0.05pt;"> </span>one patent<span style="letter-spacing:0.05pt;"> </span>issues<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>such applications.<span style="letter-spacing:0.1pt;"> </span>Assuming the other requirements<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>patentability<span style="letter-spacing:0.2pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>met,<span style="letter-spacing:0.1pt;"> </span>currently,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>first<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>file<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>application<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>generally<span style="letter-spacing:0.15pt;"> </span>entitled<span style="letter-spacing:0.1pt;"> </span>to the patent.<span style="letter-spacing:0.1pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>prior<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>March<span style="letter-spacing:0.1pt;"> </span>16,<span style="letter-spacing:0.05pt;"> </span>2013,<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>first<span style="letter-spacing:0.1pt;"> </span>to invent<span style="letter-spacing:0.05pt;"> </span>was entitled<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>patent. Publications<span style="letter-spacing:0.15pt;"> </span>of discoveries<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>scientific<span style="letter-spacing:0.15pt;"> </span>literature<span style="letter-spacing:0.15pt;"> </span>often<span style="letter-spacing:0.05pt;"> </span>lag<span style="letter-spacing:0.05pt;"> </span>behind<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>actual<span style="letter-spacing:0.05pt;"> </span>discoveries,<span style="letter-spacing:0.1pt;"> </span>and patent applications<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>typically<span style="letter-spacing:0.1pt;"> </span>not published<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:0.05pt;"> </span>18 months<span style="letter-spacing:0.05pt;"> </span>after<span style="letter-spacing:0.1pt;"> </span>filing,<span style="letter-spacing:0.1pt;"> </span>or in<span style="letter-spacing:0.6pt;"> </span>some<span style="letter-spacing:0.65pt;"> </span>cases<span style="letter-spacing:0.65pt;"> </span>not<span style="letter-spacing:0.6pt;"> </span>at<span style="letter-spacing:0.65pt;"> </span>all.<span style="letter-spacing:0.65pt;"> </span>Since<span style="letter-spacing:0.65pt;"> </span>patent<span style="letter-spacing:0.65pt;"> </span>applications<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>United<span style="letter-spacing:0.6pt;"> </span>States<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>most<span style="letter-spacing:0.6pt;"> </span>other<span style="letter-spacing:0.6pt;"> </span>countries<span style="letter-spacing:0.65pt;"> </span>are<span style="letter-spacing:0.6pt;"> </span>confidential for<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.7pt;"> </span>period<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>time<span style="letter-spacing:0.75pt;"> </span>after<span style="letter-spacing:0.8pt;"> </span>filing,<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>some<span style="letter-spacing:0.7pt;"> </span>remain<span style="letter-spacing:0.75pt;"> </span>so<span style="letter-spacing:0.65pt;"> </span>until<span style="letter-spacing:0.7pt;"> </span>issued,<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>cannot<span style="letter-spacing:0.7pt;"> </span>be<span style="letter-spacing:0.65pt;"> </span>certain<span style="letter-spacing:0.75pt;"> </span>that<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>were<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>first<span style="letter-spacing:0.75pt;"> </span>to file<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>invent<span style="letter-spacing:0.1pt;"> </span>(prior<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>March<span style="letter-spacing:0.1pt;"> </span>16,<span style="letter-spacing:0.05pt;"> </span>2013)<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>application<span style="letter-spacing:0.15pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable<span style="letter-spacing:0.2pt;"> </span>aspects<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>research<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>output,<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees,<span style="letter-spacing:0.15pt;"> </span>collaborators,<span style="letter-spacing:0.2pt;"> </span>CROs, CMOs, hospitals,<span style="letter-spacing:0.15pt;"> </span>independent<span style="letter-spacing:0.1pt;"> </span>treatment<span style="letter-spacing:0.2pt;"> </span>centers,<span style="letter-spacing:0.1pt;"> </span>consultants,<span style="letter-spacing:0.1pt;"> </span>independent<span style="letter-spacing:0.05pt;"> </span>contractors,<span style="letter-spacing:0.1pt;"> </span>suppliers,<span style="letter-spacing:0.1pt;"> </span>advisors<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>third parties&#59;<span style="letter-spacing:0.15pt;"> </span>however,<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>breach<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>and disclose<span style="letter-spacing:0.1pt;"> </span>such output<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>a patent application<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>filed,<span style="letter-spacing:0.05pt;"> </span>thereby<span style="letter-spacing:0.05pt;"> </span>jeopardizing<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to seek<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>protection.<span style="letter-spacing:0.1pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>have filed<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>related<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or technology,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>our own patent<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to those<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or technology.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.73%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,<span style="letter-spacing:0.1pt;"> </span>because<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>issuance<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>not conclusive<span style="letter-spacing:0.1pt;"> </span>as to its<span style="letter-spacing:0.05pt;"> </span>inventorship,<span style="letter-spacing:0.1pt;"> </span>scope,<span style="letter-spacing:0.05pt;"> </span>validity<span style="letter-spacing:0.1pt;"> </span>or enforceability,<span style="letter-spacing:0.2pt;"> </span>our patents<span style="letter-spacing:0.05pt;"> </span>or pending<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be challenged<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>courts<span style="letter-spacing:0.05pt;"> </span>or patent<span style="letter-spacing:0.05pt;"> </span>offices<span style="letter-spacing:0.1pt;"> </span>in the United<span style="letter-spacing:0.1pt;"> </span>States<span style="letter-spacing:0.1pt;"> </span>and abroad.<span style="letter-spacing:0.05pt;"> </span>For example,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to a third-party<span style="letter-spacing:0.15pt;"> </span>pre-issuance<span style="letter-spacing:0.1pt;"> </span>submission<span style="letter-spacing:0.1pt;"> </span>of prior<span style="letter-spacing:0.05pt;"> </span>art<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.1pt;"> </span>USPTO or become<span style="letter-spacing:0.05pt;"> </span>involved<span style="letter-spacing:0.05pt;"> </span>in post-grant<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>procedures,<span style="letter-spacing:0.1pt;"> </span>oppositions,<span style="letter-spacing:0.1pt;"> </span>derivations,<span style="letter-spacing:0.1pt;"> </span>revocation, reexaminations,<span style="letter-spacing:1.25pt;"> </span>inter<span style="letter-spacing:1.15pt;"> </span>partes<span style="letter-spacing:1.15pt;"> </span>review<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>interference<span style="letter-spacing:1.25pt;"> </span>proceedings,<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>United<span style="letter-spacing:1.1pt;"> </span>States<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>elsewhere,<span style="letter-spacing:1.1pt;"> </span>challenging our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>others.<span style="letter-spacing:0.1pt;"> </span>An<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:0.1pt;"> </span>determination<span style="letter-spacing:0.2pt;"> </span>in any such submission,<span style="letter-spacing:0.1pt;"> </span>proceeding<span style="letter-spacing:0.05pt;"> </span>or litigation<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>reduce<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>scope<span style="letter-spacing:0.05pt;"> </span>of, or invalidate,<span style="letter-spacing:0.1pt;"> </span>our patent<span style="letter-spacing:0.05pt;"> </span>rights,<span style="letter-spacing:0.05pt;"> </span>allow<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to commercialize<span style="letter-spacing:0.15pt;"> </span>our technology<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.1pt;"> </span>directly<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>without<span style="letter-spacing:0.1pt;"> </span>payment<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>or result<span style="letter-spacing:0.1pt;"> </span>in our inability<span style="letter-spacing:0.1pt;"> </span>to manufacture<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>commercialize<span style="letter-spacing:0.25pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>without<span style="letter-spacing:0.1pt;"> </span>infringing<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>rights.<span style="letter-spacing:0.05pt;"> </span>Moreover,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>have to participate<span style="letter-spacing:0.4pt;"> </span>in<span style="letter-spacing:0.25pt;"> </span>interference<span style="letter-spacing:0.4pt;"> </span>proceedings<span style="letter-spacing:0.35pt;"> </span>declared<span style="letter-spacing:0.35pt;"> </span>by<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>USPTO<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>determine<span style="letter-spacing:0.3pt;"> </span>priority<span style="letter-spacing:0.3pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>invention<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>post-grant challenge<span style="letter-spacing:0.15pt;"> </span>proceedings,<span style="letter-spacing:0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>oppositions<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>a foreign<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>office,<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>challenge<span style="letter-spacing:0.1pt;"> </span>priority<span style="letter-spacing:0.1pt;"> </span>of invention<span style="letter-spacing:0.05pt;"> </span>or other features<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patentability.<span style="letter-spacing:0.2pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>challenges<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of exclusivity<span style="letter-spacing:0.1pt;"> </span>or in our patent<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>being<span style="letter-spacing:0.05pt;"> </span>narrowed, invalidated<span style="letter-spacing:0.1pt;"> </span>or held<span style="letter-spacing:0.05pt;"> </span>unenforceable,<span style="letter-spacing:0.1pt;"> </span>in whole or in part,<span style="letter-spacing:0.05pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to stop<span style="letter-spacing:0.05pt;"> </span>others from using or commercializing<span style="letter-spacing:0.25pt;"> </span>similar<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>identical<span style="letter-spacing:0.15pt;"> </span>technology<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>duration<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>of our technology<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>products.<span style="letter-spacing:1.1pt;"> </span>Such<span style="letter-spacing:1pt;"> </span>challenges<span style="letter-spacing:1.1pt;"> </span>also<span style="letter-spacing:1.05pt;"> </span>may<span style="letter-spacing:1.05pt;"> </span>result<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1pt;"> </span>substantial<span style="letter-spacing:1.1pt;"> </span>cost<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1pt;"> </span>require<span style="letter-spacing:1.1pt;"> </span>significant<span style="letter-spacing:1.15pt;"> </span>time<span style="letter-spacing:1.05pt;"> </span>from our<span style="letter-spacing:0.3pt;"> </span>scientists<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.3pt;"> </span>management,<span style="letter-spacing:0.4pt;"> </span>even<span style="letter-spacing:0.3pt;"> </span>if<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>eventual<span style="letter-spacing:0.35pt;"> </span>outcome<span style="letter-spacing:0.35pt;"> </span>is<span style="letter-spacing:0.35pt;"> </span>favorable<span style="letter-spacing:0.4pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>us.<span style="letter-spacing:0.3pt;"> </span>Any<span style="letter-spacing:0.3pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>foregoing<span style="letter-spacing:0.3pt;"> </span>could<span style="letter-spacing:0.3pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>given<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>amount<span style="letter-spacing:0.05pt;"> </span>of time<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>and regulatory<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>of new product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>protecting<span style="letter-spacing:0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>might<span style="letter-spacing:0.1pt;"> </span>expire<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>or shortly<span style="letter-spacing:0.05pt;"> </span>after<span style="letter-spacing:0.1pt;"> </span>such product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>commercialized.<span style="letter-spacing:0.25pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>result,<span style="letter-spacing:0.1pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not provide<span style="letter-spacing:0.05pt;"> </span>us with sufficient rights<span style="letter-spacing:1.9pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>exclude<span style="letter-spacing:1.9pt;"> </span>others<span style="letter-spacing:1.9pt;"> </span>from<span style="letter-spacing:1.9pt;"> </span>commercializing<span style="letter-spacing:2.05pt;"> </span>products<span style="letter-spacing:1.9pt;"> </span>similar<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.85pt;"> </span>identical<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>ours.<span style="letter-spacing:1.9pt;"> </span>Moreover,<span style="letter-spacing:1.85pt;"> </span>some<span style="letter-spacing:1.85pt;"> </span>of<span style="letter-spacing:1.8pt;"> </span>our patents<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>co-owned<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>unable<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors<span style="letter-spacing:0.2pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>competing<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>technology.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>cooperation<span style="letter-spacing:0.15pt;"> </span>of any such<span style="letter-spacing:0.05pt;"> </span>co-owners<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>enforce<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>and such cooperation<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be<span style="letter-spacing:2.1pt;"> </span>provided<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2.1pt;"> </span>us.<span style="letter-spacing:2.1pt;"> </span>Any<span style="letter-spacing:2.05pt;"> </span>of<span style="letter-spacing:2.05pt;"> </span>the<span style="letter-spacing:2.1pt;"> </span>foregoing<span style="letter-spacing:2.1pt;"> </span>could<span style="letter-spacing:2.1pt;"> </span>have<span style="letter-spacing:2.05pt;"> </span>a<span style="letter-spacing:2.05pt;"> </span>material<span style="letter-spacing:2.2pt;"> </span>adverse<span style="letter-spacing:2.1pt;"> </span>effect<span style="letter-spacing:2.15pt;"> </span>on<span style="letter-spacing:2.05pt;"> </span>our<span style="letter-spacing:2.05pt;"> </span>competitive<span style="letter-spacing:2.2pt;"> </span>position, business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>conditions,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>pending<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>being<span style="letter-spacing:0.05pt;"> </span>issued<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:0.1pt;"> </span>our product candidates,<span style="letter-spacing:0.1pt;"> </span>in whole or in part,<span style="letter-spacing:0.05pt;"> </span>or which effectively<span style="letter-spacing:0.15pt;"> </span>prevent<span style="letter-spacing:0.05pt;"> </span>others from commercializing<span style="letter-spacing:0.15pt;"> </span>competitive<span style="letter-spacing:0.1pt;"> </span>products. Changes<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>either<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>laws or interpretation<span style="letter-spacing:0.15pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>laws in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>may diminish<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>value<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>narrow<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>scope<span style="letter-spacing:0.1pt;"> </span>of our patent<span style="letter-spacing:0.05pt;"> </span>protection.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>laws of foreign countries<span style="letter-spacing:0.85pt;"> </span>may<span style="letter-spacing:0.8pt;"> </span>not<span style="letter-spacing:0.75pt;"> </span>protect<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>rights<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.8pt;"> </span>same<span style="letter-spacing:0.8pt;"> </span>extent<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>same<span style="letter-spacing:0.75pt;"> </span>manner<span style="letter-spacing:0.75pt;"> </span>as<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>laws<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>United<span style="letter-spacing:0.75pt;"> </span>States. For<span style="letter-spacing:1.1pt;"> </span>example,<span style="letter-spacing:1.15pt;"> </span>European<span style="letter-spacing:1.15pt;"> </span>patent<span style="letter-spacing:1.15pt;"> </span>law<span style="letter-spacing:1.1pt;"> </span>restricts<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>patentability<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>methods<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>treatment<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>human<span style="letter-spacing:1.1pt;"> </span>body<span style="letter-spacing:1.05pt;"> </span>more than<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>law does.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>as patents,<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not issue<span style="letter-spacing:0.05pt;"> </span>in a form<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>provide<span style="letter-spacing:0.05pt;"> </span>us with any meaningful<span style="letter-spacing:0.15pt;"> </span>protection,<span style="letter-spacing:0.15pt;"> </span>prevent<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>with us or otherwise<span style="letter-spacing:0.05pt;"> </span>provide<span style="letter-spacing:0.05pt;"> </span>us with<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:0.2pt;"> </span>advantage.<span style="letter-spacing:0.1pt;"> </span>Moreover,<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claimed</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can be significantly reduced</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scope</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reinterpreted</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issuance.</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently,</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not know</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protectable</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remain</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protected</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">valid</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceable patents.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be able</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to circumvent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our patents</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by developing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or alternative</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a non-infringing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manner.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also seek</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to market</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to or otherwise</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitive</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with our products.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alternatively, our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generic</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">versions</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or &#8220;follow-on&#8221;</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">versions</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any approved</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submitting</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">abbreviated</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANDAs, or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug applications</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under Section</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505(b)(2)</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDCA, respectively,</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA during</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owned</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us are</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalid,</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unenforceable</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringed.</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumstances,</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assert</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents, or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">both,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lawsuits</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alleging</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement.</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">types</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of proceedings,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a court</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agency</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with jurisdiction</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">find</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our patents</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalid</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or unenforceable,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our competitors</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are competing</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-infringing</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manner.</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus,</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">valid</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceable</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents,</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">still may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or processes</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sufficient</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to achieve</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">objectives. Any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foregoing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our competitive</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">position,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial conditions,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:0.15pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to a reservation<span style="letter-spacing:0.1pt;"> </span>of rights<span style="letter-spacing:0.05pt;"> </span>by one or more<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:0.1pt;"> </span>For example,<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>extent<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.1pt;"> </span>resulting<span style="letter-spacing:0.1pt;"> </span>in future<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>or technologies<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>funded<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>in part by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>U.S. government,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>have certain<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>in any resulting<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>and technology, including<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>non-exclusive<span style="letter-spacing:0.15pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>authorizing<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.1pt;"> </span>to use the<span style="letter-spacing:0.05pt;"> </span>invention<span style="letter-spacing:0.05pt;"> </span>or to have others<span style="letter-spacing:0.05pt;"> </span>use the invention<span style="letter-spacing:1.9pt;"> </span>on<span style="letter-spacing:1.85pt;"> </span>its<span style="letter-spacing:1.9pt;"> </span>behalf<span style="letter-spacing:1.9pt;"> </span>for<span style="letter-spacing:1.9pt;"> </span>non-commercial<span style="letter-spacing:2pt;"> </span>purposes.<span style="letter-spacing:1.9pt;"> </span>If<span style="letter-spacing:1.9pt;"> </span>the<span style="letter-spacing:1.9pt;"> </span>U.S.<span style="letter-spacing:1.8pt;"> </span>government<span style="letter-spacing:1.9pt;"> </span>then<span style="letter-spacing:1.85pt;"> </span>decides<span style="letter-spacing:1.85pt;"> </span>to<span style="letter-spacing:1.8pt;"> </span>exercise<span style="letter-spacing:1.9pt;"> </span>these rights,<span style="letter-spacing:0.1pt;"> </span>it<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>engage<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:0.1pt;"> </span>contractor<span style="letter-spacing:0.1pt;"> </span>in connection<span style="letter-spacing:0.05pt;"> </span>with doing so. These rights<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>permit the<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>disclose<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>confidential<span style="letter-spacing:0.2pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>exercise<span style="letter-spacing:0.15pt;"> </span>march-in<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>to use or allow<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to use our licensed<span style="letter-spacing:0.1pt;"> </span>technology.<span style="letter-spacing:0.05pt;"> </span>The government<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>exercise<span style="letter-spacing:0.1pt;"> </span>its<span style="letter-spacing:0.05pt;"> </span>march-in<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>it determines<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>action<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:0.1pt;"> </span>because<span style="letter-spacing:0.05pt;"> </span>we failed<span style="letter-spacing:0.1pt;"> </span>to achieve<span style="letter-spacing:0.05pt;"> </span>practical<span style="letter-spacing:0.1pt;"> </span>application<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>government-funded technology,<span style="letter-spacing:0.1pt;"> </span>because<span style="letter-spacing:0.1pt;"> </span>action<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>necessary<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>alleviate<span style="letter-spacing:0.15pt;"> </span>health<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:0.1pt;"> </span>needs,<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>meet<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>of federal regulations,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>give<span style="letter-spacing:0.1pt;"> </span>preference<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>U.S. industry.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>in such government-funded<span style="letter-spacing:0.15pt;"> </span>inventions may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to certain<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>to manufacture<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>embodying<span style="letter-spacing:0.05pt;"> </span>such inventions<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States. Any<span style="letter-spacing:0.05pt;"> </span>exercise<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>aforementioned<span style="letter-spacing:0.2pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our competitive<span style="letter-spacing:0.15pt;"> </span>position, business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes to the patent<span style="letter-spacing:0.05pt;"> </span>law in the United States<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.1pt;"> </span>could diminish<span style="letter-spacing:0.05pt;"> </span>the value<span style="letter-spacing:0.05pt;"> </span>of patents in general,<span style="letter-spacing:0.05pt;"> </span>thereby<span style="letter-spacing:0.05pt;"> </span>impairing<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to protect<span style="letter-spacing:0.05pt;"> </span>our products.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>case<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>pharmaceutical<span style="letter-spacing:0.2pt;"> </span>companies,<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>heavily<span style="letter-spacing:0.05pt;"> </span>dependent<span style="letter-spacing:0.05pt;"> </span>on intellectual property,<span style="letter-spacing:0.05pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>patents.<span style="letter-spacing:0.05pt;"> </span>Obtaining<span style="letter-spacing:0.05pt;"> </span>and enforcing<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>industry<span style="letter-spacing:0.05pt;"> </span>involves<span style="letter-spacing:0.05pt;"> </span>both technological<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>legal<span style="letter-spacing:0.1pt;"> </span>complexity<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>therefore<span style="letter-spacing:0.1pt;"> </span>costly,<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>consuming<span style="letter-spacing:0.05pt;"> </span>and inherently<span style="letter-spacing:0.1pt;"> </span>uncertain.<span style="letter-spacing:0.1pt;"> </span>Changes in either<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>or interpretation<span style="letter-spacing:0.15pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>laws in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>uncertainties<span style="letter-spacing:0.15pt;"> </span>and costs<span style="letter-spacing:0.1pt;"> </span>surrounding<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>prosecution<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>enforcement<span style="letter-spacing:0.1pt;"> </span>or defense<span style="letter-spacing:0.05pt;"> </span>of issued<span style="letter-spacing:0.05pt;"> </span>patents.<span style="letter-spacing:0.05pt;"> </span>Recent patent<span style="letter-spacing:1.2pt;"> </span>reform<span style="letter-spacing:1.2pt;"> </span>legislation<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>United<span style="letter-spacing:1.15pt;"> </span>States<span style="letter-spacing:1.15pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>other<span style="letter-spacing:1.15pt;"> </span>countries,<span style="letter-spacing:1.2pt;"> </span>including<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>Leahy-Smith<span style="letter-spacing:1.2pt;"> </span>America<span style="letter-spacing:1.15pt;"> </span>Invents Act,<span style="letter-spacing:1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1.05pt;"> </span>Leahy-Smith<span style="letter-spacing:1.05pt;"> </span>Act,<span style="letter-spacing:0.95pt;"> </span>signed<span style="letter-spacing:1pt;"> </span>into<span style="letter-spacing:1pt;"> </span>law<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.95pt;"> </span>September<span style="letter-spacing:1.05pt;"> </span>2011,<span style="letter-spacing:0.95pt;"> </span>could<span style="letter-spacing:1pt;"> </span>increase<span style="letter-spacing:1.05pt;"> </span>those<span style="letter-spacing:1pt;"> </span>uncertainties<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>costs. The<span style="letter-spacing:0.1pt;"> </span>Leahy-Smith<span style="letter-spacing:0.2pt;"> </span>Act<span style="letter-spacing:0.1pt;"> </span>includes<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>number<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>changes<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>U.S. patent<span style="letter-spacing:0.1pt;"> </span>law.<span style="letter-spacing:0.05pt;"> </span>These<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:0.1pt;"> </span>provisions<span style="letter-spacing:0.15pt;"> </span>that affect<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>way patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>prosecuted,<span style="letter-spacing:0.1pt;"> </span>redefine<span style="letter-spacing:0.1pt;"> </span>prior<span style="letter-spacing:0.05pt;"> </span>art<span style="letter-spacing:0.05pt;"> </span>and provide<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>efficient<span style="letter-spacing:0.15pt;"> </span>and cost-effective avenues<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>competitors<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>challenge<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>validity<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patents.<span style="letter-spacing:0.1pt;"> </span>For example,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Leahy-Smith<span style="letter-spacing:0.1pt;"> </span>Act allows<span style="letter-spacing:0.05pt;"> </span>third-party submission<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>prior<span style="letter-spacing:0.7pt;"> </span>art<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>USPTO<span style="letter-spacing:0.6pt;"> </span>during<span style="letter-spacing:0.7pt;"> </span>patent<span style="letter-spacing:0.7pt;"> </span>prosecution<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>additional<span style="letter-spacing:0.75pt;"> </span>procedures<span style="letter-spacing:0.75pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>attack<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>validity of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>USPTO administered<span style="letter-spacing:0.2pt;"> </span>post-grant<span style="letter-spacing:0.15pt;"> </span>proceedings,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>post-grant<span style="letter-spacing:0.1pt;"> </span>review,<span style="letter-spacing:0.05pt;"> </span>inter<span style="letter-spacing:0.05pt;"> </span>partes<span style="letter-spacing:0.05pt;"> </span>review,<span style="letter-spacing:0.05pt;"> </span>and derivation proceedings. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a &#8220;first-to-invent&#8221;<span style="letter-spacing:0.2pt;"> </span>system<span style="letter-spacing:0.05pt;"> </span>to a &#8220;first-to-file&#8221;<span style="letter-spacing:0.25pt;"> </span>system<span style="letter-spacing:0.05pt;"> </span>in which, assuming<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>patentability<span style="letter-spacing:0.15pt;"> </span>are met,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>first<span style="letter-spacing:0.1pt;"> </span>inventor<span style="letter-spacing:0.05pt;"> </span>to file<span style="letter-spacing:0.05pt;"> </span>a patent<span style="letter-spacing:0.05pt;"> </span>application<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be entitled<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>on an invention regardless<span style="letter-spacing:0.05pt;"> </span>of whether<span style="letter-spacing:1.3pt;"> </span>a<span style="letter-spacing:1.25pt;"> </span>third<span style="letter-spacing:1.3pt;"> </span>party<span style="letter-spacing:1.3pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>first<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>invent<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>claimed<span style="letter-spacing:1.35pt;"> </span>invention.<span style="letter-spacing:1.3pt;"> </span>The<span style="letter-spacing:1.25pt;"> </span>first-to-file<span style="letter-spacing:1.45pt;"> </span>provisions,<span style="letter-spacing:1.3pt;"> </span>however,<span style="letter-spacing:1.2pt;"> </span>only became<span style="letter-spacing:0.1pt;"> </span>effective<span style="letter-spacing:0.15pt;"> </span>on March<span style="letter-spacing:0.05pt;"> </span>16, 2013. It<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>not yet<span style="letter-spacing:0.05pt;"> </span>clear<span style="letter-spacing:0.05pt;"> </span>what, if<span style="letter-spacing:0.05pt;"> </span>any, impact<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Leahy-Smith<span style="letter-spacing:0.1pt;"> </span>Act will<span style="letter-spacing:0.05pt;"> </span>have on the operation<span style="letter-spacing:0.1pt;"> </span>of our business.<span style="letter-spacing:0.05pt;"> </span>However, the<span style="letter-spacing:0.05pt;"> </span>Leahy-Smith<span style="letter-spacing:0.1pt;"> </span>Act and its<span style="letter-spacing:0.05pt;"> </span>implementation<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>make<span style="letter-spacing:0.05pt;"> </span>it more difficult<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>protection<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inventions<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>uncertainties<span style="letter-spacing:0.15pt;"> </span>and costs<span style="letter-spacing:0.05pt;"> </span>surrounding<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>prosecution<span style="letter-spacing:0.1pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>collaboration<span style="letter-spacing:0.2pt;"> </span>partners&#8217;<span style="letter-spacing:0.15pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applications<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>enforcement<span style="letter-spacing:0.15pt;"> </span>or defense<span style="letter-spacing:0.05pt;"> </span>of our or our future collaboration<span style="letter-spacing:0.2pt;"> </span>partners&#8217;<span style="letter-spacing:0.15pt;"> </span>issued<span style="letter-spacing:0.1pt;"> </span>patents,<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>financial condition<span style="letter-spacing:0.05pt;"> </span>and prospects.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>positions<span style="letter-spacing:0.1pt;"> </span>of companies<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>of biologics<span style="letter-spacing:0.1pt;"> </span>and pharmaceuticals<span style="letter-spacing:0.2pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>particularly<span style="letter-spacing:0.2pt;"> </span>uncertain.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>U.S. Supreme<span style="letter-spacing:0.05pt;"> </span>Court has ruled<span style="letter-spacing:0.05pt;"> </span>on several<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>cases<span style="letter-spacing:0.05pt;"> </span>in recent years,<span style="letter-spacing:0.55pt;"> </span>either<span style="letter-spacing:0.6pt;"> </span>narrowing<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>scope<span style="letter-spacing:0.55pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>patent<span style="letter-spacing:0.55pt;"> </span>protection<span style="letter-spacing:0.6pt;"> </span>available<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>certain<span style="letter-spacing:0.6pt;"> </span>circumstances<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>weakening<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span>rights of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>owners<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>situations.<span style="letter-spacing:0.15pt;"> </span>This combination<span style="letter-spacing:0.1pt;"> </span>of events<span style="letter-spacing:0.05pt;"> </span>has created<span style="letter-spacing:0.1pt;"> </span>uncertainty<span style="letter-spacing:0.1pt;"> </span>with respect<span style="letter-spacing:0.1pt;"> </span>to the validity and enforceability of patents, once obtained. Additionally, there have been recent proposals for additional<span style="letter-spacing:0.1pt;"> </span>changes<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>laws of the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and other countries<span style="letter-spacing:0.05pt;"> </span>that, if adopted, could impact<span style="letter-spacing:0.05pt;"> </span>our ability<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>enforce<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>proprietary<span style="letter-spacing:0.2pt;"> </span>technology.<span style="letter-spacing:0.15pt;"> </span>Depending<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.15pt;"> </span>actions<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>U.S. Congress,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>U.S. courts, the<span style="letter-spacing:0.1pt;"> </span>USPTO and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>relevant<span style="letter-spacing:0.15pt;"> </span>law-making<span style="letter-spacing:0.15pt;"> </span>bodies<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>countries,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>laws and regulations<span style="letter-spacing:0.1pt;"> </span>governing<span style="letter-spacing:0.05pt;"> </span>patents could<span style="letter-spacing:0.1pt;"> </span>change<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>unpredictable<span style="letter-spacing:0.15pt;"> </span>ways<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our existing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portfolio</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and weaken</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforce</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we might</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the future.</span></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span>involved<span style="letter-spacing:0.05pt;"> </span>in lawsuits<span style="letter-spacing:0.05pt;"> </span>or administrative<span style="letter-spacing:0.15pt;"> </span>disputes<span style="letter-spacing:0.05pt;"> </span>to protect<span style="letter-spacing:0.05pt;"> </span>or enforce<span style="letter-spacing:0.05pt;"> </span>our patents<span style="letter-spacing:0.05pt;"> </span>or other intellectual<span style="letter-spacing:0.15pt;"> </span>property,<span style="letter-spacing:0.05pt;"> </span>which could be expensive,<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>consuming<span style="letter-spacing:0.05pt;"> </span>and unsuccessful.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents, trademarks,<span style="letter-spacing:0.5pt;"> </span>copyrights,<span style="letter-spacing:0.5pt;"> </span>trade<span style="letter-spacing:0.45pt;"> </span>secrets<span style="letter-spacing:0.5pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>other<span style="letter-spacing:0.45pt;"> </span>intellectual<span style="letter-spacing:0.5pt;"> </span>property.<span style="letter-spacing:0.4pt;"> </span>To<span style="letter-spacing:0.35pt;"> </span>counter<span style="letter-spacing:0.4pt;"> </span>infringement,<span style="letter-spacing:0.5pt;"> </span>misappropriation<span style="letter-spacing:0.5pt;"> </span>or other<span style="letter-spacing:0.65pt;"> </span>violations,<span style="letter-spacing:0.7pt;"> </span>we<span style="letter-spacing:0.6pt;"> </span>may<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.55pt;"> </span>required<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.55pt;"> </span>file<span style="letter-spacing:0.6pt;"> </span>infringement,<span style="letter-spacing:0.7pt;"> </span>misappropriation<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>other<span style="letter-spacing:0.6pt;"> </span>violation<span style="letter-spacing:0.65pt;"> </span>claims,<span style="letter-spacing:0.65pt;"> </span>which<span style="letter-spacing:0.55pt;"> </span>can be<span style="letter-spacing:2.35pt;"> </span>expensive<span style="letter-spacing:2.4pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>time<span style="letter-spacing:2.4pt;"> </span>consuming<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>divert<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.35pt;"> </span>time<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>attention<span style="letter-spacing:2.4pt;"> </span>of<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>management<span style="letter-spacing:2.4pt;"> </span>and<span style="letter-spacing:2.3pt;"> </span>business<span style="letter-spacing:2.35pt;"> </span>and scientific<span style="letter-spacing:0.2pt;"> </span>personnel.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>of our adversaries<span style="letter-spacing:0.1pt;"> </span>in these<span style="letter-spacing:0.05pt;"> </span>proceedings<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>have the<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to dedicate substantially<span style="letter-spacing:0.15pt;"> </span>greater<span style="letter-spacing:0.1pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>to prosecuting<span style="letter-spacing:0.1pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>legal<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we can.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:2.35pt;"> </span>claims<span style="letter-spacing:2.4pt;"> </span>we<span style="letter-spacing:2.3pt;"> </span>assert<span style="letter-spacing:2.4pt;"> </span>against<span style="letter-spacing:2.35pt;"> </span>perceived<span style="letter-spacing:2.4pt;"> </span>infringers<span style="letter-spacing:2.4pt;"> </span>could<span style="letter-spacing:2.35pt;"> </span>provoke<span style="letter-spacing:2.35pt;"> </span>these<span style="letter-spacing:2.35pt;"> </span>parties<span style="letter-spacing:2.4pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>assert<span style="letter-spacing:2.4pt;"> </span>counterclaims against<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>alleging<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we infringe,<span style="letter-spacing:0.1pt;"> </span>misappropriate<span style="letter-spacing:0.15pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>violate<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>or their<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>intellectual property,<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>counterclaims<span style="letter-spacing:0.2pt;"> </span>asserting<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>invalid<span style="letter-spacing:0.05pt;"> </span>or unenforceable,<span style="letter-spacing:0.1pt;"> </span>or both. In patent litigation<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.1pt;"> </span>counterclaims<span style="letter-spacing:0.2pt;"> </span>challenging<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>validity,<span style="letter-spacing:0.1pt;"> </span>enforceability<span style="letter-spacing:0.15pt;"> </span>or scope<span style="letter-spacing:0.05pt;"> </span>of asserted<span style="letter-spacing:0.1pt;"> </span>patents are<span style="letter-spacing:0.1pt;"> </span>commonplace.<span style="letter-spacing:0.15pt;"> </span>Similarly,<span style="letter-spacing:0.15pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>initiate<span style="letter-spacing:0.15pt;"> </span>legal<span style="letter-spacing:0.1pt;"> </span>proceedings<span style="letter-spacing:0.15pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>seeking<span style="letter-spacing:0.1pt;"> </span>a declaration<span style="letter-spacing:0.1pt;"> </span>that certain of our intellectual property is non-infringed, invalid or unenforceable. The outcome of any such proceeding<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>generally<span style="letter-spacing:0.1pt;"> </span>unpredictable.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.4pt;"> </span>any<span style="letter-spacing:0.4pt;"> </span>patent<span style="letter-spacing:0.45pt;"> </span>infringement<span style="letter-spacing:0.55pt;"> </span>proceeding,<span style="letter-spacing:0.45pt;"> </span>there<span style="letter-spacing:0.45pt;"> </span>is<span style="letter-spacing:0.45pt;"> </span>a<span style="letter-spacing:0.4pt;"> </span>risk<span style="letter-spacing:0.45pt;"> </span>that<span style="letter-spacing:0.45pt;"> </span>a<span style="letter-spacing:0.4pt;"> </span>court<span style="letter-spacing:0.45pt;"> </span>will<span style="letter-spacing:0.45pt;"> </span>decide<span style="letter-spacing:0.4pt;"> </span>that<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.35pt;"> </span>patent<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>ours<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.4pt;"> </span>invalid or<span style="letter-spacing:0.05pt;"> </span>unenforceable,<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>whole<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>part,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not have the<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:0.05pt;"> </span>to stop<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>using<span style="letter-spacing:0.05pt;"> </span>the invention<span style="letter-spacing:0.6pt;"> </span>at<span style="letter-spacing:0.6pt;"> </span>issue.<span style="letter-spacing:0.6pt;"> </span>There<span style="letter-spacing:0.6pt;"> </span>is<span style="letter-spacing:0.55pt;"> </span>also<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:0.5pt;"> </span>risk<span style="letter-spacing:0.55pt;"> </span>that,<span style="letter-spacing:0.55pt;"> </span>even<span style="letter-spacing:0.5pt;"> </span>if<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>validity<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.5pt;"> </span>such<span style="letter-spacing:0.5pt;"> </span>patents<span style="letter-spacing:0.55pt;"> </span>is<span style="letter-spacing:0.55pt;"> </span>upheld,<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>court<span style="letter-spacing:0.55pt;"> </span>will<span style="letter-spacing:0.55pt;"> </span>construe the<span style="letter-spacing:0.1pt;"> </span>patent&#8217;s<span style="letter-spacing:0.15pt;"> </span>claims<span style="letter-spacing:0.15pt;"> </span>narrowly<span style="letter-spacing:0.05pt;"> </span>or decide<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we do not have the<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:0.05pt;"> </span>to stop<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>using<span style="letter-spacing:0.05pt;"> </span>the invention<span style="letter-spacing:1.25pt;"> </span>at<span style="letter-spacing:1.25pt;"> </span>issue<span style="letter-spacing:1.25pt;"> </span>on<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>grounds<span style="letter-spacing:1.25pt;"> </span>that<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>patent<span style="letter-spacing:1.25pt;"> </span>claims<span style="letter-spacing:1.3pt;"> </span>do<span style="letter-spacing:1.2pt;"> </span>not<span style="letter-spacing:1.2pt;"> </span>cover<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>invention.<span style="letter-spacing:1.2pt;"> </span>An<span style="letter-spacing:1.15pt;"> </span>adverse<span style="letter-spacing:1.2pt;"> </span>outcome<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>a litigation<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proceeding<span style="letter-spacing:0.1pt;"> </span>involving<span style="letter-spacing:0.05pt;"> </span>our patents<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to assert<span style="letter-spacing:0.1pt;"> </span>our patents<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.1pt;"> </span>competitors,<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>curtail<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>preclude<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>exclude<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>making<span style="letter-spacing:0.05pt;"> </span>and selling<span style="letter-spacing:0.1pt;"> </span>similar or<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:0.2pt;"> </span>products.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>defendant<span style="letter-spacing:0.1pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>prevail<span style="letter-spacing:0.1pt;"> </span>on a legal<span style="letter-spacing:0.05pt;"> </span>assertion<span style="letter-spacing:0.1pt;"> </span>of invalidity<span style="letter-spacing:0.1pt;"> </span>or unenforceability<span style="letter-spacing:0.15pt;"> </span>of our patents<span style="letter-spacing:0.1pt;"> </span>covering<span style="letter-spacing:0.1pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates,<span style="letter-spacing:0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>lose<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>least<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>part,<span style="letter-spacing:0.05pt;"> </span>and perhaps<span style="letter-spacing:0.05pt;"> </span>all,<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent protection<span style="letter-spacing:0.15pt;"> </span>covering<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate.<span style="letter-spacing:0.15pt;"> </span>Competing<span style="letter-spacing:0.1pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>be sold<span style="letter-spacing:0.05pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>in which our patent<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:0.1pt;"> </span>might<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>exist<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>strong.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we lose<span style="letter-spacing:0.05pt;"> </span>a foreign<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>lawsuit,<span style="letter-spacing:0.05pt;"> </span>alleging<span style="letter-spacing:0.1pt;"> </span>our infringement<span style="letter-spacing:0.15pt;"> </span>of a competitor&#8217;s<span style="letter-spacing:0.2pt;"> </span>patents,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>prevented<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>countries.<span style="letter-spacing:0.1pt;"> </span>Any of these<span style="letter-spacing:0.1pt;"> </span>occurrences<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>adversely<span style="letter-spacing:0.15pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:0.2pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>position,<span style="letter-spacing:0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>prospects<span style="letter-spacing:0.1pt;"> </span>and financial condition.<span style="letter-spacing:0.1pt;"> </span>Similarly,<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>assert<span style="letter-spacing:0.15pt;"> </span>trademark<span style="letter-spacing:0.15pt;"> </span>infringement<span style="letter-spacing:0.2pt;"> </span>claims,<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>court<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>determine<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>marks<span style="letter-spacing:0.05pt;"> </span>we have asserted<span style="letter-spacing:1.05pt;"> </span>are<span style="letter-spacing:0.95pt;"> </span>invalid<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>unenforceable,<span style="letter-spacing:1pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>that<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>party<span style="letter-spacing:0.95pt;"> </span>against<span style="letter-spacing:0.95pt;"> </span>whom<span style="letter-spacing:0.9pt;"> </span>we<span style="letter-spacing:0.9pt;"> </span>have<span style="letter-spacing:0.9pt;"> </span>asserted<span style="letter-spacing:1pt;"> </span>trademark<span style="letter-spacing:1pt;"> </span>infringement has<span style="letter-spacing:0.05pt;"> </span>superior<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>marks<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>question.<span style="letter-spacing:0.05pt;"> </span>In this<span style="letter-spacing:0.05pt;"> </span>case,<span style="letter-spacing:0.05pt;"> </span>we could<span style="letter-spacing:0.05pt;"> </span>ultimately<span style="letter-spacing:0.15pt;"> </span>be forced<span style="letter-spacing:0.05pt;"> </span>to cease<span style="letter-spacing:0.05pt;"> </span>use of such trademarks.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, third parties may also raise invalidity or unenforceability claims before administrative bodies in the United States or foreign authorities, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with the prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution of the patent. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. Moreover, it is possible that prior art may exist that we are aware of but do not believe is relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such loss</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of patent</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have a material adverse</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our business,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to effectively<span style="letter-spacing:0.15pt;"> </span>protect<span style="letter-spacing:0.05pt;"> </span>or enforce<span style="letter-spacing:0.05pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>and proprietary<span style="letter-spacing:0.1pt;"> </span>rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing,<span style="letter-spacing:0.1pt;"> </span>prosecuting<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>defending<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>respect<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>in all<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>throughout the<span style="letter-spacing:0.1pt;"> </span>world<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>prohibitively<span style="letter-spacing:0.2pt;"> </span>expensive,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>countries<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:0.15pt;"> </span>our rights<span style="letter-spacing:0.05pt;"> </span>to the same<span style="letter-spacing:0.1pt;"> </span>extent<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States.<span style="letter-spacing:0.1pt;"> </span>The requirements<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>patentability<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>differ<span style="letter-spacing:0.1pt;"> </span>in certain<span style="letter-spacing:0.1pt;"> </span>countries, particularly<span style="letter-spacing:0.2pt;"> </span>in developing<span style="letter-spacing:0.05pt;"> </span>countries.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>any future<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.1pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not always<span style="letter-spacing:0.1pt;"> </span>include<span style="letter-spacing:0.1pt;"> </span>worldwide<span style="letter-spacing:0.1pt;"> </span>rights.<span style="letter-spacing:0.1pt;"> </span>Consequently,<span style="letter-spacing:0.1pt;"> </span>competitors<span style="letter-spacing:0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>use our technologies<span style="letter-spacing:0.1pt;"> </span>in jurisdictions<span style="letter-spacing:2.05pt;"> </span>where<span style="letter-spacing:1.9pt;"> </span>we<span style="letter-spacing:1.85pt;"> </span>have<span style="letter-spacing:1.85pt;"> </span>not<span style="letter-spacing:1.85pt;"> </span>obtained<span style="letter-spacing:1.9pt;"> </span>patent<span style="letter-spacing:1.9pt;"> </span>protection<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>develop<span style="letter-spacing:1.9pt;"> </span>their<span style="letter-spacing:1.9pt;"> </span>own<span style="letter-spacing:1.85pt;"> </span>products<span style="letter-spacing:1.9pt;"> </span>and,<span style="letter-spacing:1.85pt;"> </span>further,<span style="letter-spacing:1.95pt;"> </span>may export<span style="letter-spacing:0.1pt;"> </span>otherwise<span style="letter-spacing:0.1pt;"> </span>infringing<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>territories<span style="letter-spacing:0.2pt;"> </span>where<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>protection,<span style="letter-spacing:0.15pt;"> </span>but where patent enforcement<span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>strong<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and where our ability<span style="letter-spacing:0.1pt;"> </span>to enforce<span style="letter-spacing:0.05pt;"> </span>our patents<span style="letter-spacing:0.05pt;"> </span>to stop infringing<span style="letter-spacing:0.15pt;"> </span>activities<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>inadequate.<span style="letter-spacing:0.15pt;"> </span>These<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:0.05pt;"> </span>with our products<span style="letter-spacing:0.05pt;"> </span>in such territories<span style="letter-spacing:0.15pt;"> </span>and in jurisdictions<span style="letter-spacing:0.15pt;"> </span>where we do not have any patent<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>or where any future<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>or other intellectual property<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not be effective<span style="letter-spacing:0.1pt;"> </span>or sufficient<span style="letter-spacing:0.15pt;"> </span>to prevent<span style="letter-spacing:0.05pt;"> </span>them<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>with us, which could<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our ability to protect and enforce our intellectual property and proprietary rights may be adversely<span style="letter-spacing:0.1pt;"> </span>affected<span style="letter-spacing:0.1pt;"> </span>by unforeseen<span style="letter-spacing:0.1pt;"> </span>changes<span style="letter-spacing:0.05pt;"> </span>in foreign<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>laws. Additionally,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>laws of some countries<span style="letter-spacing:0.15pt;"> </span>outside<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and Europe do not afford<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>defending<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>jurisdictions.<span style="letter-spacing:0.15pt;"> </span>The legal systems<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.1pt;"> </span>countries,<span style="letter-spacing:0.15pt;"> </span>including,<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>example,<span style="letter-spacing:0.1pt;"> </span>India,<span style="letter-spacing:0.1pt;"> </span>China<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>developing<span style="letter-spacing:0.05pt;"> </span>countries,<span style="letter-spacing:0.1pt;"> </span>do not view favorably<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>enforcement<span style="letter-spacing:0.1pt;"> </span>of patents<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or proprietary<span style="letter-spacing:0.1pt;"> </span>rights,<span style="letter-spacing:0.05pt;"> </span>particularly<span style="letter-spacing:0.15pt;"> </span>those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents or other intellectual property or proprietary rights. For example,<span style="letter-spacing:0.1pt;"> </span>many<span style="letter-spacing:0.1pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>countries<span style="letter-spacing:0.15pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>compulsory<span style="letter-spacing:0.15pt;"> </span>licensing<span style="letter-spacing:0.1pt;"> </span>laws under<span style="letter-spacing:0.05pt;"> </span>which a patent<span style="letter-spacing:0.05pt;"> </span>owner must<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:0.05pt;"> </span>licenses to<span style="letter-spacing:1.55pt;"> </span>third<span style="letter-spacing:1.6pt;"> </span>parties.<span style="letter-spacing:1.65pt;"> </span>Consequently,<span style="letter-spacing:1.6pt;"> </span>we<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>not<span style="letter-spacing:1.55pt;"> </span>be<span style="letter-spacing:1.55pt;"> </span>able<span style="letter-spacing:1.6pt;"> </span>to<span style="letter-spacing:1.55pt;"> </span>prevent<span style="letter-spacing:1.6pt;"> </span>third<span style="letter-spacing:1.55pt;"> </span>parties<span style="letter-spacing:1.6pt;"> </span>from<span style="letter-spacing:1.55pt;"> </span>practicing<span style="letter-spacing:1.6pt;"> </span>our<span style="letter-spacing:1.5pt;"> </span>inventions<span style="letter-spacing:1.6pt;"> </span>in certain<span style="letter-spacing:1.35pt;"> </span>countries<span style="letter-spacing:1.35pt;"> </span>outside<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>United<span style="letter-spacing:1.25pt;"> </span>States<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>Europe.<span style="letter-spacing:1.2pt;"> </span>In<span style="letter-spacing:1.2pt;"> </span>addition,<span style="letter-spacing:1.25pt;"> </span>many<span style="letter-spacing:1.25pt;"> </span>countries<span style="letter-spacing:1.3pt;"> </span>limit<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>enforceability<span style="letter-spacing:1.35pt;"> </span>of patents<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>agencies<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>government<span style="letter-spacing:0.15pt;"> </span>contractors.<span style="letter-spacing:0.15pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>countries,<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>owner may<span style="letter-spacing:0.05pt;"> </span>have limited<span style="letter-spacing:0.15pt;"> </span>remedies,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>materially<span style="letter-spacing:0.2pt;"> </span>diminish<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>value<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patent.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>forced<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:0.05pt;"> </span>a license<span style="letter-spacing:0.1pt;"> </span>to third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>respect<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>any patents<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:0.1pt;"> </span>to our business,<span style="letter-spacing:0.05pt;"> </span>our competitive<span style="letter-spacing:0.15pt;"> </span>position<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be impaired,<span style="letter-spacing:0.1pt;"> </span>and our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations,<span style="letter-spacing:0.1pt;"> </span>and prospects<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be adversely<span style="letter-spacing:0.1pt;"> </span>affected.<span style="letter-spacing:0.1pt;"> </span>Proceedings<span style="letter-spacing:0.05pt;"> </span>to enforce<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:0.1pt;"> </span>jurisdictions,<span style="letter-spacing:0.2pt;"> </span>whether<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>not successful,<span style="letter-spacing:0.1pt;"> </span>could result<span style="letter-spacing:0.15pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and divert<span style="letter-spacing:0.05pt;"> </span>our efforts<span style="letter-spacing:0.1pt;"> </span>and resources<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>aspects<span style="letter-spacing:0.05pt;"> </span>of our business,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>put our patents,<span style="letter-spacing:0.1pt;"> </span>trademarks<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>risk<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>being<span style="letter-spacing:0.1pt;"> </span>invalidated<span style="letter-spacing:0.15pt;"> </span>or interpreted narrowly,<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>put our patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of not issuing,<span style="letter-spacing:0.05pt;"> </span>and could<span style="letter-spacing:0.05pt;"> </span>provoke<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>to assert<span style="letter-spacing:0.1pt;"> </span>claims against<span style="letter-spacing:0.9pt;"> </span>us.<span style="letter-spacing:0.8pt;"> </span>We<span style="letter-spacing:0.8pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>not<span style="letter-spacing:0.8pt;"> </span>prevail<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>any<span style="letter-spacing:0.8pt;"> </span>lawsuits<span style="letter-spacing:0.85pt;"> </span>that<span style="letter-spacing:0.85pt;"> </span>we<span style="letter-spacing:0.8pt;"> </span>initiate,<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>damages<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>other<span style="letter-spacing:0.85pt;"> </span>remedies<span style="letter-spacing:0.9pt;"> </span>awarded,<span style="letter-spacing:0.85pt;"> </span>if any, may<span style="letter-spacing:0.05pt;"> </span>not be commercially<span style="letter-spacing:0.15pt;"> </span>meaningful.<span style="letter-spacing:0.1pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>while<span style="letter-spacing:0.05pt;"> </span>we intend<span style="letter-spacing:0.05pt;"> </span>to protect<span style="letter-spacing:0.1pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property and proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>major<span style="letter-spacing:0.1pt;"> </span>markets<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our products,<span style="letter-spacing:0.05pt;"> </span>we cannot<span style="letter-spacing:0.05pt;"> </span>ensure<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>be able<span style="letter-spacing:0.05pt;"> </span>to initiate<span style="letter-spacing:0.1pt;"> </span>or maintain similar<span style="letter-spacing:1.65pt;"> </span>efforts<span style="letter-spacing:1.65pt;"> </span>in<span style="letter-spacing:1.55pt;"> </span>all<span style="letter-spacing:1.6pt;"> </span>jurisdictions<span style="letter-spacing:1.7pt;"> </span>in<span style="letter-spacing:1.55pt;"> </span>which<span style="letter-spacing:1.55pt;"> </span>we<span style="letter-spacing:1.55pt;"> </span>may<span style="letter-spacing:1.6pt;"> </span>wish<span style="letter-spacing:1.55pt;"> </span>to<span style="letter-spacing:1.5pt;"> </span>market<span style="letter-spacing:1.6pt;"> </span>our<span style="letter-spacing:1.5pt;"> </span>products.<span style="letter-spacing:1.55pt;"> </span>Accordingly,<span style="letter-spacing:1.55pt;"> </span>our<span style="letter-spacing:1.5pt;"> </span>efforts<span style="letter-spacing:1.6pt;"> </span>to protect<span style="letter-spacing:0.1pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>and proprietary<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>in such countries<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be inadequate.</p>
<p style="margin-top:15pt;margin-bottom:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we are sued for<span style="letter-spacing:0.05pt;"> </span>infringing,<span style="letter-spacing:0.05pt;"> </span>misappropriating<span style="letter-spacing:0.1pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>violating<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or proprietary rights<span style="letter-spacing:0.05pt;"> </span>of third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.05pt;"> </span>such litigation<span style="letter-spacing:0.1pt;"> </span>or disputes<span style="letter-spacing:0.05pt;"> </span>could be costly<span style="letter-spacing:0.05pt;"> </span>and time<span style="letter-spacing:0.05pt;"> </span>consuming<span style="letter-spacing:0.05pt;"> </span>and could prevent or delay<span style="letter-spacing:0.05pt;"> </span>us from<span style="letter-spacing:0.05pt;"> </span>developing<span style="letter-spacing:0.05pt;"> </span>or commercializing<span style="letter-spacing:0.15pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:2.1pt;"> </span>commercial<span style="letter-spacing:2.25pt;"> </span>success<span style="letter-spacing:2.15pt;"> </span>depends,<span style="letter-spacing:2.15pt;"> </span>in<span style="letter-spacing:2.1pt;"> </span>part,<span style="letter-spacing:2.15pt;"> </span>on<span style="letter-spacing:2.1pt;"> </span>our<span style="letter-spacing:2.1pt;"> </span>ability<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2.05pt;"> </span>develop,<span style="letter-spacing:2.1pt;"> </span>manufacture,<span style="letter-spacing:2.15pt;"> </span>market<span style="letter-spacing:2.15pt;"> </span>and<span style="letter-spacing:2.05pt;"> </span>sell<span style="letter-spacing:2.1pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and use our proprietary<span style="letter-spacing:0.1pt;"> </span>technologies<span style="letter-spacing:0.1pt;"> </span>without<span style="letter-spacing:0.05pt;"> </span>infringing,<span style="letter-spacing:0.1pt;"> </span>misappropriating<span style="letter-spacing:0.15pt;"> </span>or otherwise violating<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>of third<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any third-party<span style="letter-spacing:0.15pt;"> </span>patents,<span style="letter-spacing:0.05pt;"> </span>patent applications<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>found to cover<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or any related<span style="letter-spacing:0.1pt;"> </span>companion diagnostics<span style="letter-spacing:0.15pt;"> </span>or their<span style="letter-spacing:0.05pt;"> </span>compositions,<span style="letter-spacing:0.1pt;"> </span>methods<span style="letter-spacing:0.05pt;"> </span>of use or manufacturing,<span style="letter-spacing:0.15pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>be required<span style="letter-spacing:0.1pt;"> </span>to pay damages,<span style="letter-spacing:0.05pt;"> </span>which could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>substantial,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>free<span style="letter-spacing:0.1pt;"> </span>to manufacture<span style="letter-spacing:0.1pt;"> </span>or market<span style="letter-spacing:0.1pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or to do so without<span style="letter-spacing:0.05pt;"> </span>obtaining<span style="letter-spacing:0.05pt;"> </span>a license,<span style="letter-spacing:0.1pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>not be available<span style="letter-spacing:0.1pt;"> </span>on commercially<span style="letter-spacing:0.15pt;"> </span>reasonable<span style="letter-spacing:0.1pt;"> </span>terms,<span style="letter-spacing:0.1pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>all.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>future<span style="letter-spacing:0.1pt;"> </span>become<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>to,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>threatened<span style="letter-spacing:0.15pt;"> </span>with, adversarial<span style="letter-spacing:0.15pt;"> </span>proceedings<span style="letter-spacing:0.1pt;"> </span>or litigation<span style="letter-spacing:0.15pt;"> </span>regarding intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>respect<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:0.1pt;"> </span>we use in our business.<span style="letter-spacing:0.1pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>assert<span style="letter-spacing:0.1pt;"> </span>infringement<span style="letter-spacing:0.15pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>us, alleging<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>covered<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>patents.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we do not infringe<span style="letter-spacing:0.1pt;"> </span>existing<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>or that<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>infringe<span style="letter-spacing:0.15pt;"> </span>patents<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be granted<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>future.<span style="letter-spacing:0.05pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>because<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>can take<span style="letter-spacing:0.7pt;"> </span>many<span style="letter-spacing:0.7pt;"> </span>years<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>issue<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>may<span style="letter-spacing:0.7pt;"> </span>be<span style="letter-spacing:0.65pt;"> </span>confidential<span style="letter-spacing:0.8pt;"> </span>for<span style="letter-spacing:0.65pt;"> </span>18<span style="letter-spacing:0.6pt;"> </span>months<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>more<span style="letter-spacing:0.65pt;"> </span>after<span style="letter-spacing:0.7pt;"> </span>filing,<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>because<span style="letter-spacing:0.65pt;"> </span>patent<span style="letter-spacing:0.65pt;"> </span>claims can<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>revised<span style="letter-spacing:0.1pt;"> </span>before<span style="letter-spacing:0.1pt;"> </span>issuance,<span style="letter-spacing:0.1pt;"> </span>there<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be applications<span style="letter-spacing:0.1pt;"> </span>now pending<span style="letter-spacing:0.05pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>later<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in issued<span style="letter-spacing:0.05pt;"> </span>patents that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be infringed<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>manufacture,<span style="letter-spacing:0.1pt;"> </span>use or sale<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>a patent<span style="letter-spacing:0.05pt;"> </span>holder<span style="letter-spacing:0.05pt;"> </span>believes<span style="letter-spacing:0.1pt;"> </span>our product<span style="letter-spacing:0.1pt;"> </span>candidate<span style="letter-spacing:0.15pt;"> </span>infringes<span style="letter-spacing:0.15pt;"> </span>its<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holder</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sue us even if</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have received</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent protection</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology.</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:1.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-practicing</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entities that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have no relevant</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug revenue</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and against</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whom our own patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portfolio</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thus</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have no deterrent</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect.</span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.15pt;"> </span>amount<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>biotechnology<span style="letter-spacing:0.1pt;"> </span>and pharmaceutical industries,<span style="letter-spacing:0.1pt;"> </span>and we may<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>to, or threatened<span style="letter-spacing:0.1pt;"> </span>with, litigation<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>adversarial<span style="letter-spacing:0.15pt;"> </span>proceedings<span style="letter-spacing:0.05pt;"> </span>regarding intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or proprietary<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>with respect<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>interference proceedings<span style="letter-spacing:0.7pt;"> </span>before<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>USPTO.<span style="letter-spacing:0.55pt;"> </span>Third<span style="letter-spacing:0.65pt;"> </span>parties<span style="letter-spacing:0.7pt;"> </span>may<span style="letter-spacing:0.65pt;"> </span>assert<span style="letter-spacing:0.7pt;"> </span>infringement,<span style="letter-spacing:0.75pt;"> </span>misappropriation<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>other<span style="letter-spacing:0.6pt;"> </span>claims<span style="letter-spacing:0.65pt;"> </span>against us<span style="letter-spacing:0.05pt;"> </span>based<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or proprietary<span style="letter-spacing:0.1pt;"> </span>rights.<span style="letter-spacing:0.05pt;"> </span>The outcome<span style="letter-spacing:0.05pt;"> </span>of intellectual<span style="letter-spacing:0.15pt;"> </span>property litigation<span style="letter-spacing:0.2pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>disputes<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to uncertainties<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.05pt;"> </span>be adequately<span style="letter-spacing:0.1pt;"> </span>quantified<span style="letter-spacing:0.1pt;"> </span>in advance.<span style="letter-spacing:0.05pt;"> </span>The pharmaceutical<span style="letter-spacing:2.05pt;"> </span>and<span style="letter-spacing:1.9pt;"> </span>biotechnology<span style="letter-spacing:2pt;"> </span>industries<span style="letter-spacing:2pt;"> </span>have<span style="letter-spacing:1.85pt;"> </span>produced<span style="letter-spacing:1.9pt;"> </span>a<span style="letter-spacing:1.85pt;"> </span>significant<span style="letter-spacing:2pt;"> </span>number<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:1.85pt;"> </span>patents,<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:1.85pt;"> </span>it<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.9pt;"> </span>not always<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.6pt;"> </span>clear<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>industry<span style="letter-spacing:0.65pt;"> </span>participants,<span style="letter-spacing:0.75pt;"> </span>including<span style="letter-spacing:0.65pt;"> </span>us,<span style="letter-spacing:0.55pt;"> </span>which<span style="letter-spacing:0.55pt;"> </span>patents<span style="letter-spacing:0.6pt;"> </span>cover<span style="letter-spacing:0.6pt;"> </span>various<span style="letter-spacing:0.6pt;"> </span>types<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>products<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>methods of<span style="letter-spacing:1.1pt;"> </span>using<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>manufacturing<span style="letter-spacing:1.25pt;"> </span>products.<span style="letter-spacing:1.15pt;"> </span>The<span style="letter-spacing:1.1pt;"> </span>coverage<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>patents<span style="letter-spacing:1.15pt;"> </span>is<span style="letter-spacing:1.1pt;"> </span>subject<span style="letter-spacing:1.1pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>interpretation<span style="letter-spacing:1.2pt;"> </span>by<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>courts,<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>the interpretation<span style="letter-spacing:0.2pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>always<span style="letter-spacing:0.1pt;"> </span>uniform.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>sued<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>infringement,<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>to demonstrate<span style="letter-spacing:0.1pt;"> </span>that our<span style="letter-spacing:1.25pt;"> </span>product<span style="letter-spacing:1.3pt;"> </span>candidates,<span style="letter-spacing:1.35pt;"> </span>products<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>methods<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>use,<span style="letter-spacing:1.2pt;"> </span>manufacturing<span style="letter-spacing:1.35pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>other<span style="letter-spacing:1.25pt;"> </span>applicable<span style="letter-spacing:1.3pt;"> </span>activities<span style="letter-spacing:1.35pt;"> </span>either<span style="letter-spacing:1.3pt;"> </span>do<span style="letter-spacing:1.2pt;"> </span>not infringe<span style="letter-spacing:1.15pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>patent<span style="letter-spacing:1.1pt;"> </span>claims<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>relevant<span style="letter-spacing:1.15pt;"> </span>patent<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>that<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>patent<span style="letter-spacing:1.1pt;"> </span>claims<span style="letter-spacing:1.15pt;"> </span>are<span style="letter-spacing:1.1pt;"> </span>invalid<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>unenforceable,<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:1pt;"> </span>we may<span style="letter-spacing:0.75pt;"> </span>not<span style="letter-spacing:0.7pt;"> </span>be<span style="letter-spacing:0.7pt;"> </span>successful<span style="letter-spacing:0.8pt;"> </span>in<span style="letter-spacing:0.7pt;"> </span>doing<span style="letter-spacing:0.7pt;"> </span>so.<span style="letter-spacing:0.7pt;"> </span>However,<span style="letter-spacing:0.7pt;"> </span>proving<span style="letter-spacing:0.7pt;"> </span>invalidity<span style="letter-spacing:0.75pt;"> </span>or<span style="letter-spacing:0.65pt;"> </span>unenforceability<span style="letter-spacing:0.8pt;"> </span>is<span style="letter-spacing:0.7pt;"> </span>difficult.<span style="letter-spacing:0.8pt;"> </span>For<span style="letter-spacing:0.65pt;"> </span>example,<span style="letter-spacing:0.7pt;"> </span>in the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.1pt;"> </span>States,<span style="letter-spacing:0.1pt;"> </span>proving<span style="letter-spacing:0.1pt;"> </span>invalidity<span style="letter-spacing:0.15pt;"> </span>requires<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>showing of clear<span style="letter-spacing:0.05pt;"> </span>and convincing<span style="letter-spacing:0.05pt;"> </span>evidence<span style="letter-spacing:0.05pt;"> </span>to overcome<span style="letter-spacing:0.05pt;"> </span>the presumption<span style="letter-spacing:0.15pt;"> </span>of validity<span style="letter-spacing:0.1pt;"> </span>enjoyed<span style="letter-spacing:0.05pt;"> </span>by issued<span style="letter-spacing:0.05pt;"> </span>patents.<span style="letter-spacing:0.05pt;"> </span>Even if<span style="letter-spacing:0.05pt;"> </span>we believe<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>are without<span style="letter-spacing:0.1pt;"> </span>merit,<span style="letter-spacing:0.15pt;"> </span>there<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>no assurance<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>a court<span style="letter-spacing:0.05pt;"> </span>would find<span style="letter-spacing:0.05pt;"> </span>in our favor<span style="letter-spacing:0.05pt;"> </span>on questions<span style="letter-spacing:0.05pt;"> </span>of infringement,<span style="letter-spacing:0.15pt;"> </span>validity,<span style="letter-spacing:0.1pt;"> </span>or enforceability.<span style="letter-spacing:0.15pt;"> </span>Even if<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>successful<span style="letter-spacing:0.1pt;"> </span>in these<span style="letter-spacing:0.05pt;"> </span>proceedings,<span style="letter-spacing:0.1pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>and attention<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:0.15pt;"> </span>and business<span style="letter-spacing:0.05pt;"> </span>and scientific<span style="letter-spacing:0.15pt;"> </span>personnel<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be diverted<span style="letter-spacing:0.1pt;"> </span>in pursuing<span style="letter-spacing:0.05pt;"> </span>these proceedings,<span style="letter-spacing:1.3pt;"> </span>which<span style="letter-spacing:1.2pt;"> </span>could<span style="letter-spacing:1.25pt;"> </span>significantly<span style="letter-spacing:1.35pt;"> </span>harm<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>business<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>operating<span style="letter-spacing:1.25pt;"> </span>results.<span style="letter-spacing:1.25pt;"> </span>In<span style="letter-spacing:1.15pt;"> </span>addition,<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>not<span style="letter-spacing:1.15pt;"> </span>have sufficient<span style="letter-spacing:0.15pt;"> </span>resources<span style="letter-spacing:0.1pt;"> </span>to bring<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>to a successful<span style="letter-spacing:0.1pt;"> </span>conclusion.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>infringe,<span style="letter-spacing:0.15pt;"> </span>misappropriate<span style="letter-spacing:0.2pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>violate<span style="letter-spacing:0.1pt;"> </span>a third<span style="letter-spacing:0.05pt;"> </span>party&#8217;s<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or proprietary<span style="letter-spacing:0.9pt;"> </span>rights<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.8pt;"> </span>we<span style="letter-spacing:0.8pt;"> </span>are<span style="letter-spacing:0.85pt;"> </span>unsuccessful<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.8pt;"> </span>demonstrating<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.85pt;"> </span>such<span style="letter-spacing:0.8pt;"> </span>intellectual<span style="letter-spacing:0.95pt;"> </span>property<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>proprietary<span style="letter-spacing:0.9pt;"> </span>rights are<span style="letter-spacing:0.05pt;"> </span>invalid<span style="letter-spacing:0.05pt;"> </span>or unenforceable,<span style="letter-spacing:0.1pt;"> </span>we could<span style="letter-spacing:0.05pt;"> </span>be forced,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>by court<span style="letter-spacing:0.05pt;"> </span>order,<span style="letter-spacing:0.05pt;"> </span>to cease developing, manufacturing<span style="letter-spacing:0.1pt;"> </span>or commercializing<span style="letter-spacing:2.1pt;"> </span>the<span style="letter-spacing:1.95pt;"> </span>infringing<span style="letter-spacing:2pt;"> </span>product<span style="letter-spacing:1.95pt;"> </span>candidate<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:1.9pt;"> </span>product.<span style="letter-spacing:1.95pt;"> </span>Alternatively,<span style="letter-spacing:2.05pt;"> </span>we<span style="letter-spacing:1.9pt;"> </span>may<span style="letter-spacing:1.9pt;"> </span>be<span style="letter-spacing:1.85pt;"> </span>required<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>obtain<span style="letter-spacing:1.9pt;"> </span>a license<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>in order<span style="letter-spacing:0.05pt;"> </span>to use the<span style="letter-spacing:0.05pt;"> </span>infringing<span style="letter-spacing:0.1pt;"> </span>technology<span style="letter-spacing:0.05pt;"> </span>and continue<span style="letter-spacing:0.05pt;"> </span>developing,<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:0.15pt;"> </span>or marketing<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>infringing<span style="letter-spacing:0.15pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidate.<span style="letter-spacing:0.15pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>any required<span style="letter-spacing:0.1pt;"> </span>license<span style="letter-spacing:0.1pt;"> </span>on commercially<span style="letter-spacing:1.15pt;"> </span>reasonable<span style="letter-spacing:1.1pt;"> </span>terms<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>at<span style="letter-spacing:1.05pt;"> </span>all.<span style="letter-spacing:1.05pt;"> </span>Even<span style="letter-spacing:1pt;"> </span>if<span style="letter-spacing:1.05pt;"> </span>we<span style="letter-spacing:1pt;"> </span>were<span style="letter-spacing:1pt;"> </span>able<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:1pt;"> </span>obtain<span style="letter-spacing:1.05pt;"> </span>such<span style="letter-spacing:1pt;"> </span>a<span style="letter-spacing:0.95pt;"> </span>license,<span style="letter-spacing:1.05pt;"> </span>it<span style="letter-spacing:1pt;"> </span>could<span style="letter-spacing:1pt;"> </span>be<span style="letter-spacing:0.95pt;"> </span>granted<span style="letter-spacing:1pt;"> </span>on non-exclusive<span style="letter-spacing:0.15pt;"> </span>terms,<span style="letter-spacing:0.15pt;"> </span>thereby<span style="letter-spacing:0.05pt;"> </span>giving<span style="letter-spacing:0.05pt;"> </span>our competitors<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>access<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>technologies licensed<span style="letter-spacing:0.1pt;"> </span>to us. In addition,<span style="letter-spacing:0.05pt;"> </span>we could<span style="letter-spacing:0.05pt;"> </span>be found liable<span style="letter-spacing:0.05pt;"> </span>for significant<span style="letter-spacing:0.1pt;"> </span>monetary<span style="letter-spacing:0.05pt;"> </span>damages, including treble<span style="letter-spacing:0.05pt;"> </span>damages and<span style="letter-spacing:0.05pt;"> </span>attorneys&#8217;<span style="letter-spacing:0.15pt;"> </span>fees<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>found to have willfully<span style="letter-spacing:0.1pt;"> </span>infringed<span style="letter-spacing:0.1pt;"> </span>such third-party<span style="letter-spacing:0.15pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>rights.<span style="letter-spacing:0.05pt;"> </span>A finding<span style="letter-spacing:0.05pt;"> </span>of infringement<span style="letter-spacing:1.4pt;"> </span>could<span style="letter-spacing:1.3pt;"> </span>prevent<span style="letter-spacing:1.3pt;"> </span>us<span style="letter-spacing:1.25pt;"> </span>from<span style="letter-spacing:1.3pt;"> </span>commercializing<span style="letter-spacing:1.45pt;"> </span>our<span style="letter-spacing:1.25pt;"> </span>product<span style="letter-spacing:1.3pt;"> </span>candidates<span style="letter-spacing:1.35pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>force<span style="letter-spacing:1.25pt;"> </span>us<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>cease<span style="letter-spacing:1.25pt;"> </span>some<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>our business<span style="letter-spacing:0.1pt;"> </span>operations,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>materially<span style="letter-spacing:0.2pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>Claims<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we have misappropriated<span style="letter-spacing:0.15pt;"> </span>the confidential<span style="letter-spacing:0.2pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>secrets<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>have a similar<span style="letter-spacing:0.1pt;"> </span>negative<span style="letter-spacing:0.05pt;"> </span>impact<span style="letter-spacing:0.1pt;"> </span>on our business, financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to claims<span style="letter-spacing:0.1pt;"> </span>by third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>asserting<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>our employees<span style="letter-spacing:0.1pt;"> </span>or consultants<span style="letter-spacing:0.05pt;"> </span>or we have misappropriated<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property,<span style="letter-spacing:0.05pt;"> </span>or claiming<span style="letter-spacing:0.1pt;"> </span>ownership of what we regard<span style="letter-spacing:0.05pt;"> </span>as our own intellectual<span style="letter-spacing:0.15pt;"> </span>property.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>currently<span style="letter-spacing:0.15pt;"> </span>or have been previously<span style="letter-spacing:0.1pt;"> </span>employed<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>universities<span style="letter-spacing:0.15pt;"> </span>or at other<span style="letter-spacing:0.1pt;"> </span>biotechnology<span style="letter-spacing:0.15pt;"> </span>or pharmaceutical<span style="letter-spacing:0.15pt;"> </span>companies,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>our competitors<span style="letter-spacing:0.15pt;"> </span>or potential<span style="letter-spacing:0.1pt;"> </span>competitors.<span style="letter-spacing:0.15pt;"> </span>These employees and consultants may have executed proprietary rights, non-disclosure and non-competition agreements,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:0.15pt;"> </span>agreements,<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>connection<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>such other<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:0.1pt;"> </span>or previous<span style="letter-spacing:0.05pt;"> </span>employment.<span style="letter-spacing:0.1pt;"> </span>Although we try<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>ensure<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consultants<span style="letter-spacing:0.1pt;"> </span>do not use the<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.15pt;"> </span>or know-how of others<span style="letter-spacing:0.05pt;"> </span>in their<span style="letter-spacing:0.05pt;"> </span>work for<span style="letter-spacing:0.05pt;"> </span>us, we may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to claims<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we or these<span style="letter-spacing:0.05pt;"> </span>individuals<span style="letter-spacing:0.1pt;"> </span>have used or disclosed<span style="letter-spacing:0.05pt;"> </span>intellectual property,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>secrets<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>information,<span style="letter-spacing:0.15pt;"> </span>of third<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:0.1pt;"> </span>Litigation<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be necessary<span style="letter-spacing:0.1pt;"> </span>to defend<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>such claims.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we fail<span style="letter-spacing:0.05pt;"> </span>in defending<span style="letter-spacing:0.05pt;"> </span>any such claims,<span style="letter-spacing:0.1pt;"> </span>in addition<span style="letter-spacing:0.05pt;"> </span>to paying<span style="letter-spacing:0.05pt;"> </span>monetary<span style="letter-spacing:0.1pt;"> </span>damages, we may<span style="letter-spacing:0.05pt;"> </span>lose<span style="letter-spacing:0.05pt;"> </span>valuable<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or personnel<span style="letter-spacing:0.05pt;"> </span>or sustain<span style="letter-spacing:0.05pt;"> </span>damages.<span style="letter-spacing:0.05pt;"> </span>Such intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be awarded<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>to commercialize<span style="letter-spacing:0.2pt;"> </span>our technology<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>products.<span style="letter-spacing:0.1pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>commercially<span style="letter-spacing:0.2pt;"> </span>reasonable<span style="letter-spacing:0.15pt;"> </span>terms<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all.<span style="letter-spacing:0.05pt;"> </span>Even if we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>successful<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>defending<span style="letter-spacing:0.1pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>such claims,<span style="letter-spacing:0.1pt;"> </span>litigation<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>result<span style="letter-spacing:0.1pt;"> </span>in substantial<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and be a distraction to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management.<span style="letter-spacing:0.15pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>foregoing<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:2.3pt;"> </span>addition,<span style="letter-spacing:2.35pt;"> </span>while<span style="letter-spacing:2.35pt;"> </span>it<span style="letter-spacing:2.35pt;"> </span>is<span style="letter-spacing:2.35pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>policy<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>require<span style="letter-spacing:2.4pt;"> </span>our<span style="letter-spacing:2.25pt;"> </span>employees,<span style="letter-spacing:2.35pt;"> </span>consultants<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.25pt;"> </span>contractors<span style="letter-spacing:2.35pt;"> </span>who<span style="letter-spacing:2.25pt;"> </span>may<span style="letter-spacing:2.3pt;"> </span>be involved<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>conception<span style="letter-spacing:0.05pt;"> </span>or development<span style="letter-spacing:0.1pt;"> </span>of intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>to execute<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>assigning<span style="letter-spacing:0.05pt;"> </span>such intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>be unsuccessful<span style="letter-spacing:0.1pt;"> </span>in executing<span style="letter-spacing:0.05pt;"> </span>such an agreement<span style="letter-spacing:0.1pt;"> </span>with each<span style="letter-spacing:0.05pt;"> </span>party<span style="letter-spacing:0.05pt;"> </span>who, in fact, conceives<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>develops<span style="letter-spacing:0.65pt;"> </span>intellectual<span style="letter-spacing:0.75pt;"> </span>property<span style="letter-spacing:0.65pt;"> </span>that<span style="letter-spacing:0.65pt;"> </span>we<span style="letter-spacing:0.6pt;"> </span>regard<span style="letter-spacing:0.65pt;"> </span>as<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>own,<span style="letter-spacing:0.6pt;"> </span>which<span style="letter-spacing:0.6pt;"> </span>may<span style="letter-spacing:0.65pt;"> </span>result<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.55pt;"> </span>claims<span style="letter-spacing:0.65pt;"> </span>by<span style="letter-spacing:0.55pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>against us<span style="letter-spacing:0.05pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>ownership<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not be self-executing such<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>agreements<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>assigned<span style="letter-spacing:0.05pt;"> </span>to us without<span style="letter-spacing:0.05pt;"> </span>additional assignments<span style="letter-spacing:0.1pt;"> </span>being<span style="letter-spacing:0.05pt;"> </span>executed,<span style="letter-spacing:0.05pt;"> </span>and we may<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>such assignments.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>such agreements<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be breached.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiple</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sponsored</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our lead</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates with</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">various</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">academic</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institutions.</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">academic</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institutions</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not have intellectual</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property assignments</span><span style="letter-spacing:2.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:2.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employees</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consultants,</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or against</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:1.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:1.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property.</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forced</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bring</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims against</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties,</span><span style="letter-spacing:1.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:1.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bring</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</span><span style="letter-spacing:1.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">what</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we regard</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property.</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecuting</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defending</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to paying monetary</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lose</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">valuable</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property.</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successful</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in prosecuting</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or defending</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantial</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a distraction</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our senior management</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and scientific</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which would have a material</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our business, financial condition,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and prospects.</span></p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rights to improvements<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be held by third<span style="letter-spacing:0.05pt;"> </span>parties.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:2.05pt;"> </span>the<span style="letter-spacing:2.1pt;"> </span>course<span style="letter-spacing:2.1pt;"> </span>of<span style="letter-spacing:2.05pt;"> </span>testing<span style="letter-spacing:2.15pt;"> </span>our<span style="letter-spacing:2.05pt;"> </span>product<span style="letter-spacing:2.1pt;"> </span>candidates,<span style="letter-spacing:2.15pt;"> </span>we<span style="letter-spacing:2.05pt;"> </span>have<span style="letter-spacing:2.05pt;"> </span>entered<span style="letter-spacing:2.1pt;"> </span>into<span style="letter-spacing:2.1pt;"> </span>agreements<span style="letter-spacing:2.15pt;"> </span>with<span style="letter-spacing:2.05pt;"> </span>third<span style="letter-spacing:2.1pt;"> </span>parties<span style="letter-spacing:2.15pt;"> </span>to conduct<span style="letter-spacing:0.1pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>testing,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>provide<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>improvements<span style="letter-spacing:0.15pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be owned solely<span style="letter-spacing:0.05pt;"> </span>by a party<span style="letter-spacing:0.1pt;"> </span>or jointly<span style="letter-spacing:0.1pt;"> </span>between<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we determine<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to such improvements<span style="letter-spacing:0.15pt;"> </span>owned solely<span style="letter-spacing:0.05pt;"> </span>by a third party<span style="letter-spacing:1.5pt;"> </span>are<span style="letter-spacing:1.5pt;"> </span>necessary<span style="letter-spacing:1.55pt;"> </span>to<span style="letter-spacing:1.45pt;"> </span>commercialize<span style="letter-spacing:1.65pt;"> </span>our<span style="letter-spacing:1.45pt;"> </span>product<span style="letter-spacing:1.5pt;"> </span>candidates<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>maintain<span style="letter-spacing:1.5pt;"> </span>our<span style="letter-spacing:1.4pt;"> </span>competitive<span style="letter-spacing:1.55pt;"> </span>advantage,<span style="letter-spacing:1.45pt;"> </span>we<span style="letter-spacing:1.4pt;"> </span>may need<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2.15pt;"> </span>obtain<span style="letter-spacing:2.2pt;"> </span>a<span style="letter-spacing:2.15pt;"> </span>license<span style="letter-spacing:2.25pt;"> </span>from<span style="letter-spacing:2.2pt;"> </span>such<span style="letter-spacing:2.15pt;"> </span>third<span style="letter-spacing:2.2pt;"> </span>party<span style="letter-spacing:2.2pt;"> </span>in<span style="letter-spacing:2.15pt;"> </span>order<span style="letter-spacing:2.2pt;"> </span>to<span style="letter-spacing:2.15pt;"> </span>use<span style="letter-spacing:2.15pt;"> </span>the<span style="letter-spacing:2.2pt;"> </span>improvements<span style="letter-spacing:2.25pt;"> </span>and<span style="letter-spacing:2.1pt;"> </span>continue<span style="letter-spacing:2.15pt;"> </span>developing, manufacturing<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates.<span style="letter-spacing:0.15pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>any required<span style="letter-spacing:0.1pt;"> </span>license on<span style="letter-spacing:0.05pt;"> </span>commercially<span style="letter-spacing:0.2pt;"> </span>reasonable<span style="letter-spacing:0.15pt;"> </span>terms<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all.<span style="letter-spacing:0.1pt;"> </span>Even<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>license,<span style="letter-spacing:0.15pt;"> </span>it<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be granted<span style="letter-spacing:0.05pt;"> </span>on non-exclusive<span style="letter-spacing:0.15pt;"> </span>terms,<span style="letter-spacing:0.15pt;"> </span>thereby<span style="letter-spacing:0.05pt;"> </span>giving<span style="letter-spacing:0.05pt;"> </span>our competitors<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties<span style="letter-spacing:0.1pt;"> </span>access<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>technologies licensed<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>Failure<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>commercially<span style="letter-spacing:0.2pt;"> </span>reasonable<span style="letter-spacing:0.15pt;"> </span>terms<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>all,<span style="letter-spacing:0.1pt;"> </span>or to obtain<span style="letter-spacing:0.05pt;"> </span>an exclusive license,<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>commercializing<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or force<span style="letter-spacing:0.05pt;"> </span>us to cease<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>of our business operations,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>materially<span style="letter-spacing:0.2pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>determine<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>to improvements<span style="letter-spacing:0.15pt;"> </span>jointly<span style="letter-spacing:0.1pt;"> </span>owned between<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>necessary<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>commercialize<span style="letter-spacing:0.2pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or maintain<span style="letter-spacing:0.1pt;"> </span>our competitive advantage,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>exclusive<span style="letter-spacing:0.15pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>an exclusive<span style="letter-spacing:0.45pt;"> </span>license<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>any<span style="letter-spacing:0.35pt;"> </span>such<span style="letter-spacing:0.35pt;"> </span>third-party<span style="letter-spacing:0.5pt;"> </span>co-owners&#8217;<span style="letter-spacing:0.4pt;"> </span>interest<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>such<span style="letter-spacing:0.35pt;"> </span>improvements,<span style="letter-spacing:0.5pt;"> </span>such<span style="letter-spacing:0.35pt;"> </span>co-owners<span style="letter-spacing:0.4pt;"> </span>may<span style="letter-spacing:0.4pt;"> </span>be<span style="letter-spacing:0.35pt;"> </span>able to<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.15pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>parties,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>our competitors,<span style="letter-spacing:0.15pt;"> </span>and our competitors<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>market competing<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>technology.<span style="letter-spacing:0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>need<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>cooperation<span style="letter-spacing:0.15pt;"> </span>of any such co-owners<span style="letter-spacing:0.05pt;"> </span>of our intellectual<span style="letter-spacing:0.2pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>in order<span style="letter-spacing:0.05pt;"> </span>to enforce<span style="letter-spacing:0.05pt;"> </span>such intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties,<span style="letter-spacing:0.1pt;"> </span>and such cooperation<span style="letter-spacing:0.1pt;"> </span>may not<span style="letter-spacing:1.1pt;"> </span>be<span style="letter-spacing:1.1pt;"> </span>provided<span style="letter-spacing:1.15pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>us.<span style="letter-spacing:1.1pt;"> </span>Any<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>foregoing<span style="letter-spacing:1.15pt;"> </span>could<span style="letter-spacing:1.15pt;"> </span>have<span style="letter-spacing:1.1pt;"> </span>a<span style="letter-spacing:1.1pt;"> </span>material<span style="letter-spacing:1.25pt;"> </span>adverse<span style="letter-spacing:1.15pt;"> </span>effect<span style="letter-spacing:1.2pt;"> </span>on<span style="letter-spacing:1.1pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>competitive<span style="letter-spacing:1.2pt;"> </span>position, business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>conditions,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations,<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The term<span style="letter-spacing:0.05pt;"> </span>of our patents<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be inadequate<span style="letter-spacing:0.05pt;"> </span>to protect<span style="letter-spacing:0.05pt;"> </span>our competitive<span style="letter-spacing:0.15pt;"> </span>position<span style="letter-spacing:0.05pt;"> </span>on our products.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>amount<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:0.1pt;"> </span>testing<span style="letter-spacing:0.1pt;"> </span>and regulatory<span style="letter-spacing:0.1pt;"> </span>review<span style="letter-spacing:0.05pt;"> </span>of new product candidates,<span style="letter-spacing:0.1pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>protecting<span style="letter-spacing:0.1pt;"> </span>such candidates<span style="letter-spacing:0.1pt;"> </span>might<span style="letter-spacing:0.05pt;"> </span>expire<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>or shortly<span style="letter-spacing:0.05pt;"> </span>after<span style="letter-spacing:0.1pt;"> </span>such candidates<span style="letter-spacing:0.1pt;"> </span>are commercialized.<span style="letter-spacing:0.3pt;"> </span>Depending<span style="letter-spacing:0.1pt;"> </span>upon<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>timing,<span style="letter-spacing:0.2pt;"> </span>duration<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>factors<span style="letter-spacing:0.15pt;"> </span>relating<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>FDA marketing<span style="letter-spacing:0.15pt;"> </span>approval we<span style="letter-spacing:0.1pt;"> </span>receive<span style="letter-spacing:0.2pt;"> </span>for<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.15pt;"> </span>candidates,<span style="letter-spacing:0.2pt;"> </span>one<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>U.S. patents<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>eligible<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>patent term<span style="letter-spacing:1.3pt;"> </span>extension<span style="letter-spacing:1.3pt;"> </span>under<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.3pt;"> </span>Drug<span style="letter-spacing:1.25pt;"> </span>Price<span style="letter-spacing:1.3pt;"> </span>Competition<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>Patent<span style="letter-spacing:1.25pt;"> </span>Term<span style="letter-spacing:1.25pt;"> </span>Restoration<span style="letter-spacing:1.3pt;"> </span>Action<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>1984,<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>Hatch- Waxman<span style="letter-spacing:0.1pt;"> </span>Amendments.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>seek<span style="letter-spacing:0.1pt;"> </span>extensions<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>terms<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and, if<span style="letter-spacing:0.05pt;"> </span>available,<span style="letter-spacing:0.1pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:0.1pt;"> </span>where we are<span style="letter-spacing:0.05pt;"> </span>prosecuting<span style="letter-spacing:0.1pt;"> </span>patents.<span style="letter-spacing:0.05pt;"> </span>In the United States, the Hatch-Waxman<span style="letter-spacing:0.05pt;"> </span>Amendments permit<span style="letter-spacing:0.05pt;"> </span>a patent<span style="letter-spacing:0.1pt;"> </span>term<span style="letter-spacing:0.1pt;"> </span>extension<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>up to five<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:0.05pt;"> </span>beyond the<span style="letter-spacing:0.05pt;"> </span>normal<span style="letter-spacing:0.05pt;"> </span>expiration<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent,<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>approved indication<span style="letter-spacing:1.3pt;"> </span>(or<span style="letter-spacing:1.25pt;"> </span>any<span style="letter-spacing:1.2pt;"> </span>additional<span style="letter-spacing:1.3pt;"> </span>indications<span style="letter-spacing:1.3pt;"> </span>approved<span style="letter-spacing:1.25pt;"> </span>during<span style="letter-spacing:1.25pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>period<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>extension),<span style="letter-spacing:1.25pt;"> </span>as<span style="letter-spacing:1.15pt;"> </span>compensation<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>patent term<span style="letter-spacing:0.1pt;"> </span>lost<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.15pt;"> </span>review<span style="letter-spacing:0.1pt;"> </span>process<span style="letter-spacing:0.1pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>which the<span style="letter-spacing:0.05pt;"> </span>sponsor<span style="letter-spacing:0.05pt;"> </span>was unable<span style="letter-spacing:0.05pt;"> </span>to commercially<span style="letter-spacing:0.15pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>its<span style="letter-spacing:0.05pt;"> </span>new product.<span style="letter-spacing:0.8pt;"> </span>A<span style="letter-spacing:0.75pt;"> </span>patent<span style="letter-spacing:0.8pt;"> </span>term<span style="letter-spacing:0.8pt;"> </span>extension<span style="letter-spacing:0.8pt;"> </span>cannot<span style="letter-spacing:0.8pt;"> </span>extend<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.8pt;"> </span>remaining<span style="letter-spacing:0.85pt;"> </span>term<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.75pt;"> </span>patent<span style="letter-spacing:0.8pt;"> </span>beyond<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.75pt;"> </span>total<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>14<span style="letter-spacing:0.7pt;"> </span>years<span style="letter-spacing:0.75pt;"> </span>from the<span style="letter-spacing:0.1pt;"> </span>date<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>approval,<span style="letter-spacing:0.1pt;"> </span>only<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>approved<span style="letter-spacing:0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>eligible<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>extension<span style="letter-spacing:0.05pt;"> </span>and only those<span style="letter-spacing:2.15pt;"> </span>claims<span style="letter-spacing:2.15pt;"> </span>covering<span style="letter-spacing:2.1pt;"> </span>the<span style="letter-spacing:2.1pt;"> </span>approved<span style="letter-spacing:2.1pt;"> </span>drug,<span style="letter-spacing:2.05pt;"> </span>a<span style="letter-spacing:2.05pt;"> </span>method<span style="letter-spacing:2.1pt;"> </span>for<span style="letter-spacing:2.1pt;"> </span>using<span style="letter-spacing:2.1pt;"> </span>it,<span style="letter-spacing:2.1pt;"> </span>or<span style="letter-spacing:2.05pt;"> </span>a<span style="letter-spacing:2.05pt;"> </span>method<span style="letter-spacing:2.1pt;"> </span>for<span style="letter-spacing:2.1pt;"> </span>manufacturing<span style="letter-spacing:2.2pt;"> </span>it<span style="letter-spacing:2.1pt;"> </span>may<span style="letter-spacing:2.1pt;"> </span>be extended,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>application<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>extension<span style="letter-spacing:0.1pt;"> </span>must<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>submitted<span style="letter-spacing:0.15pt;"> </span>prior<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>expiration<span style="letter-spacing:0.15pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent.<span style="letter-spacing:0.05pt;"> </span>However, the<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.15pt;"> </span>authorities,<span style="letter-spacing:0.2pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>FDA and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>USPTO in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>and any equivalent<span style="letter-spacing:0.1pt;"> </span>regulatory authority<span style="letter-spacing:0.1pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>countries,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not agree<span style="letter-spacing:0.05pt;"> </span>with our assessment<span style="letter-spacing:0.1pt;"> </span>of whether<span style="letter-spacing:0.05pt;"> </span>such extensions<span style="letter-spacing:0.05pt;"> </span>are available<span style="letter-spacing:0.05pt;"> </span>for our patents,<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>refuse<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:0.05pt;"> </span>extensions<span style="letter-spacing:0.1pt;"> </span>to our patents,<span style="letter-spacing:0.05pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.1pt;"> </span>extensions<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we request.<span style="letter-spacing:0.05pt;"> </span>We may<span style="letter-spacing:1.4pt;"> </span>not<span style="letter-spacing:1.35pt;"> </span>be<span style="letter-spacing:1.3pt;"> </span>granted<span style="letter-spacing:1.35pt;"> </span>an<span style="letter-spacing:1.3pt;"> </span>extension<span style="letter-spacing:1.35pt;"> </span>because<span style="letter-spacing:1.35pt;"> </span>of,<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.35pt;"> </span>example,<span style="letter-spacing:1.35pt;"> </span>failing<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:1.3pt;"> </span>exercise<span style="letter-spacing:1.4pt;"> </span>due<span style="letter-spacing:1.3pt;"> </span>diligence<span style="letter-spacing:1.4pt;"> </span>during<span style="letter-spacing:1.35pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:0.15pt;"> </span>patents,<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:0.1pt;"> </span>failing<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>satisfy<span style="letter-spacing:0.15pt;"> </span>applicable<span style="letter-spacing:0.15pt;"> </span>requirements.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:0.05pt;"> </span>to obtain patent<span style="letter-spacing:0.1pt;"> </span>term<span style="letter-spacing:0.1pt;"> </span>extension<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>term<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>extension<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>we request,<span style="letter-spacing:0.05pt;"> </span>our competitors<span style="letter-spacing:0.15pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>third parties<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:0.1pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>competing<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>following<span style="letter-spacing:0.05pt;"> </span>our patent<span style="letter-spacing:0.05pt;"> </span>expiration<span style="letter-spacing:0.1pt;"> </span>and take<span style="letter-spacing:0.05pt;"> </span>advantage of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>investment<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>referencing<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:0.15pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>and launch their<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:0.1pt;"> </span>earlier<span style="letter-spacing:0.15pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>might<span style="letter-spacing:0.1pt;"> </span>otherwise<span style="letter-spacing:0.05pt;"> </span>be the<span style="letter-spacing:0.05pt;"> </span>case.<span style="letter-spacing:0.05pt;"> </span>Any of the<span style="letter-spacing:0.05pt;"> </span>foregoing<span style="letter-spacing:0.05pt;"> </span>would have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect on our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining<span style="letter-spacing:0.05pt;"> </span>our patent<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>depends on compliance<span style="letter-spacing:0.1pt;"> </span>with various<span style="letter-spacing:0.05pt;"> </span>procedural, documentary,<span style="letter-spacing:0.05pt;"> </span>fee<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.1pt;"> </span>imposed<span style="letter-spacing:0.05pt;"> </span>by governmental<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>offices,<span style="letter-spacing:0.1pt;"> </span>and our patent<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>could be reduced<span style="letter-spacing:0.05pt;"> </span>or eliminated<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>noncompliance<span style="letter-spacing:0.05pt;"> </span>with these<span style="letter-spacing:0.05pt;"> </span>requirements.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic<span style="letter-spacing:1.75pt;"> </span>maintenance<span style="letter-spacing:1.8pt;"> </span>fees,<span style="letter-spacing:1.75pt;"> </span>renewal<span style="letter-spacing:1.75pt;"> </span>fees,<span style="letter-spacing:1.75pt;"> </span>annuity<span style="letter-spacing:1.75pt;"> </span>fees<span style="letter-spacing:1.75pt;"> </span>and<span style="letter-spacing:1.7pt;"> </span>various<span style="letter-spacing:1.75pt;"> </span>other<span style="letter-spacing:1.75pt;"> </span>government<span style="letter-spacing:1.8pt;"> </span>fees<span style="letter-spacing:1.75pt;"> </span>on<span style="letter-spacing:1.65pt;"> </span>any<span style="letter-spacing:1.65pt;"> </span>issued patent<span style="letter-spacing:0.4pt;"> </span>are<span style="letter-spacing:0.4pt;"> </span>due<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>be<span style="letter-spacing:0.35pt;"> </span>paid<span style="letter-spacing:0.4pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>USPTO<span style="letter-spacing:0.3pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>patent<span style="letter-spacing:0.4pt;"> </span>offices<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>foreign<span style="letter-spacing:0.4pt;"> </span>countries<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>several<span style="letter-spacing:0.45pt;"> </span>stages<span style="letter-spacing:0.4pt;"> </span>over<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with a number of procedural,<span style="letter-spacing:2.3pt;"> </span>documentary,<span style="letter-spacing:2.3pt;"> </span>fee<span style="letter-spacing:2.25pt;"> </span>payment<span style="letter-spacing:2.25pt;"> </span>and<span style="letter-spacing:2.2pt;"> </span>other<span style="letter-spacing:2.25pt;"> </span>requirements<span style="letter-spacing:2.35pt;"> </span>during<span style="letter-spacing:2.25pt;"> </span>the<span style="letter-spacing:2.25pt;"> </span>patent<span style="letter-spacing:2.25pt;"> </span>application<span style="letter-spacing:2.3pt;"> </span>process.<span style="letter-spacing:2.25pt;"> </span>In<span style="letter-spacing:2.2pt;"> </span>the future,<span style="letter-spacing:1.55pt;"> </span>we<span style="letter-spacing:1.5pt;"> </span>may<span style="letter-spacing:1.55pt;"> </span>rely<span style="letter-spacing:1.55pt;"> </span>on<span style="letter-spacing:1.5pt;"> </span>licensing<span style="letter-spacing:1.6pt;"> </span>partners<span style="letter-spacing:1.6pt;"> </span>to<span style="letter-spacing:1.5pt;"> </span>pay<span style="letter-spacing:1.5pt;"> </span>these<span style="letter-spacing:1.55pt;"> </span>fees<span style="letter-spacing:1.55pt;"> </span>due<span style="letter-spacing:1.5pt;"> </span>to<span style="letter-spacing:1.5pt;"> </span>U.S.<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:1.45pt;"> </span>non-U.S.<span style="letter-spacing:1.45pt;"> </span>patent<span style="letter-spacing:1.5pt;"> </span>agencies<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.45pt;"> </span>to comply<span style="letter-spacing:0.7pt;"> </span>with<span style="letter-spacing:0.6pt;"> </span>these<span style="letter-spacing:0.65pt;"> </span>other<span style="letter-spacing:0.65pt;"> </span>requirements<span style="letter-spacing:0.75pt;"> </span>with<span style="letter-spacing:0.6pt;"> </span>respect<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>any<span style="letter-spacing:0.6pt;"> </span>future<span style="letter-spacing:0.65pt;"> </span>licensed<span style="letter-spacing:0.7pt;"> </span>patents<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>patent<span style="letter-spacing:0.65pt;"> </span>applications.<span style="letter-spacing:0.7pt;"> </span>While an<span style="letter-spacing:0.05pt;"> </span>inadvertent<span style="letter-spacing:0.15pt;"> </span>lapse<span style="letter-spacing:0.1pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>cured<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>late<span style="letter-spacing:0.1pt;"> </span>fee<span style="letter-spacing:0.05pt;"> </span>or by other<span style="letter-spacing:0.05pt;"> </span>means<span style="letter-spacing:0.05pt;"> </span>in accordance<span style="letter-spacing:0.1pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>applicable rules,<span style="letter-spacing:0.1pt;"> </span>there<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>situations<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>noncompliance<span style="letter-spacing:0.15pt;"> </span>can result<span style="letter-spacing:0.1pt;"> </span>in abandonment<span style="letter-spacing:0.05pt;"> </span>or lapse<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance<span style="letter-spacing:1pt;"> </span>events<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.95pt;"> </span>could<span style="letter-spacing:0.95pt;"> </span>result<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.85pt;"> </span>abandonment<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.85pt;"> </span>lapse<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>a<span style="letter-spacing:0.85pt;"> </span>patent<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.85pt;"> </span>patent<span style="letter-spacing:0.9pt;"> </span>application<span style="letter-spacing:0.95pt;"> </span>include,<span style="letter-spacing:0.9pt;"> </span>but are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:0.15pt;"> </span>to,<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:0.15pt;"> </span>to respond<span style="letter-spacing:0.05pt;"> </span>to official<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.05pt;"> </span>within<span style="letter-spacing:0.05pt;"> </span>prescribed<span style="letter-spacing:0.1pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>limits,<span style="letter-spacing:0.1pt;"> </span>non-payment<span style="letter-spacing:0.1pt;"> </span>of fees<span style="letter-spacing:0.05pt;"> </span>and failure<span style="letter-spacing:1.85pt;"> </span>to<span style="letter-spacing:1.75pt;"> </span>properly<span style="letter-spacing:1.8pt;"> </span>legalize<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.7pt;"> </span>submit<span style="letter-spacing:1.75pt;"> </span>formal<span style="letter-spacing:1.8pt;"> </span>documents.<span style="letter-spacing:1.75pt;"> </span>In<span style="letter-spacing:1.7pt;"> </span>such<span style="letter-spacing:1.7pt;"> </span>an<span style="letter-spacing:1.7pt;"> </span>event,<span style="letter-spacing:1.75pt;"> </span>our<span style="letter-spacing:1.7pt;"> </span>competitors<span style="letter-spacing:1.85pt;"> </span>and<span style="letter-spacing:1.7pt;"> </span>other<span style="letter-spacing:1.75pt;"> </span>third parties<span style="letter-spacing:0.15pt;"> </span>might<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to enter<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>with similar<span style="letter-spacing:0.1pt;"> </span>or identical<span style="letter-spacing:0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>of technology,<span style="letter-spacing:0.05pt;"> </span>which would have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we are unable to protect<span style="letter-spacing:0.05pt;"> </span>the confidentiality<span style="letter-spacing:0.15pt;"> </span>of our trade<span style="letter-spacing:0.05pt;"> </span>secrets,<span style="letter-spacing:0.1pt;"> </span>the value<span style="letter-spacing:0.05pt;"> </span>of our technology<span style="letter-spacing:0.05pt;"> </span>could be materially<span style="letter-spacing:0.15pt;"> </span>adversely<span style="letter-spacing:0.1pt;"> </span>affected<span style="letter-spacing:0.1pt;"> </span>and our business<span style="letter-spacing:0.05pt;"> </span>would be harmed.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>rely<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:0.15pt;"> </span>know-how<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>secret<span style="letter-spacing:0.15pt;"> </span>protection<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>confidentiality<span style="letter-spacing:0.15pt;"> </span>agreements<span style="letter-spacing:0.1pt;"> </span>to protect proprietary<span style="letter-spacing:0.95pt;"> </span>know-how<span style="letter-spacing:0.8pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>trade<span style="letter-spacing:0.85pt;"> </span>secrets<span style="letter-spacing:0.9pt;"> </span>that<span style="letter-spacing:0.85pt;"> </span>are<span style="letter-spacing:0.85pt;"> </span>not<span style="letter-spacing:0.8pt;"> </span>patentable<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.8pt;"> </span>that<span style="letter-spacing:0.85pt;"> </span>we<span style="letter-spacing:0.8pt;"> </span>elect<span style="letter-spacing:0.85pt;"> </span>not<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>patent.<span style="letter-spacing:0.85pt;"> </span>We<span style="letter-spacing:0.8pt;"> </span>seek<span style="letter-spacing:0.85pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>protect our trade secrets and proprietary know-how in part by entering into non-disclosure and confidentiality agreements<span style="letter-spacing:0.1pt;"> </span>with parties<span style="letter-spacing:0.1pt;"> </span>who have access<span style="letter-spacing:0.05pt;"> </span>to such knowledge, such as our employees,<span style="letter-spacing:0.05pt;"> </span>consultants,<span style="letter-spacing:0.05pt;"> </span>independent contractors,<span style="letter-spacing:0.15pt;"> </span>advisors,<span style="letter-spacing:0.1pt;"> </span>CMOs,<span style="letter-spacing:0.05pt;"> </span>CROs, hospitals,<span style="letter-spacing:0.15pt;"> </span>independent<span style="letter-spacing:0.1pt;"> </span>treatment<span style="letter-spacing:0.2pt;"> </span>centers,<span style="letter-spacing:0.1pt;"> </span>suppliers,<span style="letter-spacing:0.1pt;"> </span>collaborators<span style="letter-spacing:0.15pt;"> </span>and other third<span style="letter-spacing:0.95pt;"> </span>parties.<span style="letter-spacing:1pt;"> </span>We<span style="letter-spacing:0.9pt;"> </span>also<span style="letter-spacing:0.9pt;"> </span>enter<span style="letter-spacing:0.9pt;"> </span>into<span style="letter-spacing:0.9pt;"> </span>confidentiality<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>invention<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.85pt;"> </span>patent<span style="letter-spacing:0.9pt;"> </span>assignment<span style="letter-spacing:0.95pt;"> </span>agreements<span style="letter-spacing:0.95pt;"> </span>with<span style="letter-spacing:0.85pt;"> </span>employees and<span style="letter-spacing:1.5pt;"> </span>certain<span style="letter-spacing:1.6pt;"> </span>consultants.<span style="letter-spacing:1.55pt;"> </span>However,<span style="letter-spacing:1.45pt;"> </span>we<span style="letter-spacing:1.45pt;"> </span>cannot<span style="letter-spacing:1.5pt;"> </span>guarantee<span style="letter-spacing:1.55pt;"> </span>that<span style="letter-spacing:1.5pt;"> </span>we<span style="letter-spacing:1.45pt;"> </span>have<span style="letter-spacing:1.45pt;"> </span>entered<span style="letter-spacing:1.5pt;"> </span>into<span style="letter-spacing:1.5pt;"> </span>such<span style="letter-spacing:1.45pt;"> </span>agreements<span style="letter-spacing:1.55pt;"> </span>with<span style="letter-spacing:1.45pt;"> </span>each party<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>had<span style="letter-spacing:0.05pt;"> </span>access<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>secrets<span style="letter-spacing:0.1pt;"> </span>or proprietary<span style="letter-spacing:0.1pt;"> </span>know-how. Additionally,<span style="letter-spacing:0.1pt;"> </span>our confidentiality<span style="letter-spacing:0.2pt;"> </span>agreements<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>contractual<span style="letter-spacing:0.15pt;"> </span>protections<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>adequate<span style="letter-spacing:0.1pt;"> </span>to protect<span style="letter-spacing:0.1pt;"> </span>our intellectual property<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>unauthorized<span style="letter-spacing:0.1pt;"> </span>disclosure,<span style="letter-spacing:0.1pt;"> </span>third-party<span style="letter-spacing:0.15pt;"> </span>infringement<span style="letter-spacing:0.15pt;"> </span>or misappropriation.<span style="letter-spacing:0.15pt;"> </span>Any party<span style="letter-spacing:0.05pt;"> </span>with whom we have<span style="letter-spacing:0.05pt;"> </span>executed<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>agreement<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>breach<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>agreement<span style="letter-spacing:0.1pt;"> </span>and disclose<span style="letter-spacing:0.1pt;"> </span>our proprietary<span style="letter-spacing:0.1pt;"> </span>information,<span style="letter-spacing:0.15pt;"> </span>including our trade<span style="letter-spacing:0.05pt;"> </span>secrets,<span style="letter-spacing:0.1pt;"> </span>and we may<span style="letter-spacing:0.05pt;"> </span>not be able<span style="letter-spacing:0.05pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>adequate<span style="letter-spacing:0.05pt;"> </span>remedies<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such breaches.<span style="letter-spacing:0.05pt;"> </span>Enforcing<span style="letter-spacing:0.05pt;"> </span>a claim<span style="letter-spacing:0.1pt;"> </span>that a party<span style="letter-spacing:0.1pt;"> </span>illegally<span style="letter-spacing:0.15pt;"> </span>disclosed<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>misappropriated<span style="letter-spacing:0.15pt;"> </span>a trade<span style="letter-spacing:0.05pt;"> </span>secret<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>difficult,<span style="letter-spacing:0.15pt;"> </span>expensive<span style="letter-spacing:0.05pt;"> </span>and time-consuming,<span style="letter-spacing:0.15pt;"> </span>and the outcome<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>unpredictable.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>courts<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>and certain<span style="letter-spacing:0.1pt;"> </span>foreign<span style="letter-spacing:0.05pt;"> </span>jurisdictions<span style="letter-spacing:0.15pt;"> </span>are less willing<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unwilling<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:0.15pt;"> </span>trade<span style="letter-spacing:0.1pt;"> </span>secrets.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>any of our trade<span style="letter-spacing:0.05pt;"> </span>secrets<span style="letter-spacing:0.1pt;"> </span>were to be lawfully<span style="letter-spacing:0.05pt;"> </span>obtained<span style="letter-spacing:0.05pt;"> </span>or independently<span style="letter-spacing:0.15pt;"> </span>developed<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>competitor<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party,<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have no right<span style="letter-spacing:0.05pt;"> </span>to prevent<span style="letter-spacing:0.05pt;"> </span>such third<span style="letter-spacing:0.05pt;"> </span>party, or<span style="letter-spacing:0.5pt;"> </span>those<span style="letter-spacing:0.55pt;"> </span>to<span style="letter-spacing:0.5pt;"> </span>whom<span style="letter-spacing:0.5pt;"> </span>they<span style="letter-spacing:0.55pt;"> </span>communicate<span style="letter-spacing:0.6pt;"> </span>such<span style="letter-spacing:0.5pt;"> </span>technology<span style="letter-spacing:0.55pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>information,<span style="letter-spacing:0.65pt;"> </span>from<span style="letter-spacing:0.55pt;"> </span>using<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:0.55pt;"> </span>technology<span style="letter-spacing:0.55pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>information to<span style="letter-spacing:2.4pt;"> </span>compete<span style="letter-spacing:2.45pt;"> </span>with<span style="letter-spacing:2.4pt;"> </span>us.<span style="letter-spacing:2.4pt;"> </span>If<span style="letter-spacing:2.4pt;"> </span>any<span style="letter-spacing:2.35pt;"> </span>of<span style="letter-spacing:2.35pt;"> </span>our<span style="letter-spacing:2.35pt;"> </span>trade<span style="letter-spacing:2.4pt;"> </span>secrets<span style="letter-spacing:2.45pt;"> </span>were<span style="letter-spacing:2.35pt;"> </span>to<span style="letter-spacing:2.35pt;"> </span>be<span style="letter-spacing:2.35pt;"> </span>disclosed<span style="letter-spacing:2.45pt;"> </span>to<span style="letter-spacing:2.35pt;"> </span>or<span style="letter-spacing:2.35pt;"> </span>independently<span style="letter-spacing:2.45pt;"> </span>developed<span style="letter-spacing:2.4pt;"> </span>by<span style="letter-spacing:2.35pt;"> </span>a competitor<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.1pt;"> </span>third<span style="letter-spacing:0.1pt;"> </span>party,<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>condition,<span style="letter-spacing:0.1pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prospects<span style="letter-spacing:0.1pt;"> </span>our business and competitive<span style="letter-spacing:0.15pt;"> </span>position<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>be materially<span style="letter-spacing:0.15pt;"> </span>harmed.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual<span style="letter-spacing:0.1pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>do not necessarily<span style="letter-spacing:0.1pt;"> </span>address<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:0.1pt;"> </span>threats.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree<span style="letter-spacing:0.05pt;"> </span>of future<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>afforded<span style="letter-spacing:0.1pt;"> </span>by our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>rights is uncertain<span style="letter-spacing:0.05pt;"> </span>because intellectual property<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:0.2pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>not adequately<span style="letter-spacing:0.1pt;"> </span>protect<span style="letter-spacing:0.1pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>or permit<span style="letter-spacing:0.1pt;"> </span>us to maintain<span style="letter-spacing:0.1pt;"> </span>our competitive<span style="letter-spacing:0.15pt;"> </span>advantage.<span style="letter-spacing:0.05pt;"> </span>For example:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others<span style="letter-spacing:1.75pt;"> </span>may<span style="letter-spacing:1.75pt;"> </span>be<span style="letter-spacing:1.7pt;"> </span>able<span style="letter-spacing:1.75pt;"> </span>to<span style="letter-spacing:1.7pt;"> </span>make<span style="letter-spacing:1.75pt;"> </span>products<span style="letter-spacing:1.75pt;"> </span>similar<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:1.7pt;"> </span>any<span style="letter-spacing:1.7pt;"> </span>product<span style="letter-spacing:1.75pt;"> </span>candidates<span style="letter-spacing:1.8pt;"> </span>we<span style="letter-spacing:1.65pt;"> </span>may<span style="letter-spacing:1.7pt;"> </span>develop<span style="letter-spacing:1.7pt;"> </span>or<span style="letter-spacing:1.65pt;"> </span>utilize similarly<span style="letter-spacing:0.2pt;"> </span>related<span style="letter-spacing:0.15pt;"> </span>technologies<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not covered<span style="letter-spacing:0.05pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:0.1pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>own in the<span style="letter-spacing:0.05pt;"> </span>future&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we,<span style="letter-spacing:1.1pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>any<span style="letter-spacing:1.1pt;"> </span>future<span style="letter-spacing:1.15pt;"> </span>license<span style="letter-spacing:1.2pt;"> </span>partners<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>current<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>future<span style="letter-spacing:1.1pt;"> </span>collaborators,<span style="letter-spacing:1.2pt;"> </span>might<span style="letter-spacing:1.1pt;"> </span>not<span style="letter-spacing:1.05pt;"> </span>have<span style="letter-spacing:1.05pt;"> </span>been<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>first<span style="letter-spacing:1.15pt;"> </span>to make<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>inventions<span style="letter-spacing:0.15pt;"> </span>covered<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>issued<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pending<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>application<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we license<span style="letter-spacing:0.1pt;"> </span>or may own in the<span style="letter-spacing:0.05pt;"> </span>future&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.15pt;"> </span>future<span style="letter-spacing:0.2pt;"> </span>license<span style="letter-spacing:0.25pt;"> </span>partners<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.15pt;"> </span>current<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.15pt;"> </span>future<span style="letter-spacing:0.2pt;"> </span>collaborators,<span style="letter-spacing:0.3pt;"> </span>might<span style="letter-spacing:0.2pt;"> </span>not<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.1pt;"> </span>been<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>first<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>file patent<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:0.1pt;"> </span>covering<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>of our or their<span style="letter-spacing:0.05pt;"> </span>inventions&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies<span style="letter-spacing:0.15pt;"> </span>without<span style="letter-spacing:0.1pt;"> </span>infringing,<span style="letter-spacing:0.1pt;"> </span>misappropriating<span style="letter-spacing:0.15pt;"> </span>or otherwise<span style="letter-spacing:0.05pt;"> </span>violating<span style="letter-spacing:0.1pt;"> </span>any of our owned or licensed intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">it<span style="letter-spacing:0.6pt;"> </span>is<span style="letter-spacing:0.6pt;"> </span>possible<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>pending<span style="letter-spacing:0.6pt;"> </span>patent<span style="letter-spacing:0.6pt;"> </span>applications<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>those<span style="letter-spacing:0.6pt;"> </span>that<span style="letter-spacing:0.55pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.55pt;"> </span>own<span style="letter-spacing:0.5pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.55pt;"> </span>future<span style="letter-spacing:0.55pt;"> </span>will<span style="letter-spacing:0.55pt;"> </span>not<span style="letter-spacing:0.5pt;"> </span>lead to issued<span style="letter-spacing:0.05pt;"> </span>patents&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issued<span style="letter-spacing:0.2pt;"> </span>patents<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.2pt;"> </span>we<span style="letter-spacing:0.15pt;"> </span>hold<span style="letter-spacing:0.15pt;"> </span>rights<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.2pt;"> </span>be<span style="letter-spacing:0.1pt;"> </span>held<span style="letter-spacing:0.15pt;"> </span>invalid<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>unenforceable,<span style="letter-spacing:0.2pt;"> </span>including<span style="letter-spacing:0.15pt;"> </span>as<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>result<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>legal challenges<span style="letter-spacing:0.1pt;"> </span>by our competitors<span style="letter-spacing:0.15pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:0.05pt;"> </span>parties&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<span style="letter-spacing:1pt;"> </span>competitors<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1pt;"> </span>other<span style="letter-spacing:1.05pt;"> </span>third<span style="letter-spacing:1.05pt;"> </span>parties<span style="letter-spacing:1.1pt;"> </span>might<span style="letter-spacing:1pt;"> </span>conduct<span style="letter-spacing:1pt;"> </span>research<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:0.95pt;"> </span>development<span style="letter-spacing:1.05pt;"> </span>activities<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.95pt;"> </span>countries where<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>then<span style="letter-spacing:0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>information<span style="letter-spacing:0.2pt;"> </span>learned<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>such activities<span style="letter-spacing:0.15pt;"> </span>to develop competitive<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>in our major<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:0.15pt;"> </span>markets&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may<span style="letter-spacing:0.05pt;"> </span>not develop<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>proprietary<span style="letter-spacing:0.1pt;"> </span>technologies<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>patentable&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:0.05pt;"> </span>of others<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business&#59;<span style="letter-spacing:0.1pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<span style="letter-spacing:0.6pt;"> </span>may<span style="letter-spacing:0.65pt;"> </span>choose<span style="letter-spacing:0.65pt;"> </span>not<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>file<span style="letter-spacing:0.65pt;"> </span>a<span style="letter-spacing:0.6pt;"> </span>patent<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.6pt;"> </span>order<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>maintain<span style="letter-spacing:0.7pt;"> </span>certain<span style="letter-spacing:0.7pt;"> </span>trade<span style="letter-spacing:0.65pt;"> </span>secrets<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>know<span style="letter-spacing:0.55pt;"> </span>how,<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>a<span style="letter-spacing:0.55pt;"> </span>third party<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>subsequently<span style="letter-spacing:0.1pt;"> </span>file<span style="letter-spacing:0.05pt;"> </span>a patent<span style="letter-spacing:0.05pt;"> </span>covering<span style="letter-spacing:0.05pt;"> </span>such intellectual<span style="letter-spacing:0.15pt;"> </span>property.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>events<span style="letter-spacing:0.05pt;"> </span>occur,<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>have a material<span style="letter-spacing:0.15pt;"> </span>adverse<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>on our business,<span style="letter-spacing:0.05pt;"> </span>financial condition,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and prospects.</p>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related<span style="letter-spacing:0.05pt;"> </span>to Our Common Stock</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An<span style="letter-spacing:-0.05pt;"> </span>active<span style="letter-spacing:0.05pt;"> </span>and liquid<span style="letter-spacing:0.05pt;"> </span>trading<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>never<span style="letter-spacing:0.05pt;"> </span>be sustained.<span style="letter-spacing:0.05pt;"> </span>As a result,<span style="letter-spacing:0.05pt;"> </span>you may not be able<span style="letter-spacing:0.05pt;"> </span>to resell<span style="letter-spacing:0.1pt;"> </span>your shares<span style="letter-spacing:0.05pt;"> </span>of common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>at or above the purchase price.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An<span style="letter-spacing:0.05pt;"> </span>active<span style="letter-spacing:0.1pt;"> </span>trading<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>never<span style="letter-spacing:0.05pt;"> </span>be sustained.<span style="letter-spacing:0.1pt;"> </span>The market value<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.75pt;"> </span>common<span style="letter-spacing:0.8pt;"> </span>stock<span style="letter-spacing:0.8pt;"> </span>may<span style="letter-spacing:0.8pt;"> </span>decrease<span style="letter-spacing:0.85pt;"> </span>from<span style="letter-spacing:0.8pt;"> </span>the<span style="letter-spacing:0.8pt;"> </span>purchase<span style="letter-spacing:0.8pt;"> </span>price.<span style="letter-spacing:0.75pt;"> </span>As<span style="letter-spacing:0.7pt;"> </span>a<span style="letter-spacing:0.7pt;"> </span>result<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>these<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>other<span style="letter-spacing:0.75pt;"> </span>factors, you<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be unable<span style="letter-spacing:0.05pt;"> </span>to resell<span style="letter-spacing:0.1pt;"> </span>your shares<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>or above the<span style="letter-spacing:0.05pt;"> </span>purchase<span style="letter-spacing:0.05pt;"> </span>price.<span style="letter-spacing:0.05pt;"> </span>The lack<span style="letter-spacing:0.05pt;"> </span>of an active<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>impair<span style="letter-spacing:0.15pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>sell<span style="letter-spacing:0.1pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>shares<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>you wish to sell<span style="letter-spacing:0.05pt;"> </span>them<span style="letter-spacing:0.05pt;"> </span>or at<span style="letter-spacing:0.05pt;"> </span>a price<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>you consider<span style="letter-spacing:0.1pt;"> </span>reasonable.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>lack<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>active<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>also<span style="letter-spacing:0.1pt;"> </span>reduce<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>fair<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>value<span style="letter-spacing:0.05pt;"> </span>of your shares. Furthermore,<span style="letter-spacing:1.35pt;"> </span>an<span style="letter-spacing:1.25pt;"> </span>inactive<span style="letter-spacing:1.35pt;"> </span>market<span style="letter-spacing:1.35pt;"> </span>may<span style="letter-spacing:1.3pt;"> </span>also<span style="letter-spacing:1.3pt;"> </span>impair<span style="letter-spacing:1.35pt;"> </span>our<span style="letter-spacing:1.25pt;"> </span>ability<span style="letter-spacing:1.35pt;"> </span>to<span style="letter-spacing:1.25pt;"> </span>raise<span style="letter-spacing:1.3pt;"> </span>capital<span style="letter-spacing:1.35pt;"> </span>by<span style="letter-spacing:1.25pt;"> </span>selling<span style="letter-spacing:1.35pt;"> </span>shares<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>common stock<span style="letter-spacing:0.05pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:0.1pt;"> </span>our ability<span style="letter-spacing:0.1pt;"> </span>to enter<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>strategic<span style="letter-spacing:0.1pt;"> </span>collaborations<span style="letter-spacing:0.15pt;"> </span>or acquire<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>or products<span style="letter-spacing:0.05pt;"> </span>by using our shares<span style="letter-spacing:0.05pt;"> </span>of common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>as consideration.</p>
<p style="margin-top:0pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our quarterly<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>fluctuate<span style="letter-spacing:0.1pt;"> </span>significantly<span style="letter-spacing:0.15pt;"> </span>or may<span style="letter-spacing:0.05pt;"> </span>fall<span style="letter-spacing:0.05pt;"> </span>below the expectations<span style="letter-spacing:0.1pt;"> </span>of investors or securities<span style="letter-spacing:0.1pt;"> </span>analysts,<span style="letter-spacing:0.05pt;"> </span>each of which may<span style="letter-spacing:0.05pt;"> </span>cause our stock<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>to fluctuate<span style="letter-spacing:0.1pt;"> </span>or decline.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to quarterly<span style="letter-spacing:0.1pt;"> </span>fluctuations.<span style="letter-spacing:0.15pt;"> </span>Our net<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>operating results<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be affected<span style="letter-spacing:0.1pt;"> </span>by numerous<span style="letter-spacing:0.05pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>including:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">variations<span style="letter-spacing:2pt;"> </span>in<span style="letter-spacing:1.9pt;"> </span>the<span style="letter-spacing:1.95pt;"> </span>level<span style="letter-spacing:1.95pt;"> </span>of<span style="letter-spacing:1.9pt;"> </span>expense<span style="letter-spacing:1.95pt;"> </span>related<span style="letter-spacing:2pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>the<span style="letter-spacing:1.95pt;"> </span>planned<span style="letter-spacing:1.95pt;"> </span>and<span style="letter-spacing:1.9pt;"> </span>ongoing<span style="letter-spacing:1.9pt;"> </span>development<span style="letter-spacing:2pt;"> </span>of<span style="letter-spacing:1.9pt;"> </span>our<span style="letter-spacing:1.85pt;"> </span>product candidates<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>programs,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>scale-up<span style="letter-spacing:0.1pt;"> </span>CMC<span style="letter-spacing:-0.05pt;"> </span>expenses&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">results<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>clinical<span style="letter-spacing:0.7pt;"> </span>trials,<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>addition<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>termination<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>future<span style="letter-spacing:0.6pt;"> </span>preclinical<span style="letter-spacing:0.7pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>clinical<span style="letter-spacing:0.65pt;"> </span>trials<span style="letter-spacing:0.65pt;"> </span>or<span style="letter-spacing:0.55pt;"> </span>funding support<span style="letter-spacing:0.05pt;"> </span>by us, or future<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:0.15pt;"> </span>or licensing<span style="letter-spacing:0.1pt;"> </span>partners&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<span style="letter-spacing:0.75pt;"> </span>execution<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.75pt;"> </span>any<span style="letter-spacing:0.75pt;"> </span>collaboration,<span style="letter-spacing:0.9pt;"> </span>licensing<span style="letter-spacing:0.85pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>similar<span style="letter-spacing:0.85pt;"> </span>arrangements,<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>timing<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.7pt;"> </span>payments<span style="letter-spacing:0.75pt;"> </span>we may<span style="letter-spacing:0.1pt;"> </span>make<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:0.1pt;"> </span>under<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>arrangements<span style="letter-spacing:0.15pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>termination<span style="letter-spacing:0.15pt;"> </span>or modification<span style="letter-spacing:0.15pt;"> </span>of any such existing<span style="letter-spacing:0.1pt;"> </span>or future<span style="letter-spacing:0.05pt;"> </span>arrangements&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any<span style="letter-spacing:0.45pt;"> </span>intellectual<span style="letter-spacing:0.6pt;"> </span>property<span style="letter-spacing:0.5pt;"> </span>infringement<span style="letter-spacing:0.6pt;"> </span>lawsuit<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>opposition,<span style="letter-spacing:0.45pt;"> </span>interference<span style="letter-spacing:0.55pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>cancellation<span style="letter-spacing:0.55pt;"> </span>proceeding<span style="letter-spacing:0.45pt;"> </span>in which we may<span style="letter-spacing:0.05pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span>involved&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">additions<span style="letter-spacing:0.1pt;"> </span>and departures<span style="letter-spacing:0.1pt;"> </span>of key personnel&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">strategic<span style="letter-spacing:0.35pt;"> </span>decisions<span style="letter-spacing:0.35pt;"> </span>by<span style="letter-spacing:0.25pt;"> </span>us<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.25pt;"> </span>our<span style="letter-spacing:0.25pt;"> </span>competitors,<span style="letter-spacing:0.35pt;"> </span>such<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.2pt;"> </span>acquisitions,<span style="letter-spacing:0.3pt;"> </span>divestitures,<span style="letter-spacing:0.35pt;"> </span>spin-offs,<span style="letter-spacing:0.3pt;"> </span>joint<span style="letter-spacing:0.25pt;"> </span>ventures, strategic<span style="letter-spacing:0.1pt;"> </span>investments<span style="letter-spacing:0.1pt;"> </span>or changes<span style="letter-spacing:0.05pt;"> </span>in business<span style="letter-spacing:0.05pt;"> </span>strategy&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if<span style="letter-spacing:0.95pt;"> </span>any<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>our<span style="letter-spacing:0.9pt;"> </span>product<span style="letter-spacing:0.95pt;"> </span>candidates<span style="letter-spacing:1pt;"> </span>receives<span style="letter-spacing:1pt;"> </span>regulatory<span style="letter-spacing:0.95pt;"> </span>approval,<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>terms<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>such<span style="letter-spacing:0.85pt;"> </span>approval<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>market acceptance<span style="letter-spacing:0.1pt;"> </span>and demand<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory<span style="letter-spacing:0.1pt;"> </span>developments<span style="letter-spacing:0.1pt;"> </span>affecting<span style="letter-spacing:0.1pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>or those<span style="letter-spacing:0.05pt;"> </span>of our competitors&#59;<span style="letter-spacing:0.15pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes<span style="letter-spacing:0.05pt;"> </span>in general<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>and economic<span style="letter-spacing:0.05pt;"> </span>conditions,<span style="letter-spacing:0.1pt;"> </span>such as due to the<span style="letter-spacing:0.05pt;"> </span>COVID-19<span style="letter-spacing:-0.05pt;"> </span>pandemic.</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>quarterly<span style="letter-spacing:0.15pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>fall<span style="letter-spacing:0.1pt;"> </span>below<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>expectations<span style="letter-spacing:0.15pt;"> </span>of investors<span style="letter-spacing:0.1pt;"> </span>or securities<span style="letter-spacing:0.15pt;"> </span>analysts,<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>decline<span style="letter-spacing:0.05pt;"> </span>substantially.<span style="letter-spacing:0.15pt;"> </span>Furthermore,<span style="letter-spacing:0.1pt;"> </span>any quarterly<span style="letter-spacing:0.1pt;"> </span>fluctuations<span style="letter-spacing:0.15pt;"> </span>in our operating<span style="letter-spacing:0.1pt;"> </span>results may,<span style="letter-spacing:0.05pt;"> </span>in turn,<span style="letter-spacing:0.05pt;"> </span>cause<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>to fluctuate<span style="letter-spacing:0.1pt;"> </span>substantially.<span style="letter-spacing:0.15pt;"> </span>We believe<span style="letter-spacing:0.05pt;"> </span>that quarterly comparisons<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.15pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>necessarily<span style="letter-spacing:0.15pt;"> </span>meaningful<span style="letter-spacing:0.15pt;"> </span>and should<span style="letter-spacing:0.05pt;"> </span>not be relied<span style="letter-spacing:0.1pt;"> </span>upon as an indication of our future<span style="letter-spacing:0.05pt;"> </span>performance.</p>
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;text-indent:0%;font-size:9.5pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.1pt;"> </span>to be highly<span style="letter-spacing:0.05pt;"> </span>volatile,<span style="letter-spacing:0.1pt;"> </span>which could result<span style="letter-spacing:0.05pt;"> </span>in substantial losses<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>purchasers<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.55pt;"> </span>market<span style="letter-spacing:0.65pt;"> </span>price<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>common<span style="letter-spacing:0.6pt;"> </span>stock<span style="letter-spacing:0.6pt;"> </span>has<span style="letter-spacing:0.55pt;"> </span>been<span style="letter-spacing:0.55pt;"> </span>highly<span style="letter-spacing:0.6pt;"> </span>volatile<span style="letter-spacing:0.65pt;"> </span>since<span style="letter-spacing:0.6pt;"> </span>our initial public offering, or<span style="letter-spacing:0.5pt;"> </span>IPO. From March 31, 2021 to March 31, 2022, the closing price o<span style="Background-color:#FFFFFF;color:#000000;">f common stock</span><span style="Background-color:#FFFFFF;color:#000000;letter-spacing:0.5pt;">&#160;on the</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;letter-spacing:0.5pt;">Nasdaq Global Select Market&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">has</span><span style="Background-color:#FFFFFF;color:#000000;letter-spacing:0.5pt;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">ranged</span><span style="Background-color:#FFFFFF;color:#000000;letter-spacing:0.55pt;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">from</span><span style="letter-spacing:0.5pt;"> </span>$6.76 to<span style="letter-spacing:0.05pt;"> </span>$45.42<span style="letter-spacing:0.05pt;"> </span>per<span style="letter-spacing:0.1pt;"> </span>share.<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>likely<span style="letter-spacing:0.05pt;"> </span>to continue<span style="letter-spacing:0.05pt;"> </span>to be highly<span style="letter-spacing:0.05pt;"> </span>volatile<span style="letter-spacing:0.1pt;"> </span>and subject to<span style="letter-spacing:0.05pt;"> </span>wide<span style="letter-spacing:0.05pt;"> </span>fluctuations<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>response<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>various<span style="letter-spacing:0.1pt;"> </span>factors,<span style="letter-spacing:0.1pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>of which we cannot<span style="letter-spacing:0.05pt;"> </span>control.<span style="letter-spacing:0.05pt;"> </span>As a result<span style="letter-spacing:0.1pt;"> </span>of this<span style="letter-spacing:0.05pt;"> </span>volatility, investors<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>able<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>sell<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>above<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.1pt;"> </span>paid.<span style="letter-spacing:0.15pt;"> </span>The market<span style="letter-spacing:0.1pt;"> </span>price for<span style="letter-spacing:0.7pt;"> </span>our<span style="letter-spacing:0.65pt;"> </span>common<span style="letter-spacing:0.7pt;"> </span>stock<span style="letter-spacing:0.7pt;"> </span>may<span style="letter-spacing:0.7pt;"> </span>be<span style="letter-spacing:0.65pt;"> </span>influenced<span style="letter-spacing:0.75pt;"> </span>by<span style="letter-spacing:0.65pt;"> </span>many<span style="letter-spacing:0.7pt;"> </span>factors,<span style="letter-spacing:0.75pt;"> </span>including<span style="letter-spacing:0.7pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>other<span style="letter-spacing:0.7pt;"> </span>risks<span style="letter-spacing:0.7pt;"> </span>described<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.65pt;"> </span>this<span style="letter-spacing:0.65pt;"> </span>section<span style="letter-spacing:0.65pt;"> </span>of this Quarterly Report on Form 10-Q<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>following:</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">enrollment<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:1.45pt;"> </span>results<span style="letter-spacing:1.55pt;"> </span>of<span style="letter-spacing:1.45pt;"> </span>clinical<span style="letter-spacing:1.55pt;"> </span>trials<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>our<span style="letter-spacing:1.4pt;"> </span>product<span style="letter-spacing:1.45pt;"> </span>candidates,<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>those<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:1.4pt;"> </span>our<span style="letter-spacing:1.4pt;"> </span>competitors<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:1.4pt;"> </span>our future<span style="letter-spacing:0.05pt;"> </span>collaborators,<span style="letter-spacing:0.15pt;"> </span>or changes<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:0.1pt;"> </span>status<span style="letter-spacing:0.05pt;"> </span>of our product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory<span style="letter-spacing:0.2pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>legal<span style="letter-spacing:0.15pt;"> </span>developments<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>United<span style="letter-spacing:0.15pt;"> </span>States<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>other<span style="letter-spacing:0.15pt;"> </span>countries,<span style="letter-spacing:0.2pt;"> </span>especially<span style="letter-spacing:0.2pt;"> </span>changes<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>or regulations<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>to our product<span style="letter-spacing:0.05pt;"> </span>candidates&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>of competitive<span style="letter-spacing:0.15pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>or technologies&#59;</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">introductions<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>announcements<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>new<span style="letter-spacing:0.35pt;"> </span>products<span style="letter-spacing:0.4pt;"> </span>by<span style="letter-spacing:0.35pt;"> </span>us,<span style="letter-spacing:0.35pt;"> </span>our<span style="letter-spacing:0.35pt;"> </span>future<span style="letter-spacing:0.4pt;"> </span>commercialization<span style="letter-spacing:0.55pt;"> </span>partners,<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.3pt;"> </span>our competitors,<span style="letter-spacing:0.15pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>timing<span style="letter-spacing:0.1pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>introductions<span style="letter-spacing:0.1pt;"> </span>or announcements&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actions<span style="letter-spacing:2.35pt;"> </span>taken<span style="letter-spacing:2.35pt;"> </span>by<span style="letter-spacing:2.3pt;"> </span>regulatory<span style="letter-spacing:2.4pt;"> </span>agencies<span style="letter-spacing:2.35pt;"> </span>with<span style="letter-spacing:2.3pt;"> </span>respect<span style="letter-spacing:2.4pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>products,<span style="letter-spacing:2.35pt;"> </span>clinical<span style="letter-spacing:2.35pt;"> </span>studies,<span style="letter-spacing:2.3pt;"> </span>manufacturing process<span style="letter-spacing:0.05pt;"> </span>or sales<span style="letter-spacing:0.05pt;"> </span>and marketing<span style="letter-spacing:0.1pt;"> </span>terms&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.85pt;"> </span>anticipated<span style="letter-spacing:0.95pt;"> </span>variations<span style="letter-spacing:0.95pt;"> </span>in<span style="letter-spacing:0.85pt;"> </span>our<span style="letter-spacing:0.85pt;"> </span>financial<span style="letter-spacing:0.95pt;"> </span>results<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.85pt;"> </span>those<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>companies<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.9pt;"> </span>are<span style="letter-spacing:0.9pt;"> </span>perceived<span style="letter-spacing:0.9pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>be similar<span style="letter-spacing:0.1pt;"> </span>to us&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of our efforts to acquire or in-license additional technologies, products or product candidates&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments concerning any future collaborations, including but not limited to those with development<span style="letter-spacing:0.1pt;"> </span>and commercialization<span style="letter-spacing:0.2pt;"> </span>partners&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">market<span style="letter-spacing:0.1pt;"> </span>conditions<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:0.15pt;"> </span>and biotechnology<span style="letter-spacing:0.1pt;"> </span>sectors&#59;</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">announcements<span style="letter-spacing:2.45pt;"> </span>by<span style="letter-spacing:2.35pt;"> </span>us<span style="letter-spacing:2.35pt;"> </span>or<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>competitors<span style="letter-spacing:2.45pt;"> </span>of<span style="letter-spacing:2.3pt;"> </span>significant<span style="letter-spacing:2.45pt;"> </span>acquisitions,<span style="letter-spacing:2.4pt;"> </span>strategic<span style="letter-spacing:2.4pt;"> </span>collaborations,<span style="letter-spacing:2.45pt;"> </span>joint ventures<span style="letter-spacing:0.05pt;"> </span>or capital<span style="letter-spacing:0.1pt;"> </span>commitments&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:1.35pt;"> </span>disputes<span style="letter-spacing:1.4pt;"> </span>concerning<span style="letter-spacing:1.4pt;"> </span>patents<span style="letter-spacing:1.4pt;"> </span>or<span style="letter-spacing:1.35pt;"> </span>other<span style="letter-spacing:1.4pt;"> </span>proprietary<span style="letter-spacing:1.45pt;"> </span>rights,<span style="letter-spacing:1.4pt;"> </span>including<span style="letter-spacing:1.4pt;"> </span>patents,<span style="letter-spacing:1.4pt;"> </span>litigation matters<span style="letter-spacing:0.1pt;"> </span>and our ability<span style="letter-spacing:0.1pt;"> </span>to obtain<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>protection<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:0.1pt;"> </span>and products&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<span style="letter-spacing:0.1pt;"> </span>or inability<span style="letter-spacing:0.1pt;"> </span>to raise<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:0.1pt;"> </span>capital<span style="letter-spacing:0.1pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>terms<span style="letter-spacing:0.1pt;"> </span>on which we raise<span style="letter-spacing:0.05pt;"> </span>it&#59;</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>recruitment<span style="letter-spacing:0.15pt;"> </span>or departure<span style="letter-spacing:0.1pt;"> </span>of key personnel&#59;</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>structure<span style="letter-spacing:0.1pt;"> </span>of healthcare<span style="letter-spacing:0.1pt;"> </span>payment<span style="letter-spacing:0.05pt;"> </span>systems&#59;</p></td></tr></table></div>
<p style="line-height:7pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:7pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations<span style="letter-spacing:0.15pt;"> </span>regarding<span style="letter-spacing:0.1pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock,<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:0.1pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>or our industry<span style="letter-spacing:0.05pt;"> </span>generally&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<span style="letter-spacing:1.05pt;"> </span>failure<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>the<span style="letter-spacing:1.1pt;"> </span>failure<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:1.05pt;"> </span>competitors<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.05pt;"> </span>meet<span style="letter-spacing:1.1pt;"> </span>analysts&#8217;<span style="letter-spacing:1.15pt;"> </span>projections<span style="letter-spacing:1.15pt;"> </span>or<span style="letter-spacing:1.05pt;"> </span>guidance<span style="letter-spacing:1.1pt;"> </span>that<span style="letter-spacing:1.05pt;"> </span>we<span style="letter-spacing:1pt;"> </span>or<span style="letter-spacing:1pt;"> </span>our competitors<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>give<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>market&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fluctuations<span style="letter-spacing:0.15pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>valuation<span style="letter-spacing:0.1pt;"> </span>of companies<span style="letter-spacing:0.1pt;"> </span>perceived<span style="letter-spacing:0.1pt;"> </span>by investors<span style="letter-spacing:0.1pt;"> </span>to be comparable<span style="letter-spacing:0.1pt;"> </span>to us&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">announcement<span style="letter-spacing:0.1pt;"> </span>and expectation<span style="letter-spacing:0.1pt;"> </span>of additional<span style="letter-spacing:0.1pt;"> </span>financing<span style="letter-spacing:0.1pt;"> </span>efforts&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">speculation<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>press<span style="letter-spacing:0.05pt;"> </span>or investment<span style="letter-spacing:0.1pt;"> </span>community&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">share<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>and fluctuations<span style="letter-spacing:0.15pt;"> </span>of trading<span style="letter-spacing:0.05pt;"> </span>volume<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sales<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>by us, insiders<span style="letter-spacing:0.1pt;"> </span>or our stockholders&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<span style="letter-spacing:0.05pt;"> </span>concentrated<span style="letter-spacing:0.1pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes<span style="letter-spacing:0.05pt;"> </span>in accounting<span style="letter-spacing:0.05pt;"> </span>principles&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">terrorist<span style="letter-spacing:0.15pt;"> </span>acts,<span style="letter-spacing:0.05pt;"> </span>acts<span style="letter-spacing:0.05pt;"> </span>of war or periods<span style="letter-spacing:0.05pt;"> </span>of widespread<span style="letter-spacing:0.05pt;"> </span>civil<span style="letter-spacing:0.05pt;"> </span>unrest (including the current conflict in Ukraine)&#59;</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">natural<span style="letter-spacing:0.1pt;"> </span>disasters<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>calamities&#59;<span style="letter-spacing:0.15pt;"> </span>and</p></td></tr></table></div>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6.5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general<span style="letter-spacing:2.25pt;"> </span>economic,<span style="letter-spacing:2.25pt;"> </span>industry<span style="letter-spacing:2.25pt;"> </span>and<span style="letter-spacing:2.2pt;"> </span>market<span style="letter-spacing:2.3pt;"> </span>conditions,<span style="letter-spacing:2.3pt;"> </span>or<span style="letter-spacing:2.2pt;"> </span>other<span style="letter-spacing:2.25pt;"> </span>events<span style="letter-spacing:2.25pt;"> </span>or<span style="letter-spacing:2.2pt;"> </span>factors,<span style="letter-spacing:2.3pt;"> </span>many<span style="letter-spacing:2.2pt;"> </span>of<span style="letter-spacing:2.15pt;"> </span>which<span style="letter-spacing:2.15pt;"> </span>are beyond our control,<span style="letter-spacing:0.05pt;"> </span>such as the<span style="letter-spacing:0.05pt;"> </span>COVID-19<span style="letter-spacing:-0.05pt;"> </span>pandemic.</p></td></tr></table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>in general,<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>markets<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>pharmaceutical,<span style="letter-spacing:0.15pt;"> </span>biopharmaceutical<span style="letter-spacing:0.15pt;"> </span>and biotechnology<span style="letter-spacing:0.15pt;"> </span>stocks<span style="letter-spacing:0.05pt;"> </span>in particular,<span style="letter-spacing:0.15pt;"> </span>have experienced<span style="letter-spacing:0.1pt;"> </span>extreme<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>and volume<span style="letter-spacing:0.05pt;"> </span>fluctuations<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>have been often unrelated<span style="letter-spacing:0.1pt;"> </span>or disproportionate<span style="letter-spacing:0.15pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.1pt;"> </span>performance<span style="letter-spacing:0.1pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>issuer.<span style="letter-spacing:0.05pt;"> </span>These broad<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>and industry factors may<span style="letter-spacing:0.1pt;"> </span>seriously<span style="letter-spacing:0.15pt;"> </span>harm<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>price<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock,<span style="letter-spacing:0.1pt;"> </span>regardless<span style="letter-spacing:0.15pt;"> </span>of our actual<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.1pt;"> </span>performance.<span style="letter-spacing:0.1pt;"> </span>The realization<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>above<span style="letter-spacing:0.05pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>or any of a broad<span style="letter-spacing:0.05pt;"> </span>range<span style="letter-spacing:0.05pt;"> </span>of other<span style="letter-spacing:0.05pt;"> </span>risks,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>described<span style="letter-spacing:0.1pt;"> </span>in this<span style="letter-spacing:0.05pt;"> </span>&#8220;Risk Factors&#8221;<span style="letter-spacing:0.05pt;"> </span>section,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>have a dramatic<span style="letter-spacing:0.1pt;"> </span>and adverse<span style="letter-spacing:0.05pt;"> </span>impact<span style="letter-spacing:0.1pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal<span style="letter-spacing:0.05pt;"> </span>stockholders<span style="letter-spacing:0.1pt;"> </span>and management<span style="letter-spacing:0.05pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>a significant<span style="letter-spacing:0.1pt;"> </span>percentage<span style="letter-spacing:0.05pt;"> </span>of our stock<span style="letter-spacing:0.05pt;"> </span>and are able<span style="letter-spacing:0.05pt;"> </span>to exert<span style="letter-spacing:0.05pt;"> </span>significant<span style="letter-spacing:0.1pt;"> </span>control<span style="letter-spacing:0.05pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>matters<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>to stockholder<span style="letter-spacing:0.05pt;"> </span>approval.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>March<span style="letter-spacing:0.65pt;">&#160;31, </span>2022,<span style="letter-spacing:0.75pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>executive<span style="letter-spacing:0.7pt;"> </span>officers,<span style="letter-spacing:0.7pt;"> </span>directors,<span style="letter-spacing:0.7pt;"> </span>beneficial<span style="letter-spacing:0.7pt;"> </span>owners<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>5% or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:0.15pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>respective<span style="letter-spacing:0.1pt;"> </span>affiliates<span style="letter-spacing:0.15pt;"> </span>beneficially<span style="letter-spacing:0.15pt;"> </span>owned a substantial portion of our common<span style="letter-spacing:0.1pt;"> </span>stock.<span style="letter-spacing:0.1pt;"> </span>The voting<span style="letter-spacing:0.05pt;"> </span>power of this group may<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:0.1pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>extent<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>convert<span style="letter-spacing:0.05pt;"> </span>shares<span style="letter-spacing:0.05pt;"> </span>of non-voting<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>hold into<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<span style="letter-spacing:1.25pt;"> </span>group<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.25pt;"> </span>stockholders<span style="letter-spacing:1.35pt;"> </span>have<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>ability<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>control<span style="letter-spacing:1.25pt;"> </span>us<span style="letter-spacing:1.2pt;"> </span>through<span style="letter-spacing:1.25pt;"> </span>this<span style="letter-spacing:1.25pt;"> </span>ownership<span style="letter-spacing:1.25pt;"> </span>position<span style="letter-spacing:1.25pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>are<span style="letter-spacing:1.25pt;"> </span>able<span style="letter-spacing:1.25pt;"> </span>to determine all matters requiring stockholder approval.<span style="letter-spacing:0.05pt;"> </span>For example, these stockholders are able<span style="letter-spacing:0.05pt;"> </span>to control elections<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>directors,<span style="letter-spacing:0.15pt;"> </span>amendments<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>organizational<span style="letter-spacing:0.2pt;"> </span>documents<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of any merger,<span style="letter-spacing:0.1pt;"> </span>sale<span style="letter-spacing:0.05pt;"> </span>of assets<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:0.1pt;"> </span>major<span style="letter-spacing:0.1pt;"> </span>corporate<span style="letter-spacing:0.15pt;"> </span>transaction.<span style="letter-spacing:0.15pt;"> </span>This<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>prevent<span style="letter-spacing:0.1pt;"> </span>or discourage<span style="letter-spacing:0.1pt;"> </span>unsolicited<span style="letter-spacing:0.1pt;"> </span>acquisition<span style="letter-spacing:0.1pt;"> </span>proposals<span style="letter-spacing:0.05pt;"> </span>or offers<span style="letter-spacing:0.1pt;"> </span>for our<span style="letter-spacing:1.05pt;"> </span>common<span style="letter-spacing:1.1pt;"> </span>stock<span style="letter-spacing:1.1pt;"> </span>that<span style="letter-spacing:1.1pt;"> </span>you<span style="letter-spacing:1.05pt;"> </span>may<span style="letter-spacing:1.1pt;"> </span>feel<span style="letter-spacing:1.1pt;"> </span>are<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:1.05pt;"> </span>your<span style="letter-spacing:1.05pt;"> </span>best<span style="letter-spacing:1.05pt;"> </span>interest<span style="letter-spacing:1.1pt;"> </span>as<span style="letter-spacing:1pt;"> </span>one<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:1pt;"> </span>stockholders.<span style="letter-spacing:1.1pt;"> </span>The<span style="letter-spacing:1pt;"> </span>interests<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:1pt;"> </span>this group<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>stockholders<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>not always<span style="letter-spacing:0.05pt;"> </span>coincide<span style="letter-spacing:0.05pt;"> </span>with your interests<span style="letter-spacing:0.1pt;"> </span>or the<span style="letter-spacing:0.05pt;"> </span>interests<span style="letter-spacing:0.1pt;"> </span>of other<span style="letter-spacing:0.05pt;"> </span>stockholders<span style="letter-spacing:0.1pt;"> </span>and they may<span style="letter-spacing:0.1pt;"> </span>act<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>manner<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>advances<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>best<span style="letter-spacing:0.05pt;"> </span>interests<span style="letter-spacing:0.1pt;"> </span>and not necessarily<span style="letter-spacing:0.1pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>of other<span style="letter-spacing:0.05pt;"> </span>stockholders,<span style="letter-spacing:0.1pt;"> </span>including seeking<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>premium<span style="letter-spacing:0.15pt;"> </span>value<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>might<span style="letter-spacing:0.1pt;"> </span>affect<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>prevailing<span style="letter-spacing:0.15pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>price<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>our common stock.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The dual class<span style="letter-spacing:0.05pt;"> </span>structure<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>your ability<span style="letter-spacing:0.1pt;"> </span>to influence<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:0.05pt;"> </span>matters<span style="letter-spacing:0.1pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>your visibility<span style="letter-spacing:0.15pt;"> </span>with respect<span style="letter-spacing:0.05pt;"> </span>to certain<span style="letter-spacing:0.05pt;"> </span>transactions.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>dual<span style="letter-spacing:0.1pt;"> </span>class<span style="letter-spacing:0.1pt;"> </span>structure<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>limit<span style="letter-spacing:0.15pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to influence<span style="letter-spacing:0.1pt;"> </span>corporate<span style="letter-spacing:0.1pt;"> </span>matters.<span style="letter-spacing:0.1pt;"> </span>Holders of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.1pt;"> </span>entitled<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>one vote<span style="letter-spacing:0.05pt;"> </span>per<span style="letter-spacing:0.05pt;"> </span>share,<span style="letter-spacing:0.05pt;"> </span>while<span style="letter-spacing:0.05pt;"> </span>holders<span style="letter-spacing:0.05pt;"> </span>of our non-voting<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not entitled<span style="letter-spacing:0.1pt;"> </span>to any votes.<span style="letter-spacing:0.05pt;"> </span>Nonetheless,<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:0.05pt;"> </span>share<span style="letter-spacing:0.05pt;"> </span>of our non-voting<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be converted<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>any time into one<span style="letter-spacing:0.05pt;"> </span>share<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>option<span style="letter-spacing:0.1pt;"> </span>of its<span style="letter-spacing:0.05pt;"> </span>holder<span style="letter-spacing:0.05pt;"> </span>by providing<span style="letter-spacing:0.05pt;"> </span>written<span style="letter-spacing:0.05pt;"> </span>notice<span style="letter-spacing:0.05pt;"> </span>to us, subject<span style="letter-spacing:0.05pt;"> </span>to the limitations<span style="letter-spacing:0.2pt;"> </span>provided<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>restated<span style="letter-spacing:0.15pt;"> </span>certificate<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>incorporation.<span style="letter-spacing:0.15pt;"> </span>Consequently,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>holders<span style="letter-spacing:0.05pt;"> </span>of our non-voting common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>exercise<span style="letter-spacing:0.15pt;"> </span>their<span style="letter-spacing:0.1pt;"> </span>option<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>make<span style="letter-spacing:0.1pt;"> </span>this<span style="letter-spacing:0.1pt;"> </span>conversion,<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>have the<span style="letter-spacing:0.05pt;"> </span>effect<span style="letter-spacing:0.1pt;"> </span>of increasing<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>relative voting<span style="letter-spacing:0.1pt;"> </span>power<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.1pt;"> </span>prior<span style="letter-spacing:0.1pt;"> </span>holders<span style="letter-spacing:0.1pt;"> </span>of our non-voting<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock,<span style="letter-spacing:0.05pt;"> </span>and correspondingly<span style="letter-spacing:0.1pt;"> </span>decreasing<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>voting power<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>holders<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock,<span style="letter-spacing:0.1pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>limit<span style="letter-spacing:0.15pt;"> </span>your<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to influence<span style="letter-spacing:0.1pt;"> </span>corporate<span style="letter-spacing:0.1pt;"> </span>matters.<span style="letter-spacing:0.1pt;"> </span>For example,<span style="letter-spacing:1.05pt;"> </span>at<span style="letter-spacing:1.05pt;"> </span>March 31, 2022,<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1.05pt;"> </span>common<span style="letter-spacing:1.05pt;"> </span>stock<span style="letter-spacing:1.05pt;"> </span>will<span style="letter-spacing:1.05pt;"> </span>have<span style="letter-spacing:0.95pt;"> </span>100%<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:1pt;"> </span>voting<span style="letter-spacing:1pt;"> </span>power,<span style="letter-spacing:0.95pt;"> </span>but<span style="letter-spacing:0.95pt;"> </span>if<span style="letter-spacing:1pt;"> </span>the<span style="letter-spacing:1pt;"> </span>holders<span style="letter-spacing:1pt;"> </span>of non-voting<span style="letter-spacing:0.1pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>were to convert<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>of their<span style="letter-spacing:0.05pt;"> </span>shares<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>prior<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>would have<span style="letter-spacing:0.05pt;"> </span>76.1%<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>voting<span style="letter-spacing:0.1pt;"> </span>power,<span style="letter-spacing:0.05pt;"> </span>and the<span style="letter-spacing:0.05pt;"> </span>former<span style="letter-spacing:0.1pt;"> </span>non-voting<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>would represent<span style="letter-spacing:0.1pt;"> </span>23.9% of the<span style="letter-spacing:0.05pt;"> </span>voting power. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting<span style="letter-spacing:2.15pt;"> </span>common<span style="letter-spacing:2.15pt;"> </span>stock,<span style="letter-spacing:2.15pt;"> </span>but<span style="letter-spacing:2.1pt;"> </span>10%<span style="letter-spacing:2.1pt;"> </span>or<span style="letter-spacing:2.1pt;"> </span>less<span style="letter-spacing:2.15pt;"> </span>of<span style="letter-spacing:2.1pt;"> </span>our<span style="letter-spacing:2.1pt;"> </span>common<span style="letter-spacing:2.15pt;"> </span>stock,<span style="letter-spacing:2.15pt;"> </span>and<span style="letter-spacing:2.1pt;"> </span>are<span style="letter-spacing:2.15pt;"> </span>not<span style="letter-spacing:2.1pt;"> </span>otherwise<span style="letter-spacing:2.1pt;"> </span>an<span style="letter-spacing:2.05pt;"> </span>insider<span style="letter-spacing:2.15pt;"> </span>of<span style="letter-spacing:2.05pt;"> </span>the company,<span style="letter-spacing:2.35pt;"> </span>may<span style="letter-spacing:2.35pt;"> </span>not<span style="letter-spacing:2.3pt;"> </span>be<span style="letter-spacing:2.3pt;"> </span>required<span style="letter-spacing:2.4pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>report<span style="letter-spacing:2.35pt;"> </span>changes<span style="letter-spacing:2.35pt;"> </span>in<span style="letter-spacing:2.3pt;"> </span>their<span style="letter-spacing:2.35pt;"> </span>ownership<span style="letter-spacing:2.35pt;"> </span>due<span style="letter-spacing:2.3pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>transactions<span style="letter-spacing:2.45pt;"> </span>in<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.25pt;"> </span>non-voting common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>pursuant<span style="letter-spacing:0.05pt;"> </span>to Section<span style="letter-spacing:0.05pt;"> </span>16(a)<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>Securities<span style="letter-spacing:0.1pt;"> </span>Exchange Act of 1934, as amended,<span style="letter-spacing:0.05pt;"> </span>or the Exchange Act, and may<span style="letter-spacing:0.05pt;"> </span>not be subject<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>short-swing<span style="letter-spacing:0.1pt;"> </span>profit<span style="letter-spacing:0.1pt;"> </span>provisions<span style="letter-spacing:0.1pt;"> </span>of Section<span style="letter-spacing:0.05pt;"> </span>16(b)<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>Exchange Act.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging<span style="letter-spacing:0.05pt;"> </span>growth company&#8221;<span style="letter-spacing:0.05pt;"> </span>and a &#8220;smaller<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.05pt;"> </span>company&#8221;<span style="letter-spacing:0.05pt;"> </span>and we cannot be certain<span style="letter-spacing:0.05pt;"> </span>if the reduced<span style="letter-spacing:0.05pt;"> </span>reporting<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:0.1pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>to emerging<span style="letter-spacing:0.05pt;"> </span>growth companies<span style="letter-spacing:0.05pt;"> </span>or smaller<span style="letter-spacing:0.1pt;"> </span>reporting companies<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>make<span style="letter-spacing:0.05pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>attractive<span style="letter-spacing:0.1pt;"> </span>to investors.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.65pt;"> </span>are<span style="letter-spacing:0.7pt;"> </span>an<span style="letter-spacing:0.65pt;"> </span>&#8220;emerging<span style="letter-spacing:0.75pt;"> </span>growth<span style="letter-spacing:0.65pt;"> </span>company&#8221;<span style="letter-spacing:0.7pt;"> </span>as<span style="letter-spacing:0.65pt;"> </span>defined<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>Jumpstart<span style="letter-spacing:0.75pt;"> </span>Our<span style="letter-spacing:0.65pt;"> </span>Business<span style="letter-spacing:0.7pt;"> </span>Startups<span style="letter-spacing:0.7pt;"> </span>Act<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>2012,<span style="letter-spacing:0.6pt;"> </span>or the<span style="letter-spacing:1.9pt;"> </span>JOBS<span style="letter-spacing:1.8pt;"> </span>Act.<span style="letter-spacing:1.85pt;"> </span>For<span style="letter-spacing:1.85pt;"> </span>as<span style="letter-spacing:1.85pt;"> </span>long<span style="letter-spacing:1.85pt;"> </span>as<span style="letter-spacing:1.85pt;"> </span>we<span style="letter-spacing:1.85pt;"> </span>continue<span style="letter-spacing:1.9pt;"> </span>to<span style="letter-spacing:1.85pt;"> </span>be<span style="letter-spacing:1.85pt;"> </span>an<span style="letter-spacing:1.85pt;"> </span>emerging<span style="letter-spacing:1.9pt;"> </span>growth<span style="letter-spacing:1.8pt;"> </span>company,<span style="letter-spacing:1.85pt;"> </span>we<span style="letter-spacing:1.8pt;"> </span>may<span style="letter-spacing:1.85pt;"> </span>take<span style="letter-spacing:1.85pt;"> </span>advantage<span style="letter-spacing:1.85pt;"> </span>of exemptions<span style="letter-spacing:0.15pt;"> </span>from<span style="letter-spacing:0.1pt;"> </span>various<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.15pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>to other<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not emerging<span style="letter-spacing:0.15pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>companies,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>(i)<span style="letter-spacing:0.1pt;"> </span>not being<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to comply<span style="letter-spacing:0.05pt;"> </span>with the<span style="letter-spacing:0.05pt;"> </span>auditor<span style="letter-spacing:0.05pt;"> </span>attestation<span style="letter-spacing:0.15pt;"> </span>requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, (ii) reduced disclosure<span style="letter-spacing:1.25pt;"> </span>obligations<span style="letter-spacing:1.25pt;"> </span>regarding<span style="letter-spacing:1.25pt;"> </span>executive<span style="letter-spacing:1.25pt;"> </span>compensation<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>our Annual Reports on<span style="letter-spacing:1.2pt;"> </span>Form 10-K<span style="letter-spacing:1.2pt;"> </span>as<span style="letter-spacing:1.1pt;"> </span>well<span style="letter-spacing:1.15pt;"> </span>as<span style="letter-spacing:1.1pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>periodic<span style="letter-spacing:1.2pt;"> </span>reports<span style="letter-spacing:1.2pt;"> </span>and proxy<span style="letter-spacing:0.85pt;"> </span>statements<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:0.85pt;"> </span>(iii)<span style="letter-spacing:0.95pt;"> </span>exemptions<span style="letter-spacing:0.95pt;"> </span>from<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.9pt;"> </span>requirements<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.85pt;"> </span>holding<span style="letter-spacing:0.9pt;"> </span>nonbinding<span style="letter-spacing:0.9pt;"> </span>advisory<span style="letter-spacing:0.9pt;"> </span>stockholder<span style="letter-spacing:0.9pt;"> </span>votes on<span style="letter-spacing:0.05pt;"> </span>executive<span style="letter-spacing:0.15pt;"> </span>compensation<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>stockholder<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.1pt;"> </span>of any golden<span style="letter-spacing:0.05pt;"> </span>parachute<span style="letter-spacing:0.1pt;"> </span>payments<span style="letter-spacing:0.05pt;"> </span>not approved<span style="letter-spacing:0.05pt;"> </span>previously. In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>emerging<span style="letter-spacing:0.1pt;"> </span>growth company,<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>only required<span style="letter-spacing:0.1pt;"> </span>to provide<span style="letter-spacing:0.05pt;"> </span>two years<span style="letter-spacing:0.05pt;"> </span>of audited<span style="letter-spacing:0.05pt;"> </span>financial statements<span style="letter-spacing:0.15pt;"> </span>in our Annual Reports on<span style="letter-spacing:0.05pt;"> </span>Form 10-K.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could<span style="letter-spacing:0.05pt;"> </span>be an emerging<span style="letter-spacing:0.1pt;"> </span>growth company<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:0.05pt;"> </span>December<span style="letter-spacing:0.05pt;"> </span>31, 2025, although<span style="letter-spacing:0.05pt;"> </span>circumstances<span style="letter-spacing:0.15pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>cause<span style="letter-spacing:0.05pt;"> </span>us to lose<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>status<span style="letter-spacing:0.05pt;"> </span>earlier,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>deemed<span style="letter-spacing:0.05pt;"> </span>to be a &#8220;large<span style="letter-spacing:0.05pt;"> </span>accelerated<span style="letter-spacing:0.15pt;"> </span>filer,&#8221;<span style="letter-spacing:0.1pt;"> </span>which occurs<span style="letter-spacing:0.05pt;"> </span>when the market<span style="letter-spacing:0.15pt;"> </span>value<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>held<span style="letter-spacing:0.05pt;"> </span>by non-affiliates<span style="letter-spacing:0.2pt;"> </span>equals<span style="letter-spacing:0.05pt;"> </span>or exceeds<span style="letter-spacing:0.05pt;"> </span>$700 million<span style="letter-spacing:0.1pt;"> </span>as of the<span style="letter-spacing:0.05pt;"> </span>prior June<span style="letter-spacing:0.05pt;"> </span>30,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>total<span style="letter-spacing:0.1pt;"> </span>annual<span style="letter-spacing:0.1pt;"> </span>gross<span style="letter-spacing:0.1pt;"> </span>revenue<span style="letter-spacing:0.05pt;"> </span>of $1.07 billion<span style="letter-spacing:0.1pt;"> </span>or more<span style="letter-spacing:0.05pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>any fiscal<span style="letter-spacing:0.1pt;"> </span>year<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>time, in<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>cases<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>emerging<span style="letter-spacing:0.15pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>company<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>following<span style="letter-spacing:0.1pt;"> </span>December<span style="letter-spacing:0.1pt;"> </span>31, or if<span style="letter-spacing:0.05pt;"> </span>we issue<span style="letter-spacing:0.1pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>$1.0 billion<span style="letter-spacing:0.1pt;"> </span>in non-convertible<span style="letter-spacing:0.15pt;"> </span>debt<span style="letter-spacing:0.05pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>any three-year<span style="letter-spacing:0.1pt;"> </span>period<span style="letter-spacing:0.05pt;"> </span>before<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>time,<span style="letter-spacing:0.05pt;"> </span>in which case we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>emerging<span style="letter-spacing:0.15pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>immediately.<span style="letter-spacing:0.15pt;"> </span>Even after<span style="letter-spacing:0.1pt;"> </span>we no longer<span style="letter-spacing:0.05pt;"> </span>qualify<span style="letter-spacing:0.05pt;"> </span>as an emerging<span style="letter-spacing:0.1pt;"> </span>growth company,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>still<span style="letter-spacing:0.1pt;"> </span>qualify<span style="letter-spacing:0.05pt;"> </span>as a &#8220;smaller<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>company,&#8221;<span style="letter-spacing:0.05pt;"> </span>which would allow<span style="letter-spacing:0.05pt;"> </span>us to take advantage<span style="letter-spacing:0.05pt;"> </span>of many<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:0.05pt;"> </span>exemptions<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>disclosure<span style="letter-spacing:0.1pt;"> </span>requirements,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>not being<span style="letter-spacing:0.05pt;"> </span>required<span style="letter-spacing:0.1pt;"> </span>to comply with<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>auditor<span style="letter-spacing:0.1pt;"> </span>attestation<span style="letter-spacing:0.2pt;"> </span>requirements<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Section<span style="letter-spacing:0.1pt;"> </span>404<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Sarbanes-Oxley<span style="letter-spacing:0.15pt;"> </span>Act,<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>our revenues<span style="letter-spacing:0.05pt;"> </span>remain<span style="letter-spacing:0.1pt;"> </span>less than<span style="letter-spacing:0.1pt;"> </span>$100.0<span style="letter-spacing:0.05pt;"> </span>million,<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>reduced<span style="letter-spacing:0.05pt;"> </span>disclosure<span style="letter-spacing:0.1pt;"> </span>obligations<span style="letter-spacing:0.1pt;"> </span>regarding<span style="letter-spacing:0.1pt;"> </span>executive<span style="letter-spacing:0.1pt;"> </span>compensation<span style="letter-spacing:0.1pt;"> </span>in our Annual Reports on Form 10-K<span style="letter-spacing:0.1pt;"> </span>as well<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>periodic<span style="letter-spacing:0.15pt;"> </span>reports<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>proxy<span style="letter-spacing:0.05pt;"> </span>statements.<span style="letter-spacing:0.2pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:0.1pt;"> </span>predict<span style="letter-spacing:0.15pt;"> </span>if<span style="letter-spacing:0.1pt;"> </span>investors<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>find<span style="letter-spacing:0.05pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>less attractive<span style="letter-spacing:0.2pt;"> </span>because<span style="letter-spacing:0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>rely<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.1pt;"> </span>exemptions.<span style="letter-spacing:0.15pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>some<span style="letter-spacing:0.1pt;"> </span>investors<span style="letter-spacing:0.1pt;"> </span>find<span style="letter-spacing:0.05pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>attractive<span style="letter-spacing:0.15pt;"> </span>as a result,<span style="letter-spacing:0.1pt;"> </span>there<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be a less<span style="letter-spacing:0.05pt;"> </span>active<span style="letter-spacing:0.05pt;"> </span>trading<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>and our share<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be more<span style="letter-spacing:0.05pt;"> </span>volatile.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>JOBS Act,<span style="letter-spacing:0.05pt;"> </span>emerging<span style="letter-spacing:0.15pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.15pt;"> </span>can also<span style="letter-spacing:0.05pt;"> </span>delay<span style="letter-spacing:0.05pt;"> </span>adopting<span style="letter-spacing:0.05pt;"> </span>new or revised<span style="letter-spacing:0.05pt;"> </span>accounting standards<span style="letter-spacing:0.15pt;"> </span>until<span style="letter-spacing:0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>as those<span style="letter-spacing:0.05pt;"> </span>standards<span style="letter-spacing:0.1pt;"> </span>apply<span style="letter-spacing:0.05pt;"> </span>to private<span style="letter-spacing:0.1pt;"> </span>companies.<span style="letter-spacing:0.1pt;"> </span>We have elected<span style="letter-spacing:0.1pt;"> </span>to take<span style="letter-spacing:0.05pt;"> </span>advantage<span style="letter-spacing:0.05pt;"> </span>of the benefits<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:0.05pt;"> </span>extended<span style="letter-spacing:0.05pt;"> </span>transition<span style="letter-spacing:0.1pt;"> </span>period.<span style="letter-spacing:0.05pt;"> </span>Our financial<span style="letter-spacing:0.1pt;"> </span>statements<span style="letter-spacing:0.15pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>therefore<span style="letter-spacing:0.1pt;"> </span>not be comparable<span style="letter-spacing:0.1pt;"> </span>to those<span style="letter-spacing:0.05pt;"> </span>of companies<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>comply<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>revised<span style="letter-spacing:0.1pt;"> </span>accounting<span style="letter-spacing:0.1pt;"> </span>standards.<span style="letter-spacing:0.15pt;"> </span>Until<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>date<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>no longer<span style="letter-spacing:0.05pt;"> </span>an &#8220;emerging growth company&#8221; or affirmatively and irrevocably opt out of the exemption provided by Section<span style="letter-spacing:0.95pt;"> </span>7(a)(2)(B)<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>the<span style="letter-spacing:0.95pt;"> </span>Securities<span style="letter-spacing:1pt;"> </span>Act,<span style="letter-spacing:0.9pt;"> </span>upon<span style="letter-spacing:0.9pt;"> </span>issuance<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.9pt;"> </span>a<span style="letter-spacing:0.9pt;"> </span>new<span style="letter-spacing:0.9pt;"> </span>or<span style="letter-spacing:0.9pt;"> </span>revised<span style="letter-spacing:0.95pt;"> </span>accounting<span style="letter-spacing:0.95pt;"> </span>standard<span style="letter-spacing:0.95pt;"> </span>that<span style="letter-spacing:0.95pt;"> </span>applies<span style="letter-spacing:0.95pt;"> </span>to our financial<span style="letter-spacing:0.1pt;"> </span>statements<span style="letter-spacing:0.15pt;"> </span>and that<span style="letter-spacing:0.05pt;"> </span>has a different<span style="letter-spacing:0.1pt;"> </span>effective<span style="letter-spacing:0.1pt;"> </span>date<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:0.05pt;"> </span>and private<span style="letter-spacing:0.1pt;"> </span>companies,<span style="letter-spacing:0.1pt;"> </span>we will<span style="letter-spacing:0.05pt;"> </span>disclose the<span style="letter-spacing:0.1pt;"> </span>date<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>adoption<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>required<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>non-emerging<span style="letter-spacing:0.15pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>date<span style="letter-spacing:0.05pt;"> </span>on which we will<span style="letter-spacing:0.05pt;"> </span>adopt the<span style="letter-spacing:0.05pt;"> </span>recently<span style="letter-spacing:0.1pt;"> </span>issued<span style="letter-spacing:0.05pt;"> </span>accounting<span style="letter-spacing:0.05pt;"> </span>standard.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates<span style="letter-spacing:0.25pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>less<span style="letter-spacing:0.1pt;"> </span>than<span style="letter-spacing:0.1pt;"> </span>$700.0<span style="letter-spacing:0.05pt;"> </span>million as of the prior June 30<span style="letter-spacing:0.1pt;"> </span>and our annual<span style="letter-spacing:0.05pt;"> </span>revenue<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>$100.0 million<span style="letter-spacing:0.1pt;"> </span>during<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>most recently<span style="letter-spacing:0.15pt;"> </span>completed<span style="letter-spacing:0.15pt;"> </span>fiscal<span style="letter-spacing:0.15pt;"> </span>year.<span style="letter-spacing:0.1pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to be a smaller<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>either<span style="letter-spacing:0.1pt;"> </span>(i)<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0<span style="letter-spacing:2.35pt;"> </span>million<span style="letter-spacing:2.45pt;"> </span>during<span style="letter-spacing:2.4pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>most<span style="letter-spacing:2.4pt;"> </span>recently<span style="letter-spacing:2.45pt;"> </span>completed<span style="letter-spacing:2.45pt;"> </span>fiscal<span style="letter-spacing:2.45pt;"> </span>year<span style="letter-spacing:2.4pt;"> </span>and<span style="letter-spacing:2.35pt;"> </span>the<span style="letter-spacing:2.4pt;"> </span>market<span style="letter-spacing:2.45pt;"> </span>value<span style="letter-spacing:2.35pt;"> </span>of<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>stock<span style="letter-spacing:2.35pt;"> </span>held<span style="letter-spacing:2.35pt;"> </span>by non-affiliates<span style="letter-spacing:0.25pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>$700.0 million as of the prior June 30.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are<span style="letter-spacing:0.05pt;"> </span>a smaller<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>we cease<span style="letter-spacing:0.05pt;"> </span>to be an emerging<span style="letter-spacing:0.1pt;"> </span>growth company,<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to rely<span style="letter-spacing:0.05pt;"> </span>on exemptions<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>disclosure<span style="letter-spacing:0.1pt;"> </span>requirements<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>are available<span style="letter-spacing:0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>smaller<span style="letter-spacing:0.15pt;"> </span>reporting<span style="letter-spacing:0.15pt;"> </span>companies.<span style="letter-spacing:0.1pt;"> </span>Specifically,<span style="letter-spacing:0.15pt;"> </span>as a smaller<span style="letter-spacing:0.1pt;"> </span>reporting<span style="letter-spacing:0.1pt;"> </span>company<span style="letter-spacing:0.05pt;"> </span>we may<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:0.05pt;"> </span>to present only<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>two<span style="letter-spacing:0.05pt;"> </span>most<span style="letter-spacing:0.1pt;"> </span>recent<span style="letter-spacing:0.1pt;"> </span>fiscal<span style="letter-spacing:0.15pt;"> </span>years<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>audited<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>statements<span style="letter-spacing:0.15pt;"> </span>in our Annual Report<span style="letter-spacing:0.05pt;"> </span>on Form<span style="letter-spacing:0.05pt;"> </span>10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding<span style="letter-spacing:0.1pt;"> </span>executive<span style="letter-spacing:0.1pt;"> </span>compensation.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover<span style="letter-spacing:0.1pt;"> </span>provisions<span style="letter-spacing:0.05pt;"> </span>in our charter<span style="letter-spacing:0.05pt;"> </span>documents<span style="letter-spacing:0.05pt;"> </span>and under Delaware law could prevent<span style="letter-spacing:0.05pt;"> </span>or delay<span style="letter-spacing:0.05pt;"> </span>an acquisition<span style="letter-spacing:0.1pt;"> </span>of us, which may<span style="letter-spacing:0.05pt;"> </span>be beneficial<span style="letter-spacing:0.1pt;"> </span>to our stockholders,<span style="letter-spacing:0.1pt;"> </span>and may<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:0.05pt;"> </span>attempts<span style="letter-spacing:0.1pt;"> </span>by our stockholders<span style="letter-spacing:0.1pt;"> </span>to replace<span style="letter-spacing:0.05pt;"> </span>or remove<span style="letter-spacing:0.05pt;"> </span>our current<span style="letter-spacing:0.05pt;"> </span>management.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated<span style="letter-spacing:0.1pt;"> </span>certificate<span style="letter-spacing:0.15pt;"> </span>of incorporation<span style="letter-spacing:0.1pt;"> </span>and our restated<span style="letter-spacing:0.1pt;"> </span>bylaws contain<span style="letter-spacing:0.05pt;"> </span>provisions<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>could delay or prevent<span style="letter-spacing:1.25pt;"> </span>a<span style="letter-spacing:1.2pt;"> </span>change<span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>control<span style="letter-spacing:1.2pt;"> </span>of<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>company.<span style="letter-spacing:1.2pt;"> </span>These<span style="letter-spacing:1.15pt;"> </span>provisions<span style="letter-spacing:1.25pt;"> </span>could<span style="letter-spacing:1.2pt;"> </span>also<span style="letter-spacing:1.2pt;"> </span>make<span style="letter-spacing:1.2pt;"> </span>it<span style="letter-spacing:1.2pt;"> </span>difficult<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>stockholders<span style="letter-spacing:1.25pt;"> </span>to elect<span style="letter-spacing:1.75pt;"> </span>directors<span style="letter-spacing:1.8pt;"> </span>who<span style="letter-spacing:1.7pt;"> </span>are<span style="letter-spacing:1.75pt;"> </span>not<span style="letter-spacing:1.7pt;"> </span>nominated<span style="letter-spacing:1.75pt;"> </span>by<span style="letter-spacing:1.65pt;"> </span>current<span style="letter-spacing:1.75pt;"> </span>members<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:1.65pt;"> </span>our<span style="letter-spacing:1.65pt;"> </span>board<span style="letter-spacing:1.7pt;"> </span>of<span style="letter-spacing:1.65pt;"> </span>directors<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.65pt;"> </span>take<span style="letter-spacing:1.7pt;"> </span>other<span style="letter-spacing:1.7pt;"> </span>corporate actions,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>effecting<span style="letter-spacing:0.1pt;"> </span>changes<span style="letter-spacing:0.05pt;"> </span>in our management.<span style="letter-spacing:0.1pt;"> </span>These provisions:</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish<span style="letter-spacing:0.1pt;"> </span>a classified<span style="letter-spacing:0.15pt;"> </span>board<span style="letter-spacing:0.05pt;"> </span>of directors<span style="letter-spacing:0.1pt;"> </span>so that<span style="letter-spacing:0.05pt;"> </span>not all<span style="letter-spacing:0.05pt;"> </span>members<span style="letter-spacing:0.1pt;"> </span>of our board<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>elected<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>one time&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">permit<span style="letter-spacing:0.1pt;"> </span>only the<span style="letter-spacing:0.05pt;"> </span>board<span style="letter-spacing:0.05pt;"> </span>of directors<span style="letter-spacing:0.1pt;"> </span>to establish<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>number<span style="letter-spacing:0.05pt;"> </span>of directors<span style="letter-spacing:0.1pt;"> </span>and fill<span style="letter-spacing:0.1pt;"> </span>vacancies<span style="letter-spacing:0.1pt;"> </span>on the<span style="letter-spacing:0.05pt;"> </span>board&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide<span style="letter-spacing:0.2pt;"> </span>that<span style="letter-spacing:0.15pt;"> </span>directors<span style="letter-spacing:0.2pt;"> </span>may<span style="letter-spacing:0.15pt;"> </span>only<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.1pt;"> </span>removed<span style="letter-spacing:0.15pt;"> </span>&#8220;for<span style="letter-spacing:0.15pt;"> </span>cause&#8221;<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>only<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.15pt;"> </span>approval<span style="letter-spacing:0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>two-thirds<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our stockholders&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require<span style="letter-spacing:0.4pt;"> </span>super-majority<span style="letter-spacing:0.45pt;"> </span>voting<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>amend<span style="letter-spacing:0.35pt;"> </span>some<span style="letter-spacing:0.35pt;"> </span>provisions<span style="letter-spacing:0.4pt;"> </span>in<span style="letter-spacing:0.3pt;"> </span>our<span style="letter-spacing:0.3pt;"> </span>restated<span style="letter-spacing:0.4pt;"> </span>certificate<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>incorporation<span style="letter-spacing:0.35pt;"> </span>and restated<span style="letter-spacing:0.1pt;"> </span>bylaws&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">authorize<span style="letter-spacing:2.3pt;"> </span>the<span style="letter-spacing:2.2pt;"> </span>issuance<span style="letter-spacing:2.2pt;"> </span>of<span style="letter-spacing:2.15pt;"> </span>&#8220;blank<span style="letter-spacing:2.2pt;"> </span>check&#8221;<span style="letter-spacing:2.2pt;"> </span>preferred<span style="letter-spacing:2.25pt;"> </span>stock<span style="letter-spacing:2.2pt;"> </span>that<span style="letter-spacing:2.2pt;"> </span>our<span style="letter-spacing:2.15pt;"> </span>board<span style="letter-spacing:2.2pt;"> </span>could<span style="letter-spacing:2.2pt;"> </span>use<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2.15pt;"> </span>implement<span style="letter-spacing:2.25pt;"> </span>a stockholder<span style="letter-spacing:0.1pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>plan&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">eliminate<span style="letter-spacing:0.15pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>of our stockholders<span style="letter-spacing:0.1pt;"> </span>to call<span style="letter-spacing:0.05pt;"> </span>special<span style="letter-spacing:0.1pt;"> </span>meetings<span style="letter-spacing:0.1pt;"> </span>of stockholders&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prohibit<span style="letter-spacing:0.9pt;"> </span>stockholder<span style="letter-spacing:0.9pt;"> </span>action<span style="letter-spacing:0.85pt;"> </span>by<span style="letter-spacing:0.75pt;"> </span>written<span style="letter-spacing:0.8pt;"> </span>consent,<span style="letter-spacing:0.8pt;"> </span>which<span style="letter-spacing:0.75pt;"> </span>requires<span style="letter-spacing:0.85pt;"> </span>all<span style="letter-spacing:0.8pt;"> </span>stockholder<span style="letter-spacing:0.85pt;"> </span>actions<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>be<span style="letter-spacing:0.75pt;"> </span>taken<span style="letter-spacing:0.8pt;"> </span>at<span style="letter-spacing:0.8pt;"> </span>a meeting<span style="letter-spacing:0.1pt;"> </span>of our stockholders&#59;</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:5.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prohibit<span style="letter-spacing:0.1pt;"> </span>cumulative<span style="letter-spacing:0.1pt;"> </span>voting&#59;<span style="letter-spacing:0.05pt;"> </span>and</p></td></tr></table></div>
<p style="margin-top:0pt;line-height:6pt;margin-bottom:0pt;margin-left:7.41%;text-indent:-3.7%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish<span style="letter-spacing:2.45pt;"> </span>advance<span style="letter-spacing:2.4pt;"> </span>notice<span style="letter-spacing:2.35pt;"> </span>requirements<span style="letter-spacing:2.45pt;"> </span>for<span style="letter-spacing:2.35pt;"> </span>nominations<span style="letter-spacing:2.4pt;"> </span>for<span style="letter-spacing:2.35pt;"> </span>election<span style="letter-spacing:2.4pt;"> </span>to<span style="letter-spacing:2.3pt;"> </span>our<span style="letter-spacing:2.3pt;"> </span>board<span style="letter-spacing:2.35pt;"> </span>or<span style="letter-spacing:2.3pt;"> </span>for<span style="letter-spacing:2.35pt;"> </span>proposing matters<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>can be acted<span style="letter-spacing:0.05pt;"> </span>upon by stockholders<span style="letter-spacing:0.1pt;"> </span>at<span style="letter-spacing:0.05pt;"> </span>annual<span style="letter-spacing:0.05pt;"> </span>stockholder<span style="letter-spacing:0.1pt;"> </span>meetings.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:1.3pt;"> </span>addition,<span style="letter-spacing:1.35pt;"> </span>Section<span style="letter-spacing:1.35pt;"> </span>203<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:1.3pt;"> </span>the<span style="letter-spacing:1.35pt;"> </span>Delaware<span style="letter-spacing:1.35pt;"> </span>General<span style="letter-spacing:1.35pt;"> </span>Corporation<span style="letter-spacing:1.35pt;"> </span>Law,<span style="letter-spacing:1.3pt;"> </span>or<span style="letter-spacing:1.25pt;"> </span>DGCL,<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.3pt;"> </span>discourage,<span style="letter-spacing:1.35pt;"> </span>delay<span style="letter-spacing:1.3pt;"> </span>or prevent<span style="letter-spacing:0.05pt;"> </span>a change<span style="letter-spacing:0.05pt;"> </span>in control<span style="letter-spacing:0.05pt;"> </span>of our company.<span style="letter-spacing:0.05pt;"> </span>Section<span style="letter-spacing:0.05pt;"> </span>203 imposes<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:0.1pt;"> </span>restrictions<span style="letter-spacing:0.15pt;"> </span>on mergers,<span style="letter-spacing:0.1pt;"> </span>business combinations<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>transactions<span style="letter-spacing:0.15pt;"> </span>between<span style="letter-spacing:0.05pt;"> </span>us and holders<span style="letter-spacing:0.05pt;"> </span>of 15% or more<span style="letter-spacing:0.05pt;"> </span>of our common<span style="letter-spacing:0.05pt;"> </span>stock.</p>
<p style="margin-top:0pt;line-height:7pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The exclusive<span style="letter-spacing:0.1pt;"> </span>forum<span style="letter-spacing:0.05pt;"> </span>provision<span style="letter-spacing:0.05pt;"> </span>in our organizational<span style="letter-spacing:0.1pt;"> </span>documents<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>a stockholder&#8217;s<span style="letter-spacing:0.1pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to bring a claim<span style="letter-spacing:0.05pt;"> </span>in a judicial<span style="letter-spacing:0.1pt;"> </span>forum<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>finds<span style="letter-spacing:0.05pt;"> </span>favorable<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>disputes<span style="letter-spacing:0.05pt;"> </span>with us or any of our directors,<span style="letter-spacing:0.1pt;"> </span>officers,<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>employees,<span style="letter-spacing:0.1pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>discourage<span style="letter-spacing:0.05pt;"> </span>lawsuits<span style="letter-spacing:0.05pt;"> </span>with respect<span style="letter-spacing:0.05pt;"> </span>to such claims.</p>
<p style="margin-top:0pt;line-height:5pt;margin-bottom:0pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>restated<span style="letter-spacing:0.15pt;"> </span>certificate<span style="letter-spacing:0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>incorporation<span style="letter-spacing:0.15pt;"> </span>provides<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Court<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Chancery<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>State<span style="letter-spacing:0.1pt;"> </span>of Delaware<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:0.05pt;"> </span>the exclusive<span style="letter-spacing:0.15pt;"> </span>forum<span style="letter-spacing:0.1pt;"> </span>for:<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>derivative<span style="letter-spacing:0.15pt;"> </span>action<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proceeding<span style="letter-spacing:0.1pt;"> </span>brought<span style="letter-spacing:0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>behalf&#59;<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>action<span style="letter-spacing:0.05pt;"> </span>asserting<span style="letter-spacing:0.1pt;"> </span>a breach<span style="letter-spacing:0.05pt;"> </span>of fiduciary<span style="letter-spacing:0.15pt;"> </span>duty&#59;<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>action<span style="letter-spacing:0.1pt;"> </span>asserting<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>claim<span style="letter-spacing:0.15pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>arising<span style="letter-spacing:0.15pt;"> </span>pursuant<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>DGCL, our<span style="letter-spacing:0.05pt;"> </span>restated<span style="letter-spacing:0.1pt;"> </span>certificate<span style="letter-spacing:0.15pt;"> </span>of incorporation,<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>restated<span style="letter-spacing:0.15pt;"> </span>bylaws&#59;<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>action<span style="letter-spacing:0.1pt;"> </span>asserting<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>claim<span style="letter-spacing:0.15pt;"> </span>against<span style="letter-spacing:0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>is<span style="letter-spacing:0.1pt;"> </span>governed<span style="letter-spacing:0.05pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>internal affairs<span style="letter-spacing:0.15pt;"> </span>doctrine.<span style="letter-spacing:0.15pt;"> </span>This<span style="letter-spacing:0.05pt;"> </span>exclusive<span style="letter-spacing:0.15pt;"> </span>forum<span style="letter-spacing:0.1pt;"> </span>provision<span style="letter-spacing:0.05pt;"> </span>does not apply<span style="letter-spacing:0.05pt;"> </span>to suits<span style="letter-spacing:0.05pt;"> </span>brought<span style="letter-spacing:0.05pt;"> </span>to enforce<span style="letter-spacing:0.05pt;"> </span>a duty or liability created<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>Exchange Act. It<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:0.05pt;"> </span>apply,<span style="letter-spacing:0.05pt;"> </span>however, to a suit<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>falls<span style="letter-spacing:0.1pt;"> </span>within<span style="letter-spacing:0.05pt;"> </span>one or more<span style="letter-spacing:0.05pt;"> </span>of the categories enumerated<span style="letter-spacing:0.1pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>exclusive<span style="letter-spacing:0.1pt;"> </span>forum<span style="letter-spacing:0.05pt;"> </span>provision.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This choice<span style="letter-spacing:0.05pt;"> </span>of forum<span style="letter-spacing:0.05pt;"> </span>provision<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:0.1pt;"> </span>a stockholder&#8217;s<span style="letter-spacing:0.1pt;"> </span>ability<span style="letter-spacing:0.1pt;"> </span>to bring<span style="letter-spacing:0.05pt;"> </span>a claim<span style="letter-spacing:0.1pt;"> </span>in a judicial<span style="letter-spacing:0.05pt;"> </span>forum that it finds<span style="letter-spacing:0.1pt;"> </span>favorable<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>disputes<span style="letter-spacing:0.1pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any of our directors,<span style="letter-spacing:0.1pt;"> </span>officers,<span style="letter-spacing:0.1pt;"> </span>or other<span style="letter-spacing:0.05pt;"> </span>employees,<span style="letter-spacing:0.1pt;"> </span>which may<span style="letter-spacing:0.05pt;"> </span>discourage lawsuits<span style="letter-spacing:2.25pt;"> </span>with<span style="letter-spacing:2.15pt;"> </span>respect<span style="letter-spacing:2.25pt;"> </span>to<span style="letter-spacing:2.15pt;"> </span>such<span style="letter-spacing:2.15pt;"> </span>claims.<span style="letter-spacing:2.25pt;"> </span>Alternatively,<span style="letter-spacing:2.3pt;"> </span>if<span style="letter-spacing:2.2pt;"> </span>a<span style="letter-spacing:2.15pt;"> </span>court<span style="letter-spacing:2.2pt;"> </span>were<span style="letter-spacing:2.15pt;"> </span>to<span style="letter-spacing:2.15pt;"> </span>find<span style="letter-spacing:2.2pt;"> </span>the<span style="letter-spacing:2.2pt;"> </span>choice<span style="letter-spacing:2.2pt;"> </span>of<span style="letter-spacing:2.15pt;"> </span>forum<span style="letter-spacing:2.2pt;"> </span>provisions contained<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.15pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>restated<span style="letter-spacing:1.2pt;"> </span>certificate<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.1pt;"> </span>incorporation<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.1pt;"> </span>be<span style="letter-spacing:1.1pt;"> </span>inapplicable<span style="letter-spacing:1.2pt;"> </span>or<span style="letter-spacing:1.1pt;"> </span>unenforceable<span style="letter-spacing:1.2pt;"> </span>in<span style="letter-spacing:1.1pt;"> </span>an<span style="letter-spacing:1.1pt;"> </span>action,<span style="letter-spacing:1.15pt;"> </span>we<span style="letter-spacing:1.1pt;"> </span>may incur<span style="letter-spacing:0.1pt;"> </span>additional<span style="letter-spacing:0.15pt;"> </span>costs<span style="letter-spacing:0.1pt;"> </span>associated<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>resolving<span style="letter-spacing:0.1pt;"> </span>such action<span style="letter-spacing:0.05pt;"> </span>in other<span style="letter-spacing:0.05pt;"> </span>jurisdictions,<span style="letter-spacing:0.15pt;"> </span>which could<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our business, results<span style="letter-spacing:0.1pt;"> </span>of operations<span style="letter-spacing:0.1pt;"> </span>and financial<span style="letter-spacing:0.1pt;"> </span>condition.</p>
<p style="margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section<span style="letter-spacing:0.1pt;"> </span>22<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Securities<span style="letter-spacing:0.15pt;"> </span>Act<span style="letter-spacing:0.05pt;"> </span>creates<span style="letter-spacing:0.15pt;"> </span>concurrent<span style="letter-spacing:0.15pt;"> </span>jurisdiction<span style="letter-spacing:0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>and state<span style="letter-spacing:0.05pt;"> </span>courts<span style="letter-spacing:0.05pt;"> </span>over<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>claims brought<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>enforce<span style="letter-spacing:0.1pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>duty<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>created<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Securities<span style="letter-spacing:0.1pt;"> </span>Act or the<span style="letter-spacing:0.05pt;"> </span>rules<span style="letter-spacing:0.05pt;"> </span>and regulations<span style="letter-spacing:0.1pt;"> </span>thereunder.<span style="letter-spacing:0.1pt;"> </span>Our restated<span style="letter-spacing:0.1pt;"> </span>bylaws provide<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>district<span style="letter-spacing:0.1pt;"> </span>courts<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:0.05pt;"> </span>United<span style="letter-spacing:0.05pt;"> </span>States<span style="letter-spacing:0.05pt;"> </span>of America<span style="letter-spacing:0.05pt;"> </span>will,<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:0.05pt;"> </span>fullest extent<span style="letter-spacing:0.1pt;"> </span>permitted<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>law,<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>exclusive<span style="letter-spacing:0.15pt;"> </span>forum<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>resolving<span style="letter-spacing:0.15pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>complaint<span style="letter-spacing:0.15pt;"> </span>asserting<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>cause<span style="letter-spacing:0.1pt;"> </span>of action<span style="letter-spacing:0.05pt;"> </span>arising under<span style="letter-spacing:2.3pt;"> </span>the<span style="letter-spacing:2.3pt;"> </span>Securities<span style="letter-spacing:2.35pt;"> </span>Act,<span style="letter-spacing:2.25pt;"> </span>or<span style="letter-spacing:2.2pt;"> </span>a<span style="letter-spacing:2.2pt;"> </span>Federal<span style="letter-spacing:2.25pt;"> </span>Forum<span style="letter-spacing:2.25pt;"> </span>Provision.<span style="letter-spacing:2.25pt;"> </span>Our<span style="letter-spacing:2.2pt;"> </span>decision<span style="letter-spacing:2.25pt;"> </span>to<span style="letter-spacing:2.2pt;"> </span>adopt<span style="letter-spacing:2.25pt;"> </span>a<span style="letter-spacing:2.2pt;"> </span>Federal<span style="letter-spacing:2.25pt;"> </span>Forum<span style="letter-spacing:2.25pt;"> </span>Provision followed<span style="letter-spacing:0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>decision<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Supreme<span style="letter-spacing:0.1pt;"> </span>Court<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>State<span style="letter-spacing:0.1pt;"> </span>of Delaware<span style="letter-spacing:0.05pt;"> </span>holding<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>such provisions<span style="letter-spacing:0.1pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>facially<span style="letter-spacing:0.1pt;"> </span>valid under<span style="letter-spacing:0.1pt;"> </span>Delaware<span style="letter-spacing:0.1pt;"> </span>law.<span style="letter-spacing:0.05pt;"> </span>While<span style="letter-spacing:0.1pt;"> </span>there<span style="letter-spacing:0.1pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:0.15pt;"> </span>that<span style="letter-spacing:0.1pt;"> </span>federal<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:0.1pt;"> </span>courts<span style="letter-spacing:0.1pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>follow<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>holding<span style="letter-spacing:0.1pt;"> </span>of the Delaware<span style="letter-spacing:0.5pt;"> </span>Supreme<span style="letter-spacing:0.5pt;"> </span>Court<span style="letter-spacing:0.45pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>determine<span style="letter-spacing:0.55pt;"> </span>that<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.45pt;"> </span>Federal<span style="letter-spacing:0.45pt;"> </span>Forum<span style="letter-spacing:0.45pt;"> </span>Provision<span style="letter-spacing:0.45pt;"> </span>should<span style="letter-spacing:0.45pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>enforced<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.4pt;"> </span>particular<span style="letter-spacing:0.55pt;"> </span>case, application<span style="letter-spacing:0.75pt;"> </span>of<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>Federal<span style="letter-spacing:0.7pt;"> </span>Forum<span style="letter-spacing:0.7pt;"> </span>Provision<span style="letter-spacing:0.7pt;"> </span>means<span style="letter-spacing:0.7pt;"> </span>that<span style="letter-spacing:0.65pt;"> </span>suits<span style="letter-spacing:0.65pt;"> </span>brought<span style="letter-spacing:0.65pt;"> </span>by<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>stockholders<span style="letter-spacing:0.7pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>enforce<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:0.6pt;"> </span>duty<span style="letter-spacing:0.6pt;"> </span>or liability<span style="letter-spacing:0.15pt;"> </span>created<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>Securities<span style="letter-spacing:0.1pt;"> </span>Act must<span style="letter-spacing:0.05pt;"> </span>be brought<span style="letter-spacing:0.05pt;"> </span>in federal<span style="letter-spacing:0.1pt;"> </span>court<span style="letter-spacing:0.05pt;"> </span>and cannot<span style="letter-spacing:0.05pt;"> </span>be brought<span style="letter-spacing:0.05pt;"> </span>in state<span style="letter-spacing:0.05pt;"> </span>court.</p>
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;text-indent:3.7%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section<span style="letter-spacing:0.1pt;"> </span>27<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Exchange<span style="letter-spacing:0.05pt;"> </span>Act<span style="letter-spacing:0.05pt;"> </span>creates<span style="letter-spacing:0.15pt;"> </span>exclusive<span style="letter-spacing:0.15pt;"> </span>federal<span style="letter-spacing:0.15pt;"> </span>jurisdiction<span style="letter-spacing:0.2pt;"> </span>over<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.1pt;"> </span>claims<span style="letter-spacing:0.15pt;"> </span>brought<span style="letter-spacing:0.1pt;"> </span>to enforce<span style="letter-spacing:0.05pt;"> </span>any duty<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:0.2pt;"> </span>created<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Exchange<span style="letter-spacing:0.05pt;"> </span>Act<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>rules<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:0.15pt;"> </span>thereunder.<span style="letter-spacing:0.1pt;"> </span>In addition,<span style="letter-spacing:0.05pt;"> </span>neither<span style="letter-spacing:0.1pt;"> </span>the exclusive<span style="letter-spacing:2.05pt;"> </span>forum<span style="letter-spacing:2pt;"> </span>provision<span style="letter-spacing:2pt;"> </span>nor<span style="letter-spacing:1.95pt;"> </span>the<span style="letter-spacing:2pt;"> </span>Federal<span style="letter-spacing:2pt;"> </span>Forum<span style="letter-spacing:2pt;"> </span>Provision<span style="letter-spacing:2pt;"> </span>applies<span style="letter-spacing:2pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>suits<span style="letter-spacing:1.95pt;"> </span>brought<span style="letter-spacing:1.95pt;"> </span>to<span style="letter-spacing:1.9pt;"> </span>enforce<span style="letter-spacing:1.95pt;"> </span>any<span style="letter-spacing:1.9pt;"> </span>duty<span style="letter-spacing:1.9pt;"> </span>or liability<span style="letter-spacing:0.2pt;"> </span>created<span style="letter-spacing:0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Exchange<span style="letter-spacing:0.05pt;"> </span>Act.<span style="letter-spacing:0.05pt;"> </span>Accordingly,<span style="letter-spacing:0.1pt;"> </span>actions<span style="letter-spacing:0.1pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>stockholders<span style="letter-spacing:0.1pt;"> </span>to enforce<span style="letter-spacing:0.05pt;"> </span>any duty or liability created<span style="letter-spacing:0.1pt;"> </span>by the<span style="letter-spacing:0.05pt;"> </span>Exchange Act or the<span style="letter-spacing:0.05pt;"> </span>rules<span style="letter-spacing:0.05pt;"> </span>and regulations<span style="letter-spacing:0.1pt;"> </span>thereunder<span style="letter-spacing:0.1pt;"> </span>must<span style="letter-spacing:0.05pt;"> </span>be brought<span style="letter-spacing:0.05pt;"> </span>in federal<span style="letter-spacing:0.1pt;"> </span>court.</p>
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;text-indent:3.7%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:0.05pt;"> </span>stockholders<span style="letter-spacing:0.15pt;"> </span>will<span style="letter-spacing:0.1pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>deemed<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>waived<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:0.15pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>federal<span style="letter-spacing:0.1pt;"> </span>securities<span style="letter-spacing:0.15pt;"> </span>laws and the regulations<span style="letter-spacing:0.1pt;"> </span>promulgated<span style="letter-spacing:0.1pt;"> </span>thereunder.</p>
<p style="margin-top:0pt;line-height:9pt;margin-bottom:0pt;text-indent:3.7%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:0.05pt;"> </span>person<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>entity<span style="letter-spacing:0.1pt;"> </span>purchasing<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:0.1pt;"> </span>acquiring<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>holding<span style="letter-spacing:0.05pt;"> </span>any interest<span style="letter-spacing:0.1pt;"> </span>in any of our securities<span style="letter-spacing:0.15pt;"> </span>shall be<span style="letter-spacing:0.05pt;"> </span>deemed<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>notice<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>consented<span style="letter-spacing:0.05pt;"> </span>to our exclusive<span style="letter-spacing:0.1pt;"> </span>forum<span style="letter-spacing:0.05pt;"> </span>provisions,<span style="letter-spacing:0.1pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Federal<span style="letter-spacing:0.05pt;"> </span>Forum Provision.<span style="letter-spacing:2.25pt;"> </span>These<span style="letter-spacing:2.2pt;"> </span>provisions<span style="letter-spacing:2.3pt;"> </span>may<span style="letter-spacing:2.25pt;"> </span>limit<span style="letter-spacing:2.3pt;"> </span>a<span style="letter-spacing:2.2pt;"> </span>stockholders&#8217;<span style="letter-spacing:2.3pt;"> </span>ability<span style="letter-spacing:2.3pt;"> </span>to<span style="letter-spacing:2.2pt;"> </span>bring<span style="letter-spacing:2.25pt;"> </span>a<span style="letter-spacing:2.2pt;"> </span>claim<span style="letter-spacing:2.3pt;"> </span>in<span style="letter-spacing:2.2pt;"> </span>a<span style="letter-spacing:2.2pt;"> </span>judicial<span style="letter-spacing:2.3pt;"> </span>forum<span style="letter-spacing:2.2pt;"> </span>of<span style="letter-spacing:2.15pt;"> </span>their choosing<span style="letter-spacing:1.85pt;"> </span>for<span style="letter-spacing:1.85pt;"> </span>disputes<span style="letter-spacing:1.85pt;"> </span>with<span style="letter-spacing:1.75pt;"> </span>us<span style="letter-spacing:1.75pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>our<span style="letter-spacing:1.75pt;"> </span>directors,<span style="letter-spacing:1.85pt;"> </span>officers,<span style="letter-spacing:1.85pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>other<span style="letter-spacing:1.8pt;"> </span>employees,<span style="letter-spacing:1.85pt;"> </span>which<span style="letter-spacing:1.75pt;"> </span>may<span style="letter-spacing:1.8pt;"> </span>discourage<span style="letter-spacing:1.85pt;"> </span>lawsuits against<span style="letter-spacing:0.05pt;"> </span>us and our directors,<span style="letter-spacing:0.1pt;"> </span>officers,<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>employees.</p>
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will<span style="letter-spacing:0.05pt;"> </span>continue<span style="letter-spacing:0.05pt;"> </span>to incur increased<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>as a result<span style="letter-spacing:0.05pt;"> </span>of operating<span style="letter-spacing:0.05pt;"> </span>as a public<span style="letter-spacing:0.05pt;"> </span>company,<span style="letter-spacing:0.05pt;"> </span>and our management<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be required<span style="letter-spacing:0.05pt;"> </span>to devote<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:0.1pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>to new compliance<span style="letter-spacing:0.1pt;"> </span>initiatives<span style="letter-spacing:0.15pt;"> </span>and corporate governance<span style="letter-spacing:0.05pt;"> </span>practices.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:2.25pt;"> </span>a<span style="letter-spacing:2.25pt;"> </span>public<span style="letter-spacing:2.3pt;"> </span>company,<span style="letter-spacing:2.3pt;"> </span>and<span style="letter-spacing:2.25pt;"> </span>particularly<span style="letter-spacing:2.4pt;"> </span>after<span style="letter-spacing:2.3pt;"> </span>we<span style="letter-spacing:2.2pt;"> </span>are<span style="letter-spacing:2.25pt;"> </span>no<span style="letter-spacing:2.2pt;"> </span>longer<span style="letter-spacing:2.25pt;"> </span>an<span style="letter-spacing:2.2pt;"> </span>emerging<span style="letter-spacing:2.3pt;"> </span>growth<span style="letter-spacing:2.2pt;"> </span>company,<span style="letter-spacing:2.25pt;"> </span>we<span style="letter-spacing:2.2pt;"> </span>will continue<span style="letter-spacing:0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>legal,<span style="letter-spacing:0.1pt;"> </span>accounting<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>expenses<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>we did not incur<span style="letter-spacing:0.05pt;"> </span>as a private<span style="letter-spacing:0.1pt;"> </span>company.<span style="letter-spacing:0.05pt;"> </span>The Sarbanes-Oxley<span style="letter-spacing:0.1pt;"> </span>Act, the<span style="letter-spacing:0.05pt;"> </span>Dodd-Frank Wall<span style="letter-spacing:0.05pt;"> </span>Street<span style="letter-spacing:0.05pt;"> </span>Reform<span style="letter-spacing:0.05pt;"> </span>and Consumer<span style="letter-spacing:0.05pt;"> </span>Protection<span style="letter-spacing:0.1pt;"> </span>Act, the<span style="letter-spacing:0.05pt;"> </span>listing<span style="letter-spacing:0.05pt;"> </span>requirements of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Nasdaq Global<span style="letter-spacing:0.05pt;"> </span>Select<span style="letter-spacing:0.05pt;"> </span>Market<span style="letter-spacing:0.05pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>securities<span style="letter-spacing:0.15pt;"> </span>rules<span style="letter-spacing:0.05pt;"> </span>and regulations<span style="letter-spacing:0.1pt;"> </span>impose<span style="letter-spacing:0.05pt;"> </span>various requirements<span style="letter-spacing:0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:0.1pt;"> </span>companies,<span style="letter-spacing:0.15pt;"> </span>including<span style="letter-spacing:0.1pt;"> </span>establishment<span style="letter-spacing:0.2pt;"> </span>and maintenance<span style="letter-spacing:0.1pt;"> </span>of effective<span style="letter-spacing:0.1pt;"> </span>disclosure<span style="letter-spacing:0.1pt;"> </span>and financial controls<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:0.1pt;"> </span>governance<span style="letter-spacing:0.05pt;"> </span>practices.<span style="letter-spacing:0.1pt;"> </span>Our management<span style="letter-spacing:0.1pt;"> </span>and other<span style="letter-spacing:0.05pt;"> </span>personnel<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>need to devote<span style="letter-spacing:0.05pt;"> </span>a substantial<span style="letter-spacing:0.15pt;"> </span>amount<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.1pt;"> </span>to these<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>initiatives.<span style="letter-spacing:0.15pt;"> </span>Moreover,<span style="letter-spacing:0.05pt;"> </span>we expect<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:0.05pt;"> </span>rules<span style="letter-spacing:0.05pt;"> </span>and regulations<span style="letter-spacing:0.1pt;"> </span>to substantially<span style="letter-spacing:0.2pt;"> </span>increase<span style="letter-spacing:0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>legal<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>compliance<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and to make<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:0.05pt;"> </span>activities<span style="letter-spacing:0.15pt;"> </span>more<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>consuming and<span style="letter-spacing:2.25pt;"> </span>costly.<span style="letter-spacing:2.3pt;"> </span>For<span style="letter-spacing:2.25pt;"> </span>example,<span style="letter-spacing:2.3pt;"> </span>we<span style="letter-spacing:2.25pt;"> </span>expect<span style="letter-spacing:2.3pt;"> </span>that<span style="letter-spacing:2.3pt;"> </span>these<span style="letter-spacing:2.25pt;"> </span>rules<span style="letter-spacing:2.25pt;"> </span>and<span style="letter-spacing:2.2pt;"> </span>regulations<span style="letter-spacing:2.3pt;"> </span>may<span style="letter-spacing:2.25pt;"> </span>make<span style="letter-spacing:2.25pt;"> </span>it<span style="letter-spacing:2.25pt;"> </span>more<span style="letter-spacing:2.25pt;"> </span>difficult<span style="letter-spacing:2.35pt;"> </span>and<span style="letter-spacing:2.2pt;"> </span>more expensive<span style="letter-spacing:1.3pt;"> </span>for<span style="letter-spacing:1.25pt;"> </span>us<span style="letter-spacing:1.2pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>obtain<span style="letter-spacing:1.25pt;"> </span>director<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>officer<span style="letter-spacing:1.3pt;"> </span>liability<span style="letter-spacing:1.35pt;"> </span>insurance<span style="letter-spacing:1.3pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.2pt;"> </span>may<span style="letter-spacing:1.25pt;"> </span>be<span style="letter-spacing:1.2pt;"> </span>required<span style="letter-spacing:1.3pt;"> </span>to<span style="letter-spacing:1.2pt;"> </span>incur<span style="letter-spacing:1.25pt;"> </span>substantial costs<span style="letter-spacing:0.05pt;"> </span>to maintain<span style="letter-spacing:0.1pt;"> </span>sufficient<span style="letter-spacing:0.15pt;"> </span>coverage.<span style="letter-spacing:0.05pt;"> </span>We cannot<span style="letter-spacing:0.05pt;"> </span>predict<span style="letter-spacing:0.1pt;"> </span>or estimate<span style="letter-spacing:0.1pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or timing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of additional</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs we may</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incur</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respond</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements.</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficult for</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attract</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">retain</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qualified</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">serve</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directors,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">board</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">committees</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or as executive</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">officers.</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduce</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">areas</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase the</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">once</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialized.</span><span style="letter-spacing:2.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rules</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">often</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to varying</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interpretations,</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">many</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cases</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lack</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specificity,</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result,</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in practice may</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evolve</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as new guidance</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by regulatory</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and governing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bodies.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This could result</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in continuing</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncertainty</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliance</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matters</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">higher</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessitated</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by ongoing revisions</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to disclosure</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and governance</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practices.</span></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate<span style="letter-spacing:0.1pt;"> </span>paying any cash dividends<span style="letter-spacing:0.05pt;"> </span>on our capital<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>in the foreseeable<span style="letter-spacing:0.1pt;"> </span>future, capital<span style="letter-spacing:0.05pt;"> </span>appreciation,<span style="letter-spacing:0.1pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>any, will<span style="letter-spacing:0.05pt;"> </span>be your sole<span style="letter-spacing:0.05pt;"> </span>source<span style="letter-spacing:0.05pt;"> </span>of gain.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>never<span style="letter-spacing:0.1pt;"> </span>declared<span style="letter-spacing:0.1pt;"> </span>or paid<span style="letter-spacing:0.05pt;"> </span>cash<span style="letter-spacing:0.05pt;"> </span>dividends<span style="letter-spacing:0.05pt;"> </span>on our capital<span style="letter-spacing:0.1pt;"> </span>stock.<span style="letter-spacing:0.05pt;"> </span>We currently<span style="letter-spacing:0.1pt;"> </span>intend<span style="letter-spacing:0.05pt;"> </span>to retain<span style="letter-spacing:0.1pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>of our future<span style="letter-spacing:0.7pt;"> </span>earnings,<span style="letter-spacing:0.7pt;"> </span>if<span style="letter-spacing:0.7pt;"> </span>any,<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.6pt;"> </span>finance<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>growth<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>development,<span style="letter-spacing:0.7pt;"> </span>operation<span style="letter-spacing:0.7pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>expansion<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.6pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>business<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>do not<span style="letter-spacing:0.35pt;"> </span>anticipate<span style="letter-spacing:0.45pt;"> </span>declaring<span style="letter-spacing:0.4pt;"> </span>or<span style="letter-spacing:0.3pt;"> </span>paying<span style="letter-spacing:0.35pt;"> </span>any<span style="letter-spacing:0.3pt;"> </span>cash<span style="letter-spacing:0.35pt;"> </span>dividends<span style="letter-spacing:0.35pt;"> </span>for<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>foreseeable<span style="letter-spacing:0.4pt;"> </span>future.<span style="letter-spacing:0.35pt;"> </span>As<span style="letter-spacing:0.3pt;"> </span>a<span style="letter-spacing:0.3pt;"> </span>result,<span style="letter-spacing:0.4pt;"> </span>capital<span style="letter-spacing:0.4pt;"> </span>appreciation, if<span style="letter-spacing:0.05pt;"> </span>any, of our common<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:0.05pt;"> </span>be your sole<span style="letter-spacing:0.05pt;"> </span>source<span style="letter-spacing:0.05pt;"> </span>of gain<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>foreseeable<span style="letter-spacing:0.1pt;"> </span>future.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General<span style="letter-spacing:0.05pt;"> </span>Risk Factors</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>securities<span style="letter-spacing:0.1pt;"> </span>or industry<span style="letter-spacing:0.05pt;"> </span>analysts<span style="letter-spacing:0.05pt;"> </span>do not publish<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:0.05pt;"> </span>or reports<span style="letter-spacing:0.05pt;"> </span>about our business,<span style="letter-spacing:0.05pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:0.05pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>an adverse<span style="letter-spacing:0.05pt;"> </span>or misleading<span style="letter-spacing:0.1pt;"> </span>opinion regarding<span style="letter-spacing:0.05pt;"> </span>our stock,<span style="letter-spacing:0.05pt;"> </span>our stock<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>and trading<span style="letter-spacing:0.05pt;"> </span>volume<span style="letter-spacing:0.05pt;"> </span>could decline.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:1.15pt;"> </span>trading<span style="letter-spacing:1.2pt;"> </span>market<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.2pt;"> </span>our<span style="letter-spacing:1.1pt;"> </span>common<span style="letter-spacing:1.15pt;"> </span>stock<span style="letter-spacing:1.15pt;"> </span>will<span style="letter-spacing:1.15pt;"> </span>be<span style="letter-spacing:1.1pt;"> </span>influenced<span style="letter-spacing:1.2pt;"> </span>by<span style="letter-spacing:1.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>research<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:1.1pt;"> </span>reports<span style="letter-spacing:1.2pt;"> </span>that<span style="letter-spacing:1.15pt;"> </span>industry<span style="letter-spacing:1.15pt;"> </span>or securities<span style="letter-spacing:0.2pt;"> </span>analysts<span style="letter-spacing:0.15pt;"> </span>publish<span style="letter-spacing:0.1pt;"> </span>about<span style="letter-spacing:0.05pt;"> </span>us or our business.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>no or few securities<span style="letter-spacing:0.15pt;"> </span>or industry<span style="letter-spacing:0.05pt;"> </span>analysts<span style="letter-spacing:0.1pt;"> </span>commence coverage<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:1.2pt;"> </span>us,<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.25pt;"> </span>trading<span style="letter-spacing:1.25pt;"> </span>price<span style="letter-spacing:1.25pt;"> </span>for<span style="letter-spacing:1.25pt;"> </span>our<span style="letter-spacing:1.2pt;"> </span>common<span style="letter-spacing:1.25pt;"> </span>stock<span style="letter-spacing:1.25pt;"> </span>could<span style="letter-spacing:1.25pt;"> </span>be<span style="letter-spacing:1.2pt;"> </span>impacted<span style="letter-spacing:1.3pt;"> </span>negatively.<span style="letter-spacing:1.3pt;"> </span>In<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:1.2pt;"> </span>event<span style="letter-spacing:1.2pt;"> </span>we<span style="letter-spacing:1.15pt;"> </span>obtain securities<span style="letter-spacing:2.1pt;"> </span>or<span style="letter-spacing:1.95pt;"> </span>industry<span style="letter-spacing:2pt;"> </span>analyst<span style="letter-spacing:2pt;"> </span>coverage,<span style="letter-spacing:2pt;"> </span>if<span style="letter-spacing:2pt;"> </span>any<span style="letter-spacing:1.95pt;"> </span>of<span style="letter-spacing:1.95pt;"> </span>the<span style="letter-spacing:2pt;"> </span>analysts<span style="letter-spacing:2.05pt;"> </span>who<span style="letter-spacing:1.95pt;"> </span>cover<span style="letter-spacing:2pt;"> </span>us<span style="letter-spacing:1.95pt;"> </span>issue<span style="letter-spacing:2pt;"> </span>an<span style="letter-spacing:1.95pt;"> </span>adverse<span style="letter-spacing:1.95pt;"> </span>or<span style="letter-spacing:1.9pt;"> </span>misleading opinion<span style="letter-spacing:0.1pt;"> </span>regarding<span style="letter-spacing:0.15pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.1pt;"> </span>model,<span style="letter-spacing:0.05pt;"> </span>our intellectual<span style="letter-spacing:0.15pt;"> </span>property<span style="letter-spacing:0.05pt;"> </span>or our stock<span style="letter-spacing:0.05pt;"> </span>performance,<span style="letter-spacing:0.1pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>our preclinical studies<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.15pt;"> </span>trials<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>results<span style="letter-spacing:0.1pt;"> </span>fail<span style="letter-spacing:0.05pt;"> </span>to meet<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>expectations<span style="letter-spacing:0.1pt;"> </span>of analysts,<span style="letter-spacing:0.1pt;"> </span>our stock<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>would likely<span style="letter-spacing:0.1pt;"> </span>decline.<span style="letter-spacing:0.1pt;"> </span>If<span style="letter-spacing:0.1pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>analysts<span style="letter-spacing:0.15pt;"> </span>cease<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:0.05pt;"> </span>of us or fail<span style="letter-spacing:0.05pt;"> </span>to publish<span style="letter-spacing:0.05pt;"> </span>reports<span style="letter-spacing:0.1pt;"> </span>on us regularly,<span style="letter-spacing:0.1pt;"> </span>we could<span style="letter-spacing:0.1pt;"> </span>lose<span style="letter-spacing:0.1pt;"> </span>visibility<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.15pt;"> </span>markets,<span style="letter-spacing:0.15pt;"> </span>which<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>turn<span style="letter-spacing:0.1pt;"> </span>could<span style="letter-spacing:0.1pt;"> </span>cause<span style="letter-spacing:0.1pt;"> </span>a decline<span style="letter-spacing:0.05pt;"> </span>in our stock<span style="letter-spacing:0.05pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>or trading volume.</p>
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and the<span style="letter-spacing:0.05pt;"> </span>listing<span style="letter-spacing:0.05pt;"> </span>requirements of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>Nasdaq Global<span style="letter-spacing:0.05pt;"> </span>Select<span style="letter-spacing:0.05pt;"> </span>Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404(a) of the Sarbanes-Oxley Act. This requires that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the Securities and Exchange Commission, or SEC, or other regulatory authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:0.05pt;"> </span>be subject<span style="letter-spacing:0.05pt;"> </span>to securities<span style="letter-spacing:0.1pt;"> </span>litigation,<span style="letter-spacing:0.1pt;"> </span>which is<span style="letter-spacing:0.05pt;"> </span>expensive<span style="letter-spacing:0.05pt;"> </span>and could divert<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:0.05pt;"> </span>attention.</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>price<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:0.1pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>may<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>volatile.<span style="letter-spacing:0.15pt;"> </span>The<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.1pt;"> </span>market<span style="letter-spacing:0.15pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>general,<span style="letter-spacing:0.05pt;"> </span>and Nasdaq and biopharmaceutical<span style="letter-spacing:0.2pt;"> </span>companies<span style="letter-spacing:0.1pt;"> </span>in particular,<span style="letter-spacing:0.15pt;"> </span>have experienced<span style="letter-spacing:0.1pt;"> </span>extreme<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>and volume<span style="letter-spacing:0.05pt;"> </span>fluctuations<span style="letter-spacing:0.1pt;"> </span>that have often<span style="letter-spacing:0.1pt;"> </span>been<span style="letter-spacing:0.05pt;"> </span>unrelated<span style="letter-spacing:0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>disproportionate<span style="letter-spacing:0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>operating<span style="letter-spacing:0.15pt;"> </span>performance<span style="letter-spacing:0.15pt;"> </span>of these<span style="letter-spacing:0.05pt;"> </span>companies.<span style="letter-spacing:0.1pt;"> </span>In the<span style="letter-spacing:0.05pt;"> </span>past,<span style="letter-spacing:0.05pt;"> </span>companies that<span style="letter-spacing:0.1pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>experienced<span style="letter-spacing:0.15pt;"> </span>volatility<span style="letter-spacing:0.2pt;"> </span>in the<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:0.1pt;"> </span>price<span style="letter-spacing:0.05pt;"> </span>of their<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:0.05pt;"> </span>have been subject<span style="letter-spacing:0.05pt;"> </span>to securities<span style="letter-spacing:0.15pt;"> </span>class<span style="letter-spacing:0.05pt;"> </span>action litigation.<span style="letter-spacing:0.45pt;"> </span>We<span style="letter-spacing:0.3pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>be<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.35pt;"> </span>target<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>this<span style="letter-spacing:0.35pt;"> </span>type<span style="letter-spacing:0.35pt;"> </span>of<span style="letter-spacing:0.25pt;"> </span>litigation<span style="letter-spacing:0.4pt;"> </span>in<span style="letter-spacing:0.25pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>future.<span style="letter-spacing:0.3pt;"> </span>Securities<span style="letter-spacing:0.35pt;"> </span>litigation<span style="letter-spacing:0.4pt;"> </span>against<span style="letter-spacing:0.3pt;"> </span>us<span style="letter-spacing:0.25pt;"> </span>could<span style="letter-spacing:0.3pt;"> </span>result in substantial<span style="letter-spacing:0.1pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and divert<span style="letter-spacing:0.05pt;"> </span>our management&#8217;s<span style="letter-spacing:0.15pt;"> </span>attention<span style="letter-spacing:0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>concerns,<span style="letter-spacing:0.05pt;"> </span>which could seriously harm<span style="letter-spacing:0.05pt;"> </span>our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, we completed our IPO and sold 9,573,750 shares of common stock at an IPO price of $19.00 per share. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to registration statements on Form&#160;S-1 (File No. 333-248628), which was declared effective by the SEC on September 24, 2020, as supplemented by a registration statement on Form S-1 filed pursuant to Rule 462(b) (File No. 333-248628). We received net proceeds from the IPO of approximately $166.6 million, after deducting underwriting discounts and commissions of approximately $12.7 million and offering expenses of approximately $2.5 million. Morgan Stanley, Goldman Sachs &#38; Co. LLC and BofA Securities acted as joint book-running managers of the offering and as representatives of the underwriters. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our IPO as described in the prospectus filed with the SEC pursuant to Rule&#160;424(b)(4)&#160;under the Securities Act on September 25, 2020.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">Item 3. Defaults Upon Senior Securities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION">Item 5. Other Information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS">Item 6. Exhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnish the exhibits required by Item 601 of Regulation S-K (&#167; 229.601 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;width:0.62%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Filing Date</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished Herewith</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="prld-ex101_194.htm"><span style="text-decoration:underline;">Executive Employment Agreement, dated January 21, 2022, by and between the Registrant and Jane Huang</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="prld-ex311_6.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="prld-ex312_7.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="prld-ex321_9.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="prld-ex322_8.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:3.25pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:3.25pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:7.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:48.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:8.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.8pt;padding-Top:0.8pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*<span style="font-style:italic;">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act</span>.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prelude Therapeutics Incorporated</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Krishna Vaddi</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Krishna Vaddi, PhD</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>prld-ex101_194.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
prld-ex101_194.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Executive Employment Agreement (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;), made between Prelude Therapeutics Incorporated, a Delaware corporation (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;), and Jane Huang (&#8220;<font style="font-weight:bold;">Executive</font>&#8221; and, collectively with the Company, the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;), is entered into as of January&#160;21, 2022 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, the Company desires to employ Executive as the Company&#8217;s President and Chief Medical Officer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Now, Therefore<font style="font-weight:normal;font-variant: normal;">, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Employment by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Employment.</font><font style="font-weight:normal;color:#000000;"> This Agreement shall govern the terms of Executive&#8217;s employment with the Company, effective as of the Effective Date, which shall commence on or before February&#160;28, 2022 or on or as soon as practicable following March&#160;28, 2022, as mutually determined by Executive and the Company (such date, the &#8220;</font><font style="color:#000000;">Start Date</font><font style="font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Position.</font><font style="font-weight:normal;color:#000000;"> Executive shall serve as the Company&#8217;s President and Chief Medical Officer. During the term of Executive&#8217;s employment with the Company hereunder, Executive will devote Executive&#8217;s best efforts and substantially all of Executive&#8217;s business time and attention to the business of the Company, except as otherwise set forth in Section&#160;11.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Duties and Location.</font><font style="font-weight:normal;color:#000000;"> Executive shall perform such duties as are commensurate with those of a President and Chief Medical Officer, which as of the Effective Date shall include those duties as are set forth in the position description previously provided to Executive by the Company. Executive will report to the Company&#8217;s Chief Executive Officer. Executive&#8217;s primary office location shall be at Executive&#8217;s current principal place of residence in Redwood City, California, although she will be required to travel on occasion to fulfill her duties as CMO, including routine travel to the Company&#8217;s headquarters. If and when the Company establishes a California office in the San Francisco Bay Area (within 30 miles of Redwood City), within 30 days thereafter, Executive will be required to report to and work from such office. The parties intend for the Company&#8217;s California office to be in Redwood City.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Policies and Procedures.</font><font style="font-weight:normal;color:#000000;"> The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compensation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Salary.</font><font style="font-weight:normal;color:#000000;"> For services to be rendered hereunder, Executive shall receive a base salary at the rate of Five Hundred Twenty-Five Thousand U.S. Dollars ($525,000) per year (such base salary, as in effect from time to time, the &#8220;</font><font style="color:#000000;">Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221;), subject to standard payroll deductions and withholdings and payable in accordance with the Company&#8217;s regular payroll </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font><font style="font-size:8pt;">&nbsp;</font>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">schedule. Executive shall be entitled to a salary review on a periodic basis, but no less than annually, with the first such review commencing in calendar year 2023.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Bonus.</font><font style="font-weight:normal;color:#000000;"> Executive will be eligible for an annual discretionary bonus with a target amount equal to 50% of Executive&#8217;s Base Salary (the &#8220;</font><font style="color:#000000;">Annual Bonus</font><font style="font-weight:normal;color:#000000;">&#8221;). Whether Executive receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the board of directors of the Company (the &#8220;</font><font style="color:#000000;">Board</font><font style="font-weight:normal;color:#000000;">&#8221;) or the compensation committee thereof in its sole discretion based upon the Company&#8217;s and Executive&#8217;s achievement of objectives and milestones to be determined on an annual basis by the Board or the compensation committee thereof. Executive will not be eligible for, and will not earn, any Annual Bonus (including a prorated bonus) if Executive&#8217;s employment terminates for any reason before any Annual Bonus is paid, except as otherwise set forth in Section&#160;5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sign-On Bonus.</font><font style="font-weight:normal;color:#000000;"> Executive will also receive, with her first payroll with the Company, a sign-on bonus in an aggregate amount equal to the excess (if any) of (i)&#160;Three Hundred Thousand Dollars ($300,000.00), </font><font style="font-style:italic;text-decoration:underline;font-weight:normal;color:#000000;">over</font><font style="font-weight:normal;color:#000000;"> (ii)&#160;the amount of the 2021 annual bonus the Executive receives from her current employer, less standard payroll deductions and all required withholdings (the &#8220;</font><font style="color:#000000;">Sign-On Bonus</font><font style="font-weight:normal;color:#000000;">&#8221;). The Sign-On Bonus is repayable if Executive is terminated for Cause or terminates her employment without Good Reason, in each case within 12 months of the Start Date, in which event Executive shall pay back a pro-rated portion of the Sign-On Bonus based upon the number of days remaining in such 12 month period prior to the first anniversary of the Start Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Options.</font><font style="color:#000000;"> Subject to approval by the Board or the compensation committee thereof, the Company will grant Executive an option to purchase Four Hundred Sixty Thousand (460,000) shares of the Company&#8217;s common stock, with a per share exercise price equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant, as determined by the Board or the compensation committee thereof in accordance with the Company&#8217;s customary stock option granting practices (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option</font><font style="color:#000000;">&#8221;). Subject to approval by the Board, the Option will be granted on the first business day of the month following the Start Date. 1/4<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of the shares underlying the Option will vest and become exercisable on the one-year anniversary of the Start Date, and 1/48<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of the shares underlying the Option will vest and become exercisable on a monthly basis thereafter, such that 100% of the shares underlying the Option shall be vested and exercisable as of the four-year anniversary of the Start Date, in each case so long as Executive remains employed by the Company through each applicable vesting date, except as otherwise set forth in Section&#160;5. If the applicable vesting schedule results in a fractional share, such fractional share shall not vest until the immediately following vesting date. The Option will be subject to the terms and conditions consistent with those provided in the Company&#8217;s 2020 Equity Incentive Plan and will be governed in all respects by the terms of the applicable stock option agreement to be entered into between Executive and the Company, except as specifically provided herein. Further details regarding the Option will be provided to the Executive upon approval of such grant by the Board. Executive may be considered for future grants of equity awards in the discretion of the Board or the compensation committee thereof pursuant to its regular review process.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">RSU Grant.</font><font style="color:#000000;"> Subject to approval by the Board, the Company will grant Executive One Hundred Fifty Thousand (150,000) restricted stock units (the &#8220;</font><font style="font-weight:bold;color:#000000;">RSUs</font><font style="color:#000000;">&#8221;). Subject to approval by the Board, the RSUs will be granted on the first business day of the month following the Start Date. 1/4</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#000000;"> </font><font style="color:#000000;">of the RSUs will vest on the first anniversary of the Start Date, and 1/16</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#000000;"> </font><font style="color:#000000;">of the RSUs will vest on a quarterly basis thereafter, such that 100% of the RSUs will be vested as of the four-year anniversary of the Start Date, in each case so long as Executive remains employed by the Company through each applicable vesting date, except as otherwise set forth in Section&#160;5. If the applicable vesting schedule results in a fractional share, such fractional share shall not vest until the immediately following vesting date. The RSUs will be subject to terms and conditions consistent with those provided in the Company&#8217;s 2020 Equity Incentive </font><font style="color:#000000;">Plan, and</font><font style="color:#000000;"> will be governed in all respects by the terms of the applicable RSU agreement to be entered into between Executive and the Company, except as specifically provided herein. Further details regarding the RSUs will be provided to Executive upon approval of such grant by the Board.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Standard Company Benefits.</font><font style="font-weight:normal;color:#000000;"> Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expenses.</font><font style="font-weight:normal;color:#000000;"> The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time. Executive will be entitled to Directors and Officers liability insurance coverage to the same extent as other senior management of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination of Employment; Severance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">At-Will Employment.</font><font style="font-weight:normal;color:#000000;"> Executive&#8217;s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause (as defined below); provided that in the event Executive terminates the employment relationship without Good Reason or the Company terminates the employment relationship without Cause, such party must provide the other party with no less than thirty (30) days&#8217; advance written notice. In the event Executive&#8217;s employment relationship is terminated for any reason, Executive shall be entitled to receive Executive&#8217;s earned but unpaid Base Salary, unreimbursed business expenses properly incurred by Executive pursuant to Section&#160;4 and any other compensation or benefit earned by or owed to (but not yet paid to) Executive through and including the date of termination, payable in a lump sum on the next regularly scheduled payroll date following the date on which Executive&#8217;s employment terminated, or at such other date as shall be specified under the terms of the employee benefit plan pursuant to which such compensation or benefit is payable. Executive shall also resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Severance Benefits for Termination Without Cause or Resignation with Good Reason Outside the Change in Control Period.</font><font style="font-weight:normal;color:#000000;"> In the event Executive&#8217;s employment with the Company is terminated by the Company without Cause or Executive resigns for Good Reason </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">prior to or following the Change in Control Period (as defined below), the Company shall provide Executive with the following payments and benefits, </font><font style="font-weight:normal;color:#000000;">provided that</font><font style="font-weight:normal;color:#000000;"> Executive remains in compliance with the terms of this Agreement and the Restrictive Covenant Agreement (as defined below) and subject to Section&#160;6 below:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall pay Executive, as severance, the equivalent of nine (9) months of Executive&#8217;s Base Salary as in effect as of the date of Executive&#8217;s employment termination. This severance will be paid in the form of salary continuation, payable on the Company&#8217;s regular payroll dates, subject to standard payroll deductions and withholdings, starting on the 60<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day after Executive&#8217;s termination date, with the first payment to include those payments that would have occurred earlier but for the 60-day delay.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition, the Company shall pay Executive, as severance, an amount equal to a prorated portion of Executive&#8217;s target Annual Bonus as in effect as of the date of Executive&#8217;s employment termination, with such proration to be determined based on the number of calendar days elapsed in the applicable performance period as of the date of such termination, payable in a lump sum, less deductions and withholdings, at the same time as the first severance payment described in Section&#160;5.2(i) above.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provided that Executive is then eligible for and timely elects continued coverage under COBRA, the Company shall directly pay, or reimburse Executive for, the monthly COBRA premiums to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) through the period starting on Executive&#8217;s termination date and ending on the earliest to occur of: (a)&#160;nine (9) months following Executive&#8217;s termination date; (b)&#160;the date Executive becomes eligible for group health insurance coverage through a new employer; or (c)&#160;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#8217;s group health plan or otherwise ceases to be eligible for COBRA during this time period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without a substantial risk of violating applicable law, the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA premium period. Executive may, but is not obligated to, use such payments toward the cost of COBRA premiums.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any Options that are unvested and held by Executive as of the date of such termination shall be partially accelerated such that the portion of such Options that would have vesting during the nine-month period immediately following the date of such termination had Executive remained employed by the Company through the end of such nine-month period shall be deemed immediately vested and exercisable; </font><font style="font-style:italic;color:#000000;">provided that</font><font style="color:#000000;">, this Section&#160;5.2(iii) shall not apply to any equity-based incentive compensation awards other than the Options described in Section&#160;2.4(i).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Severance Benefits for Termination Without Cause or Resignation with Good Reason During the Change in Control Period.</font><font style="font-weight:normal;color:#000000;"> In the event Executive&#8217;s employment with the Company is terminated by the Company without Cause or Executive resigns for Good Reason </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">4</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">in each case during the Change in Control Period, the Company shall provide Executive with the following payments and benefits, </font><font style="font-weight:normal;color:#000000;">provided that</font><font style="font-weight:normal;color:#000000;"> Executive remains in compliance with the terms of this Agreement and the Restrictive Covenant Agreement and subject to Section&#160;6 below:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall pay Executive, as severance, the equivalent of twelve (12) months of Executive&#8217;s Base Salary as in effect as of the date of Executive&#8217;s employment termination (disregarding any change to Executive&#8217;s Base Salary giving rise to Good Reason). This severance will be paid in the form of salary continuation, payable on the Company&#8217;s regular payroll dates, subject to standard payroll deductions and withholdings, starting on the 60<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day after Executive&#8217;s termination date, with the first payment to include those payments that would have occurred earlier but for the 60-day delay.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition, the Company shall pay Executive, as severance, an amount equal to one hundred percent (100%) of Executive&#8217;s target annual bonus as in effect as of the date of Executive&#8217;s employment termination (disregarding any change to Executive&#8217;s Base Salary giving rise to Good Reason), payable in a lump sum, less deductions and withholdings, at the same time as the first severance payment described in Section&#160;5.3(i) above. For the avoidance of doubt, the amount payable pursuant to this Section&#160;5.3(ii) shall not be subject to proration based on the portion of the year elapsed as of the date of termination. In the event that such termination of employment occurs following a Potential Change in Control Date and prior to the consummation of a Change in Control, the amount described in this Section&#160;5.3(ii) shall be paid in a lump sum as soon as practicable following the consummation of such Change in Control, Tess any amount previously paid to Executive in connection with such termination pursuant to Section&#160;5.2(ii).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provided that Executive is then eligible for and timely elects continued coverage under COBRA, the Company shall directly pay, or reimburse Executive for, the monthly COBRA premiums to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) through the period starting on Executive&#8217;s termination date and ending on the earliest to occur of: (a)&#160;twelve (12) months following Executive&#8217;s termination date; (b)&#160;the date Executive becomes eligible for group health insurance coverage through a new employer; or (c)&#160;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. hi the event Executive becomes covered under another employer&#8217;s group health plan or otherwise ceases to be eligible for COBRA during this time period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without a substantial risk of violating applicable law, the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA premium period. Executive may, but is not obligated to, use such payments toward the cost of COBRA premiums.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The vesting of all unvested equity-based incentive compensation awards outstanding as of the date of such Change in Control and held by Executive as of the date of such termination shall be accelerated such that 100% of the shares underlying such awards shall be deemed immediately vested and, in the case of stock options, exercisable; </font><font style="font-style:italic;color:#000000;">provided that</font><font style="color:#000000;">, in the case of any unvested equity-based incentive compensation awards that are subject to performance-</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">5</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">based vesting terms as of the date of such termination, the treatment of such performance-based vesting conditions shall be governed by the applicable equity plan and award agreement; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">further</font><font style="color:#000000;">, that, in the event that such termination of employment occurs following a Potential Change in Control Date and prior to the consummation of a Change in Control, each outstanding and unvested equity-based incentive compensation award (other than any Option or portion thereof that has vested in connection with such termination in accordance with Section&#160;5.2(iv)) shall cease vesting pursuant to its normal vesting schedule on the date of such termination of employment but shall not lapse or be forfeited on such date, and instead such award shall remain outstanding until the three-month anniversary of the Potential Change in Control Date, and in the event that a Change in Control subsequently occurs during such 3-month period, such award shall become vested and, if applicable, exercisable, in each case to the extent set forth in this Section&#160;5.3(iv) as if such termination occurred immediately following the Change in Control, and in the event that a Change in Control does not subsequently occur during such 3-month period such award shall be canceled for no consideration upon the conclusion of such three-month period.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In no event shall a termination by the Company without Cause or a resignation by Executive for Good Reason that occurs following a Potential Change in Control Date and before the consummation of a Change in Control result in duplicate payments or benefits to Executive under Section&#160;5.2 and Section&#160;5.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause; Resignation Without Good Reason; Death or Disability.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Executive resigns without Good Reason or the Company terminates Executive&#8217;s employment for Cause, Executive shall not be entitled to receive any payments or benefits under this Agreement, other than as set forth in Section&#160;5.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death or Total Disability. &#8220;</font><font style="font-weight:bold;color:#000000;">Total Disability</font><font style="color:#000000;">&#8221; shall mean Executive&#8217;s inability, with reasonable accommodation, to perform the duties of Executive&#8217;s position for a period of (i)&#160;180 consecutive days or (ii)&#160;180 non-consecutive days during any 12-month period. as a result of physical or mental illness, loss of legal capacity or any other cause beyond Executive&#8217;s control as determined by a qualified independent physician selected by the Company and approved by Executive (which approval shall not be unreasonably withheld). Executive and the Company hereby acknowledge that Executive&#8217;s ability to perform the duties specified in Section&#160;1 is the essence of this Agreement. Termination hereunder shall be deemed to be effective (a)&#160;at the end of the calendar month in which Executive&#8217;s death occurs or (b)&#160;immediately upon a determination by the Board or the compensation committee thereof of Executive&#8217;s Total Disability. In the case of termination of employment under this Section&#160;5.4(ii), Executive shall not be entitled to receive any payments or benefits under this Agreement, other than as set forth in Section&#160;5.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Conditions to Receipt of Severance Benefits.</font><font style="font-weight:normal;color:#000000;"> As a condition to receiving the payments and benefits set forth in Section&#160;5.2 and Section&#160;5.3, (i)&#160;Executive must execute and deliver to the Company a release of claims in a form reasonably acceptable to the Company and such release must have become effective and the revocation period provided therein must have expired without Executive having revoked such release within the 60-day period following the date of termination, and (ii)&#160;Executive must not have revoked or breached the provisions of such </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">6</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">release or breached the provisions of the Restrictive Covenant Agreement. In the event that Executive does not execute and deliver such release, such release does not become effective and irrevocable within such period or Executive revokes or breaches the provisions of the release or breaches the provisions of the Restrictive Covenant Agreement, Executive (A</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">will be deemed to have voluntarily resigned Executive&#8217;s employment hereunder without Good Reason, (B</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">will not be entitled to the payments, benefits or accelerated vesting described in </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">5.2 or </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">5.3 and (C</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">will be required to reimburse the Company, in cash within five business days after written demand is made by the Company therefore, for an amount equal to the value of any payments or benefits Executive received pursuant to </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">5.2 or </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">5.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section&#160;409A.</font><font style="font-weight:normal;color:#000000;"> It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&#160;409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;">Code</font><font style="font-weight:normal;color:#000000;">&#8221; and &#8220;</font><font style="color:#000000;">Section&#160;409A</font><font style="font-weight:normal;color:#000000;">&#8221;) provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section&#160;409A. All payments and benefits that are payable upon a termination of employment hereunder shall be paid or provided only upon Executive&#8217;s &#8220;separation from service&#8221; from the Company (within the meaning of Section&#160;409A). For purposes of Section&#160;409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive&#8217;s termination to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i), and if any of the payments upon termination set forth herein and/or under any other agreement with the Company are deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) and the related adverse taxation under Section&#160;409A, such payments shall not be provided to Executive prior to the earliest of (i)&#160;the expiration of the six-month period measured from the date of Executive&#8217;s termination with the Company, (ii)&#160;the date of Executive&#8217;s death or (iii)&#160;such earlier date as permitted under Section&#160;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section&#160;7 shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section&#160;280G.</font><font style="font-weight:normal;color:#000000;"> In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i)&#160;constitute &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code and (ii)&#160;but for this Section&#160;8, would be subject to the excise tax imposed by Section&#160;4999 of the Code, then, Executive&#8217;s severance and other benefits under this Agreement shall be payable either (i)&#160;in full, or (ii)&#160;as to such lesser amount which would result in no portion of such severance and other benefits being subject to the excise tax under Section&#160;4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section&#160;4999 of the Code, </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">7</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">results in the receipt by Executive on an after-tax basis of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">4999 of the Code. Any reduction shall be made in the following order: (</font><font style="font-weight:normal;color:#000000;">i</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">reduction of cash payments, (ii</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">cancellation of accelerated vesting of equity awards, and (iii</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">reduction of other benefits payable to Executive. Unless the Company and Executive otherwise agree in writing, any determination required under this </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">8 shall be made in writing by the Company&#8217;s independent public accountants (the &#8220;</font><font style="color:#000000;">Accountants</font><font style="font-weight:normal;color:#000000;">&#8221;), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">8, the </font><font style="font-weight:normal;color:#000000;">Accountants</font><font style="font-weight:normal;color:#000000;"> may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the </font><font style="font-weight:normal;color:#000000;">Accountants</font><font style="font-weight:normal;color:#000000;"> such information and documents as the Accountants may reasonably request in order to make a determination under this </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">8. The Company shall bear all costs the </font><font style="font-weight:normal;color:#000000;">Accountants</font><font style="font-weight:normal;color:#000000;"> may reasonably incur in connection with any calculations contemplated by this </font><font style="font-weight:normal;color:#000000;">Section&#160;</font><font style="font-weight:normal;color:#000000;">8.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definitions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Cause.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; for termination will mean: (i)&#160;a material breach of any of Executive&#8217;s obligations or duties pursuant to this Agreement or the Restrictive Covenant Agreement, which remains uncured ten business days after Executive becomes aware of the breach by formal written notification by the Company; (ii)&#160;gross negligence, willful misconduct or breach of fiduciary duty in the course of employment, which if curable remains uncured ten days after the Executive becomes aware of the breach by formal written notification by the Company; (iii)&#160;any action or activity that is contrary to applicable insider trading rules or any other applicable securities rules or legislation; (iv)&#160;a material act or omission involving substantial dishonesty or fraud that harms or would reasonably be expected to harm the Company; or (v)&#160;commission of, conviction or indictment for, or plea of no contest to, any felony (or state law equivalent) or any crime involving moral turpitude.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Change in Control.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Change in Control</font><font style="font-weight:normal;color:#000000;">&#8221; means the occurrence of one or more of the following: (a)&#160;a merger, a consolidation, a reorganization or an arrangement that results in a transfer of more than fifty percent (50%) of the total voting power of the Company&#8217;s outstanding securities to a person or a group of persons different from a person or a group of persons holding those securities immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company); (b)&#160;a direct or indirect sale or other transfer of beneficial ownership of securities of the Company possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities to a person or a group of persons different from a person or a group of persons holding those securities immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company); (c)&#160;a direct or indirect sale or other transfer of the right to appoint more than fifty percent (50%) of the directors of the Board or otherwise directly or indirectly control the management, affairs and business of the Company to a person or a group of persons different from a person or a group of persons holding this right immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company); (d)&#160;a direct </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">8</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">or indirect sale or other transfer of all or substantially all of the assets of the Company to a person or a group of persons different from a person or a group of persons holding those assets immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company); or (e</font><font style="font-weight:normal;color:#000000;">)&#160;</font><font style="font-weight:normal;color:#000000;">a complete liquidation, dissolution or winding-up of the Company; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that a Change in Control will not be deemed to have occurred if such Change in Control results solely from the issuance, in connection with a bona fide financing or series of financings by the Company, of voting securities of the Company or any rights to acquire voting securities of the Company which are convertible into voting securities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Change in Control Period.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Change in Control Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period (i)&#160;commencing on the later of (a)&#160;the date that is three (3) months prior to the effective date of a Change in Control and (b)&#160;the Potential Change in Control Date, and (ii)&#160;ending on the date that is twelve (12) months following the effective date of a Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Good Reason.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Good Reason</font><font style="font-weight:normal;color:#000000;">&#8221; will mean any of the following actions taken by the Company without Executive&#8217;s prior written consent: (i)&#160;a material adverse change in Executive&#8217;s position, title, office or duties or assignment of any significant duties to Executive that are materially inconsistent with the position or offices held by Executive; (ii)&#160;Executive no longer serving as a Section&#160;16 officer or, if the Company&#8217;s ultimate parent following a Change in Control is not a public company, not reporting to the Chief Executive Officer of the Company&#8217;s ultimate parent; (iii)&#160;a decrease in Executive&#8217;s aggregate base salary and target Annual Bonus by more than 10% (other than in connection with a broad-based reduction in the base salaries or target annual bonuses of all other officers of the Company); (iv)&#160;a relocation that increases Executive&#8217;s one-way commute by more than 30 miles; and (v)&#160;any directive by the Company to undertake any action or to omit to take any action in violation of Executive&#8217;s professional medical obligations or any law, rule, regulation or Company policy. In order to resign for Good Reason, (A)&#160;Executive must provide written notice to the Company&#8217;s Chief Executive Officer within 60 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive&#8217;s resignation, (B)&#160;Executive must allow the Company at least 30 days from receipt of such written notice to cure such event, and (C)&#160;if such event is not reasonably cured within such period, Executive must resign from all positions Executive then holds with the Company not later than 90 days after the expiration of such cure period. In addition, in order to resign for Good Reason under clause&#160;(v) above, (1)&#160;the notice described in clause&#160;(A) of the foregoing sentence must be accompanied by a written legal opinion from Executive&#8217;s legal counsel concluding that such action or omission would be in violation of Executive&#8217;s professional medical obligations or any law, rule, regulation or Company policy, and (2)&#160;during the 30-day cure period described in clause&#160;(B) of the foregoing sentence, the Company must be provided with an opportunity to discuss in good faith such legal opinion with Executive&#8217;s legal counsel.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Potential Change in Control Date.</font><font style="font-weight:normal;color:#000000;"> For purposes of this Agreement, &#8220;</font><font style="color:#000000;">Potential Change in Control Date</font><font style="font-weight:normal;color:#000000;">&#8221; means the date on which the Company commences its engagement with the applicable counterparty to pursue the transaction that will constitute a Change in Control if such transaction is consummated.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">9</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">10.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Proprietary Information Obligations.</font><font style="font-weight:normal;color:#000000;"> As an employee of the Company, Executive will have access to certain confidential information of the Company and Executive may, </font><font style="font-weight:normal;color:#000000;">during the course of</font><font style="font-weight:normal;color:#000000;"> Executive&#8217;s employment develop certain information or inventions that will be the property of the Company. To the protect the Company&#8217;s interests, as a condition of employment, Executive must execute and abide by the Employee Proprietary Information, Restrictive Covenant and Invention Assignment Agreement attached here to as Exhibit&#160;A (the &#8220;</font><font style="color:#000000;">Restrictive Covenant Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Outside Activities During Employment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Company Business.</font><font style="font-weight:normal;color:#000000;"> Except with the prior written consent of the Board, Executive will not during the term of Executive&#8217;s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor, provided that they do not violate the Restrictive Covenant Agreement. Executive may engage in civic and not-for-profit activities, as well as (i)&#160;assume no more than two non-competitive board positions and (ii)&#160;maintain her current Stanford faculty position, so long as such activities do not materially interfere with the performance of Executive&#8217;s duties hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Adverse Interests.</font><font style="font-weight:normal;color:#000000;"> Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Dispute Resolution.</font><font style="font-weight:normal;color:#000000;"> To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to statutory claims, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in California conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;">JAMS</font><font style="font-weight:normal;color:#000000;">&#8221;) under the then applicable JAMS rules or by another arbitration company if mutually agreed upon by Executive and Board. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a)&#160;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&#160;issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">10</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">13.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General Provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notices.</font><font style="font-weight:normal;color:#000000;"> Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Severability.</font><font style="font-weight:normal;color:#000000;"> Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Waiver.</font><font style="font-weight:normal;color:#000000;"> Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Complete Agreement.</font><font style="font-weight:normal;color:#000000;"> This Agreement, together with the Restrictive Covenant Agreement, constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties&#8217; agreement with regard to this subject matter, and supersedes all prior or contemporaneous offers, negotiations and agreements, whether written or oral, relating to such subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Counterparts.</font><font style="font-weight:normal;color:#000000;"> This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Headings.</font><font style="font-weight:normal;color:#000000;"> The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns.</font><font style="font-weight:normal;color:#000000;"> This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of Executive&#8217;s duties hereunder and Executive may not assign any of Executive&#8217;s rights hereunder without the written consent of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tax Withholding and Indemnification.</font><font style="font-weight:normal;color:#000000;"> All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">11</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.9</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Choice of Law.</font><font style="font-weight:normal;color:#000000;"> All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of Page Intentionally Left Blank</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">12</a><font style="margin-left:36pt;"></font><font style="font-size:8pt;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the Parties have executed this Agreement on the day and year first written above.</font></p>
<p style="margin-bottom:30pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Prelude Therapeutics Incorporated</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Krishna Vaddi </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: <font style="text-decoration:underline;">CEO</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:24pt;margin-top:36pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Jane Huang</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Jane Huang</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Employment Agreement</font>]</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>prld-ex311_6.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
prld-ex311_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Krishna Vaddi, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Prelude Therapeutics Incorporated;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk96678235"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other <a name="_Hlk96678235"></a>certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk96678249"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Krishna Vaddi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Krishna Vaddi, PhD</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>prld-ex312_7.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
prld-ex312_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Laurent Chardonnet, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Prelude Therapeutics Incorporated;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk96678235"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other <a name="_Hlk96678235"></a>certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk96678249"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Accounting and Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>prld-ex321_9.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
prld-ex321_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Krishna Vaddi, Chief Executive Officer of Prelude Therapeutics Incorporated (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">the Quarterly Report on Form&#160;10-Q&#160;of the Company for the fiscal quarter ended March 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Krishna Vaddi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Krishna Vaddi, PhD</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>prld-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
prld-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I, Laurent Chardonnet, Chief Financial Officer of Prelude Therapeutics Incorporated (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:<font style="color:#000000;"> </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the </font><font style="color:#000000;">Quarterly Report on Form&#160;10-Q&#160;of the Company for the fiscal quarter ended March 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;</font><font style="color:#000000;"> and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 10, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurent Chardonnet</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Accounting and Finance Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>prld-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:prld="http://preludetx.com/20220331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://preludetx.com/20220331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://preludetx.com/20220331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED" id="Role_StatementSTATEMENTOFBALANCESHEETSUNAUDITED">
        <link:definition>100010 - Statement - STATEMENT OF BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED" id="Role_StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED">
        <link:definition>100020 - Statement - STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" id="Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED">
        <link:definition>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED" id="Role_StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED">
        <link:definition>100040 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED" id="Role_StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED">
        <link:definition>100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED" id="Role_StatementSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>100060 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureBackground" id="Role_DisclosureBackground">
        <link:definition>100070 - Disclosure - Background</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity" id="Role_DisclosureRisksAndLiquidity">
        <link:definition>100080 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100110 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100120 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100130 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments" id="Role_DisclosureCommitments">
        <link:definition>100140 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100180 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100190 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100200 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables" id="Role_DisclosureCommitmentsTables">
        <link:definition>100210 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100220 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails" id="Role_DisclosureRisksAndLiquidityAdditionalInformationDetails">
        <link:definition>100230 - Disclosure - Risks and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>100270 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100280 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100290 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" id="Role_DisclosureCommitmentsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" id="Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails">
        <link:definition>100320 - Disclosure - Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2" id="Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2">
        <link:definition>100330 - Disclosure - Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails">
        <link:definition>100350 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100360 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" id="Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails">
        <link:definition>100370 - Disclosure - Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails">
        <link:definition>100380 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails" id="Role_DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="prld_VotingCommonStockMember" name="VotingCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_PaymentsOfOfferingCosts" name="PaymentsOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_UnrealizedGainLossOnMarketableSecurities" name="UnrealizedGainLossOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_BackgroundAbstract" name="BackgroundAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_RisksAndLiquidityTextBlock" name="RisksAndLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_RisksAndLiquidityAbstract" name="RisksAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_OperatingLeaseUntilJune302023Member" name="OperatingLeaseUntilJune302023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ChestnutRunLeaseMember" name="ChestnutRunLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" name="AccruedResearchAndDevelopmentLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" name="OperatingLeaseEstimatedIncrementalBorrowingRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_DarwinHealthIncMember" name="DarwinHealthIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_LeaseLiabilityLineItems" name="LeaseLiabilityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_LeaseLiabilityTable" name="LeaseLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_AreaOfLeasePremises" name="AreaOfLeasePremises" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="prld_InitialTermOfLease" name="InitialTermOfLease" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_NumberOfLeaseExtensions" name="NumberOfLeaseExtensions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" name="AggregateEstimatedRentPaymentsDueOverInitialTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_ReimbursementsForDevelopmentOfLabSpace" name="ReimbursementsForDevelopmentOfLabSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" name="ReimbursementsForDevelopmentOfLabSpacePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" name="ReimbursementsForDevelopmentOfLabSpaceExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_DisbursementIncurredCostsForLabSpace" name="DisbursementIncurredCostsForLabSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" name="ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="prld_GrantForDevelopmentOfLabSpace" name="GrantForDevelopmentOfLabSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_EstimatedNumberOfYearResearchCollaborationAgreement" name="EstimatedNumberOfYearResearchCollaborationAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" name="EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="prld_GracePeriodForPotentialRefund" name="GracePeriodForPotentialRefund" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_PotentialRefundReceivableFromAgreement" name="PotentialRefundReceivableFromAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_NumberOfEqualInstalments" name="NumberOfEqualInstalments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_ResearchTerm" name="ResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" name="PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_NumberOfEquityIncentivePlans" name="NumberOfEquityIncentivePlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" name="TwoThousandTwentyEmployeesStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="prld_EligibleEmployeesContributionPercentage" name="EligibleEmployeesContributionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" name="ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>prld-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="prld-20220331.xsd#TemplateLink" roleURI="http://preludetx.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCash" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED">
    <link:loc xlink:href="prld-20220331.xsd#prld_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="prld_IncreaseDecreaseInOperatingLeaseLiabilities" order="10160.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="prld-20220331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="prld-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" xlink:type="locator" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>prld-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="prld-20220331.xsd#TemplateLink" roleURI="http://preludetx.com/20220331/role/TemplateLink" />
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10220.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11670.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="prld_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="prld_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="prld-20220331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="prld-20220331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_BeneficialOwnershipPercentage" xlink:type="locator" xlink:label="prld_BeneficialOwnershipPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_FollowOnOfferingMember" xlink:type="locator" xlink:label="prld_FollowOnOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prld_FollowOnOfferingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prld_BeneficialOwnershipPercentage" order="10430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_PotentialRefundReceivableFromAgreement" xlink:type="locator" xlink:label="prld_PotentialRefundReceivableFromAgreement" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GracePeriodForPotentialRefund" xlink:type="locator" xlink:label="prld_GracePeriodForPotentialRefund" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEqualInstalments" xlink:type="locator" xlink:label="prld_NumberOfEqualInstalments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ResearchTerm" xlink:type="locator" xlink:label="prld_ResearchTerm" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" xlink:type="locator" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedNumberOfYearResearchCollaborationAgreement" xlink:type="locator" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" xlink:type="locator" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" />
    <link:loc xlink:href="prld-20220331.xsd#prld_DisbursementIncurredCostsForLabSpace" xlink:type="locator" xlink:label="prld_DisbursementIncurredCostsForLabSpace" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GrantForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_GrantForDevelopmentOfLabSpace" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpacePeriod" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" xlink:type="locator" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfLeaseExtensions" xlink:type="locator" xlink:label="prld_NumberOfLeaseExtensions" />
    <link:loc xlink:href="prld-20220331.xsd#prld_InitialTermOfLease" xlink:type="locator" xlink:label="prld_InitialTermOfLease" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AreaOfLeasePremises" xlink:type="locator" xlink:label="prld_AreaOfLeasePremises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" xlink:type="locator" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="prld-20220331.xsd#prld_DarwinHealthIncMember" xlink:type="locator" xlink:label="prld_DarwinHealthIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:type="locator" xlink:label="srt_ProFormaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementScenarioAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="prld_DarwinHealthIncMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_AreaOfLeasePremises" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_InitialTermOfLease" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_NumberOfLeaseExtensions" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDeposit" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpace" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_GrantForDevelopmentOfLabSpace" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_DisbursementIncurredCostsForLabSpace" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_EstimatedNumberOfYearResearchCollaborationAgreement" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ResearchTerm" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_NumberOfEqualInstalments" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_GracePeriodForPotentialRefund" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_PotentialRefundReceivableFromAgreement" order="11580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityTable" xlink:type="locator" xlink:label="prld_LeaseLiabilityTable" />
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityLineItems" xlink:type="locator" xlink:label="prld_LeaseLiabilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="prld_LeaseLiabilityTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="prld_LeaseLiabilityTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" xlink:type="locator" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EligibleEmployeesContributionPercentage" xlink:type="locator" xlink:label="prld_EligibleEmployeesContributionPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="prld-20220331.xsd#prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" xlink:type="locator" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEquityIncentivePlans" xlink:type="locator" xlink:label="prld_NumberOfEquityIncentivePlans" />
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="prld_TwoThousandTwentyEquityIncentivePlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_NumberOfEquityIncentivePlans" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_EligibleEmployeesContributionPercentage" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" order="12890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFiveMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFourMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeThreeMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeTwoMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeOneMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeTwoMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeThreeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeFourMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeFiveMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10530.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>prld-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="prld_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_VotingCommonStockMember" xlink:to="prld_VotingCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments (Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Per share information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of common stock, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, net of offering costs, (shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (shares)</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_PaymentsOfOfferingCosts" xlink:type="locator" xlink:label="prld_PaymentsOfOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="prld_PaymentsOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_PaymentsOfOfferingCosts" xlink:to="prld_PaymentsOfOfferingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_PaymentsOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock, offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_PaymentsOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Offering Costs</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="prld_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_UnrealizedGainLossOnMarketableSecurities" xlink:type="locator" xlink:label="prld_UnrealizedGainLossOnMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="prld_UnrealizedGainLossOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized gain (loss) on marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_UnrealizedGainLossOnMarketableSecurities" xlink:to="prld_UnrealizedGainLossOnMarketableSecurities_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium and discount on marketable securities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by (used in) investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of common stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_UnrealizedGainLossOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_UnrealizedGainLossOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Marketable Securities</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_BackgroundAbstract" xlink:type="locator" xlink:label="prld_BackgroundAbstract" />
    <link:label xml:lang="en-US" xlink:label="prld_BackgroundAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Background.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_BackgroundAbstract" xlink:to="prld_BackgroundAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_BackgroundAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Background [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Background</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_RisksAndLiquidityTextBlock" xlink:type="locator" xlink:label="prld_RisksAndLiquidityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="prld_RisksAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_RisksAndLiquidityTextBlock" xlink:to="prld_RisksAndLiquidityTextBlock_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_RisksAndLiquidityAbstract" xlink:type="locator" xlink:label="prld_RisksAndLiquidityAbstract" />
    <link:label xml:lang="en-US" xlink:label="prld_RisksAndLiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_RisksAndLiquidityAbstract" xlink:to="prld_RisksAndLiquidityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_RisksAndLiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_RisksAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_RisksAndLiquidityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Liquidity [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:type="locator" xlink:label="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseUntilJune302023Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, until June 30, 2023.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_OperatingLeaseUntilJune302023Member" xlink:to="prld_OperatingLeaseUntilJune302023Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseUntilJune302023Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, until June 30, 2023</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseUntilJune302023Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Until June302023 [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ChestnutRunLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chestnut run lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ChestnutRunLeaseMember" xlink:to="prld_ChestnutRunLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ChestnutRunLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chestnut Run Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ChestnutRunLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chestnut Run Lease [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Annual Lease Payments Under Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Stock Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity related to RSA Stock-Based Payment Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="prld_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_SummaryOfSignificantAccountingPoliciesTable" xlink:to="prld_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201613 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, ASU, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities accumulated gross unrealized gain net of tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities accumulated gross unrealized loss net of tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, Gross unrealized gain</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, Gross unrealized loss</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant other observable inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant unobservable inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement, recurring basis, assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" xlink:type="locator" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development liabilities, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" xlink:to="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Compensation and related benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_FollowOnOfferingMember" xlink:type="locator" xlink:label="prld_FollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="prld_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_FollowOnOfferingMember" xlink:to="prld_FollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_BeneficialOwnershipPercentage" xlink:type="locator" xlink:label="prld_BeneficialOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="prld_BeneficialOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beneficial ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_BeneficialOwnershipPercentage" xlink:to="prld_BeneficialOwnershipPercentage_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_BeneficialOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_BeneficialOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Percentage</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" xlink:type="locator" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" />
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease estimated incremental borrowing rate percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" xlink:to="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:type="locator" xlink:label="srt_ProFormaMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ProFormaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProFormaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pro Forma [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_DarwinHealthIncMember" xlink:type="locator" xlink:label="prld_DarwinHealthIncMember" />
    <link:label xml:lang="en-US" xlink:label="prld_DarwinHealthIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Darwin Health, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_DarwinHealthIncMember" xlink:to="prld_DarwinHealthIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_DarwinHealthIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DarwinHealth</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_DarwinHealthIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Darwin Health Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease estimated incremental borrowing rate percent</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Estimated Incremental Borrowing Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityLineItems" xlink:type="locator" xlink:label="prld_LeaseLiabilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="prld_LeaseLiabilityLineItems_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityTable" xlink:type="locator" xlink:label="prld_LeaseLiabilityTable" />
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_LeaseLiabilityTable" xlink:to="prld_LeaseLiabilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_LeaseLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liability [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 (remaining)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current and noncurrent lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_AreaOfLeasePremises" xlink:type="locator" xlink:label="prld_AreaOfLeasePremises" />
    <link:label xml:lang="en-US" xlink:label="prld_AreaOfLeasePremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of lease premises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AreaOfLeasePremises" xlink:to="prld_AreaOfLeasePremises_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_InitialTermOfLease" xlink:type="locator" xlink:label="prld_InitialTermOfLease" />
    <link:label xml:lang="en-US" xlink:label="prld_InitialTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_InitialTermOfLease" xlink:to="prld_InitialTermOfLease_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfLeaseExtensions" xlink:type="locator" xlink:label="prld_NumberOfLeaseExtensions" />
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfLeaseExtensions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of lease extensions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_NumberOfLeaseExtensions" xlink:to="prld_NumberOfLeaseExtensions_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" xlink:type="locator" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" />
    <link:label xml:lang="en-US" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate estimated rent payments due over initial term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" xlink:to="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_AreaOfLeasePremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of lease premises</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AreaOfLeasePremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Lease Premises</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_InitialTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of lease</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_InitialTermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfLeaseExtensions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of lease extensions</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfLeaseExtensions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Lease Extensions</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate estimated rent payments due over initial term</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Estimated Rent Payments Due Over Initial Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace" />
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements for development of lab space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ReimbursementsForDevelopmentOfLabSpace" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpace_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpacePeriod" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" />
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements for development of lab space period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpacePeriod_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements for development of lab space expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_DisbursementIncurredCostsForLabSpace" xlink:type="locator" xlink:label="prld_DisbursementIncurredCostsForLabSpace" />
    <link:label xml:lang="en-US" xlink:label="prld_DisbursementIncurredCostsForLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disbursement incurred costs for lab space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_DisbursementIncurredCostsForLabSpace" xlink:to="prld_DisbursementIncurredCostsForLabSpace_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" xlink:type="locator" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" />
    <link:label xml:lang="en-US" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Received cash for satisfying performance benchmark measurement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" xlink:to="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GrantForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_GrantForDevelopmentOfLabSpace" />
    <link:label xml:lang="en-US" xlink:label="prld_GrantForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant for development of lab space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_GrantForDevelopmentOfLabSpace" xlink:to="prld_GrantForDevelopmentOfLabSpace_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements for development of lab space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements For Development Of Lab Space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements for development of lab space period</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements For Development Of Lab Space Period</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements for development of lab space expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements For Development Of Lab Space Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_GrantForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant for development of lab space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_GrantForDevelopmentOfLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant For Development Of Lab Space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_DisbursementIncurredCostsForLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disbursement incurred costs for lab space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_DisbursementIncurredCostsForLabSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disbursement Incurred Costs For Lab Space</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received cash for satisfying performance benchmark measurement</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Received Cash For Satisfying Performance Benchmark Measurement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percent of employee&apos;s gross pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedNumberOfYearResearchCollaborationAgreement" xlink:type="locator" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated number of year research collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_EstimatedNumberOfYearResearchCollaborationAgreement" xlink:to="prld_EstimatedNumberOfYearResearchCollaborationAgreement_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" xlink:type="locator" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" />
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated amount of payment over a agreement term in three equal installments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" xlink:to="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GracePeriodForPotentialRefund" xlink:type="locator" xlink:label="prld_GracePeriodForPotentialRefund" />
    <link:label xml:lang="en-US" xlink:label="prld_GracePeriodForPotentialRefund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grace period for potential refund.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_GracePeriodForPotentialRefund" xlink:to="prld_GracePeriodForPotentialRefund_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_PotentialRefundReceivableFromAgreement" xlink:type="locator" xlink:label="prld_PotentialRefundReceivableFromAgreement" />
    <link:label xml:lang="en-US" xlink:label="prld_PotentialRefundReceivableFromAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential refund receivable from agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_PotentialRefundReceivableFromAgreement" xlink:to="prld_PotentialRefundReceivableFromAgreement_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEqualInstalments" xlink:type="locator" xlink:label="prld_NumberOfEqualInstalments" />
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEqualInstalments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equal instalments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_NumberOfEqualInstalments" xlink:to="prld_NumberOfEqualInstalments_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ResearchTerm" xlink:type="locator" xlink:label="prld_ResearchTerm" />
    <link:label xml:lang="en-US" xlink:label="prld_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ResearchTerm" xlink:to="prld_ResearchTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated years of research collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Number Of Year Research Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amount of payment over a agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Amount Of Payment Over Agreement Term In Three Equal Installments</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research term</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement is eligible to receive payment in future research, development and regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEqualInstalments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equal instalments</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEqualInstalments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equal Instalments</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_GracePeriodForPotentialRefund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grace period following research term for potential refund</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_GracePeriodForPotentialRefund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grace Period For Potential Refund</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_PotentialRefundReceivableFromAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential refund receivable from agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_PotentialRefundReceivableFromAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Refund Receivable From Agreement</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" xlink:type="locator" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" />
    <link:label xml:lang="en-US" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" xlink:to="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEquityIncentivePlans" xlink:type="locator" xlink:label="prld_NumberOfEquityIncentivePlans" />
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEquityIncentivePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equity incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_NumberOfEquityIncentivePlans" xlink:to="prld_NumberOfEquityIncentivePlans_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting After One Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="prld_TwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" xlink:to="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employees Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEquityIncentivePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equity incentive plans</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_NumberOfEquityIncentivePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equity Incentive Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Outstanding Used To Calculate Annual Increase In Number Of Shares That Can Be Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of stock options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Exercisable at March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price per share, Outstanding at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price per share, Outstanding at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price per share, Exercisable at March 31, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (years), Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (years), Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of outstanding options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of exercisable options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeOneMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ExercisePriceRangeOneMember" xlink:to="prld_ExercisePriceRangeOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$0.31 - $5.99</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeTwoMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ExercisePriceRangeTwoMember" xlink:to="prld_ExercisePriceRangeTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$6.00 - $11.72</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeThreeMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ExercisePriceRangeThreeMember" xlink:to="prld_ExercisePriceRangeThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$11.73 - $13.04</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFourMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ExercisePriceRangeFourMember" xlink:to="prld_ExercisePriceRangeFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$13.05 - $31.13</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFiveMember" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price range five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ExercisePriceRangeFiveMember" xlink:to="prld_ExercisePriceRangeFiveMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$31.14 - $88.98</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ExercisePriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of Exercise Prices, Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of Exercise Prices, Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, Number Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense related to unvested stock option awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense, weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Unvested balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Unvested balance at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average grant date fair value, Unvested balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average grant date fair value, Unvested balance at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangement, nonvested award, unrecognized expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">weighted-average grant date fair value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="prld-20220331.xsd#prld_EligibleEmployeesContributionPercentage" xlink:type="locator" xlink:label="prld_EligibleEmployeesContributionPercentage" />
    <link:label xml:lang="en-US" xlink:label="prld_EligibleEmployeesContributionPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligible employees contribution percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_EligibleEmployeesContributionPercentage" xlink:to="prld_EligibleEmployeesContributionPercentage_lbl" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" xlink:type="locator" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" />
    <link:label xml:lang="en-US" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Participants accrue rights to purchase maximum common stock amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" xlink:to="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible employees purchase common stock percentage of lower of fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_EligibleEmployeesContributionPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible employees contribution percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_EligibleEmployeesContributionPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Eligible Employees Contribution Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Participants accrue rights to purchase maximum common stock amount</link:label>
    <link:label xml:lang="en-US" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Participants Accrue Rights To Purchase Maximum Common Stock Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>prld-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-10T01:12:41.4441491+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cf630bc5b7fd42d58b6de8e2f562bf29 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://preludetx.com/20220331/role/TemplateLink" xlink:href="prld-20220331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="prld-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTOFBALANCESHEETSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_VotingCommonStockMember" xlink:type="locator" xlink:label="prld_VotingCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="prld_VotingCommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED">
    <link:loc xlink:href="prld-20220331.xsd#prld_PaymentsOfOfferingCosts" xlink:type="locator" xlink:label="prld_PaymentsOfOfferingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="prld_PaymentsOfOfferingCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:href="prld-20220331.xsd#Role_StatementSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED">
    <link:loc xlink:href="prld-20220331.xsd#prld_UnrealizedGainLossOnMarketableSecurities" xlink:type="locator" xlink:label="prld_UnrealizedGainLossOnMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="prld-20220331.xsd#prld_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="prld_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="prld_IncreaseDecreaseInOperatingLeaseLiabilities" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="prld_UnrealizedGainLossOnMarketableSecurities" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureBackground" xlink:href="prld-20220331.xsd#Role_DisclosureBackground" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureBackground">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="prld-20220331.xsd#prld_BackgroundAbstract" xlink:type="locator" xlink:label="prld_BackgroundAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_BackgroundAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity" xlink:href="prld-20220331.xsd#Role_DisclosureRisksAndLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity">
    <link:loc xlink:href="prld-20220331.xsd#prld_RisksAndLiquidityTextBlock" xlink:type="locator" xlink:label="prld_RisksAndLiquidityTextBlock" />
    <link:loc xlink:href="prld-20220331.xsd#prld_RisksAndLiquidityAbstract" xlink:type="locator" xlink:label="prld_RisksAndLiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_RisksAndLiquidityAbstract" xlink:to="prld_RisksAndLiquidityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities" xlink:href="prld-20220331.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments" xlink:href="prld-20220331.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="prld-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="prld-20220331.xsd#prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:type="locator" xlink:label="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock" xlink:href="prld-20220331.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments" xlink:href="prld-20220331.xsd#Role_DisclosureCommitments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="prld-20220331.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="prld-20220331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="prld-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="prld-20220331.xsd#prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureRisksAndLiquidityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="prld-20220331.xsd#prld_RisksAndLiquidityAbstract" xlink:type="locator" xlink:label="prld_RisksAndLiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_RisksAndLiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="prld_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="prld_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_SummaryOfSignificantAccountingPoliciesTable" xlink:to="prld_SummaryOfSignificantAccountingPoliciesLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="prld-20220331.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" xlink:type="locator" xlink:label="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="prld-20220331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="prld-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" xlink:type="locator" xlink:label="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="prld_AccruedResearchAndDevelopmentLiabilitiesCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_BeneficialOwnershipPercentage" xlink:type="locator" xlink:label="prld_BeneficialOwnershipPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_FollowOnOfferingMember" xlink:type="locator" xlink:label="prld_FollowOnOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prld_FollowOnOfferingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prld_BeneficialOwnershipPercentage" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_PotentialRefundReceivableFromAgreement" xlink:type="locator" xlink:label="prld_PotentialRefundReceivableFromAgreement" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GracePeriodForPotentialRefund" xlink:type="locator" xlink:label="prld_GracePeriodForPotentialRefund" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEqualInstalments" xlink:type="locator" xlink:label="prld_NumberOfEqualInstalments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ResearchTerm" xlink:type="locator" xlink:label="prld_ResearchTerm" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" xlink:type="locator" xlink:label="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EstimatedNumberOfYearResearchCollaborationAgreement" xlink:type="locator" xlink:label="prld_EstimatedNumberOfYearResearchCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" xlink:type="locator" xlink:label="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" />
    <link:loc xlink:href="prld-20220331.xsd#prld_DisbursementIncurredCostsForLabSpace" xlink:type="locator" xlink:label="prld_DisbursementIncurredCostsForLabSpace" />
    <link:loc xlink:href="prld-20220331.xsd#prld_GrantForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_GrantForDevelopmentOfLabSpace" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpacePeriod" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ReimbursementsForDevelopmentOfLabSpace" xlink:type="locator" xlink:label="prld_ReimbursementsForDevelopmentOfLabSpace" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" xlink:type="locator" xlink:label="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfLeaseExtensions" xlink:type="locator" xlink:label="prld_NumberOfLeaseExtensions" />
    <link:loc xlink:href="prld-20220331.xsd#prld_InitialTermOfLease" xlink:type="locator" xlink:label="prld_InitialTermOfLease" />
    <link:loc xlink:href="prld-20220331.xsd#prld_AreaOfLeasePremises" xlink:type="locator" xlink:label="prld_AreaOfLeasePremises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" xlink:type="locator" xlink:label="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="prld-20220331.xsd#prld_DarwinHealthIncMember" xlink:type="locator" xlink:label="prld_DarwinHealthIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProFormaMember" xlink:type="locator" xlink:label="srt_ProFormaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementScenarioAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="prld_DarwinHealthIncMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_AreaOfLeasePremises" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_InitialTermOfLease" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_NumberOfLeaseExtensions" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_AggregateEstimatedRentPaymentsDueOverInitialTerm" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDeposit" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpace" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpacePeriod" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_GrantForDevelopmentOfLabSpace" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_DisbursementIncurredCostsForLabSpace" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_EstimatedNumberOfYearResearchCollaborationAgreement" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_ResearchTerm" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_NumberOfEqualInstalments" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_GracePeriodForPotentialRefund" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="prld_PotentialRefundReceivableFromAgreement" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:href="prld-20220331.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityLineItems" xlink:type="locator" xlink:label="prld_LeaseLiabilityLineItems" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ChestnutRunLeaseMember" xlink:type="locator" xlink:label="prld_ChestnutRunLeaseMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_OperatingLeaseUntilJune302023Member" xlink:type="locator" xlink:label="prld_OperatingLeaseUntilJune302023Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_LeaseLiabilityTable" xlink:type="locator" xlink:label="prld_LeaseLiabilityTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="prld_LeaseLiabilityTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_OperatingLeaseUntilJune302023Member" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="prld_ChestnutRunLeaseMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityTable" xlink:to="prld_LeaseLiabilityLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prld_LeaseLiabilityLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="prld-20220331.xsd#prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" xlink:type="locator" xlink:label="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" />
    <link:loc xlink:href="prld-20220331.xsd#prld_EligibleEmployeesContributionPercentage" xlink:type="locator" xlink:label="prld_EligibleEmployeesContributionPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="prld-20220331.xsd#prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" xlink:type="locator" xlink:label="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="prld-20220331.xsd#prld_NumberOfEquityIncentivePlans" xlink:type="locator" xlink:label="prld_NumberOfEquityIncentivePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="prld-20220331.xsd#prld_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="prld_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="prld_TwoThousandTwentyEquityIncentivePlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_li0l2" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="prld_TwoThousandTwentyEmployeesStockPurchasePlanMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_NumberOfEquityIncentivePlans" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_EligibleEmployeesContributionPercentage" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFiveMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFiveMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeFourMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeFourMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeThreeMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeThreeMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeTwoMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeTwoMember" />
    <link:loc xlink:href="prld-20220331.xsd#prld_ExercisePriceRangeOneMember" xlink:type="locator" xlink:label="prld_ExercisePriceRangeOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeTwoMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeThreeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeFourMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="prld_ExercisePriceRangeFiveMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails" xlink:href="prld-20220331.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061605544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRELUDE THERAPEUTICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001678660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,695,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1384762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Powder Mill Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">467-1280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062040776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,634<span></span>
</td>
<td class="nump">$ 31,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">214,555<span></span>
</td>
<td class="nump">259,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">3,882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">269,972<span></span>
</td>
<td class="nump">295,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">4,044<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,122<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">280,671<span></span>
</td>
<td class="nump">305,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,820<span></span>
</td>
<td class="nump">9,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,069<span></span>
</td>
<td class="nump">19,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,859<span></span>
</td>
<td class="nump">19,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">512,705<span></span>
</td>
<td class="nump">505,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(2,313)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(248,585)<span></span>
</td>
<td class="num">(219,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">261,812<span></span>
</td>
<td class="nump">285,897<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">280,671<span></span>
</td>
<td class="nump">305,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062002024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">487,149,741<span></span>
</td>
<td class="nump">487,149,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">36,293,331<span></span>
</td>
<td class="nump">36,200,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">36,293,331<span></span>
</td>
<td class="nump">36,200,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">12,850,259<span></span>
</td>
<td class="nump">12,850,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">11,402,037<span></span>
</td>
<td class="nump">11,402,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">11,402,037<span></span>
</td>
<td class="nump">11,402,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prld_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061568040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,821<span></span>
</td>
<td class="nump">$ 16,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">5,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,288<span></span>
</td>
<td class="nump">21,967<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(30,288)<span></span>
</td>
<td class="num">(21,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,465)<span></span>
</td>
<td class="num">$ (21,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock, basic and diluted</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">47,066,427<span></span>
</td>
<td class="nump">45,121,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,465)<span></span>
</td>
<td class="num">$ (21,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (31,067)<span></span>
</td>
<td class="num">$ (21,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062177384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Common Stock </div>
<div>Voting Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Non-voting Common Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 212,183<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 319,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (107,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,595,301<span></span>
</td>
<td class="nump">11,110,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">161,412<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,583,334<span></span>
</td>
<td class="nump">291,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">356,567<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">485,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,726)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,388,909<span></span>
</td>
<td class="nump">11,402,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">285,897<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">505,723<span></span>
</td>
<td class="num">$ (711)<span></span>
</td>
<td class="num">(219,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,299<span></span>
</td>
<td class="nump">11,402,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (shares)</a></td>
<td class="nump">93,032<span></span>
</td>
<td class="nump">93,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">$ (1,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,465)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 261,812<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 512,705<span></span>
</td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (248,585)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,293,331<span></span>
</td>
<td class="nump">11,402,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067710920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_PaymentsOfOfferingCosts', window );">Sale of common stock, offering costs</a></td>
<td class="nump">$ 739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_PaymentsOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_PaymentsOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062236776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (29,465)<span></span>
</td>
<td class="num">$ (21,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash lease expense</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,829<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium and discount on marketable securities, net</a></td>
<td class="nump">748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,895)<span></span>
</td>
<td class="num">(16,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">42,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(952)<span></span>
</td>
<td class="num">(986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">41,548<span></span>
</td>
<td class="num">(986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">161,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">19,806<span></span>
</td>
<td class="nump">144,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">35,872<span></span>
</td>
<td class="nump">218,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">55,678<span></span>
</td>
<td class="nump">362,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_UnrealizedGainLossOnMarketableSecurities', window );">Unrealized loss on marketable securities</a></td>
<td class="num">$ (1,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_UnrealizedGainLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain (loss) on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_UnrealizedGainLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067700040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_BackgroundAbstract', window );"><strong>Background [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Background</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Background</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prelude Therapeutics Incorporated (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;5, 2016 and is a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. Since beginning operations, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_BackgroundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Background.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_BackgroundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066327944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Risks and liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is subject to a number of risks common to early-stage companies in the biotechnology industry. Principal among these risks are the uncertainties in the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology, dependence on key personnel, compliance with government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval, or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and contractors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has incurred operating losses and has an accumulated deficit of $248.6&#160;million at March&#160;31, 2022. The Company has no revenue to date and devotes its efforts to research and development. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash <span style="color:#000000;">equivalents, and marketable securities as of March&#160;31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2024.</span>&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fund its operating expenses and capital expenditure requirements after that date, the Company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;10, 2020, the World Health Organization characterized the novel&#160;COVID-19&#160;virus as a global pandemic. There is significant uncertainty as to the likely effects of this disease and emerging variants which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, CROs, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br/></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067706440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Summary of significant accounting policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary of significant accounting policies included in the Company&#8217;s financial statements for the year ended December&#160;31, 2021 can be found in &#8220;Note 3. Summary of significant accounting policies&#8221; of the Company&#8217;s Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 17, 2022. Those policies have not materially changed, except as set forth below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, the instructions to&#160;Form&#160;10-Q&#160;and&#160;Article&#160;10&#160;of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 found in the Form 10-K filed with the SEC on March 17, 2022. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the historical and anticipated future losses, management has determined that the deferred tax assets generated by net operating losses and research and development credits do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of March&#160;31, 2022 and December&#160;31, 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted cash</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents include short-term highly liquid investments with an original maturity of 90&#160;days or less when purchased and are carried at fair value in the accompanying balance sheets.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#8217;s Chestnut Run Lease. See Note 8 for further details. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,678</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,872</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of investments in corporate debt securities and commercial paper that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity (deficit). Realized gains and losses as well as credit losses, if </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any, on marketable securities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are included in the Company's</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements of operations.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> classifies marketable securities that are available for use in current operations as current assets on the balance sheets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#8217;s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,009,462</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,732,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,127</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,115,785</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,742,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the above table reflect the common stock equivalents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited interim financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In</span><span style="font-weight:bold;Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">June 2016, the FASB iss</span>ued ASU No. 2016-13, &#8220;<span style="font-style:italic;Background-color:#FFFFFF;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="Background-color:#FFFFFF;">&#8221; which has subsequently been amended by ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11, and ASU No. 2020-03 (&#8220;ASU 2016-03&#8221;). This guidance replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted this standard as of January 1, 2022 using a modified retrospective approach. It did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU No. 2021-10,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">&#8220;Government Assistance: Disclosures by Business Entities about Government Assistance&#8221;</span><span style="Background-color:#FFFFFF;">. The amendments in this Update improve financial reporting by requiring disclosures that increase the transparency of transactions with a government. The amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy (i) the type of transaction (ii) the accounting for the transaction, and (iii) the effect of the transaction on the entity&#8217;s financial statements. The Company adopted this </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">standard as of </span><span style="Background-color:#FFFFFF;">January 1, 2022</span><span style="Background-color:#FFFFFF;"> using a </span><span style="Background-color:#FFFFFF;">prospe</span><span style="Background-color:#FFFFFF;">ctive approach</span><span style="Background-color:#FFFFFF;"> and i</span><span style="Background-color:#FFFFFF;">t did </span><span style="Background-color:#FFFFFF;">no</span><span style="Background-color:#FFFFFF;">t have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066384440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following is a summary of the Company&#8217;s marketable securities.</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,237</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,555</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s marketable securities generally have contractual maturity dates of 15 months or less. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary, is primarily related to market factors and believes that it is more likely than not that it will be able to hold its debt securities to maturity. </span>Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066332696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The Company follows the provisions of ASC 820, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Level&#160;1:</span><span style="color:#000000;"> Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Level&#160;2:</span><span style="color:#000000;"> Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Level&#160;3:</span><span style="color:#000000;"> Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurement at reporting date using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,920</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,920</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067710088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,919</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,615</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,820</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066364280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Offering</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company sold 2,875,000 shares of its common stock at a public offering price of $60.00 per share. The Company received net proceeds of $161.4 million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has two classes of common stock; &#8220;voting common stock&#8221; and &#8220;non-voting common stock.&#8221; <span style="color:#000000;">The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders</span>. Except as otherwise required by law, the holders of non-voting common stock shall not be entitled to vote at any meetings of stockholders (or written actions in lieu of meetings) and the shares of non-voting common stock shall not be included in determining the number of shares voting or entitled to vote on any matter. Unless required by law, there shall be no cumulative voting. Any holder of non-voting common stock may elect to convert each share of non-voting common stock into one fully paid and non-assessable share of voting common stock at any time by providing written notice to the Company; provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule&#160;13(d) group with such holder, would not beneficially own in excess of 9.99% of the Company&#8217;s common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in the Company&#8217;s restated certificate of incorporation. However, this ownership limitation may be increased (not to exceed 19.99%) or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#8217; notice to the Company.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067712872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:66.11%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8<span style="color:#231F20;">. Commitments</span></p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company </span><span style="Background-color:#FFFFFF;">leases office and laboratory space in Wilmington, Delaware under a noncancelable lease (the &#8220;Lease&#8221;). During the first quarter of 2022, the Lease was amended to allow the Company the option to renew the Lease for two 6-month periods and the Company exercised its option to renew the lease for an additional 6 months until June 30, 2023. </span><span style="color:#231F20;">The</span><span style="color:#231F20;letter-spacing:0.05pt;"> second </span><span style="color:#231F20;">option</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">to</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">extend the Lease for an additional 6 months</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">was</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">not</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">recognized</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">as part</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">of the</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">Company&#8217;s measurement</span><span style="color:#231F20;letter-spacing:0.2pt;"> </span><span style="color:#231F20;">of the</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">right-of-use</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">asset</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">and operating</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">lease</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">liability</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">as of March&#160;31, 2022</span><span style="Background-color:#FFFFFF;">.&#160;</span><span style="color:#231F20;">The</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">discount</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">rate</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">used</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">to</span><span style="color:#231F20;letter-spacing:1.15pt;"> </span><span style="color:#231F20;">account</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">for</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">the</span><span style="color:#231F20;letter-spacing:1.2pt;"> </span><span style="color:#231F20;">Company&#8217;s operating</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">lease</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">under</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">ASC 842</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">is</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">the</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">Company&#8217;s</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">estimated</span><span style="color:#231F20;letter-spacing:0.15pt;"> </span><span style="color:#231F20;">incremental</span><span style="color:#231F20;letter-spacing:0.2pt;"> </span><span style="color:#231F20;">borrowing</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">rate</span><span style="color:#231F20;letter-spacing:0.1pt;"> </span><span style="color:#231F20;">of</span><span style="color:#231F20;letter-spacing:0.05pt;"> </span><span style="color:#231F20;">6.0</span>%.<span style="color:#231F20;letter-spacing:0.05pt;"> </span></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent<span style="letter-spacing:0.05pt;"> </span>expense<span style="letter-spacing:0.1pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>three months<span style="letter-spacing:0.1pt;"> </span>ended<span style="letter-spacing:0.05pt;"> March&#160;31, 2022 </span>and<span style="letter-spacing:0.05pt;"> 2021 </span><span style="color:#000000;">was</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">$0.5</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">million</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">and $0.3 million, respectively. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future<span style="letter-spacing:0.25pt;"> </span>minimum<span style="letter-spacing:0.3pt;"> </span>annual<span style="letter-spacing:0.25pt;"> </span>lease<span style="letter-spacing:0.25pt;"> </span>payments<span style="letter-spacing:0.25pt;"> </span>under<span style="letter-spacing:0.25pt;"> the L</span>ease<span style="letter-spacing:0.2pt;"> </span>at<span style="letter-spacing:0.2pt;"> March&#160;31, 2022</span><span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.15pt;"> </span>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:9.81%;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and noncurrent lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,249</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the fourth quarter of 2021, the Company </span>entered into a lease agreement (the &#8220;Chestnut Run Lease&#8221;)&#160;with a commencement date of the earlier of (i)&#160;the Landlord Work Substantial Completion Date (as such term is defined in the Chestnut Run Lease), or (ii)&#160;<span style="Background-color:#FFFFFF;">the date the Company takes possession of the premises for the conduct of the Company&#8217;s business (the &#8220;Commencement Date&#8221;). The Chestnut Run Lease premises includes approximately 81,000 square feet, located at Chestnut Run Plaza in Wilmington, Delaware (the Premises). The Premises contains both office and lab space the Company intends to use for administrative, research and development and other activities. Upon the Commencement Date, the Company will recognize a right-of-use asset and operating lease liability in accordance with ASC 842. The Chestnut Run Lease has an initial term of 162 months with 3 <span style="-sec-ix-hidden:F_000309">five-year</span> extension options and certain expansion rights. The aggregate estimated rent payments due over the initial term of the Chestnut Run Lease is approximately $33.8&#160;million. The estimated rent payments due for the remainder of 2022 along with each of the next five years and thereafter is as follows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining 9 months)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,384</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company paid a security deposit for the Chestnut Run Lease in the form of a letter of credit of $4.0&#160;million, which is included in the balance sheet as restricted cash as of March 31, 2022. The security deposit may be reduced to $0.5&#160;million over time in accordance with the terms of the Chestnut Run Lease.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s expansion of operations in the State of Delaware, the Company was approved for a grant from the State of Delaware in 2021 that will provide up to $5.5 million in reimbursements over three years for the development of lab space in addition to increasing jobs in Delaware to meet specific targeted levels through 2023. During the first quarter of 2022, the Company received cash of $2.4 million from the grant for the development of lab space. The Company has deferred the recognition of these grant funds as they relate to capitalized costs and has classified them as long-term liabilities on the balance sheet.&#160;The Company will recognize the grant funds in other income as grant income over the useful life of the related assets. If, after two years from the disbursement date, the incurred costs for lab space are less than the $2.4 million received, the Company is required to pay back the difference between total funds received and allowable costs incurred. Additionally, if the Company leaves the State of Delaware within five years of the disbursement, the Company is required to return an amount equal to the amount of grant funds disbursed on a pro-rated basis. During the first quarter of 2022, the Company also received cash of $0.3 million for satisfying the first performance benchmark measurement. The Company recognized this in other income, net on the statement of operations and comprehensive loss. </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the Company&#8217;s employee headcount is fewer than the performance benchmark, the Company is required to repay the amount of grant funds received for the number of employees below the benchmark.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Defined Contribution Plan</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a 401(k)&#160;defined&#8209;contribution plan covering all employees. Participants are permitted to contribute up to 100% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. The Company provides a safe harbor match with a maximum amount of 3% of the participant&#8217;s compensation. For both the<span style="color:#000000;"> three months ended March&#160;31, 2022 and 2021, the Company made matching contributions of $0.2 million.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Collaboration Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into a research collaboration agreement estimated to last for approximately one year (the &#8220;Darwin Health Agreement&#8221;) with Darwin Health, Inc. (&#8220;DarwinHealth&#8221;). Under the terms of the Darwin Health Agreement, DarwinHealth will utilize their drug discovery technologies and certified methodologies in precision oncology to advance and accelerate clinical development for certain of the Company&#8217;s programs across a broad range of tumor subtypes. The Company will pay DarwinHealth a total of $3.0 million in three equal installments over the <span style="-sec-ix-hidden:F_000331">one-year</span> term (the &#8220;Research Term&#8221;) to fund the research and, if the Company adopts any of DarwinHealth&#8217;s development ideas, the Company will be responsible for the development, manufacturing, and commercialization of any such products. In addition to research funding, DarwinHealth is eligible to receive future research, development and regulatory milestones of up to $3.0 million for each product candidate and is also eligible to receive tiered royalties in the low single digits on net sales of each product developed using DarwinHealth&#8217;s development technologies or methods. However, within <span style="-sec-ix-hidden:F_000334">eighteen-months</span> following the Research Term, the Company, in its sole discretion, may notify DarwinHealth that it will not utilize its development ideas and will be entitled to receive a refund of $0.5 million.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Research and Development Arrangements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to assist in the performance of research and development activities. Expenditures to CROs will represent a significant cost in clinical development for the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066302664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has two equity incentive plans: the 2016 Equity Incentive Plan, as amended, and the 2020 Equity Incentive Plan. New awards can only be granted under the 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and as of March&#160;31, 2022, 6,240,398 shares were available for future grants. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January 1st of each year, commencing on January 1, 2021, and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options vest based on the terms in each award agreement, generally over <span style="-sec-ix-hidden:F_000341">four-year</span> periods with 25% of options vesting after 1 year and then monthly thereafter, and have a term of ten years. <span style="color:#000000;">&#160;</span> &#160;&#160; &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,629</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,046</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,179,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000363">8.66</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,646,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(191,849</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000364">8.70</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000365">7.85</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $11.3&#160;million and $6.7&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding at March&#160;31, 2022 under the Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.31 - $5.99</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,213,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">7.52</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,300,092</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.00 - $11.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000385">9.88</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11.73 - $13.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392,956</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000386">8.42</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">893,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.05 - $31.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000387">9.48</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,469</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.14 - $88.98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700,999</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000388">9.23</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,635</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted was $7.62 and $68.39 per share for the three months ended March&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $0.6 million for the three months ended March&#160;31, 2022. The Company recorded stock-based compensation expense of $6.5&#160;million and $3.7&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, related to stock options.&#160;As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $72.2&#160;million, which the Company expects to recognize over a weighted-average period of 3.01&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.97</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000416">6.06</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000417">6.06</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Awards and Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issues restricted stock awards (&#8220;RSA&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_000418">four-year</span> period with 25% of awards vesting after one year and then monthly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSA is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSA expense is recorded on a straight-line basis over the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSA stock-based payment awards:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,967</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $0.2&#160;million for both the three months ended March&#160;31, 2022 and 2021 related to RSAs. As of March&#160;31, 2022, the total unrecognized expense related to all RSAs was $1.1&#160;million, which the Company expects to recognize over a weighted-average period of 1.63&#160;years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, the Company granted restricted stock units (&#8220;RSU&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_000430">four-year</span> period with 25% of awards vesting after one year and then quarterly thereafter. Any unvested units will be forfeited upon termination of services. At March 31, 2022 there were 20,000 RSUs outstanding which had a weighted-average grant date fair value of $18.32. There were no RSUs granted or forfeited during the three months ended March 31, 2022. The Company recorded stock-based compensation expense of $24 thousand for the three months ended March 31, 2022 related to RSUs. At March&#160;31, 2022 the total unrecognized expense related to the RSUs was $0.3&#160;million, which the Company expects to recognize over 3.51&#160;years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:18pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which, as of March&#160;31, 2022, had 1,407,365 shares of common stock reserved for future issuance. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year and continuing for&#160;ten years beginning in 2021, in an amount equal to&#160;one&#160;percent of the total number of shares of all classes of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. On January 1, 2022, 476,023 shares were added to the ESPP. &#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at&#160;85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to&#160;15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000&#160;worth of the Company&#8217;s common stock for each calendar&#160;year in which such right is outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP is considered compensatory under the FASB stock compensation rules. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of&#160;$0.1&#160;million and nil for the three months ended March&#160;31, 2022 and 2021, respectively, related to the ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062251624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, the instructions to&#160;Form&#160;10-Q&#160;and&#160;Article&#160;10&#160;of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 found in the Form 10-K filed with the SEC on March 17, 2022. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the historical and anticipated future losses, management has determined that the deferred tax assets generated by net operating losses and research and development credits do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of March&#160;31, 2022 and December&#160;31, 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted cash</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents include short-term highly liquid investments with an original maturity of 90&#160;days or less when purchased and are carried at fair value in the accompanying balance sheets.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#8217;s Chestnut Run Lease. See Note 8 for further details. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,678</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,872</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of investments in corporate debt securities and commercial paper that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity (deficit). Realized gains and losses as well as credit losses, if </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any, on marketable securities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are included in the Company's</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements of operations.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> classifies marketable securities that are available for use in current operations as current assets on the balance sheets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#8217;s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,009,462</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,732,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,127</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,115,785</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,742,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the above table reflect the common stock equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited interim financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In</span><span style="font-weight:bold;Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">June 2016, the FASB iss</span>ued ASU No. 2016-13, &#8220;<span style="font-style:italic;Background-color:#FFFFFF;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="Background-color:#FFFFFF;">&#8221; which has subsequently been amended by ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11, and ASU No. 2020-03 (&#8220;ASU 2016-03&#8221;). This guidance replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted this standard as of January 1, 2022 using a modified retrospective approach. It did not have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU No. 2021-10,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">&#8220;Government Assistance: Disclosures by Business Entities about Government Assistance&#8221;</span><span style="Background-color:#FFFFFF;">. The amendments in this Update improve financial reporting by requiring disclosures that increase the transparency of transactions with a government. The amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy (i) the type of transaction (ii) the accounting for the transaction, and (iii) the effect of the transaction on the entity&#8217;s financial statements. The Company adopted this </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">standard as of </span><span style="Background-color:#FFFFFF;">January 1, 2022</span><span style="Background-color:#FFFFFF;"> using a </span><span style="Background-color:#FFFFFF;">prospe</span><span style="Background-color:#FFFFFF;">ctive approach</span><span style="Background-color:#FFFFFF;"> and i</span><span style="Background-color:#FFFFFF;">t did </span><span style="Background-color:#FFFFFF;">no</span><span style="Background-color:#FFFFFF;">t have a material impact on the Company&#8217;s financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370140150408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,044</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,678</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,872</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock awards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,009,462</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,732,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,127</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,115,785</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,742,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067699480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following is a summary of the Company&#8217;s marketable securities.</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,237</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,555</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066344360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurement at reporting date using</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,920</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,920</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (Money Market Funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066372888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,919</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,615</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,820</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061333832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member', window );">Operating Lease, until June 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Lease Payments Under Lease</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future<span style="letter-spacing:0.25pt;"> </span>minimum<span style="letter-spacing:0.3pt;"> </span>annual<span style="letter-spacing:0.25pt;"> </span>lease<span style="letter-spacing:0.25pt;"> </span>payments<span style="letter-spacing:0.25pt;"> </span>under<span style="letter-spacing:0.25pt;"> the L</span>ease<span style="letter-spacing:0.2pt;"> </span>at<span style="letter-spacing:0.2pt;"> March&#160;31, 2022</span><span style="letter-spacing:0.15pt;"> </span>is<span style="letter-spacing:0.2pt;"> </span>as<span style="letter-spacing:0.15pt;"> </span>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:9.81%;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,341</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and noncurrent lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,249</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember', window );">Chestnut Run Lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Lease Payments Under Lease</a></td>
<td class="text">The estimated rent payments due for the remainder of 2022 along with each of the next five years and thereafter is as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">(in thousands)</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 (remaining 9 months)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,384</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061405912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations</a></td>
<td class="text">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,629</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,046</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,179,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000363">8.66</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,646,416</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(191,849</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000364">8.70</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at March&#160;31, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000365">7.85</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Information about Stock Options Outstanding</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options outstanding at March&#160;31, 2022 under the Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Prices</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.31 - $5.99</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,213,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">7.52</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,300,092</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.00 - $11.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000385">9.88</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.09</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11.73 - $13.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392,956</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000386">8.42</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">893,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.05 - $31.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000387">9.48</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,469</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.14 - $88.98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700,999</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000388">9.23</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,635</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,541,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.97</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000416">6.06</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000417">6.06</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Activity related to RSA Stock-Based Payment Awards</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSA stock-based payment awards:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at January 1, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,967</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370066348120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Risks and Liquidity - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (248,585)<span></span>
</td>
<td class="num">$ (219,120)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062119016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,634<span></span>
</td>
<td class="nump">$ 31,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">4,044<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in statement of cash flows</a></td>
<td class="nump">$ 55,678<span></span>
</td>
<td class="nump">$ 35,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062069736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">9,115,785<span></span>
</td>
<td class="nump">7,742,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">514,641<span></span>
</td>
<td class="nump">1,009,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">8,541,017<span></span>
</td>
<td class="nump">6,732,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">40,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067129032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - ASU 2016-13<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, ASU, adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, ASU, adoption date</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, ASU, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062688536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized cost</a></td>
<td class="nump">$ 216,868<span></span>
</td>
<td class="nump">$ 260,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax', window );">Marketable securities, Gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax', window );">Marketable securities, Gross unrealized loss</a></td>
<td class="num">(2,313)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, Fair value</a></td>
<td class="nump">214,555<span></span>
</td>
<td class="nump">259,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized cost</a></td>
<td class="nump">180,532<span></span>
</td>
<td class="nump">193,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax', window );">Marketable securities, Gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax', window );">Marketable securities, Gross unrealized loss</a></td>
<td class="num">(2,237)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, Fair value</a></td>
<td class="nump">178,295<span></span>
</td>
<td class="nump">193,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized cost</a></td>
<td class="nump">36,336<span></span>
</td>
<td class="nump">66,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax', window );">Marketable securities, Gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax', window );">Marketable securities, Gross unrealized loss</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, Fair value</a></td>
<td class="nump">$ 36,260<span></span>
</td>
<td class="nump">$ 66,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities accumulated gross unrealized gain net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities accumulated gross unrealized loss net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061447896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, recurring basis, assets</a></td>
<td class="nump">$ 47,920<span></span>
</td>
<td class="nump">$ 30,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, recurring basis, assets</a></td>
<td class="nump">47,920<span></span>
</td>
<td class="nump">30,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, recurring basis, assets</a></td>
<td class="nump">214,555<span></span>
</td>
<td class="nump">259,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, recurring basis, assets</a></td>
<td class="nump">178,295<span></span>
</td>
<td class="nump">193,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value measurement, recurring basis, assets</a></td>
<td class="nump">$ 36,260<span></span>
</td>
<td class="nump">$ 66,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062122456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">$ 3,025<span></span>
</td>
<td class="nump">$ 4,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AccruedResearchAndDevelopmentLiabilitiesCurrent', window );">Research and development</a></td>
<td class="nump">3,441<span></span>
</td>
<td class="nump">4,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,820<span></span>
</td>
<td class="nump">$ 9,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AccruedResearchAndDevelopmentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AccruedResearchAndDevelopmentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061629992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_BeneficialOwnershipPercentage', window );">Beneficial ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_BeneficialOwnershipPercentage', window );">Beneficial ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 161,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prld_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prld_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370058825016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Extension</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent', window );">Operating lease estimated incremental borrowing rate percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The second option to extend the Lease for an additional 6 months was not recognized as part of the Company&#8217;s measurement of the right-of-use asset and operating lease liability as of March&#160;31, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ReimbursementsForDevelopmentOfLabSpace', window );">Reimbursements for development of lab space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ReimbursementsForDevelopmentOfLabSpacePeriod', window );">Reimbursements for development of lab space period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear', window );">Reimbursements for development of lab space expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_GrantForDevelopmentOfLabSpace', window );">Grant for development of lab space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement', window );">Received cash for satisfying performance benchmark measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percent of employee's gross pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=prld_DarwinHealthIncMember', window );">DarwinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_EstimatedNumberOfYearResearchCollaborationAgreement', window );">Estimated years of research collaboration agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments', window );">Estimated amount of payment over a agreement term</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ResearchTerm', window );">Research term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_NumberOfEqualInstalments', window );">Number of equal instalments | Installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_GracePeriodForPotentialRefund', window );">Grace period following research term for potential refund</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_PotentialRefundReceivableFromAgreement', window );">Potential refund receivable from agreement</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_DisbursementIncurredCostsForLabSpace', window );">Disbursement incurred costs for lab space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | DarwinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Agreement is eligible to receive payment in future research, development and regulatory milestones</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member', window );">Operating Lease, until June 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember', window );">Chestnut Run Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AreaOfLeasePremises', window );">Area of lease premises | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_InitialTermOfLease', window );">Initial term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">162 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_NumberOfLeaseExtensions', window );">Number of lease extensions | Extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_AggregateEstimatedRentPaymentsDueOverInitialTerm', window );">Aggregate estimated rent payments due over initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember', window );">Chestnut Run Lease | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember', window );">Chestnut Run Lease | Letter of Credit | Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AggregateEstimatedRentPaymentsDueOverInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate estimated rent payments due over initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AggregateEstimatedRentPaymentsDueOverInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_AreaOfLeasePremises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of lease premises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_AreaOfLeasePremises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_DisbursementIncurredCostsForLabSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disbursement incurred costs for lab space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_DisbursementIncurredCostsForLabSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of payment over a agreement term in three equal installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_EstimatedNumberOfYearResearchCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated number of year research collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_EstimatedNumberOfYearResearchCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_GracePeriodForPotentialRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grace period for potential refund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_GracePeriodForPotentialRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_GrantForDevelopmentOfLabSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant for development of lab space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_GrantForDevelopmentOfLabSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_InitialTermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_InitialTermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_NumberOfEqualInstalments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal instalments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_NumberOfEqualInstalments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_NumberOfLeaseExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lease extensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_NumberOfLeaseExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease estimated incremental borrowing rate percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_PotentialRefundReceivableFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential refund receivable from agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_PotentialRefundReceivableFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received cash for satisfying performance benchmark measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ReimbursementsForDevelopmentOfLabSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements for development of lab space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ReimbursementsForDevelopmentOfLabSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements for development of lab space expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ReimbursementsForDevelopmentOfLabSpacePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements for development of lab space period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ReimbursementsForDevelopmentOfLabSpacePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=prld_DarwinHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=prld_DarwinHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062021800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member', window );">Operating Lease, until June 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_LeaseLiabilityLineItems', window );"><strong>Lease Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining)</a></td>
<td class="nump">$ 1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current and noncurrent lease liability</a></td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember', window );">Chestnut Run Lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_LeaseLiabilityLineItems', window );"><strong>Lease Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 24,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_LeaseLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_LeaseLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_OperatingLeaseUntilJune302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=prld_ChestnutRunLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370058316824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | Plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options</a></td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,829,000<span></span>
</td>
<td class="nump">$ 3,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">weighted-average grant date fair value | $ / shares</a></td>
<td class="nump">$ 18.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted | $ / shares</a></td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 68.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation expense, weighted-average period</a></td>
<td class="text">3 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation expense, weighted-average period</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, unrecognized expense</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">weighted-average grant date fair value | $ / shares</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation expense, weighted-average period</a></td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, unrecognized expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Outstanding | shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prld_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants | shares</a></td>
<td class="nump">6,240,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award</a></td>
<td class="text">The Company&#8217;s stock options vest based on the terms in each award agreement, generally over four-year periods with 25% of options vesting after 1 year and then monthly thereafter, and have a term of ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued', window );">Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prld_TwoThousandTwentyEmployeesStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants | shares</a></td>
<td class="nump">1,407,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued', window );">Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Eligible employees purchase common stock percentage of lower of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount', window );">Participants accrue rights to purchase maximum common stock amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prld_EligibleEmployeesContributionPercentage', window );">Eligible employees contribution percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting After One Year | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of stock options vested</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting After One Year | Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting After One Year | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of stock options vested</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_EligibleEmployeesContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible employees contribution percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_EligibleEmployeesContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Participants accrue rights to purchase maximum common stock amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prld_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prld_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prld_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prld_TwoThousandTwentyEmployeesStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prld_TwoThousandTwentyEmployeesStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370062019864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,829<span></span>
</td>
<td class="nump">$ 3,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">1,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,629<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370058775768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="nump">7,179,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">1,646,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(93,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(191,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">8,541,017<span></span>
</td>
<td class="nump">7,179,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable at March 31, 2022</a></td>
<td class="nump">2,285,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Outstanding at beginning of period</a></td>
<td class="nump">$ 15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Granted</a></td>
<td class="nump">10.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Exercised</a></td>
<td class="nump">1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Forfeited</a></td>
<td class="nump">17.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Outstanding at end of period</a></td>
<td class="nump">14.54<span></span>
</td>
<td class="nump">$ 15.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price per share, Exercisable at March 31, 2022</a></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (years), Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (years), Exercisable</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370058682312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">8,541,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">2,285,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeOneMember', window );">$0.31 - $5.99</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Minimum</a></td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Maximum</a></td>
<td class="nump">$ 5.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">2,213,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">1,300,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeTwoMember', window );">$6.00 - $11.72</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Minimum</a></td>
<td class="nump">6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Maximum</a></td>
<td class="nump">$ 11.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">1,625,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeThreeMember', window );">$11.73 - $13.04</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Minimum</a></td>
<td class="nump">11.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Maximum</a></td>
<td class="nump">$ 13.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">2,392,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">893,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFourMember', window );">$13.05 - $31.13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Minimum</a></td>
<td class="nump">13.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Maximum</a></td>
<td class="nump">$ 31.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">607,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 20.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">11,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 15.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFiveMember', window );">$31.14 - $88.98</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, Minimum</a></td>
<td class="nump">31.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, Maximum</a></td>
<td class="nump">$ 88.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number | shares</a></td>
<td class="nump">1,700,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 35.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number Exercisable | shares</a></td>
<td class="nump">78,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 57.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=prld_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370067079400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.57%<span></span>
</td>
<td class="nump">117.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.97%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140370061634152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested balance at end of period</a></td>
<td class="nump">$ 18.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested balance at beginning of period | shares</a></td>
<td class="nump">611,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(96,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested balance at end of period | shares</a></td>
<td class="nump">514,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested balance at beginning of period</a></td>
<td class="nump">$ 2.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested</a></td>
<td class="nump">2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested balance at end of period</a></td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>prld-10q_20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prld="http://preludetx.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="prld-20220331.xsd" xlink:type="simple"/>
    <context id="C_0001678660_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="C_0001678660_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prld:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:OperatingLeaseUntilJune302023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prld:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prld:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:OperatingLeaseUntilJune302023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_srtStatementScenarioAxis_srtProFormaMember_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">prld:ChestnutRunLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMaximumMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prld:DarwinHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prld:DarwinHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">prld:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prld:TwoThousandTwentyEmployeesStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_prldExtension">
        <measure>prld:Extension</measure>
    </unit>
    <unit id="U_prldInstallment">
        <measure>prld:Installment</measure>
    </unit>
    <unit id="U_prldPlan">
        <measure>prld:Plan</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001678660_20220101_20220331" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001678660_20220101_20220331" id="F_000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001678660_20220101_20220331" id="F_000007">0001678660</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001678660_20220101_20220331" id="F_000009">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331"
      id="F_000247">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331"
      id="F_000249">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231"
      id="F_000309">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <prld:ResearchTerm
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      id="F_000331">P1Y</prld:ResearchTerm>
    <prld:GracePeriodForPotentialRefund
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      id="F_000334">P18M</prld:GracePeriodForPotentialRefund>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      id="F_000341">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331"
      id="F_000418">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      id="F_000430">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001678660_20220331"
      id="F_000060"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001678660_20211231"
      id="F_000061"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001678660_20210101_20211231" id="F_000363">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001678660_20220101_20220331" id="F_000364">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001678660_20220101_20220331" id="F_000365">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331"
      id="F_000384">P7Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331"
      id="F_000385">P9Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331"
      id="F_000386">P8Y5M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331"
      id="F_000387">P9Y5M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331"
      id="F_000388">P9Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331"
      decimals="INF"
      id="F_000368"
      unitRef="U_iso4217USD_xbrlishares">0.31</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331"
      decimals="INF"
      id="F_000369"
      unitRef="U_iso4217USD_xbrlishares">6.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331"
      decimals="INF"
      id="F_000370"
      unitRef="U_iso4217USD_xbrlishares">11.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331"
      decimals="INF"
      id="F_000371"
      unitRef="U_iso4217USD_xbrlishares">13.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331"
      decimals="INF"
      id="F_000372"
      unitRef="U_iso4217USD_xbrlishares">31.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220101_20220331"
      decimals="INF"
      id="F_000373"
      unitRef="U_iso4217USD_xbrlishares">5.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220101_20220331"
      decimals="INF"
      id="F_000374"
      unitRef="U_iso4217USD_xbrlishares">11.72</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220101_20220331"
      decimals="INF"
      id="F_000375"
      unitRef="U_iso4217USD_xbrlishares">13.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220101_20220331"
      decimals="INF"
      id="F_000376"
      unitRef="U_iso4217USD_xbrlishares">31.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220101_20220331"
      decimals="INF"
      id="F_000377"
      unitRef="U_iso4217USD_xbrlishares">88.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      id="F_000416">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000417">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001678660_20220101_20220331" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001678660_20220101_20220331" id="F_000028">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001678660_20220101_20220331" id="F_000002">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001678660_20220101_20220331" id="F_000003">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001678660_20220101_20220331" id="F_000029">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001678660_20220101_20220331" id="F_000019">001-39527</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001678660_20220101_20220331" id="F_000006">PRELUDE THERAPEUTICS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001678660_20220101_20220331" id="F_000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001678660_20220101_20220331" id="F_000021">81-1384762</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001678660_20220101_20220331" id="F_000022">200 Powder Mill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001678660_20220101_20220331" id="F_000023">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001678660_20220101_20220331" id="F_000024">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001678660_20220101_20220331" id="F_000025">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001678660_20220101_20220331" id="F_000026">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001678660_20220101_20220331" id="F_000027">467-1280</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001678660_20220101_20220331" id="F_000016">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001678660_20220101_20220331" id="F_000005">PRLD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001678660_20220101_20220331" id="F_000017">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001678660_20220101_20220331" id="F_000008">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001678660_20220101_20220331" id="F_000018">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001678660_20220101_20220331" id="F_000010">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001678660_20220101_20220331" id="F_000011">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001678660_20220101_20220331" id="F_000012">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001678660_20220101_20220331" id="F_000013">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="C_0001678660_20220101_20220331" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001678660_20220504"
      decimals="INF"
      id="F_000014"
      unitRef="U_xbrlishares">47695639</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">51634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">31828000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">214555000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">259405000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">3783000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">3882000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">269972000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">295115000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCash
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">4044000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">4044000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">4122000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">3929000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">2224000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">1707000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">309000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">303000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">280671000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">305098000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">7390000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">7840000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">6820000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">9621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">1859000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">1740000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">16069000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">19201000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">2400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">390000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">18859000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">19201000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000076"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000077"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">487149741</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">487149741</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">36293331</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">36293331</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">36200299</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">36200299</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000085"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">12850259</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">12850259</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">11402037</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">11402037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">11402037</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">11402037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20220331"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">512705000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">505723000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">-2313000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">-711000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">-248585000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">-219120000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">261812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">285897000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">280671000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">305098000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">22821000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">16470000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">7467000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">5497000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">30288000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">21967000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">-30288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">-21967000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">823000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">667000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">-29465000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-21300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001678660_20220101_20220331"
      decimals="2"
      id="F_000104"
      unitRef="U_iso4217USD_xbrlishares">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001678660_20210101_20210331"
      decimals="2"
      id="F_000105"
      unitRef="U_iso4217USD_xbrlishares">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001678660_20220101_20220331"
      decimals="0"
      id="F_000106"
      unitRef="U_xbrlishares">47066427</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001678660_20210101_20210331"
      decimals="0"
      id="F_000107"
      unitRef="U_xbrlishares">45121955</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-29465000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-21300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-1602000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-31067000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-21300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">36200299</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">11402037</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">505723000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-219120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">285897000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000121"
      unitRef="U_xbrlishares">93032</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-1602000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-1602000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">6829000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">6829000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-29465000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-29465000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="INF"
      id="F_000130"
      unitRef="U_xbrlishares">36293331</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="INF"
      id="F_000132"
      unitRef="U_xbrlishares">11402037</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">512705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-2313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">-248585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">261812000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">32595301</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000140"
      unitRef="U_xbrlishares">11110371</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">319605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-107426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">212183000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000145"
      unitRef="U_xbrlishares">210274</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">386000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">386000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <prld:PaymentsOfOfferingCosts
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">739000</prld:PaymentsOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000148"
      unitRef="U_xbrlishares">2583334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">291666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">161411000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">161412000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">3886000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">3886000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-21300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-21300000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000157"
      unitRef="U_xbrlishares">35388909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">11402037</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">485288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-128726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001678660_20210331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">356567000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-29465000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-21300000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">307000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">160000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">411000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">282000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">6829000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">3886000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-748000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-93000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-761000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">2000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">1601000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-401000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-1372000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <prld:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">419000</prld:IncreaseDecreaseInOperatingLeaseLiabilities>
    <prld:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">161000</prld:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-21895000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-16143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">42500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">952000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">986000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">41548000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-986000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">161424000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">153000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">386000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">153000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">161810000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">19806000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">144681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">35872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001678660_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">218309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">55678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001678660_20210331"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">362990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">928000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">354000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">86000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <prld:UnrealizedGainLossOnMarketableSecurities
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-1602000</prld:UnrealizedGainLossOnMarketableSecurities>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000204">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Background&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prelude Therapeutics Incorporated (the &#x201c;Company&#x201d;) was incorporated in Delaware on February&#160;5, 2016 and is a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. Since beginning operations, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital.&#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <prld:RisksAndLiquidityTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000205">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Risks and liquidity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company is subject to a number of risks common to early-stage companies in the biotechnology industry. Principal among these risks are the uncertainties in the development process, development of the same or similar technological innovations by competitors, protection of proprietary technology, dependence on key personnel, compliance with government regulations and approval requirements, and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval, or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and contractors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company has incurred operating losses and has an accumulated deficit of $248.6&#160;million at March&#160;31, 2022. The Company has no revenue to date and devotes its efforts to research and development. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its cash, cash &lt;span style="color:#000000;"&gt;equivalents, and marketable securities as of March&#160;31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2024.&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To fund its operating expenses and capital expenditure requirements after that date, the Company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;10, 2020, the World Health Organization characterized the novel&#160;COVID-19&#160;virus as a global pandemic. There is significant uncertainty as to the likely effects of this disease and emerging variants which may, among other things, materially impact the Company&#x2019;s planned clinical trials. This pandemic or outbreak could result in difficulty securing clinical trial site locations, CROs, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#x2019;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#x2019;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#x2019;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</prld:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001678660_20220331"
      decimals="-5"
      id="F_000232"
      unitRef="U_iso4217USD">-248600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000206">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Summary of significant accounting policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The summary of significant accounting policies included in the Company&#x2019;s financial statements for the year ended December&#160;31, 2021 can be found in &#x201c;Note 3. Summary of significant accounting policies&#x201d; of the Company&#x2019;s Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 17, 2022. Those policies have not materially changed, except as set forth below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information, the instructions to&#160;Form&#160;10-Q&#160;and&#160;Article&#160;10&#160;of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 found in the Form 10-K filed with the SEC on March 17, 2022. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the unaudited interim financial statements in conformity with&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based upon the historical and anticipated future losses, management has determined that the deferred tax assets generated by net operating losses and research and development credits do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted cash&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents include short-term highly liquid investments with an original maturity of 90&#160;days or less when purchased and are carried at fair value in the accompanying balance sheets.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#x2019;s Chestnut Run Lease. See Note 8 for further details. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,678&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,872&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of investments in corporate debt securities and commercial paper that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity (deficit). Realized gains and losses as well as credit losses, if &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;any, on marketable securities&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; are included in the Company's&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;statements of operations.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The Company&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; classifies marketable securities that are available for use in current operations as current assets on the balance sheets&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#x2019;s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,009,462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,732,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,127&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,115,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,742,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the above table reflect the common stock equivalents.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited interim financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In&lt;/span&gt;&lt;span style="font-weight:bold;Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;June 2016, the FASB iss&lt;/span&gt;ued ASU No. 2016-13, &#x201c;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#x201d; which has subsequently been amended by ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11, and ASU No. 2020-03 (&#x201c;ASU 2016-03&#x201d;). This guidance replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted this standard as of January 1, 2022 using a modified retrospective approach. It did not have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2021, the FASB issued ASU No. 2021-10,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;&#x201c;Government Assistance: Disclosures by Business Entities about Government Assistance&#x201d;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. The amendments in this Update improve financial reporting by requiring disclosures that increase the transparency of transactions with a government. The amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy (i) the type of transaction (ii) the accounting for the transaction, and (iii) the effect of the transaction on the entity&#x2019;s financial statements. The Company adopted this &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;standard as of &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;January 1, 2022&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; using a &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;prospe&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;ctive approach&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; and i&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;t did &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;no&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;t have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000213">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information, the instructions to&#160;Form&#160;10-Q&#160;and&#160;Article&#160;10&#160;of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021 found in the Form 10-K filed with the SEC on March 17, 2022. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001678660_20220101_20220331" id="F_000214">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the unaudited interim financial statements in conformity with&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000215">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based upon the historical and anticipated future losses, management has determined that the deferred tax assets generated by net operating losses and research and development credits do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001678660_20220101_20220331" id="F_000216">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:4.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted cash&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents include short-term highly liquid investments with an original maturity of 90&#160;days or less when purchased and are carried at fair value in the accompanying balance sheets.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#x2019;s Chestnut Run Lease. See Note 8 for further details. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,678&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,872&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000220">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that total to the amounts shown in the statement of cash flows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash shown in statement of cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,678&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,872&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">51634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">31828000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">4044000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">4044000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">55678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">35872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001678660_20220101_20220331" id="F_000217">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of investments in corporate debt securities and commercial paper that are classified as available-for-sale. The securities are carried at fair value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity (deficit). Realized gains and losses as well as credit losses, if &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;any, on marketable securities&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; are included in the Company's&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;statements of operations.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The Company&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; classifies marketable securities that are available for use in current operations as current assets on the balance sheets&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000218">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, and the effect from unvested restricted stock awards and restricted stock units which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#x2019;s unvested restricted stock awards entitle the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock awards have no obligation to fund losses.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,009,462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,732,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,127&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,115,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,742,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the above table reflect the common stock equivalents.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000221">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,009,462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,732,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,127&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,115,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,742,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20220101_20220331"
      decimals="0"
      id="F_000239"
      unitRef="U_xbrlishares">514641</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20210101_20210331"
      decimals="0"
      id="F_000240"
      unitRef="U_xbrlishares">1009462</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331"
      decimals="0"
      id="F_000241"
      unitRef="U_xbrlishares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="0"
      id="F_000242"
      unitRef="U_xbrlishares">8541017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="0"
      id="F_000243"
      unitRef="U_xbrlishares">6732969</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20220101_20220331"
      decimals="0"
      id="F_000244"
      unitRef="U_xbrlishares">40127</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_20220101_20220331"
      decimals="0"
      id="F_000245"
      unitRef="U_xbrlishares">9115785</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001678660_20210101_20210331"
      decimals="0"
      id="F_000246"
      unitRef="U_xbrlishares">7742431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000219">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited interim financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.27%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In&lt;/span&gt;&lt;span style="font-weight:bold;Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;June 2016, the FASB iss&lt;/span&gt;ued ASU No. 2016-13, &#x201c;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#x201d; which has subsequently been amended by ASU No. 2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11, and ASU No. 2020-03 (&#x201c;ASU 2016-03&#x201d;). This guidance replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted this standard as of January 1, 2022 using a modified retrospective approach. It did not have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2021, the FASB issued ASU No. 2021-10,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;&#x201c;Government Assistance: Disclosures by Business Entities about Government Assistance&#x201d;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. The amendments in this Update improve financial reporting by requiring disclosures that increase the transparency of transactions with a government. The amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy (i) the type of transaction (ii) the accounting for the transaction, and (iii) the effect of the transaction on the entity&#x2019;s financial statements. The Company adopted this &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;standard as of &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;January 1, 2022&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; using a &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;prospe&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;ctive approach&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; and i&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;t did &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;no&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;t have a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331"
      id="F_000248">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000207">
&lt;p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following is a summary of the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;216,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s marketable securities generally have contractual maturity dates of 15 months or less. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary, is primarily related to market factors and believes that it is more likely than not that it will be able to hold its debt securities to maturity. &lt;/span&gt;Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000222">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following is a summary of the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;216,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">180532000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">2237000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">178295000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">36336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">76000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">36260000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">216868000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">2313000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">214555000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">193798000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">1000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">696000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">193103000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">66318000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">1000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">17000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">66302000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">260116000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">2000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax>
    <prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">713000</prld:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">259405000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000208">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The Company follows the provisions of ASC 820, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;"&gt; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;"&gt; Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;"&gt; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurement at reporting date using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents (Money Market Funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents (Money Market Funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000223">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurement at reporting date using&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2022:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents (Money Market Funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents (Money Market Funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;259,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">47920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20220331"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">178295000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20220331"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">36260000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">47920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20220331"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">214555000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">30520000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">193103000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">66302000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">30520000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">259405000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000224">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000209">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">3025000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">4919000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <prld:AccruedResearchAndDevelopmentLiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">3441000</prld:AccruedResearchAndDevelopmentLiabilitiesCurrent>
    <prld:AccruedResearchAndDevelopmentLiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">4615000</prld:AccruedResearchAndDevelopmentLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">354000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">87000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001678660_20220331"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">6820000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001678660_20211231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">9621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000210">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Company sold 2,875,000 shares of its common stock at a public offering price of $60.00 per share. The Company received net proceeds of $161.4 million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.26%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has two classes of common stock; &#x201c;voting common stock&#x201d; and &#x201c;non-voting common stock.&#x201d; &lt;span style="color:#000000;"&gt;The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders&lt;/span&gt;. Except as otherwise required by law, the holders of non-voting common stock shall not be entitled to vote at any meetings of stockholders (or written actions in lieu of meetings) and the shares of non-voting common stock shall not be included in determining the number of shares voting or entitled to vote on any matter. Unless required by law, there shall be no cumulative voting. Any holder of non-voting common stock may elect to convert each share of non-voting common stock into one fully paid and non-assessable share of voting common stock at any time by providing written notice to the Company; provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule&#160;13(d) group with such holder, would not beneficially own in excess of 9.99% of the Company&#x2019;s common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in the Company&#x2019;s restated certificate of incorporation. However, this ownership limitation may be increased (not to exceed 19.99%) or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#x2019; notice to the Company.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131"
      decimals="INF"
      id="F_000289"
      unitRef="U_xbrlishares">2875000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210131"
      decimals="INF"
      id="F_000290"
      unitRef="U_iso4217USD_xbrlishares">60.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_prldFollowOnOfferingMember_20210101_20210131"
      decimals="-5"
      id="F_000291"
      unitRef="U_iso4217USD">161400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      id="F_000292">The holders of the voting common stock are entitled to one vote for each share of voting common stock held at all meetings of stockholders</us-gaap:CommonStockVotingRights>
    <prld:BeneficialOwnershipPercentage
      contextRef="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000293"
      unitRef="U_xbrlipure">0.0999</prld:BeneficialOwnershipPercentage>
    <prld:BeneficialOwnershipPercentage
      contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000294"
      unitRef="U_xbrlipure">0.1999</prld:BeneficialOwnershipPercentage>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000211">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:66.11%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;span style="color:#231F20;"&gt;. Commitments&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;leases office and laboratory space in Wilmington, Delaware under a noncancelable lease (the &#x201c;Lease&#x201d;). During the first quarter of 2022, the Lease was amended to allow the Company the option to renew the Lease for two 6-month periods and the Company exercised its option to renew the lease for an additional 6 months until June 30, 2023. &lt;/span&gt;&lt;span style="color:#231F20;"&gt;The&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; second &lt;/span&gt;&lt;span style="color:#231F20;"&gt;option&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;to&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;extend the Lease for an additional 6 months&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;was&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;not&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;recognized&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;as part&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;of the&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;Company&#x2019;s measurement&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;of the&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;right-of-use&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;asset&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;and operating&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;lease&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;liability&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;as of March&#160;31, 2022&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;.&#160;&lt;/span&gt;&lt;span style="color:#231F20;"&gt;The&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;discount&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;rate&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;used&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;to&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;account&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;for&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;the&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:1.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;Company&#x2019;s operating&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;lease&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;under&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;ASC 842&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;is&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;the&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;estimated&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.15pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;incremental&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.2pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;borrowing&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;rate&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;of&lt;/span&gt;&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;"&gt;6.0&lt;/span&gt;%.&lt;span style="color:#231F20;letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;expense&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;for&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;three months&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;ended&lt;span style="letter-spacing:0.05pt;"&gt; March&#160;31, 2022 &lt;/span&gt;and&lt;span style="letter-spacing:0.05pt;"&gt; 2021 &lt;/span&gt;&lt;span style="color:#000000;"&gt;was&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;$0.5&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;million&lt;/span&gt;&lt;span style="letter-spacing:0.1pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;and $0.3 million, respectively. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;minimum&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;annual&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;lease&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;payments&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;under&lt;span style="letter-spacing:0.25pt;"&gt; the L&lt;/span&gt;ease&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; March&#160;31, 2022&lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:9.81%;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 (remaining)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current and noncurrent lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the fourth quarter of 2021, the Company &lt;/span&gt;entered into a lease agreement (the &#x201c;Chestnut Run Lease&#x201d;)&#160;with a commencement date of the earlier of (i)&#160;the Landlord Work Substantial Completion Date (as such term is defined in the Chestnut Run Lease), or (ii)&#160;&lt;span style="Background-color:#FFFFFF;"&gt;the date the Company takes possession of the premises for the conduct of the Company&#x2019;s business (the &#x201c;Commencement Date&#x201d;). The Chestnut Run Lease premises includes approximately 81,000 square feet, located at Chestnut Run Plaza in Wilmington, Delaware (the Premises). The Premises contains both office and lab space the Company intends to use for administrative, research and development and other activities. Upon the Commencement Date, the Company will recognize a right-of-use asset and operating lease liability in accordance with ASC 842. The Chestnut Run Lease has an initial term of 162 months with 3 &lt;span style="-sec-ix-hidden:F_000309"&gt;five-year&lt;/span&gt; extension options and certain expansion rights. The aggregate estimated rent payments due over the initial term of the Chestnut Run Lease is approximately $33.8&#160;million. The estimated rent payments due for the remainder of 2022 along with each of the next five years and thereafter is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 (remaining 9 months)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company paid a security deposit for the Chestnut Run Lease in the form of a letter of credit of $4.0&#160;million, which is included in the balance sheet as restricted cash as of March 31, 2022. The security deposit may be reduced to $0.5&#160;million over time in accordance with the terms of the Chestnut Run Lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s expansion of operations in the State of Delaware, the Company was approved for a grant from the State of Delaware in 2021 that will provide up to $5.5 million in reimbursements over three years for the development of lab space in addition to increasing jobs in Delaware to meet specific targeted levels through 2023. During the first quarter of 2022, the Company received cash of $2.4 million from the grant for the development of lab space. The Company has deferred the recognition of these grant funds as they relate to capitalized costs and has classified them as long-term liabilities on the balance sheet.&#160;The Company will recognize the grant funds in other income as grant income over the useful life of the related assets. If, after two years from the disbursement date, the incurred costs for lab space are less than the $2.4 million received, the Company is required to pay back the difference between total funds received and allowable costs incurred. Additionally, if the Company leaves the State of Delaware within five years of the disbursement, the Company is required to return an amount equal to the amount of grant funds disbursed on a pro-rated basis. During the first quarter of 2022, the Company also received cash of $0.3 million for satisfying the first performance benchmark measurement. The Company recognized this in other income, net on the statement of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent the Company&#x2019;s employee headcount is fewer than the performance benchmark, the Company is required to repay the amount of grant funds received for the number of employees below the benchmark.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employment Agreements&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;401(k) Defined Contribution Plan&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sponsors a 401(k)&#160;defined&#x2011;contribution plan covering all employees. Participants are permitted to contribute up to 100% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. The Company provides a safe harbor match with a maximum amount of 3% of the participant&#x2019;s compensation. For both the&lt;span style="color:#000000;"&gt; three months ended March&#160;31, 2022 and 2021, the Company made matching contributions of $0.2 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research Collaboration Agreement&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company entered into a research collaboration agreement estimated to last for approximately one year (the &#x201c;Darwin Health Agreement&#x201d;) with Darwin Health, Inc. (&#x201c;DarwinHealth&#x201d;). Under the terms of the Darwin Health Agreement, DarwinHealth will utilize their drug discovery technologies and certified methodologies in precision oncology to advance and accelerate clinical development for certain of the Company&#x2019;s programs across a broad range of tumor subtypes. The Company will pay DarwinHealth a total of $3.0 million in three equal installments over the &lt;span style="-sec-ix-hidden:F_000331"&gt;one-year&lt;/span&gt; term (the &#x201c;Research Term&#x201d;) to fund the research and, if the Company adopts any of DarwinHealth&#x2019;s development ideas, the Company will be responsible for the development, manufacturing, and commercialization of any such products. In addition to research funding, DarwinHealth is eligible to receive future research, development and regulatory milestones of up to $3.0 million for each product candidate and is also eligible to receive tiered royalties in the low single digits on net sales of each product developed using DarwinHealth&#x2019;s development technologies or methods. However, within &lt;span style="-sec-ix-hidden:F_000334"&gt;eighteen-months&lt;/span&gt; following the Research Term, the Company, in its sole discretion, may notify DarwinHealth that it will not utilize its development ideas and will be entitled to receive a refund of $0.5 million.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.27%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Other Research and Development Arrangements&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to assist in the performance of research and development activities. Expenditures to CROs will represent a significant cost in clinical development for the Company.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="C_0001678660_20220331" id="F_000295">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      id="F_000297">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="C_0001678660_20220101_20220331" id="F_000298">The second option to extend the Lease for an additional 6 months was not recognized as part of the Company&#x2019;s measurement of the right-of-use asset and operating lease liability as of March&#160;31, 2022</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <prld:OperatingLeaseEstimatedIncrementalBorrowingRatePercent
      contextRef="C_0001678660_20220101_20220331"
      decimals="3"
      id="F_000296"
      unitRef="U_xbrlipure">0.060</prld:OperatingLeaseEstimatedIncrementalBorrowingRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-5"
      id="F_000299"
      unitRef="U_iso4217USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-5"
      id="F_000300"
      unitRef="U_iso4217USD">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331"
      id="F_000225">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;minimum&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;annual&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;lease&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;payments&lt;span style="letter-spacing:0.25pt;"&gt; &lt;/span&gt;under&lt;span style="letter-spacing:0.25pt;"&gt; the L&lt;/span&gt;ease&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;at&lt;span style="letter-spacing:0.2pt;"&gt; March&#160;31, 2022&lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;is&lt;span style="letter-spacing:0.2pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:0.15pt;"&gt; &lt;/span&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:9.81%;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 (remaining)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current and noncurrent lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">1377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">964000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">2341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">92000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">2249000</us-gaap:OperatingLeaseLiability>
    <prld:AreaOfLeasePremises
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231"
      decimals="INF"
      id="F_000306"
      unitRef="U_utrsqft">81000</prld:AreaOfLeasePremises>
    <prld:InitialTermOfLease
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231"
      id="F_000307">P162M</prld:InitialTermOfLease>
    <prld:NumberOfLeaseExtensions
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211001_20211231"
      decimals="INF"
      id="F_000308"
      unitRef="U_prldExtension">3</prld:NumberOfLeaseExtensions>
    <prld:AggregateEstimatedRentPaymentsDueOverInitialTerm
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20211231"
      decimals="-5"
      id="F_000310"
      unitRef="U_iso4217USD">33800000</prld:AggregateEstimatedRentPaymentsDueOverInitialTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220101_20220331"
      id="F_000226">The estimated rent payments due for the remainder of 2022 along with each of the next five years and thereafter is as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="bottom"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 (remaining 9 months)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">1873000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">2326000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">2384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">2444000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_20220331"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">24670000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:SecurityDeposit
      contextRef="C_0001678660_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331"
      decimals="-5"
      id="F_000317"
      unitRef="U_iso4217USD">4000000.0</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001678660_srtStatementScenarioAxis_srtProFormaMember_us-gaapLeaseContractualTermAxis_prldChestnutRunLeaseMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20220331"
      decimals="-5"
      id="F_000318"
      unitRef="U_iso4217USD">500000</us-gaap:SecurityDeposit>
    <prld:ReimbursementsForDevelopmentOfLabSpace
      contextRef="C_0001678660_20220101_20220331"
      decimals="-5"
      id="F_000319"
      unitRef="U_iso4217USD">5500000</prld:ReimbursementsForDevelopmentOfLabSpace>
    <prld:ReimbursementsForDevelopmentOfLabSpacePeriod contextRef="C_0001678660_20220101_20220331" id="F_000320">P3Y</prld:ReimbursementsForDevelopmentOfLabSpacePeriod>
    <prld:ReimbursementsForDevelopmentOfLabSpaceExpirationYear contextRef="C_0001678660_20220101_20220331" id="F_000321">2023</prld:ReimbursementsForDevelopmentOfLabSpaceExpirationYear>
    <prld:GrantForDevelopmentOfLabSpace
      contextRef="C_0001678660_20220101_20220331"
      decimals="-5"
      id="F_000322"
      unitRef="U_iso4217USD">2400000</prld:GrantForDevelopmentOfLabSpace>
    <prld:DisbursementIncurredCostsForLabSpace
      contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_20220101_20220331"
      decimals="-5"
      id="F_000323"
      unitRef="U_iso4217USD">2400000</prld:DisbursementIncurredCostsForLabSpace>
    <prld:ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement
      contextRef="C_0001678660_20220101_20220331"
      decimals="-5"
      id="F_000324"
      unitRef="U_iso4217USD">300000</prld:ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_0001678660_20220101_20220331"
      decimals="INF"
      id="F_000325"
      unitRef="U_xbrlipure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001678660_20220101_20220331"
      decimals="2"
      id="F_000326"
      unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001678660_20220101_20220331"
      decimals="-5"
      id="F_000328"
      unitRef="U_iso4217USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001678660_20210101_20210331"
      decimals="-5"
      id="F_000327"
      unitRef="U_iso4217USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <prld:EstimatedNumberOfYearResearchCollaborationAgreement
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      id="F_000329">P1Y</prld:EstimatedNumberOfYearResearchCollaborationAgreement>
    <prld:EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      decimals="-5"
      id="F_000330"
      unitRef="U_iso4217USD">3000000.0</prld:EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments>
    <prld:NumberOfEqualInstalments
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      decimals="INF"
      id="F_000333"
      unitRef="U_prldInstallment">3</prld:NumberOfEqualInstalments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      decimals="-5"
      id="F_000332"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <prld:PotentialRefundReceivableFromAgreement
      contextRef="C_0001678660_us-gaapTypeOfArrangementAxis_prldDarwinHealthIncMember_20210901_20210930"
      decimals="-5"
      id="F_000335"
      unitRef="U_iso4217USD">500000</prld:PotentialRefundReceivableFromAgreement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000212">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has two equity incentive plans: the 2016 Equity Incentive Plan, as amended, and the 2020 Equity Incentive Plan. New awards can only be granted under the 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;) and as of March&#160;31, 2022, 6,240,398 shares were available for future grants. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January 1st of each year, commencing on January 1, 2021, and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options vest based on the terms in each award agreement, generally over &lt;span style="-sec-ix-hidden:F_000341"&gt;four-year&lt;/span&gt; periods with 25% of options vesting after 1 year and then monthly thereafter, and have a term of ten years. &lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt; &#160;&#160; &#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,629&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,829&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,179,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000363"&gt;8.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,646,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(191,849&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000364"&gt;8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000365"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At March&#160;31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $11.3&#160;million and $6.7&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options outstanding at March&#160;31, 2022 under the Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.31 - $5.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,213,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000384"&gt;7.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,300,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$6.00 - $11.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,625,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000385"&gt;9.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$11.73 - $13.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,392,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000386"&gt;8.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;893,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.05 - $31.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;607,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000387"&gt;9.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$31.14 - $88.98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000388"&gt;9.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of options granted was $7.62 and $68.39 per share for the three months ended March&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $0.6 million for the three months ended March&#160;31, 2022. The Company recorded stock-based compensation expense of $6.5&#160;million and $3.7&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, related to stock options.&#160;As of March&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $72.2&#160;million, which the Company expects to recognize over a weighted-average period of 3.01&#160;years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000416"&gt;6.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000417"&gt;6.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Stock Awards and Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issues restricted stock awards (&#x201c;RSA&#x201d;) to employees that generally vest over a &lt;span style="-sec-ix-hidden:F_000418"&gt;four-year&lt;/span&gt; period with 25% of awards vesting after one year and then monthly thereafter. Any unvested shares will be forfeited upon termination of services. The fair value of an RSA is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSA expense is recorded on a straight-line basis over the vesting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity related to RSA stock-based payment awards:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;grant date fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;611,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense of $0.2&#160;million for both the three months ended March&#160;31, 2022 and 2021 related to RSAs. As of March&#160;31, 2022, the total unrecognized expense related to all RSAs was $1.1&#160;million, which the Company expects to recognize over a weighted-average period of 1.63&#160;years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2021, the Company granted restricted stock units (&#x201c;RSU&#x201d;) to employees that generally vest over a &lt;span style="-sec-ix-hidden:F_000430"&gt;four-year&lt;/span&gt; period with 25% of awards vesting after one year and then quarterly thereafter. Any unvested units will be forfeited upon termination of services. At March 31, 2022 there were 20,000 RSUs outstanding which had a weighted-average grant date fair value of $18.32. There were no RSUs granted or forfeited during the three months ended March 31, 2022. The Company recorded stock-based compensation expense of $24 thousand for the three months ended March 31, 2022 related to RSUs. At March&#160;31, 2022 the total unrecognized expense related to the RSUs was $0.3&#160;million, which the Company expects to recognize over 3.51&#160;years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-size:18pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has an Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which, as of March&#160;31, 2022, had 1,407,365 shares of common stock reserved for future issuance. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year and continuing for&#160;ten years beginning in 2021, in an amount equal to&#160;one&#160;percent of the total number of shares of all classes of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. On January 1, 2022, 476,023 shares were added to the ESPP. &#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the ESPP, eligible employees can purchase the Company&#x2019;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#x2019;s common stock at&#160;85% of the lower of the fair market value of the Company&#x2019;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to&#160;15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000&#160;worth of the Company&#x2019;s common stock for each calendar&#160;year in which such right is outstanding.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.27%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ESPP is considered compensatory under the FASB stock compensation rules. Accordingly, share-based compensation expense is determined based on the option&#x2019;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of&#160;$0.1&#160;million and nil for the three months ended March&#160;31, 2022 and 2021, respectively, related to the ESPP.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <prld:NumberOfEquityIncentivePlans
      contextRef="C_0001678660_20220101_20220331"
      decimals="INF"
      id="F_000336"
      unitRef="U_prldPlan">2</prld:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220331"
      decimals="INF"
      id="F_000337"
      unitRef="U_xbrlishares">6240398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      id="F_000339">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      decimals="2"
      id="F_000340"
      unitRef="U_xbrlipure">0.05</prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      id="F_000338">The Company&#x2019;s stock options vest based on the terms in each award agreement, generally over four-year periods with 25% of options vesting after 1 year and then monthly thereafter, and have a term of ten years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331"
      decimals="2"
      id="F_000343"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001678660_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      id="F_000342">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEquityIncentivePlanMember_20220101_20220331"
      id="F_000344">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000227">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,629&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,829&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">1840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20220101_20220331"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">3629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">2046000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_20220101_20220331"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">6829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_20210101_20210331"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">3886000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000228">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity for the periods indicated:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,179,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000363"&gt;8.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,646,416&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(93,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(191,849&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000364"&gt;8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000365"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001678660_20211231"
      decimals="INF"
      id="F_000351"
      unitRef="U_xbrlishares">7179482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001678660_20211231"
      decimals="2"
      id="F_000357"
      unitRef="U_iso4217USD_xbrlishares">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001678660_20220101_20220331"
      decimals="INF"
      id="F_000352"
      unitRef="U_xbrlishares">1646416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001678660_20220101_20220331"
      decimals="2"
      id="F_000358"
      unitRef="U_iso4217USD_xbrlishares">10.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001678660_20220101_20220331"
      decimals="INF"
      id="F_000353"
      unitRef="U_xbrlishares">93032</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001678660_20220101_20220331"
      decimals="2"
      id="F_000359"
      unitRef="U_iso4217USD_xbrlishares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001678660_20220101_20220331"
      decimals="INF"
      id="F_000354"
      unitRef="U_xbrlishares">191849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001678660_20220101_20220331"
      decimals="2"
      id="F_000360"
      unitRef="U_iso4217USD_xbrlishares">17.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001678660_20220331"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">8541017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001678660_20220331"
      decimals="2"
      id="F_000361"
      unitRef="U_iso4217USD_xbrlishares">14.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001678660_20220331"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">2285520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001678660_20220331"
      decimals="2"
      id="F_000362"
      unitRef="U_iso4217USD_xbrlishares">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001678660_20220331"
      decimals="-5"
      id="F_000366"
      unitRef="U_iso4217USD">11300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001678660_20220331"
      decimals="-5"
      id="F_000367"
      unitRef="U_iso4217USD">6700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000229">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options outstanding at March&#160;31, 2022 under the Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Prices&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&#160;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.31 - $5.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,213,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000384"&gt;7.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,300,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$6.00 - $11.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,625,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000385"&gt;9.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$11.73 - $13.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,392,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000386"&gt;8.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;893,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.05 - $31.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;607,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000387"&gt;9.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$31.14 - $88.98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000388"&gt;9.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,541,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331"
      decimals="INF"
      id="F_000378"
      unitRef="U_xbrlishares">2213458</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331"
      decimals="2"
      id="F_000389"
      unitRef="U_iso4217USD_xbrlishares">1.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331"
      decimals="INF"
      id="F_000394"
      unitRef="U_xbrlishares">1300092</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeOneMember_20220331"
      decimals="2"
      id="F_000400"
      unitRef="U_iso4217USD_xbrlishares">1.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331"
      decimals="INF"
      id="F_000379"
      unitRef="U_xbrlishares">1625800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331"
      decimals="2"
      id="F_000390"
      unitRef="U_iso4217USD_xbrlishares">10.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331"
      decimals="INF"
      id="F_000395"
      unitRef="U_xbrlishares">2250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeTwoMember_20220331"
      decimals="2"
      id="F_000401"
      unitRef="U_iso4217USD_xbrlishares">10.09</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331"
      decimals="INF"
      id="F_000380"
      unitRef="U_xbrlishares">2392956</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331"
      decimals="2"
      id="F_000391"
      unitRef="U_iso4217USD_xbrlishares">12.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331"
      decimals="INF"
      id="F_000396"
      unitRef="U_xbrlishares">893074</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeThreeMember_20220331"
      decimals="2"
      id="F_000402"
      unitRef="U_iso4217USD_xbrlishares">12.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">607804</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331"
      decimals="2"
      id="F_000392"
      unitRef="U_iso4217USD_xbrlishares">20.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331"
      decimals="INF"
      id="F_000397"
      unitRef="U_xbrlishares">11469</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFourMember_20220331"
      decimals="2"
      id="F_000403"
      unitRef="U_iso4217USD_xbrlishares">15.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlishares">1700999</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331"
      decimals="2"
      id="F_000393"
      unitRef="U_iso4217USD_xbrlishares">35.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331"
      decimals="INF"
      id="F_000398"
      unitRef="U_xbrlishares">78635</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001678660_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_prldExercisePriceRangeFiveMember_20220331"
      decimals="2"
      id="F_000404"
      unitRef="U_iso4217USD_xbrlishares">57.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="C_0001678660_20220331"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlishares">8541017</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="C_0001678660_20220331"
      decimals="INF"
      id="F_000399"
      unitRef="U_xbrlishares">2285520</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="2"
      id="F_000405"
      unitRef="U_iso4217USD_xbrlishares">7.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000406"
      unitRef="U_iso4217USD_xbrlishares">68.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="-5"
      id="F_000407"
      unitRef="U_iso4217USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="-5"
      id="F_000408"
      unitRef="U_iso4217USD">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="-5"
      id="F_000409"
      unitRef="U_iso4217USD">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220331"
      decimals="-5"
      id="F_000410"
      unitRef="U_iso4217USD">72200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      id="F_000411">P3Y3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000230">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three months ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000416"&gt;6.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000417"&gt;6.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="4"
      id="F_000412"
      unitRef="U_xbrlipure">0.8457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="4"
      id="F_000413"
      unitRef="U_xbrlipure">1.1713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331"
      decimals="4"
      id="F_000414"
      unitRef="U_xbrlipure">0.0197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="4"
      id="F_000415"
      unitRef="U_xbrlipure">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20220101_20220331"
      decimals="2"
      id="F_000419"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001678660_20220101_20220331" id="F_000231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity related to RSA stock-based payment awards:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;grant date fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;611,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at March&#160;31, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlishares">611608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231"
      decimals="2"
      id="F_000423"
      unitRef="U_iso4217USD_xbrlishares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">96967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331"
      decimals="2"
      id="F_000424"
      unitRef="U_iso4217USD_xbrlishares">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331"
      decimals="INF"
      id="F_000422"
      unitRef="U_xbrlishares">514641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331"
      decimals="2"
      id="F_000425"
      unitRef="U_iso4217USD_xbrlishares">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331"
      decimals="-5"
      id="F_000426"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20210101_20210331"
      decimals="-5"
      id="F_000427"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220331"
      decimals="-5"
      id="F_000428"
      unitRef="U_iso4217USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20220101_20220331"
      id="F_000429">P1Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231"
      decimals="2"
      id="F_000431"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331"
      decimals="INF"
      id="F_000432"
      unitRef="U_xbrlishares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001678660_20220331"
      decimals="2"
      id="F_000433"
      unitRef="U_iso4217USD_xbrlishares">18.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220331"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220331"
      id="F_000438">P3Y6M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220331"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">1407365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331"
      decimals="2"
      id="F_000439"
      unitRef="U_xbrlipure">0.01</prld:PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">476023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331"
      decimals="2"
      id="F_000442"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <prld:EligibleEmployeesContributionPercentage
      contextRef="C_0001678660_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlipure">0.15</prld:EligibleEmployeesContributionPercentage>
    <prld:ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331"
      decimals="0"
      id="F_000444"
      unitRef="U_iso4217USD">25000</prld:ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001678660_us-gaapPlanNameAxis_prldTwoThousandTwentyEmployeesStockPurchasePlanMember_20220101_20220331"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZV&O!^ G"H+25VWM;%->/542'(+J//>: /X/HN *JJK -PU3GK]'8772>_$
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MNKUV0#2KT1B*[^PX;KC2PVV/I?Z;8&$"]'W!N3H8)D'W?PK^ %!+ P04
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M"KP4S4];WOL1H>0<'CE1Z\$D%JX;G$%<EK3!_#9HP!-Q&P/E'"R.+#E]%6B
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MDOGM_+'I+G]C6;;G+U7@&%1J5)9:'#U?__C]*O/T])#\(%]<*I^2[^5G1[@
M!-Z ]=;#S_+ "N9/<+?_!5!+ P04    " !<0:I4OR(SNR$.  #O)@  &0
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M 1.#Z4 "2*6AW,A0A?5AIZ>H#4[$$3.5N!L2,K1@9*$(5,0;1U.I@,*@7_F
M":C:&%N5-FJT1E&PCJ>QWX $5%#FI&45"#9 #Z3TNZA=(]V[JJ]KJ! G4.7
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MAV?#B^ZQ-SL ]UI6>4_IU1S1.P5ZSE)[BAZ@XH,I;HZHJP$DR0.Q=MO<KK:
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M-9G,BA#T\*(,@E6=G^)K9>E-\,N&'F'4SH#V-TK9H^ "C,_ZZE]02P,$%
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M[.0@CO/-3; 5?Y '=P5;\"65=.7H!3Q?6AN:&SJ@_87F\K]02P,$%     @
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MQ8[GAP7^Q0#M#'!_K5 ?[<0EZ/ZTS/X'4$L#!!0    ( %Q!JE3#3U, ^0(
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MV@70_EY14[031]"][JM_ %!+ P04    " !<0:I410Q1$(\"  " !0  &0
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M;, -"H^+SN1E:S)XP61(/\O&+#6]:DI>[NN/ 5Z/,=ABO P&#7YFRJ6A[]#
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M NW@(*3::U6[,')EKS(S:>!B9!^7<!/E"@7@^UQ*LUV@@_YN>_$_4$L#!!0
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MRYI23<=#*;9(6K3)9ANU-G6T60TK[6><:6G>,A.GQ^^IO %-YQS0#/)*,LU
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M LS[I1#ZOF,/Y^UE;/P+4$L#!!0    ( %Q!JE27YIV4>0,  $P-   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;,U776_B.!3]*U?1/+12M_DBH8P
MJ0556ZF5V#*=>5CM@PD7L)K8K.W C#0_?J]-&M)",[O2(O4%XN2>ZW//L7.=
M_E:J9[U"-/"]R(4>>"MCUI]]7V<K+)B^E&L4]&0A5<$,#=72UVN%;.Y 1>Y'
M09#Z!>/"&_;=O8D:]F5I<BYPHD"71<'4CQO,Y7;@A=[+C4>^7!E[PQ_VUVR)
M4S1/ZXFBD5]GF?,"A>92@,+%P+L./X_"U )<Q%>.6]VX!EO*3,IG.[B;#[S
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MT1NG_<91UWYG4 M=<J$AQP7A@LLN2:YV1_?=P,BU._W.I*&SM+M<T><.*AM
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M,<#]E1!Z-S']J_]=)7\ 4$L#!!0    ( %Q!JE1AKBG-JP,  *$,   9
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MT#<$:C>!QG-%%T+3< NT7R6+;U!+ P04    " !<0:I4E157"PT'  " '0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU66UOVS80_BN$VW4MD,86
M)3M.FP1(XFS-D*Q!LFX?AGV@K;--5!)5DLK+L!^_(R6+LB-3+M!\26R9=WSN
MR'N>(W7T(.17M030Y#%-,G7<6VJ=?^CWU6P)*5/[(H<,?YD+F3*-7^6BKW()
M++9&:=*G@\&HGS*>]4Z.[+,;>7(D"IWP#&XD446:,OET!HEX..X%O=6#6[Y8
M:O.@?W*4LP7<@?Z2WTC\UJ^]Q#R%3'&1$0GSX]YI\.$B&AH#.^)/#@^J\9F8
M4*9"?#5?+N/CWL @@@1FVKA@^.\>SB%)C"?$\:URVJOG-(;-SROOO]C@,9@I
M4W NDK]XK)?'O7&/Q#!G1:)OQ<,GJ *R &<B4?8O>:C&#GID5B@MTLH8$:0\
M*_^SQRH1#8.0;C&@E0'=,-@Z0U@9A)LSA%L,HLH@VC"@P1:#865@0^^7L=O$
M39AF)T=2/!!I1J,W\\%FWUICOGAF-LJ=EO@K1SM]<B[2E&M<>:W(>W(:Q]RL
M'TO(95;N0K.:;R>@&4_4._*:\(Q<\R3!Q^JHKQ&!\=.?5;.=E;/1+;,%Y%ID
M>JG(119#W&)_[K<//?9]C+P.GZ["/Z->AW>0[Y-PL$?H@ 9?[B;D[>MWEYG2
M+$E,3MH0^AU>,XD. ^N05@Y;O$S\7B8PJ[VL8,WUFU?!P?CCQ:,NZ[3%[<7N
MX()6<&M)#.L]%%JWX1:WG_42)&GNI+^O< BYU)"J?SP31/4$D9T@VC+!%2 5
M("UE\( [,P?)1>OF\7L9D=1N'@^@80UHZ'7U&3%@:60+DEAHH#3'6H$8RV,F
MP20!@4Z%1+]F% X&@WNV94_Y9QOM#P8_>5"/:M2CCC0J!;!'Q#IZ\\"6N18$
MS.9JS:W?]1]+( IF(HN?.2.X.TBY@L@HA*$X.)99K0EY8(ID0N,BS\0BX_]B
M*O%)SJ0F8FY=X/[*6?;TYM68!@<?%4G195'F>C5$&E5X+^;O"YR,8; :IXLW
MXR4)9U.></UDID!3+(O9$HMK-/BXJEQ/M@_J;!]X4W)K@,$C*KJ"MH26UH?6
MVLCY_<E@?WC4OV^6<]N8L!ZS!FM<PQIWP.+IM) *RDHU2Q+#/38,^2J3"9L2
ME;-9*^KQ,T3#!NHU1(<UHL,?A<A3^_XY0O($3/I*/Q@XQ1S\,+RX_ER6(FH
MM"J>?S;<C:$/=D/H Z^C7R5#=-^[WI73YH+3_:A]P0/JL-".%,X ^\.8S)A:
M6DP*DZ3F3Z9(<8UMZY%A_J:0S9;8P7YMEGLK3KI[J01.V(+0BW,"<WR",)&D
M))\6=B'SA&5[I@?C:9$BP60%$EESA#(A$$CS1#P9OO40?\?\P6#0P?V!T]#
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MRV?0?NZ&/5>W+[9,S,%?7U5(\$7RK/S;(X@V@F@EB#H$=4S(>_#[)KOG OP
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MH %#DL2=@SOG4;P^I^+-;T2CWU!+ P04    " !<0:I4EXJ[',     3 @
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MFN,3OYQ:U4*,7-M"7BE:[MZH[-X&??X+4$L#!!0    ( %Q!JE1 N\,MAP$
M +P7   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,MNPC 0A>%7
M07D G)GA6@&K;MA6O$ $YB)R4^RJ\/:-8 $'==$-\EE%MI7)O_H4>?'ERR*>
MFCH<3VT87*JR#LOL&&/[X5S8'GU5A&'3^KH_V3==5<1^V1U<6VS/Q<$[S?.)
MZYYG9*O%\\S!YMKZ_TQL]OO3UG\VV^_*U_&/P>ZGZ<[AZ'W,!INB._BXS-RE
M?&P'=WO(L)^<#=:[9=:M=Y*YU$$*09H^R"#(T@>-(&B4/F@,0>/T01,(FJ0/
MFD+0-'W0#()FZ8/F$#1/'R0YRI@3)+U@3:"U(-="X+4@V$(@MB#90F"V(-I"
MH+8@VT+@MB#<0B"W(-U"8+<@WD*@MZ+>2J"WHMY*H+>^_&P3Z*VHMQ+HK:BW
M$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1Z&VHMQ'H;2^7
M)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;>_4.\1KZ<.CY[[&V\AW
M4AW[=_WC\[?E?1-Q'MUP=G!9O_H%4$L#!!0    ( %Q!JE3_>6J2GP$  !T8
M   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9S6Z#,!"$7P5QC8)CNTU_E.32
M]MKFT!=P80DH@"W;29.WKR$_4JL4)4JES@4+O#LS>*7O )/WK2$7;>JJ<=.X
M\-X\,N;2@FKE$FVH"3NYMK7RX=8NF%'I4BV(B=%HS%+=>&K\T+<:\6SR3+E:
M53YZV83'KM3--+94N3AZVA6V7M-8&5.5J?)AGZV;[(?+<.^0A,ZNQA6E<8-0
M$+.3#NW.[P;[OK<U65MF%,V5]:^J#E5L4S'GMQ6YI%_B1$:=YV5*F4Y7=6A)
MG+&D,E<0^;I*=J*#?F<?3IAV5WZU?R?39Q@JYU8;%R9FZ7*[PTC:[J$)0F1]
MV?^*1\<@??7[43OMC+(SO</Q?FJ[[.;A6+=<?\;?9WS4OS"' ,DA07+<@.2X
M!<DQ!LEQ!Y+C'B3' T@./D()@D)4CH)4CL)4C@)5CD)5CH)5CL)5C@)6CD)6
M@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6B4)6B4)6B4)6B4)6B4)6
MB4)6B4)6B4)6B4)6^9]D_=!Z^=<?K-LUJ579'/Q9]U=@]@502P$"% ,4
M" !<0:I4!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( %Q!JE39.O7E[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %Q!JE297)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 7$&J5 +G@5I<!0  %!8  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %Q!JE0+;K.&
M0 4  +D5   8              " @9\-  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " !<0:I4KC(_"<P"  "R"0  &
M@($5$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 7$&J
M5)X_9B7V P  ?PP  !@              ("!%Q8  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( %Q!JE1=%!H;,04   @5   8
M      " @4,:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" !<0:I4K-ILSE\"  "K!   &               @(&J'P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 7$&J5(5-Y.7:!0  "Q8  !@
M             ("!/R(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( %Q!JE0\'62$$0,  %H&   8              " @4\H  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !<0:I4TZ(E^?('  ".
M$P  &               @(&6*P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ 7$&J5+\B,[LA#@  [R8  !D              ("!OC,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !<0:I4I+43
MZ:(#  #B!P  &0              @($60@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( %Q!JE0",DZ/9 4  %T-   9
M  " @>]%  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M7$&J5 /5H)Y\ @  :P4  !D              ("!BDL  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " !<0:I4T?#?*^P"  ![!@  &0
M            @($]3@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( %Q!JE3TD"^Y(0H  *T9   9              " @6!1  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 7$&J5.&X_6N1"@
MBAX  !D              ("!N%L  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " !<0:I4F< W?R(.  !4*   &0              @(&
M9@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %Q!JE0.
MY0>HRP,  , (   9              " @=ET  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ 7$&J5,-/4P#Y @  5P8  !D
M     ("!VW@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %Q!JE3R@^4D%0(  (,$   9              "
M@>:+  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 7$&J
M5*HY;72. @  3@8  !D              ("!,HX  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " !<0:I40^6QA6T#  #\#   &0
M        @('WD   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( %Q!JE3K/ZE,,P(  )L%   9              " @9N4  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 7$&J5-,&%/16 P  F T
M !D              ("!!9<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " !<0:I4E^:=E'D#  !,#0  &0              @(&2F@
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %Q!JE1).G=!
MF@(  +H&   9              " @4*>  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ 7$&J5&&N*<VK P  H0P  !D
M ("!$Z$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !<
M0:I4E157"PT'  " '0  &0              @('UI   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %Q!JE0X ZOQ+P,  +H)   9
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M970S-RYX;6Q02P$"% ,4    " !<0:I477[-S\8"  !F!P  &0
M    @('?Q   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M %Q!JE3"*1"=& ,  ,\)   9              " @=S'  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ 7$&J5+@2 P@; P  ,!(   T
M             ( !*\L  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !<0:I4
MEXJ[',     3 @  "P              @ %QS@  7W)E;',O+G)E;'-02P$"
M% ,4    " !<0:I4Z4M.*ZX#  "1&@  #P              @ %:SP  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 7$&J5$"[PRV' 0  O!<  !H
M         ( !-=,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 7$&J5/]Y:I*? 0  '1@  !,              ( !]-0  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "\ +P# #   Q-8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>221</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - STATEMENT OF BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED</Role>
      <ShortName>STATEMENT OF BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED</Role>
      <ShortName>STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED</Role>
      <ShortName>STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureBackground</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Risks and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Risks and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails</Role>
      <ShortName>Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="prld-10q_20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="prld-10q_20220331.htm">prld-10q_20220331.htm</File>
    <File>prld-20220331.xsd</File>
    <File>prld-20220331_cal.xml</File>
    <File>prld-20220331_def.xml</File>
    <File>prld-20220331_lab.xml</File>
    <File>prld-20220331_pre.xml</File>
    <File>prld-ex101_194.htm</File>
    <File>prld-ex311_6.htm</File>
    <File>prld-ex312_7.htm</File>
    <File>prld-ex321_9.htm</File>
    <File>prld-ex322_8.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="374">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "prld-10q_20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 110,
   "dts": {
    "calculationLink": {
     "local": [
      "prld-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prld-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "prld-10q_20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prld-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prld-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prld-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 339,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 28,
    "http://preludetx.com/20220331": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 34
   },
   "keyCustom": 31,
   "keyStandard": 190,
   "memberCustom": 12,
   "memberStandard": 22,
   "nsprefix": "prld",
   "nsuri": "http://preludetx.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Marketable Securities",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Common Stock",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock-Based Compensation",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Marketable Securities (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - STATEMENT OF BALANCE SHEETS (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
     "shortName": "STATEMENT OF BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Risks and Liquidity - Additional Information (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
     "shortName": "Risks and Liquidity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
     "shortName": "STATEMENT OF BALANCE SHEETS (PARENTHETICAL) (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapStatementClassOfStockAxis_prldVotingCommonStockMember_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "prld:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "prld:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Commitments - Additional Information (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
     "shortName": "Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails",
     "shortName": "Commitments - Schedule of Future Minimum Annual Lease Payments Under Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapLeaseContractualTermAxis_prldOperatingLeaseUntilJune302023Member_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "prld:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_prldPlan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "prld:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_prldPlan",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails",
     "shortName": "Stock-Based Compensation - Summary of Information about Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20220101_20220331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails",
     "shortName": "Stock-Based Compensation - Summary of Activity related to RSA Stock-Based Payment Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "prld:PaymentsOfOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED",
     "shortName": "STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL) (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "prld:PaymentsOfOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Background",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureBackground",
     "shortName": "Background",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Risks and Liquidity",
     "role": "http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "prld-10q_20220331.htm",
      "contextRef": "C_0001678660_20220101_20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prld:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "prld_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prld_AccruedResearchAndDevelopmentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development liabilities, current.",
        "label": "Accrued Research And Development Liabilities Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentLiabilitiesCurrent",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_AggregateEstimatedRentPaymentsDueOverInitialTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate estimated rent payments due over initial term.",
        "label": "Aggregate Estimated Rent Payments Due Over Initial Term",
        "terseLabel": "Aggregate estimated rent payments due over initial term"
       }
      }
     },
     "localname": "AggregateEstimatedRentPaymentsDueOverInitialTerm",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_AreaOfLeasePremises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of lease premises.",
        "label": "Area Of Lease Premises",
        "terseLabel": "Area of lease premises"
       }
      }
     },
     "localname": "AreaOfLeasePremises",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale debt securities accumulated gross unrealized gain net of tax.",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Net Of Tax",
        "terseLabel": "Marketable securities, Gross unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale debt securities accumulated gross unrealized loss net of tax.",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Net Of Tax",
        "negatedLabel": "Marketable securities, Gross unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_BackgroundAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Background.",
        "label": "Background [Abstract]"
       }
      }
     },
     "localname": "BackgroundAbstract",
     "nsuri": "http://preludetx.com/20220331",
     "xbrltype": "stringItemType"
    },
    "prld_BeneficialOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial ownership percentage.",
        "label": "Beneficial Ownership Percentage",
        "terseLabel": "Beneficial ownership percentage"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentage",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prld_ChestnutRunLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chestnut run lease.",
        "label": "Chestnut Run Lease [Member]",
        "terseLabel": "Chestnut Run Lease"
       }
      }
     },
     "localname": "ChestnutRunLeaseMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_DarwinHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Darwin Health, Inc.",
        "label": "Darwin Health Inc [Member]",
        "terseLabel": "DarwinHealth"
       }
      }
     },
     "localname": "DarwinHealthIncMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_DisbursementIncurredCostsForLabSpace": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disbursement incurred costs for lab space.",
        "label": "Disbursement Incurred Costs For Lab Space",
        "terseLabel": "Disbursement incurred costs for lab space"
       }
      }
     },
     "localname": "DisbursementIncurredCostsForLabSpace",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_EligibleEmployeesContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible employees contribution percentage.",
        "label": "Eligible Employees Contribution Percentage",
        "terseLabel": "Eligible employees contribution percentage"
       }
      }
     },
     "localname": "EligibleEmployeesContributionPercentage",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prld_EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of payment over a agreement term in three equal installments.",
        "label": "Estimated Amount Of Payment Over Agreement Term In Three Equal Installments",
        "terseLabel": "Estimated amount of payment over a agreement term"
       }
      }
     },
     "localname": "EstimatedAmountOfPaymentOverAgreementTermInThreeEqualInstallments",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_EstimatedNumberOfYearResearchCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated number of year research collaboration agreement.",
        "label": "Estimated Number Of Year Research Collaboration Agreement",
        "terseLabel": "Estimated years of research collaboration agreement"
       }
      }
     },
     "localname": "EstimatedNumberOfYearResearchCollaborationAgreement",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prld_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range five.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$31.14 - $88.98"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range four.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$13.05 - $31.13"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range one.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$0.31 - $5.99"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range three.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$11.73 - $13.04"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range two.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$6.00 - $11.72"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_GracePeriodForPotentialRefund": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grace period for potential refund.",
        "label": "Grace Period For Potential Refund",
        "terseLabel": "Grace period following research term for potential refund"
       }
      }
     },
     "localname": "GracePeriodForPotentialRefund",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prld_GrantForDevelopmentOfLabSpace": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant for development of lab space.",
        "label": "Grant For Development Of Lab Space",
        "terseLabel": "Grant for development of lab space"
       }
      }
     },
     "localname": "GrantForDevelopmentOfLabSpace",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_InitialTermOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of lease.",
        "label": "Initial Term Of Lease",
        "terseLabel": "Initial term of lease"
       }
      }
     },
     "localname": "InitialTermOfLease",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prld_LeaseLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "Lease Liability [Line Items]",
        "terseLabel": "Lease Liability [Line Items]"
       }
      }
     },
     "localname": "LeaseLiabilityLineItems",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prld_LeaseLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "Lease Liability [Table]",
        "terseLabel": "Lease Liability [Table]"
       }
      }
     },
     "localname": "LeaseLiabilityTable",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prld_NumberOfEqualInstalments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal instalments.",
        "label": "Number Of Equal Instalments",
        "terseLabel": "Number of equal instalments"
       }
      }
     },
     "localname": "NumberOfEqualInstalments",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prld_NumberOfEquityIncentivePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity incentive plans.",
        "label": "Number Of Equity Incentive Plans",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "localname": "NumberOfEquityIncentivePlans",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prld_NumberOfLeaseExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of lease extensions.",
        "label": "Number Of Lease Extensions",
        "terseLabel": "Number of lease extensions"
       }
      }
     },
     "localname": "NumberOfLeaseExtensions",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prld_OperatingLeaseEstimatedIncrementalBorrowingRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease estimated incremental borrowing rate percent.",
        "label": "Operating Lease Estimated Incremental Borrowing Rate Percent",
        "terseLabel": "Operating lease estimated incremental borrowing rate percent"
       }
      }
     },
     "localname": "OperatingLeaseEstimatedIncrementalBorrowingRatePercent",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prld_OperatingLeaseUntilJune302023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, until June 30, 2023.",
        "label": "Operating Lease Until June302023 [Member]",
        "terseLabel": "Operating Lease, until June 30, 2023"
       }
      }
     },
     "localname": "OperatingLeaseUntilJune302023Member",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Participants accrue rights to purchase maximum common stock amount.",
        "label": "Participants Accrue Rights To Purchase Maximum Common Stock Amount",
        "terseLabel": "Participants accrue rights to purchase maximum common stock amount"
       }
      }
     },
     "localname": "ParticipantsAccrueRightsToPurchaseMaximumCommonStockAmount",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_PaymentsOfOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of offering costs.",
        "label": "Payments Of Offering Costs",
        "terseLabel": "Sale of common stock, offering costs"
       }
      }
     },
     "localname": "PaymentsOfOfferingCosts",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITPARENTHETICALUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued.",
        "label": "Percentage Of Shares Outstanding Used To Calculate Annual Increase In Number Of Shares That Can Be Issued",
        "terseLabel": "Percentage of shares outstanding used to calculate annual increase in number of shares that can be issued"
       }
      }
     },
     "localname": "PercentageOfSharesOutstandingUsedToCalculateAnnualIncreaseInNumberOfSharesThatCanBeIssued",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prld_PotentialRefundReceivableFromAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential refund receivable from agreement.",
        "label": "Potential Refund Receivable From Agreement",
        "terseLabel": "Potential refund receivable from agreement"
       }
      }
     },
     "localname": "PotentialRefundReceivableFromAgreement",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Received cash for satisfying performance benchmark measurement.",
        "label": "Received Cash For Satisfying Performance Benchmark Measurement",
        "terseLabel": "Received cash for satisfying performance benchmark measurement"
       }
      }
     },
     "localname": "ReceivedCashForSatisfyingPerformanceBenchmarkMeasurement",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_ReimbursementsForDevelopmentOfLabSpace": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements for development of lab space.",
        "label": "Reimbursements For Development Of Lab Space",
        "terseLabel": "Reimbursements for development of lab space"
       }
      }
     },
     "localname": "ReimbursementsForDevelopmentOfLabSpace",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_ReimbursementsForDevelopmentOfLabSpaceExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements for development of lab space expiration year.",
        "label": "Reimbursements For Development Of Lab Space Expiration Year",
        "terseLabel": "Reimbursements for development of lab space expiration year"
       }
      }
     },
     "localname": "ReimbursementsForDevelopmentOfLabSpaceExpirationYear",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "prld_ReimbursementsForDevelopmentOfLabSpacePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements for development of lab space period.",
        "label": "Reimbursements For Development Of Lab Space Period",
        "terseLabel": "Reimbursements for development of lab space period"
       }
      }
     },
     "localname": "ReimbursementsForDevelopmentOfLabSpacePeriod",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prld_ResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research term.",
        "label": "Research Term",
        "terseLabel": "Research term"
       }
      }
     },
     "localname": "ResearchTerm",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prld_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and liquidity.",
        "label": "Risks And Liquidity [Abstract]"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://preludetx.com/20220331",
     "xbrltype": "stringItemType"
    },
    "prld_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and liquidity.",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prld_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prld_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prld_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prld_TwoThousandTwentyEmployeesStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employees Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeesStockPurchasePlanMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prld_UnrealizedGainLossOnMarketableSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized gain (loss) on marketable securities.",
        "label": "Unrealized Gain Loss On Marketable Securities",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnMarketableSecurities",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prld_VotingCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting common stock.",
        "label": "Voting Common Stock [Member]",
        "terseLabel": "Voting Common Stock"
       }
      }
     },
     "localname": "VotingCommonStockMember",
     "nsuri": "http://preludetx.com/20220331",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r165",
      "r174",
      "r206",
      "r208",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r370",
      "r371",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r165",
      "r174",
      "r206",
      "r208",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r370",
      "r371",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r95",
      "r151",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Forma [Member]",
        "terseLabel": "Pro Forma"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r165",
      "r174",
      "r197",
      "r206",
      "r208",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r370",
      "r371",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r165",
      "r174",
      "r197",
      "r206",
      "r208",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r370",
      "r371",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r90",
      "r95",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r90",
      "r95",
      "r151",
      "r207",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update201613 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r331"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of premium and discount on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r43",
      "r44",
      "r45",
      "r363",
      "r379",
      "r383"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r52",
      "r53",
      "r54",
      "r79",
      "r80",
      "r81",
      "r280",
      "r374",
      "r375",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r251",
      "r252",
      "r253",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r83",
      "r84",
      "r85",
      "r86",
      "r95",
      "r127",
      "r128",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r153",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r267",
      "r268",
      "r269",
      "r270",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r328",
      "r345",
      "r346",
      "r347",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r210",
      "r243",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r118",
      "r120",
      "r124",
      "r133",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r275",
      "r281",
      "r302",
      "r329",
      "r331",
      "r351",
      "r361"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r41",
      "r77",
      "r133",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r275",
      "r281",
      "r302",
      "r329",
      "r331"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r131",
      "r145"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Marketable securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r130",
      "r145"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "verboseLabel": "Marketable securities, Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r212",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r78",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Background"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureBackground"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r29",
      "r68"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r69",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r63",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r312"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r79",
      "r80",
      "r82",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r153",
      "r247",
      "r248",
      "r249",
      "r267",
      "r285",
      "r286",
      "r287",
      "r303",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r319",
      "r328",
      "r345",
      "r346",
      "r372",
      "r373",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, ASU, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r79",
      "r80",
      "r89",
      "r127",
      "r128",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r153",
      "r247",
      "r248",
      "r249",
      "r267",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r303",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r319",
      "r328",
      "r345",
      "r346",
      "r372",
      "r373",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, ASU, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r83",
      "r94",
      "r129",
      "r142",
      "r254",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, ASU, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r77",
      "r96",
      "r97",
      "r98",
      "r100",
      "r102",
      "r106",
      "r107",
      "r108",
      "r133",
      "r154",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r172",
      "r173",
      "r177",
      "r181",
      "r302",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r150",
      "r353",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r331"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r56",
      "r355",
      "r369"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r198",
      "r205",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of employee's gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r117"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share of common stock, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "verboseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Total unrecognized compensation expense, weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Share-based payment arrangement, nonvested award, unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Total unrecognized compensation expense related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r52",
      "r53",
      "r54",
      "r79",
      "r80",
      "r81",
      "r84",
      "r91",
      "r93",
      "r105",
      "r141",
      "r188",
      "r195",
      "r251",
      "r252",
      "r253",
      "r269",
      "r270",
      "r294",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r374",
      "r375",
      "r376",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r298",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r166",
      "r198",
      "r199",
      "r204",
      "r205",
      "r298",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r198",
      "r199",
      "r204",
      "r205",
      "r298",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant other observable inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r298",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value",
        "terseLabel": "Fair value measurement, recurring basis, assets"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r348",
      "r358",
      "r400",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Annual Lease Payments Under Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2022 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lease renewal period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r77",
      "r121",
      "r133",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r276",
      "r281",
      "r282",
      "r302",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r77",
      "r133",
      "r302",
      "r331",
      "r352",
      "r365"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r77",
      "r133",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r276",
      "r281",
      "r282",
      "r302",
      "r329",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r8",
      "r33"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows provided by (used in) investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r46",
      "r48",
      "r54",
      "r55",
      "r67",
      "r77",
      "r83",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r99",
      "r118",
      "r119",
      "r122",
      "r123",
      "r125",
      "r133",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r296",
      "r302",
      "r354",
      "r368"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Summary of Activity related to RSA Stock-Based Payment Awards"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvotingCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Non-voting Common Stock"
       }
      }
     },
     "localname": "NonvotingCommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r119",
      "r122",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Current and noncurrent lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumAnnualLeasePaymentsUnderLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Asset Amortization Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r34"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r17",
      "r350",
      "r360"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r273",
      "r274",
      "r279"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r212",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r246"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r46",
      "r48",
      "r54",
      "r62",
      "r77",
      "r83",
      "r92",
      "r93",
      "r118",
      "r119",
      "r122",
      "r123",
      "r125",
      "r133",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r273",
      "r277",
      "r278",
      "r283",
      "r284",
      "r296",
      "r302",
      "r356"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r146",
      "r331",
      "r359",
      "r366"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross",
        "terseLabel": "Agreement is eligible to receive payment in future research, development and regulatory milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r258",
      "r343",
      "r403"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r73",
      "r349",
      "r362"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock Awards",
        "verboseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Unvested Restricted Stock Units",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r195",
      "r254",
      "r331",
      "r364",
      "r378",
      "r383"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r79",
      "r80",
      "r81",
      "r84",
      "r91",
      "r93",
      "r141",
      "r251",
      "r252",
      "r253",
      "r269",
      "r270",
      "r294",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r325",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "verboseLabel": "Number of shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "verboseLabel": "Public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recorded in Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r212",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]",
        "terseLabel": "Summary of Information about Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r219",
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Fair Value of Each Option Estimated on Date of Grant Using Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r38",
      "r75",
      "r106",
      "r107",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r181",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "terseLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of shares, Unvested balance at end of period",
        "periodStartLabel": "Number of shares, Unvested balance at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value, Unvested balance at end of period",
        "periodStartLabel": "Weighted-average grant date fair value, Unvested balance at beginning of period",
        "terseLabel": "weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecordedInStatementsOfOperationsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
        "terseLabel": "Number of shares, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of shares, Exercisable at March 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Exercisable at March 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r221",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price per share, Outstanding at end of period",
        "periodStartLabel": "Weighted average exercise price per share, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award",
        "terseLabel": "Terms of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r209",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails",
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatedToRSAStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Vesting After One Year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit",
        "terseLabel": "Range of Exercise Prices, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options",
        "terseLabel": "Options Exercisable, Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options",
        "terseLabel": "Options Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit",
        "terseLabel": "Range of Exercise Prices, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Percentage of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r237",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionEstimatedOnDateOfGrantUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate intrinsic value of exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual term (years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average remaining contractual term (years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Eligible employees purchase common stock percentage of lower of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1",
        "terseLabel": "Options Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1",
        "terseLabel": "Options Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r75",
      "r77",
      "r96",
      "r97",
      "r98",
      "r100",
      "r102",
      "r106",
      "r107",
      "r108",
      "r133",
      "r154",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r172",
      "r173",
      "r177",
      "r181",
      "r188",
      "r302",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r39",
      "r52",
      "r53",
      "r54",
      "r79",
      "r80",
      "r81",
      "r84",
      "r91",
      "r93",
      "r105",
      "r141",
      "r188",
      "r195",
      "r251",
      "r252",
      "r253",
      "r269",
      "r270",
      "r294",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r374",
      "r375",
      "r376",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r105",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsTables",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSPARENTHETICALUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Sale of common stock, net of offering costs, (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r188",
      "r195",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r188",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r195",
      "r211",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r188",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r77",
      "r126",
      "r133",
      "r302",
      "r331"
     ],
     "calculation": {
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED",
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTOFBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r83",
      "r84",
      "r85",
      "r86",
      "r95",
      "r127",
      "r128",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r153",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r267",
      "r268",
      "r269",
      "r270",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r328",
      "r345",
      "r346",
      "r347",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://preludetx.com/20220331/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r405": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r407": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r408": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r409": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r411": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r412": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001564590-22-019085-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-019085-xbrl.zip
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M[)F9\\^:7M*QP'5PQ>]*!J!E/15GPK6:CL?+ =R.$[/Q;.!%MH'O<)%5%]=
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MO9(N=5[N#NX=Z?3MC5&'66???O":G:2D%#:,J;1J3->&JU'S3WC,-7SC[F9
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M_!4KTC+>?4$FU.%KS6>79 -9UM%B*?MS;HABXF[3]T:V S*LGYK-&_)7-DG
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M;#*Z]UDO1%Q$W.SR23[$1:<V'L2MG@QQ-YVT/AQ>R_5"I8Y^K70BB0"+ (L
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M E,E'C#=OHFU/)O^"*8Q1Q(.C>J<.I(@.4=NF4=$GVN?M^%:+)8&*^DYT:0
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MLDV.9]0_/J.^*DL;C[G)P"Y9(_)XS"T[O,1C;DE94=NV6[^.]/.1VJW'$IC
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MZ0?7 ZN&P?OA L<WQ,4@+T!'<?R/7^LQ;11=3(?# J'Z&.YVO6#L8<\?"L2
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M(N8ZF_*%.9*O(>)3\P?@.S/:B.L$8,+%\FK91%XZ'OD'2IU#K<G7JYPBE!1
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MN'CV?_]/'];BZ\B 67[G1*1<57WC@?L\9)XW,\;LD=,*0_E/F <WQ'C5S'#
MPHZ,8&28'6,"%XSA0VAX/(H:1NY-QI![+G^$2^,QBPW\)LDL<L,#DQQ^8E$4
MV"Z:[,:3&X_A4JST;WNNSPW7QT66<'R5&T?Y8;KP4#[!8BGAK(:?IB$LXQ!8
M8(2</  C#N04C1%,( CA7;ZS,"8WQGLG0<@-S_W.X6[XV@?ZQMGO3Z[GP5T&
M$0J>.0X\AT:ST(] O$]0J&'\SR_(&:1[R(&+O$832PD#3'1M=TID9,8H@3>$
MW X>>3C#N>*E+-US!!9$L3'$7<>4#HMOAH%FO,$YP@R @\$3\VV.*L^P0^[
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M($?B)-<WY7^!>OWX#GZ\$3'<*3Q=>@9>*U(49HK=PS6(D@QE,#X2BVLIDHC
M5U%RJ^Y14T!,O=]J0]X!2P'FLA%I$,(!ZJ'A>BR+0-Y?F.$RH8=1.L$OX8Y+
M@9B+<HXT4.9',!>X9K5/2/T@@\=0@-[!Y<14/G@$/AY%4V_OIJR*3@FW!D/H
M>JW$=T3L(4C@GJ=YB*;+-A4K0?LD]0%<!*X1. +]XC^PX:0FH:;%\>H'9 CX
M]Q_>T4HZU"PUO27H$Y>7T[G\HV:<(.5Q^R?R$ 1<4##H@/KD$0&!?A5D0<".
MP%D"4U2'A]^#2?E!4&P*J00MQ2H,0F);W\S/KZ:7C9'H&-6!X/Z(/T G08I@
M#P_'*6+Z94$_X*;7MQP5+*WKT58J1D._!/93I$@&,%0J-C34WOT%-BU%!,P@
MH85'*UPB[.RYVOF*0J6&!$^#2@1<' 1-C@0&^Y1EQ6:KR0%H:>,3Q=V0!%K
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MD>5R=YV63NGQH]E('^&6(F$N8G1T5\ )#2<TG-!X3D(#<X7??_J?CQ].9F]
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M.@3CI,)1$;F3"DXJ.*GPC*1"HZ<5_,M7I=5F@+Z6=0^<NVD7E $%"3D54;V
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M )3<^1'O F_]NSZX[J9KCAO8ZY?WT^(M&_\KN^$.=VK E:]#^S4WIS8@V%:
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M][=9:86XV"[N^*L_,HU"Z>[<R&UJ_*^O9/+?MD2"L9<O!H%*?5A#T%1"?YL
M[#RCY.T>#$7K]VF>A:HS-QNQ_K65_Z7>[,L^UM03_'8!M&RU"+[V3:=^;&^/
M)MGGT8O?.;,<.K"!&%3&1P&;_P2YP;IS+[!D'!C<T8OLSJA57;8&;9CU7]7"
M*$JR@B4WQ,L;956".7.[EF%8*$H[Z!0DN2IJ-Q2C$:E=]9' :,*Q.)WU8#Z6
MNS>,'1H!8K_E4G^.+I?KVKPY66GSR4@,T-ZH'3F E:? ]'[%2B266(E$FF$
M_D^I9%*]X4:>D<*$?,4Z%;X&_^2"$<T?1^L<$JIB7*IM;L+LE>-H%+%8"WQU
M \,R ]JX04/N8XEXCH?[;C&C8P@)!&9W]>& P(I,Y<WR5(H]8U9P6S66FZ+,
MJZBLA(8:+0%\!;_7J<U:5P@O8U%6Z-,6T=I:X(G8Q %+2&#DY3R FR2=@M@;
M\#UX+\T?FO85,F1 B^G[[S[*M<Q77)Q)CA#;5BSY0 4YH"P"]W5587*HEWQ<
M9Z!)"%+ "TJNQ55$DXS[B'OCQ2G*)6E%#HHI'U1&3#V\YDT5>D7_2-UJ39X6
MBLQCZ]PX"6']FL@H5J.N#@O/A?MT+$!^$%9T_!$E?BR^O6)/5\0,\G\>#*;
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M+:/Y(,*D.",6-*DZ:&@U[4IL%C#(].V. +:9#-#SE.66.-:X?P<"V,(BWH,
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MMJRFI$^,QRL"4I5MW>.1F5%'9Q##C#V.?W4CXLR&?G24UZ%W#^)5G%+I/';
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M[)ST\$V89;&_;2<+17XY-$H_N7 ZR$]3^T4[$AY7&-,#N/@\>1L<Z$Y6(L@
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MGS_]\N;U*X6Z^W;8S=65JN_)I?I%#H#QAAM;F#Y6KEP_]N.UB(UB.PT2!8.
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MT+SN@^/FS0Y<I24V1 1'L8G)\ PV0(+6'_<1: JYA,T"R5+8C(2BB)>7K_K
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MY2W.Z%S:?38B3E78V7K:K^PT)KR!W]OCXF05M(&RU\0&K+7DD_ (AS&8M7C
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M97T Z"5V*21Z[#T67_2&B_7NYZ_\$[&L<BGZ 07<O2RZ@!M@I]0AWI#?%R0
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M<=4HPP\L6ZYJ_-H-J88<%_<S[)UT7SCMS%][&0%49L_D\7H3"<C4>0V*%N^
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MN/3<]3H5P_]HD"(7Z[H2?SDX-N[,+1JF+]=%KZ%M5I7)3ZO)PAI87?V(NYA
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MT>\MS1/TWH>RJMHM<2=VW:=/OSULK$*,BI!$@7HQ?__AY_?8;==Z<*T6?'?
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MKMJ 0GU)*^)P84]M[TPXM_<164O(=YA-SVHX22#-"1ZGSJ6HYH06)LSW=7?
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M8BPV[V3=:C>?></C$^LD#AI* %FI>/'D8; !TFD:7DYY@7#J"Q^L<W)B#3*
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M_R%=&ZM%C *H"8%/,E52(37&H7V4TSCCJI\KH^9S:)E #H;IRC:VR5%L'7!
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M=1G2LG02\4Y>GB:(GWC/ PQJ5]/1JDF.2</7/#T'.?9:DWQ"1D?AF%K6]2;
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MV"DB[+R"GPSRUT<%!!CV.$X61.[2_]))UY_+>5QQLH/[1-W')/%0L]""=TU
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M7J']>$Q?N?,:TKDM43D[_9SMF.?E[66[%8HH&3:6:S8$$QNF'IW+? ('?Z:
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M12L?#4T 5,=+HABE6 3+_MDZ'5>#R[M2.VG[(K\RM_(8F!4E5)V'^)YQJ%F
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MDZ6>S]=)?IO<U5^(+^.!FH<) \R1_K&N+U :&$B?!=;0!80N7+.3L\NFD9K
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M#OV5^! ?;S$FU9.J(57LRGR'8J!/FSEY:[@^R.&.:Q!8J?HC3'_:AC<HGYC
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M[(V/?5[*S7:=<$ED-Q GPXW+D7JZHMY]?-M6]6G2$_>-0&S5FSYC+-SXZ@]
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M5/T1;#.Z*W.6+W/$']I+"%3M:K>CO"TBL!O *[V^]\IC/OAQHU/0_TBK5M%
MA:U9T++?_(N=-S4B2Z50M<&2BEKMI'U.G\;+M"SJ=M._FI9MKL6=S),[DPO1
M=Z;+D[9(UU?B!\.>%]S5[)5+L4J_<OJ5EQC9T MGUZ"G@S3R2V=WN[H5:!:L
M'A]^Q*AQ:":WS'A>C!X8: [8T@9<N)?N$G&V_DOW@D(C"C0R7D:9#"_O5_OZ
MWD&7V5P^L$*?O(M2?XJ CS)-3_>!GTP#8P-/25T6N(EHY(O!;;>5W"3DIX*N
MO9YK6Q22C'NM\, H@"H,G@#R'QB6L&-0/(0GSO=GBYK7"$/?RGQ8+O4&81@B
MVN"81I>R/:)]M&Q!RU(W.=I_F?I.:LUL<?N #CK#8V3.D/YT7H*@O\(\:7U>
MM;C7=PI4QN1Z@=A );=EK=!$0%K#)[1LMK+2=[Z0N6<6#V*:XW9Q0$S3&L(W
M_RQ Y_=)0/]K3]2 E%DH-*Z*M5IPFM\_91$R2(N'8Y$)<7Y&YQB4A>A-?MMI
M5GI]9H-SJ-BC^GKF:)P3J.8$JF>;0&5-D#B6QLZ#@C ]XY?#JAJW)Z**MFP+
M<%#:+H7MG\73@J'.X8/;+% ) ZPCL+3;66_,>F/6&_^:>B-18$[74G^J2$&Q
MU^,CZ/ 6K<I!Z$DO!@J-.![)<=+"+*9G,3V+Z5E,/W[!\(T;( @2Z3=.%.)T
M?$I_ S-\O4'M[5?HK=.)JNZH;+((](&$3:Z9.*:PKB'>;IP,9+C?D%F;,FZ2
M/W%NG6!/S/N$]<2@5[0C%MIFQ7$5:\J_07/F%K*02X7!@4[ET#GI^5G+SUI^
MUO+/5,NWQ3+9E16?Z^_X.N?/O32@48(&J0J3O+.2Y4K?DO7=.0G;DX4,YDTK
M<5-3H'/\K8"$.ZPZ\J$OU\O7W7S653^AK=[XRT4EDX^7R5+/Y^LDOTWNZB_$
ME_%QS2<J 7VP3\[*=%:FLS)]%B>)<COS)/U(=?Y4.YP;W9-4^T10XRXLI&U2
M)C.QN.M23/=^ZH6P10B;1+_4-J*M1=)TI<@QO;TR52?93L^(5:%NI6X>TJYF
M)&5!_W]\/>G@/9.BO"GAI*O&)N-"\:P(&B_2Z"$T-5[=PYF8#+-*F57*K%*>
MJ4K1_ID6C+64A4D5K4V909\-*Y*Z+E.5-%J5&"&:4KL%6XP@2!SHQT@F=$IF
MD 4@CMDU@EE>YDS%D5/W P1BGZXUN/$RGSFB!??W.9X%#V0-K USP6(Z<-!,
MV#(R#\3F.1E@F-QM6RXKVE[H$R%1",\4.#VHP>-!B3I>:$16.^KB>C*CRHM<
MG*YT< ?65S-U? UHZQDT+HY5'%;E4C5=!(I)*W,"Z%P_=F<>:+(^5A.8JX]\
M10=PXD>"#R(O;\'ZT69].G#S *4">DB&-2>$4<6O,(8)58ZJ\_ 4<\'5BWDU
M20'L15[6N*U&!GF(P 1);<>3_H?R,,')1[+/= 0$RY;95X_!PBA,,-\'YR;Z
M/ 75H#<><I?>8F+ZC:-UN&OW!A3K;\8T#O2)T-9HPXES48DWV)E^XPI=Y-<M
MA1CT >[X#C^004_7T--<]MKP:?VW#;1/?(7/&U#_NL]KL;-M^ UX.V']6TZJ
M#Q_G*)^&3UL+@F43N79L08Z1Z-HUG;6AU9Q>)/<3J7:?JI(9E?,5BOY!+U S
M+.8%S"OQOM#)XI,ZTYTZ(U?=03'<..[CI[.H_!DSO(C>C*/7"%DB1J9ZGU@F
M"CM*I^^HNTK:9BM/9QZ-+!/V_#[+6 3R8OJ-YOY_]MZUN8TC21?^*Q6>V DY
M@J1%ZD;99S]H9'M&,ZNQ0[+'\9YOC48!J%&C&],74MQ?_V96=0/H*A!93X.4
MT3XXL6=L2UVH6U;>\TE,::&_S@=TRQB@7$\'Z/&#JQ;71339'8K:B5HIT\*"
M!/P>T)XJ%J[3?U@;35HH- \(5$91"OGU7N*Z#- (]NN#X?>WX.]C/[\_C3/X
M/!K%R;\2R7<6S!3#@0<(J2N?P*%%R2J&-T#  KCT'LQ^K=G_.LY@],\)A6L.
MY+2'Z8[E-@WJXCP8U:XD>0/&2P]"P-N+<W!]4/#@>D_LX(00?R!"_"P!P=*K
M9D("D50+"= J0*9T.0VH ZK+D( 623I6DX& )[G#V@,1B$QEDQ;I+Z%MM5Y"
M\;&%X$4>!QNF14WT#$W!H*GAM(UM;0320Q?TJ=7 ]K*5 R$I#GG2QQ22_ 4L
M26AI#\42<IAW!U0OVLJ+>,#=AVB6 .*)+>A.0)2LK5PMS!YI>:_:8HRP<QGE
MB8Q<!4W"[1.Y:-4!BR/4\N54)-L0 X73A<5>_#6%(8"XD_</?AM3,OID4(BD
MQXWV>$J[UI\>,=@YI&V()T\AX*4! .JSANNVL9@RW-)OF?P;-!H.X,KK'- S
MQ31.IXB5^3_$U"BST)]--0"37A.9S,%A$U/4.EWD15;,H7/9G"NTNS29ZJ5)
M4;F@DY*4;)/3L=2-V"#M*H [E7)>^@Z1.2O,N<V6%DIU/133N<Y3-$<(7-NJ
MF63[S^_@&4IS(Y:Y/M]Y0\@8X#+[(J HL^FMF>[79OQ-6?1L)83?@E0I)9?O
MAJ6QC\;9?&\/YF]'7OHP/G:8:!_6&P8%1UTU9=6@1BTJ10?:+VQ^E"2B*L/(
MAWD*\V3V#B0K4. 4*VZN_K\8CCOW>=C$.3"Z(#L5"\6@Q_])WZDI,3&XSV1*
M5KVII!2 (,>'=-\4=<M8M9NM.=60H,&L$.ZT<=9"8H+B_DUY8_*D4N_R].),
MO6E*PSVRSM1?;*'0]R99%B!;^<72G.5?F"K@EO"70B_8-Z5+6M-<9PMMEF?J
M[7/5^UWUEH1$K;,,[U#Q<X_!BDOT$]AXC3]D1OT/V6]W-F?]K6O#>*9^O%!_
M*V:S99*?_T^B/A3I@@[RQV*^*,J\M_SVM'^D+^AA^PM2?[W<]?5?Z5YR9MAG
MZA]ED1>5^HLISMQ?QEW0/YHR43^U;*0=V6WL'W>D*R:[YHWZ[?>&HTR[AO^S
MN;%WQ*NU?]3-^$&O4%Z]_?,P94$S?= W11;1$,8;]IX[TW(]U@#"_V#;,ASX
M>CZN^.V01O2I\AY,^_=W^33Y')*<^UNFYO]KE5S)"W7YL$\*VZB*R@N%PX=^
MFCN:[['?/1,,B'3/^+%9R;C>.8^HK/FSQ#G[P[P:V846KB_*4>0O4%(F@VD$
M7N-?_R2I]BM 09(3%IMW2H^-AB3U@E$#'M&F2*;)"JV6)0O.<-0LE9P_08["
M$"UD25I'IX-,)O\RNON/JBX38DDZ3=0J2S$F_M<L^5Q\7))B]0^.P43\@,=I
MICJY2UAP5:EM5DB,\N_%(J](FOWY3\^NOUO_U\>NO*5=]L\STI_+]C]^2?)Y
ML9,;_\NPGMBQX^Y/_UG<<'9$I=[\U;'DOYI,)U/U<;T(RS)/(/URG.DC._BX
M#[246^3;TMM.<-6&%'[^\/Z7%^S?GI?)DF[AYP^_O'C^S-X0_>OUY>69JC2C
MP62;.G/;<WG#3-O?:&'ZB[)JZR+I\GB1JJ8-9!69>O."OMY2Z95[(4_>O/_K
MY>MG7Y,VZ-'VD[]^_,>S9U<O7[Q^07\;4JYZ\N[['YZ]?O7U?23\Y.___/OY
MR^<O+U]?OKK^>DW"3W[^\?SIR]?/7M/_^]J18TC/ZLDO__SKZZ?77U\H[G+%
MA_7^[?]<=F=EC^KR^>7K,Q>OOO]X["C_=,@"*9PA:_7M;YP'?$)FB]4KH\[L
MU<NO^\SDR9O_^_V+UZ\OO]YZ;T_>O_O'RY<OONZ].CK8\]>O+E]N[>WM]_]X
MW=O;U8NK5V>*GL0BF./YBU=\7=U+?_*O=S^_N+QJIVCU^"?_^,OYTU?/K[YV
MK7.V?[ZB[3![J+2Z],FDMZ#GW[SL+>G9R^<OMK=6FDF1&OJ%"<WM;)<GR423
MUM;]87?AJR3;^M2W19[\]?*79]?M^G<;,.K)CV__>?[\V:MV/_=0]X7C+^Y_
MNYU\?/_FP]LW5^K)7SZ\_YHH@_8SU>5F9Q[]!+>];<(&-N/&/I,,M(X5[["*
M: 9G,O<LLMU6*Y^1.VO7$\EZ:NF_. 4C*RINCTD?\O;T^?J4UL[MMBO'B=/'
M</KW:+]64(5"74[#0CWSA)W@F-^H2Y]#C>G6_H"#2@<M$LV*<HO$-C8\RJEB
M^K+Z_N:,J!(\PH-;LH(FMN4^E9GG5A>"7>ISAFW @AXMK#F6<!=;9K C/+K2
M+.;0;N(Q4:J=#8,W[GS(H" ^V,P21D(W<O*=;UGK3D) GG)MX\:8W906.5OQ
M+%3CYO1YI97SV)P.I9BG+/6\R1)2_S!.T67U>C@BV%NVOX$%/H96:6..19=9
MJ-[K<BX&%D)Z3=+_-,8UH$-#&2@G/2 [@E?:BTDR1DS#K;D?MU)+SKSU9Y#J
M,/JV),-10)Y'(6=UUP9DONGO8:)1YQZQ!8;M+!.AE6107$@&'#;3WF:T_G%5
MI !F4AE0?T5R$#\L'()J&-&ZH<X73#;OA?HH;VCGV\'[KI/PR^Y(Y9;!]QY
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MSBXOGONB9$7':6*B_+[2)W"0RXMGH)[[+'BG$C9L,$;2<I]A6F[_\Y@@B'_
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MMB.U"0W!4.,R<7P434DR^TYUHF2+,RDHR$&/.I(%*3$6 <0F6)V @Q:<02P
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M._^.=(,%3\1_QZ*9_L;I1#V&VZ/&;1;Q%^-(_6U1KM@CK=4'YF#N/*<Z-?:
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M[J!+8+]G"WT"22NTM0(CJ:!88:"&:&%:(+J)4D7NUPP>.%S^$*10K.JNF'J
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M;Y(/P-0FT1L=^@D8U;]$8T:KTI!Y:&P7]\=DSSJ1</7\FP('X- 9R*^W7:F
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M)51L$K38)?FDS5R:HB^=DS*G/Q?WCNEZ/HP.=E13/6W2VLBP^YB=>.WK)3+
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M@M00UMK1%NUN%.A3S:=F*J6V[;BH6J>+O,B*N1% 1(,\R[5MA6VN8#\$JUJ
MF/63!$ Y^Z6X @G7K)F"!0W6):,QOSV1%K=_TB6(W3RH_)&,)#9A6"YBS,,=
M!RO.U8I>$5M&9]$:F4<U25FWIA_(.O_-;A9DU8RZ33HZ6I_8M:N+2)'ILZ.I
MN:'!)FK.%X??)LF!B<F'E;.:G)=J"0%C%?F=->&A/($M]K!_G)?**;[T9][-
MD4B5HK%0J\QP)WN3>\,$"0X<(%L@+>V\U.R7$T64WW9&F,=OV2*'T;PV)U'!
M>+_L$+J_.(/&W[=TP/TGRM$@[,:UF \$7H07<5VW&F:K;.J8Q[Y?N/+?\MYD
M.2_73&YDZ$EXJ7^CESH6VUW5NW>2(J680A4V'%PD6:;EBE,4F]S+DY5[H0>M
M-44 <)_/Q71?.70C43 S_E9&  3QA3$=6O0;#,\ANCPNS!\''3R#57'<,U<G
M!C,8\F:I2PY9KJ\,1&4:?&>F^@1:;FN-]]M]Z4TOAV8W66?.R]"!1"ID-X^#
M3V8O+GU$?^6R&B9%2;;,?W_U]"N5ZBQKU[_^[Q5'!-K_;G_'C3A/BRQ+5I7^
MMON7[]2MF=:+;R^?TJ+<#*7]WRG'+VGN__Z*=K#^&?>Q=5414ZBU/3KV-MV6
MR>JK 9#$#^; &I@N]G^^J:<1^[U^J/W^OPW!;*/K+[]K7]>>\Q\-)9'"5L@-
M@7SV7*@F_T1$E*O,N*"6T=6?__3B]88FZ7]*_A]^[_1/8@F'\9_M>-"KBQ?]
M>-"YI? MGK0KO>S$E4Y<Z<251D%)K;DBVE)(&154!3&DAS6*2?+:-]'8V!"W
M'$!20I/(%8;W&75,9)>OOI/Z:T,A-C#@XJTMJ:WG'CPP*5,[,$\%I[L?),3N
MW/5G<7$TL<AF=UAF+,&<8U(/3LK!23DX*0<C50[:0@:Y/Z<?HMPJS("R>/0$
MS(8JU=1D36VP4E=350V,V$O;<IG96+H(1V=P.#FR^U:)+?S W*A;62*0%!AY
M Z[G?Z0&7 \_Y<D%<)+R)RE_DO*[*6E!DZ(UL@NI1>Z.&G,<NGXCS?!\E:@8
M<8C*7]5'93Z=6.N)M9Y8ZVA9ZVW)5#$M;L'V2ES/A6.AD34T+XJI!%JY:QQ7
MHIA22BG9U9& L[Q.'//$,4\<\\0Q'\;E9),Z(9S)9,FUFP-P,+O2MA,#.S&P
M$P,[,; '":C/9HPA(_F)^SC=8D0V@(.L!$W-SY4'?YY+1>2: L\I(*7B][7.
M6$Q=+X._NJMJO10T8PRE/-@_+:TJ\EP+>K2W(2%!(.@4)5"(E[D?%;CVYH@M
MXNQOQ(*M]%.EL::2,3<4^FS6AWY,TO@DBT^R^"2+1RJ+8[T:SWWO"U9&V+:G
MY I51.8SFX6X^2<M20P?.\ V<2PQ60E6!J9-11</3_+0LG)'Y$ 4EL^&R4HO
ML4R"D#ZL)'0+LBRN[&N79%V#9SG)BO@&67,Z2>*3)#Y)XI,D/LBM-PRCNM01
MW2-](:GT<I45=QK.[^+FYX,2A#>RXV((M[R.X9;WE@5>G]#5'Q5=G8$!9T5F
M!,$=4-,69@8R<@"*> N:BU:6T:E_TE+;EB"IG_Y:2\ZG4 5Q0)G05%R%BV:E
M8#.@1UTR$BM6P&? &*Z% @Y Z!ZPAOB/ P?_"]@L+:+=2QB&9S?8%WK(4YWR
M/6-C'()R%S6#UL=(X0->\X"V=IP ,2^3*8@AZ:"],698Y-MXOI#7,C)3VP<C
ML<!?:/L8!YA>+,EPC@ G\+@6O0F,LARCAUAVFA8-"-TY2$ZZ9+VJCE,/@V-$
MZ6.>%1,0MFZ-(-'*2ZDN#Y-)?B&?$S%8[9_4\=1KR]FAQT+[$"H^AY4]^*U5
M8QZ3OYW]UD%8Q2EA[=Q'U'L!7/Q%[>\L/:"O=+ N\=+]EO0__>O=]^>7KZ&B
M2?K_4[TT*>/_PUZC!U7$_#3=O#:YV+L-\KL-!"3R1L4@$D$7&30IC,2SV24
M4.V@*B3<WC"1, %S#ZV8*>7RJ+[GO"BSZ:V9:@%5R9OKAR1=M/U"*FVAXQ]8
MH?.H-&FP#G%-I:S+(RU*[/FT:9BH_3? G$'EK>VS(.81>#"<A^OIR'3#S/M2
M$7/ 2'W+C) +^_Q6VA+69X!'#SG-1+""P9498=H*AA^:U8NBF0MQL@#T%]L,
M_?5R/V+?COI,3+[14<WE=N,PF-L.V#+P.9?PZ;;H&8S:&-'%]C![^C"MHE43
M"@FTU>/R16[J0@94#?Q]Q;:O, ;$(\0-O[&=I- [QZPT[H\BX@J"C75_?T^+
MZ\]'"T599>MUV>MR.] _/W;O?)0S'O !#G7X?6#^ICYHV^0(57:X05R6D7;>
M8)@$/Y><!4?6\K&Z9(\V=O).R/$(H?J3<KM-4S&!N[VZ)I$FAP=6#6?M&E1U
M3&JTOPVQWUI'0)M[5A^( ^$:H!T"/X0Y>&T/-]204%5*3VN 1UA]L7,WF#K%
M[18WE 3Z#B9ED4RY"9L!K3_;M12]L35>+4Q7W$Y&UZPB85G!KN55B\,%O^J-
MKYQ8$72N'7@7Q@]<4S[0)#3,<TDOA@2,:T%5G:W[I@[+E!A^0(<S"Y#5IBGI
M:+,FP]"^!\3%#T 5W]&3^U&!G,<9@OT)]!NT=X_IY]SG '1=0HO*V'F&B?T2
M0YT'6]8/Y@&MD ,]/SQLQ8V(DA*;< MR$'1.P4V<)CKCONN8V"!MTBS9(A?:
M2X# DICGK/]Y5%.%( X3*:S]Z U)E8;^!IO+:=WH7#*BJ,?+G8XN3(-KV_X1
M1&I]P7GO__PZT&61S?_*G>JAX_KH6K9ONL^NHR8V@\-VV[4JP(WKR6UUM*+%
M@>.(QY)]G*7:'\2]"NH@]M-V\'VK1*@M*X(=W>M6%NKG#[^\>/[,_O/Z\M+^
M\_+YY6N[,?KWJQ=7KVP78E.JI:X7W'Z8%M]4-+1T5G\/YW3K0-AQE+OMVE[@
MT6__4,\NZCGO& #D!=\?3MX1NYS"H$G@MF/>XN4]3Q%K=88Z\[,*"N24H'98
MY-R]$.ST5^FT!,.OPZ1Y4C',%IQEQ4I 7$LY5))[RY.Z'_0_)W,:N_NEMLXC
M\+VCK@[0SX$=$4CN4^S9HB<:UPO3N^25TR?E<)?OX@+AM0]Q F'L%W9D3@O%
MOB#B$_]I:)F@)\@J;EB$QFEMT)!.!\/8<1Q3.NC)Z)QH 80<MK&C: =_L"7K
MX4=;;3V.G^Z>1JJ/Z*:[\L@"DH<34#S+[/D0M423!@JG+.5:#LT''LF[]0'+
MV--!9AGII(GD<@B9"NH 6R0WI#@/[<BW2*1&ECN(;EB78=+BA_D[DG0!>P5L
M_+M+-][KX[L']OJXXK'/+EX]^WVK,-:*JO)\2:HS08D(M6)J5 Y.OL[N%.<@
M3-M CDJX3MVED]A*9S9AG96L6M-W;?X5:LM=O65I.K/OEDU?I[)LS+]NT-KW
MHC;MJ7<MP!7TTU\ZK_HN0]I:VOQ)QVG)'I]69RXX51:I+06TMB_=0#-+VO;0
MMA7RYGMKOY)UJRQB?N]OW"&4R8I[LZO?VN-CXV;_R=&4=+6Y^C?-5TU-&N[(
MM\%;VYOM\. U/"XE_D'H?QV/W+X,>ZQ6$[Y)LHXDE*E<V][*,&?FGCWG3*[-
MDN^FC7*M,OW9WKA-:B$EDN,8;43<)N[PKW%Z?:W5=KB;,V])E/$\_/:X,X*N
M3&F'[B(6=I(H+AHJ7,"=4_-X%/^271H]4CJ^G-U&[D_I]WMD95=I29*>(:]T
MQ35^]"IO%]HZ9>J=1U.I-M*_80:=IU(Q=*GB[@ST1=6.M73- M?J3VF3):6_
MCG<U'ZU="KW6RMCC:OF!_<E98C);)V4#=+.[]J?MQEN;6;5V<*DKG93T&/EP
MVV@E)R317]:KAJ^#WY@R=LJZ*!0SIDVZ0K?A+5-#O:<!S##.E MF6,;AN!PQ
MDZ6=FC<X:[B;LZ*#8E!"E<Q+K5VZ*/V\D^-.#:!%$*70%_9,[LZZ/^9+L(R"
M?[ID$G<\+*_+(FN9DZ8AB>/*1$[L'K8[[8B*:9>6L^/:SI@.;-5H2W";ZZ6_
M6W/$M8/NKMO(5,W*8ND"VZI5@B\4O9O2'N59FX_=W;9=S0ZJV7H/ZQ<PM5^W
M!L/4T6Y+M%8.5/9G+)X5KW:BB<:[FK?UC6]<<B?V![._'QM.NBN7W46NZ;^5
MFGS($U-L486]7]8NDU0W-EINV5Z2LT=WKG.; GG'KXN!Z>G?FCPE\XPH[D+]
ML]B^UU5!U'%'+W:>E/91V3LFGC:M;9Y_FB5FR7PA*VX==8@K^?_9>]LFMY$C
M7?3[C;C_H6)\KL,;T=U6MZ26-'/V1.B./>N).-Z98XWO? ;!8K-&(, !B*;:
MO_Y6%@"2R(*0]0#=+4#FQJ[7DE"LMZQ\SR<;(EQ;]F/?7GY7Z1RD8G0K)A5O
MW+CGVR5[':$K:H:SM(LL*I*VPQ</'3_V<TWV=EV_D).1RC;43Y1/HJO71R,^
M_/S+3]6;;2:LCSQS'SIV>9=3\YV#?E,X?NL\$JX+RF$596KHAA,G+VKV;9GB
M@V6I]BDUA4ENWJ4F7F72B+$(QV:*ZHW99T6\E$[,GC0YZ>E,NXZYSLEP60M9
M2M>=WF?)O2X:$:@2>ZO56*<^V?_^>VE?;<6)*F;H6)W=;:ZI9XUZL'R[L&]<
M5_=4%\4[K8V4JZ3*P78<^7WAA!]UYJYVUW0$NJB2DBX<R@85R5TTW*6V&%0[
M&46Y5->&D[2/A,[<)^%?UF7A&'8M-.VM66[ED"?L&G+7EL@*?"MMJEU:;=5)
MAXO#71Z%Y 6G>/H9ITD>^#+G+C-O]//Z:VKT<T:Z^5^UJEC;YE-9E9K8>@C^
M;%HKFMH).7:XG-BBIG9(M5"8V*JF=DJN?<:TEC2U(UKHB2UH:@>T(B_>Q-8T
MM3.R&C_IV!-;U=1.R;F(TX,-DIQ?7O]ZK!WK[*,SBQ+6LUM;F\GJ V>M21)V
M9]U;HB3*A)C6FJ9V1K7;>V*KFMHI$?,^.P3"' +J;/*>3=ZSR?M<Z]&N*M#<
M4R[GM%8VM9/:Y@Y9:V*KFMHIN;*5,U\2W"AYMIG8DJ9V1*=EWQ3PK;-2T[N)
MK7-JY]8J7IW6TJ9V5-'9E2F*O H]85JKFMHI'9-UKR:VLJF=U*]K<W;T2C;+
M^8#ZUT/941-;TM2.R*723VQ-4SNCNLQR6HN:VB&=)BI/;&E3.ZHF47QBRYK:
M,365_--:U=1.J<Z[K2M))K:XJ1W6V4K!K)2+B:UL:B=UUL E4FH*W":VKJF=
MT]E2D05=>J8B\8C.1'1.DA^]GG]>?;A29Z/W;,D]UGHJP 57CSZQE4WMI,S9
MW!624#YM'33UQ)8UM6/:902S8?*S/M"_GC2;V(*F=D ZRA-S3D85\[^C=&)+
MFMH1O2_ORN(L_OO7\^[L<.M?S\V+EV_/9S3("R"A DYE^9\WT04TQ*EL0#"?
M9[*+/M-V)ENH\/T^:W;.9!?=)N%,%M]GKLUD"[M.$V$NW/3S5N!,CC^UENSG
M;9"9;.)S]L%<J.CO! <YYPU<O[I05G=\-[%E_?$/K]]]5_5P275=SJA.](<C
MIF33)\9A>M8@JG$-!UR]<75\*?15JO[;CMTL[)_>5GN?7,KQKX<N 0\Z3$)/
ME+HJ%+YPO76BV^BI%)W+%C('TCOK':Q.X;WGO)..8H='PGFMUEPU;?@:$&3%
M'I)O6A=< R@+0_!6,6Q(*Z.W=^#;UK@*U1.:2FJAT=Y_ W:,[>8N,FF!+2N@
MP0F[F1KC KJ9/(IW)D8O5.RXUU[9$?,7&>7@@RO<8(>I&DX2;3V\3),A+3'*
M=&>$1C9\%-8-*=&11!*\Q4<ZJ/>V4PZP W"5O\@ [X:@#D_OBQJ$G_!TJXZ"
MN?Z]M(JEPU_O_ZEV_YR5U.VHJZEE4/N3]CQ@+[6-WF'=NIO<1:P]E/@P6=,O
MDTLD.*X](U7X( N*H%_'NR">4"BT;:D1?7N6 XHZ- >U1M@EDF3QFO <0=^A
M)_>W;*^I)P)VX+G!GA=(+I6I#_S^]2VV@9L7UR^Q$6 S:_ !AO2B;8^HH.K1
M7FE8CZ80ML#)L.H "TVS)Y#_P40_@%-<J9_+1:@.X77I7)JB\HA@[;:KM@68
M,(V-ZY-B8FB-5H19MD,]3,"MV;/!-)<(ZX>WT&LC-:@>2;)10-]!WKOS>)^0
M:/Y,@Q1,GDR2JX"G@.FN#E8.&='JXP&=KJB;\>-]V%);#*P3L>NX1.RD6$MG
MS:;#+8OKMVICK?<U:,50/P9,'70-B9 AKO]*_X#;-F_+-L+EW+(>N%$A428;
M(3H VBN2S#;VZY9.!$6+#?A@4JF;ZFV7M,)6%<R)WD",Z!;C0[<P'[J%^= M
MQH=>MP]JDTFJS2W*M]H#XLR^;UE)X/<GL2P^2;JJFJE%B1)-7NZ-POQ]5N?'
MO%V9T*^9.8>,Q!#X\F6V]A9G:WP2B:S8_<ELK;WK7%,?-VA)A6!+W<)2AK$"
M%T.2CJFMP:.L/, Y"_EF^015ER?0ERD)@%%[WFOQ98_RK0;8:GS#52-+3,J#
M-K-L"[8G^%.(9V&4)^I97 O_ 7J9L8;2S^?NJMO]/N5]9%+8R>\;[6*2P.Y/
M8X# L-/6>Y@_0RO7THU:7%)J07I))F:2%=15M.I;=Y3:KI?=L<.HZ]]71W#4
M?IW5#8=CU[>V:B)Z%/A9?M) %7):UZ@FR+U*TOP:N]9K1FA5MU=H$Z#E>=)$
M%MNX:S@+64,4!<%8 &;1H8]&;[9)]J!E!P<3HUF21(LLCW99+@UMW\WW__BI
MN%#?_YW^<YT56[.+$G!RBHM3D!ED=3MJIR'?<7NY50M&S/WC.D8GU-@<&Q>\
MKQ?\,JPY$<4!5\%IT349!4=%RWM3V*E 0;94N'^GU9#8):-!=+(>$L! 1:[$
M_'P_70$I5D$Q>Q9)C+ M4&].D"O!SM>#'$/]J+6 A,[,A9HKY@QZH:VA#&ZL
MP]&+,3/H1!P>(AS:R?4"HXC?=+:ECLT$6 W*=A44*??"-876'Q]=U?45Q*;C
M.[*ZTP;:$#M'.8.8S>,= <P:G,Y8@6H^\6$/S<4),RPX^9SF)$*B\V  @"[M
M8\(2; &@[)G"" NKZ8N:/"<H>RP+V=GA*Y JVZ=#LHBJKMKH&G=KD;L/,?0>
M_Z*OIIL?^D730_]N&6,FZUGMDUWH."HQJ0Z&.)N&\=!]8RS[\7.1O+P\F%-8
M8R!.RL+<8UE5SH5@P-=;>?&L+; V6\SRB+.M)$S97*X5*:A7V.=[Z,OIE!+(
M4G4RI:XY@#BH'1:2 OWE9"QL(&@5KZ,DT>D=)ID'9+;$]M@''#A^>-EJ9>(A
MB3KJF9(GK,3/LV@IZ*IL5S\0S7^*-ML$?%\#%!-+%D6Y^$V#HM@RFD@Y;?>2
M-%@L!7*;Z\LAG-TN=&/'R=89HQ$5$';@KS*'SP/-WOGP\R\_D8_72E$QJNCS
M["RY!_5_2_C;K-A=WEF% /*YY?K>Z#VJW<5Z6>9@SE6VM2MT+GELW%+GYC["
MQ]F=917KO5"YIB=GTH"?N;ZZX4>[Z_>*77M/P!)8/S/QALC7X WI)_IKCS/:
M?UWI7 O/TMN^NVU-PE(\-S8ALCSA?7F;ESD\GT'F\'R$=,#<49\4>D^N'.&8
MF"NZ%MOVWQ0<3X.#B2$&X*BP,<@GGV4'F,E0=17$2E\P SY:6EL,LZR6VOYK
MP[\0%=G*!6ITZ_RM1PD+\=$C T!U/JO0FSO<X6H5S 23?KD51Y*V,=(_[@PB
M4'V]4"ZUTAE&EM Q:5D.TIFKYP$&5)(DPS2 9_&$NHCYL3,CF!!?GCJ&GI#A
MU:ZN)\V[KAI28@S#Y%;K!ZN7*($!6E@)4AI-D$DA'RXA'@*B_HQPGG03&14V
M4O@8-$R))"T''Q1\V41IN:+Z"+0N!"-FX+WY6B+\# 90@TE7A&8BRB*N7 XS
M92MFBIGW@;[6\;:]"Q19TG"<-38D*_K'OP+4<^]^0\T'/LV)]= _["5/^(F3
M*)>,8#9(BJ'>,*K 2-S9]!#]2(SHAFVYTO&$5;UDYVNR7.0G[3&20LPU2'(A
MRVHGQG@06Y%_?71T')V>H(LJS*3U!CYY;MC110*M"XP@1E1NH,T=-FJP!Q?2
M>^54;BZS DE@P+/Q7(V!;\%7&"H\A)5VE9V/F[O9>4NUEB&(KO:S^H 2]^'D
ML0V)@LY++Y5UK5'/(<E :!%+"?I3%</#XUVU)CC@-3DP%4C#6FC4:D^C/,_V
M>GEQ8K="@12[P[4&S?<R/00!Q:"(IU;OUUFB*T/;Z4*@XK4V\5KA'H?$; RD
MN8Y(O-IEVP$>+$7X+\K2*#D6\Y8I+1(%$^:%W:S5QI[2\JCRXF.I_)LK6(,L
M?-3\'F+;@-L/(:=1CM9EF8<XXL9(GB=W_1ZS T&Q'>X,XMYY@52\&$!#*KV"
MUXM,"(*W.V" Q3*BI+_TT-N)(*6][V4Q[4>DPC==E(N"TO5-/X/P@BM"H;"W
M"^F^V98=O!6RH,(JW80)(@1IO7"75&#K;<0Q?S&>U+8+:\B20N)TKZ SX[-L
MHC2Z<YGF@J1N.Q+TO01PTIY&RNU]"3(O]CTM1T8K88.R<B=G [ Q4H(9^WP5
MW6>YG(C:/EO)3]$^V5+RB+4_?R^5:V#.B9>CKHWLWKM,U']>,BXB:H?M 57=
MG]I8"9<+',O'/0D)#O+(\VHEIO@PH5@9(0M2#W4!.L!7)HW26-X8.\1T2#UF
M)5; >*_*MCH?D#'B4('RK"JP])*)$WM4E^LJ*]?E!D,YP"^^SM3B']'0=Q 1
M,"@^(_+^L<5/&P+\0'T ,NJ%1\Q.88#L:1$89.363RIK,3^=+G9@&(:>EV6_
M94(UJ: /"$Y2L_>3VD<PJN0<<PX/R]Z!6%MC 8GG/M)M/>K4,&<@<2)D'EWU
M(T%V,Z!H,,M5L<YR,8 ^%JW+Y>4\WVF#@+>M<+"4YLQ\1N_!\N,!6@&<3T-!
M3&L[!\ ,^@$CJU%(GCO,@NZL#;$3W9LE1JMEC3Q1E!1M(1-.R4ERUU?O !/@
M^NHMTSC)_=V_3CY#Y95$1D@ UOQ[P,5Y,\3'Q^<+<(O:(5C2+COG(+>H-PEX
MF?9I2 ZK]L:#<AR\:21X+7]=O:;@-4,("RX&&ND,'@/@\Z2!LJ?%(UV5 <E'
M3.QBT:WL,MNG8-D#G+$6D+G8B>X@Y0.W9_D1PMN1T,B\ZA7H&LKTF>J2[9=-
M5%0K2_$Z+5R"TB'_^"0-2]6WG1=__,/;F^LWWSG9;,7Z[M JHG[+1Z"D%E+O
M1?71X6<H?:JIP:9)#_-;@SVOY2']?16(;\&64*B3I)FI,O!5E6UI'%A+U5JK
M_9>"&H2ZCGCA7_Y18Y&@>FF@3? <>:NGE=G -,_A4P#?',B*4PWR,9 9Q]G!
MPX69J*O#:QS"FR7:'U=W\?3F,PJTD"\Q:PY,/*Z3'E![\:E/*:C1T6,5!,#^
MV9KMA]+_:(NL7XNY\1TT9+_U'L4-EB;*IQ#"+_QS(?SB&4+]K];[7&!<?#5!
M\1<^2!2B? #%7Z!=]'H?O*]#XCHW'/!0#NOP7<A1'8^2^I^#?]?]+-?[OE&"
M!.@*OO<FI_7BB\2;T*+A<[QIRO$FL=,A%S,A.!_CM%S<,IZN#T&$]H:S?L8F
MYPY08/"LU[KU+J;Q@'GJ=>P&]5G7=IH*CTJQTQZ9(&O'53FRE3BRK!\L*MSF
M&NXJ=9K!"B6N=IO&DL#J"+-567SJ^W4DY[=[4!R8%6!DU-5QN9\XNTFB?5%1
MC/W*7N!ND*DYK,$7-,0M= "&40A $!L2@A#D9Q,.P-0-;#[BF39J:38F-86$
MD#^*ENZCI'Q*P+9G\ * "155103D!L".- !9H#.C^?GP50>CZ://LN([JZ8\
M304^A;>@SM,.'*&]IH,$N1]B@^8(03EI[T+R/:'=G]N_7D12JE/[>ZO0B[3Y
M%GJ56,NK-]AF>9<><;=O.,6EJ<3E>7,BJ,47N@-Z2,CO@^V>P-6$2-LW7=+V
M2OV H5R% .MYR?5_+2F](Y+PJE!EQ1MB+P79"T7#<B/F)-Q #_LS^PBH3./X
M7E)TGCO-]&Z=+3'\+6R&H.X1(W<AGV[;$5EN1+)JFZ[9$BN[(<QSJ_WVS_*%
MU%]+[VJ9Z;-G*\BS]5<TR5FJ</%\"8]NC WV4?G.%\RN*IKL %@=??H4/GP[
MA-%&*F]OLMMX!]3>)%C'VC')B!1FWEB9:C]:E7"R96VD8/G70QQ-P6D=7G7S
MT&8YX".$4=.DI,G/'0'F(W=W7#H?D3N'O<$[! RE+= %@[W@8(^A%]ZSW#RZ
MTY!=/0B7GPLY)V*BQ)K+WU:ML$Z%W&>D:Y<X_3)2[_5MO9]UWFQH:X_QDCH>
M?;QT^?3?1LD^>BB^47\>+MRQ30[6)[[@0;9(Z NN@S3DFE 1HI[(ZF-ZCI;^
MYKP%0HFQROU\=^#TH5K_#-D%8^%3V<9IO['Y7D9L5T%M!([ !<F#JO!V0VB,
MV]M3V59=$S;?#83QV:FN/OAU3W4#IICUXEVZPWPW0"DZ(:N_GJ9DH"Y.\SW\
M*EXYW_5;&39GXEF$G?U$5Y_K0TY)( =Z.<E]5)7>08]@FA?1M&BZFO%+_CY+
M"_U[J4DGO9CQ/O:S?M+++&SUDUP\>>P_IME^SA>P7VOGBY[O R O[8PO(%O-
M>O5E&.E,=/D->LI\J?\$S&7&"H4++\[W$N:M5M<Q4U?I/V,:RF;-B7*](<R$
M^;Z!FHIF[1I:!&H2DUR\0]R?\Q,(=LQ-<O4G70B:!*,0\WBR$:B?&'!)4!1J
MFELYEM+,^#ZJ!* 9;Z#)1YIO.),R^F9\ 37"T9RW0&T]31Z7F_O0^/XT*>D4
M;V[&U[%X4#4$,*4 SG@C#1KCC+>0Y2I*[$JIS?-]V".?IA)^ /X*%A:3O9 #
M3MJ,Z<HE5-D/+D_:I\Z7\5;%=F?%?!I;.2OF4]C 63'_TL\@*3)5:/UQUIO8
M4EE&%.+&G^P>7+-TAZ$ZW[?@0&OG? G9/OTJ%"?$II@H*67M&JT97\9I:=:,
M%297.G>"[#5O%_/[H[V:/%RHL%R"R>X&U<FG:7T'15$G>P?AQL1$.6ZP+3'-
M]4.FQ#1)*-26F.8%!%L1TUS^+B0==++<![$=IKF#.YWJW,1SO@2"RG8H(C/>
M@]6ZJ;7)S0O[09)D^\LL=7^^_F[&;_NKN)BJ!T;EZYAUG31D84]S"T'96I,E
MI:)<;,QN%QQ.F>8NHL6"^JM&87E_D]U&JD.*."9+2\N\G'7XO=6<:\YT-&_K
M^?U__^5]<:'FO8FOX"FWFM7-6$"7Z5+GZD.%QS;G9_WZQ>L_+?[C3S?_,6?'
M7DB=V62?Q;R1H7[XR_?O+U2N7;.>RML]8TJ:MY-F[I3T7BW+?-Y)6*XGS,QI
M:,Y.XGF[N!U&W9RU"0>^.]_S1_+6I[F#JE7XC/G/O#U?9:&B(/B\%U?3W(!)
M7:UEF XWS2V4Z4F]8M@^IKF10&?%JVFNGMH'S7CY=4F 7H:E(4V4A'X,\TU,
M] ZL+AJ8FC?-]5?U?,6.\,0"G;\3I:,@)"Y+1Y-<?*A-,-%7D.I C6Z:IQ_H
M4IGFXI=ZI8.@&R9+/:%*Q"07'Q6%SL/4B(F>?F#>[S2/OVDF-/.PV2+;K<.D
M[T0W8-(X*9?S=HS.VZY?F63FV2S4^;(, ]B>*@E%2:+#:[2G>0U ^XYI7D)C
M%U-#R3#3>)J1OD#+>*+\* P8=K++SU8JW+:?Z!YV#]O :I");L!>PC;/8FM=
MVF6&YJ9-<B<1-40/M!.F>ADY@!8QT5NXTVD\Y^BKJT#]K<Q-L32SS^N:.6[$
MR@2Z72:Z_J\$!:T.!\YY"Y:SMB*"<Q9T=B_!&193O8ZO".(IU^K8)5C>R&31
MB0/!N2=*45'(XB>Y<AAZ;JH T>'0<Y.EHE_699 --,T+H [OLUV\"6L3,U'"
M"6M2-<FEKZ,@R*!I+CZ\)\!$"2>P)\ DUXYEV$U5;#7QS3E34:@?=;(;"+>2
M)[N%8F>21,V[]" T77.B5T"@%68YY_*GNLG0S-V.T5UDTF+. 4[$HI_L-7P-
M(*,5R'RLBV+6 ,Y%N5J9V 1'_:=Y&;M,1?':Z$",T:F25)FK15F8U!+5K/>Q
M^*VJMBZNU/NYIP+,>?7SKKBV'^B[;-YYA7%6)G,&*POTP4SV!81XWR>[^(VU
M/>W?A0'[3S./+5H2^."<N9!>K710G^K)*D=9JD[#FC,'8M]FA2$S=-8I\XV6
M-^M-K$P:I;'E3Y:TTJ5!,.0FN9]<%V4RZQ3T;*6RK<XA.+]);H3:4UGKVJ$V
M'3LM_'G[O_[O_^M_;IOU;:+\SJ27BVRWRS;?TC+JO]EE6_='-Z%)E]:X_?;%
M_W.ZYDI8_O$/U[<OOAOULR^OWM0__(50B<J<\C(W5E6^@-CYJMR5N49HH_&$
M T/(YPQ\OM"J*)WM"/%#,OX)XDOG]X[RD2GMB\GI,H1ML1D7#\K>";5HH8/'
M%NOZ#" C:F3_*V1;/]BEZ4_19IN(9,&.$MP,MGE+U^1H>LHIB ZB/%XCNZX8
M/QF:P""3JI WY%TF? (#Z),2\4Y[>2+;PF9:$=(D1L_VX-!+'7#0=A9Z.&HA
M<""4W-JG]<^K#U?J+K,V3DH51Q@+!N<Z3@/-4GD@D#,@FU_%.M]%!N*E PB5
M6IRF#VK0 PR21VP^TBL.+^/A0AU+5X&)(VA*RJ+3G^PT!1E>R,TE)M9I@8V)
MRMTZR\V_Y"T]#RUR05T6&G[])J6>XZ)@[^"!F7*T[$I7,$*IUZF"YKZ^>M>>
M6OCZ+=M?/Q'S7U_H=92LD!%6BT0^)XJ-L\U&YV3<]8UL^YRV96Z-<T%3X9/]
M".U$(!W^.;%GX2H&D'7'HK +7^K8+/O%LC>F7S/C&]&?Z/+Z>4?'-BS15TP<
M4AH-Q 0D!>.:T2*H+.G?2Y-+&@EG?IC6J].[Z YBER4HI4 ABAEEL;4D\RC>
M]3.%#G77#DSK%!!D>:YN;4EQ'%5D5^J7$S*#?D<T)ODI)@5VKUMK1YN=+)X>
M12T#:6YIBCC)0&6 X%V02>P%KPRY-02VSX,-AM(M-P&V]\V8(PBPG+F"6+7$
M0XZ,LEZA18&L(X O>VO:D#U[*>KBN-78J9U9O2FBSE?/X]48LL R5[5J#)'#
M4>\77"ELI99AJ6'Z[I-SK$!RPJ2%QW:#J&^T)=BK!W;(/+74.V+8*?C"784B
ML)<(EWB@#\4*55T440[Z2N.HE&Z>2V*M5I%)P&=S3*V"WC>I&":6! D[ZV/W
M%=")B]J4QP=]6;FP3MT"CWX/.$6-TID#Z6F4)".T(]=]#)IDK:-D!_EF)2V5
M+:N(5GH'/23"K\3L'?"D-EI##*<V838!P9;7_!FL]%+G4:)R?5<F31@0^@WL
MN,&CN)-=8(R)Z)7.=1IC5 :NRCEQ3;HLBUTNZ0;M]?V(R85HN:Q3%Y ' "KQ
MP[RP11FOE<<4H5,_N,H*!<?]L#<>$B/TA-@0A_;0EVBGVT1IN;*<'@VR-IGQ
MR('HS2);/H@N7^\8[94?+PUT!J "]Y^IV8&!H@\[*U[J%&+H.(8864\;)QKH
M),@PI3BBC-E-=9_26=]PLMOF1N] )70 KQD2CLHWF.>?);LA)W[(+E/'%"UD
M[D-.%.B1"Q(,?JC;Y2LAPJ2=( 2,Y!DYG3DS389,8D_N<EUEN5P3>+"?4_/Y
MW)P*;'A@;D[]QT2OZMR<KGGJ_)M%EBQ/LV_,+K+6!Y+- R3J?+^.TCO[6U8T
M4%QI0!Y $NU5Q7A5Q4Q5Q2 Q%F&OL4)R0T:=HHZ!OF;[VM726#/=%(+>[W-8
M=1\E)29F"#6PB@O36=WIE-1A[%G1Z6A0')C--C*Y*($]S4Y%"Y,8S&"Q%%07
M8\)<L=$N^MZO_%R_=,[;>U"[Q9R,F&"/(\SVIV (=FWR8V4:),G+*-9E@/?E
MACU62\6IT:C)"!HH5N\D_\13>M36.KJWA(E%6/16._K&KB>U?&:GD\0^Q](:
MWJ1(64-#\B%U.<-C:['GTJ*YNE+Q.LRA_=."#"'47"#)4>%J@&QN2)[.  ,#
MH7O/<JUL?W")]UER#XI?POH_2<U#%XI&IQ)]AVJBE#+Z299(X]8%L^1<K\1$
M6[Z38I> SW!GY1AHS*1%N1GRDDQ*FTIWXGMOC2S3VHL!>:D:U=,^*FT"Q,DH
M2S=$L6V/(.A_C.?FCN?FV]P:K &N=$]#A%G+(&6]4,_I)GEB(]RD<:Y!70?=
M^X&ZAT3M%3UXB*T499YG98IF?Z+OP=K,.BX'D.FCD^AG8VU/G"*!%@E4X%UH
ML-UR!=<."XR)6G9@BJ($W]P@O>L?.K:# DS_:Z:8.^G7ZP/C(Z@329&(S-$.
MX\^\_W/H*7B LC)S\X;(S,T;(M GWX1H8'D36.Z9[G+)3N)7$I1J[LV%'O'_
MUM'ZX?+#1C S^>+>;W1NF0$TU8\N=%"H]W%_W0,2SP7IZ\7 S;-QT@Y>7+UC
M)JRY$QSL/%XBI.]RW0%:C1348I]_T-N=WBPDHF=G=//B^AH[)%')X&<D:QC>
MJG9K(2?R,_JSI&%P)B'*/&_O5AEQN:Z(" ND7^ZW>8_%0BM&A&I8R QI*9'7
M6'6''J!968XEZ0C,PU590IBW%=/?*9=@D T$)R6"BDY][:#N>F\*6$&D##L5
M5; 9V#@PG2UZ&!)' 13?]CBTU+/6_/42"K3EVJJQ)@4ORH").U$.'EH5_G,@
MEL@XN#Y:'^#H(/94&X"7%5J+N=<JLMI)B;UUH4ZJRUG6](D F!#(42S/2A*=
MB@4GH[PV#JT:]?H-,E&?JHY]I-$9+'K;Z[.BM\J6Q_PO+EW^DKS^#X1XL+$6
MJ.@?>(,=_BUG1B*'>(,QB#<04=^"U]/^]7]^^/F7GX0)VL&<4@[&ONF@3FA$
MJ&?GC<>KH+-JL@8E3_X;3_S$VIZ#Q +9,/$BVVO;[:+XX^->/?N^84T*389Z
M8O\9F"'@2%A%2Y<)8;\$\[-(MMWEHKK+PX.G#121@8/JXH,7R?2=>Z/W&'=W
M[G_P?G/423YD8:2'+'5N*B":TP:65^K'5!T2@%T6SXG,(2>*6D>%.F1 4$4"
M9?H<[0E5/%C"V:A5GFU4I/[XA[<W-R^^6YG<GOHNNZPR.=W?7G^'T%;ULYC\
MRCH6L#*)#IO^]=CY3:KV:Q.O+U14# C R25 >!)&=QTRGCHLZJ"=C"LLC8B;
M %IMM.3Y&JE7.>K O!-$QG 9@B+JPY[J2-L1V=3>)(+PYGD"6E$:[PZOU7J&
MV&9&H"W'S'$J-HGR98+F]&0K^XBU['U_&2[6O7B&6)?*?][IY,B ?7^Q?L>*
M! _G2^S]V &( M<1\;D7HU$OQ^P@3B*SD:(^+[L696E+0.]HSR1X6[VMMR17
M_\A7GEY5.\:$$%![@>MLK^]U#H6-LC1Y4%1D**6FM#G!P0^"6?2I^KL,GL;>
M\?7MA;IY<?W2:C@8'T'+9+.=>I!*Z;CS)-$1)DKV5C>X4& U<I02EM3&_C-6
ME?1\3@I8 E7 256Z^:%D )F52@U.^AE@[NV_U2\%%F=C_#B4EH7F*9)GBI0\
M/ \)S\'91!]!E__.X5.JI2&G:IF@)7/9 JV8P\WHD[Y"R.F!KEHT1SFX+&YD
M'F185M4HU^Z39U5YZ=V!:54C+8OPQ*H.MH0IJN#GX,_C2+QQEB31(@OAR<R-
M9+7;5.<%F>G7;P0SO3/5'%GF=#+,F&X4G&#&Z6!HAAD)0CN:_E]UV^J+7&%(
MHEMG[CY6*2AI&OQ!@OJ9 ?73 $';7I%<<#I.N RK+'W6:L\.:'_8#QI<+0H4
MA[Z[JN;Y"I#;GP,[XAF<04W!-$J8AV(SS#D(&P1+:T<DV1;-)JYTGP8#U?P+
MYM-VBPM3%?E@62;T<EJE3%!R@9BDT@&1%U1XUIXFN!#%RUK"@F84_?A0;LF1
M#@W\WO+D*J"2EZ(/U7=O%F1\8I53 YX.U8["97%YE43^H*-<8NFO669-0.U/
M.[J;1E:5WXN*_&M0&V/?%[$54M (267 F=IKS[8(,DI9,/P^,HGK.0X,DNQK
M1C(A(#;M"6*3Q^6FV%EY+E';+6;W,,5,1Q^U7%6*TDI;!W)X(V@F &ZY9/L4
M!0R7+H6__2 T(I[TNBLK70[ENJ8@8;:P2MT <UG?P^6[Q'C)LR&6LGW.50%5
M13J 8:L>;W%0J!IDHDHP.58XZSJ>JHYP$A<JLZNK76)Z>:7>'])RD@?GI[16
MG7.:+K0^L&DJ!\\**\/5BG!5 S-YF+4?DK3L!T2?J\AQ0#WE\Q0Y'J!.U*%@
M!_0J5)$ >VW9EK)X585F$N+G[\#>" K18YFBG6X-S*4AF:Z>LS8,)HKM(Q1Y
MEZWN+PZ2010IC&-!_"W(^<;H*@@&AYG\&,*+Z,_J4)._S]*[7/8JC"IF=1/%
MI%L7 :$9-K9*@'M:UUZN$WV/9LE9-G:YB3[*=,;N-%O"YBO&->"LH[#*Q+%>
M L?VB;N>H(PB\U5@>&A\H(%U@MUYE?Q\PGLJ4VN@$CJ6K/LS$MI'#[A,0G;"
M/63./V7UG;OT6])/='[J(7-=$<.<<5_&9?;Z3;V?==YL:!O=Z<N%534_7D8K
MNY]OHX0.]1OUY_&M(L,V.=@9^04/LD5"Y^[HY^[H<UP\U!U]HLVLD?;H$[T&
MI#_Z)#=0MT?7GTSA6A#.=R>U"3]C8MIF^6Z5)2:;\2V09EPY0^=\$^09F/'R
M&V_+C&7#+NP13/0"ZMS!^3[C5._G?/X-ZN9\+R";-0.:]^MM?,DSIIYYRR],
M&YWF'N;/@LA;/6,BFO\%.'_G?)>_UVI#/S9G(@(4N8GNH&Z:487ZKC[C&1^>
MD_J5-BSY5<MMO+RJY3@#$_5J%'6T;$91#*I$J[5<"D8%P$%)T6!QY-(4VQ)-
M0AC:K"-70>'\CCR#(7#[5)O@,B5.>QE AS.L[X%+YJ_3*JCD_=-6IX6]E\G"
MMI=IW;UB52;S;J+R_1&\3!TS95R]O*I[,]/[MQ2Q(B@E?6$E61%MJPP02V*J
MH9F]*;2Z-UGB_O)(@!>$9;+4]A0^BHFJ[':V#U6B'S3,S=8_@%5Q%SK.M?12
ML)3(5V@ _Q7G;*'OK_OY"?DU[>7](J07O>3W4LJP.Z_8=BKBH>Q[Z#);M":F
M+'8SL_XQ'&7*$7! G4P; VP/Y?J*\O26RU-AW[Q"R&'.8.AB4HX9FT.&6>'I
MS<$4\&8$!;R!7BE/)T?SX@_$ IVT \*0R.NV0T!"FXGMI_UT<\,?]D'L]H]Z
MQ:4A-(DDI/GO!\EH;Q9Y54REN]?].(?^/OJ3I0;L>]P6HMVNJE1'#K<_@9Y/
M(22)\L^M\A+=B=6U.#VU66-=0XD>K2H<N"QA1_<_*U9UJ_,B2U.=3* ]M(<*
M ;;'K>N1J]2#2$Z+[BK! TN@3W#PD+E0^].EWZ/9C,,Z,"XIX8\TWJ)<4&W-
MSE = &0RW;D""2C_.M>%O3JQCJ>K7V2%E0"WN@$O.J#A&#_^D&QJ/PL2>UE[
MK:Q<] RV5IO:[N3'@#3!RD:[&>,$FI)A*'3;]IAJI=8@K+Y?:?8$7%&(,IJ)
MDKO(I/VH:=XN+(./M1$<47RB1KGM+Q7S-1LA@=E?7)[=9_W8/UUZ2O_;]6>I
MK'YD*_W&P_B;K$W.BL14P+UZ%65@R5!"C9/ .@ T)]LRHX-3!9*&+?\+M,13
M7PUT(+5?!Q0:9@B$*>RQQ"?""RJ&]'8=54O0Z("8@ >]GR>/"E&"J_?[U,\#
M15,90CUH*P^3NB)1E$++]%!.*O8O\)K94:M8!QI=HS];)=7<P3 4(/FA-5T!
MA9SM$54=)W06@^FUZ9R!4^R@WAG0IMIUQB@S#X!,\(V^ZOD.PG]2(*P((:=D
MZ3:)8HU5?'XP5N4E,!(,KEZ$^>W$/0'A\$1KE#-^^V!100TW; ZWK!D'?')=
MJM ZH*2RO2AK5MMGCF.-NHY3-7: JOT;G:);F<):.NEEHX M+U3-VQ7GUZY[
MF_VE'<6TZ4>CE)JUQ.L35'],B&#G=Z=3PJ!!&T2?E"*>[=W'P.'B;DKA/EYU
M\$\P!'B,F$">_R-9"LSSE2?N).[.ERA0,OM<Z,32/K'<%$(_&6_YDGXY9CFN
MV!WZ>1EIF0VP/$_LJO8*W3*R8\\/$$"S0#C!F\ >J41 &+EUZ>H*1&V%='7^
M8C%GY#H#6U6 6P'70[H0!O )8SB@#A+HYY>8^4LP\H,"!2XG!=MX9K_,MH]K
M@8WV:8@M+GR$XCS#^O-0< Y&?SYV%.D?R3N0(5\[!%S!)&F/^$66CGP*2&I'
M28%E8 C,G-.L)$T]\+Y(S-1AV0/VTI E2:T51J()AG6R;%\9AB=(-@#R?9"#
MBNT")*)RN]:)U&9VY,$&:$)LA*P)>5-8DS0O UASEY>B1L3&[. 0KQ(;4J%B
M2G:9[PT,T?-@R>D'.I>9.HNX68LXKU%1/Q'X+9U(R$$CQ/4@]^?]^IWK!X&V
MR0(W+80-^!YD(\>;0685O-]3OV;*EV1?+?)Y3"A:X)EB]Q;:A:N]KO<"+7%'
M9(V  LQ0^^20(?TFD;^H@=$6M'=CH"/1ZY"8)?<H]QE:&H*W*4K,QJ 1OS!T
M3"^O2<XHZ)IK4,0PQ%_N,?P,S9,+"DMPQ2) /GZV<;V@,[( ,&CX@Q&3N"0'
M/E9W!+\X38V-(>T2#4@/B>F!(7S]"=Y%0(AL/#'"6E0([&9'&5:ADP3DFD45
M643=@LU3$8L%;SAG7Y:N]0FPQ!\%,Y1YX3 G&34N6H*MN?>BZ\.S!M#7>"\_
M>*:I*BN<\2S3*G4%QCZOG<F@9&J'$@=$^%<J6$YQSFZU*?!E9"F:2H J'JA2
M1$\'VK7E"689DEC"K>7'5H7:ZTI$^<^>-+3K1$=8 !_C& %A@0[.O-7Y.MK"
M69?81 ,@Y^LDJH'=)H<\*]E-R(_AV9X)EI-35PICNU_FY2/7>O F<Y+;O/W]
M0JLB PT9RB49#L&-F72J*H4_LGV8ZT<8QO5&=O6U!PCNB0X=U6#L"=3,I.)8
M3P. /B]V>9;>84V+)?W-]]7* H+O@OJ(:'.'1G@'M?8H#2H PM+G/8,\/.7%
M5Y0B=;1FPR( 78Y +"/UJ?4&D+1)C28P=V@.V53C_#G_&"(%QBE_L-A 6RJ@
MNBZV?.JV#5W"@,=\$#"0;?D^?:@[]6 J:1;'99YKN7<8WMV<"?3*#PS64$85
M^/13DN1 #T!(@;(7QZQ[:4+,*&PB7WNL>K-"5V3U^X[&L! =#DSPEI(&1O'G
M("\R<W0TT#;8+H+E' OUA"!'\)>!,A7I!%#?KN> LO^\,1+_]?.Z09<[=O4.
MG0C5VEQH/:2:XAJN.WKG1>#DNJ-WF,AZU_HZ/.T14];?@??X#KS'=US#%0/^
M;$100(>-V:\EG>D=Q(?:7[MF(L#W012(<RVN7QU9%O73Q8RH<JMS(Y$*8UP5
M]!?$)3"O,YA<%, B1JFDOY>Z"!"CW-8D& ZPHH3Z#8/X?#JDW1;/C$EVAGJS
M@*K<0BO'B,#<XDQ9W@5:T67A"GI<,<\1I.YS>'Z3:AHUI<J9OUJKD_IC6BJQ
M)&P%B"G6+5O>]0BL^@4Z+,$J \ZEI]E[N[.3[)2]-9/^5J;.*=N4^*N5'5+A
M4;I?L_^K""CDOFG32A_I:*FB?90O598F#VIC5TJ-*=4RVD1WNKBH76HT<9:[
M_T<36S*S4]H[_[TD^!;J++Y\N%(_5!.2 7=AOXFCFD9H R<0+RK:D/E%_[(T
MA?.[/:@&=\VNBK3BM'(P*]>6MKL*[9A=TG2.-86*%&7K*E?+5M0U9^0=L3^Y
M,G3A-+\A:;UQ0X^XF62B6'/>%'8-BP>WLB0K2ONSRY*.[V0^5]66U\]:D1>5
M?F!;VLN+[<&D&?7@W;B:SWKWN2[LBW9_7.N(?LX>[29SJ"VJ!1R:F\U);9S[
MQZ6^UTFV=3]XI7ZT;TY;>](X=,DHC9*'8N>^HU2CPF%1-D <E:EZF'WGUIGJ
M.X?;>J',KMY"I8RIIAE4#6MD*=)9AI8TW":VN8FK-[^V.EAQ/%JJ4[6/+XL_
M7JF_V\NG&VWNI()2LU1#REZ94P/MZG8LP5-N:S5W4:Y6QH%*G1A'AW,Y(/;0
M#@@\SY'OMLR+4E<,J"5A:TV_)MW=P];$5 *HDH@>A?U5U_?=KHH\![3,!RK-
M)1)Q"0'+*W7R*(^,6-615J)0-VDS#YW-X>'$6;$[\,4CR;@5TX<.+:V@OZE)
MXX ]UISG$?I+M;&VU % J[ZVK-PY3N2J*A<ZU2OCSI7Z)ANG7M-[<)??S'9"
M6F=6#;+J%GOS05X='\@C0G(]1KQ51QB[)IR& -MHRJKJB*IJO.T*'$!5%?_T
M8[6W2T7E;IU53.#"=1<G:BA(,E3B(J6-T:V?LJT/1)0;3<T\3;&A21S%6QJY
MU)_LF:8U.W6,R&W.3FJIWNC]A=I:RKZLY$WS5^Z[E7:NK5/2NK \*S?W%>6?
M<C/7'=PR>GL\=23Q\$]VP\W>?K/<K: "7,<>_Z2O[JXN5+9M/#NGP_ZCWM3I
M+U6/HZ9[0VW$[[.XWEE,#"BI@"?I."/[SI;NK5G6<I(O<'CDD=K;NW4<RW$*
MR\B2C."*E!-<%2>J J+5^"JDJ([A]'8-]"I+DFSOY DE8*A#4H7CIR>$4R$E
M,\JQ$JY=G:S^J\H+KEJC']NP-[ -^BC@2&)3;,&2T\JR,9)L=L\;K7>.?Q#/
MTA0"2^SCC':E%20'J;RIL(@K<G%KC^*/-"*U9Y#L'NSM+.Y-5A;D0[MPQ>$Z
MI?6YD[4KVUM*M>=JR:*(<[.MJ+&U]-3?[.%H_#U4]W>0\O;1-DJ#W9W3&6IF
M5R&V';EM'<*F3ZC:0S6]CELZ ;GUJ]='[98O*LUGZ22D*1*K,M$1T"'5"EJM
M('QVNBOU*RW)4B2Y"U755_YX5^U,E0MW'O0<MXGE,Q7J6JUT-=7Y#3E6.H\E
MR9INHEVU#D,GFKOG7PG!O?TEFL,J*#HM*&7Q9$K7VKVP4J614?5?5RS!TCBE
M,-GK(3U1=VSV5.A; 6179%]J8>SU5PL]KH?8I MI'E0 ^L7J=^U:%^6NJ;Q8
MZ,18:J0?.UQ1_4(K7[HCJZH;P?'DZ <J& -',"G1L]U08JF2CN_@/EO2;]D?
ML5R*/7IWC$[)BDY8_$-U! X$L-(!CBE4)V3:?L =G+^Z3K<VBEI:V:]< HJ;
MY$*=Y'X0F5\PHCWF72CWOPX^G*31@8(Z> _%++ZR!L9OSPV,OZH&QI6J;%E&
M[5F8RKK4Q-9C7_GGFY.>S^G8L>F8GS:MA4WMH#[;.?Q\1JWNY!VND8FM<FJG
M9C;;J+N?]?F0>,_L)O?@8F++F]IQ'1R#$UO7U,[ID%-R)JC^]=1N\8FM:FJG
M1+:E-4JKOCX36]O4SJIV!E9984*3Q %X@6\?RY/^3+;MU]26L0E[+D#8L5U6
M1]',/1K,?^:>AZ/;%F+Y@M53V>;&Q<V0W) JN47MUGE6WJTSY_/3:I_ER?)Q
M8EJ.IFZ_FK"5H3)?*!TVO-6)=ZE@/B,5U(+%#@,J.LG=#RVL=M5CZ:Q8!M6S
MEG1BJ5?D?!Z63H_EI9Z^7^@ZZ:EC.5AP A9</I*MS<*$</EV6K(.;-<Z%CT2
M.F J7,*(&:O:"BK9Z "P#R"Q4> 9:'E>D(3V2R=42'JFKT>X-*I(:M/+(/(_
MH7608'KJQ"CKF7HO0.4:O[@$L&,@'2*7%0K.XJ3C$, $N!C!6+T6@LRAU+XJ
M@CWHY5]4Z39QZ6I?$"9KTB:)3M0U'J50[$=*CAS2AY 2,:J@-C3L>57W*HD
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MH1P1+P5G&8@8WY"!X7W,N1 XH/95\T0VZ!8.:5W C"<Y3A#GJC-^D+VUTE^
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M[0!XS%R'(;7S'@VYD:QM7]M&(]Q8G#/-5&0)+X_$!SD26R]2SO.%>P_4RH"
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M^WPOJ<FWC&;$TJKV /&UWG:IX2"!]'_.6H6&Y OP9KK"'EYCC^(UEP?.6:'
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MO%0(_):=FW2G8\_A5-$0N.K(F0Y'AYR9R(S;GTO! TYE]J$ID!\/87Q51UF
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M-YB8\2X?2X& TDS$S)<A]1^?"[-##R7#ZDS1:AF1PX[25]"$HG]>?;@*LQ#
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MB'PN&C'>*<D*UFO^FJ!KQK9+$'C]W[^"N([W/34WAR>17S??1T19;8+@]<:
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M&'>]-:),,I47XOOKNO/4:R,HLTPS3*I9/XZCH* DHT]?,JG9\0\] ^\9>,_
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MDM<TA[[5@W;9/%U#_=?UUMRAG4K-:(O.\^SV-M.B1\R^-I^N<F?7F]J'>X>
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MF+&G0W5=->32,@,C++8PI;ON5C4PI> +IZTJ*^-1#&U5HJBI@NA1M<P9Z]5
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MGO<I0^0,XH#ZP(ZH65^'R'F<6X/].%>PX\1>LT^Q(F?57M6*W%'@6CCKO_Y
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M@9MX:TCPSRWUX++;@B*8]^L+79M'1.6,Z'WOVY@*<#JF+ !BS8*0$*5\2E-
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MA8N!64JM-HLRK^_FXF3I]ML7M6(KA\-#?5N_/_RA^O%&?M7D'4<5[V .:,#
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M>B2>=;19%1>FS\;&9H0BFAU2M, X[,'([8GH<^\1>=!N >KQN<#X_ Y<$5Y
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M:G-@XT9==>%-ME5J^3O%Y.]A94%)4@>BT'4_2>@G?P0+73],?K230O'D^5/
MQ-E^R'NL;X2^@ FU758]:=@C'TJI5EH^.]Q;'B7)[/H6NC*:B8"]H<S!5=$<
M8O*[QN#+?:?[WV.$W^FRSBK23E!SI^^U38&X\HVO$51D8)MP\7_;2RZI9-P9
M)B]3B\>XK=%VV6R5HHIT5=L4=WA?^5$2+Z(>C'E=6$Z@EFG()G0@I3 Y'7D8
MTFP]:#NF 4.3XPIW]L]P0>HZXNQW.!A<*:ZMBP*7M;TI7'C <H=H%'O0L_EV
MS/WU3WQ0;!$,\%$(M9/:@)LB(?]C?'&^5=)-TK*U0&Y";@ M%/;,?\>+J<5=
MDYA&,C"SR=-UCM%!OFPZ)7Z7'C7!/'Q$AZ1A_1$@"E.KT5(P)*3J&@T+0IO=
M<X=Y +!8GA^ +[(!\ZZ35*63'#19X?I!BUV3W=!O9ZT9I!9BD4LJ#3)9F'90
M;<8"\=*+KJ-XU"6#,%WI5U$HY^I,$0\5/LWYTFRWO>7;2;SG\!TNTO-21FJ>
M,!>>PK%A)DK-$^:K#3XJS$2IVE[^L+&]8WW'%E\'UR_$6O8@1<3>]J8M'@Z'
M&0QK#+QGV.>1;\MQH"5E?G1KEG_J)Z>Q(&K3L]C%B7.E.G'!*W3IXFRI3C2A
M12^9R'H@1,J/*G1)Y7CLI+C.A3ZEIN#6I;&3+7HJ=)7F0+8D(FNE2L[9E/,4
MO&B2G$@I]+FWPVC(EA K] &YPPB23XP6^CC=862EI<<+?<SN,$I4"R)*9_/>
MR-JL6D-3.LSW9CG;JK 6^A3@"=B1JKD7^FRA&GGR>S64SB*6]>T-BEYR/A"L
M41Y #-"SAQQD">=X\<!P9#V"D<41B7=GVP'FH6H?6H1'<A@MU^^4TVN;Z8:F
M>,L$?F5UYV:CO)7+:_=2;KC_?L7KC_6^YH.RA=K*"^=@+X[#U &'?7^XO'_*
M5N3DUQNHINIU&=>DI%RT:B=]JF8G#^XG?Y.G#D'+?L'5 9E[0@=@78N1?]!W
M$TB+WFTB4G8O;_:R+COVSJ_/E##VY'$7%Z,_>5@@^?K7(W:F%>=G@#QM.-<[
MT[/A=;>JBY2,R%8Q_Q-@2&ZKJ[3L_&V4,A_DJ&.O9.?/)E&3&XEI+VDL8.7^
M$ Z53<C!!7A=#M0R.;4ZIK7*3"V!Q%(NKQ%SYCO4/"U]"N7ODFG JN_;B8[Q
MO1S[)*EY+ MYR<<MU?15DZO%#VGQZ4SFD*\-X;I^V'AD$/8&O_0E%RNU%R&1
M&I9"YS<RD:'V#!;;E9&9)/O6TL*X*&+O'EH4JZ-\Q7W@BYP&\I ;N W/"P .
MBT2K34E/W$;3SJ*<I.*&'+?3_%V-(^'1\L4:D#$(4UZGNU*M&<"&XT/Z/_[<
MWZ.I5*5 L0,]WRJ24;=3XCYGR"2@)X,<RCX[R$/>\\F&>2G\_$"_D)-!%J+/
M"O C7^B'+Q!/X0/Q_+'<]QXI]W$^%/2A"Y P-=PB<8,%L!BFHY.0TLOYT-"4
MJW=GEYF_XRJ-GQQG< L=!9V<M,1EH= !D@[*7FU(H0]9:6-JX6 4^LB5+JX6
M#FBASU]IHRH,3PI]^$H'51L1[)F_3^_8V8IZ+CF?^KH35_RD3UU/$2EY,DM5
MC])$Y._C<U*7QW!$\<[B31NN^.MH#G]Z!_F#_SO 45_,T\?UAXUM4A_ST^U:
M77X@_AGQ/G_]"U!+ P04    " !<0:I4G4W\UH@@    2@( %0   '!R;&0M
M,C R,C S,S%?9&5F+GAM;.U=6W?B.I9^G[7F/S#IE^XUDPHD=5]=W8O<SJ&'
M"AD@U=U/9RFV".XR%L>7)/2O'\D&RP9?)&'K0C@/=:H ;^UO6]K:VC?]^:^O
M"[?S#/W 0=ZWD]Z[[DD'>A:R'>_IVTD4G(+ <IR3O_[E/__CS_]U>MJYOAW<
M=?I6Z#S#:R>P7!1$/OSCY/N?.O^X' \[0\?[^0@"V+E&5K2 7M@Y[<S#</GU
M[.SEY>6=/7.\ +E1B <+WEEH<=8Y/=V0OO(A(%]TKD$(._%_7SOGW?/ST^Z'
MTUYWVNU][9U_?=][]_[]^][[+[W_[G:_=KL9 C\2%)W,?U\[']YUW_7>?7K_
M*?/#>V#]!$^P,[C._-":?;SH/EH?'C_-[/?G]H?/CQ]M^!F>SSY\/'^<G7_)
M<HJ6*]]YFH>=/UI_BEG$>#T/NBY<=6X=#WB6 ]S.9(/T?SH#SWK7Z;MN9TP>
M"SIC&$#_&=KOUE1=++>O[D9X^)5X0?S/;R<9Z;T^^NX[Y#^=G7>[%V>;7Y^L
M?TZ^M</T@>R//YPE7Z8_W2']<A'_MO?ERY>S^-OTIX%3]$-,M'?VC^_#B36'
M"W"*WVJ(01-> N=K$'\X1%;\.AD@=$I_0?YUNOG9*?GHM'=^>M%[]QK8)UAP
MG4XB.N!;/G+A&,XZ,?M?P]42?CL)G,72)5S%G\U]."OE9B,C,L@'0OX/P'5/
M.FO"#^/!KF0=+SRSG<79^C=G\0-G+7.%!X0>F>:G-IR!R WY>"QX7"+': $<
M3YCA]=.M\QN/<[J BT?H<S*;?[1M3N>8A&]%C_ TE1(?OX4$LERSLKS$C)T2
M1=B]2!;G'Z80_PHK\F&L3+8Y6OK0C6P8OL:;P.;!LYBI_)-%W#!2"\$K\M!B
ME9"=A)@FV9(FT_[TYOO-W71T>]D?]N^N;B:_WMQ,)P]W_8?KP?3FN@[:&)/[
MC9]<7GI97'@I.IY#E"7!G/LY? VA9T-[0X1 :0UWS-*&*1=9.[,RV$RF&0@>
MXQF%+80G )9D\-X9=,-@\PD16>^TVULKZS^L/_YMZ(!'Q\5@8=#W[$F(K)]S
MY-IXZ[[Y/7+"55Y:+ME$D+_YT 6/T(W-$D9:9S(@[0="&=MC&&)E!>T;X'O8
MV@OZ%C;9(K+R[&L\(2TGY('!0DT*K,S HW ._2NTP.MD3K3;,\1V&%K (0J"
M.QB.9E/PRH.1F[0<P+8=ZP[@W@/''GA78.F$P,7,+9 7SRXNC S4I,#*C/@#
MN!'D ;'[K")%T'\,0A]87"NIBHHTR3LAV3*(6KU"7H@7-#X48C7+^Q)*R4@!
MDMD?!+<528R.L!D&B'B&$)]S-N.O[I!G1;Z/)<C#/@,Q.:"(BLS(4A!-!179
MD^B*G_VBIU5.*0$(=91D[>I^!.W]7D8%$5D@4(35X3U8@4<7BB$HI*!H)8AL
M;U549,,H/#7L":J&IIR)%@0PY-KS-D_(VQGX><P]ID")QK[;T>PA@#$3XCIT
MAY 4,/<^PER$JWL7X#7GV61F+HEY=L>'I9J.I*,K7DZ.A<]A5R"8\QU3\T]*
M7(XBZC[_H*1I I?XY'?SNL3G6HC?;V;9"4!@(B<%V'?@_X0AV38G$)N0HD9$
M)1DYYS,\<\F)"O^/K+UGX,9GK/ *^/X*ZQC^XS(;0?EK160K+B$@D7EQKB6S
MB\]2SXCL2AE_R?=U[(*=]2HJU3!V7>ODD]]^B/-4_;R<U>F"(!C-XH&OUR$K
MCJ58\+21;/]V+LWIMHYO9'GHOSI<IF4%$;D@IF1C$>)\_:1<=H>.!P?XKV+"
MSCR=9YL&Q/J^E:,,?&M#=1W$9(S+)\_,?+2H9F0]&"J7,/+QN>[;28_HK7?=
M[DEGZ3L(VP&K;R=XSD<!Y@@M$Q<Z)A>';+]:R OA:WCCQH2^G03P:9'8'>OO
M711 ^]M)Z.]NM,T*HS#D6RF<_)0L$LSNHJ$R^E OHS;A%N0[5((M52*H3ME1
MR!^U@9S3XXTBSN+]K!AO/NFB"&S%YH;JC(84YT77<)PL!AM%RZ#<%*-E4]_;
MEC5%J%HUU2,L.4_LH-LY[:0@WU\8 K+LQ(>XCZDI]@^]P\%>Z76@B$V9T@R(
MF1Q'%/F7PT%>AO&C*6NY"MRV Y:B^W0 Z*I]XRG63Z9HIBJL-3$-"M84I50)
M-AM[HM!,T3KUZB:#ZK/^>H;-]&./RE+L^FLA[OAUL43*;<8O^B]8AE2$[ PO
MR9K8("9GNX-#7);I0D$;-=490-<E*J7(>_IOOWS(*]]SSZCES*W2JA($J0ST
MWZCWDD%]RF<JBG.C=-T^.UP6M%&ZCAMT9:IU*H0+H]0>MQ!8[+N> 4X__E>?
M+W5(L1K@^^/#RE*;DJ(WP/O'B9ZW^HB*XM F/4NQ&45_V'M_4?U@BMT EV%#
MFWU) 2B5!+,%\.>S+4$,\3^E52'?]\?XPU]OIH.K_K#ADN1JVKK6)Y=P+;D&
M<3('/@Q&44@Z79#N*%SI495T9)=3)BP,@B"B[TT(Q8:$&@#]*)SCI?SO/4%D
MR<@&<@_\D1\O #LVWNZA'S,E"*B<W#&=])A.*C6=])B5><S*5).5V64X][WU
MK,SN^[>5HFA J*.1%,6N_D?=!E,4>_J_539=QF3"Z9-?W +L75/<I+1;0;B;
MXQ.%JEHMMP8U=]ZE>)DSQR7[9":CVZM?^W>_W$P&=Y/IZ.I_?QT-KV_&DYO_
M>QA,_WE]<SNX&DSW=<Z(#:*-EX:3?2D'4!A2/SC7F3/_H+QF48D*N(Y\O#"P
MJG=0HO7C17,)L/%)G/S85(H[J?)9\_S4Y?5^* A=])^!XQ*;=H;\ &33G/OV
MOZ(@7"=1QJ&->^3'*B\,?><QBK.BIPCOG"*MA=ID1>4\2O3N'7R)O^(\";)1
M5+Y,FD2W35#]NXN_',4;87#SBH^'3L#GZA2AKOR=MH6ZBK@<T/L$$%1%#0QM
M;7KT1!\]T0?EB=Y.>."?S&44=.G)RX^(@ZC*/KP"P*H)R0Y2\@-0I:&2/8;,
M ^3AM<JOI$H(&,R\_#8L6VP$PJJVF- Q\'<,_!T#?Y6"*5XX.@;_F%JR5"H4
MQ*#_*'+5>;!\8<^]@)L5_:S>_(HC"R9&/YEQUMB )L5 V3&S&_04_P&]\[(C
M&HW\*BYID-T[3'4+(MF-M%1O3Y*R5 PHQFNRD98)=4ALAG=Y>47WHVJCLC&4
M%?D*'P\E\T8@1D([9*C6RBT+H3(\1J5P,/.=+1Q*NT8<2CH6:Y2;(C^4B=]Z
MW@-MNZ!_:] &%&9).@VM.3^4;6,K38I6V#(KPU;S^.B%Y)E^"/$))$53F:+'
M\+RB[+LJSJ1<F02# ,*2+B/?04C4Q"KF9XK!7KJ<=TX*D1>*P%_-81!Z43B.
MO'@4S@!\V>-"O.3Q/GBAX_XM\N %WF?.+S@98Z(EYW8MP@#I0$)JMB/@3J&_
MX(]E55$Y"!C2XG)%+/"&Y,II'*-QQVC<,1I7))CR-6-:(*Y6@]2@-C80UPQP
MLP)Q#/L>XK$Y3 K.<6 O,P1I7$KU#&^LAZZ(;4Y=_;J=#"?18@'\U6@V<9X\
M9^98I$]WTAZ6G.J1ZY"F>1-K#NW(A:/9/<)GM]#!N^3JVG&CT'G.N$5N7BTR
MMGV+Y4K._E$8'_U'L_BGT/X[)$VQH=U_QM)[@FO7\BP3+<CXF:])],_E/:D:
M@T?YR5E_24E)4L60;'8XFU#TI@RYOR#RXDIF;69 .2F8>'*B%82"::^%C\MG
M/(E:[,E^GHBD'/?-S1 Q!P]8)P3CR8-(JGLE(15@]@8A-Y.]<,W>@07D=X'4
MTSHX2-)\.WOJULM5,0%>]U"K;,AQV:2[_IY8^#U4#8]LPKP3\HLU-Z82;UKC
M(D/MS:&WXL-K9]$C28K1-#>BC,VJ5O;Y3=HP?Z1F$C3+L<EL !;>56=LP4$#
ML+?/3]3'J7]FJPC\BG,PA:Y_7_6]H9OHTV[3S&K(DT7%J4?W,UX/*:U,&G@S
MY"]BN&TZKUD&-,2[7 E%2EG_''A/<.!E6/,=SW*PV.A'$^*7!KX=/"QM$,(!
M1A9"WP'NS6P&+2[O;S/CR>EX(,!JWTZ6ZC7^>]MBR8^EMT@X6_+O,XRL_B7%
M;)QW>Q][',EZG 2E@)MB?O$9>#V]^+$4/V\LZ_*\MVE2?7"+_#OXDIW_>).)
M/ LN1#IH<!(62EYEV^^8W:'\-%ODFLL_*497J@]R+^A(Y.4<N =1> 4@X45J
MG+=/2+FA>M5LFL^N#3F8Y7FKW*1W;^FNLXE,\+[MJW$;L8RIHT'?^C/E@DH/
M5 )NF3<EK=U3.4WR9"X)EN3(^@[\GS"N2:5^.AKM*_I6S'^U]SC*W5;B"*2<
MD#8%R7CKG( \%X\A_5=ZYSW'&8F7M-!Y8WN4/.U,OZ-??!0$#YX/@4NN/\G?
MX\MX"&EF,*DX?\&:3AK._&!RCOC5K"Y($?V_2=UX$%Z"@/.4STU;6N-8TBZ#
M-"[#QRBQYK$%!"0Q[R^1C^=.7I@B("H)20$S\)YA<O0@%O@59N:)7*X$Q%QE
M+-0.$I8T?V">%5ZG7]'34M@N,A*XTR KB"@#P>4&9"2D)/>0#1QB>AM<?BCS
M/'OLDQI5+SU]'#1L_KH*Y5.*M$Q;4NRJC]),+KJFH&=]"/HWR>+81A&S74,%
MH'^O+%$!%%JG%+AJ]WP]<.[M@/^DH4W'VB;%T>#ADS8'51W$T$4^>2=$*I_W
M^OKX&UM.M:XGVG^4.>M4DJ/U%CA^W -O-+MU/. 1O3CP FS(Q3&M3(5%$, P
MZ'OVIG5 O&D 0L/NAY2,-R;P28.]6).(N64E<Z7<B2L+KXR#6,K$FB^"X.].
M.'_PT&, _6>R;@;>,@H#S"/"4%TGWK'S',= 8S(\9[?FQSYZW(X>MT/SN)GC
MF$(>7"6[\VWDV0)SJHR"Y X"5R"88Z5-_D?ZKC]CFP&K]>)/]VDT(#+.412!
M9#=Q,1.\J[**BA08Z6:;[*A#^ Q=@43J2C+*@)PW ^1<.9!>,T!Z:H!D[+@@
M_?!7!_KX>#=?\3?^X"3\AL!*TWXI Y>K75[BN<:K"5DIRH67'-4VA[/M$]G.
MB21_(.$.OS4ZK$&"VO732!/64'%0L"T!HI9FU8&7%+2I (I>28VR,ZW<@'-;
M*)((ZS9G6 &"),GH%/&N]]F+&4U%LBDR<DVH4&A5$N>[85']XX"M2&*W:D5U
MYQ!==J(J!X0^T72VW8?!)5/87D?,RZ1//Q:F#4B><,RZ%KD1IV8V::_$6:W-
M5<FZ:)[*=#TS[AQN(67-@,N'VTU9,^!6XG92ULX-LE(E."L:"_[3)"_F^EN)
MUR.NKR%HL)L7)U7E:3.L_(H4Q%U"#X,@:V[TXD$_F#O+>[P&\9P"3^P-46JH
M2,LN64LIN=E]3&ZVX(LUEI&0 N#>1Q:$=D :])$;7(%GP=Q-'#Q0&(C):5@.
M2#Y7/.(]-B+AILD@#Y9R&K(AW$5$]>-_Q->D)-?L#KRI#[P 6&'&3N2$Q4!7
M!&K@AQF8^%_;$/%'OWT'K\XB6K#'3PL>:H\YK%_YF<L_U!IS8]*<@(^UW".:
M,B8:(F5GC37RN?6 4,7W+7)=]#+R1K,9)-8/YWVU98]+USQ@@?^:T0C\<7(6
M:@<)2UK,?Q(]!H[M '^588HWS%]!1+8=)9:AN_6PG'NE?H_P>86T-48>MCKY
M9U$) ;GW\&XQP9TK5T-(\@TU\2RX7%VY(."OLZXD(V<=D '7P^\>R%G60C$!
M)4D4U6 *KV@ID/L;26U@F<)%-TL7KSH=,Q0J/+9LR@C5:DZ3HNS5NP>JW-ZT
MB:&W-KW+[1%]RLC9PI_U]AGBM2OU21Q@6]W-2D"C= &6>Z39SQVHYOBG36B[
MZ56_=>36,=Q8M,*+70NHT+=!,:F>LI5+EA62&:'1,K<4*G39F1#KK$.4]Y":
M%,1D/RQP>;!IF%&U+FE'!%NQ"0I7M=W?(%R&L)) -%E_W*610=H 1+7]UP!:
MEE@N!:Q;CP_RCIRD@WW#R0(<5+5(%F#A5R26<H\PGR&>&?AM19X]AA9TXGP3
MH@[Z3SZ$"\;NQESDA.(^O_@@UL8.LF^1OS44,XLU5(0XVVR5-[]'2?L3X,:O
MBYFI<@*RBMPAR3#O>_8U21U'2S)ZW_>),43^>H6\$,LMG"(L.3+QL.A&X1SK
M$M)Y*QAX)!%IW5B)QZ':\,!"+V_#PQ3Z"^87EG](:-R;('1(7WL[N9UQ-+L'
M*P)Y] S]=*D0^MCHPH1@9FYPSJX&1MH/X69Z_Q/+;".Y*WP.!X\D.Y)LE]R:
M1HBVE,5T378%TI(.SUSG,2(LW+O 6]]OZA.][L-8B?NK[(\VEW2RKYY]1])!
M'-]!:,VQ]97[/C%.&A1%Y2@JQ; ^4_8]#R^Y[)?D[M;-E;C-R8-O.$%U2O;\
MI+(@[C(7.L%L1>[Y2!0X.5]@@]2:+X#_,Y/PRJ%Z10<0PH-7T6/D!S&)S783
M[SUX["%XG"RQ.<',.QLQ4>O("S&9S#XZFG$S6$-%<$8XBQ1U4$;\YG7I) J;
M:'*.V2!"O$4<B6G9,/\;HBWRW3#'LG(3DJ**U35<HL#A4I$[CXI=/_*$S8LG
M;(BD!LD8RV%M8 77$21&UH"<$H'+96'R$][KZ#+$BA(ODS!Q7_.?7':>%^(F
M@V=-DIF1HD?%WJ@/P9K"/=XYG "R2Z/P62D+8;2$1,%Y3^L7L<0O@BL]IX2
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M9$]UA]NFKYOLZ5L_)GC=I.K[Q9N_;K)GRFW+K>ZN>;\*%8[JOMILVVNA-ZD
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MHP50S'6X95[]]>?D#Q+$^<O_ U!+ P04    " !<0:I4H-MD(#51  !Z"P4
M%0   '!R;&0M,C R,C S,S%?;&%B+GAM;.U]>W/D-I+G_Q=QWP'GW=BPXZ3N
M5K<],_;NS$;IT5[=J;NTDMJS>XZ-"8J%DKA&$34D2RW-IS\\^ !9( F   F6
M9B*F+96*F<G\92: 1"+Q+__ZO$'@"29IA.,_?G/RYMTW ,8A7D7QPQ^_V:7'
M01I&T3<@S8)X%2 <PS]^\P+3;_[U3__S?_S+_SH^!N<?+S^#19A%3_ \2D.$
MTUT"O[W]]!WXC].;*W 5Q;_=!RD$YSC<;6"<@6/PF&7;G]Z^_?KUZYO5.HI3
MC'89X9Z^"?'F+3@^+DB?)3"@?P#G008!^]]/X/V[]^^/W_UP?/+N[MW)3R?O
M?_K^Y,WWWW]_\OV/)__[W;N?WKT3"/S"7PL(__L)_/#FW9N3-[___O?"%Z^#
M\+?@ 8++<^&+X?IW'][=AS_<_WZ]^O[]ZH<_W/]N!?\ WZ]_^-W[^_7['T5)
M\?8EB1X>,_!M^!T3D;QO'$.$X OX&,5!'$8! K?%FQZ!RSA\ Q8(@1OZ6 IN
M8 J3)[AZDU-%1&\_H4)Y!*,X9;_^\1M!>\_W"7J#DX>W[]^]^_"V^/8W^=>?
M][[_]0/[]LF//_[XEOVU_&H:R;Y(R)Z\_8]/5[?A(]P$QP0J8@4A99!&/Z7L
MPRL<,HP4Y *MWZ"_'1=?.Z8?'9^\/_YP\N8Y77U#M $ UT>"$;R!:T#_^^7F
MLI7GCV_I-][&\($8SNHJN(>(R,Q(/"9P+7\.)4GM,2K'CU2.D]]1.?Y!1BU[
MV1)_2*/-%A&MO!TLZF>8V96V2="VP-<PB?#J(K:L9#E9-\+?9D%B6>MMA&V_
MP!V);]"NZ/LDK0N-LP!9%GJ/I$6A#6PCVY=SJ"&L@_2>L2%#\D,0;#DK1(F^
M#9ZC]!RN@QW*]L5,R<-,QCT*9)@Z>0M1EM)/*+GTF'YT_.XD#[W_("'<+CF3
MA0[W^3<IQ8Y1@<O/QR"!,GS.8+R">=@O:>.P_<52&+YYP$]O5S!B[_37[^F/
MQ_Q']A[DU[]<Q%F4O9R1&4@2H$O"XOG_PI<Z;T3',IP4'[(7^N,W'0^_K0M)
MOT\'5/(3G3S!^/C+K2JQOZ#[AG4D,,6[A(VVROK,*N_]$V<#<CZ ,0*$T[^\
MK03:EW^1A#4I@B0L!" _]LB0?^-MB,DL89L=(]'FUPG>=&HS9XM[M?36MFV<
M83(!7MRGA%68J=I$XR$S6Z@1L6,#7.E_8I3!KP7M_YH>=KF6<:LBK,-<+$'N
MR"NJHEQ_Q@QDD88=C(FN[G'IZ>72BC*8'F>IFG&;*GQ1*=+2Y7!C7! N*\KI
M(PH>5*VQ\9"9[FI$7-ACR0!0#M,;I%S5N%4;WJ@5Z>G37H0LUU\T\Z(;*AL/
M#W/P&C&GP9-S H05RS=-;[;=8.!>/7FG^&:(5=:X/</^&*5A@/X3!LE'\DFJ
M:]I[CP_3<8.<_35 J6K."5!6@/'RQ[S;(,$*NO)0_4TCU]"\;3/G_C7 T&L$
M;.A:(.C>V//PXJ6YRZ"1&OR>QKR$H<7HU1 8;O9W24#WJVY?-O<8J9IZXR$S
MO=:(V#?IG#S@]*<W8KFB<:LNO%$JTM.GK73C#7R(:$HCSCX'&^6)M/S9(<G&
M.BUGN<:*#:!\IK?73A1PGX9\TS@R5_:T:>FZX!H9:6MI_UV2$*XW<(N3C(:6
M+,C4)T7=- 9M DAINML+X.Q R0]PAKXX:@],6%5UOD*"!J)A8:>#\ZQ6/IHY
MGO;G#?<_6NC9=X%"V^)ZS)]<3R\N6$5?/F* AJC?5OS_&"&8G!%6#SC1W/1M
M/#HDM-1(N<AEYH&%\0$%H^F-NPL#W*,@S_2-C!1MRXQO-P%"I[LTBF&J.7MI
M/#I$K352SN8JC LHV/ABQ'($<(]Z/-,V,E*T+2.^V,#D@<QV?D[PU^SQ#&^V
M0:P9DUM(#%&SE*0SXRZX <X.Y/Q\L?)NB+"BWCR% PU#PIH;/-^1M7L:T>)I
MGB?5] ')\X,TOD?/G?4_@XI7GB3VQO3;8<$JZO(1 C1 ^]8R,'BSP?%MAL/?
M;A\#\A;+7<;.E!#?T\S#=%(:M/3OH.QPNL[9 L;W"'#.0&#MBVLH08CU%.HW
M7*@5)RV8K$W_'R%"1A.F^I.#IJ,")7=S?\K$MTF15/NX6S=^:1J9*'FX\=["
M<)<0CB?O[^^B#"GG&O>?,U-GDXZ#;5I*%N U.'G_[?UWH& XO>6VJAYWJ<8G
M-><V*Q 'C/H8!GOQ'#Z25X8Z>[?R9X=I5*1EWW@++J!@X\G>;2<*N$]#OFD<
MF2G;UM3A,B:0!_R4=I %>39>;Q+11F/((">GZ6QB(;"C.P]!L0<WO;4KP815
M5><K)&@@&C;W@S[O-O<PT7,!\;FA.Q.<CC-3IRP Y^&+=4NTOK?](VK%)PWO
M;_ST*M=>[ YQLL4)Z[- 2P3@&=[%64(6P"O-FK(>4L/"1@=IAP%=X'K$"BC(
M1#P!.6] F?MB_FHX8DVE>HY9,^(+#'.TU*"RY4QWP?/EBHPQT3KBC4M,AH%6
M(D/ :"'JS'4(/U!GZ-EPT0<55M:>M["@H8C8<HO%:D7D3_/_7$4Q/-%S"2F!
M(7J7$'3F"CF3H^('VK4*@F7LS=#1!0]6TIJ74" 9"C403D8S_3/RXS*YPU]C
M(\,7'[>@ZXJ<>Z.GO.B<B7+SS. EH,C,O:DM#P&0FSI3_;)/]98MG4V[ELEU
M@I^B.-1<0;31L*#R!DWWAE^N%@J6GEE_&U R%Y JSU=0Y,[ X5BJP&'9(ZYQ
MF@7H_T5;_16UG((%Q=<HNO<%S@X0?EZMF3L!DOF!1&U^@B'W 648+!P%H:^7
MP$#'YNO/&!XW$&@X..;!M$G(>V+&4BWC-DWXHE&DI\SAQDC;R*+K1QQKIN7W
MGS-389..?<-D' !CX4V>I57KN$LK/FD8Z2O77I>-?]\%"8$8O? 3?*HVV_KX
ML-8.#7(.^VN4G/*CB],;<A\B6$%5'FH?&2O>8K/$LE;8S,KWGQ_8\:]!SZ&=
M"V72OAEZ*RK-/HM2;?F(0-/6-93?9>S=78_I)\VFQ_G'?V'+42K*<EUV\"?3
M<R:23J]8/7KZT.C0MUO+5# $R[5PR4'!TYO>LT: 8A/%:G2LM6"7=\&]6C%M
MVY,6;(U1<E"36)K6KXR#;Q945[W,5@3%^*7F/>?MU;!C,SY#09HNU^Q8Q>(Y
M4CK7K$#$@M:;1!UD*R@'6CC.>'AFY*W R.Q=KBMO0=CS H[$,D>"C%V$U>@^
M(;[K.=X$D=)>9-?3Y@#L4WL=YM^! >[7CG_Z1J*J*_OF+-0M?)L@>OO*^_?O
M/N1&2S_YRR^8-BX23N)]@JKIN^[G]1791<^.*E?YVH25YGSS)\X+A/Q88$JY
MO9G6AI4@P2JJ\E']8N3(=2\>R1S4 ,^]]*A5</ KYS/Z</,9QT_F_JM"Q3P<
MME.U;TR$U_&3KD&--1XI@(35U>8O(*C$0@+%9"Y23A"OHAA>DA_-EB?"TQ:F
MQ"4UIPMOR@4P-KZMOO>QD*U(&EKR3^_[*W$EE;LQ]$6:PBPUR6LVGS17=)V2
M?>/F]/TPYA9]XVYM^*5;)*I5*=WKTG;SPX/F)KQ'8*BV&P3=]30-&+N??++L
M-C3V#%RJ)"\U7S?W0O?3F?U9D#XNXA7]S\5?=]%3@(@\Z2(["Y+DA<R@?@G0
M3FM_0)'@@!R'"@,';D+X@2!>@9#^ "O.?CB,'H[82)VSP P)<!&6@/T@, 6+
M#!1L >,[MLM]"I+?8$;W2_)&#A%,-7HI*)$QAZJ#K'VGJIB!M.3FAT.IH(0U
MU.8Q(F@/C(K1L'8*YDYRG<!M$*TNGK<P3B%QY&7V")/:P*SC+$KDS"%2(&_?
M>7*F '*N*1N=,&4,PMJ<S@^'TD$4&ZAV!NBA.G Y0S9,,9:@/BV<= EDO/2Q
M-O&VY#$X"U#N,7?T9R^=H]<-K!J\.].>UH!O(%E%16$&V4Q3QX*;3YKKMD[)
M?M2OZ+.5B!_FVZ)XW*T6OY2,]O1[UJE?5_,>O(5)]G)-E)"1@8&N7+8TL?L9
M:DYXNN@,&2O;Z;J8XG!N;&H#"U9'((83EU%KP85UU.<S-*B!"N/$IB\E+_"Y
M"QHW/K,DT@1TN^\*!BF\B1X>L^7Z"YG)T<%(QVEZ")E#TTG8P1A!&1SC]?&.
MS"[9-,</;U$#"FOIS6M0<H<I.0'&"C!>M([J"YW]=^/CR&6J%8Z6@XB/#=!\
M1<:^\?.5E$^3>YFR<8<V/%(L$G7:M_7I<E6JOQP=OD!RM0#UR3;;S=*.13HP
MQFG,\"H*[B/$<J)DPL,*BAXQ6I' 0^<^V8O)EK$Z37, 5'DX.*Q><6;S]U3@
M_4__\(?W)[__9S:GG[K'O3'"V%3+<T$3[0-))_LB6\#Y3KB#+4@WH'JCBXH5
MN$:KXT 53T^*.100DKN2Y;(.UVA(W&7Z H]%&-+>N.EU\$*W]DRR^RT4!DP*
MI!0=U.KE?,"6,_+#'7H0P6IZ\E/[J*'XG,=D.UIAF.S@:M_Q->V_C<@@$.1$
MG7@!9=6U3RR,&=[X2 ]P6%F7WH*$ZOA(QHUI,ZF%0"\&3M-'R5;:KDG903ZI
M3-XAEKPK?,6358LB9*U)5;D"_8:G):U:,IO*?8:-,W8'&&<C2VL]A7>#B-KH
M87_8<#Q>^#!.T-F#(,=G H;!&-%!96 .7$K5U5Z#=X:O $]S_Z%#8?Y"4=N=
M$-VB8N3)#,K00?J)61^HG;K++*=2/=ZCID;O<>J=4TWG4X)G&\ZG+(WFKF90
MW@T@,HW+ITP6YTJN)DFC'ZG#FTV4;=@)IWAUAF/J3C .-<VWD\R HUCM9!WL
M253,P+>?<0;!'[[SP\)50,(:6O,8$+2/!3L8)W(:OR6&C?US-SOF8^Z1W[;N
MB7NR=Z>W#>YNXWNDK6Z_MK:%+CGZY[#WGAT6HD1:;@:*HO^9'X;?JGO<IQ??
M](QJ*N:MD"8Y^+Q8K5B_XP!=!]'J,CX+MA&9_@IOK;4MIT!MP-9/+W4'&W4E
M3T#/!QY',0@Y6S]<0@,_K*])_[%">S!1?N R!CE'Q<YOSO:Z=YL="C+(SZ\2
M6;8)?(1Q&CU!>F?R!E[A-/T,L^7Z+GC6W '7(SUHRU6'E9/=\D* 8I-<% %$
M3 ;P+2)2>+*6,44>#U3[S%!&^P#SS'&-.^#L >5/#S/18QI$A/&/LF9!%,/5
M19#$9)66"E*?PW441EH+)15J0TYC]E%WZZ8KSL0/9]0 #NNKT'^0<B\KV(&"
M'Q 1.^]#;*RLP[!L@]T%K:OLLN]U]QVH=*86[*<47*<2?#NS8KB;TD++W:F&
M$?9=#N*$2L]>38=N?<=.4OK2<A)EPAS==9 L$]:)=\7R*]<PN7T,$M.T73LY
M*QFF-O)NDWM'8!LDX*D[_311GJ\7/WGJKUN1,\!*EB D'.DMZIPG3Q<"PA4P
MMA/Z&..?+G;9(TZBO\&5H6_MD[&"4Y.L:U]*&3\0E R]\ZE6O.2^)%>@Q]C(
M?(=S @L%5$;RE\LTW0WTE8*$12PXR7%\Y A$C)NG#M( J,LY1*UY"D:'4USV
MH#"20RQW69J1*7\4/PSRBAH=BV@(=,?R#URQ]-1)9*!U><J>$GT&J,-GEBK(
MN'$<G@PO;Q<Q*=)I)6&.1@M)JT#DVP#"Q2J>W43<!PU6U-<H]PV79<5YSUNC
M2V(ZB%@HKVX2=5G^7AS%]:3(JQ\=6<&[7&'>(H&:(!1L)BSPNH$I)#C1NQ'.
MX1-$F/50S 73V^#K)#2HTVH[82?=;1D[EHY=50S]\!,UN+"6]KR&!C50H3E7
M@5?A0F.[S<\P)DZ,B#2+U2:*(^J]6?0$#1RGEY0Y/CVD[3M/SI#Y3E!CZ8?[
MJ,*&-77H.42HC@[UH3JWJ=QH;\ =-!FS.O2[VO'#>U,P/URC'8JNF9?U&9?C
MF=9D!EZ5E!F9N/BX!6U7Y.R;.2M;H[95F#J.?3-Q"1@R(V]JR4/%[QFZ4#LX
M24N&SSC&]9<UF!+U41K8#Z"5LJOV#+QBUZ-+ Q2A:K9HZ%&<W[ @$1&15^$S
M$\V!/L/,;'!H/#C@3G21D/T!@98PH\YX-*;IR]6-.[7AE6I1I=4)@WU15%O4
M@9AD4]MIF"N\C::#FV%(&&$[5R2\KW&R83,=3]*IO>A@58WYBD3N!65M=UD9
M-&$NM?G&IT$:A30W%J%=IE?\T$O*'BX-TO8=I8C_8%MZ#%[3,TW"%O ]%8*G
M7+D8?OI1&Z(=[B15K^?HM3L78\>3L'TXN?&Q/T-Z<PU<+9[([.T!?MYM[F&R
M7#/IA%WJ :YGRL$<4S..]AVUD ,$7)#21WD1@%">X:W##C0/; >4>9H":EA!
M+@/@0M!3B#P&"'),'P]4#F]>XX3.S199ED3W.W:_]!V^#DPO:K#&<N!Z>;@(
M3@J[A(.L_JSZ;)M),S-B"XL#,8E:KD7E<#/(10.B;. . RZ=<NG3A!D/R8S7
MEV"X> HB1#5*UJEI@. M#'<)/S"U^N]=FN57=/;9B(T@:4T4^YYB233[YO0E
M3F" :!D_7T<1-]D$R6^0.TE:BLD2S'1ME75U"_ A[-HV2(5P;!7= S>^_O#=
M%!=4\H)*8/4 /T$Y?A,!D[8TG60&U7JWD;6?GO=URJ8"$=;0F<=P(!D2N:=-
MUP"FK-8FZT]+S3*5" [IIZ# P'*+A:(XGRZ/#5LWCNE5>J!B(]V.4L]?RL,E
MH+Z#8];"]CG2VD;M(63!&F6$[<\2<X.KV'AF<)TXR0RM76U>8[(7&?: (4&!
M<!M_>ZK^RN=X$T2QUJ:4G," S0P90?>>X8=C=,.!E;3DI>J17.O@5\YDRA[&
MGR!-96O.\)L/6SG#R8DY.UG;T_]SY'E\B_KE)V=%S7BG:K2O9? K9S#^O;KR
MIK/Z-MY#R'I;7%>VWVB+2[L7G\V@>W&[5RCHSVMPD!07L5WQ9+[3W_[5P(_4
MB3IM7.O,O]3ZUGY[-:O&Q!WNIZ?JV6"*M."<RD6;[6+U_;&-@KT6MF-X6F^G
MVC']J0>4CG["=CS%)0"Y6^SW#>[W *T,A)O^E%N81'AUFP5)EAO1*7R(8OH&
MX#X@<H6CGVP8U.C(:G<C1QUS%'0.ON75<YZ,ATIMC*SW+G+;L&CZ'D7,IWE?
ML?-=0@2X9H;!>E:RORVW[!CDQ3-,PBC5JT<U(#ZP([4.,P?9NIPT+61@U>$
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MA9B==9"4N.MU;O9(EK1SZW6LCF_+&K=#U=YC*5W#%OQ8OQ:EBR]'R$@-O29
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MG=L4Q\<=O7$9?(KB:+/;D&5]3"=A'/+RO/:7>$46^@KF.]XLV=PHL 4T9F@
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MY=O19*/ 7@],-Z%R20LC<D&'Q<D^2N8NUTW9OC4R?G[$0$5XL)ZR_(8""2B
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MOY()_V6<9@%"+-VK;\SFG(::MBEGQX;.1RMJZ'EA/Z_I#RK;YL=BHAAD5#X
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M+1!S(;B2I]UR\72<3I7B@!.52AP<E";3E,LQ7Q*'XLH9<HY^.)\FHMA,K_-
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M/)>E[N +N2K$#Z[(3^3#XB/R#PTD?_K_4$L#!!0    ( %Q!JE3O[8 P03$
M *[/ P 5    <')L9"TR,#(R,#,S,5]P<F4N>&UL[7UM<^.X<N[W6W7_@S/Y
MDE2N9RS/^];9I&1;GE7BL1Q9GLW>+ULT"5D\0Q%:OMC6^?4!0(D@Q3< !$$*
MY*DZ.[8L-+H? (U&H[OQM_]X73LGS\#S;>C^^F;T]NS-"7!-:-GNTZ]O0O_4
M\$W;?G/B!X9K&0YTP:]OML!_\Q___G__S]_^Z?3TY.IZ>GLR-@/[&5S9ONE
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MH_/'A1TXW.S1=@T-^/T*G6 NX7ICN%N^84ZW;(@]1'^-5R8T?]ZO#*009V%
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MEE:"R/961D6U&+FGAII"5=!4,]%\'P1<>]Z^A;J=@9_'5+,6E"@I:S1;/OB
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MRY)I9MU!1;JI-]X>!?M,Y9@E=]>^9/PPVRRYSK:4C=679!\)D!W:UM2S=C9
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M, LU-6*%C[YMV8:W3;#$&R1<0D2U02*6XW706(T7B-3PP>\/01>9;_QSJ("
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MJ 4XJ9?^'6<#W<+@#Q#,@0F?7+P#44I1H\-)QH-WBTP>]R#$^32[C_#W1IU
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MN$%-JK\?HW4T-#]#'ME \E]'TY&4;O/G*]CBL)7=7_!_L%_DW_\74$L#!!0
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MC'ET"7_-B3X&-LX@!T<'$SQ!Y.6_.["@#0,6Y!$M4'S"FPF8]'%=E&VS9VT
MO< OWA(RD;@'8D]+)E:1 J5H]D_ -H%CI#5&<0!9''J0(I-$S:S(>X4Z0JV+
M$RJ>I/J*32GX=$$ZAMQ$PHZ3&LC+J&\>))$;6BPE9FB ^X*!N\I9.LZUO*C;
MQ# 0G4;^"BB0#^C& T39<SXHA7X]RA]B>MF/TAO\]WPH>,,A'.:&(% YJ-99
M#DX[4VFRK@O]P8ZQ;\+8M^H_?P^W</ FC^Z4P:NL*@R7$\T .2!K!D;/[H:$
M007!W2 B,MHQT5U>@HJ.AE";]^/+B)$5$@3QQ7TDZ[UTG_'O8H*I)M9L,J:2
MLY).CX_12CH$0VD0+5:)":'2&C V[MP:6759:K!C.9S02[4IB/=2<ZQ0&N!/
MH$0-+7,BT%%$H2MPR,C#JS!^=68+:)>23G>3K<4&J[B& \-K70D2X-VM92PZ
M#H,O(LLJM;4$_1@%_,5R0'92GZL&0S>ESQD12*V89P'*[\_HG7Y'W)(2LC2(
ME @3<XU[?7@236'G$RMB77"?7N"P#PBAO.[&FQ3H/, LF*<?,%-'W[N7[!6>
MLB4%\V8Z@GVCI$<7?ZFG*LU%[2:-P>Q.%'L,J^"Q"T]Q!S2"'945QVI:1]@Q
M]$T8^E9]\J^ .C]=\ 2,M>/612UT8'Q]5P62HP_$&]U+!Y?;+[VA &V_S.UP
M__?.'Z9F&,A%3K^V AKF\9*HO@0PUT%:4U3,3#K%K"GC"3*WGXJFM(+T??JQ
MGCMQNG?_X3'[&H&+E9V0B@OEPFXPWEL7\8>!L>K0/4FO@2#798SZ)/"D6(="
M?JS2,H);^ "J)N:I2IR=7UQAN4CX8R+N5#HT^3^[QM(:X%S5PQ@#J144_);=
M,(!I%\B=733J)BFZ(E*M@E).>-Z$6XPU_&5K9=+FV3!RLL.FWH#XL=G))&]<
MPEU+H$3#H_O/JF86:ESDA'SPPU-4K XF?-[AR?$/3['2"/,HA(D!B[KWO)X\
M.X(O/#<K"AJR9C8W:_K[O](5YV:,@ 5,+>Z1KB ' H9P0 ZJI?*0K34XPJ,O
M[0R* 9_-Q5KUP_VD"E"$$QVT*RUI78:XK.:,<7]%E\<R!E:Q$N0"[0GLA:Q
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M4M=U/)YN-2_UO8GR& [T0N=Z#$K G57.M'*+J#  RS=J;2A$F"&VQZ"U$><
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M= I4M6LYB)H_K5UU1X8\[6UGE!=15L#)2B[0Y,$DJM7,[J%\%;Y>MF<162B
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M1"\RE7\0\/R_?NFY1=[_M<GKDR].7GLX39;-9BC=8:-K0'Q3A);2Y6AXC*E
MGQD1/VF"G3U[!2?/#F(UJ^X>RO>>O\[1\J%*I#_91703(U]P,P,_(L3Q5.N@
M;<^U,AU F:'/<;@A=PVS"=G8/VIY*JJ ^+3GHGWRNO_P</C@A]7P=TL@?POV
M%R:57P"\U4R#FA976'!1E!CPJK%1]9(#]^'4B@?^/#+HQ?Q)M#13DS3++"78
M'%5'T7^6:37)5?1?V(ALN<WVM<+D M/QUP#+^:LW?0)B\2M+),PR0)[<#P%)
MKW[AY/0/E>OH%S F+K\M'%F+9GP@?!(\6:@&+U'#^F#)\!JNHJ1M50]^;^*
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MG 4>GP4V#_(9KPD+C0?_Z02XSWL]QX(/R;OK#-J%W]M_^%LKGY$/=B[];R[
M_/;BAQBX%;3DE]TE"OSFE.+=[[*\G3P\K*2OZSVLI*\%_C]02P,$%     @
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M1F/%SBFT^WT6(;0F?3B3E(]C"N&02I)2'(\R.!91(M-$$D5CV%1#"B\W]H+
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M>8E3+G0@=BTQNXKB+#$NTN[KA-C'>S&#'D,!0"*5L(,6EKP=N%^+JY*32ST
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M@"4Y?;S:(S\5[<H#T:?D'S_SBWW2^8/!.;_YA8[<GYA<[L+UMT\W6:ZBJH<
M.WRF6(\YI8+=+];1[\=ZD?];K@'^4XGJ>16P8#YW"7AA_H?WP6/+D>?*_ ^!
M]0OSWR?SWSVQST'&#0Z>_-;0O\X;,1?_K__+%SZ>$@9+!YJC]2F:WTH2-9$&
M(R,_12QP814JR^=$[\:'A1>]]G+QL6#3+U^,:_KE"WC_ 5!+ 0(4 Q0    (
M %Q!JE3\"-9COH$# "BV,P 5              "  0    !P<FQD+3$P<5\R
M,#(R,#,S,2YH=&U02P$"% ,4    " !<0:I41DZ_L+0/   +F0  $0
M        @ 'Q@0, <')L9"TR,#(R,#,S,2YX<V102P$"% ,4    " !<0:I4
MPQVY&,P*  #^C@  %0              @ '4D0, <')L9"TR,#(R,#,S,5]C
M86PN>&UL4$L! A0#%     @ 7$&J5)U-_-:((    $H" !4
M ( !TYP# '!R;&0M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( %Q!JE2@
MVV0@-5$  'H+!0 5              "  8Z] P!P<FQD+3(P,C(P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " !<0:I4[^V ,$$Q  "NSP, %0
M@ 'V#@0 <')L9"TR,#(R,#,S,5]P<F4N>&UL4$L! A0#%     @ 7$&J5*B,
MMF#L,@  ST,! !(              ( !:D $ '!R;&0M97@Q,#%?,3DT+FAT
M;5!+ 0(4 Q0    ( %Q!JE2'KUO9E@D  &Y8   0              "  89S
M! !P<FQD+65X,S$Q7S8N:'1M4$L! A0#%     @ 7$&J5&7"F"N8"0  AU@
M !               ( !2GT$ '!R;&0M97@S,3)?-RYH=&U02P$"% ,4
M" !<0:I4:HRK^8(%  "9)P  $               @ $0AP0 <')L9"UE>#,R
M,5\Y+FAT;5!+ 0(4 Q0    ( %Q!JE2,*EX+C@4  /$G   0
M  "  <",! !P<FQD+65X,S(R7S@N:'1M4$L%!@     +  L Q@(  'R2!
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
